6. パーキンソン病 [臨床試験数:1,307,薬物数:1,322(DrugBank:270),標的遺伝子数:161,標的パスウェイ数:166]
Searched query = "Parkinson disease"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/21/2019, 11/20/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04147949 | July 2020 | 4 November 2019 | AV-101 (L-4-chlorokynurenine) in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesia | Randomized, Double-Blind, Placebo-Controlled, Crossover, Proof-of-Concept Phase 2 Study to Test Efficacy and Safety of AV-101 (L-4-chlorokynurenine) in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesia | Parkinson Disease;Dyskinesia, Medication-Induced;L-Dopa Causing Adverse Effects in Therapeutic Use | Drug: AV-101;Drug: Placebo | VistaGen Therapeutics, Inc. | Not recruiting | 30 Years | 80 Years | All | 20 | Phase 2 | ||
2 | NCT03309514 | June 2020 | 7 October 2019 | Transplantation of Neural Stem Cell-Derived Neurons for Parkinson's Disease | Clinical Investigation of Transplantation of Neural Stem Cell-derived Neurons for the Treatment of Parkinson's Disease | Parkinson's Disease | Biological: Intracerebral microinjections | NeuroGeneration | Not recruiting | 35 Years | 85 Years | All | 12 | Phase 1/Phase 2 | ||
3 | NCT02967250 | April 1, 2020 | 11 November 2019 | Brain Bioenergetics in Parkinson's Disease and Response to Repeated Oral UDCA Treatment | 7T Magnetic Resonance Spectroscopy Monitoring Brain Bioenergetics in Parkinson's Disease and Response to Repeated Oral UDCA Treatment | Parkinson Disease | Drug: ursodeoxycholic acid | University of Minnesota | Not recruiting | 18 Years | N/A | All | 20 | Phase 1 | United States | |
4 | NCT04152655 | January 1, 2020 | 11 November 2019 | A Study of Efficacy and Safety of Idebenone vs. Placebo in Prodromal Parkinson Disease | A Study of Efficacy and Safety of Idebenone vs. Placebo in Prodromal Parkinson Disease (SEASEiPPD) | REM Sleep Behavior Disorder;Parkinson Disease | Drug: Idebenone;Drug: Placebo oral tablet | Second Affiliated Hospital, School of Medicine, Zhejiang University | Not recruiting | 18 Years | N/A | All | 180 | Phase 2/Phase 3 | China | |
5 | NCT03436953 | December 2019 | 15 April 2019 | A Phase 2 Study of CX-8998 in Adults With Tremor Associated With Parkinson's Disease | A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of CX-8998 for Tremor Associated With Parkinson's Disease | Parkinson's Disease;Tremor | Drug: CX-8998;Drug: Placebo | Cavion, Inc. | Not recruiting | 40 Years | 80 Years | All | 60 | Phase 2 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
6 | NCT04154072 | December 2019 | 11 November 2019 | A Clinical Study of NLY01 in Patient's With Early Parkinson's Disease | Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of 36 Weeks of Treatment With NLY01 in Early-stage Parkinson's Disease | Parkinson Disease | Drug: NLY01;Drug: Vehicle | Neuraly, Inc. | Not recruiting | 30 Years | 80 Years | All | 240 | Phase 2 | ||
7 | ChiCTR1900027210 | 2019-11-01 | 11 November 2019 | Effects of different anesthesia methods on postoperative delirium in patients with Parkinson's disease and biological markers of postoperative delirium in patients with Parkinson's disease | Effects of different anesthesia methods on postoperative delirium in patients with Parkinson's disease and biological markers of postoperative delirium in patients with Parkinson's disease | Delirium | 1:Total Intravenous Anesthesia;2:Balance Anesthesia; | Tsinghua University Yuquan Hospital | Recruiting | Female | 1:60;2:60; | Phase 0 | China | |||
8 | NCT03652870 | November 1, 2019 | 17 September 2018 | Antidepressants Trial in Parkinson's Disease | A Randomised Placebo-Controlled Trial of Escitalopram and Nortriptyline With Standard Psychological Care for Depression in Parkinson's Disease | Depression;Parkinson Disease | Drug: Nortriptyline;Drug: Escitalopram;Drug: Placebo | University College, London | London North West Healthcare NHS Trust;King's College London;University Hospital Plymouth NHS Trust;NHS Lothian | Not recruiting | 18 Years | 85 Years | All | 408 | Phase 3 | |
9 | NCT04148391 | November 1, 2019 | 11 November 2019 | Evaluate NYX-458 in Subjects With MCI-PD | A Study to Evaluate NYX-458 in Subjects With Mild Cognitive Impairment Associated With Parkinson's Disease | Parkinson's Disease;Mild Cognitive Impairment | Drug: Placebo Oral Capsule;Drug: NYX-458 | Aptinyx | CogState Ltd.;Worldwide Clinical Trials | Not recruiting | 50 Years | 80 Years | All | 135 | Phase 2 | |
10 | NCT04097080 | November 2019 | 7 October 2019 | Comparative Controlled Study of Analgesic, Antiasthenic and Anti-Anxiety Effects of Xenon in Patients With Parkinson's Disease | Comparative Controlled Study of Analgesic, Antiasthenic and Anti-Anxiety Effects of Xenon in Patients With Parkinson's Disease | Parkinson Disease | Drug: NBTX-001;Drug: Standard of Care | Nobilis Therapeutics Inc. | Recruiting | 18 Years | N/A | All | 60 | Phase 1 | Russian Federation | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
11 | NCT04117178 | November 2019 | 14 October 2019 | Monitoring Anti-Dementia Drugs by Serum Levels | Monitoring Anti-Dementia Drugs by Serum Levels: Importance of Serum Levels, Drug-monitoring, Side-effects, Clinical Efficacy and Compliance (Translation of Official Danish Title) | Dementia;Dementia With Lewy Bodies;Dementia in Parkinsons Disease;Dementia Alzheimers;Alzheimer Disease | Drug: Donepezil;Drug: Memantine;Diagnostic Test: Measurement of serum level of anti-dementia drug | Zealand University Hospital | Epilepsihospitalet Filadelfia | Not recruiting | 18 Years | N/A | All | 110 | Phase 4 | |
12 | NCT04127695 | October 31, 2019 | 28 October 2019 | A Study to Evaluate the Safety and Tolerability of ABBV-0805 in Patients With Parkinson's Disease | A Randomized, Double-Blind, Placebo Controlled Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of ABBV-0805 in Patients With Parkinson's Disease | Parkinson's Disease | Drug: ABBV-0805;Drug: Placebo ABBV-0805 | AbbVie | Not recruiting | N/A | 85 Years | All | 32 | Phase 1 | United States | |
13 | ChiCTR1900026956 | 2019-10-21 | 28 October 2019 | Minimum alveolar concentration-awake of sevoflurane in patients with Parkinson's disease | Minimum alveolar concentration-awake of sevoflurane in patients with Parkinson's disease | Parkinson’s disease | Parkinson’s disease group:Sevoflurane induction;Non-Parkinson’s disease group:Sevoflurane induction; | The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China | Not Recruiting | 40 | 64 | Both | Parkinson’s disease group:30;Non-Parkinson’s disease group:30; | N/A | China | |
14 | NCT04157933 | October 16, 2019 | 11 November 2019 | Staccato Apomorphine Multi-dose PK and PD in Patients With Parkinson's Disease | A Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Profile of AZ-009 in Subjects With Established Parkinson's Disease | Parkinson's Disease | Drug: 009-A1;Drug: 009-A2;Drug: 009-A3;Drug: 009-A0;Drug: 009-B1 (active --> placebo) crossover;Drug: 009-B2 (placebo --> active) crossover | Alexza Pharmaceuticals, Inc. | Recruiting | 30 Years | 85 Years | All | 32 | Phase 1 | Netherlands | |
15 | NCT04146454 | October 14, 2019 | 4 November 2019 | Smartphone-based Wearable Telerehabilitation | A New Smartphone-based Wearable Telerehabilitation System for People With Parkinson's Disease | Parkinson Disease | Other: Smartphone-based balance exercises | University of Houston | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Recruiting | 50 Years | 75 Years | All | 44 | N/A | United States |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
16 | JPRN-jRCTs031190115 | 11/10/2019 | 5 November 2019 | PK & PD of coadministration of XOR inhibitor and inosine | Pharmacokinetics and pharmacodynamics study of coadministration of either allopurinol or febuxostat and inosine | Parkinson's disease neurodegenerative disease | Coadministration of allopurinol and inosine, or coadministration of febuxostat and inosine | Naoyuki Kamatani | Recruiting | >= 20age old | <= 40age old | Male | 28 | Phase 1 | none | |
17 | NCT03987750 | October 2019 | 1 July 2019 | Safinamide for Levodopa-induced Dyskinesia (PD-LID) | A Phase 3, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of 2 Doses of Safinamide Compared to Placebo in the Treatment of LID in PD Patients With Motor Fluctuations | Dyskinesia, Drug-Induced;Parkinson Disease | Drug: Safinamide Methanesulfonate 150mg;Drug: Safinamide Methanesulfonate 100mg;Drug: Safinamide Methanesulfonate matching placebo | Zambon SpA | Not recruiting | 30 Years | N/A | All | 300 | Phase 3 | ||
18 | NCT04127578 | October 2019 | 4 November 2019 | Phase 1/2a Clinical Trial of PR001A in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL) | A Phase 1/2a Randomized, Double-Blind, Sham Procedure-Controlled, Ascending Dose Study to Evaluate the Safety of PR001A in Patients With Parkinson's Disease With at Least One GBA1 Mutation | Parkinson Disease | Biological: PR001A;Other: Sham procedure | Prevail Therapeutics | Recruiting | 40 Years | 75 Years | All | 16 | Phase 1/Phase 2 | United States | |
19 | NCT03905811 | September 23, 2019 | 30 September 2019 | Terazosin for Parkinson's Disease | A Pilot Study of Terazosin for Parkinson's Disease | Parkinson Disease | Drug: Terazosin 5 MG;Drug: Placebo oral capsule | Jordan Schultz | University of Iowa | Not recruiting | 40 Years | 90 Years | All | 20 | Phase 1/Phase 2 | |
20 | ChiCTR1900025894 | 2019-09-11 | 16 September 2019 | Parallel randomized controlled trial for Shengyang Yiwei Granule in the treatment of early Parkinson's disease | Parallel randomized controlled trial for Shengyang Yiwei Granule in the treatment of early Parkinson's disease | parkinson disease | experimental group:Parkinson's disease routine medication, plus Shengyang Yiwei granules, water blunt, one dose, morning and evening;control group:Parkinson's disease routine medication, add Buzhong Yiqi granules, water blunt, one dose, morning and evening; | Kaida Wang | Recruiting | Both | experimental group:45;control group:23; | Phase 0 | China | |||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
21 | NCT03568968 | September 1, 2019 | 18 December 2018 | A Randomized Controlled Trial of Nicotinamide Supplementation in Early Parkinson's Disease | A Randomized Controlled Trial of Nicotinamide Supplementation in Early Parkinson's Disease: the NOPARK Study | Parkinson Disease | Dietary Supplement: Nicotinamide Riboside;Drug: Placebo | Haukeland University Hospital | Not recruiting | 18 Years | N/A | All | 200 | N/A | ||
22 | NCT03968133 | September 1, 2019 | 11 June 2019 | Treating Anxiety in Parkinson's Disease With a Multi-Strain Probiotic | Treating Anxiety in Parkinson's Disease With a Multi-Strain Probiotic - a Randomized, Placebo-controlled Trial | Parkinson Disease;Anxiety | Dietary Supplement: Probiotic;Dietary Supplement: Placebo | University of British Columbia | The W. Garfield Weston Foundation | Not recruiting | 40 Years | 80 Years | All | 72 | Phase 2/Phase 3 | Canada |
23 | NCT04064983 | September 1, 2019 | 7 October 2019 | Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for Parkinson's Disease | Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells (HB-adMSCs) for Parkinson's Disease | Parkinson Disease | Drug: HB-adMSC | Hope Biosciences | Not recruiting | 18 Years | N/A | All | N/A | United States | ||
24 | NCT03665493 | September 2019 | 15 July 2019 | Dopamine Effect on Inhibitory Control | Dopamine Effect on Inhibitory Control | Idiopathic Parkinson's Disease | Drug: PD patients H&Y=1.5-2 Medications ON;Drug: PD patients H&Y=1.5-2 Medications OFF;Behavioral: Healthy age-matched controls;Drug: PD patients H&Y=3 Medications OFF;Drug: PD patients H&Y=3 Medications ON | Giovanni Mirabella | Not recruiting | 40 Years | 70 Years | All | 102 | N/A | ||
25 | NCT03947216 | September 2019 | 3 June 2019 | Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease. | Study of Pimavanserin Efficacy for the Treatment of Impulse Control Disorders in Parkinson's Disease | Parkinson Disease | Drug: Active drug: pimavanserin 17mg (2 strength tablets);Drug: Placebo: 2 tablets containing same excipients except active compound;Behavioral: Assessment of severity of ICD (impulse control disorders);Behavioral: Assessment of motor and non-motors symptoms of PD Evaluation of hyper- and hypodopaminergic behaviors;Behavioral: Assessment of quality of life;Behavioral: Assessment of depression;Behavioral: Assessment of cognition;Behavioral: Assessment of severity of Parkinson Disease;Procedure: Blood analysis;Procedure: Cardiac monitoring | University Hospital, Strasbourg, France | NS-PARK;EUCLID;F-CRIN | Not recruiting | 35 Years | 75 Years | All | 130 | Phase 2 | France |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
26 | NCT03959540 | September 2019 | 3 June 2019 | Safety and Effectiveness of Opicapone Plus Standard of Care in Elderly Patients With Parkinson's Disease | A Multinational, Multicentre, Prospective Non-interventional Study to Assess Safety and Effectiveness of Opicapone Plus Standard of Care in Elderly Patients With Parkinson's Disease | Parkinson Disease | Drug: Opicapone;Drug: Levodopa (L-DOPA) + Standard care | Bial - Portela C S.A. | Not recruiting | 75 Years | N/A | All | 100 | Phase 3 | ||
27 | NCT04075318 | August 29, 2019 | 16 September 2019 | Study of UB-312 in Healthy Participants and Parkinson's Disease Patients | A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of UBITh® PD Immunotherapeutic Vaccine (UB-312) in Healthy Participants and Participants With Parkinson's Disease | Parkinson Disease;Parkinsonism | Biological: UB-312;Biological: Placebo | United Neuroscience Ltd. | Centre for Human Drug Research, Netherlands;Worldwide Clinical Trials | Recruiting | 40 Years | 85 Years | All | 62 | Phase 1 | Netherlands |
28 | NCT04006210 | August 27, 2019 | 4 November 2019 | A Clinical Trial Investigating the Efficacy, Safety and Tolerability of Continuous Subcutaneous ND0612 Infusion in Comparison to Oral IR-LD/CD in Subjects With Parkinson's Disease Experiencing Motor Fluctuations (BouNDless). | A Multicenter, Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Clinical Trial, Investigating the Efficacy, Safety, and Tolerability of Continuous Subcutaneous ND0612 Infusion in Comparison to Oral IR-LD/CD in Subjects With Parkinson's Disease Experiencing Motor Fluctuations (BouNDless) | Parkinson's Disease | Combination Product: ND0612 Solution for SC infusion;Combination Product: Placebo for SC infusion;Drug: Carbidopa and Levodopa 25mg/100mg;Drug: Placebo for Carbidopa and Levodopa 25mg/100mg | NeuroDerm Ltd. | Recruiting | 30 Years | 80 Years | All | 300 | Phase 3 | United States | |
29 | NCT04070495 | August 27, 2019 | 16 September 2019 | A Drug Interaction Study of KW-6356 and Clarithromycin or Rifampicin | A Drug Interaction Study of KW-6356 and Clarithromycin or Rifampicin (A Drug Interaction Study With a CYP3A4/5 Inhibitor or Inducer) | Parkinson's Disease | Drug: KW-6356;Drug: Clarithromycin;Drug: Rifampicin | Kyowa Kirin Co., Ltd. | Recruiting | 20 Years | 44 Years | Male | 20 | Phase 1 | Japan | |
30 | ChiCTR1900025372 | 2019-08-18 | 27 August 2019 | Quantitative evaluation of drug response test in patients with Parkinson's disease and the influence of rehabilitation intervention on the evaluation of drug response and the exploration of related mechanisms | Quantitative evaluation of drug response test in patients with Parkinson's disease and the influence of rehabilitation intervention on the evaluation of drug response and the exploration of related mechanisms | Parkinson's disease | 1:rehabilitation;1:take levodopa;30:Wear wearable devices; | Tianjin Huanhu Hospital | Not Recruiting | Both | 1:30;1:30;30:30; | Phase 0 | China | |||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
31 | NCT04062526 | August 14, 2019 | 28 October 2019 | Evaluation of Neuroinflammation in Parkinson's Disease Using 18F-NOS PET/CT | Evaluation of in Vivo Neuroinflammation in Parkinson's Disease Using 18F-NOS Positron Emission Tomography (PET/CT) | Parkinson Disease;Healthy Volunteer | Drug: [18F]NOS | University of Pennsylvania | Recruiting | 18 Years | 70 Years | All | 30 | Early Phase 1 | United States | |
32 | NCT03976349 | August 12, 2019 | 11 November 2019 | A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB094 in Adults With Parkinson's Disease | A Phase 1 Single- and Multiple-Ascending-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB094 Administered Intrathecally to Adults With Parkinson's Disease | Parkinson's Disease | Drug: BIIB094;Drug: Placebo | Biogen | Ionis Pharmaceuticals, Inc. | Recruiting | 35 Years | 80 Years | All | 62 | Phase 1 | United States |
33 | NCT04043338 | August 11, 2019 | 30 September 2019 | Single Ascending Dose Study Investigating the Safety, Tolerability, and PK of XC130-A10H in Healthy Adult Subjects | A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Single Ascending Dose Study Investigating the Safety, Tolerability, and Pharmacokinetics of XC130-A10H in Healthy Adult Subjects | Parkinson's Disease | Drug: XC130-A10H;Drug: Placebo | Xoc Pharmaceuticals | Celerion | Recruiting | 18 Years | 75 Years | All | 40 | Phase 1 | United States |
34 | ChiCTR1900023725 | 2019-08-01 | 11 June 2019 | Study for the Role of Butylphthalide in Delaying the progression of Parkinson's disease (PD), Vascular Parkinson's disease (VP) and Parkinsonism-plus syndrome (PPS) | Study for the Role of Butylphthalide in Delaying the progression of Parkinson's disease (PD), Vascular Parkinson's disease (VP) and Parkinsonism-plus syndrome (PPS) | Parkinson's disease (PD), Vascular Parkinson's disease (VP) and Parkinsonism-plus syndrome (PPS) | PD-Placebo:Placebo;PD-Butylphthalide:Butylphthalide;VP-Placebo:Placebo;VP-Butylphthalide:Butylphthalide;MSA-Placebo:Placebo;MSA-Butylphthalide :Butylphthalide ;PSP-Placebo:Placebo;PSP-Butylphthalide:Butylphthalide; | Zhujiang Hospital of Southern Medical University | Not Recruiting | 18 | 80 | Male | PD-Placebo:50;PD-Butylphthalide:50;VP-Placebo:50;VP-Butylphthalide:50;MSA-Placebo:50;MSA-Butylphthalide :50;PSP-Placebo:50;PSP-Butylphthalide:50; | Phase 0 | China | |
35 | NCT03808961 | August 1, 2019 | 27 May 2019 | Niacin for Parkinsons Disease | NAPS: Niacin for Parkinsons Disease | Parkinson's Disease | Dietary Supplement: Niacin;Dietary Supplement: Niacinamide;Other: Placebo | VA Office of Research and Development | Not recruiting | 35 Years | N/A | All | 100 | N/A | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
36 | NCT03881371 | August 1, 2019 | 2 September 2019 | A Study to Evaluate the Efficacy and Safety of Safinamide, as add-on Therapy, in Idiopathic Chinese Parkinson's Disease (PD) Patients With Motor Fluctuations Treated With Stable Doses of Levodopa | A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Safinamide, as add-on Therapy, in Idiopathic Chinese Parkinson's Disease (PD) Patients With Motor Fluctuations Treated With Stable Doses of Levodopa | Parkinson Disease | Drug: Safinamide;Other: Placebo | Zambon SpA | Recruiting | 18 Years | N/A | All | 306 | Phase 3 | China | |
37 | NCT04056689 | July 23, 2019 | 14 October 2019 | Study to Evaluate DNL151 in Subjects With Parkinson's Disease | A Phase 1b, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL151 in Subjects With Parkinson's Disease | Parkinson Disease | Drug: DNL151 low dose;Drug: DNL151 high dose;Drug: Placebo | Denali Therapeutics Inc. | Recruiting | 30 Years | 75 Years | All | 24 | Phase 1 | Netherlands;United Kingdom | |
38 | NCT03575195 | July 15, 2019 | 26 August 2019 | Microbiota Intervention to Change the Response of Parkinson's Disease | Microbiota Intervention to Change the Response of Parkinson's Disease | Parkinson Disease | Drug: Rifaximin;Other: Placebo | University of California, San Francisco | Nova Southeastern University;Gateway Institute for Brain Research | Recruiting | 30 Years | N/A | All | 86 | Phase 1/Phase 2 | United States |
39 | ChiCTR1900021708 | 2019-07-01 | 11 March 2019 | Study for the brain network mechanism of pramipexole in the treatment of tremor-type PD patients based on DRD3 Ser9Gly polymorphi | Study for the brain network mechanism of pramipexole in the treatment of tremor-type PD patients based on DRD3 Ser9Gly polymorphism | Parkinson's Disease | Healthy control group:No;tremor-dominant phenotype PD patients group:pramipexole; | Department of Neurology, Brain Hospital Affiliated to Nanjing Medical University | Not Recruiting | 50 | 70 | Both | Healthy control group:80;tremor-dominant phenotype PD patients group:80; | Phase 0 | China | |
40 | NCT03815916 | July 1, 2019 | 26 August 2019 | 31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Parkinson's Disease | A Phase 2, Pilot Open Label, Sequential Group, Investigator Blinded Study of Magnetic Resonance Spectroscopy (31P-MRS) to Assess the Effects of CNM-Au8 for the Bioenergetic Improvement of Impaired Neuronal Redox State in Parkinson's Disease | Parkinson's Disease | Drug: Gold Nanocrystals | Clene Nanomedicine | University of Texas Southwestern Medical Center | Recruiting | 30 Years | 80 Years | All | 24 | Phase 2 | United States |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
41 | NCT03956979 | July 2019 | 11 June 2019 | A Study in Parkinson's Disease in paTients With mOderate to seveRe dyskInesiA | A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study in Parkinson's Disease Patients With Moderate to Severe Dyskinesia to Assess the Efficacy and Safety/Tolerability of Two Dose Combinations of JM-010 | Dyskinesias | Drug: JM-010 A group;Drug: JM-010 B group;Drug: Placebos | Contera Pharma | Bukwang Pharmaceutical | Not recruiting | 18 Years | 80 Years | All | 81 | Phase 2 | |
42 | NCT03977441 | July 2019 | 17 June 2019 | the Efficacy and Safety of Agomelatine in the Patients With Parkinson's Disease | A Multicenter, Randomized, Double-blind, Placebo-controlled Study: Evaluation of the Efficacy and Safety of Agomelatine in the Treatment of Sleep Disorders and Depression in Patients With Parkinson's Disease | Parkinson Disease;Depression;Sleep Disorders;Circadian Rhythm Disorders | Drug: Agomelatine or PIacebo | Second Affiliated Hospital of Soochow University | Not recruiting | 30 Years | 75 Years | All | 240 | Phase 4 | ||
43 | NCT03970239 | June 14, 2019 | 15 July 2019 | Serotonin in Impulse Control Disorders in Parkinson's Disease | Role of the Serotoninergic System in Impulse Control Disorders in Parkinson's Disease | Parkinson Disease;Impulse Control Disorders | Drug: Positron Emission Tomography using [11 Carbon]-3-amino-4-(2-dimethylaminomethylphenylsulfanyl)-benzonitrile ([11C]-DASB) and [18 Fluorine]-altanserin ([18F]-altanserin);Drug: Positron Emission Tomography using [18 Fluorine]-altanserin ([18F]-altanserin) | Hospices Civils de Lyon | Recruiting | 30 Years | 80 Years | All | 45 | N/A | France | |
44 | NCT03938922 | June 13, 2019 | 26 August 2019 | A Study to Evaluate ENT-01 for the Treatment of Parkinson's Disease Dementia | A Multicenter, Open Label Study to Evaluate Tolerability and Efficacy of Orally Administered ENT-01 for the Treatment of Parkinson's Disease Dementia. | Parkinson Disease;Dementia | Drug: Active Investigational Treatment ENT-01 | Enterin Inc. | Not recruiting | 30 Years | 90 Years | All | 40 | Phase 1 | United States | |
45 | NCT03939559 | June 10, 2019 | 27 May 2019 | The Efficiency of Home Based Dual Task Training in Parkinson Disease | The Efficiency of Home Based Dual Task Training in Parkinson Disease | Parkinson Disease | Procedure: Static, dynamic and functional balance exercises;Procedure: Static, dynamic and functional balance exercises with dual task | Istanbul University-Cerrahpasa | Not recruiting | 30 Years | 80 Years | All | 60 | N/A | ||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
46 | JPRN-UMIN000036952 | 2019/06/04 | 16 July 2019 | A PET study with 18F-FDOPA and 11C-Raclopride on Parkinson's disease and related disorders patients. | A PET study with 18F-FDOPA and 11C-Raclopride on Parkinson's disease and related disorders patients. - A PET study with 18F-FDOPA and 11C-Raclopride on Parkinson's disease and related disorders patients. | Patients who are suspected Parkinson's disease or related disorders, including dementia with Lewy bodies, multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration, frontotemporal lobe degeneration, vascular parkinsonism, drug-induced parkinsonism, normal pressure hydrocephalus, and others. | 18F-FDOPA, 11C-Raclopride PET | Nagoya City Rehabilitation Agency | Recruiting | 20years-old | Not applicable | Male and Female | 150 | Not applicable | Japan | |
47 | ChiCTR1900022534 | 2019-06-01 | 23 April 2019 | Efficacy of entacapone and pramipexole for non-motor symptoms of Parkinson’s disease: a prospective randomized controlled trial | Efficacy of entacapone and pramipexole for non-motor symptoms of Parkinson’s disease: a prospective randomized controlled trial | non-motor symptoms of Parkinson’s disease | entacapone group:Patients in the entacapone group will be administered entacapone (Novartis; import drug registration certificate number: H20160680), 10 times per day, 200 mg each time, for 3 weeks. ;pramipexole group:Patients in the pramipexole group will be administered pramipexole (Boehringer-Ingelheim; import drug registration certificate number: 20140918) , 3 times per day, 1 mg each time, for 3 weeks.; | Geriatric Hospital of Hainan | Not Recruiting | 40 | 75 | Both | entacapone group:194;pramipexole group:194; | N/A | China | |
48 | NCT03924414 | June 1, 2019 | 29 April 2019 | Trial of Parkinson's And Zoledronic Acid | TOPAZ: Trial of Parkinson's And Zoledronic Acid A Randomized Placebo-controlled Trial of Zoledronic Acid for the Prevention of Fractures in Patients With Parkinson's Disease | Parkinson Disease;Osteoporosis | Drug: Zoledronic Acid 5Mg/Bag 100Ml Inj;Other: Placebo | California Pacific Medical Center Research Institute | National Institute on Aging (NIA);University of California, San Francisco;Duke University;University of Pittsburgh;Parkinson's Foundation | Not recruiting | 65 Years | N/A | All | 3500 | Phase 4 | |
49 | NCT04064294 | June 1, 2019 | 9 September 2019 | Preventing Levodopa Induced Dyskinesia in Parkinson's Disease With HMG-CoA Reductase Inhibitors | Preventing Levodopa Induced Dyskinesia in Parkinson?s Disease With Statins | Parkinson Disease;Dyskinesia, Drug-Induced | Drug: Intravenous Infusion | VA Office of Research and Development | Oregon Health and Science University | Recruiting | 50 Years | N/A | All | 120 | Phase 1 | United States |
50 | NCT03971617 | May 29, 2019 | 17 June 2019 | Clinical Trial to Evaluate the Safety and Tolerability of Hydrogen in Patients With Parkinson's Disease | A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Tolerability of Molecular Hydrogen in Patients With Parkinson's Disease | Parkinson Disease | Drug: Hydrogen;Drug: Placebo oral tablet | Stony Brook University | Recruiting | 40 Years | 80 Years | All | 70 | Phase 2/Phase 3 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
51 | NCT03970798 | May 22, 2019 | 26 August 2019 | A Drug Interaction Study of KW-6356 With Midazolam, Caffeine, or Rosuvastatin | A Drug Interaction Study of KW-6356 With Midazolam, Caffeine, or Rosuvastatin | Parkinson's Disease | Drug: Midazolam;Drug: Caffeine;Drug: Rosuvastatin;Drug: KW-6356 | Kyowa Kirin Co., Ltd. | Not recruiting | 20 Years | 44 Years | Male | 50 | Phase 1 | Japan | |
52 | NCT03671785 | May 15, 2019 | 26 August 2019 | Study of the Fecal Microbiome in Patients With Parkinson's Disease | A Prospective, Randomized, Placebo-Controlled Pilot Study to Characterize the Intestinal Microbiome and to Evaluate the Safety and Fecal Microbiome Changes Following Twice Weekly Administration of Lyophilized PRIM-DJ2727 or Placebo Given Orally for 12 Weeks in Subjects With Parkinson's Disease | Parkinson Disease | Drug: PRIM-DJ2727;Drug: Placebo oral capsule | The University of Texas Health Science Center, Houston | Kelsey Research Foundation | Recruiting | 55 Years | 75 Years | All | 12 | Phase 1 | United States |
53 | NCT03693872 | May 15, 2019 | 11 June 2019 | Evaluation of the Nonmotor Symptomatology of Parkinsonian Patients Treated With Two Strategies Related to Apomorphine Pump Therapy in French Hospitals | Evaluation of the Nonmotor Symptomatology of Parkinsonian Patients Treated With Two Strategies Related to Apomorphine Pump Therapy in French Hospitals | Parkinson Disease | Drug: Apomorphine;Drug: Dopaminergic Agonist + Apomorphine | Rennes University Hospital | Recruiting | 18 Years | N/A | All | 42 | N/A | France | |
54 | NCT03958708 | May 13, 2019 | 3 June 2019 | Modulation of Gut Microbiota by Rifaximin in PD Patients | Modulation of Gut Microbiota by Rifaximin in PD Patients | Parkinson Disease;Inflammation | Drug: Rifaximin 550 MG | Taipei Medical University Shuang Ho Hospital | Recruiting | 45 Years | 70 Years | All | 20 | Phase 1/Phase 2 | Taiwan | |
55 | NCT03840837 | May 2, 2019 | 13 May 2019 | Cholinergic Neurotransmission in Mobility and Cognition in Parkinson Disease | Cholinergic Neurotransmission - A Common Underlying Mechanism of Cognitive and Gait Impairment in Parkinson Disease | Parkinson Disease | Drug: Rivastigmine transdermal patch | University of Maryland | National Institute on Aging (NIA) | Recruiting | 18 Years | N/A | All | 100 | Phase 4 | United States |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
56 | ChiCTR1900022715 | 2019-05-01 | 5 May 2019 | Accurate treatment under the multidisciplinary cooperative diagnosis and treatment model of Parkinson's disease | Accurate treatment under the multidisciplinary cooperative diagnosis and treatment model of Parkinson's disease | Parkinson's Disease | Anteversion group:DBS;Balance dysfunction group:DBS;Gait abnormality group:DBS; | Tianjin Huanhu Hospital | Recruiting | Both | Anteversion group:40;Balance dysfunction group:40;Gait abnormality group:40; | N/A | China | |||
57 | NCT03552068 | May 1, 2019 | 28 October 2019 | Study of Clonidine Efficacy for the Treatment of Impulse Control Disorders in Parkinson's Disease: | Study of Clonidine Efficacy for the Treatment of Impulse Control Disorders in Parkinson's Disease: A Pilot Double Blind Randomized Trial | Parkinson's Disease;Mpulse Control Disorders | Drug: placebo;Drug: Clonidine | Hospices Civils de Lyon | Recruiting | 30 Years | 80 Years | All | 38 | Phase 2 | France | |
58 | NCT03903549 | May 2019 | 15 April 2019 | Initial Investigation of [18F]P17-059 in Parkinson's Disease Patients and Healthy Volunteers | A Positron Emission Tomography (PET) Study to Investigate [18F]D6-FP-DTBZ ([18F]P17-059) for Potential Use as a Radioligand for Vesicular Monoamine Transporter (VMAT2) | Parkinson Disease | Drug: [18F]P17-059 | Five Eleven Pharma, Inc. | Not recruiting | 45 Years | 90 Years | All | 26 | Phase 1 | United States | |
59 | NCT03781167 | April 29, 2019 | 28 October 2019 | A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Parkinson's Disease (PD) | A 52-Week, Open-label, Single-arm Study to Evaluate the Safety and Tolerability of 24-hour Daily Exposure of Continuous Subcutaneous Infusion of ABBV-951 in Subjects With Parkinson's Disease | Parkinson's Disease (PD) | Drug: ABBV-951 | AbbVie | Recruiting | 30 Years | N/A | All | 130 | Phase 3 | United States;Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom | |
60 | NCT03899324 | April 26, 2019 | 26 August 2019 | Evaluation of the Efficacy and Safety of Bumetanide in Parkinson's Disease | A Randomized Double-blind Placebo-controlled Multicenter Proof-of-concept Trial to Assess the Efficacy and Safety of Bumetanide in Parkinson's Disease | Parkinson Disease | Drug: Bumetanide white, oblong, scored tablet;Drug: Placebo white, oblong, scored tablet | B&A Therapeutics | Recruiting | 40 Years | 80 Years | All | 40 | Phase 2 | France | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
61 | JPRN-JapicCTI-194763 | 22/4/2019 | 16 July 2019 | Safety and PK study of LY03003 | An open-label study in Japanese patients with Parkinson's disease to evaluate the safety, pharmacokinetics and preliminary efficacy of LY03003 following intramuscular injections and its comparative bioavailability to Rotigotine transdermal patch. | Parkinson's Disease | Intervention name : Rotigotine INN of the intervention : Rotigotine Dosage And administration of the intervention : LY03003 IM injections 14, 28 and 56 mg/week. Control intervention name : Rotigotine INN of the control intervention : Rotigotine Dosage And administration of the control intervention : Rotigotine transdermal patch applications 4.5, 9 and 18 mg/day. | Shandong Luye Pharmaceutical Co., Ltd./CMIC Co., Ltd. | Recruiting | 20 | BOTH | 32 | Phase 1 | Japan | ||
62 | NCT03661125 | April 11, 2019 | 26 August 2019 | SRC Inhibition as a Potential Target for Parkinson's Disease Psychosis | A Randomised, Balanced, Double-blind Two-way Crossover Design Study to Evaluate the Effects of SRC Kinase Inhibitor, Saracatinib, on Brain Activity Associated With Visual Processing in Patients With Parkinson's Disease Psychosis. | Parkinson Disease Psychosis | Drug: Saracatinib;Drug: Placebo Oral Tablet | King's College London | AstraZeneca;King's College Hospital NHS Trust | Recruiting | 40 Years | N/A | All | 30 | Early Phase 1 | United Kingdom |
63 | NCT03775096 | April 4, 2019 | 24 June 2019 | Adrenergic Blockers for Cardiac Changes in Early Parkinson's Disease | The Effect of Adrenergic Blocker Therapy on Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's Disease | REM Sleep Behavior Disorder;Pre-motor Parkinson Disease;Symptomatic Parkinson Disease | Drug: Carvedilol | Michele Tagliati, MD | Recruiting | 30 Years | 75 Years | All | 15 | Phase 2 | United States | |
64 | NCT03877510 | April 3, 2019 | 28 October 2019 | Open Label Extension (OLE) Study of the Safety and Clinical Utility of IPX203 in PD Patients With Motor Fluctuations | An Open-label Extension Study of the Safety and Clinical Utility of IPX203 in Parkinson's Disease Patients With Motor Fluctuations | Parkinson Disease | Drug: IPX203 140 mg;Drug: IPX203 210 mg;Drug: IPX203 280 mg;Drug: IPX203 350 mg | Impax Laboratories, LLC | Recruiting | 40 Years | N/A | All | 300 | Phase 3 | United States;Czechia;Germany;Italy;Spain | |
65 | JPRN-jRCTs051180214 | 29/03/2019 | 10 September 2019 | The usefulness of flutemetamol for diagnostic imaging of neurogenerative disease | The usefulness of brain amyloid image using flutemetamol and glucose metabolism for the neurogenerative disease - The usefulness of brain amyloid image using flutemetamol and glucose metabolism for the neurogenerative disease | Alzheimer's disease,Dementia with Lewy Bodies,Parkinson's syndrome,Frontotemporal lober degeneration Alzheimer's disease, Dementia with Lewy Bodies, Parkinson's syndrome, Frontotemporal lober degeneration, Parkinson's disease, Mild cognitive impairment, Non-Alzheimer's disease, Progressive aphasia, Neurodegenerative disease, Cerebral corticobasal degeneration, Progressive supranuclear palsy | Amyloid PET: Given the flutemetamol (3mL) intravenously FDG-PET:Given the FDG scanR (3mL) intravenously | Yoshiaki Itoh | Recruiting | Ages 20 and over | N/A | Both | 100 | N/A | none | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
66 | NCT03922711 | March 26, 2019 | 14 October 2019 | A Study to Assess the Safety and Effectiveness of Pridopidine Compared to Placebo in the Treatment of Levodopa-Induced Dyskinesia in Patients With Parkinson's Disease | A 14-week, Double-blind, Randomized, Three-arm, Parallel Group Study to Assess the Efficacy and Safety of Two Doses of Pridopidine Versus Placebo for the Treatment of Levodopa-induced Dyskinesia in Patients With Parkinson's Disease (gLIDe) | Parkinson Disease | Drug: Pridopidine;Drug: Placebo | Prilenia | Recruiting | 30 Years | 85 Years | All | 135 | Phase 2 | United States | |
67 | NCT03716570 | March 12, 2019 | 30 September 2019 | A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Japanese Participants With Parkinson's Disease | A Multicenter, Blinded, Placebo-Controlled, Randomized, Single and Multiple-Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Japanese Subjects With Parkinson's Disease | Parkinson's Disease | Drug: BIIB054;Drug: Placebo | Biogen | Recruiting | 40 Years | 80 Years | All | 24 | Phase 1 | Japan | |
68 | ChiCTR1900021760 | 2019-03-09 | 30 April 2019 | Effect-site concentration of remifentanil for I-gel insertion in male patients with Parkinson’s disease undergoing deep brain stimulator implantation during target-controlled infusion of propofol | Effect-site concentration of remifentanil for I-gel insertion in male patients with Parkinson’s disease undergoing deep brain stimulator implantation during target-controlled infusion of propofol | Parkinson’s disease | Parkinson’s disease:propofol and remifentanil;Non-Parkinson’s disease:propofol and remifentanil; | The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China | Recruiting | 40 | 64 | Male | Parkinson’s disease:25;Non-Parkinson’s disease:25; | N/A | China | |
69 | NCT03816020 | March 9, 2019 | 20 May 2019 | NAD-supplementation in Drug naïve Parkinson's Disease | NAD-PARK: A Double-blinded Randomized Pilot Trial of NAD-supplementation in Drug naïve Parkinson's Disease | Parkinson Disease;Neurodegenerative Diseases | Dietary Supplement: Nicotinamide Riboside;Other: Placebo | Haukeland University Hospital | Recruiting | 18 Years | N/A | All | 30 | N/A | Norway | |
70 | NCT03887884 | March 5, 2019 | 26 August 2019 | Pharmacokinetic Study of CVT-301 (Levodopa Inhalation Powder) | Randomized, Multi-center, Open-label, Crossover Pharmacokinetic Study of CVT-301 (Levodopa Inhalation Powder) and an Oral Dose of Carbidopa/Levodopa CD/LD Under Fed Conditions in Patients With Parkinson's Disease | Parkinson's Disease | Drug: CVT-301;Drug: Sinemet | Acorda Therapeutics | Not recruiting | 30 Years | 85 Years | All | 23 | Phase 1 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
71 | NCT03865121 | March 4, 2019 | 11 November 2019 | Pilot Trial of Transnasal Nicotine in Parkinson Disease | Uncontrolled Pilot Trial of Transnasal Nicotine in Parkinson Disease | Parkinson Disease | Drug: Nicotine Nasal Spray 10 MG/ML (0.5 MG/SPRAY) | El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez | Howard University | Not recruiting | 60 Years | N/A | All | 6 | Phase 2 | Mexico |
72 | JPRN-jRCTs031180248 | 01/03/2019 | 22 July 2019 | N/A | Intervention study for the effect of Istradefylline on adjustment of Levodopa in Parkinson's Disease - Istra adjust PD | Parkinson's disease | Arm with treatment of Istradefylline and levodopa Treatment with Istradefylline will be started at a dose of 20 mg administered once daily at Week 0. The dose of Istradefylline will be increased to 40 mg once daily if the patient has no tolerability issues and still has motor symptoms at Week 1. Dose reduction is possible if the patient has tolerability issues. Patients will visit every 4 weeks from the following day of Week0, and 50mg levodopa will be added of if CGI-S score >=4 every time. Dose reduction is possible if the patient has tolerability issues. Arm without treatment of Istradefylline 50mg levodopa will be added at Week 0. Patients will visit every 4 weeks from the following day of Week0, and 50mg levodopa will be added of if CGI-S score >=4 every time. Dose reduction is possible if the patient has tolerability issues. | Taku Hatano | Kyowa Hakko Kirin Co., Ltd | Recruiting | >=30 age old | <=84 age old | Both | 100 | N/A | none |
73 | NCT03858270 | March 1, 2019 | 11 March 2019 | Inhibition of a-synuclein Cell-cell Transmission by NMDAR Blocker, Memantine | Inhibition of a-synuclein Cell-cell Transmission by NMDAR Blocker, Memantine | Parkinson Disease | Drug: Memantine;Other: Placebo | Wayne State University | Not recruiting | 45 Years | 85 Years | All | 50 | Phase 3 | ||
74 | NCT03820037 | March 2019 | 11 February 2019 | Relative Bioavailability and Bioequivalence of Opicapone | A Phase I, Open-Label, Randomised, Three-Period, Three-Sequence, Partial Replicate Crossover Study to Investigate the Relative Bioavailability and Bioequivalence of Opicapone Obtained From Two Different Sources, Under Fasting Conditions After Single-dose Administration in Healthy Subjects | Parkinson Disease | Drug: Ongentys;Drug: BIA 9-1067 (test) | Bial - Portela C S.A. | Not recruiting | 18 Years | 55 Years | All | 45 | Phase 1 | United Kingdom | |
75 | NCT03841604 | February 28, 2019 | 18 March 2019 | Effect of Safinamide on Parkinson's Disease Related Chronic Pain | A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Safinamide 100mg Once Daily, as add-on Therapy, in Idiopathic Parkinson's Disease (PD) Patients With Motor Fluctuations and PD Related Chronic Pain | Idiopathic Parkinson Disease | Drug: Safinamide Methanesulfonate;Drug: Safinamide methanesulfonate matching placebo | Zambon SpA | Recruiting | 30 Years | N/A | All | 177 | Phase 4 | Austria;France;Germany;Italy;Spain | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
76 | NCT03830528 | February 26, 2019 | 25 March 2019 | A Study of Single and Multiple Doses of KW-6356 in Healthy Subjects | A Phase I Study of KW-6356 in Japanese and Caucasian Healthy Adults | Parkinson's Disease | Drug: KW-6356 Low Dose;Drug: KW-6356 Middle Dose;Drug: KW-6356 High Dose;Drug: KW-6356 X Dose;Drug: KW-6356 Y Dose;Drug: Placebo | Kyowa Hakko Kirin Co., Ltd | Recruiting | 20 Years | 44 Years | Male | 48 | Phase 1 | Japan | |
77 | NCT03655236 | February 18, 2019 | 28 October 2019 | PROSEEK: A Phase 2 Study In Early Parkinson's Disease Patients Evaluating The Safety And Efficacy Of Abl Tyrosine Kinase Inhibition Using K0706 | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of K0706 in Subjects With Early Parkinson's Disease | Early Parkinson Disease | Drug: K0706;Other: placebo | Sun Pharma Advanced Research Company Limited | Recruiting | 50 Years | N/A | All | 504 | Phase 2 | United States;Hungary | |
78 | NCT03968744 | February 18, 2019 | 11 June 2019 | Effect of Safinamide on Sleep Quality in Patients With Parkinson's Disease | A Prospective, Open Label, Single Arm, Clinical Study to Evaluate the Effect of Safinamide on Sleep Quality and Polysomnographic Parameters in Patients With Parkinson's Disease: the Safe Sleep Study | Idiopathic Parkinson's Disease (at Later Stage) | Drug: Safinamide | Alain Kaelin | Clinical Trial Unit Ente Ospedaliero Cantonale | Recruiting | 18 Years | N/A | All | 23 | Phase 4 | Switzerland |
79 | NCT03413384 | February 15, 2019 | 4 March 2019 | To Assess the Efficacy and Safety of Ceftriaxone in Patients With Mild to Moderate Parkinson's Disease Dementia | A Randomized, Double Blinded, Placebo-controlled Phase II Study to Assess the Efficacy and Safety of Ceftriaxone in Patients With Mild to Moderate Parkinson's Disease Dementia | Parkinson's Disease Dementia | Drug: Ceftriaxone;Other: Placebo | BrainX Corporation | Recruiting | 50 Years | 80 Years | All | 106 | Phase 2 | Taiwan | |
80 | NCT03815071 | February 1, 2019 | 11 February 2019 | A Study on the Treatment of Parkinson's Disease With Autologous Neural Stem Cells | Clinical Study of the Safety and Efficacy of Autologous Neural Stem Cells in the Treatment of Parkinson's Disease | Parkinson Disease | Drug: Ips-nsc cells | Allife Medical Science and Technology Co., Ltd. | The First People's Hospital of Yunnan Province/First People's Hospital of Yunan Provinve New Kunhua Hospital;Henan Provincial Hospital;Beijing Hospital | Not recruiting | 18 Years | 60 Years | All | 10 | Early Phase 1 | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
81 | NCT03845387 | February 2019 | 4 March 2019 | A Clinical Study of KDT-3594 in Patients With Early Parkinson's Disease. | A Phase II Clinical Study of KDT-3594 in Patients With Early Parkinson's Disease. | Parkinson Disease | Drug: KDT-3594;Drug: Pramipexole | Kissei Pharmaceutical Co., Ltd. | Recruiting | 20 Years | 79 Years | All | 100 | Phase 2 | Japan | |
82 | NCT03790670 | January 30, 2019 | 26 August 2019 | Biomarker Assessments of Leukine During Treatment of Parkinson's Disease | Safety, Tolerability and Biomarker Assessments of Leukine (Sargramostim) During Extended Timed Treatment for Parkinson's Disease: A Phase I Pilot Study | Parkinson Disease | Drug: sargramostim | University of Nebraska | Not recruiting | 35 Years | 85 Years | All | 5 | Phase 1 | United States | |
83 | EUCTR2017-002426-20-AT | 22/01/2019 | 30 April 2019 | Effect of Safinamide on Parkinson’s Disease Related Chronic Pain | A randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of safinamide 100 mg once daily, as add-on therapy, in idiopathic Parkinson’s Disease (IPD) patients with motor fluctuations and PD related chronic pain - Pain study | Idiopathic Parkinson's Disease, Hoehn and Yahr stage between 2-3 inclusive during the “ON” phase, experiencing motor fluctuations while on stable doses of L-Dopa (with or without benserazide/carbidopa, with or without addition of a catechol O-methyltransferase (COMT) inhibitor) and may be on stable doses of other PD medications (a dopamine agonist, an anticholinergic and/or amantadine), yet are experiencing more than 2 hours of OFF time per day and chronic PD related pain. MedDRA version: 20.0 Level: LLT Classification code 10013113 Term: Disease Parkinson's System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Xadago Product Name: Xadago Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Safinamide methansulfonate CAS Number: 202825-46-5 Other descriptive name: SAFINAMIDE METHANESULFONATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Trade Name: Xadago Product Name: Xadago Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Safinamide methansulfonate CAS Number: 202825-46-5 Other descriptive name: SAFINAMIDE METHANESULFONATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use | Zambon SpA | Authorised | Female: yes Male: yes | 177 | Phase 4 | Spain;Austria | |||
84 | NCT03826134 | January 17, 2019 | 23 April 2019 | A Positron Emission Tomography (PET) Study to Examine the Brain Binding Properties of a Novel Radioactive Compound [11C]-PXT012253 in Healthy Subjects | Interventional, Phase I, Open-label, First in Human, Single-center Positron Emission Tomography (PET) Study Investigating Test-retest Properties of [11C]-PXT012253 as a Radiotracer in Healthy Subjects | Parkinson Disease | Drug: [11C]PXT012253 | H. Lundbeck A/S | Not recruiting | 20 Years | 50 Years | All | 7 | Early Phase 1 | Sweden | |
85 | JPRN-UMIN000035602 | 2019/01/11 | 2 April 2019 | Hydrogen gas inhalation randomized double blinded trial for Parkinson's disease | Parkinson's disease | hydrogen gas16 weeks inhalation two times of the inhalation for 60 minutes per day 8 weeks obsebation after the inhalation placebo gas 16 weeks inhalation two times of the inhalation for 60 minutes per day 8 weeks obsebation after the inhalation | Juntendo University Koshigaya Hospital | Recruiting | 40years-old | 80years-old | Male and Female | 20 | Not selected | Japan | ||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
86 | NCT03638479 | January 8, 2019 | 11 June 2019 | Utilizing Smart Devices to Identify New Phenotypical Characteristics in Movement Disorders | Utilizing Smart Devices to Identify New Phenotypical Characteristics in Movement Disorders | Parkinson Disease;Essential Tremor;Movement Disorders;Parkinson's Syndrome;Atypical Parkinsonism | Other: Data Capture | Westfälische Wilhelms-Universität Münster | Recruiting | 18 Years | N/A | All | 500 | Phase 2 | Germany | |
87 | NCT03659682 | January 2, 2019 | 17 September 2018 | GLP1R in Parkinson's Disease | Effect of GLPIR Stimulation on Neuroprotection and Inflammation in Parkinson's Disease | Parkinson Disease | Drug: Semaglutide | Oslo University Hospital | Not recruiting | 40 Years | 75 Years | All | 120 | Phase 2 | ||
88 | NCT03727295 | January 1, 2019 | 12 November 2018 | Idebenone Treatment of Early Parkinson's Diseasesymptoms | A Multicenter, Randomized, Double-blind, Placebo-controlled Study of Idebenone in the Treatment of Early-stage Parkinson's Disease With Motor and Non-motor Symptoms | Oxidative Stress is an Important Cause of Parkinson's Disease | Drug: Idebenone/placebo | Second Affiliated Hospital of Soochow University | Qilu Pharmaceutical Co., Ltd. | Not recruiting | 30 Years | 80 Years | All | 180 | Phase 4 | |
89 | ChiCTR1800019942 | 2018-12-31 | 10 December 2018 | A Multicenter Randomized Controlled Trial for Effect of Zishen Pingchan Granules Combined with Pramipexole in the treatment of Depression in Parkinson’s Disease | A Multicenter Randomized Controlled Trial for Effect of Zishen Pingchan Granules Combined with Pramipexole in the treatment of Depression in Parkinson’s Disease | Parkinson’s Disease | Experimental group:Zishen Pingchan Granules combined with Pramipexole;Control group:Zishen Pingchan Granules placebo combined with Pramipexole; | The Affiliated Brain Hospital of Nanjing Medical University( Nanjing Brain Hospital) | Not Recruiting | 30 | 85 | Both | Experimental group:150;Control group:150; | New Treatment Measure Clinical Study | China | |
90 | NCT03391882 | December 19, 2018 | 11 November 2019 | A Study of an Investigational Drug to See How it Affects the People With Parkinson's Disease Complicated by Motor Fluctuations (OFF Episodes) Compared to an Approved Drug Used to Treat People With Parkinson's Disease Complicated by Motor Fluctuations (OFF Episodes) | An Open-Label, Randomized, Crossover Trial Utilizing a Single-Blinded Rater to Evaluate APL-130277 Compared to Subcutaneous Apomorphine in Levodopa Responsive Subjects With Parkinson's Disease Complicated by Motor Fluctuations | Motor OFF Episodes Associated With Parkinson's Disease | Drug: APL-130277;Drug: subcutaneous apomorphine | Sunovion | Recruiting | 18 Years | N/A | All | 106 | Phase 3 | Austria;France;Germany;Italy;Spain;United Kingdom | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
91 | NCT03781791 | December 10, 2018 | 29 July 2019 | Orally Administered ENT-01 for Parkinson's Disease-Related Constipation (KARMET) | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate Safety, Tolerability and Efficacy of Orally Administered ENT-01 for the Treatment of Parkinson's Disease-Related Constipation (KARMET) | Constipation;Parkinson Disease | Drug: Active Investigational Treatment ENT-01;Drug: Placebo Treatment | Enterin Inc. | Not recruiting | 30 Years | 90 Years | All | 72 | Phase 2 | United States | |
92 | NCT03710707 | December 4, 2018 | 17 June 2019 | Study to Evaluate DNL201 in Subjects With Parkinson's Disease | A Phase 1b, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL201 in Subjects With Parkinson's Disease | Parkinson Disease | Drug: DNL201 low dose;Drug: DNL201 high dose;Drug: Placebo | Denali Therapeutics Inc. | Recruiting | 30 Years | 75 Years | All | 30 | Phase 1 | United States | |
93 | NCT03944447 | December 1, 2018 | 7 October 2019 | Outcomes Mandate National Integration With Cannabis as Medicine | Outcomes Mandate National Integration With Cannabis as Medicine | Chronic Pain;Chronic Pain Syndrome;Chronic Pain Due to Injury;Chronic Pain Due to Trauma;Fibromyalgia;Seizures;Hepatitis C;Cancer;Crohn Disease;HIV/AIDS;Multiple Sclerosis;Traumatic Brain Injury;Sickle Cell Disease;Post Traumatic Stress Disorder;Tourette Syndrome;Ulcerative Colitis;Glaucoma;Epilepsy;Inflammatory Bowel Diseases;Parkinson Disease;Amyotrophic Lateral Sclerosis;Chronic Traumatic Encephalopathy;Anxiety;Depression;Insomnia;Autism;Opioid-use Disorder;Bipolar Disorder | Drug: Cannabis, Medical | OMNI Medical Services, LLC | Recruiting | 7 Years | N/A | All | 100000 | Phase 2 | United States | |
94 | NCT03639064 | December 2018 | 27 August 2018 | Cannabis Oil for Pain in Parkinson's Disease | A Phase II, Randomized, Open-label, Double-blind, Two-center Study to Evaluate the Tolerability, Safety and Dose-finding of Oil Cannabis Preparation for Pain in Parkinson's Disease | Parkinson Disease | Drug: Cannabis Oil | University Health Network, Toronto | Parkinson Society Canada | Not recruiting | 18 Years | N/A | All | 15 | Phase 2 | |
95 | NCT03942172 | November 27, 2018 | 27 May 2019 | Treatment of Balance Disorders in Parkinson's Patients Using SpotOn Balance Glasses | Treatment of Balance Disorders in Parkinson's Patients Using SpotOn Balance Glasses | Parkinson Disease | Device: SpotOn balance glasses | SpotOn Therapeutics Ltd. | Not recruiting | 30 Years | N/A | All | 50 | N/A | Israel | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
96 | NCT03822364 | November 26, 2018 | 9 September 2019 | Staccato Apomorphine Single and Multi Dose PK | A Randomized Study of the Safety, Tolerability, and Pharmacokinetics of AZ-009 (Staccato Apomorphine) in Healthy Volunteers and the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZ-009 in Subjects With Parkinson's Disease | Parkinson Disease | Drug: 009-5;Drug: 009-4;Drug: 009-3;Drug: 009-2;Drug: 009-0;Drug: active comparator;Drug: 009-1 | Alexza Pharmaceuticals, Inc. | Not recruiting | 18 Years | 60 Years | All | 56 | Phase 1 | Netherlands | |
97 | NCT03823638 | November 20, 2018 | 11 February 2019 | Safety, Tolerability and Effects of Mannitol in Parkinson's Disease | A Phase II Single Center, Randomized, Double Blind and Placebo Controlled Study Assessing the Safety, Tolerability and Effects of Progressively Increased Dose of Oral Mannitol in Parkinson's Disease | Parkinson Disease | Dietary Supplement: Oral D-Mannitol of Placebo | Hadassah Medical Organization | Recruiting | 40 Years | 75 Years | All | 60 | Phase 2 | Israel | |
98 | NCT03713957 | November 12, 2018 | 22 October 2019 | A Study to Assess the Safety of GRF6021 Infusions in Subjects With Parkinson's Disease and Cognitive Impairment | A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Tolerability of GRF6021 Infusions in Subjects With Parkinson's Disease and Cognitive Impairment | Parkinson Disease | Drug: GRF6021;Other: Placebo | Alkahest, Inc. | Michael J. Fox Foundation for Parkinson's Research | Recruiting | 40 Years | 85 Years | All | 90 | Phase 2 | United States;Australia |
99 | NCT03733561 | November 9, 2018 | 11 March 2019 | A Study to Assess Pharmacokinetic Profiles of LY03003 and Neupro | A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetic Profiles of Rotigotine After a Single Dose of LY03003 (28 mg) Versus After a Week of Daily NEUPRO® Transdermal Patch (4 mg Every 24 Hours) in Healthy Volunteers | Parkinson Disease | Drug: LY03003;Drug: Neupro 4Mg/24Hr Transdermal Patch | Luye Pharma Group Ltd. | Recruiting | 18 Years | 45 Years | All | 40 | Phase 1 | United States | |
100 | NCT03667404 | November 6, 2018 | 11 November 2019 | Resistant Maltodextrin for Gut Microbiome in Parkinson's Disease: Safety and Tolerability Study | Gut Microbial Remodeling With Resistant Maltodextrin for Motor and Non-motor Symptoms in Parkinson's Disease: Safety and Tolerability Study | Parkinson Disease;Intestinal Bacteria Flora Disturbance;Dietary Modification | Dietary Supplement: Resistant maltodextrin;Dietary Supplement: maltodextrin | Northwestern University | University of Illinois at Chicago | Recruiting | 60 Years | N/A | All | 30 | Phase 2 | United States |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
101 | NCT03670953 | November 6, 2018 | 11 November 2019 | A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Patients With Motor Fluctuations | A Randomized Controlled Study to Compare the Safety and Efficacy of IPX203 With Immediate-Release Carbidopa-Levodopa in Parkinson's Disease Patients With Motor Fluctuations | Parkinson's Disease (Disorder) | Drug: IR CD-LD;Drug: IPX203 ER CD-LD;Other: IPX203 placebo;Other: IR CD-LD placebo | Impax Laboratories, LLC | Recruiting | 40 Years | N/A | All | 510 | Phase 3 | United States;Czechia;France;Germany;Italy;Spain | |
102 | NCT03069911 | November 1, 2018 | 26 August 2019 | Trial of OnabotulinumtoxinA for Depression in Parkinson Disease | Randomized Controlled Trial of OnabotulinumtoxinA for Depression in Parkinson Disease | Parkinson Disease;Depression | Biological: OnabotulinumtoxinA;Biological: Control | Johns Hopkins University | Not recruiting | 18 Years | 95 Years | All | 3 | Phase 1 | United States | |
103 | NCT03727139 | November 1, 2018 | 19 November 2018 | Rasagiline Tablets Special Drug Use-Results Survey Survey on Long-term Safety | AZILECT Tablets Special Drug Use-Results Survey Survey on Long-term Safety | Parkinson's Disease | Drug: Rasagiline | Takeda | Recruiting | N/A | N/A | All | 1000 | N/A | Japan | |
104 | EUCTR2017-003415-19-ES | 31/10/2018 | 7 January 2019 | A Clinical Study in Parkinson’s Disease Patients With Moderate to Severe Abnormal Movements to See If JM-010 is Effective and Safe/Tolerable. | A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study in Parkinson’s Disease Patients With Moderate to Severe Dyskinesia to Assess the Efficacy and Safety/Tolerability of Two Dose Combinations Of JM-010 | Parkinson’s Disease Patients With Moderate to Severe Dyskinesia;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: JM-010 Product Code: JM-010 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Buspirone hydrochloride CAS Number: 33386-08-2 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 4- INN or Proposed INN: Zolmitriptan CAS Number: 139264-17-8 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.8- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Name: JM-010 Product Code: JM-010 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Buspirone hydrochloride CAS Number: 33386-08-2 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 8- INN or Proposed INN: Zolmitriptan CAS Number: 139264-17-8 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.8- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use | Contera Pharma | Authorised | Female: yes Male: yes | 81 | Phase 2 | France;Spain;Germany | |||
105 | ChiCTR1800017949 | 2018-10-30 | 27 August 2018 | Clinical study for the effect of the combination of Shudipingchan prescription and Monoamine oxidase inhibitor on improving early PD symptoms and delaying the progression of the disease | Clinical study for the effect of the combination of Shudipingchan prescription and Monoamine oxidase inhibitor on improving early PD symptoms and delaying the progression of the disease | Parkinson's disease | Group 1:Selegiline and Shudipingchan granule;Group 2:Selegiline and simulant TCM granule; | Longhua Hospital Shanghai University of Traditional Chinese Medicine | Not Recruiting | 30 | 85 | Both | Group 1:72;Group 2:72; | New Treatment Measure Clinical Study | China | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
106 | ChiCTR1800018017 | 2018-10-30 | 3 September 2018 | Clinical study for the effect of the combination of Shudipingchan prescription and Monoamine oxidase inhibitor on improving early Parkinson‘s Disease symptoms and delaying the progression of the disease | Clinical study for the effect of the combination of Shudipingchan prescription and Monoamine oxidase inhibitor on improving early Parkinson‘s Disease symptoms and delaying the progression of the disease | Parkinson's disease | Treatment group:Selegiline+Shudipingchan granule;Control group:Selegiline+TCM simulant; | Longhua Hospital Shanghai University of Traditional Chinese Medicine | Not Recruiting | 30 | 85 | Both | Treatment group:92;Control group:92; | New Treatment Measure Clinical Study | China | |
107 | EUCTR2017-002426-20-ES | 19/10/2018 | 7 January 2019 | Effect of Safinamide on Parkinson’s Disease Related Chronic Pain | A randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of safinamide 100 mg once daily, as add-on therapy, in idiopathic Parkinson’s Disease (IPD) patients with motor fluctuations and PD related chronic pain - Pain study | Idiopathic Parkinson's Disease, Hoehn and Yahr stage between 2-3 inclusive during the “ON” phase, experiencing motor fluctuations while on stable doses of L-Dopa (with or without benserazide/carbidopa, with or without addition of a catechol O-methyltransferase (COMT) inhibitor) and may be on stable doses of other PD medications (a dopamine agonist, an anticholinergic and/or amantadine), yet are experiencing more than 2 hours of OFF time per day and chronic PD related pain. MedDRA version: 20.0 Level: LLT Classification code 10013113 Term: Disease Parkinson's System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Xadago Product Name: Xadago Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Safinamide methansulfonate CAS Number: 202825-46-5 Other descriptive name: SAFINAMIDE METHANESULFONATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Trade Name: Xadago Product Name: Xadago Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Safinamide methansulfonate CAS Number: 202825-46-5 Other descriptive name: SAFINAMIDE METHANESULFONATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use | Zambon SpA | Authorised | Female: yes Male: yes | 177 | Phase 4 | Spain | |||
108 | NCT03720418 | October 17, 2018 | 16 September 2019 | Study of OXB-102 (AXO-Lenti-PD) in Patients With Bilateral, Idiopathic Parkinson's Disease | A Phase I/II Safety and Dose Evaluation Study of OXB-102 in Patients With Bilateral Idiopathic Parkinson's Disease | Parkinson Disease | Drug: OXB-102;Other: Imitation Surgical Procedure (ISP) | Axovant Sciences Ltd. | Oxford BioMedica | Recruiting | 48 Years | 70 Years | All | 30 | Phase 1/Phase 2 | France;United Kingdom |
109 | EUCTR2016-004610-95-DE | 01/10/2018 | 4 December 2018 | Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants with Parkinson’s Disease | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, with an Active-Treatment Dose-Blinded Period, to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Subjects with Parkinson’s Disease - SPARK | Parkinson's Disease MedDRA version: 20.0 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: BIIB054 Pharmaceutical Form: Solution for injection/infusion INN or Proposed INN: n/a Current Sponsor code: BIIB054 Other descriptive name: BIIB054 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use | Biogen Idec Research Limited | Authorised | Female: yes Male: yes | 311 | Phase 2 | France;United States;Canada;Spain;Austria;Israel;Germany;Italy;United Kingdom;Sweden | |||
110 | NCT03703570 | September 29, 2018 | 28 January 2019 | A Study of KW-6356 in Patients With Parkinson's Disease on Treatment With Levodopa-containing Preparations | A Phase 2b Study of KW-6356 in Subjects With Parkinson's Disease on Treatment With Levodopa-containing Preparations | Parkinson's Disease | Drug: KW-6356;Drug: Placebo | Kyowa Hakko Kirin Co., Ltd | Recruiting | 20 Years | 80 Years | All | 486 | Phase 2 | Japan | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
111 | NCT03665454 | September 24, 2018 | 26 August 2019 | PF 06412562 in Subjects With Advanced Stage Parkinson's Disease | A Phase Ib Safety, Tolerability, and Efficacy Study of Two Days of Oral Split Dose (25/20 mg) Administration of PF 06412562 in Subjects With Advanced Stage Parkinson's Disease | Parkinson Disease | Drug: PF-06412562;Drug: Standard of Care Placebo | Milton S. Hershey Medical Center | Pfizer | Not recruiting | N/A | N/A | All | 8 | Phase 1 | United States |
112 | NCT03582137 | September 17, 2018 | 4 February 2019 | A Study of Tolerability and Efficacy of Cannabidiol on Motor Symptoms in Parkinson's Disease | A Randomized, Double Blind, Placebo-controlled Parallel Study of Tolerability and Efficacy of Cannabidiol (CBD) on Motor Symptoms in Parkinson's Disease | Parkinson Disease | Drug: Cannabidiol;Other: Placebo | University of Colorado, Denver | Colorado Department of Public Health and Environment | Recruiting | 40 Years | 85 Years | All | 75 | Phase 2 | United States |
113 | NCT03608371 | August 31, 2018 | 17 June 2019 | BTRX-246040 Study in Subjects With Parkinson's Disease With Motor Fluctuations | Phase 2A, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BTRX-246040 in Parkinson's Disease Subjects With Motor Fluctuations | Parkinson Disease;Motor Disorder | Drug: BTRX-246040;Drug: Placebo | BlackThorn Therapeutics, Inc. | Not recruiting | 30 Years | 76 Years | All | 24 | Phase 2 | United States | |
114 | NCT03229174 | August 23, 2018 | 30 September 2019 | Brain Perfusion & Oxygenation in Parkinson's Disease With NOH | Evaluation of Brain Perfusion and Oxygenation in PD Patients With Neurogenic Orthostatic Hypotension: 4 Week Comparison of Droxidopa Versus Placebo | Parkinson Disease;Neurogenic Orthostatic Hypotension | Drug: Droxidopa;Drug: Placebo | William Ondo, MD | Lundbeck LLC | Recruiting | 18 Years | 85 Years | All | 28 | Phase 4 | United States |
115 | NCT03621046 | August 20, 2018 | 21 January 2019 | Use of Low-dose Zolpidem in Parkinson's Disease | A Placebo Controlled Double Blind Randomised Controlled Proof of Concept Study of Zolpidem for the Treatment of Motor and Cognitive Deficits in Late-stage Parkinson's | Parkinson Disease | Drug: Zolpidem;Other: Placebo | Aston University | University Hospital Birmingham NHS Foundation Trust | Recruiting | 40 Years | 80 Years | All | 28 | Phase 2 | United Kingdom |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
116 | NCT03567447 | August 17, 2018 | 4 November 2019 | Effect of L-Dihydroxyphenylserine (L-DOPS) on Falls in Patients With Neurogenic Orthostatic Hypotension (NOH) | Effect of L-Dihydroxyphenylserine (L-DOPS) on Falls in Patients With Neurogenic Orthostatic Hypotension (NOH) | Parkinson Disease;Falls Patient | Drug: Droxidopa;Other: Placebo | St. Joseph's Hospital and Medical Center, Phoenix | H. Lundbeck A/S;Arizona State University | Recruiting | 30 Years | 83 Years | All | 10 | Phase 2 | United States |
117 | NCT03675282 | August 14, 2018 | 7 October 2019 | Quantitative Mapping of Substantia Nigra Iron in Parkinson's Disease (Stages I-IV, REM Sleep Behavior Disorder) and Controls | Quantitative Mapping of Substantia Nigra Iron in Parkinson's Disease and Controls | Parkinson Disease;REM Sleep Behavior Disorder;Healthy | Drug: (11C)PE2I | Weill Medical College of Cornell University | National Institute of Neurological Disorders and Stroke (NINDS) | Recruiting | 20 Years | 100 Years | All | 100 | Phase 1/Phase 2 | United States |
118 | NCT03773796 | August 6, 2018 | 7 October 2019 | Nabilone for Non-motor Symptoms in Parkinson's Disease | Nabilone for Non-motor Symptoms in Parkinson's Disease: An Open-label Study to Evaluate Long-term Safety and Efficacy | Parkinson Disease | Drug: Nabilone 0.25 mg | Medical University Innsbruck | Recruiting | 30 Years | 100 Years | All | 48 | Phase 3 | Austria | |
119 | ChiCTR1800016949 | 2018-08-01 | 9 July 2018 | Efficacy assessment and standard treatment of rasagiline in Chinese patients with early Parkinson's disease | Efficacy assessment and standard treatment of rasagiline in Chinese patients with early Parkinson's disease | Parkinson's disease | Rasagiline early start group:rasagiline-rasagiline;Rasagiline delay start group:placebo-rasagiline; | Beijing Hospital | Not Recruiting | 30 | 80 | Both | Rasagiline early start group:130;Rasagiline delay start group:130; | New Treatment Measure Clinical Study | China | |
120 | ChiCTR1800017084 | 2018-08-01 | 27 August 2019 | Investigation of new approaches and technologies in the management of Parkinson's disease | The efficacy of Butylphthalide on cognitive impairment of patients with idiopathic PD and DBS patients: A Randomized, double-blind, placebo-controlled, multicenter trial | Parkinson's disease | Butylphthalide group:Butylphthalide, 2 capsules/time, 3 times/day, for 48 weeks;Control group:Placebo, 2 capsules/time, 3 times/day, for 48 weeks; | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Recruiting | 18 | 80 | Both | Butylphthalide group:140;Control group:140; | Phase 4 | China | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
121 | JPRN-UMIN000033285 | 2018/08/01 | 22 July 2019 | The preventive effect of medicine for osteoporosis on osteopenia in patients with Parkinson's disease: multicenter/ non-blind/ randomised/ exploratory clinical trial | The preventive effect of medicine for osteoporosis on osteopenia in patients with Parkinson's disease: multicenter/ non-blind/ randomised/ exploratory clinical trial - The preventive effect of medicine for osteoporosis on osteopenia in patients with Parkinson's disease | Parkinson's disease | Oral bisphosphonate agent group: taking orally Minodronic Acid Hydrate (50mg) 1 tablet per 4 weeks Intravenous bisphosphonate agent group: injecting Zoledronic Acid (5mg) 1 ampule per 48 weeks | Department of Orthopaedic Surgery, Niigata University Medical and Dental Hospital | Department of Neurology, Nishi-Niigata Chuo Hospital | Not Recruiting | 50years-old | Not applicable | Male and Female | 100 | Not selected | Japan |
122 | EUCTR2017-005170-19-SE | 30/07/2018 | 7 January 2019 | A Long-Term Follow-up Safety Study for Patients with Parkinson’s Disease (PD) Implanted with the Drug Delivery System (DDS) and/or Who Received Treatment in the Main Study and/or Extension Study | A Long-Term Follow-up Safety Study for Patients with Idiopathic Parkinson’s Disease (PD) Implanted with the DDS and/or Who Received Treatment in the Main Study and/or Extension Study - Long-Term Follow-up Safety After DDS Implantation with/without CDNF Infusions | Idiopathic Parkinson's Disease MedDRA version: 20.0 Level: LLT Classification code 10013113 Term: Disease Parkinson's System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Cerebral Dopamine Neurotrophic Factor Product Code: CDNF Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Not Applicable Other descriptive name: recombinant human Cerebral Dopamine Neurotrophic Factor Concentration unit: µg/µl microgram(s)/microlitre Concentration type: equal Concentration number: 1.0- | Renishaw plc | Authorised | Female: yes Male: yes | 20 | Phase 1;Phase 2 | Sweden | |||
123 | NCT03599726 | July 30, 2018 | 26 August 2019 | Improving Walking Automaticity in Parkinson's Disease: Levodopa or Donepezil | Improving Walking Automaticity in Parkinson's Disease: Levodopa or Donepezil | Parkinson Disease | Drug: Donepezil;Drug: Placebo | Oregon Health and Science University | Medical Research Foundation, Oregon | Recruiting | 50 Years | 90 Years | All | 20 | Early Phase 1 | United States |
124 | NCT03611569 | July 25, 2018 | 30 September 2019 | Lu AF82422 in Healthy Non-Japanese and Japanese Subjects and in Patients With Parkinson's Disease | Interventional, Randomized, Double-blind, Sequential-group, Placebo-controlled, Single-ascending-dose Study Investigating the Safety, Tolerability and Pharmacokinetic and Pharmacodynamic Properties of Lu AF82422 in Healthy Non-Japanese and Japanese Subjects and in Patients With Parkinson's Disease | Healthy;Parkinson Disease | Drug: Lu AF82422;Drug: Placebo | H. Lundbeck A/S | Recruiting | 18 Years | 80 Years | All | 44 | Phase 1 | United States | |
125 | NCT03587168 | July 20, 2018 | 5 November 2018 | The Reliability, Validity, and Responsiveness of the Timed 360° Turn Test in Patients With Parkinson's Disease | The Reliability, Validity, and Responsiveness of the Timed 360° Turn Test in Patients With Parkinson's Disease | Parkinson Disease | Other: Four Square Step Test;Other: Functional Reach Test;Other: Trunk Impairment Scale;Other: Timed Up and Go Test;Other: Hoehn and Yahr Scale;Other: Unified Parkinson's Disease Rating Scale;Other: Berg Balance Scale;Other: the timed 360° turn test | Gazi University | Not recruiting | 40 Years | N/A | All | 86 | Phase 3 | Turkey | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
126 | JPRN-jRCTs052180158 | 19/07/2018 | 22 July 2019 | The effect of rehabilitation robots for patients with Parkinson's disease. | A study on the effectiveness of balance rehabilitation support robot (balance exercise assist robot) for Parkinson's patient. | Parkinson's Disease;D010300 | Robot group: The participants performs twelve per a session, 2sessions per a week for 8 weeks. Control group: The participants receives balance exercise by physical therapist twice a week for 8 weeks. | Kazuhisa Domen | Recruiting | 40 age old | 80 age old | Both | 50 | N/A | none | |
127 | NCT03594656 | July 15, 2018 | 11 June 2019 | Effects of Lingzhi on Disease Progression in Patients With Untreated Early Parkinson's Disease | Effects of Lingzhi on Disease Progression in Patients With Untreated Early Parkinson's Disease: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial | Parkinson Disease | Drug: Ganoderma;Drug: Placebos | Xuanwu Hospital, Beijing | Recruiting | 30 Years | 80 Years | All | 288 | Phase 3 | China | |
128 | NCT03624920 | July 12, 2018 | 7 October 2019 | Safety and Efficacy of THN102 in Patients With Parkinson's Disease and Excessive Daytime Sleepiness | Safety and Efficacy of THN102 in Patients With Parkinson's Disease and Excessive Daytime Sleepiness | Parkinson Disease | Drug: THN102 Dosage A;Drug: THN102 Dosage B;Drug: THN102 Dosage C | Theranexus | Not recruiting | 18 Years | 80 Years | All | 71 | Phase 2 | United States;Czechia;France;Germany;Hungary | |
129 | NCT03774459 | July 9, 2018 | 26 August 2019 | ANAVEX2-73 Study in Parkinson's Disease Dementia | A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of ANAVEX2-73 for Cognitive Impairment in Patients With Parkinson's Disease With Dementia | Parkinsons Disease With Dementia | Drug: High dose ANAVEX2-73;Drug: Mid dose ANAVEX2-73;Drug: Placebo oral capsule | Anavex Life Sciences Corp. | Anavex Germany GmbH | Recruiting | 50 Years | 85 Years | All | 120 | Phase 2 | Australia;Spain |
130 | NCT03146130 | July 5, 2018 | 20 August 2018 | Study of the Efficacy of N-acetylcysteine (NAC) on Impulse Control Disorders | Study of the Efficacy of N-acetylcysteine (NAC) on Impulse Control Disorders (TCI) Induced by Dopaminergic Treatments in Parkinson's Disease | Impulse Control Disorder;Parkinson | Biological: Variation of behaviors of Parkinson's disease | Centre Hospitalier Universitaire, Amiens | Recruiting | 18 Years | N/A | All | 70 | Phase 3 | France | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
131 | NCT03775538 | July 5, 2018 | 25 March 2019 | Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease. Extension to HP-CD-CL-2002 Clinical Study | A Randomised, Double-Blind, Multi-centre, Active Treatment, Extension and Safety Study for Patients With Idiopathic Parkinson's Disease (PD) Who Previously Completed the CDNF/DDS Main Study HP-CD-CL-2002 | Parkinson Disease;Movement Disorders;Neuro-Degenerative Disease;Nervous System Diseases;Brain Diseases | Drug: Cerebral Dopamine Neurotrophic Factor;Device: Renishaw Drug Delivery System | Herantis Pharma Plc. | Renishaw plc. | Recruiting | 35 Years | 75 Years | All | 18 | Phase 1/Phase 2 | Finland;Sweden |
132 | EUCTR2017-004335-36-ES | 04/07/2018 | 24 September 2018 | A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of ANAVEX2-73 for Cognitive Impairment in Parkinson’s Disease with Dementia Patients. | A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of ANAVEX2-73 for Cognitive Impairment in Parkinson’s Disease with Dementia Patients. - A Phase II Study to Evaluate the Safety, Tolerability, and Efficacy of ANAVEX2-73 | Cognition in Parkinson’s Disease with dementia;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: ANAVEX2-73 Pharmaceutical Form: Capsule INN or Proposed INN: ANAVEX2-73 Current Sponsor code: ANAVEX2-73 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Product Name: ANAVEX2-73 Pharmaceutical Form: Capsule INN or Proposed INN: ANAVEX2-73 Current Sponsor code: ANAVEX2-73 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- | Anavex Life Sciences Corp. | Authorised | Female: yes Male: yes | 120 | Phase 2 | Spain | |||
133 | NCT03521635 | July 3, 2018 | 4 November 2019 | The SUSTAIN Study Compares the Effects of Sustained and Immediate-release Pramipexole on the noctUrnal Symptoms of paTients With Advanced ParkInsoN's Disease Who Also Take L-Dopa | A Two- Stage Multicenter, Open-label, Randomized, Active Controlled Parallel Group Study Comparing the Efficacy and Safety of Pramipexole SR Versus Pramipexole IR Administered Orally Over an 18-week Treatment on Nocturnal Symptoms in L-Dopa+ Treated Patients With Advanced Parkinson's Disease (PD) | Parkinson Disease | Drug: Pramipexole SR;Drug: Pramipexole IR | Boehringer Ingelheim | Not recruiting | 30 Years | N/A | All | 98 | Phase 4 | China | |
134 | JPRN-UMIN000033409 | 2018/07/02 | 2 April 2019 | Prevention of local skin reaction by heparinoid due to rotigotine transdermal patch: a pilot randomized clinical trial. | Parkinson's disease | Pretreatment by heparinoid In the pretreatment group, heparinoid is applied daily to the sites (shoulder, upper arm, abdomen, thigh, buttocks on both sides) to be applied rotigotine transdermal patch from the beginning of 1 week before. The dose is one finger tip unit (about 0.5 g) for two palms. The period is 8 weeks. Non-pretreatment by heparinoid. The non-pretreatment group use rotigotine without using heparinoid. The period is 8 weeks. | Wakayama Medical University | Recruiting | 20years-old | 85years-old | Male and Female | 20 | Phase 1 | Japan | ||
135 | NCT03566589 | July 2, 2018 | 20 August 2018 | Effects of PS128 on Parkinsonian Symptoms | Effects of Lactobacillus Plantarum PS128 on the Parkinsonian Symptoms in Parkinson's Disease: a Pilot Study | Parkinson Disease | Dietary Supplement: Lactobacillus plantarum PS128 | Professor Lu Neurological Clinic | Not recruiting | 40 Years | 80 Years | All | 30 | N/A | Taiwan | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
136 | JPRN-UMIN000033454 | 2018/07/01 | 2 April 2019 | A study on the effectiveness of balance rehabilitation support robot (balance exercise assist robot) for Parkinson's patient. | Parkinson's Disease | robot assisted balance training (RABT) The group is taken 40-minute / session, twice a week during 8-weeks. Total intervention sessions are 16. traditional balance training (TBT) The group is taken 40-minute / session, twice a week during 8-weeks. Total intervention sessions are 16. | Hyogo College of Medicine | Recruiting | 40years-old | 80years-old | Male and Female | 50 | Not selected | Japan | ||
137 | NCT03576638 | July 2018 | 16 July 2018 | Study to Assess Pharmacokinetics of Accordion Pill Carbidopa-Levodopa Compared to Immediate Release Carbidopa-Levodopa in Parkinson's Disease Patients | An Open Label Phase 2 Study to Assess the Pharmacokinetics of the Accordion Pill Carbidopa-Levodopa Compared to Immediate Release Carbidopa-Levodopa in Patients With Parkinson's Disease | Parkinson Disease | Drug: Accordion Pill Carbidopa/Levodopa;Drug: Sinemet CR 25Mg-100Mg Extended-Release Tablet | Intec Pharma Ltd. | Not recruiting | 30 Years | N/A | All | 12 | Phase 2 | ||
138 | NCT03562494 | June 28, 2018 | 22 October 2019 | VY-AADC02 for Parkinson's Disease With Motor Fluctuations | A Randomized, Placebo Surgery Controlled, Double-blinded, Multi-center, Phase 2 Clinical Trial, Evaluating the Efficacy and Safety of VY-AADC02 in Advanced Parkinson's Disease With Motor Fluctuations | Parkinson Disease | Biological: VY-AADC02;Other: Placebo | Neurocrine Biosciences | Voyager Therapeutics | Recruiting | 40 Years | 75 Years | All | 42 | Phase 2 | United States |
139 | NCT03407378 | June 26, 2018 | 16 September 2019 | A Study to Investigate a New Treatment in Patients With Parkinson's Disease | A Proof of Concept Study to Investigate the Effect of IPT803 Adjunct Treatment in Patients With Parkinson's Disease | Parkinson Disease | Drug: IPT803;Genetic: Optional pharmacogenetic assessment;Other: Questionnaires;Other: Optional Blood-Oxygen-level Dependent functionalMRI;Other: Motor Assessments before taking regular PD treatment;Other: Motor Assessments on regular PD treatment | Tools4Patient | Recruiting | 35 Years | N/A | All | 120 | Phase 1/Phase 2 | United States;Belgium;France | |
140 | EUCTR2017-001420-21-DE | 18/06/2018 | 28 February 2019 | Clinical Efficacy, Safety and Tolerability of P2B001 in Early Parkinson's Disease | A Phase 3, Twelve-week, Multi-Center, Multinational, Randomized, Double-Blind, Double-Dummy, Parallel Group Study to Determine the Efficacy, Safety and Tolerability of P2B001 Once Daily Compared to its Individual Components in Subjects With Early Parkinson’s Disease and to a Calibration Arm of Pramipexole ER. | Early Parkinson's Disease MedDRA version: 20.0 Level: HLT Classification code 10034005 Term: Parkinson's disease and parkinsonism System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: P2B001 Pharmaceutical Form: Capsule, hard INN or Proposed INN: PRAMIPEXOLE DIHYDROCHLORIDE CAS Number: 191217-81-9 Other descriptive name: PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.6- INN or Proposed INN: Rasagiline mesylate CAS Number: 161735-79-1 Other descriptive name: RASAGILINE MESILATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.75- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Product Name: Pramipexole dihydrochloride Pharmaceutical Form: Capsule, hard INN or Proposed INN: PRAMIPEXOLE DIHYDROCHLORIDE CAS Number: 191217-81-9 Other descriptive name: PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.6- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Product Name: Rasagiline Pharmaceutical Form: Capsule, hard INN or Proposed INN: Rasagiline mesylate CAS Number: 161735-79-1 Other descriptive name: RASAGILINE MESILATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.75- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Trade Name: Pramipexole dihydrochloride extended-release tablets | Pharma Two B Ltd | Authorised | Female: yes Male: yes | 525 | Phase 3 | France;United States;Canada;Spain;Germany | |||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
141 | EUCTR2017-001420-21-ES | 13/06/2018 | 18 June 2018 | Clinical Efficacy, Safety and Tolerability of P2B001 in Early Parkinson's Disease | A Phase 3, Twelve-week, Multi-Center, Multinational, Randomized, Double-Blind, Double-Dummy, Parallel Group Study to Determine the Efficacy, Safety and Tolerability of P2B001 Once Daily Compared to its Individual Components in Subjects With Early Parkinson’s Disease and to a Calibration Arm of Pramipexole ER. | Early Parkinson's Disease MedDRA version: 20.0 Level: HLT Classification code 10034005 Term: Parkinson's disease and parkinsonism System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: P2B001 Pharmaceutical Form: Capsule INN or Proposed INN: PRAMIPEXOLE DIHYDROCHLORIDE CAS Number: 191217-81-9 Other descriptive name: PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.6- INN or Proposed INN: Rasagiline mesylate CAS Number: 161735-79-1 Other descriptive name: RASAGILINE MESILATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.75- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Product Name: Pramipexole dihydrochloride Pharmaceutical Form: Capsule INN or Proposed INN: PRAMIPEXOLE DIHYDROCHLORIDE CAS Number: 191217-81-9 Other descriptive name: PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.6- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Product Name: Rasagiline Pharmaceutical Form: Capsule INN or Proposed INN: Rasagiline mesylate CAS Number: 161735-79-1 Other descriptive name: RASAGILINE MESILATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.75- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Trade Name: Pramipexole dihydrochloride extended-release tablets Product Name: Pramipexole dihydrochloride extended-release tablets Pharmaceutical Form: Tablet INN or Proposed INN: PRAMIPEXOLE DIHYDROCHLORIDE CAS Number: 191217-81-9 Other descriptive name: PRAMIPEXOLE DIHYDROCHLORIDE Concentration unit: mg milligram(s) Concentration type: range Concentration number: 0.375-4.5 Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | Pharma Two B Ltd | Authorised | Female: yes Male: yes | 525 | Phase 3 | France;United States;Canada;Spain;Germany | |||
142 | NCT03439943 | June 13, 2018 | 20 August 2018 | Study to Evaluate the Effect of Lixisenatide in Patient With Parkinson's Disease | Multicenter, Randomised, Placebo-controlled, Double Blinded, Parallel Arm Proof-of-concept Trial of Lixisenatide in Patients With Early Parkinson's Disease | Parkinson Disease | Drug: Lixisenatide;Drug: placebo | University Hospital, Toulouse | Cure Parkinson;Réseau NS-Park;EUCLID;Sanofi | Recruiting | 40 Years | 75 Years | All | 158 | Phase 2 | France |
143 | EUCTR2017-004006-18-NL | 07/06/2018 | 18 June 2018 | The effect of inhaled levodopa on the recovery from off periods in patients with Parkinson's disease | Therapeutic effects of an inhaled levodopa dry powder formulation on the recovery from off periods in patients with Parkinson's disease - Effectiveness of inhaled levodopa in Parkinson's disease | Parkinson's disease is a progressive neurodegenerative disorder characterized by a lack of dopamine production due to the loss of dopamine producing cells in the substantia nigra. This lack of dopamine causes disruption of motor circuits in the brain resulting in motor function impairments like tremor, rigidity and bradykinesia. MedDRA version: 20.0 Level: LLT Classification code 10013113 Term: Disease Parkinson's System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Levodopa powder for inhalation Product Code: Levodopa Cyclops Pharmaceutical Form: Inhalation powder INN or Proposed INN: levodopa CAS Number: 59-92-7 Current Sponsor code: levodopa Other descriptive name: LEVODOPA Concentration unit: mg milligram(s) Concentration type: range Concentration number: 60-90 Trade Name: Madopar 125 mg, orodispersible tablet Pharmaceutical Form: Orodispersible tablet | Pharmaceutical Technology and Biopharmacy, University of Groningen | Authorised | Female: yes Male: yes | 8 | Phase 2 | Netherlands | |||
144 | NCT03456687 | June 5, 2018 | 23 April 2019 | Effects of Exenatide on Motor Function and the Brain | Effects of Exenatide on Motor Function and the Brain | Parkinson's Disease | Drug: Exenatide | University of Florida | National Institute of Neurological Disorders and Stroke (NINDS) | Recruiting | 40 Years | 77 Years | All | 15 | Phase 1 | United States |
145 | EUCTR2018-000346-19-SE | 04/06/2018 | 11 June 2018 | An extended clinical study to test the safety of Cerebral Dopamine Neurotrophic Factor (CDNF) by brain infusion via Drug Delivery System (DDS) in patients with Parkinson's disease. | A Randomised, Double-Blind, Multi-centre, Active Treatment, Extension and Safety Study for Patients with Idiopathic Parkinson’s Disease (PD) Who Previously Completed the CDNF/DDS Main Study HP-CD-CL-2002. - Extension Study | Idiopathic Parkinson's Disease MedDRA version: 20.0 Level: LLT Classification code 10013113 Term: Disease Parkinson's System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Cerebral Dopamine Neurotrophic Factor Product Code: CDNF Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Not Applicable Other descriptive name: recombinant human Cerebral Dopamine Neurotrophic Factor Concentration unit: µg/µl microgram(s)/microlitre Concentration type: equal Concentration number: 1.0- | Herantis Pharma Plc | Authorised | Female: yes Male: yes | 18 | Phase 1;Phase 2 | Sweden | |||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
146 | NCT03684122 | June 1, 2018 | 7 October 2019 | Use of Mesenchymal Stem Cells (MSCs) Differentiated Into Neural Stem Cells (NSCs) in People With Parkinson's (PD). | A Safety and Efficacy Study of the Effects of Mesenchymal Stem Cells (MSCs) Differentiated Into Neural Stem Cells (NSCs) on the Motor and Non-motor Symptoms in People With Parkinson's Disease (PD). | Parkinson Disease | Biological: Injection of Umbilical cord derived MSCs | University of Jordan | Recruiting | 20 Years | 75 Years | All | 10 | Phase 1/Phase 2 | Jordan | |
147 | EUCTR2017-002780-17-ES | 21/05/2018 | 12 November 2018 | Study in Male and Female Patients with Advanced Parkinson’s Disease to Assess the blood levels of Levodopa Administered as ND0612 via a Pump System plus Additional Oral Administered Levodopa/Carbidopa versus Levodopa Administered as Duodopa. | A Pivotal, Open-Label, Randomized, Crossover, Four Sequences Study in Male and Female Patients with Advanced Parkinson’s Disease to Assess the Relative Bioavailability of Levodopa Administered as ND0612 Subcutaneous Infusion via a Pump System plus Additional Oral Administered Levodopa/Carbidopa versus Levodopa Administered as Carbidopa-Levodopa Enteral Suspension | Parkinson’s Disease MedDRA version: 20.0 Level: HLT Classification code 10034005 Term: Parkinson's disease and parkinsonism System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: ND0612 Product Code: ND0612 Pharmaceutical Form: Solution for infusion in administration system INN or Proposed INN: carbidopa CAS Number: 38821-49-7 Current Sponsor code: - Other descriptive name: CARBIDOPA Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 7.5- INN or Proposed INN: levodopa CAS Number: 59-92-7 Current Sponsor code: - Other descriptive name: LEVODOPA Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 60- Trade Name: SINEMET Plus Product Name: SINEMET Pharmaceutical Form: Tablet INN or Proposed INN: levodopa CAS Number: 59-92-7 Other descriptive name: LEVODOPA Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- INN or Proposed INN: carbidopa CAS Number: 38821-49-7 Other descriptive name: CARBIDOPA Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- Trade Name: Duodopa LD/CD 20/5 mg/mL Product Name: Duodopa LD/CD 20/5 mg/mL Pharmaceutical Form: Intestinal gel INN or Proposed INN: levodopa CAS Number: 59-92-7 Other descriptive name: LEVODOPA Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- INN or Proposed INN: carbidopa CAS Number: 38821-49-7 Other descriptive name: CARBIDOPA Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 5- | NeuroDerm Ltd. | Not Recruiting | Female: yes Male: yes | 50 | Phase 3 | France;United States;Spain;Austria;Netherlands;Italy | |||
148 | EUCTR2016-004610-95-ES | 18/05/2018 | 18 June 2018 | Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants with Parkinson’s Disease | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, with an Active-Treatment Dose-Blinded Period, to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Subjects with Parkinson’s Disease - SPARK | Parkinson's Disease MedDRA version: 20.0 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: BIIB054 Pharmaceutical Form: Solution for injection/infusion INN or Proposed INN: n/a Current Sponsor code: BIIB054 Other descriptive name: BIIB054 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use | Biogen Idec Research Limited | Authorised | Female: yes Male: yes | 311 | Phase 2 | France;United States;Canada;Spain;Austria;Israel;Germany;Italy;United Kingdom;Sweden | |||
149 | NCT03589066 | May 15, 2018 | 19 November 2018 | Pharmacokinetic Study of LY03003 in Patients With Parkinson's Disease | An Open-label, Randomized, Parallel-group Trial to Evaluate the Pharmacokinetics of Two Formulations of LY03003 After a Single Intramuscular Injection Administered to Patients With Parkinson's Disease | Parkinson Disease | Drug: LY03003 | Luye Pharma Group Ltd. | Not recruiting | 18 Years | N/A | All | 24 | Phase 1 | United States | |
150 | EUCTR2017-004475-31-CZ | 09/05/2018 | 30 April 2019 | Safety and efficacy study of two THN102 doses in subjects with excessive daytime sleepiness associated with Parkinson’s disease. | Randomised, double-blind, placebo-controlled, complete 3-way cross-over phase IIa trial to investigate safety and efficacy of two THN102 doses in subjects with excessive daytime sleepiness associated with Parkinson’s disease | Excessive daytime sleepiness associated with Parkinson’s disease MedDRA version: 20.0 Level: SOC Classification code 10029205 Term: Nervous system disorders System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10041349 Term: Somnolence System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Flecainide acetate Product Code: THN02 Pharmaceutical Form: Capsule, hard INN or Proposed INN: Flecainidum CAS Number: 54143-56-5 Other descriptive name: FLECAINIDE ACETATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1 - Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Product Name: Flecainide acetate Product Code: THN02 Pharmaceutical Form: Capsule, hard INN or Proposed INN: Flecainidum CAS Number: 54143-56-5 Other descriptive name: FLECAINIDE ACETATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 9 - Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Trade Name: Modiodal Product Name: over-encapsulated Modafinil Pharmaceutical Form: Capsule, hard INN or Proposed INN: MODAFINIL CAS Number: 68693-11-8 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use | Theranexus S.A. | Authorised | Female: yes Male: yes | 60 | Phase 2 | France;United States;Hungary;Czech Republic;Germany | |||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
151 | NCT03637023 | May 8, 2018 | 22 July 2019 | Virtual Reality for Parkinson's Disease | Clinical and Rest-fMRI Effects of Virtual Reality Practice on Motor and Cognitive Symptoms in Parkinson's Disease, a Randomized Control Trial | Parkinson Disease;Virtual Reality Therapy;Functional Magnetic Resonance Imaging | Behavioral: Virtual Reality;Behavioral: Exercise Therapy;Drug: Pharmacological Treatment | Farzin Hajebrahimi, PT, MSc | Recruiting | 50 Years | 85 Years | All | 45 | N/A | Turkey | |
152 | NCT03587649 | May 7, 2018 | 30 September 2019 | Evaluation of [18F]MNI-1126 as an Imaging Marker for Synaptic Density Loss | Evaluation of [18F]MNI-1126 as an Imaging Marker for Synaptic Density Loss in the Brain of Patients With Probable Alzheimer's Disease, Probable Parkinson's Disease (PD) Subjects as Compared to Healthy Volunteers (HV). | Alzheimer Disease;Parkinson Disease;Healthy Volunteers | Drug: [18F]MNI-1126 | Invicro | Recruiting | 18 Years | 55 Years | All | 15 | Phase 1 | United States | |
153 | NCT03843944 | May 1, 2018 | 22 October 2019 | Overnight Switch From Rasagiline To Safinamide | Overnight Switch From Rasagiline To Safinamide In Fluctuating Patients With Parkinson's Disease: A Tolerability And Safety Study | Parkinson Disease | Drug: Safinamide | IRCCS San Raffaele | Not recruiting | 30 Years | 80 Years | All | 20 | Phase 4 | Italy | |
154 | NCT03230526 | April 20, 2018 | 25 June 2018 | Identification of a Biomarker Predictive of Evolution of Parkinson Disease | Brain Microglial Activation in the Early Stage of the Parkinson's Disease: a Predictive Biomarker of the Evolution? | Parkinson Disease | Drug: [18F]DPA-714 PET scan | Nantes University Hospital | Recruiting | 40 Years | 67 Years | All | 64 | Phase 2 | France | |
155 | NCT03374917 | April 18, 2018 | 25 March 2019 | A Study in Subjects With Parkinson's Disease to Evaluate the Safety and Tolerability of Titration and Continuous Subcutaneous Infusion of ABBV-951 in an Outpatient Environment | An Open-Label Study in Subjects With Parkinson's Disease to Evaluate the Safety and Tolerability of Titration and Continuous Subcutaneous Infusion of ABBV-951 for up to 4 Weeks in an Outpatient Environment | Parkinson's Disease (PD) | Drug: ABBV-951 | AbbVie | Not recruiting | 30 Years | 85 Years | All | 20 | Phase 1 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
156 | EUCTR2017-004475-31-HU | 17/04/2018 | 30 April 2018 | Safety and efficacy study of two THN102 doses in subjects with excessive daytime sleepiness associated with Parkinson’s disease. | Randomised, double-blind, placebo-controlled, complete 3-way cross-over phase IIa trial to investigate safety and efficacy of two THN102 doses in subjects with excessive daytime sleepiness associated with Parkinson’s disease | Excessive daytime sleepiness associated with Parkinson’s disease MedDRA version: 20.0 Level: SOC Classification code 10029205 Term: Nervous system disorders System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10041349 Term: Somnolence System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Flecainide acetate Product Code: THN02 Pharmaceutical Form: Capsule INN or Proposed INN: Flecainidum CAS Number: 54143-56-5 Other descriptive name: FLECAINIDE ACETATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1 - Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Product Name: Flecainide acetate Product Code: THN02 Pharmaceutical Form: Capsule INN or Proposed INN: Flecainidum CAS Number: 54143-56-5 Other descriptive name: FLECAINIDE ACETATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 9 - Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Trade Name: Modiodal Product Name: over-encapsulated Modafinil Pharmaceutical Form: Capsule INN or Proposed INN: MODAFINIL CAS Number: 68693-11-8 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use | Theranexus S.A. | Authorised | Female: yes Male: yes | 60 | Phase 2 | France;United States;Czech Republic;Hungary;Germany | |||
157 | EUCTR2017-004253-16-AT | 13/04/2018 | 10 September 2018 | Investigation of the effect of Nabilon in patients suffering from Parkinson´s Disease with non-Motor symptoms (e.g.sleeping dirsorders, cognitive dysfunction, hallucinations, autonomic dysfunction,...) | Nabilone for non-motor symptoms in Parkinson’s disease: An open-label study to evaluate long-term safety and efficacy | Subject with non-Motor symptoms of Parkinson´s disease MedDRA version: 20.0 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Nabilone Pharmaceutical Form: Capsule, hard INN or Proposed INN: NABILONE CAS Number: 51022-71-0 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.25- | Medizinische Universität Innsbruck, Universitätsklinik für Neurologie | Authorised | Female: yes Male: yes | 48 | Phase 3 | Austria | |||
158 | EUCTR2017-002707-10-DK | 10/04/2018 | 23 July 2018 | Measurements of drug concentration in the blood for anti-dementia drugs, in order to improve efficacy and reduce side-effects | Serum-monitoring of anti-dementia drugs, and the relevance to side-effects, clinical efficacy and compliance | Dementia in Alzheimers Disease, Parkinsons Disease and Dementia with Lewy Bodies MedDRA version: 20.0 Level: PT Classification code 10012271 Term: Dementia Alzheimer's type System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: LLT Classification code 10012284 Term: Dementia due to Parkinson's disease System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10067889 Term: Dementia with Lewy bodies System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10075174 Term: Mixed dementia System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Memantin Orion Pharmaceutical Form: Tablet INN or Proposed INN: MEMANTINE CAS Number: 19982-08-2 Current Sponsor code: PR1 Concentration unit: mg milligram(s) Concentration type: range Concentration number: 10-20 Product Name: Donepezil Sandoz Product Code: 25330 Pharmaceutical Form: Tablet INN or Proposed INN: DONEPEZIL CAS Number: 120014-06-4 Current Sponsor code: PR2 Concentration unit: mg milligram(s) Concentration type: range Concentration number: 5-10 | Regional Dementia Research Centre, Dept of Neurology | Authorised | Female: yes Male: yes | 110 | Phase 4 | Denmark | |||
159 | EUCTR2016-003456-70-DE | 04/04/2018 | 17 September 2018 | A clinical trial to compare APL-130277 sublingual film to Subcutaneous Apomorphine in Parkinson’s Disease patients | An Open-Label, Randomized, Crossover Trial utilizing a Single-Blinded Rater to evaluate APL-130277 compared to s.c. Apomorphine in Levodopa Responsive Subjects with Parkinson’s Disease Complicated by Motor Fluctuations | Levodopa Responsive Patients with Parkinson’s Disease Complicated by Motor Fluctuations (OFF episodes) MedDRA version: 20.0 Level: LLT Classification code 10034006 Term: Parkinson's disease aggravated System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Apomorphine hydrochloride Product Code: APL-130277 Pharmaceutical Form: Sublingual film INN or Proposed INN: Apomorphine hydrochloride CAS Number: 41372-20-7 Current Sponsor code: APL-130277 Other descriptive name: APOMORPHINE HYDROCHLORIDE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Sublingual film Route of administration of the placebo: Sublingual use Trade Name: APO-go Product Name: s.c. apomorphine Pharmaceutical Form: Solution for injection INN or Proposed INN: Apomorphine hydrochloride CAS Number: 41372-20-7 Other descriptive name: APOMORPHINE HYDROCHLORIDE Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10- Product Name: Apomorphine hydrochloride Product Code: APL-130277 Pharmaceutical Form: Sublingual film INN or Proposed INN: Apomorphine hydrochloride CAS Number: 41372-20-7 Current Sponsor code: APL-130277 Other descriptive name: APOMORPHINE HYDROCHLORIDE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 15- Pharmaceutical form of the placebo: Sublingual film Route of administration of the placebo: Sublingual use Product Name: Apomorphine hydrochloride Product Code: APL-130277 Pharmaceutical Form: Sublingual film INN or Proposed INN: Apomorphine hydrochloride CAS Number: 41372-20-7 Current Sponsor code: APL-130277 Other descriptive name: APOMORPHINE HYDROCHLORIDE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Sublingual film Route of administration of the placebo: Sublingual use Product Name: Apomorphine hydrochloride Product Code: APL-130277 Pharmaceutical Form: Sublingual film INN or Proposed INN: Apomorphine hydrochloride CAS Number: 41372-20-7 Current Sponsor code: APL-130277 Other descriptive name: APOMORPHINE HYDROCHLORIDE Concentration unit: mg milligram(s) Concentration type: equal | Sunovion Pharmaceuticals Inc. | Authorised | Female: yes Male: yes | 106 | Phase 3 | United Kingdom;Italy;Germany;Austria;Spain;France | |||
160 | ChiCTR1800015331 | 2018-04-01 | 26 March 2018 | Dopaminergic Mechanisms of Temporal Working Memory in Parkinson's Disease | Dopaminergic Mechanisms of Temporal Working Memory in Parkinson's Disease | Parkinson's disease | de novo PD patients:levodopa 4 weeks;de novo PD patients:pramipexole 4 weeks;de novo PD patients:selegiline 4 weeks; | Institute of Psychology, Chinese Academy of Sciences | Recruiting | 50 | 80 | Both | de novo PD patients:50;de novo PD patients:50;de novo PD patients:50; | Other | China | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
161 | NCT03827746 | April 1, 2018 | 16 September 2019 | The Effect of Kinesiophobia on Physical Activity, Balance and Falling in Parkinson's Disease Patients | The Effect of Kinesiophobia on Physical Activity, Balance and Falling in Parkinson's Disease Patients | Parkinson Disease;Kinesiophobia;Physical Activity;Balance;Falling | Other: Tampa Kinesiophobia Scale, Berg-Balance Test, International Physical Activity Questionnaire-Short Form, Falls Efficacy Scale | Istanbul Kültür University | Marmara University;Istanbul University-Cerrahpasa;Koç University | Not recruiting | 40 Years | 85 Years | All | 60 | Phase 2 | Turkey |
162 | NCT03446807 | April 2018 | 11 June 2018 | Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism | Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism | Parkinson Disease;Multiple System Atrophy;Progressive Supranuclear Palsy | Drug: Droxidopa;Drug: Placebo Oral Tablet | Loma Linda University | H. Lundbeck A/S | Not recruiting | 50 Years | N/A | All | 32 | Phase 2 | United States |
163 | EUCTR2017-004297-34-GB | 31/03/2018 | 23 July 2018 | Use of low-dose zolpidem in Parkinson's. | A placebo controlled double blind randomised controlled proof of concept study of zolpidem for the treatment of motor and cognitive deficits in late-stage Parkinson’s - Zolpidem for treatment of motor and cognitive deficits in Parkinson's | Parkinson's Disease MedDRA version: 20.0 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Stilnoct Product Name: Stilnoct Product Code: 207-3120 Pharmaceutical Form: Coated tablet INN or Proposed INN: Zolpidem Tartrate CAS Number: 99294-93-6 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5-5 Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use | Aston University | Authorised | Female: yes Male: yes | 28 | Phase 2 | United Kingdom | |||
164 | NCT03648671 | March 28, 2018 | 3 September 2018 | Pain in Parkinson's Disease With Motor Fluctuations. | Spontaneous and Evoked Pain in Parkinson's Disease With Motor Fluctuations: an Observational, Prospective, Clinical and Neurophysiological Study in Patients Under L-dopa Add on Therapies. | Parkinson Disease | Drug: safinamide metansolfonato (12 weeks);Drug: rasagilina mesilato (12 weeks) | Universita di Verona | Azienda Ospedaliera Universitaria Integrata Verona | Recruiting | 18 Years | 80 Years | All | 48 | Phase 4 | Italy |
165 | EUCTR2018-000405-23-FI | 27/03/2018 | 30 April 2018 | Postitron emission tomography imaging of neuroinflammation in Parkinson´s disease | In vivo PET imaging of neuroinflammation in Parkinson’s disease using the purinergic P2X7 receptor ligand [11C]SMW139 (PRI-PD) - PRI-PD | Parkinson´s disease MedDRA version: 20.0 Level: LLT Classification code 10034007 Term: Parkinson's disease NOS System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: (2-chloro-5-[11C]methoxy-N-(((3s,5s,7s)-3,5,7-trifluoroadamantan-1-yl)methyl) benzamide) Product Code: [11C]SMW139 Pharmaceutical Form: Injection | Juha Rinne / PET Centre | Authorised | Female: yes Male: yes | 14 | Phase 2 | Finland | |||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
166 | EUCTR2016-004610-95-AT | 23/03/2018 | 19 November 2018 | Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants with Parkinson’s Disease | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, with an Active-Treatment Dose-Blinded Period, to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Subjects with Parkinson’s Disease - SPARK | Parkinson's Disease MedDRA version: 20.0 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: BIIB054 Pharmaceutical Form: Solution for injection/infusion INN or Proposed INN: n/a Current Sponsor code: BIIB054 Other descriptive name: BIIB054 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use | Biogen Idec Research Limited | Authorised | Female: yes Male: yes | 311 | Phase 2 | France;United States;Canada;Spain;Austria;Israel;Germany;Italy;United Kingdom;Sweden | |||
167 | NCT03301272 | March 22, 2018 | 9 September 2019 | Effectiveness of Botox on Reducing Rest Tremor in Parkinson's Disease | Effectiveness of Onabotulinumtoxin A on Reduction of Rest Tremor in Parkinson's Disease: a Pilot Study | Parkinson Disease | Drug: Onabotulinumtoxin A Injection;Other: Placebo | University of North Carolina, Chapel Hill | Not recruiting | 45 Years | 80 Years | All | 16 | Phase 2 | United States | |
168 | NCT03457493 | March 22, 2018 | 27 May 2019 | TSPO-PET for Neuroinflammation in Parkinson's Disease | UAB Neuroinflammation in Parkinson's Disease - TSPO-PET Substudy | Parkinson Disease | Drug: DPA-714-PET/MRI | University of Alabama at Birmingham | Recruiting | 30 Years | N/A | All | 20 | Phase 1/Phase 2 | United States | |
169 | NCT03462641 | March 9, 2018 | 15 July 2019 | Modulation of GABA-A Receptors in Parkinson Disease-Flumazenil Arm | Modulation of GABA-A Receptors and Axial Motor Impairments in Parkinson Disease-Flumazenil Arm | Parkinson Disease | Drug: Flumazenil;Drug: Placebo | University of Michigan | National Institute of Neurological Disorders and Stroke (NINDS) | Recruiting | 50 Years | 99 Years | All | 30 | Phase 1/Phase 2 | United States |
170 | NCT03482882 | March 9, 2018 | 26 August 2019 | Safety and Efficacy of Pimavanserin in Adults With Parkinson's Disease and Depression | An Open-label, 8-Week Study of Safety and Efficacy of Pimavanserin Treatment in Adults With Parkinson's Disease and Depression | Treatment of Depression in Adults With Parkinson's Disease (PD) | Drug: Pimavanserin | ACADIA Pharmaceuticals Inc. | Not recruiting | 50 Years | N/A | All | 47 | Phase 2 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
171 | NCT03149809 | March 1, 2018 | 15 July 2019 | Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease | Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease | Overactive Bladder;Parkinson Disease | Drug: solifenacin;Behavioral: Pelvic floor muscle exercise-based behavioral therapy | VA Office of Research and Development | Recruiting | N/A | N/A | All | 90 | Phase 3 | United States | |
172 | NCT03368170 | February 27, 2018 | 26 August 2019 | Efficacy and Tolerability of IRL790 in Parkinson's Disease Dyskinesia | A Randomized, Placebo-controlled, Phase IIa Study Evaluating the Efficacy and Tolerability of IRL790 in Parkinson's Disease Dyskinesia | Parkinson Disease | Drug: IRL790 | Integrative Research Laboratories AB | The Clinical Trial Company | Not recruiting | 18 Years | 79 Years | All | 75 | Phase 2 | Sweden;United Kingdom |
173 | NCT03419806 | February 16, 2018 | 11 June 2018 | Study Comparing Intravenous and Subcutaneous Infudopa With Intestinal Duodopa in Patients With Parkinson's Disease | Levodopa Pharmacokinetics in Patients With Parkinson's Disease and Symptom Fluctuation: A Phase I, Open-label, Randomized, Multicentre, Crossover Study Comparing Intravenous and Subcutaneous Infudopa With Intestinal Duodopa | Parkinson Disease | Drug: Infudopa i.v.;Drug: Infudopa s.c.;Drug: LCIG (Duodopa) | Vastra Gotaland Region | The Swedish Research Council;Dizlin Medical Design AB;Göteborg University | Recruiting | 30 Years | N/A | All | 28 | Phase 1 | Sweden |
174 | NCT03882398 | February 15, 2018 | 1 April 2019 | Effects of a High-intensity Progressive-cycle Program on Quality of Life and Motor Symptomatology in Parkinson's Disease | Effects of a High-intensity Progressive-cycle Program on Quality of Life and Motor Symptomatology in Parkinson's Disease Population: a Pilot Randomized Controlled Trial | Parkinson Disease;Exercise;Physical Activity;Quality of Life | Other: Balance;Other: Endurance | University of Vigo | Not recruiting | 60 Years | 80 Years | All | 14 | N/A | Spain | |
175 | NCT03496870 | February 8, 2018 | 1 April 2019 | A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of Opicapone in Subjects With Parkinson's Disease Taking Levodopa. | A Phase 1, Open-Label Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Repeated Doses of Opicapone, and Effect on Levodopa Pharmacokinetics in Subjects With Parkinson's Disease | Parkinson Disease | Drug: Opicapone;Drug: Carbidopa Levodopa | Neurocrine Biosciences | Not recruiting | 18 Years | 85 Years | All | 16 | Phase 1 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
176 | NCT03189563 | February 6, 2018 | 14 January 2019 | Safety and Efficacy of DA-9805 for Parkinson's Disease | A Phase IIa, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of DA-9805 in Subjects With Parkinson's Disease | Parkinson's Disease | Drug: DA-9805 45mg;Drug: DA-9805 90mg;Other: Placebo | Dong-A ST Co., Ltd. | Not recruiting | 30 Years | 79 Years | All | 60 | Phase 2 | United States | |
177 | JPRN-UMIN000030930 | 2018/01/29 | 2 April 2019 | Study on efficacy and safety of the simultaneous treatment with febuxostat and inosine of patients with Parkinson's disease. | Parkinson's disease | Administration of febuxostat 20 mg and inosine 500 mg twice a day for 58 days | StaGen Co. Ltd. | Recruiting | 20years-old | 80years-old | Male and Female | 30 | Not selected | Japan | ||
178 | NCT03329508 | January 29, 2018 | 11 November 2019 | A Phase 3 Study With P2B001 in Subjects With Early Parkinson's | A Phase 3, Twelve-week Study to Determine the Efficacy, Safety and Tolerability of P2B001 Once Daily Compared to Its Individual Components in Subjects With Early Parkinson's Disease and to a Calibration Arm of Pramipexole ER. | Parkinson Disease | Drug: P2B001;Drug: Rasagiline;Drug: Pramipexole;Drug: Pramipexole ER | Pharma Two B Ltd. | Recruiting | 35 Years | 80 Years | All | 525 | Phase 3 | United States;Canada;Germany;Spain | |
179 | NCT03440112 | January 29, 2018 | 15 July 2019 | Modulation of GABA-A Receptors in Parkinson Disease-Clarithromycin Arm | Modulation of GABA-A Receptors and Axial Motor Impairments in Parkinson | Parkinson Disease | Drug: Clarithromycin;Drug: Placebo | Nicolaas Bohnen, MD, PhD | National Institute of Neurological Disorders and Stroke (NINDS) | Recruiting | 50 Years | N/A | All | 30 | Phase 1/Phase 2 | United States |
180 | ChiCTR1800014542 | 2018-01-22 | 29 January 2018 | Up-down sequential testing of propofol - induced half-effective dose ( ed50 ) in patients with Parkinson's disease and non - Parkinson's disease | Up-down sequential testing of propofol - induced half-effective dose ( ed50 ) in patients with Parkinson's disease and non - Parkinson's disease | Parkinson's Disease | PD group:propofol;NPD group:propofol; | Xuanwu Hospital of CCMU | Recruiting | 18 | 65 | Both | PD group:40;NPD group:40; | Other | China | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
181 | NCT03531086 | January 19, 2018 | 25 March 2019 | Idiopathic Parkinson's Progression and Dopamine Transporter SPECT | Exploring Dopamine Transporter Single-photon Emission Computer Tomography Quantification as a Measure of Disease Progression in Idiopathic Parkinson's Disease | Parkinson Disease | Drug: Ioflupane I 123 | Julie Gurwell | Recruiting | 40 Years | 75 Years | All | 12 | Phase 1 | United States | |
182 | NCT03331848 | January 15, 2018 | 11 June 2018 | Study to Evaluate the Efficacy, Safety, and Tolerability of PXT002331 (Foliglurax) in Reducing Levodopa-Induced Dyskinesia and Wearing OFF in Subjects With Parkinson's Disease Experiencing Motor Complications of Levodopa Therapy (ATTUNED) | A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-arm Phase IIa Trial to Evaluate the Efficacy, Safety, and Tolerability of 8-week Oral Treatment With PXT002331 (Foliglurax) in Reducing Levodopa-Induced Dyskinesia and Wearing OFF in Subjects With Parkinson's Disease Experiencing Motor Complications of Levodopa Therapy (ATTUNED) | Parkinson Disease | Drug: Placebo oral capsule;Drug: PXT002331 - 20mg | Prexton Therapeutics | Not recruiting | 35 Years | 85 Years | All | 0 | Phase 2 | ||
183 | NCT03318523 | January 10, 2018 | 16 September 2019 | Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, With an Active-Treatment Dose-Blinded Period, to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Subjects With Parkinson's Disease | Parkinson's Disease | Drug: BIIB054;Drug: Placebo | Biogen | Not recruiting | 40 Years | 80 Years | All | 311 | Phase 2 | United States;Austria;Canada;France;Germany;Israel;Italy;Spain;United Kingdom | |
184 | NCT03550183 | January 10, 2018 | 11 June 2018 | Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Parkinson's Disease | Safety and Efficacy Investigation of Patients With Parkinson's Disease by Transplantation of Umbilical Cord Derived Mesenchymal Stem Cells | Parkinson's Disease | Biological: mesenchymal stem cells | Hebei Newtherapy BIo-Pharma technology Co., Ltd. | Recruiting | 40 Years | 80 Years | All | 20 | Phase 1 | China | |
185 | EUCTR2016-003456-70-AT | 04/01/2018 | 1 October 2018 | A clinical trial to compare APL-130277 sublingual film to Subcutaneous Apomorphine in Parkinson’s Disease patients | An Open-Label, Randomized, Crossover Trial utilizing a Single-Blinded Rater to evaluate APL-130277 compared to s.c. Apomorphine in Levodopa Responsive Subjects with Parkinson’s Disease Complicated by Motor Fluctuations | Levodopa Responsive Patients with Parkinson’s Disease Complicated by Motor Fluctuations (OFF episodes) MedDRA version: 20.0 Level: LLT Classification code 10034006 Term: Parkinson's disease aggravated System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Apomorphine hydrochloride Product Code: APL-130277 Pharmaceutical Form: Sublingual film INN or Proposed INN: Apomorphine hydrochloride CAS Number: 41372-20-7 Current Sponsor code: APL-130277 Other descriptive name: APOMORPHINE HYDROCHLORIDE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Sublingual film Route of administration of the placebo: Sublingual use Trade Name: APO-go Product Name: s.c. apomorphine Pharmaceutical Form: Solution for injection INN or Proposed INN: Apomorphine hydrochloride CAS Number: 41372-20-7 Other descriptive name: APOMORPHINE HYDROCHLORIDE Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10- Product Name: Apomorphine hydrochloride Product Code: APL-130277 Pharmaceutical Form: Sublingual film INN or Proposed INN: Apomorphine hydrochloride CAS Number: 41372-20-7 Current Sponsor code: APL-130277 Other descriptive name: APOMORPHINE HYDROCHLORIDE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 15- Pharmaceutical form of the placebo: Sublingual film Route of administration of the placebo: Sublingual use Product Name: Apomorphine hydrochloride Product Code: APL-130277 Pharmaceutical Form: Sublingual film INN or Proposed INN: Apomorphine hydrochloride CAS Number: 41372-20-7 Current Sponsor code: APL-130277 Other descriptive name: APOMORPHINE HYDROCHLORIDE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Sublingual film Route of administration of the placebo: Sublingual use Product Name: Apomorphine hydrochloride Product Code: APL-130277 Pharmaceutical Form: Sublingual film INN or Proposed INN: Apomorphine hydrochloride CAS Number: 41372-20-7 Current Sponsor code: APL-130277 Other descriptive name: APOMORPHINE HYDROCHLORIDE Concentration unit: mg milligram(s) Concentration type: equal | Sunovion Pharmaceuticals Inc. | Authorised | Female: yes Male: yes | 106 | Phase 3 | France;Spain;Austria;Germany;Italy;United Kingdom | |||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
186 | NCT03321019 | December 12, 2017 | 27 May 2019 | Airway Protective Mechanisms in PD (R01) | Mechanisms of Airway Protection Dysfunction in Parkinson's Disease | Parkinson Disease | Drug: Capsaicin;Device: Resistive respiratory loads;Other: Event-related evoked potential using electroencephalography (EEG).;Procedure: Fluoroscopic swallow evaluation | University of Florida | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Recruiting | 45 Years | 85 Years | All | 245 | Phase 1 | United States |
187 | JPRN-UMIN000030084 | 2017/12/01 | 2 April 2019 | Practical evaluation of PET studies with [18F]-GE180, [18F]-FDOPA and [18F]-FLT for a future clinical trial of iPSC-based cell therapy in Parkinson's disease | neuroinflammatory disorder, Parkinson's disease, Brain tumor | [18F]GE180 is injected intravenously as 3-4 MBq/Kg. PET is dynamically scanned for 90 minutes. Carbidopa 150mg is administrated orally 1hr before scan.[18F]FDOPA is injected intravenously as 3-4 MBq/Kg. Dynamic PET is scanned for 90 minutes. [18F]FLT is injected intravenously as 3-4 MBq/Kg. Statical PET is scanned after 60 minutes | Kyoto University | Not Recruiting | 50years-old | Not applicable | Male and Female | 12 | Phase 1,2 | Japan | ||
188 | NCT03377322 | December 1, 2017 | 4 November 2019 | Trial of Probiotics for Constipation in Parkinson's Disease | A Randomized Double-Blinded Placebo-Controlled Trial of Probiotics for Constipation in Parkinson's Disease | Parkinson Disease | Drug: Probiotic Capsule;Drug: Placebo Capsule | University of Malaya | Not recruiting | 40 Years | 85 Years | All | 72 | N/A | Malaysia | |
189 | NCT03944785 | November 30, 2017 | 22 October 2019 | Clinical Outcome Assessment of Parkinson's Disease Patients Treated With XADAGO (Safinamide) | A Prospective, Observational Study to Evaluate Changes in Non-Motor Symptoms and Other Clinical Outcome Assessments of Parkinson's Disease Patients Treated With XADAGO (Safinamide)Tablets | Idiopathic Parkinson Disease | Drug: XADAGO (safinamide) | US WorldMeds LLC | Recruiting | 30 Years | 80 Years | All | 540 | N/A | United States | |
190 | NCT03194217 | November 10, 2017 | 22 July 2019 | BEN-2001 in Parkinson Disease Patients With Excessive Daytime Sleepiness | Dose Finding Phase IIb Study of Bavisant to Evaluate Its Safety and effiCacy in treAtment of exceSsive Daytime sleePiness (EDS) in PARkinson's Disease (PD). | Excessive Daytime Sleepiness;Parkinson Disease | Drug: BEN-2001;Drug: Placebo | BenevolentAI Bio | Not recruiting | 50 Years | 80 Years | All | 248 | Phase 2 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
191 | NCT03305809 | November 9, 2017 | 11 November 2019 | A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB) | Effect of LY3154207 on Cognition in Mild-to-Moderate Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB) | Lewy Body Dementia | Drug: LY3154207;Drug: Placebo | Eli Lilly and Company | Recruiting | 40 Years | 85 Years | All | 340 | Phase 2 | United States;Canada;Puerto Rico;China | |
192 | NCT02611167 | November 1, 2017 | 19 November 2018 | Allogeneic Bone Marrow-Derived Mesenchymal Stem Cell Therapy for Idiopathic Parkinson's Disease | Pilot Phase I Study of Allogeneic Bone Marrow-Derived Mesenchymal Stem Cell Therapy for Idiopathic Parkinson's Disease | Parkinson's Disease | Biological: Allogeneic bone marrow-derived MSCs | The University of Texas Health Science Center, Houston | Not recruiting | 45 Years | 70 Years | All | 20 | Phase 1/Phase 2 | United States | |
193 | NCT03205956 | October 19, 2017 | 8 April 2019 | Measuring Parkinson's Disease Progression | Dopamine Buffering Capacity Measured by phMRI as a Novel Biomarker of Disease Progression in PD | Parkinson's Disease | Drug: Levodopa | Kevin J. Black, MD | The Michael J. Fox Foundation for Parkinson's Research | Recruiting | 40 Years | 79 Years | All | 40 | Phase 1 | United States |
194 | NCT03272165 | October 17, 2017 | 11 November 2019 | Single Ascending Dose Study of MEDI1341 in Healthy Volunteers | A Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of MEDI1341 in Healthy Male and Female Volunteers. | Parkinson's Disease | Drug: MEDI1341;Drug: Placebo | AstraZeneca | Covance;MMS Holdings, Inc;Catalent | Recruiting | 18 Years | 80 Years | All | 48 | Phase 1 | United States;United Kingdom |
195 | NCT03205488 | October 16, 2017 | 9 October 2018 | Nilotinib in Parkinson's Disease | A Randomized, Double-Blind, Placebo-Controlled, Phase IIa, Parallel Group, Two Cohort Study to Define the Safety, Tolerability, Clinical and Exploratory Biological Activity of the Chronic Administration of Nilotinib in Participants With Parkinson's Disease | Parkinson Disease | Drug: Cohort 1:Nilotinib Oral Capsules (150mg or 300mg);Drug: Cohort 2: Nilotinib Oral Capsules (dose to be determined from Cohort 1);Drug: Placebo | Northwestern University | University of Rochester;University of Iowa;Michael J. Fox Foundation for Parkinson's Research | Recruiting | 40 Years | 79 Years | All | 135 | Phase 2 | United States |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
196 | NCT03250117 | October 10, 2017 | 6 May 2019 | Relative Bioavailability Study of Ropinirole Implants in Parkinson's Patients on L-Dopa Switched From Oral Ropinirole | An Open-Label, Relative Bioavailability Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Ropinirole Implants in Patients With Parkinson's Disease Switched From Oral Immediate-Release Ropinirole While on L-Dopa | Parkinson Disease | Drug: Ropinirole oral product;Drug: Ropinirole Implant | Titan Pharmaceuticals | Recruiting | 30 Years | 80 Years | All | 20 | Phase 1/Phase 2 | United States | |
197 | EUCTR2017-001673-17-FI | 03/10/2017 | 19 November 2018 | A study to evaluate the safety and tolerability of IRL752 treatment in patients with Parkinson's disease dementia. | A randomized, double-blind, placebo-controlled, multi-centre phase IIa study evaluating the safety and tolerability of IRL752 in patients with Parkinson's Disease Dementia | Dementia in Parkinson's disease MedDRA version: 20.0 Level: LLT Classification code 10012284 Term: Dementia due to Parkinson's disease System Organ Class: 100000014717 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: IRL752 Pharmaceutical Form: Capsule INN or Proposed INN: IRL752 CAS Number: 1227638-29-0 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use | Integrative Research Laboratories AB | Not Recruiting | Female: yes Male: yes | 40 | Phase 2 | Finland;Sweden | |||
198 | NCT03769896 | October 3, 2017 | 7 October 2019 | Nabilone for Non-motor Symptoms in Parkinson's Disease | Nabilone for Non-motor Symptoms in Parkinson's Disease: A Randomized Placebo-controlled, Double-blind, Parallel-group, Enriched Enrolment Randomized Withdrawal Study | Parkinson Disease | Drug: Nabilone 0.25 mg;Drug: Placebo | Medical University Innsbruck | Not recruiting | 30 Years | 100 Years | All | 48 | Phase 2 | Austria | |
199 | NCT03257046 | September 28, 2017 | 20 August 2018 | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ITI-214 in Parkinson's Disease | A Randomized, Placebo-Controlled, Double-Blind Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of ITI-214 in Patients With Idiopathic Parkinson's Disease | Parkinson Disease | Drug: ITI-214;Other: Placebo | Intra-Cellular Therapies, Inc. | Recruiting | 50 Years | N/A | All | 40 | Phase 1/Phase 2 | United States | |
200 | EUCTR2015-004175-73-FI | 27/09/2017 | 12 March 2018 | A clinical study to test the safety of CDNF by brain infusion in patients with Parkinson's disease. | A Phase I-II, Randomised, Double-Blind, Placebo Controlled, Safety and Tolerability Study of Intermittent Bilateral Intraputamenal Cerebral Dopamine Neurotrophic Factor (CDNF) Infusions Administered via an Investigational Drug Delivery System to Patients with Idiopathic Parkinson’s Disease (PD) of Moderate Severity. | Idiopathic Parkinson's Disease MedDRA version: 20.0 Level: LLT Classification code 10013113 Term: Disease Parkinson's System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: CDNF Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Not Applicable Other descriptive name: recombinant human Cerebral Dopamine Neurotrophic Factor Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 1.0- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intracerebral use | Herantis Pharma Plc | Authorised | Female: yes Male: yes | 18 | Phase 1;Phase 2 | Finland | |||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
201 | NCT03295786 | September 26, 2017 | 15 July 2019 | Clinical Study to Test the Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease | Phase 1-2, Randomised, Double-Blind, Placebo Controlled, Safety and Tolerability Study of Intraputamenal Cerebral Dopamine Neurotrophic Factor (CDNF) Infusions Via an Investigational Drug Delivery System to Patients With Parkinson's Disease | Parkinson Disease;Movement Disorders;Neurodegenerative Diseases;Nervous System Diseases;Brain Diseases | Drug: Cerebral Dopamine Neurotrophic Factor;Device: Renishaw Drug Delivery System | Herantis Pharma Plc. | Renishaw plc. | Recruiting | 35 Years | 75 Years | All | 18 | Phase 1/Phase 2 | Finland;Sweden |
202 | NCT03104725 | September 25, 2017 | 8 April 2019 | Does N-Acetylcysteine Decrease Spontaneous Oxidation of Central Neural Dopamine in Parkinson's Disease? | Does N-Acetylcysteine Decrease Spontaneous Oxidation of Central Neural Dopamine in Parkinson's Disease? | Parkinson Disease | Drug: N-Acetylcysteine;Procedure: Lumbar Puncture;Radiation: Fluoroscopy | National Institute of Neurological Disorders and Stroke (NINDS) | Recruiting | 18 Years | 99 Years | All | 41 | Phase 1 | United States | |
203 | EUCTR2017-000192-86-AT | 15/09/2017 | 20 August 2018 | Investigation of the effect of Nabilon in patients suffering from Parkinson´s Disease with non-motor symptoms (e.g.sleeping disorders,cognitive dysfunction, hallucinations, autonomic dysfunction including urinary incontinence, constipation,...) | Nabilone for non-motor symptoms in Parkinson´s disease: A Randomized Placebo-controlled, double-blind, parallel-group, enriched enrollment randomized withdrawal Study | Subjects with non-motor symptoms of Parkinson´s disease MedDRA version: 20.0 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Nabilone Pharmaceutical Form: Capsule INN or Proposed INN: NABILONE CAS Number: 51022-71-0 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.25- | Medizinische Universität Innsbruck, Universitätsklinik für Neurologie | Authorised | Female: yes Male: yes | 48 | Phase 2 | Austria | |||
204 | NCT03306329 | September 13, 2017 | 12 February 2018 | DNS-7801 vs. Placebo in Parkinson's Disease | A Phase 2a, Double-Blind, Placebo-Controlled Two-Part Study To Investigate the Safety and Efficacy of Increasing Doses Of DNS-7801 In Parkinson's Disease (PD) Subjects With Motor Fluctuations | Parkinson's Disease | Drug: DNS-7801 (low-dose);Drug: DNS-7801 (high dose);Drug: Placebo | Dart NeuroScience, LLC | Not recruiting | 30 Years | N/A | All | 5 | Phase 2 | United States | |
205 | NCT03272230 | September 6, 2017 | 1 April 2019 | Assessment of Apathy in a Real-life Situation, With a Video and Sensors-based System | Assessment of Apathy in a Real-life Situation, With a Video and Sensors-based System in Healthy Subject and Patient With Cerebral Disease | Apathy;Frontotemporal Dementia;Parkinson Disease;Depressive Symptoms | Behavioral: ECOCAPTURE;Behavioral: Cognitive and Behavioral experimental tasks;Diagnostic Test: Neuropsychological assessment;Behavioral: ICM_APATHY_TASKS;Other: MRI;Biological: Neurohormonal mechanisms;Diagnostic Test: Supplementary Neuropsychological Assessment - Parkinson's Disease | Institut National de la Santé Et de la Recherche Médicale, France | Recruiting | 40 Years | 85 Years | All | 135 | N/A | France | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
206 | JPRN-jRCTs041180018 | 04/09/2017 | 10 September 2019 | Pupillary autonomic dysfunction and visual hallucination in Parkinson's disease | Association between pupillary autonomic dysfunction and visual hallucination in Parkinson's disease - Pupillary autonomic dysfunction and visual hallucination in Parkinson's disease | Parkinson's disease and related diseases | Two drops of 0.05% pilocarpine hydrochloride, which is a parasympathomimetic agent, on the right eye, 2 drops of 0.04% dipivefrin hydrochloride, which is a sympathomimetic agent, to the left eye | Masahisa katsuno | Recruiting | 40age | Not applicable | Both | 40 | Phase 2 | None | |
207 | ChiCTR-INR-17012013 | 2017-09-01 | 24 July 2017 | Clinical study of botulinum toxin type A in the treatment of depressive symptoms in patients with Parkinson's disease | Clinical study of botulinum toxin type A in the treatment of depressive symptoms in patients with Parkinson's disease | Parkinson‘s disease, Depression | BTX-A:BOTOX Allergan;Placebo:0.9% Sodium Chloride Injection; | Shanghai Tongji Hospital, Tongji University | Not Recruiting | 18 | 80 | Both | BTX-A:40;Placebo:40; | New Treatment Measure Clinical Study | China | |
208 | NCT03232996 | September 1, 2017 | 16 December 2017 | Evaluation of a Computer Game Based Rehabilitation System for Assessment and Treatment of Balance and Gait Impairments in Individuals With Parkinson's Disease. | Evaluation of a Computer Game Based Rehabilitation System for Assessment and Treatment of Balance and Gait Impairments in Individuals With Parkinson's Disease. | Parkinson Disease;Parkinson | Other: Computer game based balance and walking rehabilitation for individuals with Parkinson's Disease | University of Manitoba | Not recruiting | 55 Years | 70 Years | All | 30 | N/A | Canada | |
209 | NCT03292016 | August 22, 2017 | 13 May 2019 | A Study That Compares the Extent to Which Apomorphine Becomes Available in the Body After Taking Either an Investigational Drug Containing Apomorphine or Apomorphine That is Injected Under the Skin in People With PD Complicated by OFF Episodes | A Comparative Bioavailability Study to Evaluate the Single Dose Pharmacokinetic Properties of APL-130277 With Two Different Formulations of Subcutaneous Apomorphine in a Randomized, 3-Period Crossover Design in Subjects With Parkinson's Disease Complicated by Motor Fluctuations (OFF Episodes) | Parkinson Disease | Drug: APL-130277;Drug: APO-go;Drug: Apokyn | Sunovion | Not recruiting | 18 Years | N/A | All | 8 | Phase 2 | United States | |
210 | NCT03204929 | August 14, 2017 | 15 July 2019 | Dose Escalation Study of Cu(II)ATSM in Parkinson's Disease | A Phase 1 Dose Escalation Study of Cu(II)ATSM Administered Orally to Patients With Early Idiopathic Parkinson's Disease | Parkinson Disease | Drug: Cu(II)ATSM | Collaborative Medicinal Development Pty Limited | Not recruiting | 30 Years | N/A | All | 38 | Phase 1 | Australia | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
211 | EUCTR2017-000877-35-CZ | 09/08/2017 | 9 October 2017 | A phase IIb, randomized, double blind, parallel group, placebo control, multicentre, 6-week dose-finding study to assess the efficacy and safety of Bavisant for the treatment of excessive daytime sleepiness in subjects with Parkinson's disease. | Dose finding phase IIb study of Bavisant to evaluate its safety and efficacy in treatment of excessive daytime sleepiness (EDS) in parkinson’s Disease (PD). - Treatment of excessive daytime sleepiness with Bavisant in Parkinson’s Disease Patients (CASPAR) | Excessive daytime sleepiness with Parkinson's Disease MedDRA version: 20.0 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Bavisant Product Code: JNJ-31001074 Pharmaceutical Form: Tablet INN or Proposed INN: Bavisant dihydrochloride monohydrate Other descriptive name: BAVISANT HYDROCHLORIDE MONOHYDRATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: Bavisant Product Code: JNJ-31001074 Pharmaceutical Form: Tablet INN or Proposed INN: Bavisant dihydrochloride monohydrate Other descriptive name: BAVISANT HYDROCHLORIDE MONOHYDRATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: Bavisant Product Code: JNJ-31001074 Pharmaceutical Form: Tablet INN or Proposed INN: Bavisant dihydrochloride monohydrate Other descriptive name: BAVISANT HYDROCHLORIDE MONOHYDRATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 3- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | BenevolentAI Bio | Authorised | Female: yes Male: yes | 240 | Phase 2 | United States;Czech Republic;Poland;Spain;Germany;Italy;United Kingdom | |||
212 | NCT03187301 | August 3, 2017 | 26 November 2018 | A Cardiac Safety Study of an Investigational Drug to See How if Affects the Heart in People With Parkinson's Disease Complicated by Motor Fluctuations OFF Episodes | A Phase 2, Randomized, Double-Blind, Placebo Controlled, 3-Period Crossover, Positive Control, QT-Evaluation Study of APL-130277 in Subjects With Parkinson's Disease Complicated by Motor Fluctuations (OFF Episodes) | Parkinson's Disease;Off Episodes of Parkinson Disease | Drug: APL-130277;Drug: Placebo;Drug: Moxifloxacin | Sunovion | Not recruiting | 18 Years | N/A | All | 42 | Phase 2 | United States;Italy | |
213 | ChiCTR-IPR-17011875 | 2017-08-01 | 10 July 2017 | Effects of Baduanjin Combined Balance Training on Gait and Posture Control of Patients with Mild and Moderate Parkinson's Disease | Effects of Baduanjin Combined Balance Training on Gait and Posture Control of Patients with Mild and Moderate Parkinson's Disease | Parkinson's Disease | Control group:Conventional drug therapy;Baduanjin group:Baduanjin aerobic exercise;Balance function training group:Balance function training group; | Affiliated Lianyungang Hospital of Xuzhou Medical University | Not Recruiting | 40 | 80 | Both | Control group:30;Baduanjin group:30;Balance function training group:30; | Pilot study | China | |
214 | NCT03412513 | July 17, 2017 | 12 February 2018 | Mirabegron for Treatment of Overactive Bladder Symptoms in Patients With Parkinson's Disease | Mirabegron for Treatment of Overactive Bladder Symptoms in Patients With Parkinson's Disease: a Double-blind, Randomized Placebo-controlled Trial | Overactive Bladder;Parkinson Disease | Drug: Mirabegron;Drug: Placebo | Seoul National University Hospital | Recruiting | 40 Years | 80 Years | All | 144 | Phase 4 | Korea, Republic of | |
215 | NCT03026231 | July 15, 2017 | 20 August 2018 | Characterization of Fecal Microbiome Changes After Administration of PRIM-DJ2727 in Parkinson's Disease Patients | A Prospective, Randomized Placebo Controlled Pilot Study to Characterize the Intestinal Microbiome and to Evaluate the Safety and Fecal Microbiome Changes Following Weekly Administration of Lyophilized PRIM-DJ2727 Given Orally in Subjects With Parkinson's Disease | Parkinson's Disease | Biological: PRIM-DJ2727;Drug: Placebo (for PRIM-DJ2727) | The University of Texas Health Science Center, Houston | Kelsey Research Foundation | Not recruiting | 45 Years | 70 Years | All | 0 | Phase 1/Phase 2 | United States |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
216 | NCT03185481 | July 6, 2017 | 23 April 2019 | Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations | A PHASE 2, OPEN LABEL EXTENSION STUDY TO INVESTIGATE THE LONG TERM SAFETY AND TOLERABILITY OF PF-06649751 IN SUBJECTS WITH MOTOR FLUCTUATIONS DUE TO PARKINSON'S DISEASE | Parkinson's Disease With Motor Fluctuations | Drug: 1 mg QD to 15 mg QD PF-06649751;Drug: 3 mg QD to 15 mg QD PF-06649751;Drug: 7 mg QD to 15 mg QD PF-06649751;Drug: 15 mg QD PF-06649751;Drug: 1 mg QD to 7 mg QD PF-06649751 (if de-escalated in parent study);Drug: 3 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study);Drug: 7 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study);Drug: 15 mg QD de-escalated to 7 mg QD PF-06649751 in parent study remain at 7 mg QD | Pfizer | Not recruiting | 40 Years | 87 Years | All | 5 | Phase 2 | United States | |
217 | NCT03162874 | July 4, 2017 | 18 March 2019 | Study to Evaluate the Efficacy, Safety and Tolerability of PXT002331 (Foliglurax) in Reducing Motor Complications of Levodopa Therapy in Parkinson Disease's Patients | A Multi-centre, Double-blind, Randomised, Placebo-controlled, Parallel-arm Phase IIa Trial to Evaluate the Efficacy, Safety and Tolerability of 28-Day Oral Treatment With PXT002331 (Foliglurax) in Reducing Motor Complications of Levodopa Therapy in Subjects With Parkinson's Disease Experiencing End-of-dose Wearing Off and Levodopa-Induced Dyskinesia (AMBLED) | Parkinson Disease | Drug: Placebo oral capsule;Drug: PXT002331 - dose 1;Drug: PXT002331 - dose 2 | Prexton Therapeutics | Recruiting | 35 Years | 85 Years | All | 165 | Phase 2 | Austria;France;Germany;Italy;Spain;United Kingdom | |
218 | NCT03288155 | July 1, 2017 | 16 September 2019 | Can a Flavonoid-rich Pure Cocoa Reduce Fatigue in People With Parkinson's (PD) | A Study to Determine Whether the Daily Consumption of Flavonoid-rich Pure Cocoa Can Reduce Fatigue in People With Parkinson's (PD) | Parkinson Disease;Fatigue | Dietary Supplement: Cocoa | Oxford Brookes University | European Parkinson Therapy Centre | Not recruiting | 18 Years | N/A | All | 30 | N/A | Italy |
219 | NCT04146519 | July 1, 2017 | 4 November 2019 | Parkinson's Disease Therapy Using Cell Technology | Developent and Implement a Method of Parkinson's Disease Therapy Using Cell Technology | Transplantation:Mesenchymal Stem Cell Transplantation | Biological: Autologous mesenchymal stem cells | Belarusian Medical Academy of Post-Graduate Education | Not recruiting | 18 Years | N/A | All | 12 | Phase 2 | Belarus | |
220 | EUCTR2016-003961-25-DE | 30/06/2017 | 4 December 2018 | A study to evaluate the safety and tolerability of tozadenant in Parkinson disease patients who are taking levodopa and experiencing wearing off | A Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients with Parkinson’s Disease Experiencing End of Dose “Wearing-Off” | Parkinson's Disease MedDRA version: 19.1 Level: LLT Classification code 10013113 Term: Disease Parkinson's System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: tozadenant Product Code: TOZ Pharmaceutical Form: Film-coated tablet INN or Proposed INN: tozadenant CAS Number: 870070-55-6 Current Sponsor code: TOZ Other descriptive name: TOZADENANT Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 60- | Biotie Therapies | Not Recruiting | Female: yes Male: yes | 450 | Phase 3 | United States;Czech Republic;Hungary;European Union;Canada;Spain;Australia;Germany;Italy;United Kingdom | |||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
221 | NCT03042416 | June 29, 2017 | 28 October 2019 | 18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety | 18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety | Congenital Hyperinsulinism;Neuroblastoma;Neuroendocrine Tumors;Parkinson Disease;Brain Glioma | Drug: 18F-DOPA | University of Alberta | Alberta Health Services | Recruiting | N/A | N/A | All | 400 | Phase 3 | Canada |
222 | NCT03100149 | June 27, 2017 | 6 May 2019 | A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease | A Randomized, Double-Blind, Placebo-Controlled, 52-Week Phase II Study to Evaluate the Efficacy of Intravenous RO7046015 (PRX002) in Participants With Early Parkinson's Disease With a 52-Week Blinded Extension | Parkinson's Disease | Drug: RO7046015;Drug: Placebo | Hoffmann-La Roche | Prothena Biosciences Limited | Not recruiting | 40 Years | 80 Years | All | 316 | Phase 2 | United States;Austria;France;Germany;Spain |
223 | NCT03195231 | June 25, 2017 | 16 December 2017 | Wuling Powder for the Treatment and Underlying Mechanism of Depressive Symptoms in Patients With Parkinson's Disease | Wuling Powder for the Treatment and Underlying Mechanism of Depressive Symptoms in Patients With Parkinson's Disease: a Randomised, Double-blind, Placebo-controlled Trial. | Antidepressive Agents | Drug: Wuling Powder;Drug: Placebo | Beijing Hospital | Tongji Hospital;Shanghai Tong Ren Hospital;The First Hospital of Hebei Medical University | Not recruiting | 40 Years | N/A | All | 120 | Phase 4 | |
224 | NCT03083132 | June 13, 2017 | 26 August 2019 | Modafinil for Freezing of Gait (FOG) in Parkinson's Disease (PD) | Modafinil as a Novel Therapy for the Treatment of Freezing of Gait in Parkinson's Disease | Parkinson Disease | Drug: modafinil 50mg;Drug: Placebo oral capsule | University of Arkansas | Not recruiting | 50 Years | 90 Years | All | 20 | Early Phase 1 | United States | |
225 | NCT03973502 | June 12, 2017 | 17 June 2019 | Application of 18F-FDOPA PET and Magnetic Resonance Spectroscopy (MRS) With HCV and PD | Application of 18F-FDOPA PET and Magnetic Resonance Spectroscopy (MRS) in Research of the Association Between HCV Infection and Parkinson's Disease. | Hepatitis C;Hepatitis B;Parkinson Disease | Drug: 18F-DOPA PET | National Taiwan University Hospital | Recruiting | 20 Years | N/A | All | 230 | N/A | Taiwan | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
226 | EUCTR2017-000135-14-AT | 26/05/2017 | 7 January 2019 | A study to look at how safe, well tolerated, and what effect on the body, study drug PXT002331 has in patients with Parkinson's Disease who are already taking the drug Levodopa | A Multi-centre, Double-blind, Randomised, Placebo-controlled, Parallel-arm Phase IIa Trial to Evaluate the Efficacy, Safety and Tolerability of 28-Day Oral Treatment with PXT002331 (foliglurax) in Reducing Motor Complications of Levodopa Therapy in Subjects with Parkinson’s Disease Experiencing End-of-dose Wearing Off and Levodopa-Induced Dyskinesia (AMBLED) - AMBLED Study | Parkinson’s Disease MedDRA version: 20.0 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: foliglurax Product Code: PXT002331 Pharmaceutical Form: Capsule, hard INN or Proposed INN: foliglurax CAS Number: 1883329-52-9 Current Sponsor code: PXT002331 Other descriptive name: CVD00118-E Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Product Name: foliglurax Product Code: PXT002331 Pharmaceutical Form: Capsule, hard INN or Proposed INN: foliglurax CAS Number: 1883329-52-9 Current Sponsor code: PXT002331 Other descriptive name: CVD00118-E Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 30- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use | Prexton Therapeutics B.V. | Authorised | Female: yes Male: yes | 165 | Phase 2 | Spain;Austria;Germany | |||
227 | NCT03111485 | May 24, 2017 | 18 March 2019 | Effect of Long-acting Levodopa on Obstructive Sleep Apnea in Parkinson's Disease | Effect of Long-acting Levodopa on Obstructive Sleep Apnea in Parkinson's Disease | Parkinson's Disease;Obstructive Sleep Apnea | Drug: Sinemet CR;Drug: Placebo oral capsule | McGill University Health Center | Weston Brain Institute | Recruiting | 18 Years | N/A | All | 42 | Phase 4 | Canada |
228 | NCT03033498 | May 17, 2017 | 25 March 2019 | A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Infusions of ABBV-951 in Subjects With Parkinson's Disease | A Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of 24 Hour and 72 Hour Subcutaneous Infusions of ABBV-951 in Subjects With Parkinson's Disease | Parkinson's Disease (PD) | Drug: ABBV-951 | AbbVie | Recruiting | 45 Years | 85 Years | All | 30 | Phase 1 | United States | |
229 | NCT03174938 | May 15, 2017 | 11 June 2018 | The Swedish BioFINDER 2 Study | The Swedish BioFINDER 2 Study | Dementia;Alzheimer Disease;Parkinson Disease;Lewy Body Disease;Parkinson-Dementia Syndrome;Frontotemporal Degeneration;Semantic Dementia;Progressive Nonfluent Aphasia;Progressive Supranuclear Palsy;Corticobasal Degeneration;Multiple System Atrophy;Mild Cognitive Impairment | Diagnostic Test: Flutemetamol F18 Injection;Diagnostic Test: [18F]-RO6958948;Diagnostic Test: Elecsys (Roche) Abeta42, Ttau and Ptau;Diagnostic Test: Lumipulse (Fujirebio) Abeta42, Ttau and Ptau | Skane University Hospital | Lund University | Recruiting | 20 Years | 100 Years | All | 1505 | N/A | Sweden |
230 | NCT03242499 | May 15, 2017 | 16 December 2017 | Lovastatin as a Neuroprotective Treatment for Early Stage Parkinson's Disease | Lovastatin as a Neuroprotective Treatment for Early Stage Parkinson's Disease: a Single-center, Double-blind, Placebo-controlled Randomized Trial | Parkinson Disease | Drug: Lovastatin;Drug: Placebo | National Taiwan University Hospital | Recruiting | 30 Years | 90 Years | All | 80 | Phase 2 | Taiwan | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
231 | NCT03047629 | May 11, 2017 | 20 August 2018 | Evaluation of Safety and Tolerability of ENT-01 for the Treatment of Parkinson's Disease Related Constipation | A Multi-Center, Single-Dose, Multiple-Dose, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered ENT-01 for the Treatment of Parkinson's Disease Related Constipation | Parkinson's Disease;Constipation | Drug: ENT-01;Other: Placebo | Enterin Inc. | Not recruiting | 30 Years | 86 Years | All | 50 | Phase 1/Phase 2 | United States | |
232 | NCT03065192 | May 11, 2017 | 8 April 2019 | Safety and Efficacy Study of VY-AADC01 for Advanced Parkinson's Disease | An Open-label Safety and Efficacy Study of VY-AADC01 Administered by MRI-Guided Convective Infusion Using a Posterior Trajectory Into the Putamen of Participants With Parkinson's Disease With Fluctuating Responses to Levodopa | Idiopathic Parkinson's Disease;Parkinson's Disease;Basal Ganglia Disease;Brain Diseases;Central Nervous System Diseases;Movement Disorders;Nervous System Diseases;Neurodegenerative Diseases;Parkinsonian Disorders | Drug: VY-AADC01 | Neurocrine Biosciences | Voyager Therapeutics | Not recruiting | 40 Years | 75 Years | All | 16 | Phase 1 | United States |
233 | NCT02982512 | May 1, 2017 | 11 June 2018 | Dexmedetomidine on Basal Ganglia Neuronal Activity in Parkinson's Disease | Effects of Different Concentrations of Dexmedetomidine on Basal Ganglia Neuronal Activity (Local Field Potentials) in Parkinson's Disease | Dexmedetomidine;Deep Brain Stimulation;Parkinson Disease | Drug: Dexmedetomidine | Clinica Universidad de Navarra, Universidad de Navarra | Recruiting | 18 Years | N/A | All | 12 | Phase 4 | Spain | |
234 | NCT02702076 | May 2017 | 16 December 2017 | Apomorphine in Parkinson's Disease Patients With Visual Hallucinations | Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy of Continuous Subcutaneous Infusion in Parkinson's Disease Patients With Refractory Visual Hallucinations | Parkinson's Disease;Hallucinations, Visual | Drug: Apomorphine;Drug: Placebo | University Medical Center Groningen | Recruiting | 30 Years | N/A | All | 35 | Phase 2 | Netherlands | |
235 | NCT03119636 | May 2017 | 16 December 2017 | Safety and Efficacy Study of Human ESC-derived Neural Precursor Cells in the Treatment of Parkinson's Disease | A Phase I/II, Open-Label Study to Assess the Safety and Efficacy of Striatum Transplantation of Human Embryonic Stem Cells-derived Neural Precursor Cells in Patients With Parkinson's Disease | Parkinson's Disease | Biological: NPC transplantation;Drug: Levodopa | Chinese Academy of Sciences | The First Affiliated Hospital of Zhengzhou University | Recruiting | 50 Years | 80 Years | All | 50 | Phase 1/Phase 2 | China |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
236 | ChiCTR-IPR-17011155 | 2017-04-20 | 18 April 2017 | Dihydroergotoxine mesylate for the treatment of sialorrhea in Parkinson's disease | Dihydroergotoxine mesylate for the treatment of sialorrhea in Parkinson's disease | Parkinson’s disease | treatment group:dihydroergotoxine mesylate 2.5 mg, twice daily, two weeks;intervention group:identical placebo 2.5 mg, twice daily, two weeks; | Nanjing First Hospital Affiliated to Nanjing Medical University | Recruiting | 18 | 80 | Both | treatment group:10;intervention group:10; | Post-market | China | |
237 | NCT03140956 | April 19, 2017 | 16 December 2017 | Pharmacokinetic of Levodopa Study in Healthy Males | Pharmacokinetics of Levodopa After Repeated Doses of Different Pellet Formulations; An Open, Randomized Study With Crossover Design in Healthy Male Subjects | Parkinson Disease | Drug: Levodopa, carbidopa, ODM-104 | Orion Corporation, Orion Pharma | Not recruiting | 18 Years | 65 Years | Male | 20 | Phase 1 | Finland | |
238 | NCT03115827 | April 18, 2017 | 11 March 2019 | Norepinephrine-targeted Therapy for Action Control in Parkinson Disease | Norepinephrine-targeted Therapy for Action Control in Parkinson Disease | Parkinson Disease | Drug: Droxidopa;Drug: Carbidopa | Vanderbilt University Medical Center | H. Lundbeck A/S;American Academy of Neurology | Not recruiting | 18 Years | N/A | All | 15 | Phase 4 | United States |
239 | NCT03128450 | April 15, 2017 | 16 December 2017 | A Study To Evaluate the Safety and Efficacy of Human Neural Stem Cells for Parkinson's Disease Patient | A Single Arm, Open-Label,Pilot Study to Evaluate the Safety and Efficacy of Human Neural Stem Cells Injection (ANGE-S003) Through Nasal Way Delivery to Patients With Parkinson's Disease | Parkinson Disease | Biological: human neural stem cell | Second Affiliated Hospital of Soochow University | Recruiting | 35 Years | 70 Years | All | 12 | Phase 2/Phase 3 | China | |
240 | EUCTR2016-004629-18-NL | 13/04/2017 | 8 May 2017 | The influence of stress on Parkinson's tremor | The noradrenergic basis of Parkinson’s tremor: a systems-level fMRI approach - Noradrenergic basis of Parkinson tremor | Tremor in Parkinson's disease ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Propranolol Product Name: Propranolol HCl CF 40 mg tablet Product Code: RVG 55618 Pharmaceutical Form: Tablet | Radboud University Nijmegen | Authorised | Female: yes Male: yes | Phase 3 | Netherlands | ||||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
241 | NCT03011476 | April 11, 2017 | 11 June 2018 | Effect of Acetylcholinesterase Inhibitors on the Gait of the Patients With Parkinson Disease | Effect of Acetylcholinesterase Inhibitors on the Gait of the Patients With Parkinson Disease Characterized by Postural Instability and Gait Disturbance | Parkinson Disease | Drug: Donepezil;Drug: Placebos | Kyung Hee University Hospital | Recruiting | 40 Years | 75 Years | All | 20 | Phase 4 | Korea, Republic of | |
242 | NCT02953665 | April 3, 2017 | 13 May 2019 | Safety and Efficacy of Liraglutide in Parkinson's Disease | A Phase II, Randomized, Double-blinded, Placebo-controlled Trial of Liraglutide in Parkinson's Disease | Parkinson Disease | Drug: Liraglutide;Drug: Placebo | Cedars-Sinai Medical Center | The Cure Parkinson's Trust;Novo Nordisk A/S | Recruiting | 25 Years | 85 Years | All | 57 | Phase 2 | United States |
243 | JPRN-UMIN000026128 | 2017/04/01 | 2 April 2019 | Association between pupillary autonomic dysfunction and visual hallucination in Parkinson's disease | Parkinson's disease | administe pilocarpine and dipivefrine administe pilocarpine and dipivefrine | Nagoya University | Recruiting | 40years-old | 90years-old | Male and Female | 60 | Not selected | Japan | ||
244 | NCT02970019 | March 30, 2017 | 11 November 2019 | Safety and Tolerability Study of K0706 in Subjects With Parkinson's Disease | A Double-blind, Placebo-controlled Study to Determine Safety, Tolerability, Pharmacokinetic of K0706. | Parkinson Disease | Drug: K0706;Drug: Placebo | Sun Pharma Advanced Research Company Limited | Not recruiting | 18 Years | 65 Years | All | 58 | Phase 1 | United States | |
245 | EUCTR2016-003456-70-GB | 22/03/2017 | 3 September 2018 | A clinical trial to compare APL-130277 sublingual film to Subcutaneous Apomorphine in Parkinson’s Disease patients | An Open-Label, Randomized, Crossover Trial utilizing a Single-Blinded Rater to evaluate APL-130277 compared to s.c. Apomorphine in Levodopa Responsive Subjects with Parkinson's Disease Complicated by Motor Fluctuations | Levodopa Responsive Patients with Parkinson’s Disease Complicated by Motor Fluctuations (OFF episodes) MedDRA version: 20.0 Level: LLT Classification code 10034006 Term: Parkinson's disease aggravated System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Apomorphine hydrochloride Product Code: APL-130277 Pharmaceutical Form: Sublingual film INN or Proposed INN: Apomorphine hydrochloride CAS Number: 41372-20-7 Current Sponsor code: APL-130277 Other descriptive name: APOMORPHINE HYDROCHLORIDE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Sublingual film Route of administration of the placebo: Sublingual use Trade Name: APO-go Product Name: s.c. apomorphine Pharmaceutical Form: Solution for injection INN or Proposed INN: Apomorphine hydrochloride CAS Number: 41372-20-7 Other descriptive name: APOMORPHINE HYDROCHLORIDE Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 2- Product Name: Apomorphine hydrochloride Product Code: APL-130277 Pharmaceutical Form: Sublingual film INN or Proposed INN: Apomorphine hydrochloride CAS Number: 41372-20-7 Current Sponsor code: APL-130277 Other descriptive name: APOMORPHINE HYDROCHLORIDE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 15- Pharmaceutical form of the placebo: Sublingual film Route of administration of the placebo: Sublingual use Product Name: Apomorphine hydrochloride Product Code: APL-130277 Pharmaceutical Form: Sublingual film INN or Proposed INN: Apomorphine hydrochloride CAS Number: 41372-20-7 Current Sponsor code: APL-130277 Other descriptive name: APOMORPHINE HYDROCHLORIDE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Sublingual film Route of administration of the placebo: Sublingual use Product Name: Apomorphine hydrochloride Product Code: APL-130277 Pharmaceutical Form: Sublingual film INN or Proposed INN: Apomorphine hydrochloride CAS Number: 41372-20-7 Current Sponsor code: APL-130277 Other descriptive name: APOMORPHINE HYDROCHLORIDE Concentration unit: mg milligram(s) Concentration type: equal | Sunovion Pharmaceuticals Inc. | Authorised | Female: yes Male: yes | 106 | Phase 3 | United Kingdom;Italy;Germany;Austria;Spain;France | |||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
246 | JPRN-UMIN000026492 | 2017/03/15 | 7 October 2019 | Intervention study of Istradefylline for the Treatment of Abnormal Posture in Patients with Parkinson's Disease | Intervention study of Istradefylline for the Treatment of Abnormal Posture in Patients with Parkinson's Disease - Intervention Study of Istradefylline for the Treatment of Abnormal Posture in Patients with Parkinson's Disease. | Parkinson's disease | In this research, the duration of evaluation will be 24 weeks. Treatment with istradefylline will be started at a dose of 20 mg administered once daily. The dose of istradefylline will be increased to 40 mg once daily if the patient has no tolerability issues and still has motor symptoms at Week 4. After the Week 4, the dose will be allowed to be reduced to 20 mg once daily, if the patient exhibits any tolerability issues such as the occurrence of adverse drug reactions caused by istradefylline. | Osaka Red Cross Hospital | Clinical Research Center, Wakayama Medical University | Not Recruiting | 30years-old | Not applicable | Male and Female | 30 | Not selected | Japan |
247 | NCT02864004 | March 3, 2017 | 14 October 2019 | Apomorphine Pump in Early Stage of Parkinson's Disease (EARLY-PUMP) | Apomorphine Pump in Early Stage of Parkinson's Disease | Parkinson's Disease | Drug: Apomorphine;Other: Best Medical Treatment | Rennes University Hospital | Recruiting | 18 Years | 65 Years | All | 192 | Phase 3 | France | |
248 | NCT03068481 | February 20, 2017 | 15 April 2019 | Clinical Study of KDT-3594 in Healthy Adult Males and Patients With Parkinson's Disease | A Phase I Clinical Study of KDT-3594 in Healthy Adult Males and Patients With Parkinson's Disease | Parkinson Disease | Drug: KDT-3594;Drug: Placebo | Kissei Pharmaceutical Co., Ltd. | Not recruiting | 20 Years | 74 Years | All | 36 | Phase 1 | Japan | |
249 | NCT02799381 | February 9, 2017 | 14 October 2019 | A Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease (DYSCOVER) | An Open-label, Randomized 12 Week Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease DYSCOVER (DYSkinesia COmparative Interventional Trial on Duodopa VERsus Oral Medication) | Parkinson's Disease (PD) | Drug: ABT-SLV187;Drug: optimized antiparkinsonian treatment | AbbVie | Not recruiting | 30 Years | N/A | All | 63 | Phase 3 | United States;Finland;Greece;Hungary;Italy;Slovakia;Spain | |
250 | JPRN-UMIN000025645 | 2017/02/01 | 2 April 2019 | Cross sectional analysis of Intestinal flora of Parkinson's disease: | Parkinson's disease | Levodopa/carbidopa intestinal gel | Juntendo University School of Medicine | Not Recruiting | Not applicable | Not applicable | Male and Female | 20 | Not applicable | Japan | ||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
251 | NCT03119194 | January 27, 2017 | 16 December 2017 | Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-BIA 9-1067 | An Open-Label, Single-Dose, Single-Period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-BIA 9-1067 in Healthy Male Subjects | Parkinson Disease | Drug: [14C]-BIA 9-1067 | Bial - Portela C S.A. | Not recruiting | 30 Years | 65 Years | Male | 7 | Phase 1 | United Kingdom | |
252 | JPRN-UMIN000025703 | 2017/01/16 | 2 April 2019 | Effect of thiamine for the treatment of motor and non-motor symptom in hereditary neurological or neurodegenerative disorders | Parkinson's disease spinocerebellar ataxia | fursultiamine 100mg | Department of Neurology and Clinical Pharmacology, Ehime University Graduate School of Medicine | Not Recruiting | 20years-old | Not applicable | Male and Female | 50 | Not applicable | Japan | ||
253 | NCT03330470 | January 1, 2017 | 24 September 2018 | Molecular Mediators of Physical Exercise and Carnosine Induced Effects in Patients With Preclinical and Early Stage Neurodegenerative Disease | Molecular Mediators of Physical Exercise and Carnosine Induced Effects in Patients With Preclinical and Early Stage Neurodegenerative Disease | Subjective Cognitive Impairment;Mild Cognitive Impairment;Parkinson Disease;Healthy Volunteers | Behavioral: exercise;Dietary Supplement: carnosine supplementation;Behavioral: stretching;Dietary Supplement: supplementation with placebo | Slovak Academy of Sciences | Comenius University;University Hospital Bratislava;National Cheng Kung University | Recruiting | 55 Years | 80 Years | All | 100 | N/A | Slovakia;Taiwan |
254 | NCT02954978 | January 2017 | 25 March 2019 | Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson's Disease | A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Impact of Low Doses of Nilotinib Treatment on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson's Disease | Parkinson Disease;Parkinsons Disease With Dementia | Drug: Placebo Oral Capsule;Drug: Nilotinib 150mg oral capsule [Tasigna];Drug: Nilotinib 300mg oral capsule [Tasigna] | Georgetown University | Not recruiting | 40 Years | 90 Years | All | 75 | Phase 2 | United States | |
255 | NCT03034564 | January 2017 | 16 December 2017 | A Randomized, Double-Blind, Placebo-Controlled Study of Droxidopa for Fatigue in Parkinson's Disease | A Randomized, Double-Blind, Placebo-Controlled Study of Droxidopa for Fatigue in Parkinson's Disease | Parkinson Disease;Fatigue;Parkinsonism | Drug: Northera;Drug: Placebo Oral Tablet | The Cooper Health System | Recruiting | 18 Years | N/A | All | 70 | Phase 4 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
256 | NCT03037203 | January 2017 | 10 September 2018 | A 4-Week Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive Sleepiness | A 4-Week, Double-blind, Placebo-controlled, Randomized, Multicenter, Crossover Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive Sleepiness | Excessive Sleepiness;Parkinson Disease | Other: Placebo;Drug: JZP-110 | Jazz Pharmaceuticals | Not recruiting | 35 Years | 80 Years | All | 60 | Phase 2 | United States | |
257 | NCT02969369 | December 31, 2016 | 26 August 2019 | A Study to Evaluate the Efficacy, Safety and Tolerability of SEP-363856 in Subjects With Parkinson's Disease Psychosis | A Multicenter Randomized Double-blind Followed by an Open-label Extension Study to Evaluate the Efficacy, Safety, and Tolerability of SEP-363856 in Subjects With Parkinson's Disease Psychosis | Parkinson Disease Psychosis | Drug: Placebo capsule;Drug: SEP-363856 | Sunovion | Recruiting | 55 Years | 105 Years | All | 36 | Phase 2 | United States | |
258 | ChiCTR-IOR-16010168 | 2016-12-20 | 18 April 2017 | Propofol-remifetanyl vs dexmedetomidine continous infusion for deep brain stimulation implantation | Propofol-remifetanyl vs dexmedetomidine continous infusion for deep brain stimulation implantation | Parkinson's Disease | propofol-remifentanyl group:propofol-remifentany infusion for monitored anesthesia care during awake deep brain stimulation surgery;dexmedetomidine group:dexmedetomidine infusion for monitored anesthesia care during awake deep brain stimulation surgery; | West China Hospital, Sichuan University | Recruiting | 18 | Both | propofol-remifentanyl group:25;dexmedetomidine group:25; | Other | China | ||
259 | NCT02906020 | December 15, 2016 | 22 October 2019 | A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of GZ/SAR402671 in Parkinson's Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation | Multicenter, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GZ/SAR402671 in Patients With Early-stage Parkinson's Disease Carrying a GBA Mutation or Other Pre-specified Variant. | Parkinson's Disease | Drug: GZ/SAR402671;Drug: Placebo | Genzyme, a Sanofi Company | Recruiting | 18 Years | 80 Years | All | 243 | Phase 2 | United States;Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom | |
260 | JPRN-UMIN000024859 | 2016/12/14 | 2 April 2019 | The effectiveness of motor and psychiatric symptoms for Parkinson's disease patients by switching from Dopamine agonist to Zonisamide or combining Dopamine agonist and Zonisamide. | Parkinson's disease | Switching from Dopamine agonist to Zonisamide. Intervention period of 12 weeks. | Medical Corporation Abe Neurology Clinic | Not Recruiting | 30years-old | Not applicable | Male and Female | 50 | Not applicable | Japan | ||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
261 | NCT02789020 | December 2016 | 8 April 2019 | Image Parkinson's Disease Progression Study | Image Parkinson's Disease Progression Study | Parkinson's Disease | Drug: Rasagiline;Other: Placebo;Device: Magnetic Resonance Imaging;Device: functional Magnetic Resonance Imaging;Other: Physical Function Performance Test | University of Florida | National Institute of Neurological Disorders and Stroke (NINDS) | Recruiting | 40 Years | 77 Years | All | 116 | Phase 2 | United States |
262 | NCT02879136 | December 2016 | 9 July 2018 | TAME-PD - Physical Therapy, Atomoxetine and, Methylphenidate, to Enhance Gait and Balance in Parkinson's Disease | TAME-PD - Physical Therapy, Atomoxetine and, Methylphenidate, to Enhance Gait and Balance in Parkinson's Disease: A Single Center, Randomized Pilot Study | Parkinson's Disease, Idiopathic | Drug: Methylphenidate;Other: Physical Therapy;Drug: Atomoxetine | Shnehal Patel | Recruiting | 18 Years | 90 Years | All | 42 | Early Phase 1 | United States | |
263 | NCT02934919 | December 2016 | 24 October 2016 | Evaluation of Nalmefene in Impulse Control Disorders in Parkinson's Disease: A Prospective Open Label Study | Evaluation of Nalmefene in Impulse Control Disorders in Parkinson's Disease: A Prospective Open Label Study | Impulse Control Disorders;Parkinson Disease | Drug: Nalmefene | University Hospital, Clermont-Ferrand | Not recruiting | 18 Years | 80 Years | Both | 30 | Phase 2 | France | |
264 | NCT02941822 | December 2016 | 5 March 2018 | Ambroxol in Disease Modification in Parkinson Disease | A Phase IIA Prospective, Single-Centre, Open Label Clinical Trial to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of Ambroxol in Patients With Parkinson Disease: Ambroxol in Disease Modification in Parkinson Disease | Parkinson Disease | Drug: Ambroxol | University College, London | Cure Parkinson's Trust;PRO.MED.CS Praha a.s - Czech Republic | Not recruiting | 40 Years | 80 Years | All | 20 | Phase 2 | United Kingdom |
265 | NCT03000569 | December 2016 | 22 October 2018 | A Study to Evaluate SAGE-217 in Subjects With Parkinson's Disease | A Phase 2, Two-Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SAGE-217 in Subjects With Parkinson's Disease | Parkinson Disease | Drug: SAGE-217 | Sage Therapeutics | Not recruiting | 40 Years | 75 Years | All | 29 | Phase 2 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
266 | JPRN-UMIN000024536 | 2016/11/28 | 22 July 2019 | Intervention Study for the effect of Istradefylline on onset of Dyskinesia in Patients with Parkinson's Disease. | Intervention Study for the effect of Istradefylline on onset of Dyskinesia in Patients with Parkinson's Disease. - ODYSSEI Study(Onset of Dyskinesia and Safety/Efficacy of Istradefylline) | Parkinson's disease | Treatment with istradefylline combined with optimal medical therapy. Treatment with istradefylline will be started at a dose of 20 mg administered once daily at Week 0. The dose of istradefylline will be increased to 40 mg once daily if the patient has no tolerability issues and still has motor symptoms at Week 4. From the following day of Week 4, Optimal medical therapy including istradefylline will be applied to each patient. Optimal medical therapy without istradefylline. Treatment with increased dose of previously used antiparkinson drugs or addition of new antiparkinson drug other than istradefylline will be started at Week 0. After Week 4, Optimal medical therapy without istradefylline will be applied to each patient. | Fukuoka University | Not Recruiting | 30years-old | 80years-old | Male and Female | 280 | Not applicable | Japan | |
267 | EUCTR2016-001690-33-FI | 25/11/2016 | 5 December 2016 | Apomorfiini-infuusiohoito edenneen Parkinsonin taudin hoidossa | Apomorfiini-infuusiohoito edenneen Parkinsonin taudin hoidossa | Edennyt parkinsonin tauti MedDRA version: 19.0 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Dacepton 5 mg/ml infuusioneste, liuos Product Name: Dacepton 5 mg/ml Pharmaceutical Form: Infusion | Eero Pekkonen | Authorised | Female: yes Male: yes | Phase 4 | Finland | ||||
268 | NCT03007888 | November 14, 2016 | 13 May 2019 | A Study to Assess the PK and Pharmacodynamics of IPX203 in Subjects With Advanced Parkinson's Disease | A Randomized, Multiple Dose Study to Assess the Pharmacokinetics and Pharmacodynamics of IPX203 in Subjects With Advanced Parkinson's Disease | Advanced Parkinson's Disease | Drug: IR CD-LD;Drug: ER CD-LD | IMPAX Laboratories, Inc. | Not recruiting | 40 Years | 100 Years | All | 28 | Phase 2 | United States | |
269 | EUCTR2016-001762-29-IT | 08/11/2016 | 8 January 2018 | A Phase 2, Randomized, Double-Blind, Placebo Controlled, 3-Period Crossover, Positive Control, QT-Evaluation Study of APL-130277 in Subjects with Parkinson’s Disease Complicated by Motor Fluctuations (“OFF” Episodes) | A Phase 2, Randomized, Double-Blind, Placebo Controlled, 3-Period Crossover, Positive Control, QT-Evaluation Study of APL-130277 in Subjects with Parkinson’s Disease Complicated by Motor Fluctuations (“OFF” Episodes) - CTH-201 | Parkinson's Disease (PD) MedDRA version: 20.0 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: APL-130277 Product Code: APL-130277 Pharmaceutical Form: Sublingual film INN or Proposed INN: Apomorphine Hydrocloride Hemihydrate CAS Number: 41372-20-7 Current Sponsor code: Apomorphine Hydrocloride Other descriptive name: Apomorphine Hydrocloride Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Product Name: APL-130277 Product Code: APL-130277 Pharmaceutical Form: Sublingual film INN or Proposed INN: Apomorphine Hydrocloride Hemihydrate CAS Number: 41372-20-7 Current Sponsor code: Apomorphine Hydrocloride Other descriptive name: Apomorphine Hydrocloride Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 15- Product Name: APL-130277 Product Code: APL-130277 Pharmaceutical Form: Sublingual film INN or Proposed INN: Apomorphine Hydrocloride Hemihydrate CAS Number: 41372-20-7 Current Sponsor code: Apomorphine Hydrocloride Other descriptive name: Apomorphine Hydrocloride Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- Product Name: APL-130277 Product Code: APL-130277 Pharmaceutical Form: Sublingual film INN or Proposed INN: Apomorphine Hydrocloride Hemihydrate CAS Number: 41372-20-7 Current Sponsor code: Apomorphine Hydrocloride Other descriptive name: Apomorphine Hydrocloride Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- Product Name: APL-130277 Product Code: APL-130277 Pharmaceutical Form: Sublingual film INN or Proposed INN: Apomorphine Hydrocloride Hemihydrate CAS Number: 41372-20-7 Current Sponsor code: Apomorphine Hydrocloride Other descriptive name: Apomorphine Hydrocloride Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 30- Trade Name: AVALOX - 400 MG COMPRESSE RIVESTITE CON FILM 5 COMPRESSE IN BLISTER PP/AL Product Name: Avalox Product Code: n.a. Pharmaceutical Form: Film-coated tablet INN or Proposed INN: MOXIFLOXACINA CLORIDRATO | SUNOVION PHARMACEUTICALS | Authorised | Female: yes Male: yes | 40 | Phase 2 | Italy | |||
270 | NCT03531060 | November 8, 2016 | 11 June 2018 | A Clinical Study of IRL790 in Patients With Parkinson's Disease Experiencing Levodopa Induced Dyskinesia | A Randomised, Double-blind, Placebo-controlled, Phase Ib Study Evaluating the Safety and Tolerability of IRL790 in Patients With Parkinson's Disease (PD) Experiencing Levodopa (L-Dopa) Induced Dyskinesia (LID). | Parkinson Disease | Drug: IRL790;Drug: Placebo | Integrative Research Laboratories AB | Not recruiting | 50 Years | 85 Years | All | 15 | Phase 1/Phase 2 | ||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
271 | ChiCTR-IPR-16009395 | 2016-11-01 | 18 April 2017 | Clinical trial on efficacy and safety of add-on treatment of Butylphthalide in patients with Parkinson's disease in early and moderate stage | Clinical trial on efficacy and safety of add-on treatment of Butylphthalide in patients with Parkinson's disease in early and moderate stage | Parkinson’s disease | Butylphthalide group and Control group:Butylphthalide 200mg/time(2 capsules) , three time/day, for 24 weeks;Control:No treatment; | The Second Affiliated Hospital of Soochow University | Not Recruiting | 35 | Both | Butylphthalide group and Control group:36;Control:36; | Post-market | China | ||
272 | JPRN-UMIN000025638 | 2016/11/01 | 2 April 2019 | Adenosine A2A receptors in Parkinson's disease | Parkinson's disease | 11C-preladenant-PET scanning | Tokyo Metropolitan Institute of Gerontology | Not Recruiting | 40years-old | 89years-old | Male and Female | 40 | Not selected | Japan | ||
273 | NCT02857244 | November 2016 | 8 January 2018 | A Multidisciplinary Approach to Manage Gait Difficulty in Parkinson Patients | A Multidisciplinary Approach to Manage Gait Difficulty in Parkinson Patients | Parkinson's Disease | Drug: Duloxetine;Drug: Donepezil;Drug: Modafinil | University of Chicago | Not recruiting | 18 Years | 100 Years | All | 0 | Phase 2 | United States | |
274 | NCT02968433 | November 2016 | 15 April 2019 | The Stanford Parkinson's Disease Plasma Study | The Stanford Parkinson's Disease Plasma (SPDP) Study: Intravenously-Administered Plasma From Young Donors for Treatment of Moderate Parkinson's Disease | Parkinson Disease(PD) | Drug: Infusions of young plasma | Stanford University | Not recruiting | 50 Years | 80 Years | All | 15 | Phase 1 | United States | |
275 | EUCTR2015-001786-10-DE | 24/10/2016 | 5 February 2018 | A clinical study of the effects of EPI-589 on safety and indicators of oxidative stress in patients with Parkinson's disease. | A Phase 2A Safety and Biomarker Study of EPI-589 in Mitochondrial Subtype and Idiopathic Parkinson’s Disease Subjects - Safety and Biomarker Study with EPI-589 in Parkinson's Disease | Parkinson’s disease MedDRA version: 20.0 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: EPI-589 Product Code: EPI-589 Pharmaceutical Form: Coated tablet INN or Proposed INN: Kinoquinone (proposed) CAS Number: 1147883-03-1 Current Sponsor code: EPI-589 Other descriptive name: (R)-troloxamide quinone Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 250- | BioElectron Technology Corporation (formerly Edison Pharmaceuticals Inc.) | Authorised | Female: yes Male: yes | 40 | Phase 2 | United States;Germany;United Kingdom | |||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
276 | EUCTR2016-002680-34-ES | 20/10/2016 | 7 January 2019 | Effects of different concentrations of dexmedetomidine on basal ganglia neuronal activity (local field potentials) in Parkinson's disease. | Effects of different concentrations of dexmedetomidine on basal ganglia neuronal activity (local field potentials) in Parkinson's disease. | Parkinson's disease MedDRA version: 19.0 Level: LLT Classification code 10013113 Term: Disease Parkinson's System Organ Class: 100000004852 ;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03] | Trade Name: Dexdor Product Name: Dexdor Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: DEXMEDETOMIDINE CAS Number: 113775-47-6 Other descriptive name: DEXMEDETOMIDINA Concentration unit: µg/kg microgram(s)/kilogram Concentration type: range Concentration number: 0.15-1 | Clínica Universidad de Navarra/Universidad de Navarra | Not Recruiting | Female: yes Male: yes | 12 | Phase 4 | Spain | |||
277 | NCT02871427 | October 20, 2016 | 8 April 2019 | Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder | An Open-label Study of Nelotanserin in Patients With Lewy Body Dementia Who Have Frequent Visual Hallucinations or REM Sleep Behavior Disorder | Lewy Body Dementia;Dementia With Lewy Bodies;Parkinson's Disease Dementia;Visual Hallucinations;REM Sleep Behavior Disorder | Drug: Nelotanserin | Axovant Sciences Ltd. | Not recruiting | 50 Years | N/A | All | 80 | Phase 2 | United States | |
278 | EUCTR2016-002454-20-FR | 17/10/2016 | 3 April 2017 | Apomorphine Pump in Early Stage of Parkinson’s Disease | Apomorphine Pump in Early Stage of Parkinson’s Disease - EARLY-PUMP | Parkinson’s disease MedDRA version: 19.1 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: APOKINON Product Name: APOKINON Pharmaceutical Form: Solution for infusion | CHU de Rennes | Authorised | Female: yes Male: yes | Phase 3 | France | ||||
279 | NCT02847650 | October 17, 2016 | 28 January 2019 | Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients at Early Stage of the Disease | A 15-week, Phase 2, Double Blind, Randomized, Placebo-controlled, Flexible Dose Study To Investigate The Efficacy, Safety And Tolerability Of Pf-06649751 In Subjects With Early Stage Parkinson's Disease | Parkinson Disease | Drug: Placebo;Drug: PF-06649751 | Pfizer | Not recruiting | 45 Years | 80 Years | All | 57 | Phase 2 | United States;France;Germany;Israel | |
280 | EUCTR2015-002571-24-GB | 14/10/2016 | 28 February 2019 | A Pilot Study to Evaluate the Safety, Tolerability (any side effects of the drug) and Pharmacodynamic (biochemical and physiological effects of drugs). The effects of Ambroxol in Patients with Parkinson Disease: Ambroxol in Disease Modification in Parkinson Disease. | A Phase IIA Prospective, Single-Centre, Open Label Clinical Trial to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of Ambroxol in Patients with Parkinson Disease: Ambroxol in Disease Modification in Parkinson Disease - AiM-PD | Parkinson disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: AMBROSAN 60mg Tablets Product Name: Ambroxol Pharmaceutical Form: Tablet INN or Proposed INN: Ambroxol hydrochloride Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 60- | Joint Research Office | Not Recruiting | Female: yes Male: yes | 20 | Phase 2 | United Kingdom | |||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
281 | EUCTR2016-002391-27-GB | 07/10/2016 | 28 February 2019 | Opicapone in clinical practice (OPTIPARK) | This action will amend the information submitted in this data field for all relevant applications. Please refer to the guidance under the Amendment tab and consider whether further notification to review bodies is required. - Opicapone in clinical practice (OPTIPARK)_V1 | Parkinson's disease (PD) patients with wearing-off motor fluctuations MedDRA version: 20.0 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Ongentys Product Name: Ongentys Pharmaceutical Form: Capsule, hard | BIAL - Portela & Ca, S.A. | Not Recruiting | Female: yes Male: yes | 550 | Phase 4 | Germany;United Kingdom | |||
282 | NCT02935842 | October 1, 2016 | 5 November 2018 | Evaluation of Intensive Language Therapy | Effectiveness of High-frequency Specific Speech Therapy on Verbal Fluency Decline and/ or Verbal Apraxia in Patients With Parkinson's Disease With and Without Deep Brain Stimulation (DBS) - a Randomized Controlled Single-blinded Trial | Parkinson's Disease | Other: Specific SL-therapy;Other: Rhythmic Balance-Movement Training (rBMT) | University Hospital, Basel, Switzerland | Not recruiting | 45 Years | 80 Years | All | 64 | N/A | Switzerland | |
283 | NCT02538315 | October 2016 | 16 December 2017 | Using [18F]FDOPA PET/CT to Monitor the Effectiveness of Fetal Dopaminergic Grafts in Parkinson Disease Patients | Using 3,4-dihydroxy-6-[18F]-Fluoro-l-phenylalanine ( [18F]FDOPA) PET/CT to Monitor the Effectiveness of Fetal Dopaminergic Grafts in Parkinson Disease Patients | Parkinson`s Disease | Drug: [18F]FDOPA PET/CT | University of Saskatchewan | University of Manitoba | Recruiting | 18 Years | N/A | All | 30 | N/A | Canada |
284 | NCT02803749 | October 2016 | 27 May 2019 | Buspirone in Parkinson's Disease | The Tolerability of Buspirone for the Treatment of Anxiety in Parkinson's Disease | Parkinson Disease;Anxiety | Drug: Buspirone;Drug: Placebo | University of Rochester | Michael J. Fox Foundation for Parkinson's Research | Not recruiting | 18 Years | N/A | All | 21 | Phase 2 | United States |
285 | NCT02910102 | October 2016 | 8 January 2018 | Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia | A Phase 2, Double-blind, Randomized, Placebo-controlled Crossover Study Evaluating the Effect of RVT-101 on Gait and Balance in Subjects With Alzheimer's Disease, Dementia With Lewy Bodies, or Parkinson's Disease Dementia | Alzheimer's Disease;Dementia With Lewy Bodies;Parkinson's Disease Dementia | Drug: RVT-101 35 mg;Drug: Placebo | Axovant Sciences Ltd. | Not recruiting | 50 Years | 89 Years | All | 38 | Phase 2 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
286 | NCT02940912 | October 2016 | 16 December 2017 | Effect of Continuous Apomorphine During the Night on Sleep Disorders in Insomniac Patients With Parkinson's Disease | Double Bind Randomized Placebo-controlled Cross-over Study to Evaluate Effect of Continuous Apomorphine During the Night on Sleep Disorders in Insomniac Patients With Parkinson's Disease | Parkinson Disease | Drug: Apomorphine;Drug: Placebo | Clinique Beau Soleil | Recruiting | 35 Years | 90 Years | All | 45 | Phase 4 | France | |
287 | NCT03022799 | October 2016 | 16 December 2017 | KM-819 for Patients With Parkinson's Disease | A First in Human, Randomized, Double-blind, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Following Single and Multiple Oral Doses of KM-819 in Healthy Young Adult and Elderly Subjects With Exploration of Food Effect | Parkinson Disease | Drug: KM-819;Drug: Placebo | Kainos Medicine Inc. | Recruiting | 19 Years | N/A | All | 88 | Phase 1 | Korea, Republic of | |
288 | NCT03462680 | September 28, 2016 | 29 July 2019 | GPR109A and Parkinson's Disease: Role of Niacin in Outcome Measures | GPR109A and Parkinson's Disease: Role of Niacin in Outcome Measures | Parkinson's Disease | Dietary Supplement: niacin;Other: placebo | VA Office of Research and Development | Recruiting | 35 Years | N/A | All | 80 | N/A | United States | |
289 | EUCTR2015-005078-39-DE | 21/09/2016 | 22 January 2018 | - | A multicenter, parallel-group, rater-blinded, randomized clinical study investigating the efficacy, safety, tolerability and pharmacokinetics of 2 dosing regimens of ND0612H, a solution of levodopa/carbidopa delivered via a pump system as a continuous subcutaneous infusion in subjects with advanced Parkinson's disease | Subjects with advanced Parkinson's disease MedDRA version: 18.1 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: levodopa/carbidopa solution Product Code: ND0612 Pharmaceutical Form: Solution for injection/infusion INN or Proposed INN: Levodopa CAS Number: 59-92-7 Current Sponsor code: - Other descriptive name: LEVODOPA Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 60- INN or Proposed INN: Carbidopa CAS Number: 38821-49-7 Current Sponsor code: - Other descriptive name: CARBIDOPA Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 7.5- | NeuroDerm Ltd. | Not Recruiting | Female: yes Male: yes | 47 | Phase 2 | United States;Austria;Israel;Germany;Italy | |||
290 | JPRN-UMIN000024312 | 2016/09/20 | 2 April 2019 | Studies of efficacy and safety of the combined use of febuxostat and inosine for patients with Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis or multiple sclerosis, and changes of blood and urine purine compounds. | Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis or multiple sclerosis | Treatment with febuxostat 20 mg and inosine 0.5 g, twice a day for 2 weeks | Tsukuba International Clinical Pharmacology Clinic | Not Recruiting | 20years-old | 80years-old | Male and Female | 12 | Not selected | Japan | ||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
291 | NCT02688465 | September 5, 2016 | 11 June 2018 | Effect of an Apomorphine Pump on the Quality of Sleep in Parkinson's Disease Patients (POMPRENELLE). | Effect of an Apomorphine Pump on the Quality of Sleep in Parkinson's Disease Patients (POMPRENELLE). | Parkinson's Disease | Drug: Apomorphine | Fondation Ophtalmologique Adolphe de Rothschild | Not recruiting | 18 Years | N/A | All | 15 | Phase 4 | France | |
292 | NCT02815800 | September 2, 2016 | 11 June 2018 | Efficacy of Ethnodyne Visio in Parkinson's Disease | Parkinson's Disease | Dietary Supplement: ETHNODYNE VISIO | University Hospital, Strasbourg, France | ETHNODYNE | Not recruiting | 40 Years | 75 Years | All | 24 | N/A | France | |
293 | NCT02385500 | September 2016 | 7 October 2019 | Fesoterodine on Urgency Episodes in Parkinson's Disease Population | Randomized Cross-Over Study of Fesoterodine on Urgency Episodes in Parkinson's Disease Population | Urinary Bladder, Overactive;Parkinson Disease | Drug: Fesoterodine;Drug: Placebo | Sir Mortimer B. Davis - Jewish General Hospital | Not recruiting | 50 Years | 85 Years | All | 5 | Phase 4 | Canada | |
294 | NCT02601586 | September 2016 | 2 September 2019 | Effects of PR Oxycodone and of Levodopa, vs Placebo, on Central Neuropathic Pain in Parkinson's Disease | Evaluation of the Analgesic Effects of Prolonged-release Oxycodone and of Levodopa, Versus Placebo, on Central Neuropathic Pain in Parkinson's Disease: OXYDOPA Trial | Parkinson Disease | Drug: PR Oxycodone;Drug: Levodopa;Drug: Oxycodone Placebo;Drug: Levodopa placebo | University Hospital, Toulouse | Recruiting | 40 Years | 75 Years | All | 84 | Phase 2/Phase 3 | France | |
295 | NCT02897063 | September 2016 | 25 February 2019 | Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure | The Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure Aim 2 of RDCRN (Rare Diseases Clinical Research Network) Project 2 | Autonomic Failure;Pure Autonomic Failure;Multiple System Atrophy;Parkinson Disease;Orthostatic Hypotension | Drug: Droxidopa;Drug: Midodrine;Drug: Placebo | Vanderbilt University Medical Center | Recruiting | 40 Years | 80 Years | All | 34 | Phase 1 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
296 | NCT02939391 | September 2016 | 11 June 2018 | A Study of KW-6356 in Subjects With Early Parkinson's Disease | An Early Phase 2 Study of KW-6356 in Subject With Early Parkinson's Disease | Parkinson's Disease | Drug: KW-6356;Drug: Placebo | Kyowa Hakko Kirin Co., Ltd | Not recruiting | 20 Years | 80 Years | All | 175 | Phase 2 | Japan | |
297 | NCT03192046 | September 2016 | 11 February 2019 | Bracing for Walking in Parkinson's Disease | Impact of Carbon Fiber AFOs on Gait and Resulting Changes in Quality of Life Across Time in Persons With PD | Gait Disorders, Neurologic;Parkinson Disease | Device: Carbon Fiber Ankle Foot Orthosis (AFO) | University of Texas Southwestern Medical Center | American Orthotic and Prosthetic Association | Recruiting | 30 Years | 85 Years | All | 16 | N/A | United States |
298 | EUCTR2015-005814-31-AT | 29/08/2016 | 24 September 2018 | - | A multicenter, international, open-label, safety study of ND0612, a solution of levodopa/carbidopa delivered via a pump system as a continuous subcutaneous infusion in subjects with advanced Parkinson's Disease (BeyoND) | Subjects with advanced Parkinson's disease MedDRA version: 20.0 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: levodopa/carbidopa solution Product Code: ND0612 Pharmaceutical Form: Solution for injection/infusion INN or Proposed INN: Levodopa CAS Number: 59-92-7 Current Sponsor code: - Other descriptive name: LEVODOPA Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 60- INN or Proposed INN: carbidopa CAS Number: 38821-49-7 Current Sponsor code: - Other descriptive name: CARBIDOPA Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 7.5- | NeuroDerm Ltd. | Authorised | Female: yes Male: yes | 210 | Phase 2 | France;United States;Hungary;Czech Republic;Belgium;Spain;Poland;Austria;Israel;Germany;Italy | |||
299 | NCT02365870 | August 2016 | 4 November 2019 | Anxiety in Parkinson's: Use of Quantitative Methods to Guide Rational Treatment | Anxiety in Parkinson's: Use of Quantitative Methods to Guide Rational Treatment | Anxiety Disorders;Parkinson Disease | Drug: rotigotine transdermal patch;Drug: placebo | Johns Hopkins University | National Institute on Aging (NIA) | Not recruiting | 21 Years | 89 Years | All | 4 | Phase 4 | United States |
300 | NCT02782481 | August 2016 | 3 December 2018 | A Clinical Study Investigating the Efficacy, Tolerability, and Safety of Continuous Subcutaneous ND0612 Infusion Given as Adjunct Treatment to Oral Levodopa in Patients With Parkinson's Disease With Motor Fluctuations | A Multicenter, Randomized, Double-blind, Placebo Controlled, Parallel Group Clinical Study Investigating the Efficacy, Tolerability, and Safety of Continuous Subcutaneous ND0612 Infusion Given as Adjunct Treatment to Oral Levodopa in Patients With Parkinson's Disease With Motor Fluctuations | Parkinson's Disease | Drug: ND0612;Drug: Placebo | NeuroDerm Ltd. | Not recruiting | 30 Years | 80 Years | All | 1 | Phase 3 | Israel | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
301 | EUCTR2014-001014-25-ES | 20/07/2016 | 8 August 2016 | Brain amyloid beta burden as per florbetaben PET | Brain Amyloid-Beta burden as per florbetaben (Neuraceq) pet and cognitive outcomes after deep brain stimulation in Parkinsin's disease | Parkinson's Disease MedDRA version: 19.0 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Neuraceq Product Name: Neuraceq Pharmaceutical Form: Solution for injection INN or Proposed INN: FLORBETABEN (18F) CAS Number: 902143-01-5 Current Sponsor code: Piramal Imaging GmbH Concentration unit: MBq/mg megabecquerel(s)/milligram Concentration type: equal Concentration number: 300- | Fundació Clínic per la Recerca Biomèdica | Authorised | Female: yes Male: yes | Phase 4 | Spain | ||||
302 | NCT02382198 | July 2016 | 11 June 2018 | Study of Glycopyrrolate for Moderate-to-severe Sialorrhea in Parkinson's Disease | A Randomized, Placebo-controlled, 2-arm Parallel-group Superiority Phase II Study of GLYCOpyrrolate for Moderate-to-severe Sialorrhea in PARkinson's Disease | Sialorrhea;Parkinson's Disease | Drug: Glycopyrrolate;Drug: Placebo | Ottawa Hospital Research Institute | Recruiting | 30 Years | N/A | All | 28 | Phase 2 | Canada | |
303 | NCT02452723 | July 2016 | 15 April 2019 | A Study to Evaluate the Safety of Neural Stem Cells in Patients With Parkinson's Disease | A Single Arm, Open-Label Phase 1 Study to Evaluate the Safety and Tolerability of ISC-hpNSC Injected Into the Striatum and Substantia Nigra of Patients With Parkinson's Disease | Parkinson Disease | Biological: ISC-hpNSC | Cyto Therapeutics Pty Limited | Not recruiting | 30 Years | 70 Years | All | 12 | Phase 1 | Australia | |
304 | NCT02615873 | July 2016 | 27 August 2018 | A Study of AP-CD/LD in Fluctuating Parkinson's Disease Patients Who Completed IN 11 004 | An Open-Label,Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of AP-CD/LD in Fluctuating Parkinson's Disease Subjects Who Completed Study IN 11 004 | Parkinson's Disease | Drug: Accordion Pill™ Carbidopa/Levodopa | Intec Pharma Ltd. | Recruiting | 30 Years | 100 Years | All | 460 | Phase 3 | United States;Bulgaria;Germany;Israel;Italy;Poland;Slovakia;Spain;Ukraine;United Kingdom | |
305 | NCT02789592 | July 2016 | 13 June 2016 | Efficacy and Safety of Melatonin PR and Clonazepam in Patients With REM Sleep Behavior Disorder in Parkinson Disease | A Randomized Double-Blind, Double-Dummy, Crossover Study to Evaluate the Efficacy and Safety of Prolonged-Release Melatonin and Clonazepam in Patients With Rapid Eye Movement (REM) Sleep Behavior Disorder in Parkinson Disease | REM Sleep Behavior Disorder;Parkinson Disease | Drug: Clonazepam placebo;Drug: Melatonin PR placebo;Drug: Clonazepam;Drug: Melatonin PR | Seoul National University Hospital | Kuhnil Pharmaceutical Co., Ltd. | Not recruiting | 30 Years | N/A | Both | 30 | Phase 2 | Korea, Republic of |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
306 | NCT02818777 | July 2016 | 16 December 2017 | A Study of Tolerability and Efficacy of Cannabidiol on Tremor in Parkinson's Disease | A Randomized, Double Blind, Placebo-controlled Crossover Study of Tolerability and Efficacy of Cannabidiol (CBD) on Tremor in Parkinson's Disease | Parkinson's Disease | Drug: cannabidiol;Drug: placebo | University of Colorado, Denver | Colorado Department of Public Health and Environment;GW Research Ltd | Recruiting | 45 Years | 78 Years | All | 60 | Phase 2 | United States |
307 | EUCTR2015-005626-19-CZ | 23/06/2016 | 18 June 2018 | A study of the safety and effectiveness of levodopa inhalation powder (CVT-301) in Parkinson's Disease Patients with OFF episodes | A 12 Month, Dose-Level Blinded Study Investigating the Safety and Efficacy of CVT-301 (Levodopa Inhalation Powder) in Parkinson's Disease Patients With Motor Response Fluctuations (OFF Phenomena) | Parkinson's Disease With Motor Response Fluctuations (OFF Phenomena) MedDRA version: 20.0 Level: LLT Classification code 10034007 Term: Parkinson's disease NOS System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: CVT-301 Product Code: CVT-301 35mg Pharmaceutical Form: Inhalation powder, hard capsule INN or Proposed INN: LEVODOPA CAS Number: 59-92-7 Current Sponsor code: CVT-301 Other descriptive name: LEVODOPA Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 30- Product Name: CVT-301 Product Code: CVT-301 50mg Pharmaceutical Form: Inhalation powder, hard capsule INN or Proposed INN: LEVODOPA CAS Number: 59-92-7 Current Sponsor code: CVT-301 Other descriptive name: LEVODOPA Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 42- | Civitas Therapeutics, Inc. | Not Recruiting | Female: yes Male: yes | 440 | Phase 3 | United States;Czech Republic;Canada;Poland;Spain | |||
308 | EUCTR2015-005626-19-ES | 13/06/2016 | 11 June 2018 | A study of the safety and effectiveness of levodopa inhalation powder (CVT-301) in Parkinson's Disease Patients with OFF episodes | A 12 Month, Dose-Level Blinded Study Investigating the Safety and Efficacy of CVT-301 (Levodopa Inhalation Powder) in Parkinson's Disease Patients With Motor Response Fluctuations (OFF Phenomena) | Parkinson's Disease With Motor Response Fluctuations (OFF Phenomena) MedDRA version: 19.0 Level: LLT Classification code 10034007 Term: Parkinson's disease NOS System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: CVT-301 Product Code: CVT-301 35mg Pharmaceutical Form: Inhalation powder, hard capsule INN or Proposed INN: LEVODOPA CAS Number: 59-92-7 Current Sponsor code: CVT-301 Other descriptive name: LEVODOPA Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 30- Product Name: CVT-301 Product Code: CVT-301 50mg Pharmaceutical Form: Inhalation powder, hard capsule INN or Proposed INN: LEVODOPA CAS Number: 59-92-7 Current Sponsor code: CVT-301 Other descriptive name: LEVODOPA Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 42- | Civitas Therapeutics, a wholly owned subsidiary of Acorda | Not Recruiting | Female: yes Male: yes | 440 | Phase 3 | United States;Czech Republic;Canada;Poland;Spain | |||
309 | JPRN-jRCTs051180098 | 09/06/2016 | 22 July 2019 | The DAT-SPECT study for the benefit of Selegilline or Zonisamide in Parkinson's Disease | A comparative randomized study for the evaluation of the overlaying effect of Selegiline or Zonisamide over Levodopa in Parkinson's disease | Parkinson's disease;034034 | L-Dopa/DCI only : The drug is administered per oral at 300 mg/day. The treatment is started within 14 days after registration and continued until day 365. L-Dopa/DCI + selegiline : L-Dopa/DCI is administered per oral at 300 mg/day and selegiline is administered at 5 mg/day. The treatment is started within 14 days after registration and continued until day 365. L-Dopa/DCI + zonisamide : L-Dopa/DCI is administered per oral at 300 mg/day and zonisamide is administered at 25 mg/day. The treatment is started within 14 days after registration and continued until day 365. | Hidefumi Ito | Recruiting | >=55 age old | <80 age old | Both | 180 | Phase 2 | none | |
310 | JPRN-UMIN000022529 | 2016/06/01 | 2 April 2019 | Effects on the pharmacokinetics of L-DOPA formulation by Proton pump inhibitors in patients with Parkinson's disease | Parkinson's disease | 8-day oral administration of L-DOPA formulation(Menesit100 Tablets or DopacolL100 Tablets,dosage in taking)and Nexium10 Capsules(once a day 2Cap,after breakfast) Blood concentration measurement date only, oral administration of L-DOPA formulation 1tablet(100mg) and Nexium10 2Cap(20mg) Washout 6days 8-day oral administration of L-DOPA formulation(Menesit100 Tablets or DopacolL100 Tablets,dosage in taking)and Nexium Placebo Capsules(lactose,once a day 2Cap,after breakfast) Blood concentration measurement date only, oral administration of L-DOPA formulation 1tablet(100mg) and Nexium Placebo Capsules 2Cap 8-day oral administration of L-DOPA formulation(Menesit100 Tablets or DopacolL100 Tablets,dosage in taking)and Nexium Placebo Capsules(lactose,once a day 2Cap,after breakfast) Blood concentration measurement date only, oral administration of L-DOPA formulation 1tablet(100mg) and Nexium Placebo Capsules 2Cap Washout 6days 8-day oral administration of L-DOPA formulation(Menesit100 Tablets or DopacolL100 Tablets,dosage in taking)and Nexium10 Capsules(once a day 2Cap,after breakfast) Blood concentration measurement date only, oral administration of L-DOPA formulation 1tablet(100mg) and Nexium10 2Cap(20mg) | Utano National Hospital, National Hospital Organization | Not Recruiting | 20years-old | 85years-old | Male and Female | 8 | Phase 3 | Japan | ||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
311 | JPRN-UMIN000022533 | 2016/06/01 | 2 April 2019 | A comparative randomized study for the evaluation of the overlaying effect of Selegiline or Zonisamide over Levodopa in Parkinson's disease | Parkinson's disease | L-Dopa/DCI only The drug is administered per oral at 150 to 300 mg/day. The treatment is started within 14days after registration and continued until day 365. L-Dopa/DCI + selegiline L-Dopa/DCI is administered per oral at 150 to 300 mg/day and selegiline is administered at 5mg/day. The treatment is started within 14days after registration and continued until day 365. L-Dopa/DCI + zonisamide L-Dopa/DCI is administered per oral at 150 to 300 mg/day and zonisamide is administered at 25mg/day. The treatment is started within 14days after registration and continued until day 365. | Osaka Redcross Hospital Wakayama Prefectural Medical College | Recruiting | 55years-old | 80years-old | Male and Female | 180 | Phase 2 | Japan | ||
312 | NCT02642393 | June 2016 | 19 November 2018 | Study of Urate Elevation in Parkinson's Disease, Phase 3 | A Randomized, Double-blind, Placebo-controlled Trial of Urate-elevating Inosine Treatment to Slow Clinical Decline in Early Parkinson's Disease | Parkinson's Disease | Drug: Inosine;Drug: Placebo | Michael Alan Schwarzschild | The Parkinson Study Group;Michael J. Fox Foundation for Parkinson's Research;University of Rochester;National Institute of Neurological Disorders and Stroke (NINDS) | Not recruiting | 30 Years | N/A | All | 270 | Phase 3 | United States;Puerto Rico |
313 | NCT02785978 | June 2016 | 16 December 2017 | Pilot Study to Evaluate ActiMyo Measured Activity in Parkinson Disease Patients & Healthy Volunteers | Pilot Study to Evaluate ActiMyo Measured Activity in Parkinson Disease Patients & Healthy Volunteers | Parkinson Disease;Healthy Volunteers | Drug: Levodopa acute challenge;Other: Controlled environment tests (series of tasks of everyday life);Other: Standardized scales: MDS-UPDRS (Part II to IV) and RDRS;Device: ActiMyo recording;Other: Diary completion | Institut de Myologie, France | Not recruiting | 18 Years | N/A | All | 30 | N/A | France | |
314 | NCT02807675 | June 2016 | 16 December 2017 | A Study of the Safety and Tolerability of a Single Dose Administration of CVT-301 (Levodopa Inhalation Powder) | A Phase 1 Study of the Safety and Tolerability of a Single Dose Administration of CVT- 301 (Levodopa Inhalation Powder) When Administered for Early Morning OFF Symptoms in Patients With Parkinson's Disease | Parkinson's Disease | Other: Placebo;Drug: CVT-301, LIP | Acorda Therapeutics | Not recruiting | 30 Years | 85 Years | All | 36 | Phase 1 | United States | |
315 | NCT02812394 | June 2016 | 7 November 2016 | A Study to Compare Two Dose Strengths of CVT-301 (Levodopa Inhalation Powder) With an Oral Dose of Sinemet® (Carbidopa-levodopa) Tablets | A Phase 1 Single Dose Pharmacokinetic Bridging Study to Compare Two Dose Strengths of CVT-301 (Levodopa Inhalation Powder) With an Oral Dose of Sinemet® (Carbidopa-levodopa) Tablets | Parkinson Disease | Drug: CVT-301 (Dose Level 1);Drug: CVT-301 (Dose Level 2);Drug: Sinemet® | Acorda Therapeutics | Not recruiting | 25 Years | 65 Years | Both | 24 | Phase 1 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
316 | NCT02838797 | June 2016 | 22 October 2019 | RQ-00000010 for Gastroparesis and Constipation in Parkinson's Disease | RQ-00000010 for Gastroparesis and Constipation in Parkinson's Disease | Parkinson's Disease;Gastroparesis;Constipation | Drug: RQ-00000010;Drug: Placebo | Virginia Commonwealth University | Michael J. Fox Foundation for Parkinson's Research;RaQualia Pharma Inc. | Not recruiting | 18 Years | N/A | All | 51 | Phase 1 | United States |
317 | EUCTR2016-000679-25-ES | 31/05/2016 | 28 February 2019 | Clinical study for the assessment of security of candesartan in Parkinson?s disease population and its potential benefit in cognitive impairment associated to Parkinson?s disease. | A prospective, randomized, double-blind and placebo-controlled, parallel group, phase II study to compare the efficacy and safety of candesartan versus placebo on cognitive impairment associated with Parkinson?s disease. Exploratory study. | Parkinson's Disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Parapres Pharmaceutical Form: Tablet Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | INSTITUT DE RECERCA HSCSP | Not Recruiting | Female: yes Male: yes | 56 | Phase 2 | Spain | |||
318 | EUCTR2015-005078-39-AT | 30/05/2016 | 3 April 2017 | - | A multicenter, parallel-group, rater-blinded, randomized clinical study investigating the efficacy, safety, tolerability and pharmacokinetics of 2 dosing regimens of ND0612H, a solution of levodopa/carbidopa delivered via a pump system as a continuous subcutaneous infusion in subjects with advanced Parkinson's disease | Subjects with advanced Parkinson's disease MedDRA version: 19.0 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: levodopa/carbidopa solution Product Code: ND0612 Pharmaceutical Form: Solution for injection/infusion INN or Proposed INN: Levodopa CAS Number: 59-92-7 Current Sponsor code: - Other descriptive name: LEVODOPA Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 60- INN or Proposed INN: Carbidopa CAS Number: 38821-49-7 Current Sponsor code: - Other descriptive name: CARBIDOPA Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 7.5- | NeuroDerm Ltd. | Not Recruiting | Female: yes Male: yes | 47 | Phase 2 | United States;Austria;Israel;Germany;Italy | |||
319 | JPRN-UMIN000009062 | 2016/05/30 | 2 April 2019 | An open-label, single-centered, non-randomized trial of inosine to assess its safety for patients with Parkinson's disease | Parkinson's disease | Take oral inosine 500-3000mg/day to achieve a serum UA level between 6.0-8.0 mg/dL | Dept. of Clinical pharmacology and Neurology | Not Recruiting | 20years-old | Not applicable | Male and Female | 20 | Phase 1 | Japan | ||
320 | EUCTR2016-000636-18-GB | 12/05/2016 | 28 February 2019 | Phase 3, placebo controlled study to examine the efficacy, safety and tolerability of APL-130277 in patients with Parkinson's disease. | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Examine the Efficacy, Safety and Tolerability of APL-130277 in Levodopa Responsive Patients with Parkinson’s Disease Complicated by Motor Fluctuations (“OFF” Episodes). | Levodopa Responsive Patients with Parkinson’s Disease Complicated by Motor Fluctuations (“OFF” Episodes) MedDRA version: 19.0 Level: LLT Classification code 10034006 Term: Parkinson's disease aggravated System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Apomorphine hydrochloride Product Code: APL-130277 Pharmaceutical Form: Sublingual film INN or Proposed INN: Apomorphine hydrochloride CAS Number: 41372-20-7 Current Sponsor code: APL-130277 Other descriptive name: APOMORPHINE HYDROCHLORIDE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10 - Pharmaceutical form of the placebo: Sublingual film Route of administration of the placebo: Sublingual use Product Name: Apomorphine hydrochloride Product Code: APL-130277 Pharmaceutical Form: Sublingual film INN or Proposed INN: Apomorphine hydrochloride CAS Number: 41372-20-7 Current Sponsor code: APL-130277 Other descriptive name: APOMORPHINE HYDROCHLORIDE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 15- Pharmaceutical form of the placebo: Sublingual film Route of administration of the placebo: Sublingual use Product Name: Apomorphine hydrochloride Product Code: APL-130277 Pharmaceutical Form: Sublingual film INN or Proposed INN: Apomorphine hydrochloride CAS Number: 41372-20-7 Current Sponsor code: APL-130277 Other descriptive name: APOMORPHINE HYDROCHLORIDE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Sublingual film Route of administration of the placebo: Sublingual use Product Name: Apomorphine hydrochloride | Sunuvion Pharmaceuticals Inc | Not Recruiting | Female: yes Male: yes | 126 | Phase 3 | United States;Canada;United Kingdom | |||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
321 | JPRN-UMIN000022022 | 2016/05/10 | 23 April 2019 | A randomized controlled study comparing lubiprostone and magnesium oxide for treatment of chronic constipation in patients with Parkinson disease | A randomized controlled study comparing lubiprostone and magnesium oxide for treatment of chronic constipation in patients with Parkinson disease - A randomized controlled study comparing lubiprostone and magnesium oxide for treatment of chronic constipation in patients with Parkinson disease | Parkinson disease Chronic constipation | Study drug group: A 12-week administration of lubiprostone 24 microrgrum (adjustable) twice daily after switching from magnesium oxide Control group: Continuous administration of magnesium oxide at the same dosage regimen as before the enrollment | Dokkyo Medical University | Not Recruiting | 20years-old | 90years-old | Male and Female | 64 | Not selected | Japan | |
322 | JPRN-UMIN000022023 | 2016/05/10 | 2 April 2019 | A randomized controlled study comparing lubiprostone and magnesium oxide for treatment of chronic constipation in patients with Parkinson disease. -to evaluation by change of intestinal bacterial flora- | Parkinson disease Chronic constipation | Study drug group: A 12-week administration of lubiprostone 24 microgrum (adjustable) twice daily after switching from magnesium oxide Control group: Continuous administration of magnesium oxide at the same dosage regimen as before the enrollmen | Dokkyo Medical University | Not Recruiting | 20years-old | 90years-old | Male and Female | 64 | Not selected | Japan | ||
323 | JPRN-UMIN000022187 | 2016/05/06 | 2 April 2019 | Research on Parkinson's disease pathogenesis based on analysis of caffeine absorption in patients with Parkinson's disease | Parkinson's disease | PD group, 200 mg caffeine administration, qd, 1 day Control group, 200 mg caffeine administration, qd, 1 day | Department of Neurology, Juntendo University | Not Recruiting | 40years-old | 60years-old | Male and Female | 20 | Not applicable | Japan | ||
324 | NCT02762591 | May 3, 2016 | 16 December 2017 | Expanded Access of Pimavanserin for Patients With PD Psychosis | Expanded Access Program of Pimavanserin in Patients With Parkinson's Disease Psychosis | Parkinson's Disease Psychosis | Drug: Pimavanserin tartrate | ACADIA Pharmaceuticals Inc. | Not recruiting | 40 Years | N/A | All | N/A | |||
325 | NCT02705755 | May 2016 | 7 October 2019 | TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH) | A Phase 2 Study to Assess the Effect of TD-9855 in Subjects With Neurogenic Orthostatic Hypotension | Neurogenic Orthostatic Hypotension;Multiple System Atrophy (MSA) With Orthostatic Hypotension;Pure Autonomic Failure;Parkinson Disease;Hypotension, Orthostatic;Orthostatic Hypotension;Pure Autonomic Failure With Orthostatic Hypotension;Parkinson Disease With Orthostatic Hypotension | Drug: TD-9855;Drug: Placebo | Theravance Biopharma | Not recruiting | 40 Years | N/A | All | 34 | Phase 2 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
326 | NCT02726386 | May 2016 | 3 December 2018 | A Clinical Study in Advanced Parkinson's Disease Investigating the Long Term Safety of ND0612 Administered as a Continuous SC Infusion | A Multicenter, International, Open-label, Safety Study of ND0612, a Solution of Levodopa/Carbidopa Delivered Via a Pump System as a Continuous Subcutaneous Infusion in Subjects With Advanced Parkinson's Disease | Parkinson's Disease | Drug: ND0612 | NeuroDerm Ltd. | Not recruiting | 30 Years | N/A | All | 210 | Phase 2 | United States;Austria;Czechia;France;Germany;Israel;Italy;Poland;Spain | |
327 | NCT02728947 | May 2016 | 12 December 2016 | Pharmacokinetic Profile of Neupro Patch Administrated at 2 mg, 4 mg, 6 mg and 8 mg/Day Weekly in Patients With Early-stage Parkinson's Disease | A Single Group and Open-label Study to Evaluate Pharmacokinetic Profile of Neupro Patch Administrated at 2 mg, 4 mg, 6 mg and 8 mg/Day Weekly in Patients With Early-stage Parkinson's Disease | Parkinson's Disease | Drug: ROTIGOTINE | Luye Pharma Group Ltd. | Not recruiting | 18 Years | 99 Years | Both | 28 | Phase 1 | United States | |
328 | NCT02784145 | May 2016 | 11 June 2018 | Effects of Resistant Starch on Bowel Habits, Fecal Short Chain Fatty Acids and Gut Microbiota in Parkinson Disease | Effects of Resistant Starch on Bowel Habits, Fecal Short Chain Fatty Acids and Gut Microbiota in Parkinson Disease | Parkinson Disease | Dietary Supplement: Resistant starch;Other: Recommendation with regard to nutrition | Saarland University | Not recruiting | 18 Years | N/A | All | 95 | N/A | Germany | |
329 | NCT02812147 | May 2016 | 25 February 2019 | Effect of L-Dihydoxyphenylserine on Locomotion, Postural Stability, and Fall Risk Reduction in Parkinson Disease | Effect of L-Dihydoxyphenylserine (L-DOPS, Northera) a Central and Peripheral Norepinephrine Agent on Locomotion, Postural Stability (Balance), and Fall Risk Reduction in Parkinson Disease (PD) | Parkinson Disease | Drug: L-DOPS;Drug: Placebo | St. Joseph's Hospital and Medical Center, Phoenix | Arizona State University, Tempe | Not recruiting | 30 Years | 83 Years | All | 20 | Phase 2 | United States |
330 | EUCTR2015-003512-20-GB | 28/04/2016 | 28 February 2019 | Clinical Efficacy & Safety of AP CD/LD in Fluctuating Parkinson’s Disease | A Phase III, Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Controlled Study Comparing the Efficacy and Safety of Gastric Retentive, Controlled Release Accordion Pill™ Carbidopa/Levodopa (AP-CD/LD) to Immediate Release CD/LD in Fluctuating Parkinson’s Disease Patients | Parkinson's Disease MedDRA version: 20.0 Level: HLT Classification code 10034005 Term: Parkinson's disease and parkinsonism System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: SINEMET 25-100 Product Name: Immediate Release carbidopa/levodopa 25/100 mg Pharmaceutical Form: Tablet INN or Proposed INN: Carbidopa Other descriptive name: CARBIDOPA Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Product Name: Accordion Pill™ Carbidopa/Levodopa 50/400 mg Pharmaceutical Form: Capsule INN or Proposed INN: Carbidopa Other descriptive name: CARBIDOPA Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 400- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Product Name: Accordion Pill™ Carbidopa/Levodopa 50/500 mg Pharmaceutical Form: Capsule INN or Proposed INN: Carbidopa Other descriptive name: CARBIDOPA Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA Concentration unit: mg milligram(s) | Intec Pharma, Ltd. | Authorised | Female: yes Male: yes | 420 | Phase 3 | United States;Hungary;Slovakia;Poland;Spain;Ukraine;Russian Federation;Israel;Bulgaria;Germany;Italy;United Kingdom | |||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
331 | EUCTR2015-004507-23-DE | 25/04/2016 | 7 January 2019 | Comparison of two levodopa treatments, ODM-104 and Stalevo, in Parkinson's disease patients who have motor fluctuations. | Efficacy and safety of ODM-104 compared to a standard combination (Stalevo®); a randomised, double-blind, crossover proof-of-concept study in patients with Parkinson’s disease and end-of-dose wearing-off. - COMPOC | Parkinson’s disease (PD) patients with end-of-dose wearing-off (motor fluctuations);Therapeutic area: Diseases [C] - Symptoms and general pathology [C23] | Product Name: Levodopa 75 mg A CAP Pharmaceutical Form: Modified-release capsule, hard INN or Proposed INN: levodopa CAS Number: 59-92-7 Other descriptive name: LEVODOPA Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 75- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Product Name: Levodopa 100 mg A CAP Pharmaceutical Form: Modified-release capsule, hard INN or Proposed INN: levodopa CAS Number: 59-92-7 Other descriptive name: LEVODOPA Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Product Name: Levodopa 125 mg A CAP Pharmaceutical Form: Modified-release capsule, hard INN or Proposed INN: levodopa CAS Number: 59-92-7 Other descriptive name: LEVODOPA Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 125- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Product Name: Levodopa 150 mg A CAP Pharmaceutical Form: Modified-release capsule, hard INN or Proposed INN: levodopa CAS Number: 59-92-7 Other descriptive name: LEVODOPA Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Product Name: Carbidopa 65 mg capsule Pharmaceutical Form: Capsule, hard INN or Proposed INN: Carbidopa CAS Number: 38821-49-7 Other descriptive name: CARBIDOPA Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 65- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Product Name: ODM-104 Pharmaceutical Form: Capsule, hard INN or Proposed INN: na Other descriptive name: ODM-104 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- | Orion Corporation | Not Recruiting | Female: yes Male: yes | 80 | Phase 2 | Hungary;Finland;Latvia;Germany | |||
332 | NCT02764125 | April 8, 2016 | 11 June 2018 | Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Wearing-off (COMPOC) | Efficacy and Safety of ODM-104 Compared to a Standard Combination (Stalevo®); a Randomized Double-blind, Crossover Proof-of-concept Study in Patients With Parkinson's Disease and End-of-dose Wearing-off | Parkinson's Disease | Drug: Stalevo;Drug: levodopa MR | Orion Corporation, Orion Pharma | Not recruiting | 30 Years | N/A | All | 84 | Phase 2 | Finland;Germany;Hungary;Latvia | |
333 | NCT03034538 | April 8, 2016 | 16 December 2017 | An Open-Label Tolerability and Exploratory Efficacy Study of Zonisamide for Dyskinesias in Parkinson's Disease | An Open-Label Tolerability and Exploratory Efficacy Study of Zonisamide for Dyskinesias in Parkinson's Disease | Parkinson Disease;Parkinsonism;Dyskinesias | Drug: Zonegran | The Cooper Health System | Recruiting | 18 Years | N/A | All | 20 | Phase 4 | United States | |
334 | EUCTR2015-005067-17-CZ | 01/04/2016 | 11 April 2016 | A study of the safety and effectiveness of levodopa inhalation powder (CVT-301) in Parkinson’s Disease Patients with OFF episodes | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of CVT-301 (Levodopa Inhalation Powder) in Parkinson’s Disease Patients With Motor Response Fluctuations (OFF Phenomena) (SPAN-PD™) | Parkinson's Disease With Motor Response Fluctuations (OFF Phenomena) MedDRA version: 18.1 Level: LLT Classification code 10034007 Term: Parkinson's disease NOS System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: CVT-301 Product Code: CVT-301 35mg Pharmaceutical Form: Inhalation powder, hard capsule INN or Proposed INN: LEVODOPA CAS Number: 59-92-7 Current Sponsor code: CVT-301 Other descriptive name: LEVODOPA Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 35- Pharmaceutical form of the placebo: Inhalation powder, hard capsule Route of administration of the placebo: Inhalation use Product Name: CVT-301 Product Code: CVT-301 50mg Pharmaceutical Form: Inhalation powder, hard capsule INN or Proposed INN: LEVODOPA CAS Number: 59-92-7 Current Sponsor code: CVT-301 Other descriptive name: LEVODOPA Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Inhalation powder, hard capsule Route of administration of the placebo: Inhalation use | Civitas Therapeutics, Inc. | Authorised | Female: yes Male: yes | 345 | Phase 3 | United States;Czech Republic;Canada;Poland;Spain | |||
335 | NCT02719496 | April 2016 | 11 June 2018 | Prove of Concept Study, to Evaluate the Efficacy, Safety, and Tolerability of IBEROGAST in the Treatment of Bowel Troubles in Patients With Parkinson's Disease | Prove of Concept Study, to Evaluate the Efficacy, Safety, and Tolerability of IBEROGAST in the Treatment of Bowel Troubles in Patients With Parkinson's Disease | Gastrointestinal Disorders in Parkinson's Disease | Drug: IBEROGAST | Nantes University Hospital | Not recruiting | 30 Years | 80 Years | All | 45 | Phase 2 | France | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
336 | NCT02729714 | April 2016 | 22 July 2019 | A Pilot Study of Suvorexant for Insomnia in Parkinson Disease | A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Suvorexant for Insomnia in Parkinson Disease | Insomnia | Drug: Suvorexant;Drug: Placebo | Burdick, Daniel, M.D. | Merck Sharp & Dohme Corp. | Recruiting | 30 Years | 80 Years | All | 20 | Phase 4 | United States |
337 | NCT02775591 | April 2016 | 8 April 2019 | Effect of Short-term Motilitone Therapy on Health-related Quality of Life in PD Patients With Gastrointestinal Symptoms | Effect of Short-term Motilitone Therapy on Health-related Quality of Life in Parkinson's Disease Patients With Gastrointestinal Symptoms: a Multicenter, Double-blind Randomized, Placebo-controlled Trial | Parkinson Disease;Dyspepsia | Drug: DA-9701;Drug: DA-9701 placebo | Seoul National University Hospital | Samsung Medical Center;Korea University Guro Hospital;Hanyang University;Seoul Veterans Hospital;SMG-SNU Boramae Medical Center | Not recruiting | 50 Years | 80 Years | All | 147 | Phase 4 | Korea, Republic of |
338 | NCT03173781 | April 2016 | 2 July 2018 | Effects of Droxidopa When Measuring Gait Speed, Kyphosis, and Functional Reach in Parkinson's Disease | Effects of Droxidopa When Measuring Gait Speed, Kyphosis, and Functional Reach in Parkinson's Disease | Parkinson's Disease | Drug: Placebo;Drug: droxidopa | Colorado Springs Neurological Associates | H. Lundbeck A/S | Not recruiting | 18 Years | N/A | All | 21 | N/A | United States |
339 | EUCTR2015-004344-19-GB | 31/03/2016 | 8 May 2017 | An international trial of deferiprone in patients with Parkinson’s disease | A Dose-Ranging Study of the Efficacy, Safety, and Pharmacokinetics of Deferiprone Delayed Release Tablets in Patients with Parkinson’s Disease - LA48-0215 | Parkinson’s disease MedDRA version: 19.1 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Deferiprone 600 mg delayed release tablet Pharmaceutical Form: Modified-release tablet INN or Proposed INN: DEFERIPRONE CAS Number: 30652-11-0 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 600- Pharmaceutical form of the placebo: Modified-release tablet Route of administration of the placebo: Oral use | ApoPharma Inc. | Authorised | Female: yes Male: yes | 140 | Phase 2 | France;Canada;Germany;United Kingdom | |||
340 | JPRN-jRCTs061180060 | 22/03/2016 | 10 September 2019 | Randomized clinical trial to assess the disease modifying effect of oral inosine for patients with Parkinson's disease | Multi-centered, placebo-controlled, double-blind, randomized clinical trial to assess the effect of oral inosine on the onset of wearing off in patients with early stage Parkinson's disease - Multi-centered, placebo-controlled, double-blind, randomized clinical trial to assess the effect of oral inosine on the onset of wearing off in patients with early stage Parkinson's disease | Parkinson's disease;D010300 | Inosine to maintain a serum urate level between 6.0-7.5 mg/dL for 2 years or placebo (500mg/CP) | Masahiro Nagai | Recruiting | 20 years old | None | Both | 100 | Phase 2 | none | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
341 | EUCTR2015-004129-15-ES | 07/03/2016 | 18 April 2017 | Subjects participating in a Parkinson Disease cohort are offered to undergo a PET imaging scan requiring an intravenous diagnostic drug (florbetaben) with the aim of identifying markers of disease progression | Evaluation of [18F] florbetaben in subjects participating in the Parkinson?s Progression Markers Initiative (PPMI) Protocol | Parkinson's Disease MedDRA version: 18.1 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Neuraceq Product Name: 18F florbetaben Pharmaceutical Form: Solution for injection INN or Proposed INN: FLORBETABEN (18F) CAS Number: 902143-01-5 Concentration unit: MBq megabecquerel(s) Concentration type: equal Concentration number: 300- | Institute for Neurodegenerative Disorders | Not Recruiting | Female: yes Male: yes | Phase 2 | Spain | ||||
342 | NCT02687542 | March 3, 2016 | 5 March 2018 | Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations | A 15-week, Phase 2, Double Blind, Randomized, Placebo-controlled, Dose Ranging Study To Investigate The Efficacy, Safety And Tolerability Of Pf-06649751 In Subjects With Motor Fluctuations Due To Parkinson's Disease | Parkinson Disease | Drug: Placebo;Drug: PF-06649751 low dose (1 mg QD);Drug: PF-06649751 middle dose 1 (3 mg QD);Drug: PF-06649751 middle dose 2 (7 mg QD);Drug: PF-06649751 high dose (15 mg QD) | Pfizer | Not recruiting | 40 Years | 85 Years | All | 108 | Phase 2 | United States;Canada;France;Germany;Japan;Spain | |
343 | JPRN-UMIN000021236 | 2016/03/01 | 2 April 2019 | Investigation in effect of aroma therapy using magnetoencepharography | Normal volunteer, Epilepsy patients, Parkinson disease patients | aroma 1 Trans-nasal administration of lavender essence Subject hold a cup with 0.05ml essence in front of the nose for 2 minutes After the administration, MEG signals will be recorded for 4 minutes Also, the subjects were evaluated their moods and awareness. aroma 2 Trans-nasal administration of grapefruit essence Subject hold a cup with 0.05ml essence in front of the nose for 2 minutes After the administration, MEG signals will be recorded for 4 minutes Also, the subjects were evaluated their moods and awareness. fragrant Trans-nasal administration of fragrant Subject hold a cup with 0.05ml essence in front of the nose for 2 minutes After the administration, MEG signals will be recorded for 4 minutes Also, the subjects were evaluated their moods and awareness. | Osaka University Graduate School of Medicine Department of Neurosurgery | Not Recruiting | 20years-old | 80years-old | Male and Female | 10 | Phase 1 | Japan | ||
344 | NCT02994719 | March 1, 2016 | 18 December 2018 | Gait Analysis in Neurological Disease | Gait Pattern Analysis in Neurological Disease | Parkinson's Disease;Parkinsonian Disorders;Atypical Parkinson Disease;Progressive Supranuclear Palsy;Multiple System Atrophy;Corticobasal Degeneration;Gait, Frontal | Drug: Anti-Parkinson medication;Device: Deep Brain Stimulation | Beth Israel Deaconess Medical Center | Recruiting | 18 Years | 85 Years | All | 110 | N/A | United States | |
345 | NCT02462603 | March 2016 | 29 July 2019 | Safety and Biomarker Study of EPI-589 in Parkinson's Disease | A Phase 2A Safety and Biomarker Study of EPI-589 in Mitochondrial Subtype and Idiopathic Parkinson's Disease Subjects | Parkinson's Disease | Drug: EPI-589 | Edison Pharmaceuticals Inc | Not recruiting | 21 Years | 75 Years | All | 44 | Phase 2 | United States;Germany;United Kingdom | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
346 | NCT02605434 | March 2016 | 26 August 2019 | A Study to Assess the Safety and Efficacy of the of the Gastric-retentive AP-CD/LD in Advanced Parkinson's Patients | Phase 3 Multicenter Randomized Double-Blind, Double-dummy, Active-Controlled Study Comparing Efficacy/Safety of Gastric-retentive, Controlled-release Accordion Pill Carbidopa/Levodopa to Immediate Release in Fluctuating Parkinson's Patients | Parkinson's Disease | Drug: Accordion Pill™ Carbidopa/Levodopa;Drug: Sinemet®;Drug: Placebo -AP-CD/LD;Drug: Placebo- Sinemet | Intec Pharma Ltd. | Not recruiting | 30 Years | N/A | All | 420 | Phase 3 | United States;Bulgaria;Germany;Israel;Italy;Poland;Slovakia;Spain;Ukraine;United Kingdom;Hungary | |
347 | NCT02668497 | March 2016 | 6 May 2019 | Kinematic-based BoNT-A Bilateral Upper Limb PD Therapy | Kinematic Characterization of Upper Limb Parkinson's Disease Tremor for Optimized Botulinum Toxin Type A Therapy | Parkinson's Disease | Drug: Botulinum Toxin Type A | Western University, Canada | Not recruiting | 18 Years | 80 Years | All | 50 | Phase 2 | Canada | |
348 | NCT02708186 | March 2016 | 5 November 2018 | Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD) | A Phase 2, Double-blind, Randomized, Placebo-controlled Study of Nelotanserin Versus Placebo in Subjects With Dementia With Lewy Bodies (DLB) or Parkinson's Disease Dementia (PDD) Who Have REM Sleep Behavior Disorder (RBD) | Dementia With Lewy Bodies;REM Sleep Behavior Disorder;Parkinson's Disease Dementia | Drug: Nelotanserin;Drug: Placebo | Axovant Sciences Ltd. | Not recruiting | 50 Years | N/A | All | 29 | Phase 2 | United States | |
349 | NCT02618941 | February 2, 2016 | 16 December 2017 | Follow-up Study to Assess a Second Boost Immunization With AFFITOPE® PD01A With Regard to Safety and Clinical Activity (AFF008AA) | Phase IB Follow-up, Controlled, Parallel Group, Single-center Study to Assess a Second Boost Immunization With AFFITOPE® PD01A With Regard to Safety/Tolerability, Immunological and Clinical Activity in Patients Who Have Participated in the AFF008 Program | Parkinson's Disease | Biological: AFFITOPE® PD01A | Affiris AG | Not recruiting | 40 Years | 68 Years | All | 26 | Phase 1 | Austria | |
350 | JPRN-UMIN000020288 | 2016/02/01 | 2 April 2019 | Intervention Study of Istradefylline for the Treatment of Gait Disorders in Patients with Parkinson's Disease. | Parkinson's disease | In this research, the duration of evaluation will be 12 weeks. Treatment with istradefylline will be started at a dose of 20 mg administered once daily. The dose of istradefylline will be increased to 40 mg once daily if the patient has no tolerability issues and still has motor symptoms at Week 4. After the Week 4, the dose will be allowed to be reduced to 20 mg once daily, if the patient exhibits any tolerability issues such as the occurrence of adverse drug reactions caused by istradefylline. | Juntendo University Shizuoka Hospital | Not Recruiting | 20years-old | Not applicable | Male and Female | 30 | Not selected | Japan | ||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
351 | JPRN-UMIN000020527 | 2016/02/01 | 2 April 2019 | Multi-centered, placebo-controlled, double-blind, randomized clinical trial to assess the effect of oral inosine on the onset of wearing off in patients with early stage Parkinson's disease | Parkinson's disease | Inosine to maintain a serum urate level between 6.0-7.5 mg/dL for 2 years Lactose as a placebo for 2 years | Ehime University Graduate School of Medicine | Recruiting | 20years-old | Not applicable | Male and Female | 100 | Phase 2 | Japan | ||
352 | NCT02524405 | February 2016 | 30 September 2019 | BEAM: Brain-Eye Amyloid Memory Study | The Brain Eye Amyloid Memory (BEAM) Study: Validation of Ocular Measures as Potential Biomarkers for Early Detection of Brain Amyloid and Neurodegeneration | Alzheimer's Disease;Mild Cognitive Impairment;Vascular Cognitive Impairment;Parkinson's Disease;Lewy Body Disease | Other: Pittsburgh Compound B [11C]-PIB | Sunnybrook Health Sciences Centre | Brain Canada;Weston Brain Institute;GE Healthcare;University Health Network, Toronto;Centre for Addiction and Mental Health;Baycrest;St. Michael's Hospital, Toronto;Kensington Eye Institute | Recruiting | 50 Years | 90 Years | All | 345 | N/A | Canada |
353 | NCT02641054 | February 2016 | 16 December 2017 | Efficacy Phase IIa Study of CVXL-0107 in Advanced Parkinson's Disease | Double-Blind Randomized Placebo-Controlled Cross-Over Phase IIa Trial to Evaluate Efficacy of CVXL-0107 on Parkinson-Related Symptoms and Levodopa-Induced Dyskinesia in Advanced Parkinson's Disease Patients Using a Levodopa Challenge Test | Idiopathic Parkinson Disease | Drug: CVXL-0107;Drug: Placebo;Drug: Levodopa | CleveXel Pharma | Not recruiting | 40 Years | 75 Years | All | 21 | Phase 2 | France | |
354 | NCT02655315 | February 2016 | 19 November 2018 | Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's Disease | Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's Disease. European Multicentre, Parallel-group, Placebo-controlled, Randomized Clinical Trial of Deferiprone | Parkinson Disease | Drug: Deferiprone;Drug: Placebo | University Hospital, Lille | European Commission;ApoPharma | Recruiting | N/A | 80 Years | All | 338 | Phase 2 | Austria;Czechia;France;Germany;Netherlands;Portugal;Spain;United Kingdom;Czech Republic |
355 | NCT02680977 | February 2016 | 17 October 2016 | Mucuna Pruriens Therapy in Parkinson's Disease | Mucuna Pruriens Therapy in Parkinson's Disease: a Double-blind, Placebo-controlled, Randomized, Crossover Study. | Parkinson's Disease | Other: MP-Equivalent;Other: MP-Low;Other: MP+DDCI;Drug: LD+DDCI;Drug: LD-DDCI;Other: Placebo | ASST Gaetano Pini-CTO | Fondazione Grigioni per il Morbo di Parkinson;Fondazione Grigioni per il Morbo di Parkinson | Not recruiting | 21 Years | N/A | Both | 18 | Phase 2 | Bolivia |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
356 | NCT02683629 | February 2016 | 27 May 2019 | Investigation of the Safety and Efficacy of NTCELL® [Immunoprotected (Alginate-Encapsulated) Porcine Choroid Plexus Cells for Xenotransplantation] in Patients With Parkinson's Disease | A Phase IIb, Randomised, Double-blind, Placebo-controlled, Dose-range Investigation of the Safety and Efficacy of NTCELL® [Immunoprotected (Alginate-Encapsulated) Porcine Choroid Plexus Cells for Xenotransplantation] in Patients With Parkinson's Disease | Parkinson's Disease | Biological: NTCELL Implantation;Other: Sham Surgery | Living Cell Technologies | Statistecol Consultants Limited | Not recruiting | 40 Years | 65 Years | All | 18 | Phase 2 | New Zealand |
357 | EUCTR2015-004238-85-ES | 27/01/2016 | 22 January 2018 | Brain SPECT in premotor stage of Parkinson disease | Ictal brain SPECT in the premotor stage of Parkinson disease | Parkinson disease MedDRA version: 18.1 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: CERETEC (TM) Estabilizado Product Name: Ceretec Pharmaceutical Form: Powder for solution for injection INN or Proposed INN: Ceretec CAS Number: 100504-35-6 Other descriptive name: TECHNETIUM (99MTC) EXAMETAZIME Concentration unit: mCi millicurie(s) Concentration type: equal Concentration number: 25- | IDIBAPS | Not Recruiting | Female: yes Male: yes | 30 | Phase 2 | Spain | |||
358 | JPRN-JapicCTI-153112 | 22/1/2016 | 16 July 2019 | ONO-2370 Phase 2 study | ONO-2370 a Phase 2 Double-Blind, Randomised, Placebo-Controlled, Parallel-Group study, and an Open-Label, Uncontrolled, Multicenter, Long-term, Extension study | Parkinson's disease | Intervention name : ONO-2370 INN of the intervention : Opicapone Dosage And administration of the intervention : ONO-2370 once-daily Control intervention name : Placebo INN of the control intervention : - Dosage And administration of the control intervention : Once-daily placebo equivalent to active control | ONO PHARMACEUTICAL CO.,LTD. | Not Recruiting | 30 | 83 | BOTH | 399 | Phase 2 | Japan | |
359 | NCT03258294 | January 13, 2016 | 16 December 2017 | Effect of Melatonin on Sleep Disturbances in Patients With Parkinson's Disease | Effect of Melatonin on Sleep Disturbances in Patients With Parkinson's Disease: Double Blind, Randomized, Placebo Controlled Trial | Parkinson's Disease | Drug: Melatonin(Circadin®);Drug: Placebo Oral Tablet | KIMJisun | Kuhnil Pharmaceutical Co., Ltd. | Recruiting | 55 Years | N/A | All | 82 | Phase 4 | |
360 | ChiCTR-CPC-15007223 | 2016-01-01 | 18 April 2017 | Characteristics andAffecting Factors Amalysis of Sleep Disorder in Parkinsons Disease | Characteristics andAffecting Factors Amalysis of Sleep Disorder in Parkinsons Disease | Parkinsons Disease; Sleep Disorder | The treatment group; The control group:Rotigotine patch; | Department of Neurology, Changzheng Hospital, Second Military Medical University | Not Recruiting | Both | The treatment group; The control group:100; | Post-market | China | |||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
361 | NCT02549573 | January 2016 | 16 December 2017 | Outpatient Physical Therapy Intervention in Subjects With Parkinson's Disease Currently Using APOKYN® | Outpatient Physical Therapy Intervention in Subjects With Parkinson's DiseaseCurrently Using APOKYN®: A Phase IV Study of Outcome Assessments of Physical Therapy in Subjects in an On Versus End-of-Dose-Off Motor State | Parkinson's Disease;Motor Symptoms | Drug: APOKYN;Behavioral: Physical Therapy | US WorldMeds LLC | Not recruiting | 18 Years | 78 Years | All | 13 | Phase 4 | United States | |
362 | NCT02579473 | January 2016 | 30 September 2019 | A Study of Weekly Subcutaneous Injections of SER-214 in Subjects With Parkinson's Disease (PD), to Determine the Safety, Tolerability and Pharmacokinetic (PK) Profile of SER-214 | A Multi-center, Open-label, Multiple Ascending Dosage-ranging Cohort (MAD) Study in Early, Untreated or Stably Treated Subjects With Parkinson's Disease (PD), to Determine the Safety, Tolerability and Pharmacokinetics (PK) of Injections of SER-214 Administered Subcutaneously Once a Week for Two Weeks After 0-2 Weeks of Dose Titration | Parkinson's Disease | Drug: SER-214 | Serina Therapeutics | Not recruiting | 40 Years | 80 Years | All | 20 | Phase 1 | United States | |
363 | NCT02589340 | January 2016 | 15 April 2019 | Buspirone, in Combination With Amantadine, for the Treatment of Levodopa-induced Dyskinesia | Buspirone, in Combination With Amantadine, for the Treatment of Levodopa-induced Dyskinesia | Parkinson's Disease;Dyskinesias;Movement Disorders | Drug: Buspirone;Drug: Placebo | Oregon Health and Science University | Portland VA Medical Center | Recruiting | 18 Years | 99 Years | All | 15 | Phase 1 | United States |
364 | NCT02639221 | January 2016 | 10 October 2016 | A Phase I, Double Blind, Placebo Controlled, First in Human, Single and Multiple Ascending Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Male and Female Subjects | PXT002331 A Phase I, Double Blind, Placebo Controlled, First in Human, Single and Multiple Ascending Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Male and Female Subjects | Parkinson's Disease | Drug: PXT002331 | Prexton Therapeutics | Not recruiting | 18 Years | 60 Years | Both | 64 | Phase 1 | United Kingdom | |
365 | NCT02649608 | January 2016 | 11 June 2018 | An Exploratory Study Investigating Safety, Tolerability and Pharmacokinetics of Ascending Doses of Lu AE04621 in Parkinson Disease Patients | Interventional, Open-label, Exploratory Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Lu AE04621 and the Active Metabolite Lu AA40326 After Ascending Oral Doses of Lu AE04621 to Patients With Parkinson's Disease | Parkinson Disease | Drug: Lu AE04621 | H. Lundbeck A/S | Not recruiting | 45 Years | 75 Years | All | 15 | Phase 1 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
366 | NCT02768077 | January 2016 | 30 May 2016 | Effect of Melatonin on Sleep Disturbances in Patients With Parkinson's Disease | Effect of Melatonin on Sleep Disturbances in Patients With Parkinson's Disease: Double Blind, Randomized, Placebo Controlled Trial | Parkinson's Disease | Drug: Melatonin(Circadin®);Drug: Placebo | Kuhnil Pharmaceutical Co., Ltd. | Recruiting | 55 Years | N/A | Both | 100 | Phase 4 | ||
367 | EUCTR2014-002600-24-SE | 03/12/2015 | 20 February 2017 | Safinamide versus placebo in patients with Parkinson’s disease for improvement of motor complications | A TWO YEAR, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF SAFINAMIDE 100 MG, ONCE DAILY, AS ADD ON THERAPY, IN IDIOPATHIC PARKINSON’S DISEASE PATIENTS WITH MOTOR FLUCTUATIONS - EVEREST | Idiopathic Parkinson's Disease MedDRA version: 18.0 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Xadago Product Name: safinamide Pharmaceutical Form: Film-coated tablet INN or Proposed INN: SAFINAMIDE CAS Number: 133865-89-1 Other descriptive name: SAFINAMIDE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Trade Name: Xadago Product Name: safinamide Pharmaceutical Form: Film-coated tablet INN or Proposed INN: SAFINAMIDE CAS Number: 133865-89-1 Other descriptive name: SAFINAMIDE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- | Zambon S.P.A. | Not Recruiting | Female: yes Male: yes | 556 | Phase 3 | France;Spain;Austria;Russian Federation;Germany;Italy;United Kingdom;Switzerland;Sweden | |||
368 | NCT02470780 | December 2015 | 16 December 2017 | Treating Bacterial Overgrowth in Parkinson's Disease | Treating Bacterial Overgrowth in Parkinson's Disease | Parkinson's Disease;Small Intestinal Bacterial Overgrowth | Drug: Rifaximin;Drug: Placebo | University of Cincinnati | Not recruiting | 18 Years | N/A | All | 24 | Phase 2/Phase 3 | United States | |
369 | NCT02610231 | December 2015 | 1 April 2019 | Long Term Study of Istradefylline in Subjects With Moderate to Severe Parkinson's Disease | A Phase 3, Long-term, Open-label Study of Istradefylline in Subjects With Moderate to Severe Parkinson's Disease | Idiopathic Parkinson's Disease | Drug: Istradefylline 20 mg or 40 mg | Kyowa Hakko Kirin Pharma, Inc. | Kyowa Hakko Kirin Co., Ltd | Not recruiting | 30 Years | N/A | All | 243 | Phase 3 | United States;Canada;Czechia;Germany;Israel;Italy;Poland;Serbia;Czech Republic |
370 | NCT02702102 | December 2015 | 22 October 2019 | Imaging Inflammation in Patients With Parkinson's Disease Dementia or Dementia With Lewy Bodies | Imaging Inflammation in Patients With Diffuse Lewy Body Disease | Diffuse Lewy Body Disease;Dementia With Lewy Bodies;Parkinson's Disease Dementia | Drug: 11C-PBR28 | William Charles Kreisl | National Institute on Aging (NIA) | Not recruiting | 60 Years | N/A | All | 5 | Phase 2 | United States |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
371 | EUCTR2015-002631-17-ES | 19/11/2015 | 28 February 2019 | A study comparing immediate-release oral Levodopa and L-dopa/carbidopa intestinal gel over cognition and mood in non-demented Parkinson?s disease (PD) patients | An intra-subject, randomized, double blind, crossover study comparing immediate-release oral LD (IR-LD) and L-dopa/carbidopa intestinal gel (LCIG) over cognition and mood in non-demented advanced Parkinson?s disease (PD) patients | Parkinson disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Duodopa Product Name: Duodopa Pharmaceutical Form: Intestinal gel Trade Name: Sinemet Plus Product Name: Sinemet Plus Pharmaceutical Form: Tablet | Institut de Recerca del Hospital de la Santa Creu i Sant Pau | Not Recruiting | Female: yes Male: yes | 18 | Phase 4 | Spain | |||
372 | NCT02565628 | November 16, 2015 | 16 December 2017 | PF-06669571 In Subjects With Idiopathic Parkinson's Disease | A Phase 1b, Double Blind, Sponsor Open, Randomized, Parallel, Group Multiple Dose Study Examining The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06669571 In Subjects With Idiopathic Parkinson's Disease. | Idiopathic Parkinson's Disease | Drug: PF-06669571;Drug: Placebo | Pfizer | Not recruiting | N/A | N/A | All | 20 | Phase 1 | United States | |
373 | JPRN-UMIN000019676 | 2015/11/10 | 23 April 2019 | The double blind, placebo controlled trial of modafinil for excessive daytime sleepiness in Parkinson's disease | The double blind, placebo controlled trial of modafinil for excessive daytime sleepiness in Parkinson's disease - The double blind, placebo controlled trial of modafinil for excessive daytime sleepiness in Parkinson's disease | Parkinson's disease | taking modafinil (200 mg/day) after breakfast for 4 weeks, wash out for 2 weeks, taking matching placebo after breakfast for 4 weeks taking matching placebo after breakfast for 4 weeks, wash out for 2 weeks, taking modafinil (200 mg/day) after breakfast for 4 weeks | Department of Neurology and Clinical Pharmacology, Ehime University Graduate School of Medicine | Not Recruiting | 20years-old | 100years-old | Male and Female | 20 | Not selected | Japan | |
374 | EUCTR2015-000148-40-GB | 09/11/2015 | 18 April 2016 | A trial comparing simvastatin to placebo as a neuronal protective treatment for Parkinson's disease. | Simvastatin as a neuroprotective treatment for Parkinson's disease: a double-blind, randomised, placebo controlled futility study in patients of moderate severity. - Simvastatin as a neuroprotective treatment for moderate PD (PD STAT) | Parkinson's disease MedDRA version: 18.0 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders MedDRA version: 18.0 Level: LLT Classification code 10013113 Term: Disease Parkinson's System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Simvastatin Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Simvastatin CAS Number: 79902-63-9 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40- Pharmaceutical form of the placebo: Capsule, soft Route of administration of the placebo: Oral use | Plymouth Hospitals NHS Trust | Authorised | Female: yes Male: yes | 198 | United Kingdom | ||||
375 | JPRN-UMIN000019654 | 2015/11/06 | 2 April 2019 | The effect of rich-hydrogen water drinking to gut peptide | Parkinson's disease, healthy control | hydrogen water natural water | Nagoya graduate school of medicine university | Not Recruiting | 20years-old | 80years-old | Male and Female | 40 | Not applicable | Japan | ||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
376 | JPRN-UMIN000019090 | 2015/11/04 | 2 April 2019 | Reduced form of CoenzymeQ10 for Parkinson's disease - open trial of dose finding test and combination with hydrogen water | Parkinson's disease | reduced form of CoQ10 300mg 16weeks reduced form of CoQ10 600mg 16weeks reduced form of CoQ10 600mg 16weeks hydrogen water 500ml(Suisosui 7.0) 16weeks | Juntendo University Koshigaya Hospital | Not Recruiting | 20years-old | 80years-old | Male and Female | 45 | Not selected | Japan | ||
377 | JPRN-jRCTs041180070 | 04/11/2015 | 10 September 2019 | Trerief Impact in PD PET Study | Randomized, multicenter, open-label, comparative study on neuroprotective effects of zonisamide (Trerief), anti-parkinsonian drug, in patients with early Parkinson's disease: Evaluation by functional PET (positron emission tomography) images - TIPPS | Parkinson's disease Parkinson's disease;D010300 | [1] Zonisamide treatment group Zonisamide (25 mg) once daily in addition to levodopa/DCI with fixed dosage and administration. Note that after one-year fixed protocol period, the followings are allowed; 1) one or two tablets per day in case of developing wearing off phenomenon, 2) change of dose and/or administration of levodopa/DCI, and 3) addition of other anti-parkinsonian drugs due to exacerbation of symptoms. [2] Zonisamide non-treatment group Only levodopa/DCI with fixed dosage and administration. Note that after one-year fixed protocol period, the followings are allowed; 1) change of dose and/or administration of levodopa/DCI and 2) addition of other anti-parkinsonian drugs except for zonisamide due to exacerbation of symptoms. | Yasuomi Ouchi | Not Recruiting | none | Under 80 years old | Both | 20 | N/A | none | |
378 | JPRN-JapicCTI-153056 | 01/11/2015 | 2 April 2019 | ME2125 Phase II/III (ME2125-3) | A Phase II/III, Double-Blind, Placebo-Controlled Study of ME2125 in Patients with Parkinson's Disease with Wearing-Off Phenomenon | Parkinson's disease | Intervention name : ME2125 INN of the intervention : safinamide Dosage And administration of the intervention : Orally administer a dose of 2 tablets once a daily in morning. Control intervention name : Placebo Dosage And administration of the control intervention : Orally administer a dose of 2 tablets once a daily in morning. | Meiji Seika Pharma Co., Ltd. | 30 | BOTH | 410 | Phase 2-3 | ||||
379 | JPRN-JapicCTI-153057 | 01/11/2015 | 2 April 2019 | ME2125 Phase III (ME2125-4) | A Phase III, Long-Term Treatment Study of ME2125 in Patients with Parkinson's Disease with Wearing-Off Phenomenon | Parkinson's disease | Intervention name : ME2125 INN of the intervention : safinamide Dosage And administration of the intervention : Orally administer a dose of 2 tablets once a daily in morning. Control intervention name : Placebo Dosage And administration of the control intervention : Orally administer a dose of 2 tablets once a daily in morning. | Meiji Seika Pharma Co., Ltd. | 30 | BOTH | 200 | Phase 3 | ||||
380 | NCT04110678 | November 1, 2015 | 14 October 2019 | Tolerance to NeuroEPO in Parkinson Disease | Nasal Administration of the NeuroEPO in Parkinson Disease: Short-term Tolerance Physician Lead Trial | Parkinson Disease | Drug: NeuroEPO | International Center for Neurological Restoration, Cuba | Center of Molecular Immunology, Cuba;University of Electronic Science and Technology of China | Not recruiting | 40 Years | 70 Years | All | 26 | Phase 1/Phase 2 | Cuba |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
381 | NCT02271503 | November 2015 | 16 December 2017 | A Study to Assess the PK and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson's Disease | A Study to Assess the Pharmacokinetics and Pharmacodynamics of a Single Dose of IPX203 in Patients With Advanced Parkinson's Disease | Parkinson's Disease | Drug: CD-LD IR;Drug: IPX203 180 mg;Drug: IPX203 270 mg;Drug: Rytary 195 mg;Drug: Rytary 145 mg | IMPAX Laboratories, Inc. | Not recruiting | 40 Years | N/A | All | 26 | Phase 2 | United States | |
382 | NCT02577523 | November 2015 | 23 April 2019 | A Clinical Study Investigating the Efficacy, Safety, Tolerability and Pharmacokinetics of ND0612H, a Solution of Levodopa/Carbidopa Administered as a Continuous Subcutaneous Infusion in Subjects With Advanced Parkinson's Disease | A Multicenter, Parallel-group, Rater-blinded, Randomized Clinical Study Investigating the Efficacy, Safety, Tolerability and Pharmacokinetics of 2 Dosing Regimens of ND0612H, a Solution of Levodopa/Carbidopa Delivered Via a Pump System as a Continuous Subcutaneous Infusion in Subjects With Advanced Parkinson's Disease | Parkinson's Disease | Drug: ND0612 (Levodopa/Carbidopa solution) | NeuroDerm Ltd. | Not recruiting | 30 Years | 80 Years | All | 38 | Phase 2 | United States;Austria;Israel;Italy | |
383 | NCT02632279 | November 2015 | 3 September 2018 | Tryptophan Depletion in PD Patients Treated With STN DBS | Tryptophan Depletion in Parkinson's Disease Patients Treated With Deep Brain Stimulation of the Subthalamic Nucleus: Effects on Mood and Motor Functions | Parkinson's Disease | Dietary Supplement: Tryptophan (TRP) depletion;Dietary Supplement: Placebo;Device: Stimulator ON;Device: Stimulator OFF | Maastricht University Medical Center | Netherlands Brain Foundation | Not recruiting | N/A | N/A | All | 7 | N/A | Netherlands |
384 | NCT02758730 | November 2015 | 15 August 2016 | Study Assessing Tolerability and Safety and Exploring the Immunogenicity and Therapeutic Activity of AFFITOPE® PD01A in PD-GBA Patients | A Randomized, Placebo-controlled, Parallel Group, Patient-blind, Single-center Phase I Pilot Study Assessing Tolerability and Safety and Exploring the Immunogenicity and Therapeutic Activity of AFFITOPE® PD01A, a New Vaccine Against Alpha-synuclein, in Patients With PD-GBA | Parkinson's Disease | Biological: AFFITOPE® PD01A + Adjuvant;Biological: Adjuvant without active component | Affiris AG | University Hospital Tuebingen | Not recruiting | 40 Years | 80 Years | Both | 0 | Phase 1 | Germany |
385 | NCT02914366 | November 2015 | 1 April 2019 | Ambroxol as a Treatment for Parkinson's Disease Dementia | Ambroxol as a Novel Disease Modifying Treatment for Parkinson's Disease Dementia | Parkinson's Disease Dementia | Drug: Ambroxol;Other: Placebo | Lawson Health Research Institute | Weston Brain Institute;University of Western Ontario, Canada;London Health Sciences Centre | Recruiting | 50 Years | N/A | All | 75 | Phase 2 | Canada |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
386 | EUCTR2015-003045-26-SE | 23/10/2015 | 16 November 2015 | Study of Dopamine Transporters (signal substance in central nervous system)in patients with early signs of Parkinson´s disease. | [18F] FE-PE2I PET/CT study of Dopamine Transporters in Early Parkinsonian disease. | Patients with newly clinically diagnosed untreated idiopathic parkinsonism MedDRA version: 18.0 Level: HLT Classification code 10034005 Term: Parkinson's disease and parkinsonism System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: [18F]FE-PE2I Pharmaceutical Form: Solution for injection INN or Proposed INN: [18F]-(E)-N-(3-iodoprop-2-enyl)-2b-carbofluoroethoxy-3b-(4'-methylphenyl)nortropane Current Sponsor code: [18F]-(E)-N-(3-iodoprop-2-enyl)-2b-carbofluoroethoxy-3b-(4'-methylphenyl)nortropane Concentration unit: MBq/kg megabecquerel(s)/kilogram Concentration type: equal Concentration number: 2.86- Trade Name: DaTSCAN Pharmaceutical Form: Solution for injection INN or Proposed INN: IOFLUPANE (123I) CAS Number: 155798-07-5 Concentration unit: MBq megabecquerel(s) Concentration type: equal Concentration number: 185- Product Name: 15O H2O Pharmaceutical Form: Solution for injection INN or Proposed INN: [15O]H2O Current Sponsor code: [15O]H2O Concentration unit: MBq megabecquerel(s) Concentration type: equal Concentration number: 800- | Umeå University Hospital | Authorised | Female: yes Male: yes | Sweden | |||||
387 | JPRN-UMIN000019082 | 2015/10/10 | 2 April 2019 | the effect of smell dysfunction using hydrogen gas for parkinson disease | parkinson's disease | we measured smell test and urine 8-OHdG before and after 3.5% hydrogen gas. After two month discontinuation of administration. we measured smell test and urine 8-OHdG before and after room air. we measured smell test and urine 8-OHdG before and after room air. After two month discontinuation of administration. we measured smell test and urine 8-OHdG before and after 3.5% hydrogen gas. | Nagoya University Graduate School of Medicine | Not Recruiting | Not applicable | Not applicable | Male and Female | 20 | Not selected | Japan | ||
388 | JPRN-UMIN000019524 | 2015/10/01 | 2 April 2019 | Randomized, multicenter, open-label, comparative study on neuroprotective effects of zonisamide (Trerief), anti-parkinsonian drug, in patients with early Parkinson's disease: Evaluation by functional PET (positron emission tomography) images | Randomized, multicenter, open-label, comparative study on neuroprotective effects of zonisamide (Trerief), anti-parkinsonian drug, in patients with early Parkinson's disease: Evaluation by functional PET (positron emission tomography) images - Trerief Impact in PD PET Study (TIPPS) | Parkinson's Disease | Zonisamide treatment group: Zonisamide (25 mg) once daily in addition to levodopa/DCI with fixed dosage and administration. Note that after one-year fixed protocol period, the followings are allowed; 1) one or two tablets per day in case of developing wearing off phenomenon, 2) change of dose and/or administration of levodopa/DCI, and 3) addition of other anti-parkinsonian drugs due to exacerbation of symptoms. Zonisamide non-treatment group: Only Levodopa/DCI with fixed dosage and administration. Note that after one-year fixed protocol period, the followings are allowed; 1) change of dose and/or administration of levodopa/DCI and 2) addition of other anti-parkinsonian drugs except for zonisamide due to exacerbation of symptoms. | Hamamatsu University School of Medicine | Not Recruiting | Not applicable | 80years-old | Male and Female | 20 | Not applicable | Japan | |
389 | NCT02572713 | October 2015 | 16 December 2017 | Systemic Synuclein Sampling Study (S4) | Systemic Synuclein Sampling Study (S4) | Parkinson's Disease | Procedure: Biofluid samplings;Procedure: Tissue samplings;Drug: DaTSCAN™ | Michael J. Fox Foundation for Parkinson's Research | Indiana University;University of Iowa;Banner Health;Paracelsus Elena Klinik | Not recruiting | 40 Years | N/A | All | 80 | N/A | United States;Canada |
390 | NCT02562768 | September 30, 2015 | 16 December 2017 | A Study of LY3154207 in Healthy Participants and Participants With Parkinson's Disease | Multiple-Ascending Dose, Safety, Tolerability, and Pharmacokinetic Study of LY3154207 in Healthy Subjects and Subjects With Parkinson's Disease | Parkinson's Disease | Drug: LY3154207;Drug: Placebo | Eli Lilly and Company | Not recruiting | 20 Years | N/A | All | 80 | Phase 1 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
391 | NCT02549092 | September 9, 2015 | 7 October 2019 | A Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Therapy Relative to That of Optimized Medical Treatment (OMT) on Non-motor Symptoms (NMS) Associated With Advanced Parkinson's Disease (PD) | An Open-label, Randomized 26-Week Study Comparing Levodopa-Carbidopa INteStInal Gel (LCIG) THerapy to Optimized Medical Treatment (OMT) on Non-Motor Symptoms (NMS) in Subjects With Advanced Parkinson's Disease - INSIGHTS Study | Advanced Parkinson's Disease | Drug: ABT-SLV187 | AbbVie | Recruiting | 30 Years | 99 Years | All | 88 | Phase 3 | United States;Australia;Canada;Germany;Greece;Italy;Korea, Republic of;Spain;Sweden | |
392 | NCT02542696 | August 31, 2015 | 14 October 2019 | An Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of OFF Episodes in Patients With Parkinson's Disease | An Open-Label, Phase 3 Study Examining the Long-Term Safety, Tolerability and Efficacy of APL-130277 in Levodopa Responsive Patients With Parkinson's Disease Complicated by Motor Fluctuations (OFF Episodes) | Parkinson Disease | Drug: APL-130277 | Sunovion | Recruiting | 18 Years | N/A | All | 226 | Phase 3 | United States;Austria;Canada;France;Germany;Italy;Spain;United Kingdom | |
393 | EUCTR2014-004865-26-DE | 27/08/2015 | 21 November 2016 | 26-Week Study Comparing Levodopa-Carbidopa Intestinal Gel to Optimized Medical Treatment on Non-Motor Symptoms in Subjects with Advanced Parkinson's Disease | An Open-label, Randomized 26-Week Study Comparing Levodopa-Carbidopa INteStInal Gel (LCIG) Therapy to Optimized Medical Treatment (OMT) on Non-Motor Symptoms (NMS) in Subjects with Advanced Parkinson's Disease – INSIGHTS Study - INSIGHTS Study | Non-motor symptoms in advanced Parkinson's disease MedDRA version: 19.0 Level: LLT Classification code 10013113 Term: Disease Parkinson's System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Duodopa Pharmaceutical Form: Intestinal gel INN or Proposed INN: Levodopa CAS Number: 59-92-7 Other descriptive name: LEVODOPA Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- INN or Proposed INN: Carbidopa CAS Number: 38821-49-7 Other descriptive name: CARBIDOPA MONOHYDRATE Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 5- | AbbVie Deutschland GmbH & Co. KG | Not Recruiting | Female: yes Male: yes | 88 | Phase 3 | European Union;Canada;Spain;Australia;Germany;Italy;Sweden | |||
394 | EUCTR2015-000373-13-DE | 18/08/2015 | 19 October 2015 | A study to examine the effectiveness and safety of a new drug for involuntary muscle movements in patients with Parkinson’s disease | Phase 2, multicenter, randomized, double-blind, placebo-controlled, four-period cross-over, dose-range finding study to evaluate the safety, tolerability and efficacy of Eltoprazine in the treatment of levodopa induced dyskinesia in patients with Parkinson's disease. | Parkinson’s disease levodopa induced dyskinesia (PD-LID) MedDRA version: 18.0 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Eltoprazine Hydrochloride Pharmaceutical Form: Capsule, hard INN or Proposed INN: ELTOPRAZINE CAS Number: 98224-03-4 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 7.5- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Product Name: Eltoprazine Hydrochloride Pharmaceutical Form: Capsule, hard INN or Proposed INN: ELTOPRAZINE CAS Number: 98224-03-4 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Product Name: Eltoprazine Hydrochloride Pharmaceutical Form: Capsule, hard INN or Proposed INN: ELTOPRAZINE CAS Number: 98224-03-4 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2.5- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use | Amarantus BioScience Holdings, Inc. | Not Recruiting | Female: yes Male: yes | 60 | Phase 2 | France;United States;Germany;Sweden | |||
395 | NCT02554734 | August 2015 | 25 January 2016 | Pharmacokinetic Study in Healthy Volunteers | Pharmacokinetics of Levodopa After Repeated Doses of Carbidopa, ODM-104 and Levodopa: an Open, Randomised Study With Crossover Design in Healthy Males and Females | Parkinson's Disease | Drug: levodopa, carbidopa, ODM-104;Drug: levodopa, carbidopa, entacapone | Orion Corporation, Orion Pharma | Not recruiting | 18 Years | 65 Years | Both | 15 | Phase 1 | Finland | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
396 | NCT02599753 | August 2015 | 22 October 2018 | Investigating the Microstructural and Functional Alterations of Brain in Parkinson's Disease Patients | Investigating the Microstructural and Functional Alterations of Brain in Parkinson's Disease Patients With Neuropsychiatric Disorders by Multimodal Neuroimaging | Parkinson's Disease | Drug: 18-FDTBZ | Chang Gung Memorial Hospital | Not recruiting | 20 Years | 80 Years | All | 35 | Phase 2 | Taiwan | |
397 | NCT02917122 | August 2015 | 10 October 2016 | The Therapeutic Effect of Transcranial Direct Current Stimulation on Depression in Parkinson's Disease | The Therapeutic Effect of Transcranial Direct Current Stimulation on Depression in Parkinson's Disease | Parkinson Disease;Depression | Device: active tDCS;Drug: Sertraline;Device: sham tDCS | National Cheng-Kung University Hospital | Not recruiting | 18 Years | 75 Years | Both | 40 | Phase 1/Phase 2 | ||
398 | NCT02337751 | July 31, 2015 | 16 December 2017 | A Phase 3, Long-term, Extension Study of TVP-1012 (1 mg) in Early Parkinson's Disease Participants | A Multicenter, Open-label, Long-term, Extension, Phase 3 Study to Evaluate the Safety and Efficacy of TVP-1012 at 1 mg in Early Parkinson's Disease Patients Not Treated With Levodopa | Parkinson's Disease | Drug: TVP-1012 1mg | Takeda | Not recruiting | 30 Years | 79 Years | All | 198 | Phase 3 | Japan | |
399 | NCT02459886 | July 1, 2015 | 26 August 2019 | Single-Ascending Dose Study of BIIB054 in Healthy Participants and Early Parkinson's Disease | A Phase 1 Randomized, Double-Blinded, Placebo-Controlled Single-Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB054 in Healthy Subjects and Subjects With Early Parkinson's Disease | Parkinson's Disease;Healthy | Drug: BIIB054;Drug: Placebo | Biogen | Not recruiting | 40 Years | 80 Years | All | 66 | Phase 1 | United States | |
400 | NCT02488265 | July 1, 2015 | 12 November 2018 | Protocol: Balance Training in Parkinson's Disease | Randomized Controlled Trial Protocol: Balance Training With Rhythmical Cues to Improve and Maintain Balance Control in Parkinson's Disease | Parkinson Disease | Other: Balance Training;Other: Screening to prevent falls | University of Sao Paulo General Hospital | Not recruiting | 50 Years | 70 Years | All | 150 | N/A | Brazil | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
401 | NCT02415062 | July 2015 | 17 August 2015 | The Efficacy and Safety Study of High Dose Donepezil in Parkinson's Disease With Dementia | The Efficacy of 23mg Versus 10mg of Donepezil in ParkInson's Disease With Dementia | Parkinson's Disease | Drug: Donepezil | Inje University | Recruiting | 50 Years | 80 Years | Both | 150 | Phase 2 | Korea, Republic of | |
402 | NCT02453386 | July 2015 | 8 April 2019 | Safety and Efficacy Study of Tozadenant to Treat End of Dose Wearing Off in Parkinson's Patients | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease Experiencing End of Dose Wearing-Off (TOZ-PD) | Idiopathic Parkinson's Disease | Drug: tozadenant;Drug: placebo | Biotie Therapies Inc. | Not recruiting | 30 Years | 80 Years | All | 449 | Phase 3 | United States;Austria;Canada;Czechia;Germany;Italy;Spain;Czech Republic | |
403 | NCT02469090 | June 30, 2015 | 3 December 2018 | Efficacy, Safety and Tolerability Study of APL-130277 for the Acute Treatment of OFF Episodes in Patients With Parkinson's Disease | Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Examine the Efficacy, Safety and Tolerability of APL-130277 in Levodopa Responsive Patients With Parkinson's Disease Complicated by Motor Fluctuations (OFF Episodes) | Parkinson Disease, Off Episodes | Drug: APL-130277;Drug: Placebo | Sunovion | Not recruiting | 18 Years | N/A | All | 219 | Phase 3 | United States;Canada;United Kingdom | |
404 | EUCTR2014-000657-36-NL | 22/06/2015 | 10 July 2015 | Trial to investigate the efficacy of treatments in apomorphine-induced skin reactions | Open-label crossover trial to investigate the efficacy of treatments in apomorphine-induced skin reactions - Treatment of apomorphine-induced skin reactions: a pilot study | Parkinson's disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Hydrocortisone cream 10mg/g FNA Fagron Product Name: Hydrocortisone cream Pharmaceutical Form: Cream Trade Name: Solu-Cortef, powder for solution for injection, 100mg, and 'Act-O-Vial' Product Name: Solu-Cortef Pharmaceutical Form: Powder and solvent for solution for injection Trade Name: APO-go Product Name: Apomorphine Pharmaceutical Form: Solution for infusion in pre-filled syringe | University Medical Center Groningen | Authorised | Female: yes Male: yes | Netherlands | |||||
405 | NCT02230930 | June 2015 | 16 December 2017 | Treatment of Apomorphine-induced Skin Reactions: a Pilot Study | Open-label Crossover Trial to Investigate the Efficacy of Treatments in Apomorphine-induced Skin Reactions | Parkinson's Disease;Apomorphine-induced Skin Reactions | Drug: Apomorphine 0.25% (2.5mg/ml);Device: Massage with a spiky ball;Drug: Hydrocortisone cream 1%;Drug: Subcutaneous hydrocortisone 10mg | University Medical Center Groningen | Recruiting | 30 Years | N/A | All | 20 | Phase 2 | Netherlands | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
406 | NCT02450786 | June 2015 | 11 February 2019 | Effect of Donepezil on Cognition in Parkinson's Disease With Mild Cognitive Impairment (PD-MCI) | Parkinson's Disease | Drug: Donepezil | Yonsei University | Not recruiting | 40 Years | N/A | All | 80 | Phase 2 | Korea, Republic of | ||
407 | NCT02604914 | June 2015 | 13 June 2016 | A Sequential Two-Part, Open-Label Study in Healthy Male and Female Subjects | 1) To Identify the Concentration of CD That Provides Optimal Bioavailability of a Concomitant Fixed Concentration of LD Infused SC Continuously; 2) To Compare the Bioavailability of the Optimal LD/CD Solution to That of LD/CD Intestinal Gel | Parkinson's Disease | Drug: ND0612;Drug: LCIG | NeuroDerm Ltd. | Quotient Clinical | Not recruiting | 40 Years | 65 Years | Both | 36 | Phase 1 | United Kingdom |
408 | NCT02769793 | June 2015 | 11 June 2018 | Efficacy of Levodopa/Benserazide Dispersible Tablet on Response Fluctuations in PD Patients With Delayed ON | Efficacy of Levodopa/Benserazide Dispersible Tablet on Response Fluctuations in Parkinson's Disease Patients With Delayed ON: a Multicenter Randomized Open-label Cross-over Trial | Parkinson Disease | Drug: Levodopa dispersible;Drug: Levodopa | Seoul National University Hospital | SMG-SNU Boramae Medical Center;Samsung Medical Center | Recruiting | 31 Years | 80 Years | All | 40 | Phase 4 | Korea, Republic of |
409 | EUCTR2014-005422-35-GB | 28/05/2015 | 30 April 2019 | The role of Buspirone in attenuating involuntary movements (Dyskinesias) in patients with Parkinson's disease. | THE ROLE OF BUSPIRONE IN ATTENUATING LEVODOPA-INDUCED DYSKINESIAS IN PATIENTS WITH PARKINSON'S DISEASE: A CLINICAL AND POSITRON EMISSION TOMOGRAPHY STUDY WITH 11C-PHNO. - The role of buspirone in LIDs in patients with Parkinson’s disease. | Levodopa induced dyskinesias within Parkinson's disease. MedDRA version: 17.1 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Buspirone Hydrochloride Product Name: Buspirone Hydrochloride Pharmaceutical Form: Tablet INN or Proposed INN: Buspirone Hydrochloride Concentration type: equal Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | Imperial College London-Imperial College Healthcare NHS Trust | Not Recruiting | Female: yes Male: yes | 24 | Phase 4 | United Kingdom | |||
410 | JPRN-jRCTs061180028 | 11/05/2015 | 10 September 2019 | Pain reduction in PD patients with depression: double blind, randomized clinical trial of duloxetine | A double-blind, randomized clinical trial to evaluate the efficacy of Duloxetine against pain associated with Parkinson's disease with depression - Pain reduction in PD patients with depression: double blind, randomized clinical trial of duloxetine | Parkinson's disease;D010300 | The treatment groups consist of an active treatment arm (40mg/day Duloxetine) and a placebo arm. During the Titration Period (2 weeks), all subjects will be started on 1 capsule (10mg or placebo). During the Maintenance Period (10 weeks), subjects will take 2 capsules. Subjects who are unable to increase their dose can stay at 1 capsule. | Rina Ando | Recruiting | 20 years old | None | Both | 50 | Phase 2 | none | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
411 | EUCTR2010-024424-26-SK | 05/05/2015 | 12 November 2018 | Clinical study for the evaluation of the safety and efficacy of masitinib in patients suffering from parkinson's disease | A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel group, phase 2 study to compare the efficacy and safety of masitinib versus placebo on cognitive impairment associated with Parkinson's disease | Parkinson's disease MedDRA version: 20.0 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: masitinib Product Code: AB1010 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: masitinib mesylate CAS Number: 790-299-79-5 Current Sponsor code: AB1010 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Name: masitinib Product Code: AB1010 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: masitinib mesylate CAS Number: 790-299-79-5 Current Sponsor code: AB1010 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use | AB Science | Not Recruiting | Female: yes Male: yes | 45 | Phase 2 | France;United States;Hungary;Czech Republic;Slovakia;Spain;Romania;Bulgaria;South Africa;Germany | |||
412 | NCT02439125 | May 2015 | 2 May 2016 | A Study of Efficacy and Safety of Eltoprazine HCl for Treating Levodopa-induced Dyskinesia in Parkinson's Disease Patients | Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, 4-way Crossover, Dose-finding Study, of Eltoprazine Safety, Tolerability and Efficacy in the Treatment of Levodopa-induced Dyskinesia in Patients With Parkinson's Disease | Parkinson's Disease;Dyskinesia | Drug: Eltoprazine HCl;Drug: Placebo | Amarantus BioScience Holdings, Inc. | Not recruiting | 30 Years | 85 Years | Both | 60 | Phase 2 | United States | |
413 | NCT02439203 | May 2015 | 25 January 2016 | Efficacy and Safety of JM-010 in PD With Levodopa-Induced Dyskinesia | A Randomized, Double-blind, Placebo-controlled, 2-way Crossover Study in Subjects With Parkinson's Disease With Moderate to Severe Levodopa-induced Dyskinesia, to Assess the Efficacy, Safety/Tolerability and Pharmacokinetics of JM-010 | Parkinson's Disease;Levodopa Induced Dyskinesia (LID) | Drug: JM-010;Drug: Placebo | Bukwang Pharmaceutical | Contera Pharma ApS | Not recruiting | 18 Years | N/A | Both | 30 | Phase 2 | South Africa |
414 | NCT02448914 | May 2015 | 19 October 2017 | A Study to Compare Plasma Levels of Levodopa, Carbidopa and Entacapone After TRIGEL or Duodopa Infusion in PD Patients | A Single Centre, Two-period, Open Label, Randomised, Cross-over Study to Assess Plasma Levodopa, Carbidopa and Entacapone Concentrations After Continuous Infusion of TRIGEL or Duodopa in Patients With Advanced Parkinson´s Disease | Parkinson's Disease | Drug: TRIGEL;Drug: Duodopa | LobSor Pharmaceuticals AB | TFS Trial Form Support | Not recruiting | 30 Years | N/A | All | 11 | Phase 1 | Sweden |
415 | NCT02452125 | May 2015 | 16 December 2017 | The Effects of Nicotine Chewing Gum in Parkinson's Disease | The Effects of Nicotine Chewing Gum on Acute Low Blood Pressure in Parkinson's Disease | Low Blood Pressure;Parkinsons Disease | Dietary Supplement: Nicotine gum | New York Institute of Technology | Not recruiting | N/A | N/A | All | 10 | N/A | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
416 | NCT02616120 | May 2015 | 5 November 2018 | Effect of SQJZ Herbal Mixtures on Non-motor Symptoms of Parkinson's Disease | Efficacy and Safety of SQJZ Herbal Mixtures on Non-motor Symptoms in Parkinson's Disease Patients | Parkinson's Disease | Drug: SQJZ herbal mixtures;Drug: Placebo | Dongzhimen Hospital, Beijing | Recruiting | 18 Years | 80 Years | All | 240 | Phase 2 | China | |
417 | JPRN-JapicCTI-152870 | 11/4/2015 | 23 April 2019 | A parallel group comparison study of HP-3000 in patients with Parkinson's disease using L-DOPA | A phase III parallel group comparison study of HP-3000 in patients with Parkinson's disease using L-DOPA | Parkinson's disease | Intervention name : HP-3000 (ropinirole hydrochloride patch) Dosage And administration of the intervention : Transdermal, once daily Control intervention name : HP-3000 placebo Dosage And administration of the control intervention : Transdermal, once daily Control intervention name : Ropinirole hydrochloride extended-release tablet Dosage And administration of the control intervention : Oral, once daily Control intervention name : Ropinirole hydrochloride extended-release tablet placebo Dosage And administration of the control intervention : Oral, once daily | Hisamitsu Pharmaceutical Co.,Inc. | 20 | 79 | BOTH | Phase 3 | ||||
418 | JPRN-UMIN000017036 | 2015/04/03 | 2 April 2019 | Association of ghrelin and leptin in cardiovascular autonomic dysfunction in patients with primary dysautonomia. | autonomic failure such as Parkinson's disease | blood test of Leptin and Ghrelin blood test of Leptin and Ghrelin | Nagoya University Graduate School of Medicine | Not Recruiting | 40years-old | Not applicable | Male and Female | 50 | Not applicable | Japan | ||
419 | JPRN-UMIN000016591 | 2015/04/01 | 2 April 2019 | Clinical trial of balance exercise "Assist" | Stroke, Parkinson disease, Osteoarthrosis | use of balance exercise assist ordinary balance exercise | Juntendo University | Not Recruiting | 20years-old | 75years-old | Male and Female | 40 | Not applicable | Japan | ||
420 | JPRN-UMIN000016734 | 2015/04/01 | 2 April 2019 | The evaluation of duloxetine effect for the parkinsonism and gait freezing | Parkinson's disease | Drug ; Duloxetine Duraion; SEP012014-AUG312016 Doseage; 20mg/day or 40mg/day Times; one time per day P.O. | Department of Neurology, Juntendo University School of Medicine | Not Recruiting | 20years-old | 85years-old | Male and Female | 30 | Not selected | Japan | ||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
421 | NCT02359448 | April 2015 | 19 February 2015 | Melatonin for Nocturia in Parkinson's Disease | Single-centre Open Label Exploratory Phase IIb Pilot Study of Exogenous Oral Melatonin for the Treatment of Nocturia in Adults With Parkinson's Disease | Parkinson's Disease;Nocturia | Drug: Melatonin | University College, London | Not recruiting | 18 Years | N/A | Both | 20 | Phase 2 | United Kingdom | |
422 | NCT02390089 | April 2015 | 25 February 2019 | Cough According to Stimulus Type in PD | Airway Protection Deficits According to Stimulus Type in Parkinson's Disease | Parkinson's Disease | Drug: Capsaicin vapor;Other: fog;Radiation: Videofluoroscopic swallow evaluation;Device: Nebulizer | University of Florida | National Institute on Deafness and Other Communication Disorders (NIDCD) | Not recruiting | 50 Years | 80 Years | All | 158 | Phase 1 | United States |
423 | NCT02424708 | April 2015 | 4 July 2016 | Phase IIb Study of Intranasal Glutathione in Parkinson's Disease | Phase IIb Study of Intranasal Glutathione in Parkinson's Disease | Parkinson's Disease | Drug: Reduced Glutathione 100mg;Drug: Reduced Glutathione 200mg;Drug: Placebo | Bastyr University | Michael J. Fox Foundation for Parkinson's Research | Not recruiting | 21 Years | N/A | Both | 45 | Phase 2 | United States |
424 | NCT02486432 | April 2015 | 3 August 2015 | A Single Period Investigation to Assess the Tolerability of Healthy Subjects to Oral Sinemet® (Levodopa/Carbidopa) | A Single Period Investigation to Assess the Tolerability of Healthy Subjects to Oral Sinemet® (Levodopa/Carbidopa) Doses Administered Using a Divided Dose Approach | Parkinson's Disease | Drug: Levodopa/Carbidopa (Sinemet) | NeuroDerm Ltd. | Quotient Clinical | Not recruiting | 40 Years | 65 Years | Both | 6 | Phase 1 | |
425 | JPRN-UMIN000016659 | 2015/03/01 | 2 April 2019 | Comparative study of the effects on L-dopa formulation absorption by the acid secretion inhibitor | healty adult Parkinson's disease | MENESIT100 1tablet once a day (p.o.) famotidine 40mg/day for previous 1day (p.o.) MENESIT100 1tablet once a day (p.o.) esomeprazole 20mg for previous three days or more (p.o.) MENESIT100 1tablet once a day (p.o.) | Utano National Hospital, National Hospital Organaization | Not Recruiting | 20years-old | 75years-old | Male and Female | 3 | Phase 1 | Japan | ||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
426 | JPRN-UMIN000016664 | 2015/03/01 | 2 April 2019 | Effect of nicotine patch in Cognitive function improvement in Parkinson's disease | Parkinson's disease | nicotine patch | Department of Clinical Pharmacology and Neurology Ehime University graduated School of Medicine | Recruiting | Not applicable | Not applicable | Male and Female | 20 | Not selected | Japan | ||
427 | NCT02066571 | March 2015 | 14 November 2016 | Study to Assess the Clinical Benefit and Safety of Droxidopa in Parkinson's Disease | A Phase II, Double-Blind, Placebo-Controlled, Crossover Study to Assess Clinical Benefit and Safety of Droxidopa in the Treatment of Parkinson's Disease | Parkinson's Disease;Freezing of Gait;Cognitive Ability, General | Drug: Droxidopa;Drug: sugar pill | Henry Ford Health System | Recruiting | 30 Years | N/A | Both | 20 | Phase 2 | United States | |
428 | NCT02242487 | March 2015 | 26 August 2019 | Twelve Month Safety and Efficacy Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes | A 12 Month, Dose-Level Blinded Study Investigating the Safety and Efficacy of CVT 301 (Levodopa Inhalation Powder) in Parkinson's Disease Patients With Motor Response Fluctuations (OFF Phenomena) | Idiopathic Parkinson's Disease | Drug: CVT-301 | Acorda Therapeutics | Not recruiting | 30 Years | 86 Years | All | 325 | Phase 3 | United States;Canada;Czechia;Poland;Spain;Czech Republic | |
429 | NCT02373072 | March 2015 | 16 December 2017 | A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 in Subjects With Idiopathic Parkinson's Disease | A Phase 1, Double Blind, Sponsor Open, Randomized, Placebo-controlled, Single Ascending Dose Study To Investigate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06649751 In Subjects With Idiopathic Parkinson's Disease | Idiopathic Parkinson Disease | Drug: PF-06649751;Drug: Trimethobenzamide Hydrochloride;Drug: Placebo | Pfizer | Not recruiting | N/A | N/A | All | 18 | Phase 1 | United States;Belgium | |
430 | NCT02393027 | March 2015 | 16 December 2017 | Quantification of Dopamine Active Transporter (DAT) in Humans: Validation of a New Radiophamaceutical, the [18F] LBT-999 | Quantification of Dopamine Active Transporter (DAT) in Humans: Validation of a New Radiophamaceutical, the [18F] LBT-999 | Idiopathic Parkinson Disease | Drug: [18F] LBT-999 PET | University Hospital, Tours | Not recruiting | 45 Years | 75 Years | All | 16 | Early Phase 1 | France | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
431 | NCT02452606 | March 2015 | 8 August 2016 | Clock and Narcolepsy Genetic Variants and the Effects of Stalevo® (Levodopa/Carbidopa/Entacapone) on Sleep Disorders in Parkinson's Disease | Clock and Narcolepsy Genetic Variants and the Effects of Stalevo® (Levodopa/Carbidopa/Entacapone) on Sleep Disorders in Parkinson's Disease | Parkinson Disease;Sleep Disorders | Drug: Stalevo® | Asan Medical Center | Recruiting | 20 Years | 79 Years | Both | 100 | N/A | Korea, Republic of | |
432 | NCT02696603 | March 2015 | 16 December 2017 | Mobile Parkinson Observatory for Worldwide, Evidence-based Research (mPower) | Mobile Parkinson Observatory for Worldwide, Evidence-based Research (mPower) | Parkinson Disease;Neurodegenerative Diseases;Movement Disorders;Central Nervous System Diseases;Brain Diseases;Basal Ganglia Diseases;Parkinsonian Disorders | Behavioral: Participant self-assessment surveys;Behavioral: Phonation;Behavioral: Gait and balance;Behavioral: Memory;Behavioral: Dexterity;Behavioral: Participant open-response writing;Other: Parkinson mPower mobile application | Sage Bionetworks | Robert Wood Johnson Foundation | Recruiting | 18 Years | N/A | All | 20000 | N/A | United States |
433 | JPRN-UMIN000016485 | 2015/02/25 | 2 April 2019 | Pilot study about imaging method of 18F-fluoro-dopa and 11C-raclopride in Parkinson's disease and Parkinson's syndrome | Healthy subjects, Parkinson's disease patients and Parkinson's syndrome patients | Intravenous injection of 18F-fluoro-dopa and 11C-raclopride PET imaging | Institute of Biomedical Research and Innovation | Not Recruiting | 35years-old | Not applicable | Male and Female | 20 | Not selected | Japan | ||
434 | EUCTR2014-003799-22-HU | 11/02/2015 | 3 July 2017 | A study of the safety and drug effects of levodopa inhalation powder (CVT-301) compared to Standard of Care Observational Cohort in patients with Parkinson’s disease | A Phase 3, Randomized Study Investigating the Safety of CVT-301 (Levodopa Inhalation Powder) in Parkinson’s Disease Patients With Motor Response Fluctuations (OFF Phenomena) Compared to an Observational Cohort Control | Parkinson's Disease With Motor Response Fluctuations (OFF Phenomena) MedDRA version: 17.1 Level: LLT Classification code 10034007 Term: Parkinson's disease NOS System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: CVT-301 Product Code: CVT-301 Pharmaceutical Form: Inhalation powder, hard capsule INN or Proposed INN: LEVODOPA CAS Number: 59-92-7 Current Sponsor code: CVT-301 Other descriptive name: LEVODOPA Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 30- Product Name: CVT-301 Product Code: CVT-301 Pharmaceutical Form: Inhalation powder, hard capsule INN or Proposed INN: LEVODOPA CAS Number: 59-92-7 Current Sponsor code: CVT-301 Other descriptive name: LEVODOPA Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 42- | Civitas Therapeutics, Inc. | Not Recruiting | Female: yes Male: yes | 365 | Phase 3 | Serbia;Spain;Austria;Israel;United Kingdom;Italy;France;Hungary;Czech Republic;Belgium;Poland;Romania;Germany | |||
435 | NCT02337725 | February 2015 | 10 October 2016 | A Phase 3 Study of TVP-1012 (1 mg) in Early Parkinson's Disease Patients | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of TVP-1012 at 1 mg in Early Parkinson's Disease Patients Not Treated With Levodopa | Parkinson's Disease | Drug: Placebo;Drug: TVP-1012 | Takeda | Not recruiting | 30 Years | 80 Years | Both | 244 | Phase 3 | Japan | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
436 | NCT02337764 | February 2015 | 7 November 2016 | A Long-term, Phase 3 Study of TVP-1012 (1 mg) in Levodopa Treated Parkinson's Disease Participants | A Multicenter, Open-label, Long-term, Phase 3 Study to Evaluate the Safety and Efficacy of TVP-1012 at 1 mg in Levodopa Treated Parkinson's Disease Patients | Parkinson's Disease | Drug: TVP-1012 1mg with levodopa | Takeda | Not recruiting | 30 Years | 79 Years | Both | 222 | Phase 3 | Japan | |
437 | NCT02339064 | February 2015 | 14 October 2019 | Infusion of Apomorphine: Long-term Safety Study | A Phase 3, Open-Label Study of the Safety, Efficacy and Tolerability of Apomorphine Administered by Continuous Subcutaneous Infusion in Advanced Parkinson's Disease Patients With Unsatisfactory Control on Available | Idiopathic Parkinson's Disease | Drug: apomorphine infusion | US WorldMeds LLC | Not recruiting | 30 Years | N/A | All | 99 | Phase 3 | United States | |
438 | NCT02409823 | February 2015 | 2 November 2015 | Clinical Registry of Patients Under Treatment With Atypical Antipsychotics | Clinical Registry of Patients Under Treatment With Atypical Antipsychotics | Schizophrenia;Major Depressive Disorder;Bipolar Depressive Disorder;Parkinson's Disease With Hallucinations | Drug: Atypical Antipsychotics | Pontifical Catholic University of Argentina | Not recruiting | 18 Years | N/A | Both | 665 | N/A | ||
439 | NCT02933372 | February 2015 | 15 July 2019 | Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease - Proj#3 | Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease - Proj#3 | Parkinson's Disease | Drug: Varenicline;Radiation: PET Scan;Other: Evaluation by Investigator | University of Michigan | Not recruiting | 45 Years | N/A | All | 58 | Phase 2 | ||
440 | JPRN-JapicCTI-152762 | 27/1/2015 | 2 April 2019 | A long-term, Phase 3 Study of TVP-1012 (1 mg) in Levodopa Treated Parkinson's Disease Patients | A Multicenter, Open-label, Long-term, Phase 3 Study to Evaluate the Safety and Efficacy of TVP-1012 at 1 mg in Levodopa Treated Parkinson's Disease Patients | Parkinson's disease | Intervention name : TVP-1012 (1 mg/day) with levodopa Dosage And administration of the intervention : TVP-1012 (1 mg/day) once daily, before or after breakfast. A levodopa combination drug will be concomitantly administered in principle without change in the dose regimen throughout the study period from the start of the screening period. Control intervention name : null | TAKEDA PHARMACEUTICAL COMPANY LTD. | 30 | 79 | BOTH | 215 | Phase 3 | |||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
441 | NCT02337738 | January 2015 | 10 October 2016 | A Phase 2/3 Study of TVP-1012 at 0.5 mg or 1 mg in Levodopa Treated Parkinson's Disease Participants | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 2/3 Study to Evaluate the Efficacy and Safety of TVP-1012 at 0.5 mg or 1 mg in Levodopa Treated Parkinson's Disease Patients With Wearing Off | Parkinson's Disease | Drug: TVP-1012 1mg;Drug: TVP-1012 0.5mg;Drug: Placebo | Takeda | Not recruiting | 30 Years | 79 Years | Both | 404 | Phase 2/Phase 3 | Japan | |
442 | NCT02347059 | January 2015 | 19 February 2015 | L-dopa Versus Dopamine Agonists After Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease | A Randomized, Single-blind Trial on the Efficacy and Safety of L-dopa Monotherapy Versus Dopamine Agonists Monotherapy After Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease | Parkinson's Disease | Drug: L-dopa;Drug: Dopamine Agonists (pramipexole, ropirinole) | University of Toronto | Michael J. Fox Foundation for Parkinson's Research | Recruiting | N/A | N/A | Both | 40 | Phase 2 | Canada |
443 | NCT02406105 | January 2015 | 13 April 2015 | An Effectiveness and Toxicity of CyberKnife Based Radiosurgery for Parkinson Disease | An Evaluation of Effectiveness and Toxicity of CyberKnife Based Functional Radiosurgery for Parkinson Disease Patients Suffering From Tremor and Its Implementation in Poland | Parkinson Disease | Radiation: Radiosurgical thalamotomy;Drug: CyberKnife | Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology | Recruiting | 18 Years | N/A | Both | 27 | Phase 2 | Poland | |
444 | NCT02763137 | January 2015 | 17 May 2016 | Intermittent Oral Administration vs. Semi-continuous Intra-oral Administration of Levodopa/Carbidopa in Fluctuating Parkinsonian Patients | A Phase IIa Study to Assess the Safety, Tolerability, Plasma Pharmacokinetics and Efficacy of Intermittent Oral Administration of Standard Levodopa/Carbidopa vs. Semi-continuous Intra-oral Administration of Levodopa/Carbidopa in Patients With Advanced Parkinson's Disease Who Suffer Motor Fluctuations | Parkinson Disease | Drug: Standard LD/CD;Drug: Semi continuous intra-oral administration of LD/CD | IRCCS San Raffaele | SynAgile Corporation | Not recruiting | 35 Years | 75 Years | Both | 18 | Phase 2 | Italy |
445 | NCT02258152 | December 22, 2014 | 29 April 2019 | SYN120 Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE) | SYN120 a Dual 5-HT6/5-HT2A Antagonist Proof of Concept Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE) | Parkinson's Disease Dementia (PDD) | Drug: SYN120;Drug: Placebo | Biotie Therapies Inc. | Michael J. Fox Foundation for Parkinson's Research;Massachusetts General Hospital;Acorda Therapeutics | Not recruiting | 50 Years | N/A | All | 82 | Phase 2 | United States |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
446 | JPRN-JapicCTI-142748 | 11/12/2014 | 23 April 2019 | Long-term study of HP-3000 in patients with Parkinson's disease | A phase III long-term study of HP-3000 in patients with Parkinson's disease | Parkinson's disease | Intervention name : HP-3000(ropinirole hydrochloride patch) Dosage And administration of the intervention : Transdermal, once daily | Hisamitsu Pharmaceutical Co.,Inc. | 20 | 79 | BOTH | Phase 3 | ||||
447 | NCT02267434 | December 2014 | 7 November 2016 | Study Assessing Tolerability and Safety of AFFITOPE® PD03A in Patients With Early Parkinson's Disease | A Randomized, Placebo-controlled, Parallel Group, Patient-blinded, Multi-center, Phase I Pilot Study to Assess Tolerability and Safety of Two Doses of AFFITOPE® PD03A Formulated With Adjuvant to Patients With Early Parkinson's Disease | Parkinson Disease;Neurodegenerative Diseases | Biological: Low dose AFFITOPE® PD03A + Adjuvant;Biological: High dose AFFITOPE® PD03A + Adjuvant;Biological: Adjuvant without active component | Affiris AG | PROSENEX AmbulatoriumbetriebsGMBH;Medical University Innsbruck;Forschungszentrum Juelich | Not recruiting | 45 Years | 70 Years | Both | 36 | Phase 1 | Austria |
448 | NCT02324426 | December 2014 | 11 May 2015 | CNS Uptake of Intranasal Glutathione | Central Nervous System Uptake of Intranasal Glutathione in Parkinson's Disease | Parkinson's Disease | Drug: Reduced Glutathione | University of Washington | Michael J. Fox Foundation for Parkinson's Research | Not recruiting | 18 Years | N/A | Both | 15 | Phase 1 | United States |
449 | NCT02480803 | December 2014 | 4 February 2019 | INfusion VErsus STimulation in Parkinson's Disease | Treatment in Advanced Parkinson's Disease: Continuous Intrajejunal Levodopa INfusion VErsus Deep Brain STimulation | Parkinson's Disease | Drug: Continuous intrajejunal infusion of levodopa-carbidopa;Device: deep brain stimulation | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | ZonMw: The Netherlands Organisation for Health Research and Development | Recruiting | 18 Years | N/A | All | 66 | Phase 4 | Netherlands |
450 | NCT03116308 | November 21, 2014 | 16 December 2017 | Effect of Food on Opicapone | Effect of Food on Opicapone Bioavailability and Pharmacodynamics in Healthy Subjects | Parkinson Disease | Drug: Opicapone (OPC) | Bial - Portela C S.A. | Not recruiting | 18 Years | 45 Years | All | 28 | Phase 1 | ||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
451 | ChiCTR-DDD-17010794 | 2014-11-08 | 18 April 2017 | The study on early diagnosis of Parkinson 's disease by transcranial ultrasonography | the study on early diagnosis of Parkinson 's disease by transcranial ultrasonography | Parkinson's Disease | Gold Standard:Diagnosis of Parkinson disease needs to meet 3 or more: unilateral onset;resting tremor;progressive course; long term asymmetry, the most obvious symptoms is the onset side; a good response to levodopa (70% ~ 100%); levodopa induced chorea; a reaction of levodopa lasts 5 years or more; clinical course last;Index test:Laboratory apparatus As shown in Figure 1, The ultrasound equipment, Philips IE33-BOMJH1 color Doppler ultrasonography, Model IE-ELite, with 2-4MHz phased array probe (S5-1 probe) was used for TCS to examine SN in our study. Transcranial ultrasound study Ultrasonography through temporal window, alon; | Department of Neurology, Fujian Institute of Geriatrics, Fujian Medical University Union Hospital | Not Recruiting | 36 | 84 | Both | Target condition:135;Difficult condition:0 | Diagnostic New Technique Clincal Study | China | |
452 | JPRN-JapicCTI-142702 | 01/11/2014 | 23 April 2019 | A Phase 1 Study of ONO-2160/CD | A Phase 1 study on single and multiple oral dose administration of ONO-2160/CD in healthy adult male subjects and on multiple oral dose administration of ONO-2160/CD in Parkinson's disease patients | Parkinson's disease | Intervention name : ONO-2160/CD Dosage And administration of the intervention : Oral administration Control intervention name : Levodopa/carbidopa hydrate INN of the control intervention : Levodopa/carbidopa hydrate Dosage And administration of the control intervention : Oral administration | ONO PHARMACEUTICAL CO.,LTD. | BOTH | 34 | Phase 1 | |||||
453 | NCT02240030 | November 2014 | 3 June 2019 | Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of CVT 301 (Levodopa Inhalation Powder) in Parkinson's Disease Patients With Motor Response Fluctuations (OFF Phenomena) (SPAN-PD™) | Idiopathic Parkinson's Disease | Drug: CVT-301 Low Dose;Drug: CVT-301 High Dose;Other: Placebo | Acorda Therapeutics | Not recruiting | 30 Years | 85 Years | All | 351 | Phase 3 | United States;Canada;Czechia;Poland;Spain;Czech Republic | |
454 | NCT02278588 | November 2014 | 29 April 2019 | Effect of 2.5 Years of Rasagiline Therapy on Progression of Cognitive Biomarkers Assessed by MRI in Parkinson's Disease. | Effect of 2.5 Years of Rasagiline Therapy on Progression of Cognitive Biomarkers Assessed by MRI in Parkinson's Disease. | Parkinson's Disease | Drug: Rasagiline | Thomas Guttuso | Not recruiting | N/A | N/A | All | 45 | Phase 4 | United States | |
455 | NCT02281474 | November 2014 | 28 December 2015 | Nilotinib in Cognitively Impaired Parkinson Disease Patients 001 | Open Label Dose Escalation of Nilotinib in Cognitively Impaired Parkinson Disease Patients With Elevated Cerebrospinal Fluid and Blood a-Synuclein | Parkinson's Disease;Parkinson's Disease Dementia;Diffuse Lewy Body Disease | Drug: Nilotinib | Georgetown University | Not recruiting | 40 Years | 90 Years | Both | 12 | Phase 1 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
456 | NCT02312232 | November 2014 | 2 March 2015 | Pharmacokinetic Study in Healthy Males | Pharmacokinetics of Levodopa, Carbidopa, 3-OMD and ODM-104 After Repeated Doses of Different Formulations: an Open, Randomised, Multicentre Study With Crossover Design in Healthy Males | Parkinson's Disease | Drug: levodopa, carbidopa, ODM-104 | Orion Corporation, Orion Pharma | Not recruiting | 18 Years | 65 Years | Male | 20 | Phase 1 | Finland | |
457 | EUCTR2014-000335-17-GB | 28/10/2014 | 4 August 2015 | Rotigotine and memory in Parkinson's. | The Effect of Rotigotine on Memory in Idiopathic Parkinson's Disease without Cognitive Impairment - Rotigotine and Memory in Parkinson's. | Idiopathic Parkinson's Disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: rotigotine Pharmaceutical Form: Transdermal patch INN or Proposed INN: Rotigotine CAS Number: 92206-54-7 Concentration unit: Other Concentration type: up to Concentration number: -16 mg/24 h Product Name: levodopa CR (controlled release) Pharmaceutical Form: Tablet INN or Proposed INN: levodopa CAS Number: 59-92-7 Concentration unit: mg milligram(s) Concentration type: up to Concentration number: -1000 Product Name: Rasagiline Pharmaceutical Form: Tablet INN or Proposed INN: Rasagiline CAS Number: 1875-50-9 Concentration unit: mg milligram(s) Concentration type: up to Concentration number: -1 mg/24h Product Name: Selegiline Pharmaceutical Form: Tablet INN or Proposed INN: selegiline CAS Number: 14611-51-9 Concentration unit: mg milligram(s) Concentration type: up to Concentration number: -12mg/24hs | Research and Development University Hospital of North Staffordshire | Keele University | Not Recruiting | Female: yes Male: yes | 0 | United Kingdom | |||
458 | EUCTR2014-001131-36-ES | 23/10/2014 | 8 August 2016 | A 16 Week Clinical Study to Evaluate the Use of Long-Acting Amantadine to Treat Parkinson's Disease Patients with Abnormal Involuntary Movements caused by Levodopa | A Multicenter, Randomized, Placebo-controlled, Double-blind, 16 Week Study to Evaluate the Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson's Disease Subjects with Levodopa-Induced Dyskinesias | Parkinson's Disease Subjects with Levodopa-Induced Dyskinesias MedDRA version: 17.0 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Amantadine HCl Extended Release Pharmaceutical Form: Prolonged-release tablet INN or Proposed INN: Amantadine hydrochloride Other descriptive name: AMANTADINE HYDROCHLORIDE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 160- Pharmaceutical form of the placebo: Prolonged-release tablet Route of administration of the placebo: Oral use Product Name: Amantadine HCl Extended Release Pharmaceutical Form: Prolonged-release tablet INN or Proposed INN: Amantadine hydrochloride Other descriptive name: AMANTADINE HYDROCHLORIDE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 240- Pharmaceutical form of the placebo: Prolonged-release tablet Route of administration of the placebo: Oral use Product Name: Amantadine HCl Extended Release Pharmaceutical Form: Prolonged-release tablet INN or Proposed INN: Amantadine hydrochloride Other descriptive name: AMANTADINE HYDROCHLORIDE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 320- Pharmaceutical form of the placebo: Prolonged-release tablet Route of administration of the placebo: Oral use | Osmotica Pharmaceutical Corp. | Not Recruiting | Female: yes Male: yes | 162 | Phase 3 | France;United States;Canada;Spain;Germany | |||
459 | EUCTR2014-001132-10-ES | 23/10/2014 | 8 August 2016 | A 26 Week Clinical Study to Evaluate the Use of Long-Acting Amantadine to Treat Parkinson's Disease Patients with Abnormal Involuntary Movements caused by Levodopa | A Multicenter, Randomized, Placebo-controlled, Double-blind, 26 Week Study to Evaluate the Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson's Disease Subjects with Levodopa-Induced Dyskinesias | Parkinson's Disease Subjects with Levodopa-Induced Dyskinesias MedDRA version: 17.0 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Amantadine HCl Extended Release Pharmaceutical Form: Prolonged-release tablet INN or Proposed INN: Amantadine hydrochloride Other descriptive name: AMANTADINE HYDROCHLORIDE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 160- Pharmaceutical form of the placebo: Prolonged-release tablet Route of administration of the placebo: Oral use Product Name: Amantadine HCl Extended Release Pharmaceutical Form: Prolonged-release tablet INN or Proposed INN: Amantadine hydrochloride Other descriptive name: AMANTADINE HYDROCHLORIDE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 240- Pharmaceutical form of the placebo: Prolonged-release tablet Route of administration of the placebo: Oral use Product Name: Amantadine HCl Extended Release Pharmaceutical Form: Prolonged-release tablet INN or Proposed INN: Amantadine hydrochloride Other descriptive name: AMANTADINE HYDROCHLORIDE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 320- Pharmaceutical form of the placebo: Prolonged-release tablet Route of administration of the placebo: Oral use | Osmotica Pharmaceutical Corp. | Not Recruiting | Female: yes Male: yes | 162 | Phase 3 | France;United States;Canada;Spain;Germany | |||
460 | EUCTR2014-002295-87-IT | 13/10/2014 | 19 February 2018 | A Phase IIa study to assess the safety, tolerability, plasma pharmacokinetics and efficacy of intermittent oral administration of standard levodopa/carbidopa vs. semi-continuous intra-oral administration of levodopa/carbidopa in patients with advanced Parkinson’s disease who suffer motor fluctuations. | A Phase IIa study to assess the safety, tolerability, plasma pharmacokinetics and efficacy of intermittent oral administration of standard levodopa/carbidopa vs. semi-continuous intra-oral administration of levodopa/carbidopa in patients with advanced Parkinson’s disease who suffer motor fluctuations. | Parkinson's disease patients who suffer motor fluctuations will participate in the study MedDRA version: 17.0 Level: SOC Classification code 10029205 Term: Nervous system disorders System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: SINEMET 100 mg + 25 mg compresse Product Name: SINEMET 100 mg + 25 mg compresse Product Code: NA Pharmaceutical Form: Oral suspension | SynAgile Corporation | Not Recruiting | Female: yes Male: yes | 18 | Phase 2 | Italy | |||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
461 | NCT02183519 | October 2014 | 16 December 2017 | Respiratory Kinematics of Cough in Healthy Older Adults and Parkinson's Disease | Respiratory Kinematics of Reflex and Voluntary Cough in Healthy Older Adults and Parkinson's Disease | Cough;Parkinson's Disease | Drug: Capsaicin;Other: Voluntary cough test | University of Florida | Not recruiting | 55 Years | 85 Years | All | 44 | Phase 1/Phase 2 | United States | |
462 | NCT02224664 | October 2014 | 16 December 2017 | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Parkinson`s Disease | A Phase 1b, 2-period, Open Label, Multicenter, Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06649751 In Subjects With Parkinson`s Disease And Motor Fluctuations | Parkinson`s Disease | Drug: PF-06649751 | Pfizer | Not recruiting | 30 Years | 80 Years | All | 50 | Phase 1 | United States;Belgium | |
463 | NCT02259049 | October 2014 | 1 February 2016 | The Effects of L-Tyrosine on 24 Hour Blood Pressure and Heart Rate in Parkinson's Disease | The Effects of L-Tyrosine on Non-invasive Ambulatory Blood Pressure and Heart Rate Monitoring in Parkinson's Disease | Blood Pressure | Dietary Supplement: L-tyrosine;Dietary Supplement: Sugar Pill | New York Institute of Technology | Not recruiting | 40 Years | 84 Years | Both | 6 | Phase 0 | United States | |
464 | NCT02274324 | October 2014 | 19 February 2015 | Dietary Modifications Effect on Continuous LCIG Infusion Outcomes in Patients With Advanced Parkinson&Apos;s Disease | Dietary Modifications Effect on Continuous LCIG Infusion Outcomes in Patients With Advanced Parkinson's Disease | Parkinson Disease | Dietary Supplement: different diets | Sheba Medical Center | Tel Aviv University | Not recruiting | 40 Years | 80 Years | Both | 20 | N/A | |
465 | NCT02274766 | October 2014 | 22 January 2018 | Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced Dyskinesia | ADS-5102 (Amantadine HCl) Extended Release Efficacy and Safety Study in Parkinson's Disease Patients With Levodopa-Induced Dyskinesia (EASE LID 3 Study) | Dyskinesia;Levodopa-Induced Dyskinesia (LID);Parkinson's Disease (PD) | Drug: ADS-5102;Other: Placebo | Adamas Pharmaceuticals, Inc. | Not recruiting | 30 Years | 85 Years | All | 77 | Phase 3 | United States;Austria;France;Germany;Spain | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
466 | JPRN-UMIN000016893 | 2014/09/22 | 21 May 2019 | A double-blind, randomized clinical trial to evaluate the efficacy of Duloxetine against pain associated with Parkinson's disease with depression. | A double-blind, randomized clinical trial to evaluate the efficacy of Duloxetine against pain associated with Parkinson's disease with depression. - Pain reduction in PD patients with depression: double blind, randomized clinical trial of duloxetine. | PD patients | The treatment groups consist of an active treatment arm (40mg/day Duloxetine) and a placebo arm. During the Titration Period (2 weeks), all subjects will be started on 1 capsule (10mg or placebo). During the Maintenance Period (10 weeks), subjects will take 2 capsules. Subjects who are unable to increase their dose can stay at 1 capsule. The treatment groups consist of an active treatment arm (40mg/day Duloxetine) and a placebo arm. During the Titration Period (2 weeks), all subjects will be started on 1 capsule (10mg or placebo). During the Maintenance Period (10 weeks), subjects will take 2 capsules. Subjects who are unable to increase their dose can stay at 1 capsule. | Ehime University Hospital Dept. of Clinical pharmacology and Neurology | Not Recruiting | 20years-old | Not applicable | Male and Female | 50 | Phase 2 | Japan | |
467 | NCT02236260 | September 3, 2014 | 16 December 2017 | Evaluation of the Benefit Provided by Acupuncture During a Surgery of Deep Brain Stimulation | Evaluation of the Benefit Provided by the Addition of Acupunctural Analgesia With Electrostimulation to Conventional Local Anesthesia Compared to Conventional Local Anesthesia Alone in Surgery of Deep Brain Stimulation for Movement Disorders. | Parkinson's Disease | Procedure: Electroacupuncture;Drug: Local Anesthesia (lidocaine hydrochloride) | Nantes University Hospital | Not recruiting | 18 Years | 74 Years | All | 20 | N/A | France | |
468 | NCT02168842 | September 2014 | 4 March 2019 | Efficacy of Isradipine in Early Parkinson Disease | Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease | Parkinson Disease | Drug: Isradipine;Drug: Placebo (for Isradipine) | University of Rochester | National Institute of Neurological Disorders and Stroke (NINDS);Michael J. Fox Foundation for Parkinson's Research;The Parkinson Study Group | Not recruiting | 30 Years | N/A | All | 336 | Phase 3 | United States;Canada |
469 | NCT02212678 | September 2014 | 14 March 2016 | Repeated-Dose Oral N-acetylcysteine for the Treatment of Parkinson's Disease | Repeated-Dose Oral N-acetylcysteine for the Treatment of Parkinson's Disease | Parkinson Disease | Drug: N-acetylcysteine capsule | University of Minnesota - Clinical and Translational Science Institute | Parkinson's Disease Society of the United Kingdom | Not recruiting | 18 Years | N/A | Both | 9 | Phase 2 | United States |
470 | NCT02225548 | September 2014 | 8 January 2018 | Sagene 2014 - Parkinson's Disease and Erectile Dysfunction | An Open-label Trial of Oral Selegiline 5 or 10 mg and Tadalafil 2.5mg Co-administration to Male Patients With Parkinson's Disease and Moderate Erectile Dysfunction. | Parkinson's Disease;Erectile Dysfunction | Drug: Selegiline;Drug: Tadalafil | University of South Florida | Recruiting | 40 Years | 64 Years | Male | 10 | Phase 4 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
471 | NCT02230904 | September 2014 | 19 October 2017 | A Study to Compare the Adhesiveness of 2 Different Rotigotine Patches Used for the Treatment of Parkinson's Disease | A Multicenter, Randomized, Double-blind, 2-way Cross-over Study to Compare the Adhesiveness of 2 Different Rotigotine Patch Formulations in Subjects With Parkinson's Disease | Parkinson's Disease | Drug: Rotigotine (Test product PR 2.3.1);Drug: Rotigotine (Reference product PR 2.1.1) | UCB BIOSCIENCES GmbH | Pharmaceutical Health Sciences;Bracket Global | Not recruiting | 18 Years | N/A | All | 57 | Phase 1 | Germany |
472 | NCT02256319 | September 2014 | 28 December 2015 | Dexmedetomidine vs Propofol on the Recordings of Deep Brain Activity Measured Through Implanted Stimulators | Effects of Dexmedetomidine vs Propofol on the Recordings of Deep Brain Activity (Local Field Potentials) Measured Through Implanted Stimulators | Parkinson's Disease | Drug: Dexmedetomidine;Drug: Propofol | Clinica Universidad de Navarra, Universidad de Navarra | Not recruiting | 18 Years | N/A | Both | 12 | Phase 4 | Spain | |
473 | NCT02777060 | September 2014 | 30 May 2016 | Exploring the Effectiveness of Sensor-based Balance Training on Patient Outcome Measures | Exploring the Effectiveness of Sensor-based Balance Training on Patient Outcome Measures | Diabetes;Cancer;Multiple Sclerosis;Arthritis;Parkinson's Disease;Cognitive Disorders;Brain Injury;Stroke | Procedure: Exergame;Procedure: Home based balance training | University of Arizona | Recruiting | 18 Years | N/A | Both | 200 | N/A | United States | |
474 | NCT03151460 | September 2014 | 16 December 2017 | Dopaminergic Modulation of Declarative Memory | Dopaminergic Modulation of Declarative Memory | Parkinson's Disease | Drug: Dopamine Agent | I.R.C.C.S. Fondazione Santa Lucia | Not recruiting | N/A | N/A | All | 40 | Phase 4 | Italy | |
475 | ChiCTR-TRC-14005143 | 2014-08-25 | 18 April 2017 | A traditional chinese medicine clinical intervention study of depressed Parkinson's disease - based on the Wenyang Jieyu method | A traditional chinese medicine clinical intervention study of depressed Parkinson's disease - based on the Wenyang Yieyu method | Depressed Parkinson's disease | Chinese Medicines:Formula granule;Western Medicine group:Venlafaxine hydrochloride sustained-release capsules ; | The Third Affiliated Hospital of Beijing University of Traditional Chinese Medicine | Recruiting | 55 | 75 | Both | Chinese Medicines:60;Western Medicine group:60; | Phase 2 study | China | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
476 | NCT02153645 | August 18, 2014 | 15 April 2019 | Efficacy and Safety of Amantadine Hydrochloride (HCl) ER Tablets to Treat Parkinson's Disease Patients With LID. | A Multicenter, Randomized, Placebo-controlled, Double-blind, 16 Week Study to Evaluate the Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesias | Parkinson's Disease;Levodopa Induced Dyskinesias (LID) | Drug: 240mg Amantadine HCl ER tablets;Drug: Placebo tablets;Drug: 320mg Amantadine HCl ER tablets | Osmotica Pharmaceutical US LLC | Not recruiting | 30 Years | 85 Years | All | 87 | Phase 3 | United States;Canada;France;Germany;Spain | |
477 | NCT02216188 | August 2014 | 24 August 2015 | Follow-up Study to Assess One Boost Immunization With AFFITOPE® PD01A With Regard to Safety and Clinical Activity | Phase IB Follow-up, Randomized, Controlled, Parallel Group, Patient-blinded, Single-center Study to Assess One Boost With AFFITOPE® PD01A With Regard to Safety/Tolerability, Immunological + Clinical Activity in Patients Who Have Received the Vaccine Within the Study AFF008 | Parkinson's Disease | Biological: AFFITOPE® PD01A;Other: Control | Affiris AG | Not recruiting | 40 Years | 68 Years | Both | 28 | Phase 1 | Austria | |
478 | NCT02228590 | August 2014 | 16 December 2017 | A Study to Examine APL-130277 in Patients With Parkinson's Disease | A Phase 2 Study to Examine the Safety, Tolerability and Efficacy of APL-130277 in Patients With Parkinson's Disease | Parkinson's Disease | Drug: APL-130277 | Sunovion | Not recruiting | 18 Years | 80 Years | All | 19 | Phase 2 | United States | |
479 | NCT02230267 | August 2014 | 23 May 2016 | High-intensity Exercise and Fall Prevention Boot Camp for Parkinson's Disease | High-intensity Exercise and Fall Prevention Boot Camp for Parkinson's Disease | Parkinson's Disease | Other: High intensity exercise and balance training;Other: Usual care arm exercise | University of Nevada, Las Vegas | Not recruiting | 45 Years | 85 Years | Both | 27 | Phase 2 | United States | |
480 | NCT02236065 | August 2014 | 16 December 2017 | Combination Therapy of Cord Blood and G-CSF for Patients With Brain Injury or Neurodegenerative Disorders | A Pilot Study of Combination Therapy of Allogeneic Umbilical Cord Blood and Granulocyte-colony Stimulating Factor for Patients With Brain Injury or Neurodegenerative Disorders | Brain Injury;Cerebral Palsy;Amyotrophic Lateral Sclerosis;Parkinson's Disease | Procedure: Umbilical cord blood therapy;Biological: Filgrastim | MinYoung Kim, M.D. | Not recruiting | 19 Years | 75 Years | All | 10 | N/A | Korea, Republic of | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
481 | NCT02438215 | August 2014 | 25 May 2015 | Study of IRX4204 for Treatment of Early Parkinson's Disease | An Open-Label, Single Site Study Using [123I]ß-CIT Single Photon Emission Tomography (SPECT) to Evaluate Dopamine Transporter Binding Following Treatment With IRX4204 in Early Parkinson's Disease Subjects | Parkinson's Disease | Drug: IRX4204 | Io Therapeutics | Not recruiting | 18 Years | N/A | Both | 15 | Phase 1 | United States | |
482 | NCT02153632 | July 30, 2014 | 15 April 2019 | Efficacy and Safety of Amantadine Hydrogen Chloride (HCl) ER Tablets in Parkinson's Disease Subjects With LID | A Multicenter, Randomized, Placebo-controlled, Double-blind, 26 Week Study to Evaluate the Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesias | Parkinson's Disease;Levodopa Induced Dyskinesia (LID) | Drug: amantadine HCl ER;Drug: Placebo | Osmotica Pharmaceutical US LLC | Not recruiting | 30 Years | 85 Years | All | 135 | Phase 3 | United States;Canada;France;Germany;Spain | |
483 | JPRN-UMIN000014709 | 2014/07/01 | 2 April 2019 | Study on Parkinson's disease and related disorders with dopamine transporter ligand [C-11]PE2I | Patients of Parkinson's disease and related disorders | The dosage in the vein of [C-11]PE2I, [C-11]raclopride, and [F-18]FDG for PET/CT imaging. | Tokyo Metropolitan Institute of Gerontology | Recruiting | 18years-old | Not applicable | Male and Female | 200 | Not selected | Japan | ||
484 | NCT02138682 | July 2014 | 19 February 2015 | Validation of DaTscan for Detection of Parkinson Disease Related Disorders | Validation of DaTscan for Detection of Parkinsonian Disease and Related Disorders Using Neuropathologically-confirmed Parkinson Disease From Human Brain Tissue | Parkinson Disease;Movement Disorders | Drug: l-123 Ioflupane | Wisconsin Institute for Neurologic and Sleep Disorders S.C. | Wisconsin Parkinson Association;Medical College of Wisconsin;GE Healthcare | Recruiting | 75 Years | N/A | Both | 20 | Phase 4 | United States |
485 | NCT02202551 | July 2014 | 16 December 2017 | Open-Label Safety Study of ADS-5102 in PD Patients With LID | Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID) | Dyskinesia;Levodopa Induced Dyskinesia (LID);Parkinson's Disease (PD) | Drug: ADS-5102 | Adamas Pharmaceuticals, Inc. | Not recruiting | 30 Years | 85 Years | All | 250 | Phase 3 | United States;Austria;Canada;France;Germany;Spain | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
486 | NCT02206620 | July 2014 | 19 February 2015 | Effects of Cholinergic Augmentation on Measures of Balance and Gait | Effects of Cholinergic Augmentation on Measures of Balance and Gait | Parkinson's Disease | Drug: Donepezil | Oregon Health and Science University | Michael J. Fox Foundation for Parkinson's Research | Recruiting | 30 Years | N/A | Both | 100 | Phase 2 | United States |
487 | NCT02472210 | July 2014 | 3 August 2015 | The Use of Botox in Advanced Parkinson's Patients Experiencing Pain | A Study of the Utility of Botulinum Toxin Type A for Pain in Advanced Parkinson's Disease Double Blind Placebo Control Crossover Pilot Study | Parkinson's Disease | Drug: Botulinum Toxin | University Health Network, Toronto | Not recruiting | 18 Years | N/A | Both | 14 | Phase 4 | ||
488 | EUCTR2014-000868-17-ES | 26/06/2014 | 18 January 2016 | Effect of dexmedetomidine vs propofol on basal ganglia activity (local field potentials) recorded through implanted stimulators | Effect of dexmedetomidine vs propofol on basal ganglia activity (local field potentials) recorded through implanted stimulators | Parkinson's disease MedDRA version: 16.1 Level: LLT Classification code 10013113 Term: Disease Parkinson's System Organ Class: 100000004852 ;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03] | Trade Name: Dexdor Product Name: Dexdor Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: DEXMEDETOMIDINE CAS Number: 113775-47-6 Other descriptive name: DEXMEDETOMIDINA Concentration unit: mg/kg/h milligram(s)/kilogram/hour Concentration type: range Concentration number: 0.0002-0.0014 Trade Name: Propofol-Lipuro Product Name: Propofol-Lipuro Pharmaceutical Form: Emulsion for infusion INN or Proposed INN: PROPOFOL Other descriptive name: PROPOFOL Concentration unit: mg/kg/h milligram(s)/kilogram/hour Concentration type: range Concentration number: 0.5-4 | Clínica Universidad de Navarra/Universidad de Navarra | Not Recruiting | Female: yes Male: yes | Spain | |||||
489 | ChiCTR-TRC-14004707 | 2014-06-09 | 18 April 2017 | The effect of different patterns of rehabilitation training in idiopathic Parkinson's disease | The effect of different patterns of rehabilitation training in idiopathic Parkinson's disease | Parkinson's disease | Tai Chi group:Tai Chi;Balance function training group:Balance function training; | Shanghai Tongji Hospital | Not Recruiting | 20 | 90 | Both | Tai Chi group:30;Balance function training group:30; | Other | China | |
490 | NCT01971242 | June 2014 | 28 November 2016 | Trial of Exenatide for Parkinson's Disease | A Randomised, Double Blind, Placebo Controlled, Single Centre, 60 Week Trial of Exenatide Once Weekly for the Treatment of Moderate Severity Parkinson's Disease | Parkinson's Disease | Drug: Exenatide;Other: Placebo | University College, London | Not recruiting | 25 Years | 75 Years | Both | 60 | Phase 2 | United Kingdom | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
491 | NCT02157714 | June 2014 | 31 October 2016 | Multiple Ascending Dose Study of PRX002 in Patients With Parkinson's Disease | A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of PRX002 Administered By Intravenous Infusion in Patients With Parkinson's Disease | Parkinson's Disease | Drug: PRX002;Other: Placebo | Prothena Biosciences Limited | Hoffmann-La Roche | Not recruiting | 40 Years | 80 Years | Both | 64 | Phase 1 | United States |
492 | NCT02174250 | June 2014 | 14 September 2015 | The Effect of Rifampin on the Metabolism of Istradefylline in Healthy Volunteers. | Effect of a Strong Enzyme Inducer, Rifampin, on the Single-Dose Pharmacokinetics of Istradefylline in Healthy Subjects | Parkinson's Disease | Drug: Istradefylline 40 mg;Drug: Rifampin 300mg BID + istradefylline 40mg Day 8 only | Kyowa Hakko Kirin Pharma, Inc. | Not recruiting | 18 Years | 65 Years | Both | 20 | Phase 1 | United States | |
493 | NCT02046447 | May 2014 | 8 January 2018 | Neuroimaging of Dystonia | Neuroimaging of Dystonia: The Bachmann-Strauss Dystonia and Parkinson Disease Center of Excellence at the University of Florida | Primary Cervical Dystonia;DYT 1 Dystonia | Drug: Primary Cervical Dystonia (Trihexyphenidyl);Other: Controls Primary Cervical Dystonia (Trihexyphenidyl);Other: DYT 1 Dystonia (Healthy Control);Other: DYT 1 Dystonia | University of Florida | Bachmann Strauss Dystonia & Parkinson Foundation, Inc. | Not recruiting | 7 Years | 70 Years | All | 20 | N/A | United States |
494 | NCT02096601 | May 2014 | 19 February 2015 | A Pharmacokinetic Study of ND0612 Delivered as a Continuous Subcutaneous in Parkinson's Disease Patients | A Phase I/II Pharmacokinetic (PK) Study of ND0612, a Liquid Formulation of Levodopa/Carbidopa (LD/CD), Delivered as a Continuous Subcutaneous in Parkinson's Disease (PD) Patients Treated With LD | Parkinson's Disease | Drug: Levodopa and carbidopa SC solution;Drug: Oral levodopa and carbidopa | NeuroDerm Ltd. | Michael J. Fox Foundation for Parkinson's Research | Not recruiting | 30 Years | 80 Years | Both | Phase 1/Phase 2 | United States;Israel | |
495 | NCT02136914 | May 2014 | 16 December 2017 | ADS-5102 for the Treatment of Levodopa Induced Dyskinesia (EASE LID Study) | Efficacy and Safety of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia in Parkinson's Disease Patients (EASE LID Study) | Dyskinesia;Levodopa Induced Dyskinesia (LID);Parkinson's Disease | Drug: ADS-5102;Other: Placebo | Adamas Pharmaceuticals, Inc. | Not recruiting | 30 Years | 85 Years | All | 126 | Phase 3 | United States;Canada | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
496 | NCT02780895 | May 2014 | 20 June 2016 | Parkinsonian Brain Repair Using Human Stem Cells | Human OK99 Allogeneic Stem Cell Transplantation for Patients With Severe Parkinson's Disease | Idiopathic Parkinson Disease | Drug: Human Stem Cells | Celavie Bioscences, LLC | Hospital Angeles del Pedregal | Not recruiting | 18 Years | 75 Years | Both | 8 | Phase 1 | Mexico |
497 | EUCTR2012-005539-10-DE | 29/04/2014 | 2 October 2017 | Clinical study to investigate the efficacy and safety of two dose levels of NT 201 versus placebo in treating chronic troublesome sialorrhea in various neurological conditions. | Prospective, randomized, double-blind, placebo-controlled, parallel-group multicenter study, with an extension period of dose-blinded active treatment, to investigate the efficacy and safety of two dose levels of NT 201 in treating chronic troublesome sialorrhea in various neurological conditions - SIAXI – Sialorrhea in Adults Xeomin Investigation | Chronic troublesome sialorrhea resulting from neurological conditions in adults with Parkinson's disease or atypical parkinsonism (multiple system atrophy, corticobasal degeneration or progressive supranuclear palsy), or after stroke or traumatic brain injury. MedDRA version: 18.1 Level: PT Classification code 10039424 Term: Salivary hypersecretion System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Xeomin Pharmaceutical Form: Powder for solution for injection INN or Proposed INN: NT 101 CAS Number: 93384-43-1 Current Sponsor code: NT 101 Other descriptive name: BOTULINUM TOXIN TYPE A Concentration unit: U unit(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Powder for solution for injection Route of administration of the placebo: Intraglandular use Trade Name: Xeomin Pharmaceutical Form: Powder for solution for injection INN or Proposed INN: NT 101 CAS Number: 93384-43-1 Current Sponsor code: NT 101 Other descriptive name: BOTULINUM TOXIN TYPE A Concentration unit: U unit(s) Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Powder for solution for injection Route of administration of the placebo: Intraglandular use | Merz Pharmaceuticals GmbH | Not Recruiting | Female: yes Male: yes | 180 | Phase 3 | United States;Poland;Germany | |||
498 | JPRN-UMIN000015559 | 2014/04/14 | 2 April 2019 | Comparative study between SSRI and SNRI treatment on depressive patients with Parkinson diseases | Parkinson's disease Depression, Depressive state | paroxetine 20mg Escitalopram 10mg Duloxetine 40mg | Osaka Redcross Hospital | Not Recruiting | 40years-old | Not applicable | Male and Female | 40 | Not selected | Japan | ||
499 | NCT03314597 | April 2, 2014 | 16 December 2017 | Instrumental or Physical-Exercise Rehabilitation of Balance in Parkinson's Disease? (IPER-PD) | Instrumental or Physical-exercise Rehabilitation of Balance Improve Both Balance and Gait in Parkinson's Disease. | Parkinson's Disease;Rehabilitation | Other: Balance exercise;Other: Mobile platform exercise | University of Pavia | Fondazione Salvatore Maugeri | Not recruiting | 50 Years | 85 Years | All | 38 | N/A | |
500 | NCT01738178 | April 2014 | 16 December 2017 | Caffeine as a Therapy for Parkinson's Disease | Caffeine as a Therapeutic Agent in Parkinson's Disease | Parkinson's Disease | Drug: Caffeine;Drug: Placebo | McGill University Health Center | Pontifícia Universidade Católica do Paraná;University of Calgary;University of Newfoundland and Eastern Health;University Health Network, Toronto;UBC Hospital;Movement Disorder Clinic - Deer Lodge Centre;The Ottawa Hospital | Not recruiting | 45 Years | 75 Years | All | 119 | Phase 3 | Brazil;Canada |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
501 | NCT02111122 | April 2014 | 19 February 2015 | Study of the Symptomatic Effects of Nocturnal Sodium Oxybate in Parkinson's Disease | A Phase II, Prospective, Randomized, Double-blind, Crossover Placebo-controlled Study of the Symptomatic Effects of Nocturnal Sodium Oxybate in Parkinson's Disease | Sleep-wake Disturbances in Motor-phase Parkinson`s Disease | Drug: Sodium Oxybate | University of Zurich | Recruiting | 18 Years | 90 Years | Both | 16 | Phase 2 | Switzerland | |
502 | NCT02365012 | April 2014 | 7 September 2015 | Treatment of Orthostatic Intolerance in Patients With Parkinson's Disease Using Midodrine | Treatment of Orthostatic Intolerance in Patients With Parkinson's Disease Using Midodrine | Orthostatic Intolerance;Parkinson's Disease | Drug: Midodrine | Philadelphia Veterans Affairs Medical Center | Recruiting | 22 Years | 89 Years | Both | 50 | N/A | United States | |
503 | NCT02741947 | April 2014 | 25 April 2016 | Levodopa Benserazide Generic Formulation Versus the Originator | Clinical and Pharmacokinetics Study to Evaluate the Therapeutic Equivalence and Bioequivalence of Levodopa Benserazide Generic Formulation (Teva Italia) Versus the Originator (Madopar®) | Parkinson Disease | Drug: Levodopa Benserazide Madopar;Drug: Levodopa Benserazide Teva Italia | IRCCS San Raffaele | Agenzia Italiana del Farmaco | Not recruiting | 30 Years | 75 Years | Both | 44 | Phase 4 | Italy |
504 | NCT02082249 | March 10, 2014 | 10 December 2018 | An Extension Study to Assess the Safety, Tolerability and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease and Persistent Motor-Complications Despite Optimized Treatment With Available Anti-Parkinsonian Medications | An Open-Label Three-Part Extension Study Assessing Safety, Tolerability and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease and Persistent Motor-Complications Despite Optimized Treatment With Available Anti-Parkinsonian Medications | Advanced Parkinson's Disease | Drug: ABT-SLV187 | AbbVie | Not recruiting | 30 Years | 99 Years | All | 1 | Phase 3 | Japan;Korea, Republic of;Taiwan | |
505 | NCT02006290 | March 2014 | 12 October 2015 | Efficacy, Safety And Tolerability Study In Subjects With Parkinson's Disease | A Phase 1b, Randomized, Subject And Investigator-Blinded, Sponsor-Open, Placebo Controlled, Cross-Over Efficacy, Safety And Tolerability Study Of Single Oral Split Dose Administration Of PF-06412562 In Subjects With Parkinson's Disease | Parkinson's Disease | Drug: PF-06412562;Drug: Placebo | Pfizer | Not recruiting | 30 Years | 75 Years | Both | 19 | Phase 1 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
506 | NCT02092181 | March 2014 | 23 July 2018 | A Pilot Study of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Parkinson's Disease (MAESTRO) | A Pilot Study of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Parkinson's Disease. (MAESTRO) | Parkinsons Disease | Drug: Mirabegron;Drug: Placebo | Daniel Burdick, MD | Astellas Pharma US, Inc. | Not recruiting | 30 Years | 85 Years | All | 30 | Phase 4 | United States |
507 | NCT02095171 | March 2014 | 19 February 2015 | Single Ascending Dose Study of PRX002 in Healthy Subjects | A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of PRX002 Administered by Intravenous Infusion in Healthy Subjects | Parkinson's Disease | Drug: PRX002;Other: Placebo | Prothena Biosciences Limited | Hoffmann-La Roche | Not recruiting | 21 Years | 65 Years | Both | 40 | Phase 1 | United States |
508 | NCT02111330 | March 2014 | 11 April 2016 | Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF -509 (80 mg, 160 mg and 240 mg) After Multiple Oral Doses in Healthy Volunteers | Randomized, Double Blind, Placebo Controlled, Parallel Groups Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF -509 (80 mg, 160 mg and 240 mg) After Multiple Oral Doses in Healthy Volunteers | Parkinson Disease | Drug: PBF-509;Drug: Placebo | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | Palo Biofarma, S.L | Not recruiting | 18 Years | 45 Years | Both | 16 | Phase 1 | Spain |
509 | NCT02305017 | March 2014 | 19 October 2017 | Effect of Paracetamol on Opicapone Pharmacokinetics in Healthy Volunteers | Effect of Paracetamol on Opicapone Pharmacokinetics in Healthy Volunteers | Parkinson's Disease | Drug: BIA 9-1067;Drug: Paracetamol | Bial - Portela C S.A. | Not recruiting | 18 Years | 45 Years | All | 28 | Phase 1 | ||
510 | NCT02305030 | March 2014 | 19 February 2015 | Effect of Opicapone at Steady State on Warfarin Pharmacokinetics | Effect of Opicapone at Steady State on Warfarin Pharmacokinetics in Healthy Volunteers | Parkinson's Disease | Drug: BIA 9-1067;Drug: Warfarin | Bial - Portela C S.A. | Not recruiting | 18 Years | 45 Years | Both | 20 | Phase 1 | ||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
511 | NCT02445651 | March 2014 | 23 April 2019 | Physiological Effects of Nutritional Support in Patients With Parkinson's Disease | Physiological Effects of Nutritional Support in Patients With Parkinson's Disease | Parkinson Disease;Idiopathic Parkinson Disease | Dietary Supplement: Intravenous and Oral n—acetyl cysteine | Thomas Jefferson University | Not recruiting | 30 Years | 80 Years | All | 65 | N/A | United States | |
512 | NCT02064166 | February 2014 | 3 December 2018 | Treatment of Parkinson Disease and Multiple System Atrophy Using Intranasal Insulin. | A Double-blinded Placebo-controlled Single-center Study to Evaluate the Efficacy of Intranasal Insulin 40 International Units Day as Treatment for Subjects With Parkinson Disease and Multiple System Atrophy | Parkinson Disease;Multiple System Atrophy | Drug: Intranasal Insulin | Peter Novak | Not recruiting | 18 Years | N/A | All | 15 | Phase 2 | United States | |
513 | NCT02103894 | February 2014 | 9 January 2017 | Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects | Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Clinically Diagnosed Tauopathies in Comparison to Healthy Subjects | Alzheimer's Disease (AD);Parkinson's Disease (PD);Chronic Traumatic Encephalopathy (CTE);Progressive Supranuclear Palsy (PSP);Frontal Temporal Dementia (FTD);Pick's Disease;Tauopathies | Drug: [18F]T807 ([18F]MNI-777) | Molecular NeuroImaging | Institute for Neurodegenerative Disorders | Not recruiting | 18 Years | 85 Years | Both | 16 | Phase 1 | United States |
514 | NCT02305316 | February 2014 | 19 October 2017 | Single-dose Pharmacokinetics and Relative Bioavailability of Two Different Formulations of Opicapone | Single-dose Pharmacokinetics and Relative Bioavailability of Two Different Formulations of Opicapone in Healthy Volunteers | Parkinson Disease | Drug: BIA 9-1067 non-micronized;Drug: BIA 9-1067 micronized | Bial - Portela C S.A. | Not recruiting | 18 Years | 45 Years | All | 28 | Phase 1 | ||
515 | EUCTR2013-002545-10-SE | 08/01/2014 | 27 June 2016 | An open safety study with the monoaminergic stabilizer (-)-OSU6162 in patients with mental fatigue and related vitality and wakefulness disturbances associated with neurologiacal disorders, e g Parkinson’s disease, Huntington’s disease, brain trauma, stroke, myalgic encephalomyelitis and narcolepsy. | An open safety study with the monoaminergic stabilizer (-)-OSU6162 in patients with mental fatigue and related vitality and wakefulness disturbances associated with neurologiacal disorders, e g Parkinson’s disease, Huntington’s disease, brain trauma, stroke, myalgic encephalomyelitis and narcolepsy. - OSU6162Open1309 | Parkinsons disease Huntingtons disease Multiple scleros Brain trauma Stroke Myalgic encephalomyelitis Narcolepsy;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: OSU6162 similar to (-)-OSU 6162 Pharmaceutical Form: Coated tablet | A. Carlsson Research AB | Authorised | Female: yes Male: yes | 240 | Phase 2 | Sweden | |||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
516 | NCT02046434 | January 2014 | 14 January 2019 | Phenylbutyrate Response as a Biomarker for Alpha-synuclein Clearance From the Brain | Phenylbutyrate Response As a Biomarker for Alpha-Synuclein Clearance From Brain | Parkinson's Disease | Drug: Glycerol Phenylbutyrate | University of Colorado, Denver | Not recruiting | 21 Years | 80 Years | All | 40 | Phase 1 | United States | |
517 | NCT02384512 | January 2014 | 20 April 2015 | Azilect® In Wearing-Off (AIWO) | Azilect® In Wearing-Off (AIWO) Non-interventional Study on Efficacy and Tolerability of Rasagiline (1mg/d) add-on in Ambulatory Parkinson's Disease Patients With Wearing-off Symptoms Diagnosed by Wearing-off Questionnaire (WOQ-32) | Parkinson's Disease | Drug: Azilect® | Teva Pharma GmbH | Anfomed GmbH | Not recruiting | 18 Years | N/A | Both | 261 | N/A | Germany |
518 | NCT01883505 | December 2013 | 11 April 2016 | A Phase 2a Study Followed to Evaluate the Safety, Tolerability and Levodopa Pharmacokinetics in Levodopa-treated Parkinson's Disease Patients Receiving ND0612 | A Phase 2a Multicentre Randomized Double Blind Placebo Controlled Study Followed by an Open Label Period, to Evaluate the Safety, Tolerability and Levodopa Pharmacokinetics in Levodopa-treated Parkinson's Disease Patients With Motor Fluctuations, Administered With Repeated Continuous Subcutaneous ND0612 | Parkinson's Disease | Drug: Levodopa and carbidopa;Drug: Placebo | NeuroDerm Ltd. | Not recruiting | 30 Years | N/A | Both | 30 | Phase 2 | Israel | |
519 | NCT01968460 | December 2013 | 16 December 2017 | Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease | A Phase 2B, Twelve-week Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study, To Determine the Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease | Parkinson's Disease | Drug: P2B001 once daily (pramipexole 0.6 mg / rasagiline 0.75 mg),;Drug: Placebo;Drug: P2B001 once daily (pramipexole 0.3 mg / rasagiline 0.75 mg), | Pharma Two B Ltd. | Not recruiting | 35 Years | 75 Years | All | 149 | Phase 2/Phase 3 | United States;Israel | |
520 | NCT02018406 | December 2013 | 8 April 2019 | Establishment of Clinical Basis for Hematopoietic Growth Factors Therapy in Brain Injury | Neurological Diseases;Ischemic Stroke;Hemorrhagic Stroke;Cerebral Palsy;Atypical Parkinson Disease | Drug: Combination injection of EPO and G-CSF;Drug: Injection of normal saline | Yonsei University | Not recruiting | 20 Years | N/A | All | 16 | Phase 1/Phase 2 | Korea, Republic of | ||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
521 | NCT02108704 | December 2013 | 4 November 2019 | Helicobacter Pylori Eradication Study in Parkinson's Disease | Helicobacter Pylori Eradication in Parkinson's Disease: A Double-blind Randomised Placebo Controlled Trial | Parkinson's Disease;Helicobacter Pylori Infection | Drug: Helicobacter pylori eradication therapy;Drug: Placebo | University of Malaya | Not recruiting | 18 Years | N/A | All | 75 | N/A | Malaysia | |
522 | NCT01856738 | November 2013 | 15 October 2018 | Cholinesterase Inhibitors to Slow Progression of Visual Hallucinations in Parkinson&Apos;s Disease | Cholinesterase Inhibitors to Slow Progression of Visual Hallucinations in Parkinson's Disease:a Multi-center Placebo-controlled Trial. | Parkinson's Disease | Drug: Rivastigmine;Drug: Placebo (for rivastigmine) | VU University Medical Center | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA);Atrium Medical Center;University Medical Center Groningen;Leiden University Medical Center;University Medical Center Nijmegen;International Parkinson Fonds Germany GmbH;ZonMw: The Netherlands Organisation for Health Research and Development | Not recruiting | 40 Years | N/A | All | 91 | Phase 4 | Netherlands |
523 | NCT01927055 | November 2013 | 19 October 2017 | A Clinical Study of Patients With Symptomatic NOH to Assess Sustained Effects of Droxidopa Therapy | A Clinical Study of Patients With Symptomatic Neurogenic Orthostatic Hypotension to Assess Sustained Effects of Droxidopa Therapy | Symptomatic Neurogenic Orthostatic Hypotension;Parkinson's Disease;Multiple Systems Atrophy;Pure Autonomic Failure;Dopamine Beta Hydroxylase Deficiency | Drug: Droxidopa;Drug: Placebo | Chelsea Therapeutics | Not recruiting | 18 Years | N/A | All | 61 | Phase 3 | United States | |
524 | EUCTR2013-000980-10-AT | 18/10/2013 | 2 October 2017 | Clinical trial of apomorphine subcutaneous infusion in patients with advanced Parkinson’s disease | TOLEDO Multicenter, parallel-group, double-blind, placebo-controlled phase III study to evaluate the efficacy and safety of apomorphine subcutaneous infusion in Parkinson’s disease patients with motor complications not well controlled on medical treatment - TOLEDO | Parkinson Disease (PD) in patients with motor fluctuations not well controlled on medical treatment MedDRA version: 18.0 Level: LLT Classification code 10034006 Term: Parkinson's disease aggravated System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Apo-go® Product Name: Apomorphine hydrochloride Product Code: Apo-go® Pharmaceutical Form: Solution for infusion in pre-filled syringe INN or Proposed INN: Apomorphine hydrochloride CAS Number: 314-19-2 Other descriptive name: Apomorphine hydrochloride Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Solution for infusion in pre-filled syringe Route of administration of the placebo: Subcutaneous use | Britannia Pharmaceuticals Limited | Not Recruiting | Female: yes Male: yes | 102 | Phase 3 | France;Spain;Denmark;Austria;Netherlands;Germany | |||
525 | NCT01960842 | October 2013 | 11 June 2018 | A Study to Assess the Efficacy, Safety and Tolerability of ABT-SLV187 Monotherapy in Subjects With Advanced Parkinson's Disease (PD) and Persistent Motor Complications, Despite Optimized Treatment With Available Anti-Parkinsonian Medications | An Open-Label, Single-Arm, Baseline-Controlled, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of ABT-SLV187 Monotherapy in Subjects With Advanced Parkinson's Disease and Persistent Motor-Complications Despite Optimized Treatment With Available Anti-Parkinsonian Medication | Advanced Parkinson's Disease | Drug: Levodopa-carbidopa intestinal gel;Device: CADD-Legacy® 1400 ambulatory infusion pump;Device: PEG tube;Device: J-tube | AbbVie | Not recruiting | 30 Years | N/A | All | 31 | Phase 3 | Japan;Korea, Republic of;Taiwan | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
526 | NCT01968031 | October 2013 | 9 January 2017 | A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease | A Phase 3, 12-week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study to Evaluate the Efficacy of Oral Istradefylline 20 and 40 mg/Day as Treatment for Subjects With Moderate to Severe Parkinson's Disease | Idiopathic Parkinson's Disease | Drug: Istradefylline 40 mg;Drug: Istradefylline 20 mg;Drug: Placebo | Kyowa Hakko Kirin Pharma, Inc. | Kyowa Hakko Kirin Co., Ltd | Not recruiting | 30 Years | N/A | Both | 613 | Phase 3 | United States;Canada;Czech Republic;Germany;Israel;Italy;Poland;Serbia |
527 | NCT01973543 | October 2013 | 8 April 2019 | Safety Study of AADC Gene Therapy (VY-AADC01) for Parkinson's Disease | An Open-label Safety and Efficacy Study of VY-AADC01 Administered by MRI-Guided Convective Infusion Into the Putamen of Subjects With Parkinson's Disease With Fluctuating Responses to Levodopa | Parkinson's Disease | Biological: VY-AADC01 | Neurocrine Biosciences | University of California, San Francisco;Veristat, Inc.;Feinstein Institute for Medical Research;Oregon Health and Science University;Voyager Therapeutics | Not recruiting | 40 Years | 70 Years | All | 15 | Phase 1 | United States |
528 | NCT02012595 | October 2013 | 8 June 2015 | [11C]Donepezil PET For Imaging The Autonomous Nervous System In Parkinsons Disease | [11C]Donepezil PET For Imaging The Autonomous Nervous System In Parkinsons Disease | Parkinson's Disease | Other: [11C]donepezil PET | Per Borghammer | Lundbeck Foundation;Jascha Fonden;Fonden af 2. Juli 1984 til bekæmpelse af Parkinsons Sygdom | Not recruiting | 40 Years | 80 Years | Both | 24 | N/A | Denmark |
529 | NCT02055274 | October 2013 | 2 November 2015 | Pharmacokinetics and Safety Study of LY03003 in Patients With Early-stage Parkinson's Disease | A Randomized, Double-blinded, Multiple Ascending Dose Study in Patients With Early-stage Parkinson's Disease to Evaluate the Pharmacokinetics and Safety of LY03003 Following Intramuscular Injections | Parkinson's Disease | Drug: LY03003;Drug: Neupro | Luye Pharma Group Ltd. | Not recruiting | 18 Years | N/A | Both | 39 | Phase 1 | United States | |
530 | NCT02207387 | October 2013 | 13 April 2015 | Ambulosono Rasagiline Musical Walking Study | A Sensorimotor Contingency-based Musical Walking Program for People Living With Parkinson's Disease | Parkinson's Disease | Drug: Azilect;Behavioral: Exercise;Other: Music | University of British Columbia | Teva Pharmaceutical Industries | Recruiting | 19 Years | N/A | Both | 60 | N/A | Canada |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
531 | EUCTR2013-001881-40-GB | 16/09/2013 | 30 April 2019 | Extension study to Assess the Benefit and Safety of Administering Intermittent GDNF Infusions in Parkinson's Disease (PD) | An Extension Study to Assess the Safety and Efficacy of Intermittent Bilateral Intraputamenal Glial Cell Line-Derived Neurotrophic Factor (GDNF) Infusions Administered via onvection Enhanced Delivery (CED) in Subjects with Parkinson’s Disease - Intermittent Bilateral GDNF for Parkinson’s Disease | Parkinson's disease MedDRA version: 18.1 Level: LLT Classification code 10034008 Term: Parkinson's syndrome System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Glial Cell Line-Derived Neurotrophic Factor (GDNF) Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Liatermin Other descriptive name: r-metHuGDNF Concentration unit: mg/ml milligram(s)/millilitre Concentration type: range Concentration number: 9.0-11.0 | North Bristol NHS Trust (NBT) | Not Recruiting | Female: yes Male: yes | 42 | Phase 2 | United Kingdom | |||
532 | NCT01882010 | September 2013 | 30 May 2016 | Leukine (Sargramostim) for Parkinson's Disease | Leukine (Sargramostim) for Parkinson's Disease | Parkinson's Disease | Procedure: blood draw;Procedure: physical exam and UPDRS part III assessment;Procedure: MEG;Drug: sargramostim;Drug: placebo;Behavioral: physical exam and UPDRS part III assessment;Procedure: Motion Analysis | Howard Gendelman, MD | Sanofi;National Institute of Neurological Disorders and Stroke (NINDS);UNeMed;Nebraska Neuroscience Alliance | Not recruiting | 35 Years | 85 Years | Both | 37 | Phase 1 | United States |
533 | NCT01923584 | September 2013 | 26 September 2016 | A Phase 2A Trial of EPI-743 for Patients With Parkinson's Disease | A Phase 2A Trial of EPI-743 for Patients With Parkinson's Disease | Parkinson's Disease | Drug: EPI-743 400mg;Drug: EPI-743 200mg | University of South Florida | Edison Pharmaceuticals Inc | Not recruiting | 40 Years | 75 Years | Both | 15 | Phase 2 | United States |
534 | NCT01955616 | September 2013 | 3 October 2016 | A Phase 2 Study to Evaluate the Safety and Efficacy of RM-131 in Patients With Parkinson's Disease & Chronic Constipation | A Phase 2, Randomized, Double-blind, Placebo-controlled, Multiple Dose, Parallel Group Study to Evaluate the Pharmacodynamics, Efficacy and Safety of RM-131 Administered to Patients With Parkinson's Disease and Chronic Constipation Dissatisfied With Current Therapy | Parkinson's Disease | Drug: RM-131;Drug: Placebo | Motus Therapeutics, Inc. | Michael J. Fox Foundation for Parkinson's Research | Not recruiting | 18 Years | 80 Years | Both | 18 | Phase 2 | United States |
535 | NCT01929317 | August 28, 2013 | 2 July 2018 | A Study to Evaluate the Efficacy of 18 to 24mg/Day Ropinirole Controlled Release (CR) Tablets in Early and Advanced Parkinson's Disease (PD) Patients. | A Study ROP116991, Clinical Evaluation of 18 to 24mg/Day Ropinirole CR for Parkinson's Disease. | Parkinson Disease | Drug: Ropinirole CR 2mg tablet;Drug: Ropinirole CR 8mg tablet;Drug: Ropinirole CR matching Placebo tablet | GlaxoSmithKline | Not recruiting | 20 Years | N/A | All | 81 | Phase 3 | Japan | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
536 | JPRN-UMIN000011111 | 2013/07/16 | 2 April 2019 | Spinal blood flow and metabolism in neurological diseases | motor neuron disease including ALS, multiple sclerosis, stroke, Parkinson disease, spinocerebellar degeneration, multiple system atrophy | PET scan study with 11C-flumazenil PET scan study with 18F- FDG PET scan study with 15O-H2O | Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences | Recruiting | 20years-old | Not applicable | Male and Female | 70 | Not applicable | Japan | ||
537 | NCT01767129 | July 2013 | 22 January 2018 | Safety and Efficacy of AVP-923 in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease Patients | A Phase 2a, Double-blind, Randomized, Placebo-controlled, Crossover Study to Evaluate the Safety and Efficacy of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease Patients. | Dyskinesia;Parkinson's Disease | Drug: AVP-923-45;Drug: Placebo | Avanir Pharmaceuticals | Michael J. Fox Foundation for Parkinson's Research | Not recruiting | 30 Years | 80 Years | All | 14 | Phase 2 | United States;Canada |
538 | EUCTR2012-001245-40-IT | 05/06/2013 | 11 April 2016 | CLINICAL AND PHARMACOLOGICAL STUDY TO EVALUATE THE THERAPEUTIC EQUIVALENCE AND BIOEQUIVALENCE OF LEVODOPA BENSERAZIDE GENERIC FORMULATION (TEVA ITALIA) VERSUS THE ORIGINATOR (MADOPAR®) | CLINICAL AND PHARMACOKINETICS STUDY TO EVALUATE THE THERAPEUTIC EQUIVALENCE AND BIOEQUIVALENCE OF LEVODOPA BENSERAZIDE GENERIC FORMULATION (TEVA ITALIA) VERSUS THE ORIGINATOR (MADOPAR®) | PARKINSON'S DISEASE MedDRA version: 16.0 Level: LLT Classification code 10013113 Term: Disease Parkinson's System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Madopar 200+50 mg Pharmaceutical Form: Tablet Trade Name: LEVODOPA / BENSERAZIDE 200 + 50 MG Pharmaceutical Form: Tablet | Not Recruiting | Female: yes Male: yes | Italy | ||||||
539 | JPRN-JapicCTI-132189 | 01/6/2013 | 23 April 2019 | A Phase 1 Study of ONO-2160/CD | A Phase 1 study on single oral dose administration of ONO-2160/CD in healthy adult male subjects and Parkinson's disease patients | Parkinson's disease | Intervention name : ONO-2160/CD Dosage And administration of the intervention : Oral administration Control intervention name : Levodopa/carbidopa hydrate INN of the control intervention : Levodopa/Carbidopa Hydrate Dosage And administration of the control intervention : Oral administration | ONO PHARMACEUTICAL CO.,LTD. | BOTH | 42 | Phase 1 | |||||
540 | NCT01850381 | June 2013 | 26 August 2019 | Phase 2A Study of GM 608 in Mild to Moderate Parkinson Disease | GM 608 in A Phase IIA Pilot Double-blinded, Randomized, Placebo Controlled Trial in Mild to Moderate Parkinson Disease | Parkinson's Disease | Drug: GM608;Drug: Placebo Comparator | Genervon Biopharmaceuticals, LLC | Columbia University | Not recruiting | 30 Years | N/A | All | 6 | Phase 2 | United States |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
541 | NCT01879748 | June 2013 | 19 February 2015 | A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Rasagiline | A Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses (0.5, 1.0, and 2.0 mg) of Rasagiline Administered to Healthy Japanese and Caucasian Subjects | Parkinson's Disease | Drug: Rasagiline;Drug: Placebo | Teva Pharmaceutical Industries | Not recruiting | 20 Years | 50 Years | Both | 64 | Phase 1 | United States | |
542 | NCT02263235 | June 2013 | 17 May 2016 | In Vivo Alzheimer Proteomics | Use of Targeted Quantitative Proteomics and Metabolic Labelling With Stable Isotopes for the Diagnosis and the Investigation of Neurological Disorders and in Particular Alzheimer Disease | Probable Alzheimer Disease;Parkinson Disease;Neurological Disease Without Cognitive Degradation;Brain Trauma;Acute Hydrocephaly | Biological: administration of stable isotope-labelled leucine-;Other: collection of CSF, blood, urine, saliva | University Hospital, Montpellier | Assistance Publique - Hôpitaux de Paris;University Hospital, Clermont-Ferrand;International Atomic Energy Agency | Recruiting | 55 Years | 85 Years | Both | 110 | N/A | France |
543 | NCT02275884 | June 2013 | 19 February 2015 | Pharmacologically Active Constituents of Chocolate and Their Symptomatic Effects in Patients With Idiopathic Parkinson's Disease | Evaluation of Plasma Concentrations of Pharmacologically Active Constituents of Chocolate and Their Symptomatic Effects in Patients With Idiopathic Parkinson's Disease | Parkinson Disease | Dietary Supplement: Dark chocolate (85% cocoa);Dietary Supplement: White chocolate (0% cocoa) | Technische Universität Dresden | University of Wuerzburg | Recruiting | 40 Years | N/A | Both | 30 | N/A | Germany |
544 | JPRN-UMIN000010752 | 2013/05/17 | 2 April 2019 | A study on usefulness and safety of donepezil for cognitive function and phychological symptoms of patients with Parkinson's disease and Alzheimer type dementia. | Parkinson's disease | donepezil | Kansai Medical University | Not Recruiting | Not applicable | Not applicable | Male and Female | 50 | Not selected | Japan | ||
545 | EUCTR2013-000827-15-IT | 11/05/2013 | 18 January 2016 | LATE ONSET PARKINSON’S DISEASE IN SUBJECTS 70 YEARS AND OLDER: POSSIBLE USE OF ROTIGOTINE | LATE ONSET PARKINSON’S DISEASE IN SUBJECTS 70 YEARS AND OLDER: POSSIBLE USE OF ROTIGOTINE - PARROT | Parkinson disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Rotigotine Product Name: neurpro Product Code: SPM962 Pharmaceutical Form: Transdermal patch Pharmaceutical form of the placebo: Transdermal patch Route of administration of the placebo: Transdermal use | Unità Malattie Neurodegenerative, Ospedale Cardinale Giovanni Panico, Tricase | Not Recruiting | Female: yes Male: yes | Italy | |||||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
546 | JPRN-UMIN000010596 | 2013/05/01 | 2 April 2019 | Randomized crossover trial comparing memantine or amantadine for Parkinson's disease with motor fluctuations in Juntendo | Parkinson's disease | Memantine preceding arm Titrate the memantine, administered for 3 months. And tapering memantine and amantadine titrate the dose for 3 months. Amantadine preceding arm Titrate the amantadine, administered for 3 months. And tapering amantadine and memantine titrate the dose for 3 months. | Department of Neurology, Juntendo University School of Medicine | Not Recruiting | 20years-old | Not applicable | Male | 40 | Not selected | Japan | ||
547 | NCT01851850 | May 2013 | 19 February 2015 | Continuation Treatment Protocol for Patient Who Participated in the BIA 9-1067-302 Clinical Trial | Continue Providing Care for Patient Who Participated in the BIA 9-1067-302 Clinical Trial | Parkinson Disease | Drug: Opicapone | Rabin Medical Center | Not recruiting | 30 Years | 80 Years | Both | 1 | Phase 3 | Israel | |
548 | NCT01860794 | May 2013 | 16 December 2017 | Evaluation of Safety and Tolerability of Fetal Mesencephalic Dopamine Neuronal Precursor Cells for Parkinson's Disease | Investigator Clinical Trial for Evaluation of Safety and Tolerability After Transplantation of Fetal Mesencephalic Dopamine Neuronal Precursor Cells in Patients With Parkinson's Disease | Idiopathic Parkinson Disease;Primary Parkinsonism | Drug: Mesencephalic Neuronal Precursor Cells | Bundang CHA Hospital | Recruiting | 18 Years | 70 Years | Female | 15 | Phase 1/Phase 2 | Korea, Republic of | |
549 | NCT01877538 | May 2013 | 19 October 2017 | Study to Investigate the Ability of [11C]Donepezil PET to Image the Parasympathetic Nervous System | [11C]Donepezil PET for Imaging the Parasympathetic Nervous System in Healthy Adults | Parkinson's Disease | Other: [11C]donepezil PET | Per Borghammer | Lundbeck Foundation | Not recruiting | 45 Years | 75 Years | Male | 7 | Phase 1 | Denmark |
550 | NCT02473562 | May 2013 | 15 October 2018 | Varenicline Treatment for Excessive Daytime Sleepiness in Parkinson's Disease | Varenicline, a Partial Nicotinic Receptor Agonist for the Treatment of Excessive Daytime Sleepiness in Parkinson's Disease: a Placebo-controlled Cross-over Pilot Study | Parkinson's Disease | Drug: Varenicline;Drug: Placebo (for varenicline) | VU University Medical Center | Centre for Human Drug Research, Netherlands | Not recruiting | N/A | N/A | All | 22 | Phase 4 | Netherlands |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
551 | NCT02500108 | May 2013 | 25 April 2016 | Domperidone and Risk of Sudden Cardiac Death | Domperidone Use in Parkinson's Disease and Risk of Sudden Cardiac Death | Parkinson's Disease | Drug: Domperidone | Canadian Network for Observational Drug Effect Studies, CNODES | Drug Safety and Effectiveness Network, Canada;Canadian Institutes of Health Research (CIHR) | Not recruiting | 50 Years | N/A | Both | 214962 | N/A | Canada |
552 | NCT03022201 | May 2013 | 1 April 2019 | Comparing the Therapeutic Efficacy and Safety of DA-9701 With Domperidone in Patients With Parkinson's Disease | Therapeutic Efficacy of DA-9701 on Gastric Motility in Patients With Parkinson's Disease Evaluated by Magnetic Resonance Imaging: A Randomized Controlled, Double-Blind, Non-Inferiority Trial | Parkinson's Disease,Idiopathic | Drug: DA-9701;Drug: Domperidone;Drug: Placebo domperidone;Drug: Placebo DA-9701 | Seoul National University Hospital | Not recruiting | 20 Years | 80 Years | All | 40 | Phase 4 | Korea, Republic of | |
553 | EUCTR2011-002827-17-EE | 23/04/2013 | 6 January 2015 | A fixed dose, dose response study for ropinirole prolonged release (PR) in patients with early stage Parkinson’s Disease. | A fixed dose, dose response study for ropinirole prolonged release (PR) in patients with early stage Parkinson’s Disease. | Early stage Parkinson's Disease. MedDRA version: 14.1 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: REQUIP-MODUTAB , 2mg Product Name: ropinirole PR, 2mg Product Code: SK&F101468 Pharmaceutical Form: Prolonged-release tablet INN or Proposed INN: ROPINIROLE CAS Number: 91374-21-9 Current Sponsor code: SK&F101468 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2- Pharmaceutical form of the placebo: Prolonged-release tablet Route of administration of the placebo: Oral use Trade Name: REQUIP-MODUTAB , 4mg Product Name: ropinirole PR, 2mg Product Code: SK&F101468 Pharmaceutical Form: Prolonged-release tablet INN or Proposed INN: ROPINIROLE CAS Number: 91374-21-9 Current Sponsor code: SK&F101468 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 4- Pharmaceutical form of the placebo: Prolonged-release tablet Route of administration of the placebo: Oral use Trade Name: REQUIP-MODUTAB , 8mg Product Name: ropinirole PR Product Code: SK&F101468 Pharmaceutical Form: Prolonged-release tablet INN or Proposed INN: ROPINIROLE CAS Number: 91374-21-9 Current Sponsor code: SK&F101468 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 8- Pharmaceutical form of the placebo: Prolonged-release tablet Route of administration of the placebo: Oral use | GlaxoSmithKline Research & Development Limited | Not Recruiting | Female: yes Male: yes | 210 | United States;Estonia;Slovakia;Russian Federation;Korea, Republic of | ||||
554 | EUCTR2011-002828-41-EE | 23/04/2013 | 10 July 2015 | A study to test the effectiveness of varying doses of ropinirole PR while taking L-dopa in patients with late stage Parkinson's disease. | A fixed dose, dose-response study of ropinirole prolonged release (PR) as adjunctive treatment to L-dopa in patients with advanced Parkinson's disease. | Advanced Parkinson's disease. MedDRA version: 14.1 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: REQUIP-MODUTAB, 2mg Product Name: ropinirole PR, 2mg Product Code: SK&F101468 Pharmaceutical Form: Prolonged-release tablet INN or Proposed INN: ROPINIROLE CAS Number: 91374-21-9 Current Sponsor code: SK&F101468 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2- Pharmaceutical form of the placebo: Prolonged-release tablet Route of administration of the placebo: Oral use Trade Name: REQUIP-MODUTAB, 4mg Product Name: ropinirole PR, 2mg Product Code: SK&F101468 Pharmaceutical Form: Prolonged-release tablet INN or Proposed INN: ROPINIROLE CAS Number: 91374-21-9 Current Sponsor code: SK&F101468 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 4- Pharmaceutical form of the placebo: Prolonged-release tablet Route of administration of the placebo: Oral use Trade Name: REQUIP-MODUTAB, 8mg Product Name: ropinirole PR Product Code: SK&F101468 Pharmaceutical Form: Prolonged-release tablet INN or Proposed INN: ROPINIROLE CAS Number: 91374-21-9 Current Sponsor code: SK&F101468 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 8- Pharmaceutical form of the placebo: Prolonged-release tablet Route of administration of the placebo: Oral use | GlaxoSmithKline Research & Development Limited | Not Recruiting | Female: yes Male: yes | 406 | United States;Taiwan;Estonia;Slovakia;Argentina;Chile;Russian Federation;Korea, Republic of | ||||
555 | JPRN-UMIN000010778 | 2013/04/10 | 2 April 2019 | Delayed start study of donepezil hydrocloride for cognitive decline in Parkinson disease following EDAP-1 | Parkinson disease | 5mg donepezil hydrocloride | National Hospital of Utano | Not Recruiting | 20years-old | Not applicable | Male and Female | 50 | Not selected | Japan | ||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
556 | JPRN-UMIN000010371 | 2013/04/08 | 2 April 2019 | Study of zonisamide ( TRERIEF® tablet 25mg ) to tremor in patients with early Parkinson's disease. | Parkinson's disease | Start 25mg of Zonisamide and carry out observation 24weeks. Evaluate start point, after 4weeks, after 8weeks, after 16weeks, and after 24weeks. | Department of Neurology, University of Yamanashi | Not Recruiting | Not applicable | Not applicable | Male and Female | 10 | Not selected | Japan | ||
557 | NCT01777555 | April 2013 | 20 August 2018 | Efficacy and Safety Study of Inhaled CVT 301 in Parkinson's Disease Patients for Treatment of OFF Episodes | A Phase 2b, Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy and Safety of Inhaled CVT 301 (Levodopa Inhalation Powder) in Parkinson's Disease Patients With Motor Response Fluctuations (OFF Phenomena) | Idiopathic Parkinson's Disease | Drug: CVT-301;Drug: Placebo | Acorda Therapeutics | Not recruiting | 30 Years | 80 Years | All | 89 | Phase 2 | United States;Italy;Serbia;United Kingdom | |
558 | NCT01829867 | April 2013 | 8 February 2016 | A Study With an Increased Dose Step in Patients That Have Previously Received Placebo or sNN0031. | A Phase I, Open-label Study in Patients With Parkinson's Disease to Further Assess Safety and Tolerability of sNN0031 Administered at the Total Dose of 95 µg by Intracerebroventricular Infusion | Parkinson's Disease | Drug: sNN0031 | Newron Sweden AB | Not recruiting | 55 Years | 75 Years | Both | 5 | Phase 1 | Sweden | |
559 | NCT02005029 | April 2013 | 19 October 2017 | Erythromycin in Parkinson's Disease | Erythromycin in Parkinson's Disease: A Pilot Study of Its Effects on Levodopa Pharmacokinetics and Pharmacodynamics | Parkinson's Disease;Levodopa | Drug: Erythromycin;Drug: placebo | Virginia Commonwealth University | Not recruiting | 18 Years | 80 Years | All | 18 | N/A | United States | |
560 | JPRN-UMIN000009958 | 2013/03/08 | 2 April 2019 | Effects of donepezil on the prognosis of Parkinson's disease with severe olfactory dysfunction | Parkinson's disease | Donepezil hydrochloride added to standard therapy Placebo added to standard therapy | National Hospital Organization, Sendai-Nishitaga Hospital | Not Recruiting | 55years-old | 75years-old | Male and Female | 200 | Not applicable | Japan | ||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
561 | EUCTR2012-002840-26-AT | 05/03/2013 | 31 March 2014 | Study to test the efficacy of two doses of Rotigotine on depressive mood (apathy) associated with Parkinson's Disease | A Multicenter, Multinational, Double-blind, Placebo-controlled, 3-arm Phase 4 Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease- Associated Apathy, Motor Symptoms, and Mood | Parkinson's disease MedDRA version: 14.1 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Neupro Product Name: Rotigotine Pharmaceutical Form: Transdermal patch INN or Proposed INN: ROTIGOTINE CAS Number: 99755-59-6 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 4.5- Pharmaceutical form of the placebo: Transdermal patch Route of administration of the placebo: Transdermal use Trade Name: Neupro Product Name: Rotigotine Pharmaceutical Form: Transdermal patch INN or Proposed INN: ROTIGOTINE CAS Number: 99755-59-6 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 9- Trade Name: Neupro Product Name: Rotigotine Pharmaceutical Form: Transdermal patch INN or Proposed INN: ROTIGOTINE CAS Number: 99755-59-6 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 13.5- Trade Name: Neupro Product Name: Rotigotine Pharmaceutical Form: Transdermal patch INN or Proposed INN: ROTIGOTINE CAS Number: 99755-59-6 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 18- | UCB Biosciences GmbH | Not Recruiting | Female: yes Male: yes | 504 | Phase 4 | United States;Serbia;Slovakia;Slovenia;Spain;Ukraine;Turkey;Austria;Italy;Hungary;Poland;Croatia;Romania;Bulgaria | |||
562 | NCT01736176 | March 2013 | 19 October 2017 | A Study to Assess the Safety and Efficacy of Levodopa-carbidopa Intestinal Gel (LCIG) for the Treatment of Non-motor Symptoms in Patients With Advanced Parkinson's Disease | An Open-Label, Two Part, Multicenter Study to Assess the Safety and Efficacy of Levodopa-Carbidopa Intestinal Gel (LCIG) for the Treatment of Non-Motor Symptoms in Subjects With Advanced Parkinson's Disease | Advanced Parkinson's Disease | Drug: Levodopa-Carbidopa Intestinal Gel;Procedure: Percutaneous Endoscopic Gastrostomy with Jejunal Extension (PEG-J);Drug: Levodopa-carbidopa Immediate Release (LC-IR) Tablets | AbbVie (prior sponsor, Abbott) | Not recruiting | 30 Years | N/A | All | 39 | Phase 3 | United States | |
563 | NCT01789047 | March 2013 | 14 November 2016 | Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's Disease | Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's Disease | Idiopathic Parkinson's Disease;Drug Induced Dyskinesia | Drug: Topiramate;Drug: Placebo | Rush University Medical Center | Michael J. Fox Foundation for Parkinson's Research | Not recruiting | 30 Years | 90 Years | Both | 44 | Phase 2 | United States |
564 | JPRN-UMIN000010014 | 2013/02/28 | 2 April 2019 | Randomized Double-blind, Placebo-controlled multi-center trial on molecular hydrogen water in Parkinson Disease | Parkinson's disesase | hydrogen water made by "Suisosui5.0" placebo-water (nitrogen filling water) | Juntendo University School of Medicine, Neurology | Not Recruiting | 20years-old | Not applicable | Male and Female | 200 | Not selected | Japan | ||
565 | EUCTR2012-000801-64-GB | 09/02/2013 | 19 November 2018 | A study of the effects of medication on memory in Parkinson's Disease | A Phase IV Acceptability and Feasibility Trial of the Effects of Medication on Memory in Idiopathic Nondementing Parkinson’s Disease. - Medication and Memory in Parkinson’s Disease (MeMory PaD) | Idiopathic Parkinson's Disease MedDRA version: 17.0 Level: LLT Classification code 10013113 Term: Disease Parkinson's System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Mirapexin extended release various strengths Product Name: Pramipexole dihydrochloride monohydrate extended release Product Code: N/A Pharmaceutical Form: Modified-release tablet INN or Proposed INN: pramipexole dihydrochloride monohydrate CAS Number: 104632-26-0 Current Sponsor code: not available Other descriptive name: Mirapexin Concentration unit: mg milligram(s) Concentration type: up to Concentration number: 3.15- Trade Name: Requip prolonged release Product Name: Ropinirole hydrochloride prolonged release Pharmaceutical Form: Modified-release tablet INN or Proposed INN: Ropinirole (as hydrochloride) CAS Number: 91374-21-9 Current Sponsor code: not available Other descriptive name: Requip XL prolonged-release Concentration unit: mg milligram(s) Concentration type: up to Concentration number: 24- | University Hospital of North Staffordshire | Keele University | Not Recruiting | Female: yes Male: yes | 55 | Phase 4 | United Kingdom | ||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
566 | NCT01766128 | February 2013 | 19 February 2015 | Study of Zonisamide in Early Parkinson Disease | Randomized Double Blind Placebo-controlled Study of Zonisamide Effectiveness in Early Parkinson Disease | Parkinson Disease | Drug: Zonisamide | Mazandaran University of Medical Sciences | Not recruiting | 45 Years | 85 Years | Both | 60 | Phase 2/Phase 3 | ||
567 | NCT01789385 | February 2013 | 19 February 2015 | Anesthesia for Deep Brain Stimulation | Anesthesia for Deep Brain Stimulation for the Treatment of Parkinsons Disease | Parkinsons Disease | Drug: Dexmedetomidine | Diskapi Teaching and Research Hospital | Not recruiting | 19 Years | 85 Years | Both | 26 | Phase 4 | Turkey | |
568 | NCT02059733 | February 2013 | 9 October 2018 | Developing a Novel Imaging Biomarker in the Differential Diagnosis of Parkinson's Disease and Parkinsonism | Developing a Novel Imaging Biomarker in the Differential Diagnosis of Parkinson's Disease and Parkinsonism by 18F-DTBZ PET | Parkinson's Disease | Drug: 18F-DTBZ | Chang Gung Memorial Hospital | Not recruiting | 20 Years | 80 Years | All | 72 | Phase 2 | Taiwan | |
569 | EUCTR2012-002608-42-DE | 10/01/2013 | 26 August 2013 | A study to evaluate the efficacy of Rotigotine (the treatment) versus placebo in patients with pain associated with Parkinson's Disease | A Multicenter, Multinational, Double-blind, Placebo-controlled, 2-arm Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated Pain | Parkinson’s disease MedDRA version: 16.0 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Neupro Product Name: Rotigotine Pharmaceutical Form: Transdermal patch INN or Proposed INN: ROTIGOTINE CAS Number: 99755-59-6 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 9- Pharmaceutical form of the placebo: Transdermal patch Route of administration of the placebo: Transdermal use Trade Name: Neupro Product Name: Rotigotine Pharmaceutical Form: Transdermal patch INN or Proposed INN: ROTIGOTINE CAS Number: 99755-59-6 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 13.5- Trade Name: Neupro Product Name: Rotigotine Pharmaceutical Form: Transdermal patch INN or Proposed INN: ROTIGOTINE CAS Number: 99755-59-6 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 18- | UCB Biosciences GmbH | Not Recruiting | Female: yes Male: yes | 64 | United States;Hungary;Slovakia;Poland;Germany;United Kingdom | ||||
570 | JPRN-UMIN000017695 | 2013/01/01 | 2 April 2019 | Oxybuprocaine for apraxia of lid opening in Parkinson's disease | apraxia of lid opening in Parkinson's disease | Arm 1 intervention consisted of 4%oxybuprocaine eye drop treatment, washout for 24 hours or more, and a saline eye drop treatment Arm 2 intervention consisted of saline eye drop treatment, a washout period, and an oxybuprocaine treatment | Utano National Hospital, National Hospital Organization | Not Recruiting | Not applicable | Not applicable | Male and Female | 10 | Not selected | Japan | ||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
571 | NCT01500707 | January 2013 | 19 February 2015 | Single Dose Study to Assess the Pharmacokinetics of SCH 900800 in Subjects With Parkinson's Disease Being Treated With Levodopa (L-DOPA) (P08235) | A Single Dose Study to Assess the Pharmacokinetics of SCH 900800 Administered as Oral Tablets in L-DOPA-treated Subjects With Parkinson's Disease | Parkinson's Disease | Drug: SCH 900800 | Merck Sharp & Dohme Corp. | Not recruiting | 30 Years | 85 Years | Both | 0 | Phase 1 | ||
572 | NCT01803945 | January 2013 | 12 October 2015 | A Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AVE8112 in Patients With Parkinson's Disease | A Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AVE8112 in Patients With Parkinson's Disease | Parkinson's Disease | Drug: AVE8112;Drug: Placebo | Michael J. Fox Foundation for Parkinson's Research | Sanofi | Not recruiting | 35 Years | 70 Years | Both | 32 | Phase 1 | United States |
573 | NCT02100176 | January 2013 | 19 February 2015 | MIRT and Rotigotine in the Early Stage of PD | Multidisciplinary Intensive Rehabilitation Treatment and Rotigotine in the Early Stages of Parkinson's Disease: a Randomized Controlled Study. | Parkinson's Disease | Other: Multidisciplinary intensive rehabilitation treatment;Drug: Rotigotine | Ospedale Generale Di Zona Moriggia-Pelascini | Recruiting | 50 Years | 75 Years | Both | 40 | N/A | Italy | |
574 | NCT03651856 | January 2013 | 10 September 2018 | Atomoxetine for Freezing of Gait in Parkinson's Disease | A Pilot Study of Atomoxetine for Freezing of Gait in Parkinson's Disease | Parkinson's Disease;Freezing of Gait | Drug: ATM FOG in PD | Medical University of South Carolina | Not recruiting | 18 Years | 80 Years | All | 10 | Phase 3 | United States | |
575 | NCT01725802 | December 2012 | 11 April 2016 | A Phase I/IIa Study of Safety, Tolerability and Plasma Concentration of Subcutaneous Continuously-delivered Levodopa/Carbidopa Solution (ND0612) in PD Patients | A Phase I/IIa, Single Dose, Single-centre, Randomized, Crossover, Double-blind, Placebo-controlled Study Evaluating Safety, Tolerability and Levodopa Plasma Concentration Following Administration of Subcutaneous Continuously-delivered Levodopa/Carbidopa Solution (ND0612) in PD Patients | Parkinson's Disease | Drug: levodopa and carbidopa solution for SC administration;Drug: Placebo | NeuroDerm Ltd. | Not recruiting | 30 Years | N/A | Both | 8 | Phase 1/Phase 2 | Israel | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
576 | NCT01741701 | December 2012 | 19 October 2017 | A Pilot Study of Oxaloacetate in Subjects With Treated PD | A Pilot Double-Blind, Parallel Group, Placebo Controlled Study of Oxaloacetate in Subjects With Treated Parkinson's Disease (PD) | Parkinson's Disease | Drug: Oxaloacetate (OAA);Drug: Placebo | University of Kansas Medical Center | Terra Biological LLC | Not recruiting | 30 Years | N/A | All | 33 | Phase 2/Phase 3 | United States |
577 | NCT01770145 | December 2012 | 16 December 2017 | Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT) | A Phase 4, Open-Label, Efficacy and Safety Study of Apokyn® for Rapid and Reliable Improvement of Motor Symptoms in Parkinson Disease Subjects With Delayed Onset of L-Dopa Action | Parkinson's Disease;Motor Symptoms;Akinesia;Hypomobility;Delayed Levodopa Onset | Drug: APOKYN;Drug: L-dopa;Drug: Trimethobenzamide | US WorldMeds LLC | Not recruiting | 18 Years | N/A | All | 127 | Phase 4 | United States | |
578 | NCT02112812 | December 2012 | 19 February 2015 | Effects of Helicobacter Pylori Infection Eradication in Patients With Parkinson's Disease | A Study on Clinical Response Following Eradication Therapy of Helicobacter Pylori Infection in Parkinson's Disease | Response to Levodopa;Motor Outcomes;Quality of Life Outcomes | Drug: Eradication therapy for H.pylori infection;Drug: Eradication of Helcobacter Pylori;Drug: Eradication therapy for Helicobacter pylori | National University of Malaysia | Not recruiting | 17 Years | N/A | Both | 82 | N/A | Malaysia | |
579 | NCT01683253 | November 2012 | 11 June 2018 | Remission of ICD by Switching Dopamine Agonist to Levodopa/Carbidopa | The REmission of the Impulse Control Disorder and the Changes of the Neuropsychiatric Characteristics After Switching Into Levodopa/Carbidopa in Patients With Parkinson's Disease Who Have Developed Impulse Control Disorders Due to the Dopamine Replacement Therapy | Impulse Control Disorder | Drug: Levodopa/Carbidopa(200mg/50mg);Drug: Dopaminergic Agonists | Sandoz | Not recruiting | 30 Years | 80 Years | All | 150 | Phase 4 | ||
580 | NCT01721460 | November 2012 | 16 December 2017 | Effects of Dexmedetomidine on Activity in the Subthalamic Nucleus | Effects of Dexmedetomidine on Neuronal Activity in the Subthalamic Nucleus During Deep Brain Stimulation (DBS) Electrode Implantation Surgery | Parkinson's Disease;Deep Brain Stimulation Surgery | Drug: Dexmedetomidine | University of Wisconsin, Madison | Not recruiting | 18 Years | 85 Years | All | 6 | Phase 4 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
581 | NCT01723228 | November 2012 | 19 October 2017 | Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's Disease | A 24-Week, Multicenter, Randomized, Double-blind, Placebo-Controlled, Add-on, Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's Disease | Parkinson's Disease | Drug: Rasagiline;Drug: Placebo | Teva Branded Pharmaceutical Products, R&D Inc. | Not recruiting | 45 Years | 80 Years | All | 170 | Phase 4 | United States | |
582 | NCT01738191 | November 2012 | 11 April 2016 | Atomoxetine Treatment for Cognitive Impairment in Parkinson's Disease (ATM-Cog) | Atomoxetine Treatment for Cognitive Impairment in Parkinson's Disease (ATM-Cog) | Parkinson's Disease;Cognitive Impairment | Drug: Atomoxetine;Drug: Placebo | Medical University of South Carolina | Michael J. Fox Foundation for Parkinson's Research | Not recruiting | 35 Years | 75 Years | Both | 30 | Phase 2 | United States |
583 | NCT03652363 | October 25, 2012 | 3 September 2018 | GDNF in ideopathicParkinsons Disease | A Placebo-Controlled, Randomised, Double-Blind Trial to Assess the Safety and Efficacy of Intermittent Bilateral Intraputamenal (GDNF) Infusions Administered Via Convection Enhanced Delivery (CED) in Subjects With Parkinson&Apos;s Disease | Idiopathic Parkinson Disease | Drug: glial cell line-derived neurotrophic factor | North Bristol NHS Trust | Not recruiting | 35 Years | 75 Years | All | 42 | Phase 2 | ||
584 | JPRN-UMIN000009099 | 2012/10/01 | 2 April 2019 | The effect of lidocaine injection into the external oblique in Parkinson's disease patients with upper camptorcormia | Parkinson's disease | lidocaine injection into the external oblique normal saline injection into the external oblique | Parkinson's disease and Movement Disorder Center | Recruiting | 20years-old | Not applicable | Male and Female | 10 | Not applicable | Japan | ||
585 | NCT01560754 | October 2012 | 12 October 2015 | Disease-modifying Potential of Transdermal NICotine in Early Parkinson's Disease | A Randomized, Placebo-controlled, Double-blind, Multi-center Trial to Assess the Disease-modifying Potential of Transdermal Nicotine in Early Parkinson's Disease in Germany and the USA | Parkinson's Disease | Drug: nicotine transdermal patch | James BOYD MD | Michael J. Fox Foundation for Parkinson's Research;Parkinson Study Group (PSG);International Parkinson Fonds (IPF);German Parkinson Study Group (GPS);German Parkinson Society (DPG);Philipps-University Marburg, Germany | Not recruiting | 30 Years | N/A | Both | 160 | Phase 2 | United States;Germany |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
586 | NCT01563913 | October 2012 | 11 July 2016 | Reducing Dyskinesia in Parkinson's Disease With Omega-3 Fatty Acids | Reducing Dyskinesia in Parkinson Disease With Omega-3 Fatty Acids | Parkinson's Disease | Drug: Docosahexaenoic Acid (DHA);Drug: Placebo | VA Office of Research and Development | Oregon Health and Science University;Oregon Health and Science University | Not recruiting | 21 Years | 99 Years | Both | 40 | Phase 1 | United States |
587 | NCT01603069 | October 2012 | 19 February 2015 | A Study to Assess Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease | A Phase IIa, 12 Week, Multicentre, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease | Parkinson's Disease | Drug: AZD3241 300 mg BID;Drug: AZD3241 600 mg BID;Drug: Placebo | AstraZeneca | Not recruiting | 30 Years | 80 Years | Both | 51 | Phase 2 | United States | |
588 | NCT01691924 | October 2012 | 11 April 2016 | Study To Assess the Safety and Tolerability of PBF-509 in Male Healthy Volunteers | Randomized, Double Blind, Placebo Controlled First In-human Study To Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-509 in Male Healthy Volunteers | Parkinson Disease | Drug: PBF-509;Drug: Placebo | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | Palo Biofarma, S.L | Not recruiting | 18 Years | 45 Years | Male | 56 | Phase 1 | Spain |
589 | NCT01723904 | October 2012 | 19 October 2017 | A Phase 3b, Open-Label, Safety and Efficacy Study of Rotigotine as Add-On Therapy With Low Doses of Pramipexole or Ropinirole in Patients With Advanced Parkinson's Disease | An Open-Label Study to Investigate the Safety and Efficacy of Rotigotine Add-On Therapy With Low Doses of Pramipexole or Ropinirole in Patients With Advanced Parkinson's Disease Phase 3B | Advanced Parkinson's Disease | Drug: Rotigotine | UCB BIOSCIENCES GmbH | Otsuka Pharmaceutical Co., Ltd. | Not recruiting | 30 Years | 80 Years | All | 90 | Phase 3 | Australia;Korea, Republic of;Malaysia;Singapore;Taiwan |
590 | NCT01796483 | October 2012 | 3 June 2019 | EEG and Pharmacological Exploration of Executive Dysfunctions Induced by STN-DBS in PD | Exploration électroencéphalographie et Pharmacologique Des Dysfonctionnements exécutifs Induits Par la Stimulation cérébrale Profonde du Noyau Sous-thalamique Dans la Maladie de Parkinson | Parkinson Disease | Device: Clonidine (Catapressan);Device: Placebo 90 minutes before EEG | Hospices Civils de Lyon | Not recruiting | 40 Years | 70 Years | All | 37 | N/A | France | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
591 | EUCTR2011-003866-34-GB | 24/09/2012 | 16 November 2015 | Assessing the Benefit and Safety of Administering Intermittent GDNF Infusions in Parkinson's Disease (PD) | A Placebo-Controlled, Randomised, Double-Blind Trial to Assess the Safety and Efficacy of Intermittent Bilateral Intraputamenal Glial Cell Line-Derived Neurotrophic Factor (GDNF) Infusions Administered via Convection Enhanced Delivery (CED) in Subjects with Parkinson’s Disease - Intermittent Bilateral GDNF for Parkinson’s Disease | Parkinson's disease MedDRA version: 18.1 Level: LLT Classification code 10034008 Term: Parkinson's syndrome System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Glial Cell Line-Derived Neurotrophic Factor (GDNF) Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Liatermin Other descriptive name: r-metHuGDNF Concentration unit: mg/ml milligram(s)/millilitre Concentration type: range Concentration number: 9.0-11.0 Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intracerebral use | North Bristol NHS Trust (NBT) | Authorised | Female: yes Male: yes | United Kingdom | |||||
592 | ChiCTR-OCS-12002720 | 2012-09-01 | 18 April 2017 | Pharmacogenetics study of anti-parkinson's disease drug levodopa | The association between polymorphisms of DRD2, DRD2, SLC6A3 and the levodopa response | Parkinson's Disease | A:levodopa; | Institute of Clinical Pharmacology, Central South University | Not Recruiting | 38 | 72 | Both | A:200; | Post-market | ||
593 | NCT01662791 | September 2012 | 19 October 2017 | Weight Loss in Parkinson's Disease and Role of Small Bowel Bacterial Overgrowth | Weight Loss in Parkinson's Disease and the Potential Role of Small Bowel Bacterial Overgrowth | Parkinson's Disease | Drug: Rifaximin | Mayo Clinic | Not recruiting | 18 Years | N/A | All | 49 | Phase 3 | United States | |
594 | NCT01676103 | September 2012 | 19 February 2015 | The Effects of Supplementing Tyrosine on Blood Pressure in Parkinson's Disease | The Effects of Supplementing Tyrosine on Blood Pressure in Parkinson's Disease | Parkinson's Disease | Dietary Supplement: Tyrosine;Other: Placebo Comparator:Sugar Pill | New York Institute of Technology | Michael J. Fox Foundation for Parkinson's Research | Not recruiting | 50 Years | 80 Years | Both | 40 | Phase 1/Phase 2 | United States |
595 | NCT01684475 | September 2012 | 19 February 2015 | A STUDY TO EVALUATE THE EFFICACY OF CJH1 (CLR4001) IN PARKINSON'S DISEASE | A STUDY TO EVALUATE THE EFFICACY OF CJH1 [CLR4001] IN THE TREATMENT OF PARKINSON'S DISEASE | Parkinson's Disease | Drug: CJH1 (CLR4001) | Alexandra Marine and General Hospital | Recruiting | 40 Years | 85 Years | Both | 21 | Phase 1/Phase 2 | Canada | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
596 | NCT01711866 | September 2012 | 19 October 2017 | A Phase 4, Open-label Study to Assess the Feasibility and Efficacy on Motor and Non-motor Symptoms of Switching From Pramipexole or Ropinirole to Rotigotine Transdermal Patch in Subjects With Advanced Idiopathic Parkinson's Disease | An Open-Label, Multicenter, Multinational Study to Assess the Feasibility of Switching Therapy From Pramipexole or Ropinirole to the Rotigotine Transdermal System and Its Effect on Motor and Non-Motor Symptoms in Subjects With Advanced Idiopathic Parkinson's Disease Phase 4 | Advanced Idiopathic Parkinson's Disease | Drug: Rotigotine | UCB BIOSCIENCES GmbH | Otsuka Pharmaceutical Co., Ltd. | Not recruiting | 30 Years | 80 Years | All | 87 | Phase 4 | United States;Korea, Republic of;Malaysia;Singapore;Taiwan |
597 | EUCTR2012-000122-21-DK | 10/08/2012 | 19 March 2018 | Improving the blood pressure regulating system in patients with parkinsons disease | Acethylcholineesterase inhibition and orthostatic hypotension in patients with parkinsons disease | Ortostatic hypotension in patients with Parkinsons disease MedDRA version: 14.1 Level: PT Classification code 10031127 Term: Orthostatic hypotension System Organ Class: 10047065 - Vascular disorders ;Therapeutic area: Body processes [G] - Circulatory and Respiratory Physiological Phenomena [G09] | Trade Name: Mestinon Product Name: Mestinon Pharmaceutical Form: Capsule INN or Proposed INN: PYRIDOSTIGMINE BROMIDE CAS Number: 101-26-8 Current Sponsor code: SJ-193 Other descriptive name: Mestinon Concentration unit: mg milligram(s) Concentration type: up to Concentration number: 60- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use | Department of Neurology, Roskilde Hospital | Not Recruiting | Female: yes Male: yes | 20 | Phase 2 | Denmark | |||
598 | EUCTR2012-001530-34-NL | 09/08/2012 | 26 March 2018 | Vareniciline treatment for Excessive Daytime Sleepiness in Parkinson’s Disease | Varenicline, a partial nicotinic receptor agonist for the treatment of Excessive Daytime Sleepiness in Parkinson’s Disease: a placebo-controlled cross-over study - Vareniciline for Excessive daytime Sleepiness in PArkinson’s disease (VESPA) | Idiopathic Parkinson's disease MedDRA version: 18.0 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Champix Pharmaceutical Form: Coated tablet INN or Proposed INN: VARENICLINE CAS Number: 375815-87-5 Other descriptive name: VARENICLINE TARTRATE Concentration unit: mg milligram(s) Concentration type: range Concentration number: 0.5-3 Pharmaceutical form of the placebo: Coated tablet Route of administration of the placebo: Oral use | VU University Medical Center | Center Human Drug Research | Not Recruiting | Female: yes Male: yes | 32 | Phase 3 | Netherlands | ||
599 | NCT00947037 | August 2012 | 7 December 2015 | Gastric Retentive Carbidopa/ Levodopa in Parkinson's Patients; a One Year, Open Label, Safety Extension Study | An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of AP-CD/LD in Fluctuating Parkinson's Disease Subjects | Parkinson's Disease | Drug: AP-CD/LD | Intec Pharma Ltd. | Not recruiting | 30 Years | 95 Years | Both | 0 | Phase 2 | Israel | |
600 | NCT02419313 | August 2012 | 19 October 2017 | Investigation of the Efficacy and Safety of IncobotulinumtoxinA (Xeomin) in Parkinson's Tremor: A Customized Approach | Investigation of the Efficacy and Safety of IncobotulinumtoxinA (Xeomin) in Parkinson's Disease Tremor: A Customized Approach | Parkinson;Tremor | Drug: incobotulinumtoxinA;Drug: Saline | Yale University | Not recruiting | 18 Years | N/A | All | 33 | Phase 2 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
601 | NCT02764892 | August 2012 | 17 May 2016 | A Study in Healthy Male Volunteers to Investigate a New Drug for the Treatment of Parkinson's Disease | An Open Label Study of V81444 Using Positron Emission Tomography to Assess Occupancy of Brain Adenosine A2A Receptors & Functional & Perfusion MRI to Explore Effects on Regional Brain Activity & Perfusion in Healthy Male Volunteers | Parkinson's Disease | Drug: V81444 | Vernalis (R&D) Ltd | Not recruiting | 25 Years | 55 Years | Male | 6 | Phase 1 | ||
602 | JPRN-UMIN000008477 | 2012/07/19 | 2 April 2019 | Clinical study of selegiline hydrochloride ( FP OD tablet 2.5) to flexion of spine in Parkinson's disease. | Parkinson disease | Selegiline hydrochloride 5mg 8weeks, 7.5mg 8weeks and stop it, followed after 8weeks, and evaluate each points. | Department of Neurology, Juntendo Koshigaya Hospital | Not Recruiting | 20years-old | Not applicable | Male and Female | 20 | Not selected | Japan | ||
603 | JPRN-UMIN000008138 | 2012/07/01 | 2 April 2019 | Efficacy and safety of silodosin on lower urinary tract symptoms (LUTS) in patients with Parkinson's disease | Parkinson's disease | Silodosin 8mg BID | Juntendo University School of Medicine | Not Recruiting | Not applicable | Not applicable | Male | 100 | Not selected | Japan | ||
604 | NCT01398748 | July 2012 | 16 December 2017 | Intranasal Glutathione in Parkinson's Disease | A Phase 1 Study of Intranasal Reduced Glutathione in Parkinson's Disease | Parkinson's Disease (PD) | Drug: Intranasal glutathione - (in)GSH;Drug: Saline Intranasal Delivery | Bastyr University | National Center for Complementary and Integrative Health (NCCIH) | Not recruiting | 21 Years | 100 Years | All | 34 | Phase 1 | United States |
605 | NCT01491022 | July 2012 | 16 December 2017 | A Randomized Trial to Evaluate Ampyra for Gait Impairment in Parkinson's Disease | A Randomized Trial to Evaluate Ampyra for Gait Impairment in Parkinson's Disease | Parkinson's Disease | Drug: Ampyra first, then Placebo;Drug: placebo first, then Ampyra | University of Miami | Acorda Therapeutics | Not recruiting | 45 Years | 80 Years | All | 22 | Phase 1/Phase 2 | United States |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
606 | NCT01602549 | July 2012 | 19 October 2017 | A Study to Assess the Effect of Repeat Doses of GSK962040 on the Pharmacokinetics of L-DOPA in Subjects With Parkinson's Disease Exhibiting Delayed Gastric Emptying | A Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose Ranging Study to Assess the Effect of Repeat Doses of GSK962040 on the Pharmacokinetics of L-DOPA in Subjects With Parkinson's Disease Exhibiting Delayed Gastric Emptying | Gastroparesis | Drug: GSK962040 (25 mg tablet);Drug: Placebo | GlaxoSmithKline | Not recruiting | 40 Years | 80 Years | All | 58 | Phase 2 | Australia;Germany;Sweden;United Kingdom | |
607 | NCT01646255 | July 2012 | 11 June 2018 | Rotigotine Versus Placebo, A Study To Evaluate The Efficacy In Advanced Stage Idiopathic Parkinson's Disease Patients | A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of The Efficacy And Safety of Rotigotine Transdermal Patch In Chinese Subjects With Advanced-stage, Idiopathic Parkinson's Disease Who Are Not Well Controlled On Levodopa | Idiopathic Parkinson's Disease | Drug: Rotigotine;Drug: Placebo Patch;Drug: L-dopa | UCB Pharma | UCB Trading (Shanghai) Co. Ltd. | Not recruiting | 30 Years | N/A | All | 346 | Phase 3 | China |
608 | NCT01646268 | July 2012 | 19 October 2017 | Rotigotine Versus Placebo As Double Blind Study To Evaluate The Efficacy In Early Stage Idiopathic Parkinson's Disease Patients | A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Of The Efficacy And Safety Of The Rotigotine Transdermal Patch In Chinese Subjects With Early-stage Idiopathic Parkinson's Disease | IDIOPATHIC PARKINSON'S DISEASE | Drug: Rotigotine;Drug: Placebo Patch | UCB Pharma | Not recruiting | 30 Years | N/A | All | 249 | Phase 3 | China | |
609 | JPRN-JapicCTI-121880 | 11/6/2012 | 2 April 2019 | Phase II clinical study in patients with Parkinson's disease not taking L-DOPA | A randomized, double-blind, placebo-controlled, comparative study of HP-3000 in patients with Parkinson's disease not taking L-DOPA | Parkinson's disease | Intervention name : HP-3000(ropinirole hydrochloride patch) Dosage And administration of the intervention : Transdermal, once daily Control intervention name : HP-3000 placebo Dosage And administration of the control intervention : Transdermal, once daily | Hisamitsu Pharmaceutical Co.,Inc. | 20 | 79 | BOTH | Phase 2 | ||||
610 | JPRN-JapicCTI-121879 | 07/6/2012 | 2 April 2019 | Phase II clinical study in patients with Parkinson's disease taking L-DOPA | A randomized, double-blind, placebo-controlled, comparative study of HP-3000 in patients with Parkinson's disease taking L-DOPA | Parkinson's disease | Intervention name : HP-3000(ropinirole hydrochloride patch) Dosage And administration of the intervention : Transdermal, once daily Control intervention name : HP-3000 placebo Dosage And administration of the control intervention : Transdermal, once daily | Hisamitsu Pharmaceutical Co.,Inc. | 20 | 79 | BOTH | Phase 2 | ||||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
611 | NCT01892176 | June 2012 | 19 February 2015 | Effects of High-dose Coenzyme Q10 on Biomarkers of Oxidative Damage and Clinical Outcome in Parkinson Disease | Effects of High-dose Coenzyme Q10 on Biomarkers of Oxidative Damage and Clinical Outcome in Parkinson Disease | Parkinson Disease | Dietary Supplement: coenzyme q10 | National University Hospital, Singapore | Not recruiting | 21 Months | N/A | Both | 20 | Phase 2/Phase 3 | Singapore | |
612 | NCT01993680 | June 2012 | 12 October 2015 | Orthostatic Dysregulation and Associated Gastrointestinal Dysfunction in Parkinson's Disease -Treatment | A Monocentric Randomized, Controlled, Double Blind, Crossover Phase II Trial to Show Non-inferiority of the Effect of Pyridostigmine Bromide vs. Fludrocortisone on Symptoms of Autonomic Dysregulation in Parkinson`s Disease | Autonomic Disturbances in Parkinson`s Disease | Drug: Pyridostigmine bromide;Drug: fludrocortisone | University of Zurich | Not recruiting | 50 Years | 80 Years | Both | 18 | Phase 2 | Switzerland | |
613 | NCT02786667 | June 2012 | 16 December 2017 | Non Motors Aspects in De Novo Parkinson's Disease | Non Motors Aspects in De Novo Parkinson's Disease: Clinical and Physiopathological Description; Dopamine Agonist Treatment Effects. | Parkinson Disease;Apathy | Drug: Rotigotine;Drug: Placebo | University Hospital, Grenoble | Not recruiting | 30 Years | 72 Years | All | 199 | Phase 3 | France | |
614 | EUCTR2012-001218-40-IT | 21/05/2012 | 31 July 2012 | EFFICACY OF ROTIGOTINE ON GAIT PERFORMANCE OF PARKINSONIAN PATIENTS | EFFICACY OF ROTIGOTINE ON GAIT PERFORMANCE OF PARKINSONIAN PATIENTS | Patients suffering for Idiopathic Parkinson’s Disease. H&Y stage > or = 2 with un-satisfactory control by on-going pharmacological therapy (Levodopa, COMT & MAO-inhibitors), characterised by an incomplete control of motor signs, in particular presence of early morning akinesia, as well as gait deficits in the morning. MedDRA version: 14.1 Level: PT Classification code 10056242 Term: Parkinsonian gait System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: NEUPRO*7CER 4MG/24H Pharmaceutical Form: Transdermal patch INN or Proposed INN: rotigotina CAS Number: 92206-54-7 Concentration unit: mg milligram(s) Concentration type: up to Concentration number: 9- Trade Name: NEUPRO*7CER 6MG/24H Pharmaceutical Form: Transdermal patch INN or Proposed INN: rotigotina CAS Number: 92206-54-7 Concentration unit: mg milligram(s) Concentration type: up to Concentration number: 13.5- Trade Name: NEUPRO*7CER 8MG/24H Pharmaceutical Form: Transdermal patch INN or Proposed INN: rotigotina CAS Number: 92206-54-7 Concentration unit: mg milligram(s) Concentration type: up to Concentration number: 18- Trade Name: NEUPRO*28CER 2MG/24H Pharmaceutical Form: Transdermal patch INN or Proposed INN: rotigotina CAS Number: 92206-54-7 Concentration unit: mg milligram(s) Concentration type: up to Concentration number: 4.5- Trade Name: NEUPRO*28CER 4MG/24H Pharmaceutical Form: Transdermal patch INN or Proposed INN: rotigotina CAS Number: 92206-54-7 Concentration unit: mg milligram(s) Concentration type: up to Concentration number: 9- Trade Name: NEUPRO*28CER 6MG/24H Pharmaceutical Form: Transdermal patch INN or Proposed INN: rotigotina CAS Number: 92206-54-7 Concentration unit: mg milligram(s) Concentration type: up to Concentration number: 13.5- Trade Name: NEUPRO*28CER 8MG/24H Pharmaceutical Form: Transdermal patch INN or Proposed INN: rotigotina CAS Number: 92206-54-7 Concentration unit: mg milligram(s) Concentration type: up to Concentration number: 18- | FONDAZIONE SANTA LUCIA | Authorised | Female: yes Male: yes | Italy | |||||
615 | JPRN-UMIN000007896 | 2012/05/01 | 2 April 2019 | Levodopa challenge test for Parkinson's disease and other parkinsonian syndromes | Parkinson's disease and other parkinsonian syndromes | The patients are given domperidone 30 mg/day for 3 days. When a patient is already on any anti-parkinson drugs, these drugs were withdrawn from the night before of the evaluation day. On the fourth day lactose powder is given to the patients and levodopa (250 mg)/carbidopa (25 mg) is given on the fifth day in a double-blind manner. On fourth and fifth day, motor symptoms of the patients are examined using the Unified Parkinson's Disease Rating Scale motor scores by a clinician who is blind to the test drug. The patients are given domperidone 30 mg/day (standard dose in Japan) for 3 days. When a patient is already on any anti-parkinson drugs, these drugs were withdrawn from the night before of the evaluation day. On the fourth day levodopa (250 mg)/carbidopa (25 mg) is given to the patients and lactose powder is given on the fifth day in a double-blind manner. Motor symptoms of the patients are examined using the Unified Parkinson's Disease Rating Scale motor scores by a clinician who is blind to the test drug. | Kansai Medical University | Recruiting | Not applicable | Not applicable | Male and Female | 100 | Not selected | Japan | ||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
616 | NCT01652313 | May 2012 | 19 February 2015 | Pharmacokinetic Properties of Rasagiline (Lu 00-773) in Healthy Young Chinese Men and Women | A Single Centre, Open-label, Multiple-dose Interventional Study Investigating the Pharmacokinetic Properties of Rasagiline (Lu 00-773) in Healthy Young Chinese Men and Women | Parkinson's Disease | Drug: Rasagiline | H. Lundbeck A/S | Not recruiting | 18 Years | 45 Years | Both | 12 | Phase 1 | China | |
617 | EUCTR2011-004438-32-GB | 25/04/2012 | 28 February 2019 | The effect of repeat doses of GSK962040 on the pharmacokinetics of L-DOPA in subjects with Parkinson’s disease with slow gastric emptying | A randomized, double-blind, placebo-controlled, parallel group, dose ranging study to assess the effect of repeat doses of GSK962040 on the pharmacokinetics of levodopa in subjects with Parkinson’s disease exhibiting delayed gastric emptying - GSK962040 Parkinson's disease PoC | Investigate the ability of the motilin receptor agonist GSK962040 to improve levodopa pharmacokinetics (PK) by enhancing GE via motilin receptor agonism. MedDRA version: 20.1 Level: PT Classification code 10051153 Term: Diabetic gastroparesis System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: GSK962040 Product Code: GSK962040 Pharmaceutical Form: Tablet INN or Proposed INN: GSK962040 CAS Number: 923565-21-3 Current Sponsor code: GSK962040 Other descriptive name: GSK962040 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: GSK962040 Product Code: GSK962040 Pharmaceutical Form: Tablet INN or Proposed INN: GSK962040 CAS Number: 923565-21-3 Current Sponsor code: GSK962040 Other descriptive name: GSK962040 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: GSK962040 Product Code: GSK962040 Pharmaceutical Form: Tablet INN or Proposed INN: GSK962040 CAS Number: 923565-21-3 Current Sponsor code: GSK962040 Other descriptive name: GSK962040 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 125- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | GlaxoSmithKline Research and Development Limited | Not Recruiting | Female: yes Male: yes | 70 | Phase 2 | Germany;United Kingdom;Sweden | |||
618 | EUCTR2012-000181-37-GB | 25/04/2012 | 21 January 2013 | A study investigating the safety of CVT-301 in patients with Parkinson's Disease | A Randomized, Placebo-Controlled Phase 2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of CVT-301 (Levodopa Inhalation Powder) in Patients with Parkinson’s Disease and Motor Response Fluctuations (“Off” Episodes) | Parkinson's Disease MedDRA version: 14.1 Level: LLT Classification code 10034007 Term: Parkinson's disease NOS System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: CVT-301 Product Code: CVT-301 Pharmaceutical Form: Inhalation powder, hard capsule INN or Proposed INN: LEVODOPA CAS Number: 59-92-7 Current Sponsor code: CVT-301 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 12.5- Pharmaceutical form of the placebo: Inhalation powder, hard capsule Route of administration of the placebo: Inhalation use Trade Name: Sinemet® Product Name: SINEMET® Plus 25 mg/100 mg Tablets Pharmaceutical Form: Tablet INN or Proposed INN: LEVODOPA CAS Number: 59-92-7 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- CAS Number: 38821-49-7 Other descriptive name: CARBIDOPA MONOHYDRATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- | Civitas Therapeutics, Inc. | Not Recruiting | Female: yes Male: yes | 24 | Phase 2 | Serbia;Israel;United Kingdom | |||
619 | EUCTR2011-005839-91-ES | 02/04/2012 | 29 January 2018 | Gabapentin in the disorder of the impulse control in the Parkinson´s Disease: multicentric study, double-blind, randomized, controlled with placebo. | Gabapentin int he disorder of the impulse control in the Parkinson´s Disease: multicentric study, double-blind, randomized, controlled with placebo. - IMULPARK | PARKINSON´S DISEASE MedDRA version: 14.1 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: GABAPENTINA KERN PHARMA Pharmaceutical Form: Capsule, hard INN or Proposed INN: GABAPENTINA CAS Number: 60142-96-3 Other descriptive name: GABAPENTIN Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 400- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use | ASOCIACIÓN INSTITUTO BIODONOSTIA | Not Recruiting | Female: yes Male: yes | 100 | Phase 2 | Spain | |||
620 | NCT01494532 | April 2, 2012 | 2 July 2018 | A Fixed Dose Study of Ropinirole Prolonged Release as Adjunctive Treatment in Patients With Advanced Parkinson's Disease | A Fixed Dose, Dose-response Study of Ropinirole Prolonged Release (PR) as Adjunctive Treatment to L-dopa in Patients With Advanced Parkinson's Disease | Parkinson Disease | Drug: ropinirole/L-dopa;Drug: placebo/L-dopa | GlaxoSmithKline | Not recruiting | 30 Years | N/A | All | 352 | Phase 4 | United States;Argentina;Chile;Estonia;Korea, Republic of;Russian Federation;Slovakia;Poland | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
621 | ChiCTR-TTRCC-12002751 | 2012-04-01 | 18 April 2017 | Clinical pharmacology study of anti-parkinson's drug pramipexole | A rondomised clinical trial of the potential drug-drug interaction between pramipexole and metformin | Parkinson's disease | A:Given pramipexole only;B:Given pramipexole and metformin simultaneously ; | Institute of Clinical Pharmacology, Central South University | Not Recruiting | 19 | 26 | Male | A:18;B:18; | Phase 1 study | China | |
622 | JPRN-JapicCTI-122000 | 01/4/2012 | 2 April 2019 | Long-term study of FPF1100NW monotherapy | Long-term study on FPF1100NW monotherapy with early Parkinson's disease patients | Early Parkinson's disease | Intervention name : FPF1100NW INN of the intervention : Selegiline Dosage And administration of the intervention : oral Control intervention name : null | FP Pharmaceutical Corp. | BOTH | 130 | Phase 2 | |||||
623 | JPRN-UMIN000007617 | 2012/04/01 | 2 April 2019 | Effect of lidocaine injection for postural deformities in Parkinson's disease | Parkinson's disease | intramuscular injection of lidocaine | Dept. of Clinical pharmacology and Neurology, Ehime University | Recruiting | 20years-old | 80years-old | Male and Female | 30 | Not selected | Japan | ||
624 | NCT01331122 | April 2012 | 19 February 2015 | Study to Assess Droxidopa in the Treatment of Freezing Of Gait Symptoms in Patients With Parkinson's Disease | A Phase II, Double-Blind, Placebo-Controlled Randomized Crossover Study to Assess the Clinical Benefit and Safety of Droxidopa in the Treatment of Freezing of Gait Symptoms in Patients With Parkinson's Disease | Gait Disorders, Neurologic | Drug: droxidopa | Chelsea Therapeutics | Not recruiting | 30 Years | N/A | Both | 0 | Phase 1/Phase 2 | United States;Canada | |
625 | NCT01486628 | April 2012 | 11 April 2016 | Study of Subcutaneous Continuous Administration of Levodopa/Carbidopa Solution (ND0612) in Healthy Volunteers | A Phase I, Single Dose, Single-centre, Randomized, Double-blind, Placebo-controlled Dose Escalation Study Evaluating Safety, Tolerability and Levodopa Plasma Concentration Following Administration of Subcutaneous Continuously-delivered Levodopa/Carbidopa Solution (ND0612) in Healthy Volunteers | Parkinson's Disease | Drug: ND0612;Drug: Placebo | NeuroDerm Ltd. | Not recruiting | 18 Years | 40 Years | Male | 36 | Phase 1 | Israel | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
626 | NCT01491529 | April 2012 | 19 February 2015 | Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias | 13-week, Double-blind, Placebo-controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of Modified Release AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's Disease | Dyskinesias;Parkinson Disease;Movement Disorders;Parkinsonian Disorders;Anti-Dyskinesia Agents | Drug: AFQ056;Drug: Placebo | Novartis Pharmaceuticals | Not recruiting | 30 Years | 80 Years | Both | 154 | Phase 2 | United States;Austria;Canada;France;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;Turkey | |
627 | NCT01523301 | April 2012 | 19 October 2017 | Rotigotine Versus Placebo to Evaluate the Efficacy on Depressive Symptoms in Idiopathic Parkinson's Disease Patients | Double Blind, Placebo-controlled, Parallel, Multicenter, Randomized Interventional Phase IV Study to Evaluate the Efficacy of Rotigotine on Depressive Symptoms in Idiopathic Parkinson's Disease Patients | Idiopathic Parkinson's Disease | Drug: Rotigotine;Drug: Placebo | UCB Korea Co., Ltd. | Not recruiting | 20 Years | N/A | All | 380 | Phase 4 | Korea, Republic of | |
628 | NCT01527695 | April 2012 | 19 February 2015 | PET Study in Parkinson's Disease Patients | A Phase IIA, Multi Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Effect of 8 Weeks Treatment With Oral AZD3241 on Microglia Activation, as Measured by Positron Emission Tomography (PET), in Patients With Parkinson's Disease | Parkinson's Disease | Drug: ER tablet 25 mg AZD3241;Drug: ER tablet 100 mg AZD3241;Drug: Placebo for AZD3241 25 mg;Drug: Placebo for AZD3241 100 mg | AstraZeneca | Not recruiting | 45 Years | 75 Years | Both | 24 | Phase 2 | Sweden | |
629 | NCT01550484 | April 2012 | 16 December 2017 | A Trial of 18F-AV-133 Positron Emission Tomography (PET) Imaging to Differentiate Subjects With Parkinson's Disease (PD) From Other Movement Disorders | An Open Label, Multicenter Study, Evaluating the Safety and Efficacy of 18F-AV-133 PET Imaging to Identify Subjects With Dopaminergic Degeneration Among Subjects Presenting to a Movement Disorders Specialty Clinic With an Uncertain Diagnosis | Parkinson's Disease;Primary Parkinsonism;Lewy Body Parkinson's Disease | Drug: 18F-AV-133 | Avid Radiopharmaceuticals | Not recruiting | 40 Years | N/A | All | 170 | Phase 2/Phase 3 | United States;Australia | |
630 | NCT01556165 | April 2012 | 19 October 2017 | Rasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa in China | Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study of Rasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa in China | Parkinson's Disease | Drug: rasagiline;Drug: placebo | H. Lundbeck A/S | Not recruiting | 35 Years | N/A | All | 130 | Phase 3 | China | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
631 | NCT01491932 | March 2012 | 16 December 2017 | Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias | An Open-label Treatment Study to Evaluate the Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias | Dyskinesias;Parkinson Disease;Movement Disorders;Parkinsonian Disorders;Anti-Dyskinesia Agents | Drug: AFQ056 | Novartis Pharmaceuticals | Not recruiting | N/A | N/A | All | 129 | Phase 2 | United States;Austria;Canada;France;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;Turkey | |
632 | NCT01538329 | March 2012 | 17 May 2016 | Amantadine and L-DOPA-induced Dyskinesia in Early Parkinson's Disease | Impact of Amantadine on L-DOPA-induced Dyskinesia in Early Parkinson's Disease: a Placebo-controlled Randomized Study (the PREMANDYSK Study) | Parkinson Disease | Drug: placebo;Drug: Amantadine | University Hospital, Toulouse | Recruiting | 35 Years | N/A | Both | 202 | Phase 2 | France | |
633 | NCT01565395 | March 2012 | 16 December 2017 | Incobotulinum Toxin A for Sialorrhea in Parkinson's Disease (PD)/Parkinsonism and Amyotrophic Lateral Sclerosis (ALS) | Randomized Double Blind Placebo Controlled Cross-Over Study of Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism and Amyotrophic Lateral Sclerosis (ALS) | Parkinson Disease;Amyotrophic Lateral Sclerosis | Drug: Incobotulinum Toxin A;Drug: placebo | Beth Israel Deaconess Medical Center | Merz Pharmaceuticals | Not recruiting | 20 Years | 80 Years | All | 0 | Phase 2 | United States |
634 | NCT01653132 | March 2012 | 16 December 2017 | Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism | Randomized Double Blind Placebo Controlled Cross-Over Study of Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism | Sialorrhea | Drug: Incobotulinum Toxin A;Drug: Placebo | Beth Israel Deaconess Medical Center | Not recruiting | 18 Years | 90 Years | All | 10 | Phase 2 | United States | |
635 | NCT02039024 | March 2012 | 25 January 2016 | Imaging Non-motor Symptoms of Parkinson's Disease by Novel 18F-DTBZ and Florbetapir F-18 PET | Imaging Non-motor Symptoms of Parkinson's Disease by Novel 18F-DTBZ and Florbetapir F-18 PET | Parkinson's Disease | Drug: 18F- DTBZ | Chang Gung Memorial Hospital | National Science Council, Taiwan | Not recruiting | 20 Years | 80 Years | Both | 18 | Phase 2 | Taiwan |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
636 | NCT03061513 | February 28, 2012 | 16 December 2017 | Ubiquinol in Parkinson's Disease: Safety, Tolerability, and Effects Upon Oxidative Damage and Mitochondrial Biomarkers | Ubiquinol in Parkinson's Disease: Safety, Tolerability, and Effects Upon Oxidative Damage and Mitochondrial Biomarkers | Parkinson Disease | Drug: Ubiquinol;Dietary Supplement: Placebo | Weill Medical College of Cornell University | Not recruiting | 40 Years | 75 Years | All | 11 | Phase 2 | ||
637 | EUCTR2011-004803-19-SE | 22/02/2012 | 18 February 2013 | PET study in PD patients | A Phase IIA, Multi centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Effect of 8 Weeks Treatment with Oral AZD3241 on Microglia Activation, as Measured by Positron Emission Tomography (PET), in Patients with Parkinson’s Disease | Parkinson's Disease; Microglia activation as measured by [11C]PBR28 binding to TSPO MedDRA version: 14.1 Level: LLT Classification code 10013113 Term: Disease Parkinson's System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: AZD3241 Extended release tablets 25 mg Product Code: AZD3241 Pharmaceutical Form: Prolonged-release film-coated tablet Current Sponsor code: AZD3241 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Name: AZD3241 Extended release tablets 100 mg Product Code: AZD3241 Pharmaceutical Form: Prolonged-release film-coated tablet Current Sponsor code: AZD3241 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Name: [11C]PBR28 Product Code: [11C]PBR28 Pharmaceutical Form: Solution for injection Current Sponsor code: [11C]PBR28 Concentration unit: µg microgram(s) Concentration type: up to Concentration number: 5- Product Name: [18F]FE-PE2I Product Code: [18F]FE-PE2I Pharmaceutical Form: Solution for injection Current Sponsor code: [18F]FE-PE2I Concentration unit: µg microgram(s) Concentration type: up to Concentration number: 5- | AstraZeneca AB | Not Recruiting | Female: yes Male: yes | 24 | Phase 2A | Finland;Sweden | |||
638 | NCT01525641 | February 2012 | 19 October 2017 | Safety and Efficacy of Long-term Daily Use of Mirapex®-LA Tablets in Patients With Parkinson's Disease | Special Survey on Long-term Drug Use of Mirapex®-LA Tablets in Patients With Parkinson's Disease | Parkinson Disease | Drug: Mirapex LA | Boehringer Ingelheim | Not recruiting | N/A | N/A | All | 615 | N/A | Japan | |
639 | NCT01568099 | February 2012 | 24 August 2015 | Tolerability and Safety of Subcutaneous Administration of Two Doses of AFFITOPE® PD01A in Early Parkinson's Disease | A Randomized, Controlled, Parallel Group, Patient-blinded, Single-center, Phase I Pilot Study to Assess Tolerability and Safety of Repeated Subcutaneous Administration of Two Doses of AFFITOPE® PD01A Formulated With Adjuvant to Patients With Parkinson's Disease | Parkinson's Disease | Biological: AFFITOPE® PD01A;Other: Control | Affiris AG | Not recruiting | 40 Years | 65 Years | Both | 32 | Phase 1 | Austria | |
640 | NCT01673724 | February 2012 | 16 December 2017 | Pramipexole and Bromocriptine on Nonmotor Symptoms of Early Parkinson's Disease | Effect of Pramipexole and Bromocriptine on Nonmotor Symptoms of Early Parkinson's Disease: Multicenter, Open-label, Parallel, Randomized Study | Parkinson's Disease | Drug: pramipexole;Drug: Bromocriptine | Sandoz | Not recruiting | 30 Years | N/A | All | 121 | Phase 4 | Korea, Republic of | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
641 | NCT01485172 | January 31, 2012 | 2 July 2018 | A Fixed Dose, Dose Response Study for Ropinirole Prolonged Release in Patients With Early Stage Parkinson's Disease | A Fixed Dose, Dose Response Study for Ropinirole Prolonged Release (PR) in Patients With Early Stage Parkinson's Disease | Parkinson Disease | Drug: ropinirole monotherapy;Drug: placebo monotherapy | GlaxoSmithKline | Not recruiting | 30 Years | N/A | All | 186 | Phase 4 | United States;Estonia;Korea, Republic of;Russian Federation;Slovakia;Poland | |
642 | NCT01470027 | January 2012 | 11 June 2018 | N-Acetylcysteine for Neuroprotection in Parkinson's Disease | N-Acetylcysteine for Neuroprotection in Parkinson's Disease | Parkinson Disease | Drug: N-acetylcysteine;Drug: Placebo | Weill Medical College of Cornell University | National Institute on Aging (NIA) | Not recruiting | 50 Years | 75 Years | All | 50 | Phase 1/Phase 2 | United States |
643 | NCT01497652 | January 2012 | 28 December 2015 | A Double Blind Placebo Controlled Trial Evaluating Rasagiline Effects on Cognition in Parkinson's Disease Patients With Mild Cognitive Impairment Receiving Dopaminergic Therapy | A Double Blind Placebo Controlled Trial Evaluating Rasagiline Effects on Cognition in Parkinson's Disease Patients With Mild Cognitive Impairment Receiving Dopaminergic Therapy | Parkinson's Disease | Drug: Rasagiline/Placebo;Drug: Rasagiline | Georgetown University | Teva Neuroscience, Inc. | Not recruiting | 40 Years | N/A | Both | 34 | Phase 4 | United States |
644 | NCT01515410 | January 2012 | 19 October 2017 | Study in Advanced Parkinson's Disease Patients With Predictable Motor Fluctuations | A Phase 2, Randomized, Open-Label, Crossover Study to Compare DM-1992, a Novel Gastric-Retentive Extended-Release Formulation of Levodopa/Carbidopa, to an Immediate-Release Carbidopa Tablet in Patients With Advanced Parkinson's Disease With Motor Fluctuations | Parkinson's Disease;Motor Fluctuations | Drug: DM-1992;Drug: Sinemet IR | Depomed | Not recruiting | 30 Years | N/A | All | 34 | Phase 2 | United States | |
645 | NCT01536015 | January 2012 | 19 October 2017 | Effect of Rotigotine on Motor Symptoms in Patients With Advanced Parkinson's Disease (PD) With Motor Fluctuations and Symptoms of Gastrointestinal Dysfunction | A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Effect of Rotigotine on Motor Symptoms in Patients With Advanced Parkinson's Disease With Motor Fluctuations and Symptoms of Gastrointestinal Dysfunction | Advanced Parkinson's Disease | Drug: Rotigotine;Drug: Placebo | UCB Pharma | Not recruiting | 30 Years | N/A | All | 25 | Phase 3 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
646 | EUCTR2009-017412-32-IT | 13/12/2011 | 15 July 2013 | RANDOMISED CONTROLLED TRIAL OF BOTULINUM TOXIN TYPE A AND B EFFICACY IN REDUCING DROOLING IN PARKINSON DISEASE - ND | RANDOMISED CONTROLLED TRIAL OF BOTULINUM TOXIN TYPE A AND B EFFICACY IN REDUCING DROOLING IN PARKINSON DISEASE - ND | Parkinson disease MedDRA version: 9.1 Level: LLT Classification code 10013363 | Trade Name: BOTOX Pharmaceutical Form: Powder for solution for injection INN or Proposed INN: Botulinum toxin Concentration unit: U unit(s) Concentration type: equal Concentration number: 100- Trade Name: NEUROBLOC Pharmaceutical Form: Solution for injection INN or Proposed INN: Botulinum toxin Concentration unit: IU/ml international unit(s)/millilitre Concentration type: equal Concentration number: 5000- | AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI | Not Recruiting | Female: yes Male: yes | Italy | |||||
647 | NCT01351168 | December 2011 | 19 February 2015 | Use of Zolpidem in Parkinson's Disease | A Randomized, Controlled, Double-Blind, Cross-over Study of Zolpidem for Patients With Parkinson's Disease | Parkinson's Disease | Drug: Levodopa;Drug: Zolpidem first dose;Drug: Zolpidem second dose;Drug: sugar pill | Rush University Medical Center | Not recruiting | 30 Years | 75 Years | Both | 0 | Phase 2 | United States | |
648 | NCT01470859 | December 2011 | 19 October 2017 | The Effect of Pramipexole on Metabolic Network Activity Compared With Levodopa in Early Parkinson's Disease | a Pilot Follow-up Study of Investigating the Effect of Pramipexole on Metabolic Network Activity Compared With Levodopa in Chinese Patients With Early Parkinson's Disease | Idiopathic Parkinson's Disease | Drug: pramipexole;Drug: Sinemet CR | Huashan Hospital | Boehringer Ingelheim | Not recruiting | 30 Years | 75 Years | All | 30 | N/A | China |
649 | NCT01479530 | December 2011 | 19 October 2017 | Azilect® (Rasagiline) in Levodopa-treated Parkinson's Patients With Motor Fluctuations in China | Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study of [Azilect®] Rasagiline in Levodopa-treated Parkinson's Patients With Motor Fluctuations in China | Parkinson's Disease | Drug: Placebo;Drug: Azilect® | H. Lundbeck A/S | Not recruiting | 30 Years | N/A | All | 321 | Phase 3 | China | |
650 | NCT01519271 | December 2011 | 16 December 2017 | Mild Cognitive Impairment in Parkinson's Disease | A Phase IV Randomized, Double-Blind, Placebo-Controlled, Crossover Single Site Study Of Exelon® Patch (Rivastigmine Transdermal System) For Mild Cognitive Impairment In Parkinson's Disease | Parkinson's Disease;Mild Cognitive Impairment | Drug: Exelon Patch (rivastigmine transdermal system);Drug: Placebo Patches | University of Pennsylvania | Not recruiting | 40 Years | 85 Years | All | 28 | Phase 4 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
651 | NCT01521117 | December 2011 | 19 February 2015 | The Effect of Donepezil on Gait and Balance in Parkinson's Disease | A Randomized, Double-blind, Placebo Controlled, Crossover Study to Evaluate the Effect of Donepezil on Gait and Balance in Parkinson's Disease | Parkinson's Disease | Drug: Donepezil | Oregon Health and Science University | Recruiting | N/A | N/A | Both | 12 | Phase 4 | United States | |
652 | NCT02302144 | December 2011 | 16 December 2017 | A Multifactorial Exercise Program to Reduce Falls in People With Parkinson Disease | A Multifactorial Exercise Program to Reduce Falls in People With Parkinson Disease | Parkinson Disease | Behavioral: Balance & Strengthening Exercises | Boston University Charles River Campus | Not recruiting | 18 Years | N/A | All | 32 | N/A | United States | |
653 | NCT01385592 | November 2011 | 19 February 2015 | Evaluation of the Efficacy and Safety of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias | 12-week, Double-blind, Placebo-controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's Disease | Dyskinesias;Parkinson Disease;Movement Disorders;Parkinsonian Disorders | Drug: AFQ056;Drug: Placebo | Novartis Pharmaceuticals | Not recruiting | 30 Years | 80 Years | Both | 78 | Phase 2 | United States;Canada;France;Germany;Hungary;Italy;Spain | |
654 | NCT01457807 | November 2011 | 19 February 2015 | To Assess the Effect of Administration of 2 Formulation of AZD3241 on Blood Concentration in Healthy Volunteers | A Phase I, Single-centre, Double-blind, Randomised, Placebo-controlled, Parallel Group Study to Assess the Pharmacokinetics, Safety and Tolerability of Two Different Extended Release Formulations of Tablets of AZD3241 (300 mg) After Administration of Multiple Doses in Healthy Male and Female Volunteers | Parkinson's Disease | Drug: AZD3241 ER formulation 1;Drug: Placebo;Drug: AZD3241 Alternative titration scheme with formulation 1 or 2 | AstraZeneca | Not recruiting | 30 Years | 65 Years | Both | 24 | Phase 1 | United Kingdom | |
655 | NCT01556100 | November 2011 | 8 January 2018 | Long-Term Vesicular Monoamine Transporter II Imaging and Clinical Assessment of Parkinson's Disease Progression | Long-Term Vesicular Monoamine Transporter II Imaging and Clinical Assessment of Parkinson's Disease Progression | Parkinson Disease | Drug: 18F-DTBZ AV-133 | Chang Gung Memorial Hospital | Not recruiting | 20 Years | N/A | All | 40 | Phase 2 | ||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
656 | NCT01736891 | November 2011 | 19 February 2015 | Clinical Trial of Rasagiline in Levodopa-Treated Parkinson's Disease Patients With Motor Fluctuations | Evaluation for the Efficacy,Tolerability,and Safety of Rasagiline in Levodopa-treated PD Patients With Motor Fluctuations: A Multicenter, Double Blind, Randomized, Placebo-Controlled Group Study (China) | Parkinson´s Disease | Drug: Rasagiline;Drug: Placebo | Chongqing Fortune Pharmaceutical Co., Ltd. | Beijing Bionovo Medicine Development Co., Ltd. | Not recruiting | 30 Years | 75 Years | Both | 268 | Phase 3 | China |
657 | JPRN-JapicCTI-111673 | 12/10/2011 | 23 April 2019 | Phase II clinical study in patients with Parkinson's disease. | Pharmacokinetic study of HP-3000 in patients with Parkinson's disease. | Parkinson's disease | Intervention name : HP-3000 (ropinirole hydrochloride patch) Dosage And administration of the intervention : Transdermal, once daily | Hisamitsu Pharmaceutical Co., Inc. | 20 | 79 | BOTH | Phase 2 | ||||
658 | EUCTR2011-000056-42-GB | 07/10/2011 | 10 December 2012 | Sleep efficiency assessed by Polysomnography (PSG sleep lab testing) in advanced Parkinson's disease | A MULTI-CENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFECTS OF ROTIGOTINE ON SLEEP EFFICIENCY IN PATIENTS WITH ADVANCED PARKINSON’S DISEASE - sleep efficiency assessed by polysomnography in advanced Parkinson's Disease | Advanced Parkinson's Disease MedDRA version: 14.1 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Neupro 4mg/24h transdermal patch Pharmaceutical Form: Transdermal patch INN or Proposed INN: ROTIGOTINE CAS Number: 99755-59-6 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 9.0- Pharmaceutical form of the placebo: Transdermal patch Route of administration of the placebo: Transdermal use Trade Name: Neupro 6mg/24h transdermal patch Pharmaceutical Form: Transdermal patch INN or Proposed INN: ROTIGOTINE CAS Number: 99755-59-6 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 13.5- Pharmaceutical form of the placebo: Transdermal patch Route of administration of the placebo: Transdermal use Trade Name: Neupro 8mg/24h transdermal patch Pharmaceutical Form: Transdermal patch INN or Proposed INN: ROTIGOTINE CAS Number: 99755-59-6 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 18.0- Pharmaceutical form of the placebo: Transdermal patch Route of administration of the placebo: Transdermal use | UCB Celltech, UK - Registered Branch of UCB Pharma SA | Not Recruiting | Female: yes Male: yes | United Kingdom | |||||
659 | JPRN-UMIN000006521 | 2011/10/01 | 2 April 2019 | Switch trial from Pramipexole IR (Bi-sifrol) to Pramipexole ER (Mirapex LA) in patients with Parkinson's disease | Parkinson's disease | Rapid switch of Pramipexole ER (once in a day) which is same dose as IR. The period of administration is 8 weeks. | Department of Neurology, Juntendo University | Recruiting | 20years-old | Not applicable | Male and Female | 30 | Not selected | Japan | ||
660 | NCT01385735 | October 2011 | 19 February 2015 | Emotion, Mood and Executive Function in Parkinson`s Disease (PD) | Effects of Azilect (Rasagiline) on Processing of Emotions, Mood and Executive Function in Parkinson`s Disease | Parkinson Disease | Drug: Rasagiline;Drug: Placebo | St. Josef Hospital Bochum | Not recruiting | 30 Years | 75 Years | Both | 70 | Phase 4 | Germany | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
661 | NCT01439100 | October 2011 | 19 February 2015 | A Randomised Placebo Controlled Study of OXN PR for Severe Parkinson's Disease Associated Pain | Parkinson's Disease With Severe Pain | Drug: Oxycodone/Naloxone Prolonged Release tablets;Drug: Placebo | Mundipharma Research GmbH & Co KG | Not recruiting | 25 Years | N/A | Both | 172 | Phase 3 | Czech Republic;Germany;Hungary;Poland;Romania;Spain;United Kingdom | ||
662 | NCT01442610 | October 2011 | 1 February 2016 | Effects of Rasagiline on Sleep Disturbances in Parkinson's Disease | Effects of Rasagiline on Sleep Disturbances in PD: A Single Center, Randomized, Double-blind, Placebo run-in, Polysomnographic Clinical Phase IV Trial | Sleep Disturbances;Parkinsons's Disease | Drug: Rasagiline;Drug: Placebo | Technische Universität Dresden | Teva Pharmaceutical Industries | Not recruiting | 50 Years | 85 Years | Both | 30 | Phase 4 | Germany |
663 | NCT01446614 | October 2011 | 19 February 2015 | Mesenchymal Stem Cells Transplantation to Patients With Parkinson's Disease | Phase?/?Trial of Autologous Bone Marrow Derived Mesenchymal Stem Cells to Patients With Parkinson's Disease. | Parkinson's Disease | Biological: bone marrow derived mesenchymal stem cells | Guangzhou General Hospital of Guangzhou Military Command | Recruiting | 30 Years | 65 Years | Both | 20 | Phase 1/Phase 2 | China | |
664 | NCT01479127 | October 2011 | 19 October 2017 | Study of Safety, Tolerability, Pharmacokinetics, and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease | An Open-Label, Single-Arm, Baseline-Controlled, Multicenter Study to Explore the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease | Advanced Parkinson's Disease | Drug: ABT-SLV187;Drug: Oral Levodopa/Carbidopa;Device: Infusion Pump: CADD-Legacy® 1400 Pump;Device: NJ-Tube: Silicon ED Tube;Device: Adaptor: Hakko Adaptor | AbbVie (prior sponsor, Abbott) | Abbott Japan Co.,Ltd | Not recruiting | 30 Years | 99 Years | All | 8 | Phase 2 | Japan |
665 | NCT02427646 | October 2011 | 26 August 2019 | Kinematic-guided BoNT-A Treatment for ET and PD Tremor | Use of Kinematic Assessment of Hand Tremor Pre- and Post- Treatment With Botulinum Toxin Type A in Essential Tremor and Parkinson Disease | Tremor | Drug: BoNT-A | Western University, Canada | Not recruiting | 18 Years | 80 Years | All | 54 | Phase 2 | ||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
666 | EUCTR2011-000612-26-IT | 19/09/2011 | 10 March 2014 | Open-label study on the use of Finasteride in prolonged treatment (4 years) of tics in Tourette's disease and Parkinson's disease in the pounding - FINTOURPARK | Open-label study on the use of Finasteride in prolonged treatment (4 years) of tics in Tourette's disease and Parkinson's disease in the pounding - FINTOURPARK | Syndrome Gilles de la Tourette's disease Parkinosn Pounding MedDRA version: 14.1 Level: LLT Classification code 10013113 Term: Disease Parkinson's System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: PROSCAR*30CPR RIV 5MG Pharmaceutical Form: Tablet INN or Proposed INN: Finasteride Concentration unit: mg milligram(s) Concentration number: 5- | AZIENDA OSPEDALIERO UNIVERSITARIA DI CAGLIARI | Authorised | Female: yes Male: yes | Italy | |||||
667 | EUCTR2011-001148-31-GB | 13/09/2011 | 19 March 2012 | A pilot clinical trial with the iron chelator Deferiprone in Parkinson's disease - Pilot clinical trial iron chelator Deferiprone in Parkinson's Vs1 | A pilot clinical trial with the iron chelator Deferiprone in Parkinson's disease - Pilot clinical trial iron chelator Deferiprone in Parkinson's Vs1 | Parkinson's disease | Trade Name: Ferrprox (Deferiprone) Product Name: Deferiprone (Ferriprox) Pharmaceutical Form: Oral liquid INN or Proposed INN: Deferiprone Concentration unit: mg/ml milligram(s)/millilitre Pharmaceutical form of the placebo: Oral solution Route of administration of the placebo: Oral use | Imperial College London | Authorised | Female: yes Male: yes | United Kingdom | |||||
668 | NCT01178047 | September 2011 | 19 February 2015 | Multicenter Placebo Controlled Study to Assess the Effect of Rasagiline on Sleep-wake Disturbances in Patients With Parkinson's Disease | A Multicenter, Randomized, Double-blind Placebo Controlled Study to Assess the Effect of Rasagiline on Sleep-wake Disturbances in Patients With Parkinson's Disease (PD) | Parkinson's Disease | Drug: Rasagiline | University of Zurich | H. Lundbeck A/S | Not recruiting | 40 Years | N/A | Both | 1 | Phase 4 | Switzerland |
669 | NCT01461083 | September 2011 | 19 February 2015 | Evaluation of [18F]MPPF as a Brain Tracer of Serotonin Receptor 5HT1a | Phase I Evaluation of [18F]MPPF as a Brain Tracer of Serotonin Receptor 5HT1a in Subjects With Parkinson Disease and Healthy Subjects | Parkinson Disease | Drug: [18F]MPPF | Institute for Neurodegenerative Disorders | Not recruiting | 18 Years | 90 Years | Both | 19 | Phase 1 | United States | |
670 | NCT01515774 | September 2011 | 19 February 2015 | Study to Observe the Effect of Mirapex ER® Once-daily (QD) Versus Twice-daily (BID) | An Open-label, Randomized, Multi-center, Crossover Study to Observe the Effect of Once-daily Mirapex ER® and Twice-daily Mirapex ER® in Patients With Parkinson Disease | Parkinson's Disease | Drug: Mirapex ER | Seoul National University Hospital | Recruiting | 30 Years | 80 Years | Both | 200 | Phase 4 | Korea, Republic of | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
671 | NCT01545856 | September 2011 | 16 December 2017 | Cardiovascular Events in Parkinson's Disease Patients | Background Incidence of Cardiovascular Ischaemic Events in Treated Parkinson's Disease Patients in the Impact Database | Cardiovascular Event;Parkinson Disease | Drug: levodopa | GlaxoSmithKline | Not recruiting | 20 Years | N/A | All | 1 | N/A | ||
672 | NCT02170376 | September 2011 | 19 October 2017 | The Effect of BIA 9-1067 at Steady-state on the Levodopa Pharmacokinetics | The Effect of BIA 9-1067 at Steady-state on the Levodopa Pharmacokinetics When Administered With Immediate-release 100/25 mg Levodopa/Carbidopa in Healthy Subjects | Parkinson's Disease (PD) | Drug: BIA 9-1067;Drug: Entacapone;Drug: Placebo;Drug: Levodopa/carbidopa | Bial - Portela C S.A. | Not recruiting | 18 Years | 45 Years | All | 80 | Phase 1 | France | |
673 | EUCTR2010-020299-42-DE | 30/08/2011 | 27 February 2017 | A study in U.S. and Germany to show if patients with an early stage of Parkinson's disease could be treated with a nicotine patch. In this study the nicotine patch is being compared to a placebo patch. The placebo patch is identical in appearance to the nicotine patch but does not contain any active ingredients. | A randomized, placebo-controlled, double-blind, multi-center trial to assess the disease-modifying potential of transdermal nicotine in early Parkinson's disease in Germany and the USA (NIC-PD) - NIC-PD | Early PD subjects within 18 months of diagnosis and not expected to require dopamine agonist or levodopa therapy for 1 year, with Hoehn and Yahr stage <2, with stable (>2 months) MAO-B inhibitor therapy allowed MedDRA version: 16.1 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Nicotinell 17,5 mg/24-Stunden-Pflaster Product Name: Nicotinell Pharmaceutical Form: Transdermal patch CAS Number: 54-11-5 Other descriptive name: NICOTINE Concentration unit: mg milligram(s) Concentration type: range Concentration number: 7-28 Pharmaceutical form of the placebo: Transdermal patch Route of administration of the placebo: Transdermal use Trade Name: Nicotinell 35 mg/24-Stunden-Pflaster Product Name: Nicotinell Pharmaceutical Form: Transdermal patch CAS Number: 54-11-5 Other descriptive name: NICOTINE Concentration unit: mg milligram(s) Concentration type: range Concentration number: 7-28 Pharmaceutical form of the placebo: Transdermal patch Route of administration of the placebo: Transdermal use | Philipps-University Marburg | Not Recruiting | Female: yes Male: yes | 160 | Phase 2 | United States;Germany | |||
674 | NCT01370811 | August 2011 | 19 February 2015 | A Relative Efficacy and Safety Study of OC Oral Solution for Sialorrhoea in Patients With Parkinson's Disease | A Phase II, Double-blind, Randomized, Placebo-controlled 4-way Crossover Study to Evaluate the Relative Efficacy and Safety of OC Oral Solution (Oxybutynin and Clonidine) for Sialorrhoea in Patients With Parkinson's Disease | Sialorrhoea | Drug: OC oral solution treatment A;Drug: OC oral solution treatment B;Drug: OC oral solution treatment C;Drug: OC oral solution treatment D | Orient Pharma Co., Ltd. | Not recruiting | 40 Years | 80 Years | Both | 24 | Phase 2 | United States | |
675 | NCT01411137 | August 2011 | 16 December 2017 | Carbidopa-Levodopa (CD-LD) ER Alone or in Combination With CD-LD IR to IPX066 Followed by IPX066 Extension Safety Study | An Open Label Conversion Study of Carbidopa-Levodopa (CD-LD) Extended-Release Taken Alone or in Combination With CD-LD Immediate Release to IPX066 Followed by an Open-Label Extension Safety Study of IPX066 in Advanced PD | Parkinson's Disease | Drug: IPX066 | IMPAX Laboratories, Inc. | Michael J. Fox Foundation for Parkinson's Research | Not recruiting | 30 Years | N/A | All | 43 | Phase 3 | United States |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
676 | NCT01437189 | August 2011 | 19 February 2015 | The Effects of Sertraline on Depression in Parkinson's Disease | Clinical Protocol of Self-Controlled Study on the Effects of Sertraline on Depression in Parkinson's Disease | Depression;Parkinson's Disease | Drug: Sertraline | Zhejiang University | Recruiting | 35 Years | 75 Years | Both | 35 | N/A | China | |
677 | NCT01461109 | August 2011 | 19 February 2015 | Research Involving Subjects With Parkinson's Disease, Alzheimer Disease and Healthy Controls | Evaluation of [18F] CFPyPB PET as a Marker of Glycine Transporter-1 (GlyT1) Receptor in Subjects With Parkinson Disease, Alzheimer Disease and Healthy Subjects | Parkinson Disease;Alzheimer Disease | Drug: [18F] CFPyPB | Institute for Neurodegenerative Disorders | Not recruiting | 18 Years | 90 Years | Both | 4 | Phase 1 | United States | |
678 | NCT01634568 | August 2011 | 19 February 2015 | A Clinical Trial to Find Out V81444's Side Effects and Blood Levels in Healthy Men | A Double-blind, Randomised, Placebo-controlled Study of the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Oral Doses of V81444 in Healthy Male Volunteers | Parkinson's Disease | Drug: V81444 | Vernalis (R&D) Ltd | Not recruiting | 18 Years | 45 Years | Male | 49 | Phase 1 | United Kingdom | |
679 | NCT01759888 | August 2011 | 19 February 2015 | Development of a Novel 18F-DTBZ PET Imaging as a Biomarker to Monitor Neurodegeneration of PARK6 and PARK8 Parkinsonism | From Mouse Models to Patients: Development of a Novel 18F-DTBZ PET Imaging as a Biomarker to Monitor Neurodegeneration of PARK6 and PARK8 Parkinsonism | Parkinson's Disease | Drug: 18F-DTBZ | Chang Gung Memorial Hospital | National Science Council, Taiwan | Not recruiting | 20 Years | 80 Years | Both | 49 | Phase 2 | Taiwan |
680 | NCT01397422 | July 2011 | 16 December 2017 | Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study) | Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study) | Dyskinesia;Levodopa Induced Dyskinesia;Parkinson's Disease | Drug: ADS-5102 (extended release amantadine HCl) | Adamas Pharmaceuticals, Inc. | Not recruiting | 30 Years | 85 Years | All | 83 | Phase 2/Phase 3 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
681 | NCT01427517 | July 2011 | 11 November 2019 | Intravenous N-acetylcysteine for the Treatment of Gaucher's Disease and Parkinson's Disease | Intravenous N-acetylcysteine for the Treatment of Gaucher's Disease and Parkinson's Disease | Parkinson's Disease;Gaucher's Disease | Drug: N-acetylcysteine | University of Minnesota | Rare Diseases Clinical Research Network;National Center for Advancing Translational Science (NCATS);National Institute of Neurological Disorders and Stroke (NINDS);National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Not recruiting | 18 Years | N/A | All | 9 | Phase 1 | United States |
682 | EUCTR2011-001092-39-DE | 29/06/2011 | 27 January 2014 | efficacy, safety and tolerability of AQW051 in reducing L-dopa induced dyskinesias in Parkinson’s patients with moderate to severe L-dopa induced dyskinesias | A multi-centre, randomized, double-blind, placebo-controlled, parallel-group, multiple oral dose study to assess the efficacy, safety and tolerability of AQW051 in reducing L-dopa induced dyskinesias in Parkinson’s patients with moderate to severe L-dopa induced dyskinesias | L-dopa induced dyskinesias in Parkinson’s patients with moderate to severe L-dopa induced dyskinesias MedDRA version: 14.1 Level: HLT Classification code 10034005 Term: Parkinson's disease and parkinsonism System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: AQW051 Product Code: AQW051 Pharmaceutical Form: Capsule, hard Current Sponsor code: AQW051 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Product Name: AQW051 Product Code: AQW051 Pharmaceutical Form: Capsule, hard Current Sponsor code: AQW051 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use | Novartis Pharma Services AG | Not Recruiting | Female: yes Male: yes | 72 | Italy;Germany;United States;France | ||||
683 | NCT01382342 | June 2011 | 19 February 2015 | The Effect of Rasagiline on Cognition in Parkinson's Disease | Parkinson's Disease | Drug: Rasagiline;Drug: Placebo | Brown University | Teva Pharmaceuticals USA | Not recruiting | 40 Years | N/A | Both | 50 | Phase 4 | United States | |
684 | NCT01528592 | June 2011 | 11 June 2018 | PharmacoMRI of Parkinson Disease | A Pilot Study of the Drug Effects on Brain Connectivity of Parkinson's Disease | Parkinson's Disease | Drug: Carbidopa-Levodopa | Northwestern University | Not recruiting | 30 Years | N/A | All | 18 | N/A | United States | |
685 | NCT01652534 | June 2011 | 16 December 2017 | Efficacy Study of Amantadine to Treat Gait Dysfunction and Freezing in Parkinson's Disease | Efficacy of Amantadine for Gait Dysfunction and Gait Freezing in Patients With Parkinson's Disease | Parkinson's Disease | Drug: Amantadine;Drug: Placebo | Northwestern University | Not recruiting | 18 Years | 85 Years | All | 1 | Phase 3 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
686 | NCT02253563 | June 2011 | 23 May 2016 | Resistance Versus Balance Training in Parkinson's Disease | Resistance Training Versus Balance Training to Improve Postural Control in Patients With Parkinson's Disease - a Randomized Controlled Rater Blinded Trial | Parkinson's Disease | Behavioral: Resistance Training;Behavioral: Balance Training | University of Kiel | Not recruiting | 40 Years | 100 Years | Both | 40 | N/A | ||
687 | EUCTR2010-022517-25-DE | 30/05/2011 | 3 December 2012 | Safety, tolerability and efficacy of ADX48621 in patients with Parkinson's disease | Phase 2, randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the safety, tolerability and efficacy of ADX48621 in the treatment of levodopa induced dyskinesia in patients with Parkinson's disease | Levodopa induced dyskinesia in Parkinson's disease patients MedDRA version: 13.1 Level: PT Classification code 10013916 Term: Dyskinesia System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: ADX48621 Product Code: ADX48621 Pharmaceutical Form: Capsule, hard INN or Proposed INN: Dipraglurant CAS Number: 872363-17-2 Current Sponsor code: ADX48621 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use | Addex Pharma SA | Authorised | Female: yes Male: yes | 90 | Phase 2 | United States;France;Austria;Germany | |||
688 | EUCTR2010-022200-46-FI | 13/05/2011 | 25 September 2012 | Efficacy and safety of ODM-101 compared to a standard combination (Stalevo®) in patients with Parkinson’s disease. | Efficacy and safety of ODM-101 compared to a standard combination (Stalevo®); a randomised, double-blind, crossover, proof of concept study in patients with Parkinson’s disease and end-of-dose motor fluctuations. - PARPOC | Parkinson's disease MedDRA version: 14.1 Level: LLT Classification code 10013113 Term: Disease Parkinson's System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: ODM-101 Product Code: 75 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: LEVODOPA CAS Number: 59-92-7 Current Sponsor code: na Other descriptive name: na Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 75- INN or Proposed INN: CARBIDOPA CAS Number: 38821-49-7 Current Sponsor code: na Other descriptive name: na Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 65- INN or Proposed INN: ENTACAPONE CAS Number: 130929-57-6 Current Sponsor code: na Other descriptive name: na Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Name: ODM-101 Product Code: 100 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: LEVODOPA CAS Number: 59-92-7 Current Sponsor code: na Other descriptive name: na Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- INN or Proposed INN: CARBIDOPA CAS Number: 38821-49-7 Current Sponsor code: na Other descriptive name: na Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 65- INN or Proposed INN: ENTACAPONE CAS Number: 130929-57-6 Current Sponsor code: na Other descriptive name: na Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Name: ODM-101 Product Code: 125 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: LEVODOPA CAS Number: 59-92-7 Current Sponsor code: na Other descriptive name: na Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 125- INN or Proposed INN: CARBIDOPA CAS Number: 38821-49-7 Current Sponsor code: na Other descriptive name: na Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 65- | Orion Corporation | Not Recruiting | Female: yes Male: yes | 100 | Finland;Germany;Latvia;Lithuania | ||||
689 | EUCTR2007-002964-90-BE | 05/05/2011 | 21 August 2017 | A trial to determine the efficacy and safety of a dose range of 50 to 100 mg/day of safinamide, as add-on therapy, in patients with Parkinson’s Disease with motor fluctuations, treated with levodopa and who may be receiving a dopamine agonist, an anticholinergic and/or amantadine. | A phase III, double-blind, placebo-controlled, randomised trial to determine the efficacy and safety of a dose range of 50 to 100 mg/day of safinamide, as add-on therapy, in subjects with idiopathic Parkinson’s Disease with motor fluctuations, treated with a stable dose of levodopa and who may be receiving concomitant treatment with stable doses of a dopamine agonist, an anticholinergic and/or amantadine. - Safinamide in IPD with motor fluctuations, as add-on to levodopa | Idiopathic Parkinson's Disease MedDRA version: 14.1 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Safinamide Product Code: NW-1015 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Safinamide CAS Number: 202825-46-5 Current Sponsor code: NW-1015 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Name: Safinamide Product Code: NW-1015 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Safinamide CAS Number: 202825-46-5 Current Sponsor code: NW-1015 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use | Newron Pharmaceuticals SpA | Not Recruiting | Female: yes Male: yes | 605 | Phase 3 | United States;Estonia;Taiwan;Slovakia;Finland;Spain;Thailand;Austria;Israel;United Kingdom;Switzerland;India;France;Czech Republic;Hungary;Canada;Belgium;Malaysia;Australia;Germany;Netherlands;New Zealand;Korea, Republic of | |||
690 | NCT01119131 | May 2011 | 19 October 2017 | Effects of Vitamin D in Parkinson's Disease (PD) | The Effects of Vitamin D on Balance in Persons With PD | Parkinson Disease;Accidental Falls | Drug: Vitamin D3;Dietary Supplement: calcium;Other: Placebo | VA Office of Research and Development | Oregon Health and Science University | Not recruiting | 50 Years | 99 Years | All | 101 | Phase 2 | United States |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
691 | NCT01361009 | May 2011 | 19 October 2017 | a PMS on Safety Profile of Pramipexole in Chinese Parkinson Disease Patients | Safety of Pramipexole Monotherapy or Combination Therapy in Chinese Patients With Parkinson¿s Disease: a 12 Week Post Marketing Surveillance | Parkinson Disease | Drug: pramipexole | Boehringer Ingelheim | Not recruiting | 30 Years | 75 Years | All | 2017 | N/A | China | |
692 | NCT01364545 | May 2011 | 19 February 2015 | Ketogenic Diets for Symptoms of Parkinson's Disease | Ketogenic Diets for Symptoms of Parkinson's Disease | Parkinson's Disease | Dietary Supplement: Ketone ester drink;Dietary Supplement: Placebo (carbohydrate containing) drink | University of Oxford | Recruiting | 42 Years | N/A | Both | 20 | N/A | United Kingdom | |
693 | NCT01462708 | May 2011 | 19 February 2015 | Evaluation of [18F]MK-9470 as a Brain Tracer of Cannabinoid-1 Receptor in Parkinson's Disease and Healthy Subjects | Evaluation of [18F] MK-9470 and PET as a Marker of Cannabinoid-1 Receptor Activity in Subjects With Parkinson Disease Compared With Healthy Controls | Parkinson Disease | Drug: [18F]MK-9470 | Institute for Neurodegenerative Disorders | Not recruiting | 18 Years | 90 Years | Both | 16 | Phase 1 | United States | |
694 | NCT01504178 | May 2011 | 16 December 2017 | Evaluation of the Role of the Noradrenergic System in Pain Perception in Parkinson's Disease | Evaluation of the Role of the Noradrenergic System in Pain Perception in Parkinson's Disease | Parkinson's Disease | Drug: duloxetine;Drug: placebo of duloxetine;Drug: injection of apomorphine;Drug: injection of placebo of apomorphine;Drug: L-Dopa;Drug: injection of placebo of L-Dopa | University Hospital, Toulouse | French Parkinson Association | Not recruiting | 30 Years | 70 Years | All | 28 | Phase 3 | France |
695 | NCT01520987 | May 2011 | 19 October 2017 | Pharmacokinetics of BIA 9-1067 in Healthy Japanese and Caucasian Subjects | Randomized, Double-Blinded, Placebo-Controlled, Multiple Ascending Dose Study to Compare the Pharmacokinetics of BIA 9-1067 in Healthy Japanese and Caucasian Subjects | Parkinson Disease | Drug: BIA 9-1067;Drug: Placebo | Bial - Portela C S.A. | Not recruiting | 18 Years | 65 Years | All | 105 | Phase 1 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
696 | NCT01766258 | May 2011 | 19 February 2015 | Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Motor Fluctuations | Efficacy and Safety of ODM-101 Compared to a Standard Combination (Stalevo®); a Randomised, Double-blind, Crossover, Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Motor Fluctuations | Parkinson's Disease | Drug: ODM-101 65mg Carbidopa;Drug: ODM-101 105mg Carbidopa;Drug: Stalevo | Orion Corporation, Orion Pharma | Not recruiting | 30 Years | N/A | Both | 117 | Phase 2 | ||
697 | NCT01856439 | May 2011 | 26 August 2019 | Long Term Safety and Efficacy Study of ProSavin in Parkinson's Disease | A Multicentre, Open-label Study to Determine the Long Term Safety, Tolerability and Efficacy of ProSavin in Patients With Bilateral, Idiopathic Parkinson's Disease. | Parkinson's Disease | Drug: ProSavin | Axovant Sciences Ltd. | Oxford BioMedica | Not recruiting | N/A | N/A | All | 15 | Phase 1/Phase 2 | France;United Kingdom |
698 | JPRN-UMIN000005403 | 2011/04/01 | 2 April 2019 | A Multi-center Randomized Placebo-controlled Double-blinded Study for the Efficacy of Donepezil against Psychosis in Parkinson Disease | Parkinson disease | 5mg of donepezil hydrochloride placebo | Designated Research, National Hospital Organization | Not Recruiting | 20years-old | 80years-old | Male and Female | 142 | Phase 3 | Japan | ||
699 | NCT01313819 | April 2011 | 19 February 2015 | The Effect of IV Amantadine on Freezing of Gait (FOG) Resistant to Dopaminergic Therapy | A Double Blind, Placebo-controlled Study for the Effect of IV Amantadine on Freezing of Gait (FOG) Resistant to Dopaminergic Therapy | Parkinson`s Disease;Freezing of Gait | Drug: PK-Merz® 200mg/500ml inj(Amantadine) , Normal saline 500ml inj | Seoul National University Hospital | Recruiting | 30 Years | 80 Years | Both | 20 | Phase 4 | Korea, Republic of | |
700 | NCT01336088 | April 2011 | 19 February 2015 | ADX48621 for the Treatment of Levodopa Induced Dyskinesia in Patients With Parkinson's Disease | Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of ADX48621 in the Treatment of Levodopa Induced Dyskinesia in Patients With Parkinson's Disease | Parkinson's Disease | Drug: ADX48621;Drug: Placebo | Addex Pharma S.A. | Not recruiting | 30 Years | 75 Years | Both | 83 | Phase 2 | United States;Austria;France;Germany | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
701 | NCT01338896 | April 2011 | 19 February 2015 | Study to Compare Adhesiveness of Two Different Rotigotine Patch Formulations | A Multicenter, Randomized, Double-blind, Two-way Cross-over Study to Compare the Adhesiveness of Two Different Rotigotine Patch Formulations in Subjects With Parkinson's Disease | Parkinson's Disease | Drug: Rotigotine transdermal patch | UCB Pharma | Not recruiting | 18 Years | N/A | Both | 56 | Phase 1 | Austria;Germany;United Kingdom | |
702 | NCT01662414 | April 2011 | 19 February 2015 | Effect of Undenatured Cysteine-Rich Whey Protein Isolate (HMS 90®) in Patients With Parkinson's Disease | Effect of Undenatured Cysteine-Rich Whey Protein Isolate (HMS 90®) in Patients With Parkinson's Disease: Changes in Biomarkers of Oxidative Stress, Profiles of Plasma Amino Acids and Their Derivatives and Brain Function | Parkinson Disease;Parkinsonian Disorders;Basal Ganglia Diseases;Brain Diseases;Central Nervous System Diseases;Nervous System Diseases;Movement Disorders;Neurodegenerative Diseases | Dietary Supplement: Whey protein;Dietary Supplement: Soy protein | Chulalongkorn University | Not recruiting | 30 Years | 80 Years | Both | 38 | Phase 4 | Thailand | |
703 | NCT01937078 | April 2011 | 19 February 2015 | Famotidine for Levodopa-induced Dyskinesia in PD | An 'N-of-1' Study of the Histamine H@ Antagonist, Famotidine in Levodopa-induced Dyskinesia in Parkinson's Disease | Dyskinesia | Drug: Famotidine | University Health Network, Toronto | Not recruiting | 18 Years | 80 Years | Both | 7 | Phase 2 | Canada | |
704 | EUCTR2010-021394-37-DE | 08/03/2011 | 16 September 2013 | Placebo-controlled study in patients with Parkinson's disease to evaluate the effect of rotigotine on nonmotor symptoms | MULTICENTER, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL-GROUP, PHASE IV STUDY TO ASSESS THE EFFECT OF ROTIGOTINE ON NON-MOTOR SYMPTOMS IN PATIENTS WITH IDIOPATHIC PARKINSON’S DISEASE - SP0976 | Parkinson's disease MedDRA version: 14.1 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Neupro 2mg/24h transdermal patch Pharmaceutical Form: Transdermal patch INN or Proposed INN: ROTIGOTINE CAS Number: 99755-59-6 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 4.5- Pharmaceutical form of the placebo: Transdermal patch Route of administration of the placebo: Transdermal use Trade Name: Neupro 4mg/24h transdermal patch Pharmaceutical Form: Transdermal patch INN or Proposed INN: ROTIGOTINE CAS Number: 99755-59-6 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 9- Pharmaceutical form of the placebo: Transdermal patch Route of administration of the placebo: Transdermal use Trade Name: Neupro 6mg/24h transdermal patch Pharmaceutical Form: Transdermal patch INN or Proposed INN: ROTIGOTINE CAS Number: 99755-59-6 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 13.5- Pharmaceutical form of the placebo: Transdermal patch Route of administration of the placebo: Transdermal use Trade Name: Neupro 8mg/24h transdermal patch Pharmaceutical Form: Transdermal patch INN or Proposed INN: ROTIGOTINE CAS Number: 99755-59-6 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 18- Pharmaceutical form of the placebo: Transdermal patch Route of administration of the placebo: Transdermal use | UCB Pharma SA | Not Recruiting | Female: yes Male: yes | 345 | Phase 4 | Czech Republic;Hungary;Spain;Belgium;Austria;Bulgaria;Germany;Italy;Switzerland | |||
705 | NCT01227655 | March 2011 | 19 October 2017 | Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients. | Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With Wearing-off Phenomenon Treated With Levodopa Plus a Dopa Decarboxylase Inhibitor (DDCI): a Double-blind, Randomised, Placebo-controlled, Parallel-group, Multicentre Clinical Study. | Parkinson's Disease | Drug: BIA 9-1067;Drug: Placebo;Drug: Levodopa;Drug: Carbidopa;Drug: Benserazide | Bial - Portela C S.A. | Not recruiting | 30 Years | 83 Years | All | 427 | Phase 3 | Portugal | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
706 | NCT01264861 | March 2011 | 16 December 2017 | A Study to Evaluate Safinamide's Effect on Dopamine and Serotonin's Availability by Using Brain Imaging | Open-Label Escalating Dose Study Using [123|]ß-CIT SPECT Single Photon Emission Computerized Tomography (SPECT) to Evaluate Dopamine and Serotonin Transporter Occupancy by Safinamide in Parkinson Disease Patients | Parkinson Disease | Drug: Safinamide | Newron | Not recruiting | 40 Years | 80 Years | All | 5 | Phase 2 | United States | |
707 | NCT01280123 | March 2011 | 19 October 2017 | Pioglitazone in Early Parkinson's Disease | A Multi-Center, Double-Blind, Placebo-Controlled Phase II Study of Pioglitazone in Early Parkinson's Disease | Parkinson's Disease | Drug: Pioglitazone;Drug: placebo | University of Rochester | National Institute of Neurological Disorders and Stroke (NINDS);Michael J. Fox Foundation for Parkinson's Research | Not recruiting | 30 Years | N/A | All | 210 | Phase 2 | United States |
708 | NCT01283594 | March 2011 | 28 January 2019 | Safety and Efficacy Study of SYN115 in Parkinson's Patients Using Levodopa to Treat End of Dose Wearing Off | A Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of SYN115 as Adjunctive Therapy in Levodopa-treated Parkinson's Subjects With End of Dose Wearing Off | Parkinson's Disease | Drug: Tozadenant (SYN115) 60 mg BID;Drug: Placebo;Drug: Levodopa (L-dopa);Drug: Tozadenant (SYN115) 120 mg BID;Drug: Tozadenant (SYN115) 180 mg BID;Drug: Tozadenant (SYN115) 240 mg BID | Biotie Therapies Inc. | Not recruiting | 30 Years | 80 Years | All | 420 | Phase 2/Phase 3 | United States;Argentina;Canada;Chile;Romania;Ukraine | |
709 | NCT01323855 | March 2011 | 19 October 2017 | A Study to Assess Pharmacokinetics (PK) of Preladenant in Participants With Chronic Renal Impairment (CRI) (P06512) | A Study to Assess Pharmacokinetics of Preladenant in Subjects With Chronic Renal Impairment | Parkinson Disease | Drug: Preladenant | Merck Sharp & Dohme Corp. | Not recruiting | 18 Years | 75 Years | All | 46 | Phase 1 | Germany | |
710 | NCT01330290 | March 2011 | 19 October 2017 | Caregivers' and Physicians' Treatment Preference in Parkinson Patients Treated With Neupro® Requiring Caregiver Support | A Multi-site, Non-interventional, Cross-sectional Evaluation of the Caregivers' and the Physicians' Preferred Route of Administration and the Physicians' Rationale for the Choice of Neupro® in Patients With Parkinson Requiring Caregiver Support | Idiopathic Parkinson's Disease | Drug: Neupro® | UCB Pharma | Not recruiting | 18 Years | N/A | All | 148 | N/A | Germany | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
711 | NCT01341431 | March 2011 | 19 February 2015 | Bee Venom for the Treatment of Parkinson Disease | Evaluation of the Symptomatic and Neuroprotective Effects of Bee Venom for the Treatment of Parkinson Disease | Parkinson Disease | Drug: bee venom | Assistance Publique - Hôpitaux de Paris | Not recruiting | 40 Years | N/A | Both | 50 | Phase 2 | France | |
712 | EUCTR2010-022363-35-DE | 18/02/2011 | 19 March 2012 | Impact of Levodopa vs. Rotigotine on stress hormones and NGF in patients with Parkinson's Disease: A randomised, placebo-controlled double-blind trial. | Impact of Levodopa vs. Rotigotine on stress hormones and NGF in patients with Parkinson's Disease: A randomised, placebo-controlled double-blind trial. | Parkinson's disease MedDRA version: 12.1 Level: LLT Classification code 10013113 Term: Disease Parkinson's | Trade Name: Madopar LT Product Name: Levodopa / Benserazid Product Code: LD / BE Pharmaceutical Form: Dispersible tablet INN or Proposed INN: LEVODOPA CAS Number: 59-92-7 Current Sponsor code: LD Other descriptive name: - Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- INN or Proposed INN: BENSERAZIDE HYDROCHLORIDE CAS Number: 14919-77-8 Current Sponsor code: BE Other descriptive name: - Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 28.5- Trade Name: Neupro Product Name: Rotigotin Product Code: RO Pharmaceutical Form: Transdermal patch INN or Proposed INN: ROTIGOTINE CAS Number: 99755-59-6 Current Sponsor code: RO Other descriptive name: - Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 9- Pharmaceutical form of the placebo: Medicated plaster Route of administration of the placebo: Cutaneous use | Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University | Authorised | Female: yes Male: yes | Germany | |||||
713 | NCT01294800 | February 2011 | 19 October 2017 | A Dose Finding Study of Preladenant (SCH 420814) for the Treatment of Parkinson's Disease (PD) in Japanese Patients (P06402) | A Phase 2, 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Assess the Efficacy and Safety of Preladenant in Japanese Subjects With Moderate to Severe Parkinson's Disease. (Phase 2; Protocol No. P06402) | Parkinson's Disease | Drug: Preladenant;Drug: Placebo tablet to match Preladenant | Merck Sharp & Dohme Corp. | Not recruiting | 30 Years | 85 Years | All | 450 | Phase 2 | Japan | |
714 | NCT01296464 | February 2011 | 19 February 2015 | Comparing Different Levodopa/Carbidopa/Entacapone Treatment Regimens | Duration of Motor Response After Administration of Experimental Levodopa/Carbidopa/Entacapone Treatment Regimens Compared to Standard Treatment (Stalevo®);a Randomised,Double-blind,Crossover,Multicentre,Single Dose Study in Patients With Parkinson?s Disease and Wearing-off Symptoms | Parkinson's Disease | Drug: Carbidopa | Orion Corporation, Orion Pharma | Not recruiting | 30 Years | N/A | Both | 27 | Phase 2 | Finland;Sweden | |
715 | NCT01313845 | February 2011 | 19 February 2015 | Effect of Intravenous Amantadine on Gait Freezing in Parkinson's Disease | Randomized Double-blind Placebo-controlled Trial of Intravenous Amantadine on Gait Freezing in Patients With Parkinson's Disease | Parkinson's Disease | Drug: amantadine sulfate;Drug: 0.9% sodium chloride | Jee-Young Lee | Seoul National University Boramae Hospital;Samsung Medical Center;Seoul National University Bundang Hospital;Hanyang University | Not recruiting | 30 Years | 79 Years | Both | 46 | Phase 4 | Korea, Republic of |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
716 | NCT02880033 | February 2011 | 15 July 2019 | Oxidative Stress and Apoptosis of Energy Metabolism by Deferiprone From the Circulating Lymphocytes | Modulation of Oxidative Stress and Apoptosis of Energy Metabolism by Deferiprone From the Circulating Lymphocytes of Patients With Parkinson's Disease or Amyotrophic Lateral Sclerosis | Parkinson's Disease;Amyotrophic Lateral Sclerosis;Oxidative Stress;Iron Overload | Drug: deferiprone;Drug: placebo | University Hospital, Lille | Not recruiting | 18 Years | 80 Years | All | 90 | N/A | France | |
717 | EUCTR2010-022915-21-FI | 10/01/2011 | 19 March 2012 | Duration of motor response after administration of experimental levodopa/carbidopa/entacapone treatment regimens compared to standard treatment (Stalevo®); a randomised, double-blind, crossover, multicentre, single dose study in patients with Parkinson’s disease and wearing-off symptoms - PARTEST | Duration of motor response after administration of experimental levodopa/carbidopa/entacapone treatment regimens compared to standard treatment (Stalevo®); a randomised, double-blind, crossover, multicentre, single dose study in patients with Parkinson’s disease and wearing-off symptoms - PARTEST | Parkinson's disease MedDRA version: 12.1 Level: LLT Classification code 10013113 Term: Disease Parkinson's | Product Name: carbidopa 20 mg Product Code: NA Pharmaceutical Form: Capsule* INN or Proposed INN: CARBIDOPA CAS Number: 38821-49-7 Current Sponsor code: NA Other descriptive name: NA Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use Product Name: carbidopa 27.5 mg Product Code: NA Pharmaceutical Form: Capsule* INN or Proposed INN: CARBIDOPA CAS Number: 38821-49-7 Current Sponsor code: NA Other descriptive name: NA Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 27.5- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use Trade Name: Stalevo 100/25/200 mg Product Name: NA Product Code: NA Pharmaceutical Form: Tablet INN or Proposed INN: LEVODOPA CAS Number: 59-92-7 Current Sponsor code: NA Other descriptive name: NA Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- INN or Proposed INN: CARBIDOPA CAS Number: 38821-49-7 Current Sponsor code: NA Other descriptive name: NA Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- INN or Proposed INN: ENTACAPONE CAS Number: 130929-57-6 Current Sponsor code: NA Other descriptive name: NA Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- Trade Name: Stalevo 150/37.5/200 mg Product Name: NA Product Code: NA Pharmaceutical Form: Tablet INN or Proposed INN: LEVODOPA CAS Number: 59-92-7 Current Sponsor code: NA Other descriptive name: NA Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- INN or Proposed INN: CARBIDOPA CAS Number: 38821-49-7 Current Sponsor code: NA Other descriptive name: NA Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 37.5- INN or Proposed INN: ENTACAPONE CAS Number: 130929-57-6 Current Sponsor code: NA | Orion Corporation | Not Recruiting | Female: yes Male: yes | 27 | Finland;Sweden | ||||
718 | NCT01229332 | January 2011 | 19 February 2015 | A Safety, Tolerability and Pharmacokinetic Study of ND0611 on the Top of Different Oral Dosage Forms of Levodopa/Carbidopa in Parkinson's Disease Patients | A Phase I/II, Single-center, Randomized, Cross-over, Double-blind, Placebo-controlled Study Evaluating Safety, Tolerability and Pharmacokinetic Profile of Levodopa Following Administration of Subcutaneous Continuously-delivered Carbidopa Solution (ND0611) on the Top of Different Oral Dosage Forms of Levodopa/Carbidopa in Levodopa-treated Parkinson's Disease Patients With Motor Fluctuations | Parkinson's Disease | Drug: Saline;Drug: Carbidopa | NeuroDerm Ltd. | Not recruiting | 30 Years | N/A | Both | 24 | Phase 1/Phase 2 | Israel | |
719 | NCT01268891 | January 2011 | 19 October 2017 | Study of Azilect® (Rasagiline) in Levodopa-treated Parkinson's Disease Patients With Motor Fluctuations in Korea | Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study of [Azilect®] Rasagiline in Levodopa-treated Parkinson's Patients With Motor Fluctuations in Korea | Parkinson's Disease | Drug: Placebo;Drug: Azilect® | H. Lundbeck A/S | Not recruiting | 30 Years | N/A | All | 132 | Phase 3 | Korea, Republic of | |
720 | NCT01301573 | January 2011 | 19 February 2015 | Long Term Follow-Up Study for rAAV-GAD Treated Subjects | Parkinson's Disease | Biological: rAAV-GAD | Neurologix, Inc. | Not recruiting | 30 Years | 90 Years | Both | 40 | N/A | United States | ||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
721 | NCT01340885 | January 2011 | 19 February 2015 | Cognitive Decline in Non-demented PD | Cognitive Dysfunction in PD: Pathophysiology and Potential Treatments, a Pilot Study | Parkinson's Disease | Drug: Strattera;Drug: Exelon;Other: Placebo | Oregon Health and Science University | National Institute of Neurological Disorders and Stroke (NINDS) | Recruiting | 18 Years | N/A | Both | 50 | Phase 4 | United States |
722 | NCT01489982 | January 2011 | 28 April 2015 | Treatments for Insomnia in Patients With Parkinson's Disease | Treatments for Insomnia in Patients With Parkinson's Disease: A Pilot Study | Parkinson's Disease;Insomnia | Device: Light box (Litebook company);Behavioral: CBT and sleep hygiene;Drug: Doxepin and Zopiclone;Device: Light box ( Litebook company) | McGill University Health Center | Not recruiting | 18 Years | N/A | Both | 20 | Phase 0 | Canada | |
723 | NCT01003002 | December 2010 | 18 April 2016 | Natural History of Levodopa-Induced Dyskinesia (LID) | Determining the Natural History of Levodopa-Induced Dyskinesia (LID) | Parkinson's Disease | Drug: Levodopa (delivered intravenously) | Oregon Health and Science University | Oregon Clinical and Translational Research Institute | Not recruiting | 21 Years | 100 Years | Both | 0 | N/A | United States |
724 | NCT01244269 | December 2010 | 19 February 2015 | The Effect of Methylphenidate on Non-motor Symptoms and Postural Control in Parkinson's Disease. | Two-phase Randomized Controlled Trial of Low and Moderate Dose Methylphenidate for Non-motor and Postural Symptoms in Parkinson's Disease. | Parkinson's Disease | Drug: Methylphenidate;Drug: Placebo 10;Drug: Placebo 20 | Laval University | Fonds de la Recherche en Santé du Québec;Quebec Memory and Motor Skills Disorders Research Center | Not recruiting | N/A | 75 Years | Both | 6 | Phase 4 | Canada |
725 | NCT01256905 | December 2010 | 19 February 2015 | Attention Modulation for Treatment of Parkinson's Disease and Dementia With Lewy Bodies | Attention Modulation for Treatment of Parkinson's Disease and Dementia With Lewy Bodies | Parkinsons Disease;Lewy Bodies Disease | Drug: Armodafinil | New York University | Cephalon | Recruiting | 50 Years | 80 Years | Both | 20 | N/A | United States |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
726 | EUCTR2010-020109-34-ES | 29/11/2010 | 19 March 2012 | Estudio Fase II, doble ciego, aleatorizado, controlado con placebo, de grupos paralelos, para explorar los posibles efectos beneficiosos de safinamida en la cognición, en pacientes no dementes con enfermedad de Parkinson (EP) idiopática y deterioro cognitivo. A double-blind, randomized, placebo-controlled, parallel-group Phase II study to explore the potential beneficial effects of safinamide on cognition in non-demented patients with idiopathic Parkinson's disease (PD) and cognitive impairment. | Estudio Fase II, doble ciego, aleatorizado, controlado con placebo, de grupos paralelos, para explorar los posibles efectos beneficiosos de safinamida en la cognición, en pacientes no dementes con enfermedad de Parkinson (EP) idiopática y deterioro cognitivo. A double-blind, randomized, placebo-controlled, parallel-group Phase II study to explore the potential beneficial effects of safinamide on cognition in non-demented patients with idiopathic Parkinson's disease (PD) and cognitive impairment. | Cognition in non-demented patients with idiopathic Parkinson's disease Cognición en sujetos no dementes con Enfermedad de Parkinson idiopática MedDRA version: 12.1 Level: LLT Classification code 10061536 Term: Parkinson's disease | Product Name: Safinamida Product Code: NW-1015 Pharmaceutical Form: Film-coated tablet CAS Number: 133865-89-1 Current Sponsor code: NW-1015 Other descriptive name: Safinamida Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use | Merck Serono S.A. - Geneva | Authorised | Female: yes Male: yes | 100 | Phase 2 | Spain;Italy | |||
727 | EUCTR2010-021860-13-HU | 11/11/2010 | 19 January 2015 | EFFICACY AND SAFETY OF BIA 9-1067 IN IDIOPATHIC PARKINSON’S DISEASE PATIENTS WITH “WEARING-OFF” PHENOMENON TREATED WITH LEVODOPA PLUS A DOPA DECARBOXYLASE INHIBITOR (DDCI): A DOUBLE-BLIND, RANDOMISED, PLACEBO- AND ACTIVE-CONTROLLED, PARALLEL-GROUP, MULTICENTRE CLINICAL STUDY - BIPARK STUDY I | EFFICACY AND SAFETY OF BIA 9-1067 IN IDIOPATHIC PARKINSON’S DISEASE PATIENTS WITH “WEARING-OFF” PHENOMENON TREATED WITH LEVODOPA PLUS A DOPA DECARBOXYLASE INHIBITOR (DDCI): A DOUBLE-BLIND, RANDOMISED, PLACEBO- AND ACTIVE-CONTROLLED, PARALLEL-GROUP, MULTICENTRE CLINICAL STUDY - BIPARK STUDY I | Adjunct to levodopa (L-DOPA)/DDCI for use in patients with Parkinson’s disease (PD) and end-of-dose motor fluctuations. MedDRA version: 12.1 Level: LLT Classification code 10061536 Term: Parkinson's disease | Product Name: BIA 9-1067 Product Code: BIA 9-1067 Pharmaceutical Form: Capsule* INN or Proposed INN: BIA 9-1067 CAS Number: 923287-50-7 Current Sponsor code: BIA 9-1067 Other descriptive name: BIA 9-1067 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use Trade Name: Comtan® Product Name: Over-encapsulated Entacapone Tablets Product Code: Over-encapsulated Entacapone Tablets Pharmaceutical Form: Capsule* INN or Proposed INN: ENTACAPONE CAS Number: 130929-57-6 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use Product Name: BIA 9-1067 Product Code: BIA 9-1067 Pharmaceutical Form: Capsule* INN or Proposed INN: BIA 9-1067 CAS Number: 923287-50-7 Current Sponsor code: BIA 9-1067 Other descriptive name: BIA 9-1067 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use Product Name: BIA 9-1067 Product Code: BIA 9-1067 Pharmaceutical Form: Capsule* INN or Proposed INN: BIA 9-1067 CAS Number: 923287-50-7 Current Sponsor code: BIA 9-1067 Other descriptive name: BIA 9-1067 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use | BIAL - Portela & Ca, S.A. | Not Recruiting | Female: yes Male: yes | 550 | Portugal;Czech Republic;Hungary;Slovakia;Spain;Romania;Lithuania;Austria;Bulgaria;Germany;Latvia;Italy | ||||
728 | NCT01060878 | November 2010 | 19 February 2015 | Investigation of Cogane (PYM50028) in Early-stage Parkinson's Disease (CONFIDENT-PD) | Phase II, Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety and Tolerability of PYM50028 in Subjects With Early-stage Parkinson's Disease Administered Once Daily for 28 Weeks | Parkinson's Disease | Drug: PYM50028;Drug: Placebo | Phytopharm | Not recruiting | 35 Years | 75 Years | Both | 425 | Phase 2 | United States;Canada;Czech Republic;France;Germany;Hungary;Poland;Romania;Serbia;United Kingdom | |
729 | NCT01190553 | November 2010 | 19 February 2015 | Pilot Study of Maintenance Therapy With Intravenous AMANTADINE | Maintenance Therapy of Intravenous Amantadine in Patients With Idiopathic Parkinson Disease Who Are Not Optimally Treated With Anti Parkinson Medications | Parkinson Disease | Drug: Amantadine | Rabin Medical Center | Not recruiting | 30 Years | 80 Years | Both | 20 | N/A | ||
730 | NCT01215227 | November 2010 | 19 October 2017 | An Active-Controlled Extension Study to NCT01155466 [P04938] and NCT01227265 [P07037] (P06153) | A Phase 3, 40-Week, Active-Controlled, Double-Blind, Double-Dummy Extension Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (Phase 3, Protocol No. P06153) | Parkinson Disease;Idiopathic Parkinson Disease | Drug: Preladenant;Drug: Rasagiline;Drug: Placebo to preladenant;Drug: Placebo to rasagiline | Merck Sharp & Dohme Corp. | Not recruiting | 30 Years | 85 Years | All | 839 | Phase 3 | Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
731 | NCT01227265 | November 2010 | 19 October 2017 | Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037) | A Phase 3, 12 Week, Double-blind, Placebo-controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. | Parkinson Disease;Idiopathic Parkinson Disease;Idiopathic Parkinson's Disease | Drug: Preladenant;Drug: Placebo | Merck Sharp & Dohme Corp. | Not recruiting | 30 Years | 85 Years | All | 476 | Phase 3 | Argentina;Chile;Colombia;Croatia;Latvia;Lithuania;Mexico;Russian Federation;Serbia;South Africa;Ukraine;United States | |
732 | NCT01270711 | November 2010 | 19 October 2017 | Study On Utilization Of Cabergoline For Compliance With Risk Minimization Activities (SUCRE) | Study on Utilization Of Cabergoline For Compliance With Risk Minimization Activities (SUCRE) | Parkinson's Disease;Hyperprolactinemia | Drug: Study Drug | Pfizer | Not recruiting | N/A | N/A | All | 22014 | N/A | ||
733 | NCT01341080 | November 2010 | 16 December 2017 | Varenicline for Gait and Balance Impairment in Parkinson Disease | Varenicline for the Treatment of Postural and Gait Dysfunction in Parkinson Disease | Parkinson Disease | Drug: Varenicline;Drug: Sugar pill | Rush University Medical Center | Recruiting | 40 Years | 90 Years | All | 40 | Phase 2 | United States | |
734 | EUCTR2010-018534-44-GB | 22/10/2010 | 18 September 2012 | Investigation of Cogane (PYM50028) in early stage Parkinson's disease | A Phase II, multi-centre, randomised, double-blind, placebo-controlled, parallel group study to investigate the efficacy, safety and tolerability of Cogane™ (PYM50028), a novel, orally active neurotrophic factor inducer, in male and female subjects with early-stage Parkinson’s disease when administered once daily for 28 weeks - CONFIDENT-PD | Early-Stage Parkinson’s Disease MedDRA version: 14.1 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: PYM50028 Product Code: PYM50028 Pharmaceutical Form: Oral solution INN or Proposed INN: SMILAGENIN CAS Number: 126-18-1 Current Sponsor code: PYM50028 Other descriptive name: (3ß, 5ß, 25R)-spirostan-3-ol Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 3- Pharmaceutical form of the placebo: Oral solution Route of administration of the placebo: Oral use Product Name: PYM50028 Product Code: PYM50028 Pharmaceutical Form: Oral solution INN or Proposed INN: SMILAGENIN CAS Number: 126-18-1 Current Sponsor code: PYM50028 Other descriptive name: (3ß, 5ß, 25R)-spirostan-3-ol Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 6- Pharmaceutical form of the placebo: Oral solution Route of administration of the placebo: Oral use Product Name: PYM50028 Product Code: PYM50028 Pharmaceutical Form: Oral solution INN or Proposed INN: SMILAGENIN CAS Number: 126-18-1 Current Sponsor code: PYM50028 Other descriptive name: (3ß, 5ß, 25R)-spirostan-3-ol Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 9- Pharmaceutical form of the placebo: Oral solution Route of administration of the placebo: Oral use | Phytopharm plc | Authorised | Female: yes Male: yes | 408 | Phase 2 | Poland;United States;Romania;France;Serbia;Canada;United Kingdom;Czech Republic;Germany;Hungary | |||
735 | EUCTR2009-015928-28-SE | 07/10/2010 | 22 October 2012 | A double-blind, randomized, placebo controlled, dose finding study of oral eltoprazine for treatment of levodopa-induced dyskinesias (LID) in a levodopa challenge-dose setting in Parkinsons Disease. - ELTODYS09 | A double-blind, randomized, placebo controlled, dose finding study of oral eltoprazine for treatment of levodopa-induced dyskinesias (LID) in a levodopa challenge-dose setting in Parkinsons Disease. - ELTODYS09 | Dyskinesias related to levodopa treatment in Parkinson´s disease | Product Name: Eltoprazine HCl Product Code: Eltoprazine HCl Pharmaceutical Form: Capsule, hard Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use | PsychoGenics Inc | Not Recruiting | Female: yes Male: yes | 24 | Sweden | ||||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
736 | NCT01192529 | October 2010 | 19 February 2015 | Evaluation of a Diet in Patients With Senile Dementia | Clinical Evaluation of an Specific Diet for People With Dementia Disease | Alzheimer's Disease;Parkinson's Disease;Senile Dementia | Dietary Supplement: Supressi. T-Diet plus Range;Dietary Supplement: High Protein. T-Diet plus Range | Vegenat, S.A. | Recruiting | 70 Years | N/A | Both | 184 | N/A | Spain | |
737 | NCT01216904 | October 2010 | 19 February 2015 | Nicotine Treatment of Impulsivity in Parkinson's Disease | Nicotine Treatment of Impulsivity in Parkinson's Disease: A Pilot Study | Parkinson's Disease | Drug: nicotine patch;Drug: placebo | University of Vermont | Parkinson's Disease Foundation;The Parkinson Study Group | Recruiting | 18 Years | N/A | Both | 20 | Phase 4 | United States |
738 | EUCTR2009-017238-39-FR | 15/09/2010 | 3 April 2012 | A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) in Advanced Parkinson’s Disease | A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) in Advanced Parkinson’s Disease | Idiopathic Parkinson’s Disease (paralysis agitans) MedDRA version: 12.1 Level: LLT Classification code 10061536 Term: Parkinson's disease | Product Name: IPX066 Product Code: IPX066-95 Pharmaceutical Form: Capsule, hard INN or Proposed INN: CARBIDOPA CAS Number: 38821-49-7 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 23.75- INN or Proposed INN: LEVODOPA CAS Number: 59-92-7 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 95- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Product Name: IPX066 Product Code: IPX066-145 Pharmaceutical Form: Capsule, hard INN or Proposed INN: CARBIDOPA CAS Number: 38821-49-7 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 36.25- INN or Proposed INN: LEVODOPA CAS Number: 59-92-7 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 145- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Product Name: IPX066 Product Code: IPX066-195 Pharmaceutical Form: Capsule, hard INN or Proposed INN: CARBIDOPA CAS Number: 38821-49-7 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 48.75- INN or Proposed INN: LEVODOPA CAS Number: 59-92-7 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 195- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Product Name: IPX066 Product Code: IPX066-245 Pharmaceutical Form: Capsule, hard INN or Proposed INN: CARBIDOPA CAS Number: 38821-49-7 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 61.25- INN or Proposed INN: LEVODOPA CAS Number: 59-92-7 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 245- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Trade Name: Nacom 100 Pharmaceutical Form: Tablet INN or Proposed INN: CARBIDOPA CAS Number: 38821-49-7 Concentration unit: mg milligram(s) | Impax Laboratories, Inc., acting through its Impax Pharmaceuticals Division (Impax) | Authorised | Female: yes Male: yes | 56 | Germany;France;Italy | ||||
739 | NCT01162226 | September 2010 | 19 February 2015 | Computer-Based Balance Training for People With Parkinson's Disease | PD Wii: Computer-based Gait and Balance Training for Parkinson's Patients. | Parkinson's Disease | Behavioral: gait and balance training program | University of California, San Francisco | National Institute of Neurological Disorders and Stroke (NINDS) | Not recruiting | N/A | N/A | Both | 62 | Phase 2 | United States |
740 | NCT01211587 | September 2010 | 19 February 2015 | A Trial to Explore the Potential Benefit of Safinamide on Cognitive Impairment Associated With Parkinson's Disease | A Double-blind, Randomized, Placebo-controlled, Parallel-group Phase II Study to Explore the Potential Beneficial Effects of Safinamide on Cognition in Non-demented Patients With Idiopathic Parkinson's Disease (PD) and Cognitive Impairment | Parkinson's Disease With Cognitive Impairments | Drug: safinamide;Drug: placebo | Newron | Not recruiting | 45 Years | 80 Years | Both | 103 | Phase 2 | United States;Spain | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
741 | NCT01536574 | September 2010 | 16 December 2017 | Open-Label Extension Study With REQUIP PR for Subjects From Study ROP111528 | An Open Label Extension Study With REQUIP PR for Subjects From Study ROP111528 | Parkinson Disease | Drug: Requip PR | GlaxoSmithKline | Not recruiting | 30 Years | N/A | All | 295 | Phase 3 | China | |
742 | EUCTR2009-017253-35-GB | 20/08/2010 | 10 July 2015 | Long-term study of patients who received ProSavin in the PS1/001/07 clinical trial. | A multicentre, open-label extension study to determine the long term safety, tolerability and efficacy of ProSavin® in patients with bilateral, idiopathic Parkinson’s disease | Patients with bilateral, idiopathic Parkinson's Disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: ProSavin Pharmaceutical Form: Suspension for injection INN or Proposed INN: ProSavin | Oxford BioMedica (UK) Ltd | Authorised | Female: yes Male: yes | 27 | United Kingdom | ||||
743 | EUCTR2009-015161-31-FI | 17/08/2010 | 13 May 2013 | A Placebo- and Active Controlled Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (Study P04938) | A Phase 3, 12-Week, Double-Blind, Double-Dummy, Placebo- and Active-Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson’s Disease (Phase 3; Protocol No. P04938) | Parkinson's disease MedDRA version: 14.1 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Preladenant Product Code: SCH 420814 Pharmaceutical Form: Coated tablet INN or Proposed INN: Preladenant CAS Number: 377727-87-2 Current Sponsor code: SCH 420814 Concentration unit: mg milligram(s) Concentration type: range Concentration number: 2-10 Pharmaceutical form of the placebo: Coated tablet Route of administration of the placebo: Oral use Trade Name: Azilect Product Name: Azilect Pharmaceutical Form: Capsule, hard INN or Proposed INN: Rasagiline mesylate CAS Number: 161735-79-1 Other descriptive name: RASAGILINE MESYLATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Trade Name: Azilect Product Name: Azilect Product Code: N04BD02 Pharmaceutical Form: Capsule, hard INN or Proposed INN: Rasagiline mesylate CAS Number: 161735-79-1 Other descriptive name: RASAGILINE MESYLATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use | Schering-Plough Research Institute, a division of Schering Corporation | Not Recruiting | Female: yes Male: yes | 750 | Phase 3 | United States;Portugal;Finland;Spain;Turkey;Austria;Russian Federation;Israel;United Kingdom;Italy;India;France;Czech Republic;Canada;Poland;Brazil;Peru;Bulgaria;Germany;Netherlands;Sweden | |||
744 | EUCTR2010-020769-25-FR | 10/08/2010 | 19 March 2012 | Evaluation médico-économique de l’infusion continue intra-duodénale d’une forme gélifiée de levodopa dans le traitement des formes avancées et sévères de maladie de parkinson par l’intermédiaire d’un dispositif médical | Evaluation médico-économique de l’infusion continue intra-duodénale d’une forme gélifiée de levodopa dans le traitement des formes avancées et sévères de maladie de parkinson par l’intermédiaire d’un dispositif médical | Parkinson's disease MedDRA version: 12.1 Level: LLT Classification code 10034006 Term: Parkinson's disease aggravated | Trade Name: DUODOPA Pharmaceutical Form: Gel Pharmaceutical Form: INN or Proposed INN: LEVODOPA/CARBIDOPA CAS Number: 59-92-7 Pharmaceutical Form: INN or Proposed INN: LEVODOPA/BENZERASIDE CAS Number: 59-92-7 Pharmaceutical Form: INN or Proposed INN: PERGOLIDE CAS Number: 66104221 Pharmaceutical Form: INN or Proposed INN: LISURIDE CAS Number: 18016803 Pharmaceutical Form: INN or Proposed INN: BROMOCRIPTINE CAS Number: 25614033 Pharmaceutical Form: INN or Proposed INN: ROPINIROLE CAS Number: 91374219 Pharmaceutical Form: INN or Proposed INN: PRAMIPEXOLE CAS Number: 104632-26-0 Pharmaceutical Form: INN or Proposed INN: IPRONIAZID CAS Number: 54922 Pharmaceutical Form: CAS Number: 71320-77-9 Other descriptive name: MOCLOBEMIDE Pharmaceutical Form: INN or Proposed INN: AMANTADINE CAS Number: 768945 Pharmaceutical Form: INN or Proposed INN: CLOZAPINE CAS Number: 5786-21-0 Pharmaceutical Form: INN or Proposed INN: SELEGILINE CAS Number: 14611519 Pharmaceutical Form: INN or Proposed INN: RASAGILINE CAS Number: 136236-51-6 Pharmaceutical Form: INN or Proposed INN: ENTACAPONE CAS Number: 130929-57-6 Pharmaceutical Form: INN or Proposed INN: TOLCAPONE CAS Number: 134308-13-7 | CHU de Poitiers | Authorised | Female: yes Male: yes | France | |||||
745 | NCT01190735 | August 2010 | 28 April 2015 | Caffeine for Motor Manifestations of Parkinson's Disease | Caffeine for Motor Manifestations of Parkinson's Disease: An Open-Label Dose-Response Study. | Parkinson's Disease | Drug: Caffeine alkaloid | Ron Postuma | Canadian Institutes of Health Research (CIHR) | Not recruiting | 18 Years | N/A | Both | 28 | Phase 2 | Canada |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
746 | NCT01191944 | August 2010 | 19 October 2017 | Pramipexole Extended Release Versus Pramipexole Immediate Release for 18 Weeks in Chinese Parkinson's Disease (PD) Patients | A Double-blind, Double-dummy, Randomised, Parallel-group Study Comparing the Efficacy, Safety and Tolerability of Pramipexole Extended Release Versus Pramipexole Immediate Release Administered Orally for 18 Weeks in Chinese Parkinson's Disease (PD) Patients Who Can be Concomitantly Treated With Levodopa | Parkinson Disease | Drug: pramipexole immediate release tablet;Drug: pramipexole extended release tablet | Boehringer Ingelheim | Not recruiting | 30 Years | N/A | All | 475 | Phase 3 | China | |
747 | NCT01228851 | August 2010 | 19 February 2015 | Balance Training in Parkinson's Disease Using the Wii Balance Board | A Pilot Study of the Effects of Balance Training Using the Wii Balance Board on Balance and Ambulation in Adults With Parkinson's Disease | Parkinson's Disease | Other: Balance Training | Rehabilitation Institute of Chicago | Not recruiting | 18 Years | N/A | Both | 10 | N/A | United States | |
748 | NCT01785628 | August 2010 | 19 October 2017 | The Impact of Pharmacological and Electric Modulation of NMDA Pathway on the Cognitive Flexibility and Volitional Movement Preparation in Patients With Parkinson's Disease | Parkinson's Disease With Dementia | Dietary Supplement: Sarcosine Capsule;Dietary Supplement: Placebo Capsule | China Medical University Hospital | National Science Council, Taiwan | Not recruiting | N/A | N/A | All | 30 | N/A | Taiwan | |
749 | NCT01824056 | August 2010 | 19 February 2015 | The Differential Diagnosis of Parkinson's Disease and Parkinsonism by Positron-emission Tomography | The Differential Diagnosis of Parkinson's Disease and Parkinsonism by Positron-emission Tomography With Vesicular Monoamine Transporter Ligand (18F-DTBZ) | Parkinson's Disease | Drug: 18F-FDG | Chang Gung Memorial Hospital | National Science Council, Taiwan | Not recruiting | 20 Years | 80 Years | Both | 120 | Phase 2 | Taiwan |
750 | NCT01155466 | July 14, 2010 | 16 December 2017 | A Placebo- and Active Controlled Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (P04938) | A Phase 3, 12-Week, Double-Blind, Double-Dummy, Placebo- and Active-Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (Phase 3;Protocol No. P04938) | Parkinson Disease | Drug: Preladenant 2 mg tablet;Drug: Preladenant 5 mg tablet;Drug: Preladenant 10 mg tablet;Drug: Placebo to Preladenant Tablet;Drug: Rasagiline 1 mg capsule;Drug: Placebo to Rasagiline capsule | Merck Sharp & Dohme Corp. | Not recruiting | 30 Years | 85 Years | All | 778 | Phase 3 | Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Japan;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
751 | EUCTR2010-018650-12-FR | 13/07/2010 | 3 October 2016 | Evaluation du système noradrénergique dans l’altération de la perception douloureuse chez le patient Parkinsonien - DOULOX | Evaluation du système noradrénergique dans l’altération de la perception douloureuse chez le patient Parkinsonien - DOULOX | maladie de Parkinson MedDRA version: 12.1 Level: LLT Classification code 10013113 Term: Disease Parkinson's | Trade Name: CYMBALTA Product Name: duloxetine Pharmaceutical Form: Capsule* Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use Trade Name: APOKINON Product Name: apomorphine Pharmaceutical Form: Solution for injection Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Trade Name: MODOPAR Product Name: levodopa Pharmaceutical Form: Tablet Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Trade Name: MOTILIUM Product Name: dompéridone Pharmaceutical Form: Tablet | CHU de Toulouse | Not Recruiting | Female: yes Male: yes | Phase 3 | France | ||||
752 | EUCTR2009-017182-38-LT | 10/07/2010 | 19 March 2012 | An Open-Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects with Parkinson´s Disease | An Open-Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects with Parkinson´s Disease | Idiopathic Parkinson´s disease (paralysis agitans) MedDRA version: 12.1 Level: LLT Classification code 10061536 Term: Parkinson's disease | Product Name: IPX066 Product Code: IPX066-95 Pharmaceutical Form: Capsule* INN or Proposed INN: CARBIDOPA CAS Number: 38821-49-7 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 23.75- INN or Proposed INN: LEVODOPA CAS Number: 59-92-7 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 95- Product Name: IPX066 Product Code: IPX066-145 Pharmaceutical Form: Capsule* INN or Proposed INN: CARBIDOPA CAS Number: 38821-49-7 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 36.25- INN or Proposed INN: LEVODOPA CAS Number: 59-92-7 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 145- Product Name: IPX066 Product Code: IPX066-195 Pharmaceutical Form: Capsule* INN or Proposed INN: CARBIDOPA CAS Number: 38821-49-7 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 48.75- INN or Proposed INN: LEVODOPA CAS Number: 59-92-7 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 195- Product Name: IPX066 Product Code: IPX066-245 Pharmaceutical Form: Capsule* INN or Proposed INN: CARBIDOPA CAS Number: 38821-49-7 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 61.25- INN or Proposed INN: LEVODOPA CAS Number: 59-92-7 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 245- | Impax Laboratories, Inc. acting through its Impax Pharmaceutical Division (Impax) | Not Recruiting | Female: yes Male: yes | 500 | Germany;Estonia;Spain;Latvia;Poland;Lithuania | ||||
753 | NCT01155479 | July 6, 2010 | 16 December 2017 | A Placebo- and Active-Controlled Study of Preladenant in Early Parkinson's Disease (PD) (P05664) | A Phase 3, Double-Blind, Double-Dummy, Placebo- and Active-Controlled Dose-Range-Finding Efficacy and Safety Study of Preladenant in Subjects With Early Parkinson's Disease | Parkinson Disease | Drug: Preladenant 2 mg tablet;Drug: Preladenant 5 mg tablet;Drug: Preladenant 10 mg tablet;Drug: Rasagiline 1 mg capsule;Drug: Placebo for Rasagiline 1 mg capsule;Drug: Placebo for Preladenant | Merck Sharp & Dohme Corp. | Not recruiting | 30 Years | 85 Years | All | 1022 | Phase 3 | Argentina;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Peru;Poland;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States | |
754 | NCT01149811 | July 2010 | 19 February 2015 | A Study Comparing the Safety and Tolerability of Two Doses of Fipamezole in Adult Patients With Parkinson's Disease | A Randomized, Double-Blind, Crossover Study Comparing the Safety and Tolerability of Two Dose Regimens of Oromucosal Fipamezole ODT in Adult Patients With Parkinson's Disease Who Are Receiving Levodopa | Parkinson's Disease | Drug: Fipamezole ODT;Drug: Fipamezole ODT Cohort 2 | Valeant Pharmaceuticals International, Inc. | Not recruiting | 30 Years | 75 Years | Both | 27 | Phase 1/Phase 2 | United States | |
755 | NCT01171313 | July 2010 | 19 February 2015 | A Efficacy, Safety and Pharmacokinetic Study of XP21279 and Sinemet® in Parkinson's Disease Subjects | A Phase 2 Efficacy, Safety and Pharmacokinetic Study of XP21279 BL2 and Sinemet® in Parkinson's Disease Subjects With Motor Fluctuations | Parkinson's Disease | Drug: XP21279 and carbidopa (experimental);Drug: Sinemet (comparator);Drug: Placebo for XP21279 and carbidopa;Drug: Placebo for Sinemet | XenoPort, Inc. | Not recruiting | 30 Years | 80 Years | Both | 35 | Phase 2 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
756 | NCT01174004 | July 2010 | 19 October 2017 | A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis | A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of Pimavanserin in the Treatment of Psychosis in Parkinson's Disease | Parkinson's Disease Psychosis | Drug: pimavanserin tartrate;Drug: placebo | ACADIA Pharmaceuticals Inc. | Not recruiting | 40 Years | N/A | All | 199 | Phase 3 | United States;Canada | |
757 | NCT01435915 | June 28, 2010 | 2 July 2018 | Ropinirole PR Pharmacokinetics Study Among Chinese Healthy Subjects | A Single Dose and Repeat Dose Study to Investigate the Pharmacokinetics of Ropinirole After Single and Multiple Doses of a PR-formulation in Chinese Healthy Male and Female Subjects | Parkinson Disease | Drug: Ropinirole | GlaxoSmithKline | Not recruiting | 18 Years | 45 Years | All | 24 | Phase 1 | China | |
758 | NCT01140841 | June 2010 | 19 February 2015 | A Study of Safety and Tolerability of Fipamezole in Adult Subjects With Parkinson's Disease Who Are Receiving Levodopa | A Randomized, Double-Blind, Placebo-Controlled, Ascending Dose-Escalation Study of Safety and Tolerability of Oromucosal Fipamezole ODT in Adult Subjects With Parkinson's Disease Who Are Receiving Levodopa | Parkinson's Disease | Drug: Fipamezole ODT;Drug: Placebo | Valeant Pharmaceuticals International, Inc. | Not recruiting | 30 Years | 75 Years | Both | 40 | Phase 1 | United States | |
759 | NCT01141023 | June 2010 | 26 August 2019 | Study to Identify Clinical, Imaging and Biologic Markers of Parkinson Disease Progression | The Parkinson's Progression Markers Initiative (PPMI) | Parkinson Disease | Drug: DaTscan | Ken Marek, MD | Institute for Neurodegenerative Disorders | Recruiting | 30 Years | N/A | All | 680 | Phase 2 | United States;Australia;Austria;France;Germany;Greece;Israel;Italy;Norway;Spain;United Kingdom |
760 | NCT01176240 | June 2010 | 19 October 2017 | A Two Part Study (306A/306B) to Assess Droxidopa in Treatment of NOH in Patients With Parkinson's Disease | A Multi-center, Double-blind, Randomized, Parallel-Group, Placebo-Controlled Study to Assess the Clinical Effect of Droxidopa in the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Patients With Parkinson's Disease | Orthostatic Hypotension;Parkinson's Disease | Drug: Droxidopa;Other: Placebo | Chelsea Therapeutics | Not recruiting | 18 Years | N/A | All | 225 | Phase 3 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
761 | NCT01227681 | June 2010 | 19 October 2017 | Study of the Neuro-protective Effect of Granulocyte-colony Stimulating Factor on Early Stage Parkinson's Disease | A Double-Blind, Placebo-Control, Study of the Neuro-protective Effect of Granulocyte-colony Stimulating Factor on Early Stage Parkinson's Disease | Parkinson Disease | Drug: G-CSF;Drug: Placebo | Buddhist Tzu Chi General Hospital | Not recruiting | 40 Years | 65 Years | All | 4 | Phase 2 | Taiwan | |
762 | EUCTR2010-018904-94-IT | 31/05/2010 | 27 January 2014 | EFFICACY AND SAFETY OF INTRAMUSCULAR NERIDRONATE IN OSTEOPOROTIC PATIENTS AFFECTED BY PARKINSON'S DISEASE | EFFICACY AND SAFETY OF INTRAMUSCULAR NERIDRONATE IN OSTEOPOROTIC PATIENTS AFFECTED BY PARKINSON'S DISEASE | Osteoporosis in patients affected by Parkinson's disaease at the stages 1-2-3-4 following Hoehn and Yahr criteria MedDRA version: 14.1 Level: SOC Classification code 10028395 Term: Musculoskeletal and connective tissue disorders System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] | Trade Name: NERIXIA*IM EV 1F 25MG Pharmaceutical Form: Solution for injection INN or Proposed INN: Bisphosphonates Other descriptive name: Neridronic acid Concentration unit: mg milligram(s) Concentration number: 25- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Intramuscular use | FONDAZIONE SALVATORE MAUGERI - CLINICA DEL LAVORO E DELLA RIABILITAZIONE | Authorised | Female: yes Male: yes | Italy | |||||
763 | EUCTR2010-019354-40-AT | 26/05/2010 | 19 March 2012 | Überprüfung des Einflusses der STN-Stimulation auf die Schmerzschwelle von Patienten mit Idiopathischem Parkinsonsyndrom | Überprüfung des Einflusses der STN-Stimulation auf die Schmerzschwelle von Patienten mit Idiopathischem Parkinsonsyndrom | Parkinson's disease MedDRA version: 12.1 Level: LLT Classification code 10013113 Term: Disease Parkinson's | Trade Name: Madopar Pharmaceutical Form: Film-coated tablet INN or Proposed INN: LEVODOPA CAS Number: 59-92-7 Concentration unit: Ci/mg curie(s)/milligram Concentration type: range Concentration number: 50-200 INN or Proposed INN: BENSERAZIDE CAS Number: 322350 Concentration unit: Ci/mg curie(s)/milligram Concentration type: range Concentration number: 12,5-50 | Universitätsklinik für Neurologie Innsbruck | Not Recruiting | Female: yes Male: yes | 15 | Austria | ||||
764 | EUCTR2010-019396-29-IT | 18/05/2010 | 27 January 2014 | Levodopa and Pramipexole dministration modalities in patients affected by parkinson desease. | Levodopa Administration Modalities and Pramipexole in Parkinson's Disease (LAMP-PD study) A multicenter, randomized, four parallel groups, active-controlled, open-label study to evaluate the risk of dyskinesia in early PD. - LAMP-PD | Patients with idiopathic Parkinson's Disease.;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Pharmaceutical Form: Tablet INN or Proposed INN: Levodopa and decarboxylase inhibitor Concentration unit: mg milligram(s) Concentration number: 125- Trade Name: COMTAN Pharmaceutical Form: Tablet INN or Proposed INN: Entacapone Concentration unit: mg milligram(s) Concentration number: 200- Pharmaceutical Form: Tablet INN or Proposed INN: Levodopa and decarboxylase inhibitor Concentration unit: mg milligram(s) Concentration number: 125- Trade Name: STALEVO*100CPR 50/12,5/200MG Pharmaceutical Form: Tablet INN or Proposed INN: Levodopa, decarboxylase inhibitor and COMT inhibitor Concentration unit: mg milligram(s) Concentration number: 262.5- Trade Name: STALEVO*100CPR 100/25/200MG Pharmaceutical Form: Tablet INN or Proposed INN: Levodopa, decarboxylase inhibitor and COMT inhibitor Concentration unit: mg milligram(s) Concentration number: 325- Pharmaceutical Form: Tablet INN or Proposed INN: Levodopa and decarboxylase inhibitor Concentration unit: mg milligram(s) Concentration number: 275- Pharmaceutical Form: Tablet INN or Proposed INN: Levodopa and decarboxylase inhibitor Concentration unit: mg milligram(s) Concentration number: 275- Pharmaceutical Form: Tablet INN or Proposed INN: Levodopa and decarboxylase inhibitor Concentration unit: mg milligram(s) Concentration number: 275- Pharmaceutical Form: Tablet INN or Proposed INN: Levodopa and decarboxylase inhibitor Concentration unit: mg milligram(s) Concentration number: 275- Pharmaceutical Form: Tablet INN or Proposed INN: Levodopa and decarboxylase inhibitor Concentration unit: mg milligram(s) Concentration number: 125- Pharmaceutical Form: Tablet INN or Proposed INN: Levodopa and decarboxylase inhibitor Concentration unit: mg milligram(s) Concentration number: 125- Pharmaceutical Form: Tablet INN or Proposed INN: Levodopa and decarboxylase inhibitor Concentration unit: mg milligram(s) Concentration number: 125- Pharmaceutical Form: Tablet INN or Proposed INN: Levodopa and decarboxylase inhibitor | AZIENDA OSPEDALIERO-UNIVERSITARIA POLICLINICO-VITTORIO EMANUELE | Authorised | Female: yes Male: yes | Italy | |||||
765 | JPRN-UMIN000003601 | 2010/05/01 | 2 April 2019 | Comparative study of ropinirole and entacapone for the treatment of wearing-off in advanced Parkinson's disease patients | Parkinson's disease | Increase dosage of ropinirole Addition of entacapone | Kansai Medical University | Not Recruiting | 20years-old | 75years-old | Male and Female | 30 | Not selected | Japan | ||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
766 | NCT01130493 | May 2010 | 4 November 2019 | A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066 | A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066 in Advanced Parkinson's Disease | Parkinson's Disease | Drug: IPX066;Drug: CLE | Impax Laboratories, LLC | Not recruiting | 30 Years | N/A | All | 110 | Phase 3 | United States;France;Germany;Italy | |
767 | NCT01283347 | May 2010 | 19 February 2015 | 18F-DTBZ for l Diagnosis of Parkinson's Disease and Monitoring the Severity of Disease by VMAT2 PET Imaging | Phase II Study of 18F-DTBZ: The Differential Diagnosis of Parkinson's Disease and Monitoring the Severity of Disease by VMAT2 PET Imaging | Parkinson's Disease | Drug: 18F-DTBZ | Chang Gung Memorial Hospital | Not recruiting | 50 Years | 80 Years | Both | 100 | Phase 2 | Taiwan | |
768 | NCT01532115 | May 2010 | 19 February 2015 | Effect of BIA 9-1067 on Cardiac Repolarization in Healthy Adult Men and Women | A Randomized, Double-blind, Placebo-controlled and Open-label Active-controlled, 4-period Crossover Trial to Evaluate the Effect of BIA 9-1067 on Cardiac Repolarization in Healthy Adult Men and Women | Parkinson Disease | Drug: BIA 9-1067;Drug: Placebo;Drug: moxifloxacin | Bial - Portela C S.A. | Not recruiting | 18 Years | 55 Years | Both | 64 | Phase 1 | France | |
769 | EUCTR2009-018137-37-GB | 14/04/2010 | 20 March 2012 | An open label, single site, 12 month, Phase II, randomised controlled trial evaluating the safety and efficacy of Exendin-4 (Exenatide) in the treatment of patients with moderate severity Parkinson's disease. - Exendin-4 as a treatment for Parkinson's disease- pilot trial | An open label, single site, 12 month, Phase II, randomised controlled trial evaluating the safety and efficacy of Exendin-4 (Exenatide) in the treatment of patients with moderate severity Parkinson's disease. - Exendin-4 as a treatment for Parkinson's disease- pilot trial | Parkinson's disease MedDRA version: 14.1 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders | Trade Name: Byetta 5 micrograms Product Name: Exenatide 5 micrograms Pharmaceutical Form: Solution for injection Trade Name: Exenatide 10 micrograms Product Name: Exenatide 10 micrograms Pharmaceutical Form: Solution for injection | University College London | Authorised | Female: yes Male: yes | Phase 2 | United Kingdom | ||||
770 | JPRN-JapicCTI-101198 | 01/4/2010 | 2 April 2019 | A double-blind confirmatory study for AD-810N (zonisamide) in patients with Parkinson's disease (Phase III) | A double-blind confirmatory study for AD-810N (zonisamide) in patients with Parkinson's disease (Phase III) | Parkinson's disease | Intervention name : Zonisamide Dosage And administration of the intervention : Oral Control intervention name : null | Dainippon Sumitomo Pharma Co., Ltd. | 20 | 74 | BOTH | 360 | Phase 3 | |||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
771 | NCT00988117 | April 2010 | 19 October 2017 | The Effects of the Rivastigmine Patch on Parkinson's Disease With Memory and/or Thinking Problems | The Effects of the Rivastigmine Patch on Attention and Behavior in Parkinson's Disease With Dementia (PDD) | Parkinsons Disease With Dementia;Parkinsons Disease With Mild to Moderate Memory and/or Thinking Problems | Drug: Rivastigmine Patch 9.5 cm2 | University of California, San Francisco | Novartis | Not recruiting | 55 Years | N/A | All | 15 | Phase 4 | United States |
772 | NCT01103011 | April 2010 | 19 February 2015 | Safety, Tolerability and Pharmacokinetic Profile of Levodopa Administered With Continuous Administration of ND0611 | A Phase I, Single Center, Blinded, Controlled Study Evaluating Safety, Tolerability and Pharmacokinetic Profile of Levodopa Following Repeated Administration of Oral Levodopa/Carbidopa and Continuously Delivered ND0611 | Parkinson's Disease | Drug: ND0611 | NeuroDerm Ltd. | Not recruiting | 18 Years | 50 Years | Male | 8 | Phase 1 | Israel | |
773 | NCT01113320 | April 2010 | 19 February 2015 | Safinamide in Levodopa Induced Dyskinesia in Parkinson's Disease Subjects | A Double-blind, Randomized, Placebo-controlled, Parallel-group, Dose Escalation Trial to Explore the Potential Antidyskinetic Properties of Safinamide in Patients With Parkinson's Disease Suffering From Levodopa Induced Dyskinesias | Parkinson's Disease | Drug: Placebo;Drug: Safinamide | Newron | Not recruiting | 30 Years | N/A | Both | 26 | Phase 2 | Austria;Canada;France;Germany;South Africa | |
774 | NCT01484990 | April 2010 | 16 December 2017 | A Pharmacokinetic Study of Levodopa and Carbidopa Intestinal Gel in Subjects With Advanced Parkinson's Disease | A Pharmacokinetic Study of Levodopa and Carbidopa Intestinal Gel in Subjects With Advanced Parkinson's Disease | Parkinson Disease | Drug: Levodopa-Carbidopa | AbbVie | Quintiles, Inc. | Not recruiting | 30 Years | 99 Years | All | 19 | Phase 1 | Germany;Sweden |
775 | EUCTR2009-017174-20-DE | 15/03/2010 | 4 March 2013 | A trial to determine if safinamide can attenuate levodopa induced dyskinesia in Parkinson’s disease. | A double-blind, randomized, placebo-controlled, parallel-group, dose escalation trial to explore the potential antidyskinetic properties of safinamide in patients with Parkinson's disease suffering from levodopa induced dyskinesias. - LID study | Idiopathic Parkinson's disease MedDRA version: 14.0 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Safinamide Product Code: NW-1015E, EMD 1195686, MSC2191632B Pharmaceutical Form: Film-coated tablet INN or Proposed INN: safinamide CAS Number: 202825-46-5 Current Sponsor code: NW-1015E, EMD 1195686, MSC2191632B Other descriptive name: (S)-(+)-2-(4-(3-fluorobenzyl)oxybenzyl)aminopropanamide methanesulfonate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use | Merck Serono S.A. - Geneva | Not Recruiting | Female: yes Male: yes | 24 | France;Canada;Austria;South Africa;Germany | ||||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
776 | EUCTR2009-013886-24-DE | 03/03/2010 | 31 March 2014 | A randomized, multicenter 12-Week double-blind placebo-controlled study to assess the efficacy and safety of BF2.649 in Excessive Daytime Sleepiness in Parkinson’s disease - HARPS-2 | A randomized, multicenter 12-Week double-blind placebo-controlled study to assess the efficacy and safety of BF2.649 in Excessive Daytime Sleepiness in Parkinson’s disease - HARPS-2 | Excessive daytime sleepiness in Parkinson’s Disease MedDRA version: 12.0 Level: LLT Classification code 10015595 Term: Excessive daytime sleepiness MedDRA version: 12.0 Level: HLT Classification code 10034005 Term: Parkinson's disease and parkinsonism | Product Name: Pitolisant Product Code: BF2.649 Pharmaceutical Form: Capsule* INN or Proposed INN: Pitolisant Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use Product Name: Pitolisant Product Code: BF2.649 Pharmaceutical Form: Capsule* INN or Proposed INN: Pitolisant Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use Product Name: Pitolisant Product Code: BF2.649 Pharmaceutical Form: Capsule* INN or Proposed INN: Pitolisant Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 05- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use | BIOPROJET | Not Recruiting | Female: yes Male: yes | 246 | Czech Republic;Germany;Sweden | ||||
777 | NCT01092065 | March 2010 | 19 February 2015 | Efficacy and Safety of AFQ056 When Combined With Increased Doses of L-dopa in Parkinson's Disease Patients With Moderate-severe L-dopa Induced Dyskinesia | A 6-week, Double-blind, Placebo-controlled, Randomized, Multicenter Study to Explore the Efficacy and Safety of AFQ056 When Combined With Increased Doses of L-dopa in Parkinson's Disease Patients With OFF Time and Moderate-severe L-dopa Induced Dyskinesia | Parkinson's Disease | Drug: AFQ056 with L-dopa;Drug: Placebo | Novartis | Not recruiting | 30 Years | 80 Years | Both | 23 | Phase 2 | United States | |
778 | NCT01096186 | March 2010 | 16 December 2017 | An Open Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects With Parkinson's Disease | An Open Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects With Parkinson's Disease | Parkinson's Disease | Drug: IPX066 95 mg;Drug: IPX066 145 mg;Drug: IPX066 195 mg;Drug: IPX066 245 mg | IMPAX Laboratories, Inc. | Not recruiting | 30 Years | N/A | All | 617 | Phase 3 | United States;Canada;Estonia;Germany;Latvia;Lithuania;Poland;Romania;Spain;Ukraine | |
779 | NCT01097421 | March 2010 | 19 October 2017 | Influence of Pramipexole Extended Release on Medication Adherence in Parkinson´s Disease | Influence of Pramipexole Extended Release on Medication Adherence in Real Life Care of Parkinson's Disease | Parkinson Disease | Drug: Pramipexole Extended Release | Boehringer Ingelheim | Not recruiting | 30 Years | N/A | All | 329 | N/A | Sweden | |
780 | NCT01503944 | March 2010 | 19 February 2015 | A Trial of 18F-AV-133 and 18F-AV-45 Positron Emission Tomography (PET) | Detection of Striatal Dopaminergic Degeneration and Neocortical Amyloid Pathology in Patients With Dementia With Lewy Bodies, Alzheimer's Disease, Parkinson's Disease, and Healthy Elderly Volunteers | Dementia With Lewy Bodies;Alzheimer's Disease;Parkinson's Disease | Drug: 18F-AV-45;Drug: 18F-AV-133 | Avid Radiopharmaceuticals | Not recruiting | 50 Years | N/A | Both | 30 | Phase 1/Phase 2 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
781 | NCT02101190 | March 2010 | 19 October 2017 | Pharmacokinetics of BIA 9-1067 in Subjects With Hepatic Impairment | Open-label, Single-dose, Multi-center Study, Investigating the Pharmacokinetics of BIA 9-1067 in Subjects With Hepatic Impairment | Parkinson's Disease | Drug: BIA 9-1067 | Bial - Portela C S.A. | Not recruiting | 18 Years | 65 Years | All | 16 | Phase 1 | France;Russian Federation | |
782 | EUCTR2009-016360-37-SE | 06/02/2010 | 19 March 2012 | TREATMENT OF DYSKINESIAS IN PARKINSON’S DISEASE WITH OSU6162 – A PILOT STUDY | TREATMENT OF DYSKINESIAS IN PARKINSON’S DISEASE WITH OSU6162 – A PILOT STUDY | Parkinsons disease is complicated by dyskinesias and dystonia. Due stabilizing properties, we believe (-)-OSU6162 may alleviate dyskinesias, without causing parkinsonism. Aim: To evaluate in a double-blind cross over pilot study whether OSU6162 attenuates dyskinesias without worsening parkinsonism in PD patients with motor complications using clinical examination and patient diaries. | Product Name: not available Product Code: OSU 6162 similar to (-)-OSU 6162 Pharmaceutical Form: Coated tablet INN or Proposed INN: not available CAS Number: 146798-66-5 Current Sponsor code: OSU 6162 similar to (-)-OSU 6162 Pharmaceutical form of the placebo: Coated tablet Route of administration of the placebo: Oral use | Björn Holmberg | Authorised | Female: yes Male: yes | Sweden | |||||
783 | NCT01154166 | February 2010 | 19 October 2017 | A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of Six Months Treatment With Ropinirole PR as Adjunctive Therapy in Patients With Parkinson's Disease Who Are Not Optimally Controlled on L-Dopa | A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of Six Months Treatment With Ropinirole PR as Adjunctive Therapy in Patients With Parkinson's Disease Who Are Not Optimally Controlled on L-Dopa | Parkinson Disease | Drug: ReQuip PR;Drug: Placebo | GlaxoSmithKline | Not recruiting | 30 Years | N/A | All | 347 | Phase 3 | China | |
784 | NCT01568047 | February 2010 | 19 October 2017 | Multicentre Study in Four Parallel Groups of Parkinson's Disease (PD) Patients | Multicentre, Double-blind, Randomised, Placebo-controlled Study in Four Parallel Groups of PD Patients Treated With Standard-release Levodopa/Carbidopa 100/25 mg (Sinemet®) or Levodopa/Benserazide 100/25 mg (Madopar®/Restex®) and With Motor Fluctuations (Wearing-off Phenomenon) | Parkinson's Disease | Drug: Placebo;Drug: BIA 9-1067;Drug: Levodopa/Carbidopa;Drug: Levodopa/Benzerazide | Bial - Portela C S.A. | Not recruiting | 30 Years | N/A | All | 40 | Phase 2 | Romania;Ukraine | |
785 | NCT02169414 | February 2010 | 19 October 2017 | Effect of Three Multiple-dose Regimens of BIA 9 1067 at Steady-state on the Levodopa Pharmacokinetics | Effect of Three Multiple-dose Regimens of BIA 9 1067 at Steady-state on the Levodopa Pharmacokinetics of a Single-dose of Immediate Release 100/25 mg Levodopa/Carbidopa and 100/25 mg Levodopa/Benserazide in Healthy Subjects | Parkinson's Disease (PD) | Drug: BIA 9-1067 5 mg;Drug: BIA 9-1067 25 mg;Drug: levodopa/carbidopa 100/25;Drug: Placebo;Drug: levodopa/benserazide 100/25 mg | Bial - Portela C S.A. | Not recruiting | 18 Years | 45 Years | All | 74 | Phase 1 | France | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
786 | EUCTR2009-017416-33-DE | 18/01/2010 | 24 June 2013 | Standardized clinical trial on the application of Levodopa (LD) / Carbidopa (CD) to patients with Parkinson disease vs LD / CD and Entacapon (EN) vs LD / CD and Tolcapon (TO) concerning the parameters motor function, pharmacokinetics of LD, plasma level of homocystein and serum level of cortisol. | Standardized clinical trial on the application of Levodopa (LD) / Carbidopa (CD) to patients with Parkinson disease vs LD / CD and Entacapon (EN) vs LD / CD and Tolcapon (TO) concerning the parameters motor function, pharmacokinetics of LD, plasma level of homocystein and serum level of cortisol. | Male and female patients with Parkinson´s disease meeting UKPDS criteria MedDRA version: 12.1 Level: LLT Classification code 10013113 Term: Disease Parkinson's ;Male and female patients with Parkinson´s disease meeting UKPDS criteria MedDRA version: 12.1 Level: LLT Classification code 10013113 Term: Disease Parkinson's | Trade Name: Tasmar Product Name: Tolcapon Product Code: TO Pharmaceutical Form: Coated tablet INN or Proposed INN: TOLCAPONE CAS Number: 134308-13-7 Current Sponsor code: TO Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Trade Name: Comtess Product Name: Entacapon Product Code: EN Pharmaceutical Form: Coated tablet INN or Proposed INN: ENTACAPONE CAS Number: 130929-57-6 Current Sponsor code: EN Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- Trade Name: Isicom Product Name: Levodopa/Carbidopa Product Code: LD/CD Pharmaceutical Form: Coated tablet INN or Proposed INN: LEVODOPA CAS Number: 59-92-7 Current Sponsor code: LD Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- CAS Number: 38821-49-7 Current Sponsor code: CD Other descriptive name: CARBIDOPA MONOHYDRATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 26.99- Product Name: Tolcapon Product Code: TO Pharmaceutical Form: Coated tablet INN or Proposed INN: TOLCAPONE CAS Number: 134308-13-7 Current Sponsor code: TO Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Trade Name: Comtess Product Name: Entacapon Product Code: EN Pharmaceutical Form: Coated tablet INN or Proposed INN: ENTACAPONE CAS Number: 130929-57-6 Current Sponsor code: EN Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- Trade Name: Isicom Product Name: Levodopa/Carbidopa Product Code: LD/CD Pharmaceutical Form: Coated tablet INN or Proposed INN: LEVODOPA CAS Number: 59-92-7 Current Sponsor code: LD Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- CAS Number: 38821-49-7 Current Sponsor code: CD Other descriptive name: CARBIDOPA MONOHYDRATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 26.99- | Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University | Not Recruiting | Female: yes Male: yes | Germany | |||||
787 | EUCTR2009-012643-42-NL | 06/01/2010 | 19 March 2012 | Freezing of gait in Parkinson's disease: in search of the underlying mechanism and the application of a new treatment option - Freezing of gait in Parkinson's disease | Freezing of gait in Parkinson's disease: in search of the underlying mechanism and the application of a new treatment option - Freezing of gait in Parkinson's disease | Parkinson's disease, in particular the symptom Freezing of Gait | Trade Name: Ritalin Product Name: Not applicable Product Code: Not applicable Pharmaceutical Form: Tablet INN or Proposed INN: METHYLPHENIDATE HYDROCHLORIDE CAS Number: 298599 Current Sponsor code: RVG 03957 Other descriptive name: Ritalin Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | University Medical Center Groningen | Authorised | Female: yes Male: yes | Netherlands | |||||
788 | JPRN-UMIN000003080 | 2010/01/01 | 2 April 2019 | Double Blind Study for Effects of Donepezil Hydrochloride on Parkinson's Disease | Parkinson's disease | Donepezil hydrochloride (3mg for 2 weeks, 5mg for 2 weeks) Placebo | Clinical Research Center, Utano National Hospital, National Hospital Organization | Not Recruiting | 40years-old | 75years-old | Male and Female | 30 | Not applicable | Japan | ||
789 | JPRN-UMIN000007497 | 2010/01/01 | 2 April 2019 | Trial of molecular hydrogen water in Parkinson disease | Parkinson disease | The subjects should make 1000 ml of molecular hydrogen water which contains 1.6 ppm dissolved hydrogen by Aquerable, and consume for 48 weeks. Placebo water which is not contained molecular hydrogen water made from pseudo-machine. The subjects consume for48 weeks. | Department of Neurology, Juntendo University School of Medicine | Not Recruiting | 20years-old | Not applicable | Male and Female | 18 | Not applicable | Japan | ||
790 | NCT01007864 | January 2010 | 19 February 2015 | Influence of Piribedil (Clarium®) on Vigilance and Cognitive Function in Patients With Parkinson's Disease Compared to Other Non-Ergot Dopamine Agonists | Influence of the Non-Ergot Dopamine Agonist Piribedil on Vigilance and Cognitive Function in Patients With Parkinson's Disease Compared to Other Oral Non-Ergot Dopamine Agonists | Idiopathic Parkinson's Disease | Drug: piribedil;Drug: pramipexole or ropinirole | Desitin Arzneimittel GmbH | FGK Clinical Research GmbH | Not recruiting | 35 Years | 80 Years | Both | 80 | Phase 3 | Germany |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
791 | NCT01018264 | January 2010 | 19 October 2017 | Solifenacin Succinate (VESIcare) for the Treatment of Overactive Bladder in Parkinson's Disease | URGE-PD: A Multi-site, Double-blind, Randomized, Placebo Controlled Trial of Solifenacin Succinate (VESIcare) for the Treatment of Overactive Bladder in Parkinson's Disease | Overactive Bladder in Parkinson's Disease | Drug: solifenacin succinate (VESIcare);Drug: placebo | University of South Florida | Not recruiting | 40 Years | 80 Years | All | 23 | Phase 4 | United States | |
792 | NCT01058291 | January 2010 | 16 December 2017 | Placebo-Controlled Double-Blind Crossover Comparative Study of KW-6500 | Phase 3 Study of KW-6500 (Placebo-Controlled Double-Blind Crossover Comparative Study in Patients With Parkinson's Disease) | Parkinson's Disease | Drug: KW-6500;Drug: KW-6500 Placebo | Kyowa Hakko Kirin Co., Ltd | Not recruiting | 20 Years | N/A | All | 31 | Phase 3 | Japan | |
793 | NCT01063621 | January 2010 | 16 December 2017 | Extended Long-Term Safety Study of KW-6500 | Phase 3 Study of KW-6500 (Safety Study for Extended Long-Term Self-Injection at Home in Patients With Parkinson's Disease) | Parkinson's Disease | Drug: KW-6500 | Kyowa Hakko Kirin Co., Ltd | Not recruiting | 20 Years | N/A | All | 27 | Phase 3 | Japan | |
794 | NCT01071395 | January 2010 | 19 October 2017 | Validation of Dyskinesia Rating Scales | Validation of Dyskinesia Rating Scales | Parkinson's Disease | Drug: Amantadine;Drug: Placebo | Rush University Medical Center | Michael J. Fox Foundation for Parkinson's Research | Not recruiting | 30 Years | 90 Years | All | 68 | Phase 4 | United States;Austria;Canada;France |
795 | NCT01417598 | January 2010 | 21 September 2015 | BETA Study: Improving Balance Function in Elderly by Progressive and Specific Training and Physical Activity | Improving Balance Function in Elderly by Progressive and Specific Training and Physical Activity- a Randomized Controlled Study. | Elderly;Parkinsons Disease;Osteoporosis | Other: Gait and balance group training;Other: Nordic walking (only osteoporosis group) | Karolinska Institutet | The Swedish Research Council | Not recruiting | 60 Years | N/A | Both | 200 | N/A | Sweden |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
796 | EUCTR2009-014688-37-DE | 15/12/2009 | 1 May 2012 | A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson’s Disease | A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson’s Disease | Advanced Parkinson’s Disease subjects with motor fluctuations MedDRA version: 12.0 Level: LLT Classification code 10061536 Term: Parkinson's disease | Product Name: IPX066 Product Code: IPX066-95 Pharmaceutical Form: Capsule* INN or Proposed INN: CARBIDOPA CAS Number: 28860-95-9 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 23.75 - INN or Proposed INN: LEVODOPA CAS Number: 59-92-7 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 95- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use Trade Name: SINEMET®-Plus Tablets Product Name: IR CD-LD Pharmaceutical Form: Tablet INN or Proposed INN: CARBIDOPA CAS Number: 28860-95-9 Current Sponsor code: CD Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- INN or Proposed INN: LEVODOPA CAS Number: 59-92-7 Current Sponsor code: LD Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: IPX066 Product Code: IPX066-145 Pharmaceutical Form: Capsule* INN or Proposed INN: CARBIDOPA CAS Number: 28860-95-9 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 36.25 - INN or Proposed INN: LEVODOPA CAS Number: 59-92-7 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 145- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use Product Name: IPX066 Product Code: IPX066-195 Pharmaceutical Form: Capsule* INN or Proposed INN: CARBIDOPA CAS Number: 28860-95-9 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 48.75 - INN or Proposed INN: LEVODOPA CAS Number: 59-92-7 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 195- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use Product Name: IPX066 Product Code: IPX066-245 Pharmaceutical Form: Capsule* INN or Proposed INN: CARBIDOPA | Impax Laboratories, Inc. | Not Recruiting | Female: yes Male: yes | 350 | Germany;France;Spain;Poland | ||||
797 | EUCTR2009-012419-16-DE | 03/12/2009 | 10 February 2014 | Influence of the Non-Ergot Dopamine agonist Piribedil on vigilance and cognitive function in patients with Parkinson's disease compared to other oral Non-Ergot Dopamine agonists - PIVICOG-PD | Influence of the Non-Ergot Dopamine agonist Piribedil on vigilance and cognitive function in patients with Parkinson's disease compared to other oral Non-Ergot Dopamine agonists - PIVICOG-PD | idiopathic Parkinson's disease MedDRA version: 12.0 Level: PT Classification code 10061536 Term: Parkinson's disease | Trade Name: Clarium 50 mg Retardtabletten Pharmaceutical Form: Modified-release tablet INN or Proposed INN: piribedil CAS Number: 3605-01-4 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- | Desitin Arzneimittel GmbH | Not Recruiting | Female: yes Male: yes | Germany | |||||
798 | NCT00660387 | December 2009 | 19 October 2017 | Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects | A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Receiving Optimized Treatments With Parkinson Medicinal Products Who Continue to Experience Persistent Motor Fluctuations | Advanced Parkinson's Disease | Drug: Levodopa carbidopa intestinal gel (LCIG);Drug: Placebo Gel;Drug: Levodopa-carbidopa (LC) oral encapsulated immediate release (IR) tablets;Drug: Placebo (PBO) oral capsules;Device: CADD-Legacy® 1400 ambulatory infusion pump;Device: PEG tube;Device: J-tube | AbbVie (prior sponsor, Abbott) | Quintiles, Inc. | Not recruiting | 30 Years | N/A | All | 35 | Phase 3 | United States;New Zealand |
799 | NCT01032486 | December 2009 | 19 February 2015 | Study for Rasagiline Effect on Sleep Trial(REST)in Parkinson's Disease | An Open-Label, Multi-Center, Single Arm Study to Evaluate the Effects of Azilect® on Sleep Disturbances in Parkinson's Disease Subjects | Parkinson's Disease | Drug: Rasagiline mesylate | Teva Pharmaceutical Industries | Not recruiting | N/A | N/A | Both | 120 | Phase 4 | Canada | |
800 | NCT01036139 | December 2009 | 19 February 2015 | Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness (EDS) in Parkinson's Disease | A Randomized, Multicenter 12-Week Double-blind Placebo-controlled Study to Assess the Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness in Parkinson's Disease Followed by a 38-Week Open-label Extension Phase | Parkinson's Disease | Drug: BF2.649 (pitolisant) | Bioprojet | Not recruiting | 30 Years | 80 Years | Both | 268 | Phase 3 | France | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
801 | NCT01049984 | December 2009 | 19 October 2017 | Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's Disease | A Double-blind, Placebo Controlled, Randomized, Multicenter Study to Assess the Safety and Clinical Benefit of Rasagiline as an Add on Therapy to Stable Dose of Dopamine Agonists in the Treatment of Early Parkinson's Disease | Parkinson's Disease | Drug: Rasagiline;Drug: Placebo | Teva Neuroscience, Inc. | H. Lundbeck A/S | Not recruiting | 30 Years | N/A | All | 328 | Phase 4 | United States |
802 | NCT01070628 | December 2009 | 19 February 2015 | Levodopa Concentration Profile With Stalevo 75/125 mg | Levodopa Concentration Profile After Repeated Doses of Different Stalevo® Strengths With 3.5 Hours Dosing Frequency; an Open, Randomised, Crossover, Levodopa/Carbidopa Controlled Single Centre Study in Healthy Subjects, Two Parallel Groups | Parkinson's Disease | Drug: Stalevo (levodopa/ carbidopa/ entacapone);Drug: Sinemet (levodopa/carbidopa) | Orion Corporation, Orion Pharma | Not recruiting | 18 Years | 70 Years | Both | 20 | Phase 1 | Finland | |
803 | NCT01168596 | December 2009 | 19 October 2017 | Rasagiline for the Symptomatic Treatment of Fatigue in Parkinson's Disease | Rasagiline for the Symptomatic Treatment of Fatigue in Parkinson's Disease: A Bi-Center, Placebo-Controlled Study (The REST Fatigue Trial) | Parkinson's Disease | Drug: Rasagiline;Drug: Placebo | University of Florida | Not recruiting | 40 Years | 85 Years | All | 30 | Phase 4 | United States | |
804 | NCT00660673 | November 13, 2009 | 18 December 2018 | Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel in Advanced PD | Open-Label Continuation Treatment Study With Levodopa - Carbidopa Intestinal Gel In Subjects With Advanced Parkinson's Disease And Severe Motor-Fluctuations Who Have Exhibited A Persistent And Positive Effect To Treatment In Previous Studies | Advanced Parkinson's Disease | Drug: Levodopa-carbidopa intestinal gel;Device: CADD-Legacy® 1400 ambulatory infusion pump | AbbVie (prior sponsor, Abbott) | Quintiles, Inc. | Not recruiting | 30 Years | 99 Years | All | 262 | Phase 3 | United States;Australia;Canada;Czechia;Israel;New Zealand;Poland;Portugal;Russian Federation;Thailand;United Kingdom;Czech Republic |
805 | EUCTR2009-013885-14-ES | 12/11/2009 | 19 March 2012 | A randomized, multicenter 12-Week double-blind placebo-controlled study to assess the efficacy and safety of BF2.649 in Excessive Daytime Sleepiness in Parkinson?s disease followed by a 38-Week open-label extension phase. Estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo y de 12 semanas de duración para evaluar la eficacia y seguridad de BF2.649 en la somnolencia diurna excesiva de la enfermedad de Parkinson, seguido de una fase de extensión abierta de 38 semanas. | A randomized, multicenter 12-Week double-blind placebo-controlled study to assess the efficacy and safety of BF2.649 in Excessive Daytime Sleepiness in Parkinson?s disease followed by a 38-Week open-label extension phase. Estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo y de 12 semanas de duración para evaluar la eficacia y seguridad de BF2.649 en la somnolencia diurna excesiva de la enfermedad de Parkinson, seguido de una fase de extensión abierta de 38 semanas. | Excessive daytime sleepiness in Parkinson?s Disease Somnolencia diurna excesiva en la enfermedad de Parkinson. MedDRA version: 12.0 Level: LLT Classification code 10015595 Term: Excessive daytime sleepiness MedDRA version: 12.0 Level: HLT Classification code 10034005 Term: Parkinson's disease and parkinsonism | Product Name: Pitolisant Product Code: BF2.649 Pharmaceutical Form: Capsule* INN or Proposed INN: Pitolisant Concentration unit: mg milligram(s) Concentration type: range Concentration number: 5-20 Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use | BIOPROJET | Authorised | Female: yes Male: yes | 246 | France;Spain | ||||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
806 | EUCTR2009-013004-31-IT | 02/11/2009 | 14 March 2016 | Early combined prolonged release ropinirole and rasagiline therapy in newly diagnosed patients with Parkinsons disease. A prospective, randomized, parallel groups, long-term follow-up study including delayed-start design of rasagiline - Early combined ropinirole and rasagiline therapy in patients with Parkinsons disease | Early combined prolonged release ropinirole and rasagiline therapy in newly diagnosed patients with Parkinsons disease. A prospective, randomized, parallel groups, long-term follow-up study including delayed-start design of rasagiline - Early combined ropinirole and rasagiline therapy in patients with Parkinsons disease | Patients with Parkinson`s diesease MedDRA version: 12.0 Level: LLT Classification code 10061536 Term: Parkinson's disease | Pharmaceutical Form: Tablet INN or Proposed INN: Rasagiline Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1- Pharmaceutical Form: Prolonged-release tablet INN or Proposed INN: Ropinirole Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 8- | UNIVERSITA` DEGLI STUDI DI PARMA | Not Recruiting | Female: yes Male: yes | Italy | |||||
807 | NCT01007630 | November 2009 | 19 February 2015 | A Study Assessing Change in Sense of Smell After Rasagiline Use in Parkinson's Patients | A Prospective Randomized Placebo-Controlled Double-Blind Study Assessing Change in Olfactory Function After Initiation of Rasagiline in Idiopathic Parkinson's Disease | Parkinson's Disease | Drug: Rasagiline;Drug: Placebo | The Parkinson's Institute | Teva Neuroscience, Inc. | Not recruiting | N/A | 90 Years | Both | 36 | Phase 4 | United States |
808 | NCT01023282 | November 2009 | 19 February 2015 | Safety and Tolerability Study Evaluating ACR325 in Parkinson's Disease Patients | Randomised, Double-blind, Placebo-controlled Study Evaluating Safety and Tolerability of ACR325 in Parkinson's Disease Patients, With Evaluation of the Effect on Levodopa Induced Dyskinesias as a Secondary Measure | Parkinson's Disease;Tolerability | Drug: ACR325;Drug: Placebo | NeuroSearch A/S | Not recruiting | 30 Years | 75 Years | Both | 22 | Phase 1 | Germany | |
809 | NCT01028209 | November 2009 | 15 April 2019 | Evaluation of [18F] PBR06 and PET as a Marker of Inflammation in Subjects With Neurological Conditions | Alzheimer Disease;Parkinson Disease;Multiple Sclerosis | Drug: [18F] PBR06 | Institute for Neurodegenerative Disorders | Not recruiting | 18 Years | N/A | All | 12 | Phase 1 | United States | ||
810 | NCT01052831 | November 2009 | 19 October 2017 | Naltrexone for Impulse Control Disorders in Parkinson's Disease | Randomized, Double-blind, Placebo-controlled Study of Naltrexone for Impulse Control Disorders in Parkinson's Disease | Impulse Control Disorder;Parkinson Disease | Drug: Naltrexone;Drug: Placebo | University of Pennsylvania | Michael J. Fox Foundation for Parkinson's Research | Not recruiting | 18 Years | 85 Years | All | 50 | Phase 4 | United States |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
811 | NCT01519284 | November 2009 | 19 October 2017 | Study of BIA 9-1067 to Investigate Its Effect on Levodopa Pharmacokinetic | A Double-blind, Randomised, Placebo- and Active-controlled Multiple-dose Study of BIA 9-1067 to Investigate Its Effect on Levodopa Pharmacokinetics Following a Levodopa/Carbidopa 100/25 mg Single-dose in Healthy Subjects | Parkinson Disease | Drug: BIA 9-1067 5 mg;Drug: Entacapone;Drug: Placebo;Drug: levodopa/carbidopa;Drug: BIA 9-1067 15 mg;Drug: BIA 9-1067 30 mg | Bial - Portela C S.A. | Not recruiting | 18 Years | 45 Years | All | 82 | Phase 1 | Portugal | |
812 | NCT01532128 | November 2009 | 19 October 2017 | Effect of BIA 9-1067 on Rasagiline Pharmacokinetics | Effect of BIA 9-1067 on Rasagiline Pharmacokinetics in Healthy Subjects | Parkinson Disease | Drug: rasagiline;Drug: BIA 9-1067 | Bial - Portela C S.A. | Not recruiting | 18 Years | 45 Years | All | 24 | Phase 1 | France | |
813 | NCT01532141 | November 2009 | 19 October 2017 | Effect of Rasagiline on BIA 9-1067 Pharmacokinetics | Effect of Rasagiline on BIA 9-1067 Pharmacokinetics in Healthy Subjects | Parkinson Disease | Drug: BIA 9-1067;Drug: Rasagiline | Bial - Portela C S.A. | Not recruiting | 18 Years | 45 Years | All | 25 | Phase 1 | France | |
814 | EUCTR2009-011541-24-GB | 09/10/2009 | 19 March 2012 | A trial to follow-up subjects with Parkinson's disease who participated to the ADAGIO study in order to study the long-term effects of the drug rasagiline | An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects who Participated in the ADAGIO Study - ADAGIO Follow-Up | Parkinson's Disease MedDRA version: 13.1 Level: LLT Classification code 10013113 Term: Disease Parkinson's System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: AZILECT Pharmaceutical Form: Tablet INN or Proposed INN: Rasagiline CAS Number: 161735-79-1 Current Sponsor code: TVP-1012 Other descriptive name: Rasagiline mesylate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1- | Teva Pharmaceutical Industries Ltd | Authorised | Female: yes Male: yes | 700 | Hungary;Portugal;Germany;Netherlands;France;Italy;Israel;United Kingdom;Canada;Argentina;Romania;Spain;United States | ||||
815 | NCT00957203 | October 2009 | 19 February 2015 | Long-Term Safety Study of KW-6002 (Istradefylline) in Parkinson's Disease Patients | Long-Term Safety Study of KW-6002 (Istradefylline) in the Treatment of Parkinson's Disease (Phase 3) | Parkinson's Disease | Drug: Istradefylline | Kyowa Hakko Kirin Company, Limited | Not recruiting | 20 Years | N/A | Both | 308 | Phase 3 | Japan | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
816 | NCT00957918 | October 2009 | 19 February 2015 | Study of NP002 in Subjects With Idiopathic Parkinson's Disease to Treat Dyskinesias Due to Levodopa Therapy | Randomized, Double-Blind, Parallel Group, Placebo Controlled Safety, Tolerability and Efficacy Study of NP002 in Subjects With Idiopathic Parkinson's Disease With Dyskinesias Due to Levodopa Therapy | Parkinson's Disease | Drug: nicotine;Other: placebo comparator | Neuraltus Pharmaceuticals, Inc. | Not recruiting | 30 Years | 83 Years | Both | 65 | Phase 1/Phase 2 | United States | |
817 | NCT01016470 | October 2009 | 19 February 2015 | Efficacy of Nutritional Supplement VIUSID/ALZER in Patients With Parkinson`s Disease | Efficacy of Nutritional Supplement VIUSID/ALZER in Patients With Parkinson`s Disease | Parkinson`s Disease | Dietary Supplement: VIUSID/ALZER;Dietary Supplement: Placebo | Catalysis SL | Not recruiting | 20 Years | 90 Years | Both | 100 | Phase 3 | Cuba | |
818 | NCT01028586 | October 2009 | 19 February 2015 | MOTION, Safinamide in Early Idiopathic Parkinson's Disease (IPD), as add-on to Dopamine Agonist (Extension of Trial 27918) | A Phase III, Double-blind, Placebo-controlled Extension Trial to Investigate the Long-term Efficacy and Safety of Low (50 mg/Day) and High (100 mg/Day) Dose Safinamide, as add-on Therapy in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist | Idiopathic Parkinson's Disease | Drug: Safinamide, MAO-B inhibitor;Drug: Placebo | Newron | Not recruiting | 30 Years | 80 Years | Both | 507 | Phase 3 | Switzerland | |
819 | NCT01631825 | October 2009 | 19 October 2017 | A Long-Term Extension Trial From of SPM 962 in Advanced Parkinson's Disease Patients | An Open-label Long-term Extension Trial From Phase III of SPM962 (243-08-002) in Advanced Parkinson's Disease Patients With Concomitant Treatment of L-dopa | Parkinson's Disease | Drug: SPM 962 | Otsuka Pharmaceutical Co., Ltd. | Not recruiting | N/A | N/A | All | 321 | Phase 3 | Japan | |
820 | ChiCTR-TRC-12002150 | 2009-09-29 | 18 April 2017 | Study on Optimization of The Comprehensive Therapeutic Plan for Parkinson's Disease in Different Stages | Study on Optimization of The Comprehensive Therapeutic Plan by Stages for Parkinson's Disease | Parkinson's Disease | The early treatment group:Xifeng Dingchan Pill;The early control group:Madopar tablets;Interim treatment group:Xifeng Dingchan Pill, Madopar tablets and Piribedil tablets; | Henan University of Traditional Chinese Medicine | Recruiting | 50 | 75 | Both | The early treatment group:80;The early control group:80;Interim treatment group:160; | Other | China | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
821 | NCT01371682 | September 18, 2009 | 2 July 2018 | A Study Conducted in Healthy Subjects to Demonstrate Bioequivalence Between Ropinirole Prolonged Release Tablets Manufactured at Crawley and Aranda | An Open Label Study Conducted in Healthy Subjects to Demonstrate Bioequivalence Between Ropinirole Prolonged Release Tablets (Ropinirole XL, Marketed as REQUIP-MODUTAB™, REQUIP XL™ at 2 mg) Manufactured at Crawley and Aranda | Parkinson Disease | Drug: Ropinirole XL | GlaxoSmithKline | Not recruiting | 18 Years | 50 Years | All | 50 | Phase 1 | Belgium | |
822 | NCT00794313 | September 2009 | 16 December 2017 | Quantification of the Antidyskinetic Effect of Amantadine and Topiramate in Parkinson's Disease | Quantification of the Antidyskinetic Effect of Amantadine and Topiramate in Parkinson's Disease | Parkinson's Disease | Drug: Amantadine 300 mg;Drug: Topiramate;Drug: Sugar Pill | Oregon Health and Science University | Not recruiting | 21 Years | N/A | All | 3 | N/A | United States | |
823 | NCT00907972 | September 2009 | 19 February 2015 | The Effects of Vitamin D and Bone Loss in Parkinson's Disease | Effect of Vitamin D3 Supplementation in Parkinson's Disease Patients - A Pilot Study | Parkinson Disease | Dietary Supplement: Vitamin D3;Other: Placebo | Memorial Medical Center | Department of Defense | Not recruiting | 18 Years | N/A | Both | 23 | Phase 2 | United States |
824 | NCT00909883 | September 2009 | 19 February 2015 | Foot Dystonia Treatment by Botulinum Toxin Injections in Parkinson Disease : Efficiency of Injections Made in Extrinsic Muscle (Flexor Digitorum Longus Muscle) Compared to Intrinsic Muscle (Flexor Digitorum Brevis or Quadratus Plantae Muscles) | Foot Dystonia Treatment by Botulinum Toxin Injections in Parkinson Disease : Efficiency of Injections Made in Extrinsic Muscle (Flexor Digitorum Longus Muscle) Compared to Intrinsic Muscle (Flexor Digitorum Brevis or Quadratus Plantae Muscles) | Parkinson's Disease;Foot Dystonia | Drug: Botulinum Toxin: Xeomin;Drug: Placebo | University Hospital, Clermont-Ferrand | Merz Pharma France | Recruiting | 30 Years | 75 Years | Both | 45 | Phase 3 | France |
825 | NCT00974974 | September 2009 | 16 December 2017 | A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease (ADVANCE-PD). | A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease | Parkinson's Disease | Drug: IPX066;Drug: IR CD-LD | IMPAX Laboratories, Inc. | Not recruiting | 30 Years | N/A | All | 471 | Phase 3 | United States;Canada;France;Germany;Poland;Romania;Spain;Ukraine | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
826 | NCT00985517 | September 2009 | 15 July 2019 | Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease | A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease | Idiopathic Parkinson's Disease | Biological: CERE-120: Adeno-Associated Virus Delivery of Neurturin;Procedure: Sham Surgery | Sangamo Therapeutics | Not recruiting | 35 Years | 70 Years | All | 57 | Phase 1/Phase 2 | United States | |
827 | NCT00986245 | September 2009 | 19 October 2017 | Study to Compare the Effect of Ropinirole Prolonged Release Once-daily Versus Twice-daily | An Open-label, Multi-center, Crossover Study to Compare the Effect of Once-daily Ropinirole PR and Twice-daily Ropinirole PR in Patients With Parkinson Disease | Parkinson Disease | Drug: Ropinirole Prolonged release | Seoul National University Hospital | Not recruiting | 30 Years | 80 Years | All | 82 | Phase 4 | Korea, Republic of | |
828 | NCT01026428 | September 2009 | 19 February 2015 | A Study to Assess the Effect of Safinamide on Levodopa Pharmacokinetics | A Randomised, Double-blind, Placebo-controlled, Two-period, Two-sequence-crossover Interaction Study to Assess the Effect of Safinamide on Levodopa Pharmacokinetics in Subjects With Parkinson's Disease | Idiopathic Parkinson's Disease | Drug: Safinamide + Levodopa;Other: Placebo + Levodopa | Newron | Not recruiting | 30 Years | N/A | Both | 24 | Phase 1/Phase 2 | Italy | |
829 | NCT00970333 | August 2009 | 19 February 2015 | Evaluation of [18F] FEPPA and PET Imaging as a Marker of Inflammation in Subjects With Neurological Conditions | Evaluation of [18F] FEPPA and PET as a Marker of Inflammation in Subjects With Neurological Conditions | Alzheimer Disease;Parkinson Disease;Multiple Sclerosis | Drug: [18F]-FEPPA | Institute for Neurodegenerative Disorders | Not recruiting | 18 Years | N/A | Both | 3 | Phase 1 | United States | |
830 | NCT01580787 | August 2009 | 19 February 2015 | Functional Improvement in Patients With Parkinson's Disease After Training in Real or Virtual Environment | Functional Improvement in Patients With Parkinson's Disease After Training in Real or Virtual Environment | Parkinson´s Disease | Device: Balance Training with Nintendo Wii Fit;Other: Physical Therapy | Sao Camilo University Center | Not recruiting | 65 Years | 85 Years | Both | 32 | N/A | ||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
831 | EUCTR2009-011736-35-FR | 27/07/2009 | 19 March 2012 | Etude pilote de phase II, N=1 en crossover répétés, en double aveugle, randomisée versus placebo, multicentrique, évaluant l’efficacité de la SIMVAstatine sur les DYSkinésies induites par la L-Dopa chez des patients atteints de maladie de Parkinson - SIMVADYS | Etude pilote de phase II, N=1 en crossover répétés, en double aveugle, randomisée versus placebo, multicentrique, évaluant l’efficacité de la SIMVAstatine sur les DYSkinésies induites par la L-Dopa chez des patients atteints de maladie de Parkinson - SIMVADYS | Maladie de Parkinson MedDRA version: 9.1 Level: LLT Classification code 10013113 Term: Disease Parkinson's | Trade Name: LODALÈS® Product Code: simvastatine Pharmaceutical Form: Capsule* Current Sponsor code: simvastatine Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use | CHU de Bordeaux | Authorised | Female: yes Male: yes | 10 | Phase 2 | France | |||
832 | NCT00909545 | July 2009 | 19 October 2017 | Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease | A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease | Parkinson Disease | Drug: Isradipine CR 5mg;Drug: Isradipine CR 10mg;Drug: Isradipine CR 20mg;Drug: Placebo | Northwestern University | Michael J. Fox Foundation for Parkinson's Research;Northwestern University Dixon Fund;The Parkinson Study Group | Not recruiting | 30 Years | N/A | All | 99 | Phase 2 | United States;Canada |
833 | NCT00918177 | July 2009 | 19 February 2015 | An Evaluation of the Pharmacokinetics and Pharmacodynamics of AP09004 in Patients With Parkinson's Disease | Dual Release Gastric Retentive AP09004, Vs. Active Control; a Pharmacokinetic/Pharmacodynamic, Comparative, Safety Evaluation in Parkinson's Patients | Parkinson's Disease | Drug: AP09004;Drug: Carbidopa/Levodopa, immediate release | Intec Pharma Ltd. | Not recruiting | 18 Years | N/A | Both | 72 | Phase 2 | Israel | |
834 | NCT00955318 | July 2009 | 16 December 2017 | Long-Term Safety Study of KW-6500 in Patients With Parkinson's Disease | Phase 3 Study of KW-6500 (Safety Study for Long-Term Self-Administration at Home in Patients With Parkinson's Disease | Parkinson's Disease | Drug: KW-6500 | Kyowa Hakko Kirin Co., Ltd | Not recruiting | 20 Years | N/A | All | 58 | Phase 3 | Japan | |
835 | NCT00955526 | July 2009 | 19 February 2015 | Study of KW-6002 (Istradefylline) for the Treatment of Parkinson's Disease in Patients Taking Levodopa | Placebo-Controlled, Double-Blind, Parallel Group, Fixed Dose Study of KW-6002 (Istradefylline) in the Treatment of Parkinson's Disease (Phase 3) | Parkinson's Disease | Drug: Istradefylline;Drug: Placebo | Kyowa Hakko Kirin Company, Limited | Not recruiting | 20 Years | N/A | Both | 373 | Phase 3 | Japan | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
836 | NCT00955604 | July 2009 | 16 December 2017 | Azilect + Antidepressant Chart Review | Investigation of the Occurrence of Serotonin Toxicity in Parkinson's Disease (PD) Patients Treated Concomitantly With Rasagiline and Antidepressants, Using Retrospective Chart Review | Serotonin Syndrome | Drug: Group R+AD Rasagiline + Antidepressant;Drug: Group R Rasagiline;Drug: Group AD Anti-PD + Antidepressant | Teva Pharmaceutical Industries | Not recruiting | N/A | N/A | All | 1500 | N/A | United States | |
837 | NCT00970229 | July 2009 | 16 December 2017 | Evaluation of [123I]MNI-420 and SPECT as a Marker of the Adenosine A2a Receptor in PD, HD and Healthy Subjects. | Evaluation of [123I]MNI-420 and SPECT as a Marker of the Adenosine A2a Receptor in Subjects With Parkinson Disease, Huntington Disease, and Healthy Controls | Parkinson Disease;Huntington Disease | Drug: [123I]MNI-420 | Institute for Neurodegenerative Disorders | Not recruiting | 18 Years | N/A | All | 19 | Phase 1 | United States | |
838 | EUCTR2009-012529-12-FR | 10/06/2009 | 19 March 2012 | A randomised, REQUIP® IR-controlled, n-of-1, multiple crossover, pilot trial of the effect of REQUIP®CR on abnormal daytime somnolence in patients with Parkinson’s Disease - REQUIP | A randomised, REQUIP® IR-controlled, n-of-1, multiple crossover, pilot trial of the effect of REQUIP®CR on abnormal daytime somnolence in patients with Parkinson’s Disease - REQUIP | parkinson's disease MedDRA version: 9.1 Level: LLT Classification code 10013113 Term: Disease Parkinson's | Trade Name: REQUIP-LP Product Name: ropinirole Pharmaceutical Form: Tablet Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Trade Name: REQUIP Product Name: ropinirole Pharmaceutical Form: Tablet Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | CHU de Toulouse | Authorised | Female: yes Male: yes | 10 | France | ||||
839 | EUCTR2009-010193-38-LT | 02/06/2009 | 19 March 2012 | A Placebo-Controlled Study to Evaluate the Safety and Efficacy of IPX066 in Subjects with Parkinson's Disease | A Placebo-Controlled Study to Evaluate the Safety and Efficacy of IPX066 in Subjects with Parkinson's Disease | Idiopathic Parkinson's disease (paralysis agitans) MedDRA version: 9.1 Level: LLT Classification code 10061536 Term: Parkinson's disease | Product Name: IPX066 Product Code: IPX066-95 Pharmaceutical Form: Capsule* INN or Proposed INN: LEVODOPA CAS Number: 59927 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 95- INN or Proposed INN: CARBIDOPA CAS Number: 28860959 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 23.75- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use Product Name: IPX066 Product Code: IPX066-145 Pharmaceutical Form: Capsule* INN or Proposed INN: LEVODOPA CAS Number: 59927 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 145- INN or Proposed INN: CARBIDOPA CAS Number: 28860959 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 36.25- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use Product Name: IPX066 Product Code: IPX066-195 Pharmaceutical Form: Capsule* INN or Proposed INN: LEVODOPA CAS Number: 59927 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 195- INN or Proposed INN: CARBIDOPA CAS Number: 28860959 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 48.75- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use Product Name: IPX066 Product Code: IPX066-245 Pharmaceutical Form: Capsule* INN or Proposed INN: LEVODOPA CAS Number: 59927 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 245- INN or Proposed INN: CARBIDOPA CAS Number: 28860959 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 61.25- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use | IMPAX Pharmaceuticals a Division of IMPAX Laboratories, Inc. | Not Recruiting | Female: yes Male: yes | 350 | Estonia;Latvia;Lithuania | ||||
840 | NCT00921128 | June 2, 2009 | 16 December 2017 | Convection-Enhanced Delivery to Study the Pathophysiology Underlying the Clinical Features of Parkinson s Disease | Convection Enhanced Delivery of Muscimol to Study the Pathophysiology Underlying the Clinical Features of Parkinson's Disease | Parkinson's Disease | Drug: Muscimol | National Institute of Neurological Disorders and Stroke (NINDS) | Not recruiting | 18 Years | N/A | All | 0 | Phase 1 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
841 | NCT00360568 | June 2009 | 19 October 2017 | Safety/Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Parkinson's Subjects | Open-Label, 12-Month Safety and Efficacy Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Disease Subjects | Dyskinesias;Parkinson's Disease;Severe Motor Fluctuations | Drug: Levodopa-carbidopa intestinal gel;Device: CADD-Legacy® 1400 ambulatory infusion pump;Device: PEG tube;Device: J-tube | AbbVie (prior sponsor, Abbott) | Quintiles, Inc. | Not recruiting | 30 Years | N/A | All | 62 | Phase 3 | United States;Germany;New Zealand |
842 | NCT00669461 | June 2009 | 19 October 2017 | Lubiprostone as a Treatment for Constipation in Parkinson's Disease | Lubiprostone as a Treatment for Constipation in Parkinson's Disease | Constipation;Parkinson's Disease | Drug: Lubiprostone | University of Arkansas | Takeda | Not recruiting | 50 Years | 85 Years | All | 1 | N/A | United States |
843 | NCT00833690 | June 2009 | 19 October 2017 | Safety of Urate Elevation in Parkinson's Disease | A Randomized, Double-blind, Placebo-controlled, Dose-ranging Trial of Oral Inosine to Assess Safety and Ability to Elevate Urate in Early Parkinson's Disease | Parkinson Disease | Drug: Placebo;Drug: inosine | The Parkinson Study Group | Massachusetts General Hospital;Harvard School of Public Health;University of Rochester;Michael J. Fox Foundation for Parkinson's Research | Not recruiting | 30 Years | N/A | All | 75 | Phase 2 | United States |
844 | NCT01519856 | June 2009 | 8 February 2016 | PIRLONG-PD Safety and Efficacy of Piribedil in Parkinson's Disease During Long Term Therapy | Efficacy and Safety of Long-term Therapy With Piribedil (CLARIUM) in Patients With M. Parkinson Under Consideration of Quality of Life Parameters and Cognitive Function | Parkinson's Disease | Drug: piribedil (Clarium) | Desitin Arzneimittel GmbH | Not recruiting | 18 Years | N/A | Both | 908 | N/A | Germany | |
845 | NCT01536366 | June 2009 | 19 October 2017 | Effect of BIA 9-1067 on the Pharmacokinetics of Repaglinide | Effect of BIA 9-1067 on the Pharmacokinetics of Repaglinide in Healthy Volunteers | Parkinson Disease | Drug: BIA 9-1067;Drug: Repaglinide | Bial - Portela C S.A. | Not recruiting | 18 Years | 45 Years | All | 27 | Phase 1 | Portugal | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
846 | NCT02169440 | June 2009 | 19 October 2017 | Effect of BIA 9-1067 on the Pharmacokinetics and Pharmacodynamics of Warfarin | Effect of BIA 9-1067 on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Volunteers | Parkinson's Disease (PD) | Drug: BIA 9-1067;Drug: Warfarin | Bial - Portela C S.A. | Not recruiting | 18 Years | 45 Years | All | 20 | Phase 1 | Portugal | |
847 | EUCTR2008-004146-88-FI | 19/05/2009 | 21 January 2013 | An extension trial to investigate the long-term efficacy and safety of safinamide, as add-on therapy in patients with early Parkinson’s disease treated with a stable dose of a dopamine agonist | A phase III, double-blind, placebo-controlled extension trial to investigate the long-term efficacy and safety of low (50 mg/day) and high (100 mg/day) dose safinamide, as add-on therapy in subjects with early idiopathic Parkinson’s disease treated with a stable dose of a single dopamine agonist - Safinamide in early PD patients treated with a single dopamine agonist. Extension Trial to 27918 | Idiopathic Parkinson's Disease MedDRA version: 14.1 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Safinamide Product Code: NW-1015 Pharmaceutical Form: Coated tablet Pharmaceutical form of the placebo: Coated tablet Route of administration of the placebo: Oral use Product Name: Safinamide Product Code: NW-1015 Pharmaceutical Form: Coated tablet Pharmaceutical form of the placebo: Coated tablet Route of administration of the placebo: Oral use | Newron Pharmaceuticals | Not Recruiting | Female: yes Male: yes | 498 | Phase 3 | United States;Portugal;Slovakia;Finland;Spain;Chile;Colombia;Italy;India;Czech Republic;Mexico;Canada;Argentina;Poland;Brazil;Croatia;Peru;South Africa;Bulgaria;Germany | |||
848 | EUCTR2008-008712-98-FI | 18/05/2009 | 19 March 2012 | 13-week, double-blind, placebo-controlled, fixed-dose, multicenter study to evaluate the efficacy and safety of AFQ056 in reducing moderate to severe L-dopa induced dyskinesias in patients with Parkinson’s disease | 13-week, double-blind, placebo-controlled, fixed-dose, multicenter study to evaluate the efficacy and safety of AFQ056 in reducing moderate to severe L-dopa induced dyskinesias in patients with Parkinson’s disease | moderate to severe levodopa induced dyskinesias in patients with Parkinson's disease MedDRA version: 9.1 Level: LLT Classification code 10013916 Term: Dyskinesia | Product Name: AFQ056 Product Code: AFQ056 Pharmaceutical Form: Capsule, hard Current Sponsor code: AFQ056 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Product Name: AFQ056 Product Code: AFQ056 Pharmaceutical Form: Capsule, hard Current Sponsor code: AFQ056 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Product Name: AFQ056 Product Code: AFQ056 Pharmaceutical Form: Capsule, hard Current Sponsor code: AFQ056 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use | Novartis Pharma AG | Not Recruiting | Female: yes Male: yes | 198 | Finland;Germany;France;Spain;Italy | ||||
849 | EUCTR2008-001966-10-HU | 04/05/2009 | 24 July 2012 | A phase III, double blind, placebo-controlled extension trial to investigate the long-term efficacy and safety of safinamide (50 to 100 mg/day), as add on therapy, in subjects with idiopathic Parkinson’s disease with motor fluctuations, treated with a stable dose of levodopa and who may be receiving concomitant treatment with stable doses of a dopamine agonist, an anticholinergic and/or amantadine - Safinamide in PD with motor fluctuations, as add-on to levodopa. Extension to trial 27919 | Idiopathic Parkinson's Disease MedDRA version: 9.1 Level: LLT Classification code 10061536 Term: Parkinson's disease | Product Name: Safinamide Product Code: NW-1015 Pharmaceutical Form: Coated tablet INN or Proposed INN: Safinamide CAS Number: 202825-46-5 Current Sponsor code: NW-1015 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Coated tablet Route of administration of the placebo: Oral use Product Name: Safinamide Product Code: NW-1015 Pharmaceutical Form: Coated tablet INN or Proposed INN: Safinamide CAS Number: 202825-46-5 Current Sponsor code: NW-1015 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Coated tablet Route of administration of the placebo: Oral use | Merck Serono SA - Geneva | Not Recruiting | Female: yes Male: yes | 416 | Phase 3 | Hungary;United Kingdom;Estonia;Austria | ||||
850 | NCT00767546 | May 2009 | 19 February 2015 | Botulinum Toxin for Treatment of Seborrhic Dermatitis in Parkinsonian Patients | Botulinum Toxin for Treatment of Seborrhic Dermatitis in Parkinsonian Patients | Parkinson Disease;Parkinsonism;Seborrheic Dermatitis | Drug: Botulinum toxin | Rabin Medical Center | Not recruiting | 18 Years | N/A | Both | 40 | Phase 1 | ||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
851 | NCT00892450 | May 2009 | 19 February 2015 | Anticholinergic Therapy for Overactive Bladder in Parkinson's Disease | Anticholinergic Therapy for Overactive Bladder in Parkinson's Disease: A Randomized, Double-blind, Crossover Pilot Study | Parkinson's Disease;Overactive Bladder | Drug: Oxybutynin and darifenacin | Department of Veterans Affairs | Not recruiting | N/A | N/A | Both | 12 | N/A | United States | |
852 | NCT00906763 | May 2009 | 19 February 2015 | Effects of Chocolate on Motor Symptoms of Parkinson's Disease | Effects of Chocolate on Motor Symptoms of Parkinson's Disease - A Monocenter, Prospective, Observer-blinded Interventional Trial | Parkinson's Disease | Dietary Supplement: Chocolate | Technische Universität Dresden | Recruiting | 18 Years | N/A | Both | 23 | N/A | Germany | |
853 | NCT00907595 | May 2009 | 19 February 2015 | Treating Sleep/Wake Cycle Disturbances in Basal Ganglia Disorders With Ramelteon | Treating Sleep Wake Cycle Disturbances in Basal Ganglia Neurodegenerative Disorder Subjects With Ramelteon- A Double Blind, Placebo Controlled Trial | Huntington's Disease;Parkinson's Disease;Dementia With Lewy Bodies;Sleep Disorders;Circadian Dysregulation | Drug: Ramelteon;Drug: Placebo | Massachusetts General Hospital | Not recruiting | 20 Years | 90 Years | Both | 0 | N/A | United States | |
854 | NCT00914602 | May 2009 | 19 February 2015 | An Exploratory Study of XP21279 (With Lodosyn®) and Sinemet® in Parkinson's Disease Subjects | An Exploratory Pharmacokinetic, Pharmacodynamic and Safety Study of XP21279 (With Lodosyn®) and Sinemet® in Parkinson's Disease Subjects With Motor Fluctuations | Parkinson's Disease | Drug: XP21279;Drug: Sinemet®;Drug: Lodosyn® | XenoPort, Inc. | Not recruiting | 30 Years | 75 Years | Both | 14 | Phase 1/Phase 2 | United States | |
855 | NCT01515891 | May 2009 | 19 October 2017 | Absorption, Distribution, Metabolism and Excretion of [14C]-Labeled BIA 9-1067 and Metabolites | An Open-label Study in Healthy Male Subjects to Assess the Absorption, Distribution, Metabolism and Excretion of [14C]-Labeled BIA 9-1067 and Metabolites Following a Single-dose Oral Administration | Parkinson Disease | Drug: BIA 9-1067 | Bial - Portela C S.A. | Not recruiting | 40 Years | 55 Years | Male | 4 | Phase 1 | Switzerland | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
856 | EUCTR2008-002769-30-IT | 30/04/2009 | 19 March 2012 | A randomised, double-blind, placebo-controlled, two-period, two-sequence-crossover interaction study to assess the effect of safinamide on levodopa pharmacokinetics in subjects with Parkinson?s disease - A study to assess the effect of safinamide on levodopa pharmacokinetics | A randomised, double-blind, placebo-controlled, two-period, two-sequence-crossover interaction study to assess the effect of safinamide on levodopa pharmacokinetics in subjects with Parkinson?s disease - A study to assess the effect of safinamide on levodopa pharmacokinetics | Parkinson Disease MedDRA version: 9.1 Level: LLT Classification code 10013113 | Product Name: Safinamide Pharmaceutical Form: Coated tablet INN or Proposed INN: Safinamide Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Coated tablet Route of administration of the placebo: Oral use Pharmaceutical Form: Tablet INN or Proposed INN: NACOM levodopa+cardidopa Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 125- | MERCK SERONO SA | Not Recruiting | Female: yes Male: yes | Italy | |||||
857 | EUCTR2008-005492-94-IT | 30/04/2009 | 9 October 2012 | OPEN LABEL TRIAL TO DETERMINE THE LONG TERM SAFETY OF SAFINAMIDE IN PARKINSON`S DISEASE PATIENTS - ND | IDIOPATHIC PARKINSON`S DISEASE MedDRA version: 9.1 Level: LLT Classification code 10061536 Term: Parkinson's disease | Product Name: SAFINAMIDE Product Code: NW-1015 Pharmaceutical Form: Coated tablet CAS Number: 202825-46-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Product Name: SAFINAMIDE Product Code: NW-1015 Pharmaceutical Form: Coated tablet CAS Number: 202825-46-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- | MERCK SERONO SA | Authorised | Female: yes Male: yes | 700 | Hungary;Portugal;Germany;Netherlands;France;Bulgaria;Italy;Austria;United Kingdom;Czech Republic;Belgium;Estonia;Spain | |||||
858 | EUCTR2008-008210-38-FR | 16/04/2009 | 19 March 2012 | Effet d’un traitement anti-glutamatergique sur les troubles de la marche avec freezing et sur l’attention dans la maladie de Parkinson: “freezing of gait and glutamate: FOGG-I” - FOGG-I | Effet d’un traitement anti-glutamatergique sur les troubles de la marche avec freezing et sur l’attention dans la maladie de Parkinson: “freezing of gait and glutamate: FOGG-I” - FOGG-I | Patients ayant une maladie de Parkinson Patients à un stade évolué de la maladie avec des troubles de la marche sévères MedDRA version: 9.1 Level: LLT Classification code 10061536 Term: Parkinson's disease MedDRA version: 9.1 Level: PT Classification code 10061536 Term: Parkinson's disease | Trade Name: EBIXA® Product Name: mémantine Pharmaceutical Form: Tablet Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Trade Name: L-Dopa/ MODOPAR Product Name: L-Dopa Pharmaceutical Form: Capsule* | Chru de Lille | Authorised | Female: yes Male: yes | 28 | France | ||||
859 | EUCTR2008-005085-30-DE | 06/04/2009 | 19 March 2012 | Reversibility of olfactory loss in patients with Idiopathic Parkinson’s disease following treatment with Rasagiline | Einfluss von Rasagilin auf das Riechvermögen von Patienten mit idiopathischem Parkinson-Syndrom (Reversibility of olfactory loss in patients with Idiopathic Parkinson’s disease following treatment with Rasagiline) - Olfaction | Idiopathic Parkinson syndrome (IPS), State according to Hoehn & Yahr: maximum III MedDRA version: 13.1 Level: LLT Classification code 10034008 Term: Parkinson's syndrome System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Azilect Pharmaceutical Form: Tablet INN or Proposed INN: Rasagilin Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | Technische Universität Dresden | Not Recruiting | Female: yes Male: yes | Germany | |||||
860 | EUCTR2008-000400-81-PT | 03/04/2009 | 1 May 2012 | A Multicenter, Randomized, Double Blind, Pramipexole Controlled Pilot Study to Assess Efficacy and Safety of Pardoprunox as Adjunct Therapy to L-dopa in the Treatment of Patients with Parkinson’s Disease Experiencing Motor Fluctuations and Dyskinesia | A Multicenter, Randomized, Double Blind, Pramipexole Controlled Pilot Study to Assess Efficacy and Safety of Pardoprunox as Adjunct Therapy to L-dopa in the Treatment of Patients with Parkinson’s Disease Experiencing Motor Fluctuations and Dyskinesia | Advanced Parkinson's Disease MedDRA version: 9.1 Level: LLT Classification code 10013113 Term: Disease Parkinson's | Product Name: Pardoprunox Product Code: SLV308 Pharmaceutical Form: Capsule, hard INN or Proposed INN: Pardoprunox hydrochloride CAS Number: 269718-83-4 Current Sponsor code: Pardoprunox hydrochloride Other descriptive name: SLV308 hydrochloride Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Product Name: Pardoprunox Product Code: SLV308 Pharmaceutical Form: Capsule, hard INN or Proposed INN: Pardoprunox hydrochloride CAS Number: 269718-83-4 Current Sponsor code: Pardoprunox hydrochloride Other descriptive name: SLV308 hydrochloride Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1.0- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Product Name: Pardoprunox Product Code: SLV308 Pharmaceutical Form: Capsule, hard INN or Proposed INN: Pardoprunox hydrochloride CAS Number: 269718-83-4 Current Sponsor code: Pardoprunox hydrochloride Other descriptive name: SLV308 hydrochloride Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2.0- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Trade Name: Mirapex Product Name: pramipexole Pharmaceutical Form: Capsule, hard INN or Proposed INN: pramipexole CAS Number: 104632-26-0 Current Sponsor code: Pramipexole Other descriptive name: pramipexole dihydrochloride monohydrate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.125- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Trade Name: Mirapex Product Name: Pramipexole Pharmaceutical Form: Capsule, hard INN or Proposed INN: Pramipexole CAS Number: 104632-26-0 Current Sponsor code: Pramipexole Other descriptive name: pramipexole dihydrochloride monohydrate | Solvay Pharmaceuticals BV | Not Recruiting | Female: yes Male: yes | 50 | Portugal;Germany;Italy | ||||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
861 | JPRN-JapicCTI-090888 | 01/4/2009 | 2 April 2019 | A Double-Blind, 3-Arm, Parallel Group, Placebo-and Ropinirole-Controlled Study of SPM 962 in Subjects with Parkinson's Disease Treated Concomitantly with L-dopa | A Double-Blind, 3-Arm, Parallel Group, Placebo-and Ropinirole-Controlled Study of SPM 962 in Subjects with Parkinson's Disease Treated Concomitantly with L-dopa | Parkinson's Disease Treated Concomitantly with L-dopa | Intervention name : SPM 962 Dosage And administration of the intervention : SPM 962: transdermal application, 1 time per day. Initial dose:4.5mg/day, weekly increment of 4.5mg/day, maximal maintenance dose : 36.0mg/day. Placebo of ropinirole: oral application 3 times per day. Initial dose:0.75mg placebo/day, weekly increment of 0.75mg placebo/day (up to 3.0mg placebo/day), then 1.5mg placebo/day (up to 15.0mg placebo/day), maximal maintenance dose 15.0 mg placebo/day Control intervention name : Ropinirole Dosage And administration of the control intervention : placebo SPM 962: transdermal application, 1 time per day. Initial dose: 4.5mg placebo/day, weekly increment of 4.5mg placebo/day, maximal maintenance dose : 36.0mg placebo/day. Ropinirole: oral application 3 times per day. Initial dose:0.75mg/day, weekly increment of 0.75mg/day (up to 3.0mg/day), then 1.5mg/day (up to 15.0mg/day), maximal maintenance dose 15.0 mg/day. Control intervention name : Placebo Dosage And administration of the control intervention : placebo SPM 962: transermal application, 1 time per day. Initial dose: 4.5mg placebo/day, weekly increment of 4.5mg placebo/day, maximal maintenance dose : 36.0mg placebo/day. Placebo ropinirole: oral application 3 times per day. Initial dose:0.75mg placebo/day, weekly increment of 0.75mg placebo/day (up to 3.0mg placebo/day), then 1.5mg placebo/day (up to 15.0mg placebo/day), maximal maintenance dose 15.0 mg placebo/day. | Otsuka Pharmaceutical Co., Ltd. | 30 | 79 | BOTH | 400 | Phase 3 | |||
862 | JPRN-UMIN000001841 | 2009/04/01 | 2 April 2019 | A randomized, double blind, comparative study of vitamin D3 versus placebo in patients with Parkinson disease aged between 45 and 85 years old to improve neurological signs and quality of life | Parkinson disease | Vitamin D3 placebo | Jikei University School of Medicine | Not Recruiting | 45years-old | 85years-old | Male and Female | 120 | Not selected | Japan | ||
863 | NCT00845000 | April 2009 | 19 October 2017 | Acute Effects of Preladenant (SCH 420814) on Dyskinesia and Parkinsonism in Levodopa Treated Participants (P05550) | Acute Effects of SCH 420814 on Dyskinesia and Parkinsonism in Levodopa Treated Patients | Parkinson Disease | Drug: SCH 420814 10 mg;Drug: SCH 420814 100 mg;Drug: Placebo;Drug: Levodopa;Drug: Carbidopa | Merck Sharp & Dohme Corp. | Oregon Health and Science University | Not recruiting | 18 Years | N/A | All | 12 | Phase 1 | United States |
864 | NCT00865579 | April 2009 | 16 December 2017 | Open-Label Trial to Determine the Long-Term Safety of Safinamide in Parkinson's Disease Patients | Open-Label Trial to Determine the Long-Term Safety of Safinamide in Parkinson's Disease Patients | Parkinson's Disease | Drug: Safinamide | Newron | Not recruiting | 30 Years | N/A | All | 964 | Phase 3 | Romania | |
865 | NCT00875316 | April 2009 | 19 February 2015 | Safety and Tolerability Study of Cogane™ in Healthy Volunteers and Parkinson's Disease Patients | A Randomised, Double-blind, Multiple Dose-ascending, Placebo-controlled Study in Healthy Volunteers and Parkinson's Disease Patients to Assess the Safety, Tolerability and PK of Daily Oral Administration of Cogane™ Over One Month | Parkinson's Disease | Drug: Cogane™ (PYM50028) | Phytopharm | Not recruiting | 40 Years | 80 Years | Both | 36 | Phase 1 | United Kingdom | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
866 | NCT00880620 | April 2009 | 4 November 2019 | A Study To Evaluate The Safety And Efficacy Of IPX066 In Subjects With Parkinson's Disease | A Placebo-Controlled Study To Evaluate The Safety And Efficacy Of IPX066 In Subjects With Parkinson's Disease | Parkinson's Disease | Drug: Placebo;Drug: IPX066 95 mg LD;Drug: IPX066 145 mg LD;Drug: IPX066 195 mg LD;Drug: IPX066 245 mg LD | Impax Laboratories, LLC | Not recruiting | 30 Years | N/A | All | 381 | Phase 3 | United States;Canada;Estonia;Latvia;Lithuania;Romania;Ukraine | |
867 | NCT00914134 | April 2009 | 19 February 2015 | Duodenal Levodopa Infusion, Quality of Life and Autonomic Nervous System in Parkinson's Disease | Effect of Duodenal Levodopa Infusion on Quality of Life and Autonomic Dysfunction in Patients With Parkinson's Disease | Parkinson's Disease | Drug: Levodopa infusion | Helsinki University | Solvay Pharmaceuticals | Not recruiting | 40 Years | 80 Years | Both | 12 | Phase 4 | Finland |
868 | NCT00758368 | March 2009 | 12 November 2018 | Comparison of Continuous and Pulsatile Apomorphine in Parkinson's Disease | Comparison of Continuous and Pulsatile Apomorphine Administration in Parkinson's Disease Complicated by Levodopa-induced Dyskinesia | Parkinson's Disease | Drug: Apomorphine | Oregon Health and Science University | National Institute of Neurological Disorders and Stroke (NINDS) | Not recruiting | 21 Years | N/A | All | 0 | Phase 2 | United States |
869 | NCT00823836 | March 2009 | 19 October 2017 | Clinical Evaluation of Ropinirole Prolonged Release/Extended Release (PR/XR) Tablet for Adjunctive Therapy to L-dopa in Subjects With Advanced Parkinson's Disease | Clinical Evaluation of Ropinirole PR/XR Tablet for Adjunctive Therapy to L-dopa in Subjects With Advanced Parkinson's Disease | Parkinson Disease | Drug: ropinirole PR/XR;Drug: ropinirole IR | GlaxoSmithKline | Not recruiting | 20 Years | N/A | All | 302 | Phase 3 | Japan | |
870 | NCT00866502 | March 2009 | 19 February 2015 | A Safety and Tolerability Study of Intracerebroventricular Administration of sNN0031 to Patients With Parkinson's Disease | A Randomized, Double-blind, Placebo Controlled, Safety and Tolerability Study of Intracerebroventricular Administration of sNN0031 to Patients With Idiopathic Parkinson's Disease (PD) of Moderate Severity, Using an Implanted Catheter and a SynchroMed® II Pump. | Parkinson's Disease | Drug: sNN0031;Drug: Placebo | Newron Sweden AB | Medtronic;Quintiles | Not recruiting | 30 Years | 75 Years | Both | 12 | Phase 1/Phase 2 | Sweden |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
871 | NCT00870974 | March 2009 | 16 December 2017 | A PET Brain Imaging Study of mGluR5 in Subjects With Neuropsychiatric Conditions | Evaluation of [18F]PEB and Positron Emission Tomography (PET) as a Marker of mGluR5 in Subjects w/ Neuropsychiatric Conditions | Parkinson Disease;Huntington Disease;Autistic Spectrum Disorders;Fragile X Syndrome;Alzheimer Disease;Mild Cognitive Impairment | Drug: [18F]FPEB | Institute for Neurodegenerative Disorders | Not recruiting | 18 Years | 85 Years | All | 48 | Phase 1 | United States | |
872 | NCT00940914 | March 2009 | 19 February 2015 | Dopaminergic Loss and Pain in Parkinson's Disease | Evaluation of Radioligand Uptake (FP-CIT) of Dopamine Transporters in Patients Suffering From Parkinson's Disease With or Without Pain | Parkinson's Disease;Pain | Drug: ioflupane 123I (DATSCAN®) | University Hospital, Toulouse | Not recruiting | 30 Years | 70 Years | Both | 20 | Phase 2 | France | |
873 | NCT01399905 | March 2009 | 19 February 2015 | High and Low Dose Carbidopa Treatment of Parkinson's Disease | A Randomized Controlled Trial of Four Week Outpatient Treatment of Parkinson's Disease Comparing High and Low Dose Carbidopa. | Parkinson's Disease | Drug: carbidopa | Oregon Health and Science University | Not recruiting | 35 Years | 85 Years | Both | 12 | Phase 2 | United States | |
874 | NCT01533077 | March 2009 | 19 October 2017 | Pharmacokinetic Interaction Between BIA 9-1067 and Standard-release Levodopa/Carbidopa | Pharmacokinetic Interaction Between BIA 9-1067 and Standard-release Levodopa/Carbidopa in Healthy Subjects | Parkinson Disease | Drug: BIA 9-1067;Drug: Sinemet® 100/25 mg | Bial - Portela C S.A. | Not recruiting | 18 Years | 45 Years | All | 18 | Phase 1 | Canada | |
875 | NCT01533116 | March 2009 | 19 October 2017 | Effect of BIA 9-1067 at Steady-state on the Pharmacokinetics of Levodopa/Carbidopa and Levodopa/Benserazide | Effect of BIA 9-1067 at Steady-state on the Pharmacokinetics of a Single-dose of Immediate-release 100/25 mg Levodopa/Carbidopa and 100/25 mg Levodopa/Benserazide in Healthy Subjects | Parkinson Disease | Drug: BIA 9-1067;Drug: Placebo;Drug: levodopa/carbidopa;Drug: levodopa/benserazide | Bial - Portela C S.A. | Not recruiting | 25 Years | 45 Years | All | 52 | Phase 1 | Canada | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
876 | EUCTR2008-006278-13-NL | 04/02/2009 | 19 March 2012 | Motor function optimization in advanced Parkinson’s disease patients, combined with galantamine to prevent visual hallucinations. | Motor function optimization in advanced Parkinson’s disease patients, combined with galantamine to prevent visual hallucinations. | patients with advanced (>5 years) Parkinson's disease and visual hallucinations. MedDRA version: 9.1 Level: LLT Classification code 10047570 Term: Visual hallucinations MedDRA version: 9.1 Level: LLT Classification code 10013113 Term: Disease Parkinson's | Trade Name: Reminyl Retard Pharmaceutical Form: Capsule* Trade Name: Sinemet 125 mg Pharmaceutical Form: Tablet | UMCG | Authorised | Female: yes Male: yes | 10 | Netherlands | ||||
877 | NCT00806468 | February 2009 | 19 February 2015 | Effect of Desmopressin on the Nocturnal Micturition Frequency in Patients With Parkinson Disease | A Double Blind, Placebo Controlled, Randomized, Monocentre Cross-over Study to Investigate the Effect of Desmopressin on the Nocturnal Micturition Frequency in Patients With Parkinson Disease | Parkinson Disease | Drug: Desmotabs | Johannes Gutenberg University Mainz | Not recruiting | 18 Years | 85 Years | Male | 1 | Phase 4 | Germany | |
878 | NCT00873392 | February 2009 | 19 February 2015 | Efficacy of Transdermal Nicotine, on Motor Symptoms in Advanced Parkinson's Disease | Efficacy of Transdermal Nicotine, on Motor Symptoms in Advanced Parkinson's Disease(One Daily Administration).A Controlled Randomised Study, in Two Parallel Groups and Single Blind in 40 Patients. | Idiopathic Parkinson's Disease | Drug: Transdermal nicotine;Other: Usual drug treatment of Parkinson's disease | Assistance Publique - Hôpitaux de Paris | Not recruiting | 35 Years | 70 Years | Both | 40 | Phase 2 | France | |
879 | NCT00908076 | February 2009 | 19 October 2017 | Amitiza in Constipation Associated With PD (Parkinson's Disease) | Randomized Double-Blind Placebo-Controlled Trial of Lubiprostone in the Treatment of Constipation Associated With Parkinson's Disease | Parkinson's Disease | Drug: LUBIPROSTONE | Baylor College of Medicine | University of South Florida | Not recruiting | 18 Years | 85 Years | All | 78 | Phase 4 | United States |
880 | NCT01421719 | February 2009 | 16 December 2017 | Safety and Efficacy of botulinumA Toxin (BotoxA) for Treatment of Neurogenic Bladder of Parkinson's Disease | Onabotulinum Toxin Type A (BTX-A) For Treatment of Neurogenic Overactive Bladder Due to Parkinson's Disease: Safety and Efficacy | Parkinson's Disease;Neurogenic Bladder;Urinary Incontinence;Clostridium Botulinum Toxin Adverse Reaction | Drug: Cystoscopic injection of Botox into the urinary bladder | Stanford University | Allergan | Not recruiting | 50 Years | 85 Years | All | 20 | Phase 4 | United States |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
881 | EUCTR2007-007853-30-SE | 28/01/2009 | 19 March 2012 | A randomized, double-blind, placebo controlled, safety and tolerability study of intracerebroventricular administration of sNN0031 to patients with idiopathic Parkinson's disease (PD) of moderate severity, using an implanted catheter and a SynchroMed® II pump. | A randomized, double-blind, placebo controlled, safety and tolerability study of intracerebroventricular administration of sNN0031 to patients with idiopathic Parkinson's disease (PD) of moderate severity, using an implanted catheter and a SynchroMed® II pump. | Idiopathic Parkinson's disease (PD) of moderate severity (modified Hoehn & Yahr Stage IIb - III) | Product Name: sNN0031 Product Code: sNN0031 Pharmaceutical Form: Concentrate for solution for infusion Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intracisternal use | NeuroNova AB | Not Recruiting | Female: yes Male: yes | Sweden | |||||
882 | EUCTR2009-015833-66-IT | 20/01/2009 | 24 April 2012 | Ropinirole 24h prolonged release and motor fluctuations: a study to control the wearing-off induced by dopamine agonists immediate release | Ropinirole 24h prolonged release and motor fluctuations: a study to control the wearing-off induced by dopamine agonists immediate release | Parkinson's Disease MedDRA version: 14.1 Level: LLT Classification code 10013113 Term: Disease Parkinson's System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: REQUIP*28CPR 8MG R.P. Pharmaceutical Form: Prolonged-release capsule, hard INN or Proposed INN: ROPINIROLE CAS Number: 91374-21-9 Current Sponsor code: NA Other descriptive name: NA Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 8- Trade Name: REQUIP*21CPR 5MG Pharmaceutical Form: Tablet INN or Proposed INN: ROPINIROLE CAS Number: 91374-21-9 Current Sponsor code: NA Other descriptive name: NA Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Trade Name: MIRAPEXIN*30CPR 0,7MG Pharmaceutical Form: Tablet INN or Proposed INN: PRAMIPEXOLE CAS Number: 104632-26-0 Current Sponsor code: NA Other descriptive name: NA Concentration unit: mg milligram(s) Concentration type: equal Concentration number: .7- | CASA DI CURA PRIVATA S.RAFFAELE - PISANA | Not Recruiting | Female: yes Male: yes | Italy | |||||
883 | EUCTR2008-004906-15-FR | 05/01/2009 | 19 March 2012 | EVALUATION DE LA CAPTATION D’UN RADIOLIGAND DES TRANSPORTEURS DE LA DOPAMINE CHEZ DES SUJETS ATTEINTS DE LA MALADIE DE PARKINSON ET PRESENTANT OU NON DES DOULEURS EN RAPPORT AVEC CETTE PATHOLOGIE - dénervation dopaminergique et douleur dans la maladie de Parkinson | EVALUATION DE LA CAPTATION D’UN RADIOLIGAND DES TRANSPORTEURS DE LA DOPAMINE CHEZ DES SUJETS ATTEINTS DE LA MALADIE DE PARKINSON ET PRESENTANT OU NON DES DOULEURS EN RAPPORT AVEC CETTE PATHOLOGIE - dénervation dopaminergique et douleur dans la maladie de Parkinson | Maladie de Parkinson MedDRA version: 9.1 Level: LLT Classification code 10013113 Term: Disease Parkinson's | Trade Name: DATSCAN Pharmaceutical Form: Solution for injection | CHU Toulouse | Authorised | Female: yes Male: yes | France | |||||
884 | NCT00357994 | January 2009 | 19 October 2017 | Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects | A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Receiving Optimized Treatments With Parkinson Medicinal Products Who Continue to Experience Persistent Motor Fluctuations | Advanced Parkinson's Disease | Drug: Levodopa carbidopa intestinal gel (LCIG);Drug: Placebo gel;Drug: Levodopa carbidopa (LC) oral encapsulated immediate release (IR) tablets;Drug: Placebo (PBO) oral capsules;Device: CADD-Legacy® 1400 ambulatory infusion pump;Device: PEG tube;Device: J-tube | AbbVie (prior sponsor, Abbott) | Quintiles, Inc. | Not recruiting | 30 Years | N/A | All | 36 | Phase 3 | United States;Germany |
885 | NCT00857532 | January 2009 | 19 October 2017 | Florbetapir F 18 PET Imaging of Beta-amyloid in Parkinson's Disease Patients | A Phase 2 Trial of Florbetapir F18 PET Imaging of ß-amyloid in Parkinson's Disease Patients With Cognitive Impairment | Parkinson's Disease | Drug: florbetapir F 18 | Avid Radiopharmaceuticals | National Institutes of Health (NIH);National Institute of Neurological Disorders and Stroke (NINDS) | Not recruiting | 60 Years | N/A | All | 31 | Phase 2 | United States |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
886 | NCT02169466 | January 2009 | 19 October 2017 | Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Benserazide | Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Benserazide: a Double-blind, Randomized, Four-way Crossover, Placebo-controlled Study in Healthy Male Subjects | Parkinson's Disease (PD) | Drug: BIA 9-1067;Drug: Placebo;Drug: Madopar® HBS | Bial - Portela C S.A. | Not recruiting | 18 Years | 45 Years | Male | 22 | Phase 1 | Portugal | |
887 | EUCTR2009-014341-84-DE | 18 April 2012 | Non-GI: A multi site, open-label, interventional Pilot study assessing the switch from oral treatment to rotigotine transdermal patch (Neupro) in Parkinson's disease patients with identified gastrointestinal symptoms. | Non-GI: A multi site, open-label, interventional Pilot study assessing the switch from oral treatment to rotigotine transdermal patch (Neupro) in Parkinson's disease patients with identified gastrointestinal symptoms. | idiopathic Parkinson's disease MedDRA version: 12.0 Level: LLT Classification code 10061536 Term: Parkinson's disease | Trade Name: Neupro 2 mg/24 h transdermal patch Product Name: Rotigotine transdermal patch 2mg/24h(10cm2) Pharmaceutical Form: Transdermal patch INN or Proposed INN: Rotigotine CAS Number: 99755-59-6 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 4.5- Trade Name: Neupro 4 mg/24 h transdermal patch Product Name: Rotigotine transdermal patch 4mg/24h (20cm2) Pharmaceutical Form: Transdermal patch INN or Proposed INN: Rotigotine CAS Number: 99755-59-6 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 9.0- Trade Name: Neupro 6 mg/24 h transdermal patch Product Name: Rotigotine transdermal patch 6mg/24h (30cm2) Pharmaceutical Form: Transdermal patch INN or Proposed INN: Rotigotine CAS Number: 99755-59-6 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 13.5- Trade Name: Neupro 8 mg/24 h transdermal patch Product Name: Rotigotine transdermal patch 8mg/24h (40cm2) Pharmaceutical Form: Transdermal patch INN or Proposed INN: rotigotine CAS Number: 99755-59-6 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 18.0- | Schwarz Pharma Deutschland GmbH, UCB Group | Authorised | Female: yes Male: yes | Germany | ||||||
888 | EUCTR2008-003966-25-DE | 23/12/2008 | 3 June 2013 | Double-blind, placebo controlled, randomised, monocenter cross-over studie to evaluate the effect of Desmopressin on the nocturnal polyuria in patients with idiopathic Parkinson Syndrome compared to placebo. - DEPOPA | Double-blind, placebo controlled, randomised, monocenter cross-over studie to evaluate the effect of Desmopressin on the nocturnal polyuria in patients with idiopathic Parkinson Syndrome compared to placebo. - DEPOPA | Effect of Desmopressin on the nocturnal polyuria in patients with idiopathic Parkinson Syndrome MedDRA version: 9.1 Level: LLT Classification code 10064016 Term: Nocturnal polyuria MedDRA version: 9.1 Level: LLT Classification code 10061536 Term: Parkinson's disease | Trade Name: Desmotabs® 0,2 mg Tabletten Product Name: Desmotabs® 0,2mg Tabletten Pharmaceutical Form: Capsule* INN or Proposed INN: Desmopressin Acetat Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0,2- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use | Universität Mainz, Klinik und Poliklinik für Neurologie | Not Recruiting | Female: no Male: yes | 20 | Germany | ||||
889 | NCT00740714 | December 2008 | 19 October 2017 | Effects of Coenzyme Q10 (CoQ) in Parkinson Disease | Effects of Coenzyme Q10 in Parkinson Disease - Phase III | Parkinson Disease | Drug: Coenzyme Q10 with vitamin E;Drug: placebo with vitamin E | Weill Medical College of Cornell University | National Institute of Neurological Disorders and Stroke (NINDS);University of Rochester | Not recruiting | 30 Years | N/A | All | 600 | Phase 3 | United States;Canada |
890 | NCT00809302 | December 2008 | 19 February 2015 | Efficacy and Safety Study of Aplindore in Patients With Early Parkinson Disease | A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Three Doses of Aplindore MR (1, 3, and 6 mg Twice Daily) in Patients With Early Parkinson Disease (APLIED) | Early Parkinson Disease | Drug: aplindore MR tablets or Placebo | Neurogen Corporation | Not recruiting | 30 Years | N/A | Both | 9 | Phase 2 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
891 | EUCTR2008-004943-12-SK | 24/11/2008 | 3 April 2017 | The Rubens Study: A Multicenter, Randomized, Double-blind, Parallel Group, Placebo and Pramipexole Controlled Study to Explore the Efficacy, Tolerability and Safety of Different Doses and Titration Schedules of Pardoprunox Monotherapy in the Treatment of Patients with Early Stage Parkinson’s Disease - The Rubens Study | The Rubens Study: A Multicenter, Randomized, Double-blind, Parallel Group, Placebo and Pramipexole Controlled Study to Explore the Efficacy, Tolerability and Safety of Different Doses and Titration Schedules of Pardoprunox Monotherapy in the Treatment of Patients with Early Stage Parkinson’s Disease - The Rubens Study | Early Stage Parkinson’s Disease MedDRA version: 9.1 Level: LLT Classification code 10013113 Term: Disease Parkinson's | Product Name: Pardoprunox Product Code: SLV308 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Pardoprunox hydrochloride CAS Number: 269718-83-4 Current Sponsor code: Pardoprunox hydrochloride Other descriptive name: SLV308 hydrochloride Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.1- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use Product Name: Pardoprunox Product Code: SLV308 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Pardoprunox hydrochloride CAS Number: 269718-83-4 Current Sponsor code: Pardoprunox hydrochloride Other descriptive name: SLV308 hydrochloride Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.2- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use Product Name: Pardoprunox Product Code: SLV308 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Pardoprunox hydrochloride CAS Number: 269718-83-4 Current Sponsor code: Pardoprunox hydrochloride Other descriptive name: SLV308 hydrochloride Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use Product Name: Pardoprunox Product Code: SLV308 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Pardoprunox hydrochloride CAS Number: 269718-83-4 Current Sponsor code: Pardoprunox hydrochloride Other descriptive name: SLV308 hydrochloride Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1.0- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use Trade Name: Mirapex Pharmaceutical Form: Tablet INN or Proposed INN: Pramipexole CAS Number: 104632-26-0 Current Sponsor code: Pramipexole Other descriptive name: pramipexole dihydrochloride monohydrate Concentration unit: mg milligram(s) | Solvay Pharmaceuticals B.V. | Authorised | Female: yes Male: yes | 320 | Phase 2 | Slovakia | |||
892 | EUCTR2007-006721-27-GB | 11/11/2008 | 19 March 2012 | A Phase II, Multicenter, Randomized and Controlled Open-Label Trial Comparing the Safety and Efficacy of Bilateral Intraputaminal (IPu) Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) Combined with Best Medical Therapy (BMT) versus BMT-alone in Subjects With Idiopathic Parkinson’s Disease. | A Phase II, Multicenter, Randomized and Controlled Open-Label Trial Comparing the Safety and Efficacy of Bilateral Intraputaminal (IPu) Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) Combined with Best Medical Therapy (BMT) versus BMT-alone in Subjects With Idiopathic Parkinson’s Disease. | idiopathic Parkinson's Disease MedDRA version: 9.1 Level: LLT Classification code 10061536 Term: Parkinson's disease | Product Name: CERE-120 Product Code: CERE-120 Pharmaceutical Form: Suspension for injection Current Sponsor code: CERE-120 Concentration type: equal Concentration number: 6.7E+12 vg/ml- | Ceregene Inc. | Not Recruiting | Female: yes Male: yes | 50 | Phase 2 | United Kingdom | |||
893 | EUCTR2007-003035-22-GB | 05/11/2008 | 28 February 2019 | A safety and tolerability study of ACP-103 in patients with Parkinson's Disease Psychosis | A Multi-Center, Open-Label Extension Study to Examine the Safety and Tolerability of ACP-103 in the Treatment of Psychosis in Parkinson’s Disease - ACP-103-015 | Psychosis in Parkinson's Disease MedDRA version: 20.0 Level: LLT Classification code 10037241 Term: Psychosis NOS System Organ Class: 100000004873 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Pimavanserin tartrate Product Code: pimavanserin (ACP-103) Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Pimavanserin tartrate CAS Number: 706782-28-7 Current Sponsor code: pimavanserin (ACP-103) Other descriptive name: N/a Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- | ACADIA Pharmaceuticals Inc. | Not Recruiting | Female: yes Male: yes | 400 | Phase 3 | United States;Portugal;Ukraine;Austria;Russian Federation;United Kingdom;Italy;India;France;European Union;Canada;Belgium;Sweden | |||
894 | NCT00629161 | November 2008 | 19 February 2015 | Clinical Trial on the Effectiveness of Traditional Chinese Medicinal Mixture in Parkinson Disease | Parkinson Disease | Drug: Traditional Chinese Medicinal Mixture (composed of Roucongrong and adjuvant);Drug: placebo | Fudan University | Recruiting | 50 Years | N/A | Both | 144 | Phase 2/Phase 3 | China | ||
895 | NCT00869791 | November 2008 | 16 December 2017 | A Study to Compare Pharmacokinetics and Pharmacodynamics of IPX066 to Standard Carbidopa-Levodopa | A Study to Compare Pharmacokinetics and Pharmacodynamics of IPX066 to Standard Carbidopa-Levodopa | Parkinson's Disease | Drug: IPX066;Drug: IR CD-LD | IMPAX Laboratories, Inc. | Not recruiting | 30 Years | N/A | All | 27 | Phase 2 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
896 | EUCTR2007-006721-27-AT | 20/10/2008 | 11 April 2016 | A Phase II, Multicenter, Randomized and Controlled Open-Label Trial Comparing the Safety and Efficacy of Bilateral Intraputaminal (IPu) Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) Combined with Best Medical Therapy (BMT) versus BMT-alone in Subjects With Idiopathic Parkinson’s Disease. | A Phase II, Multicenter, Randomized and Controlled Open-Label Trial Comparing the Safety and Efficacy of Bilateral Intraputaminal (IPu) Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) Combined with Best Medical Therapy (BMT) versus BMT-alone in Subjects With Idiopathic Parkinson’s Disease. | idiopathic Parkinson's Disease MedDRA version: 9.1 Level: LLT Classification code 10061536 Term: Parkinson's disease | Product Name: CERE-120 Product Code: CERE-120 Pharmaceutical Form: Suspension for injection Current Sponsor code: CERE-120 Concentration type: equal Concentration number: 6.7E+12 vg/ml- | Ceregene Inc. | Not Recruiting | Female: yes Male: yes | 50 | Phase 2 | Austria;United Kingdom | |||
897 | EUCTR2008-003869-72-PT | 03/10/2008 | 19 March 2012 | A DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED, CROSS-OVER STUDY TO INVESTIGATE THE TOLERABILITY AND EFFECT OF THREE SINGLE-DOSE REGIMENS OF BIA 9-1067 ON THE LEVODOPA PHARMACOKINETICS, MOTOR RESPONSE, AND ERYTHROCYTE SOLUBLE CATECHOL-O-METHYLTRANSFERASE ACTIVITY IN PARKINSON'S DISEASE PATIENTS CONCOMITANTLY TREATED WITH LEVODOPA/DOPA-DECARBOXYLASE INHIBITOR | A DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED, CROSS-OVER STUDY TO INVESTIGATE THE TOLERABILITY AND EFFECT OF THREE SINGLE-DOSE REGIMENS OF BIA 9-1067 ON THE LEVODOPA PHARMACOKINETICS, MOTOR RESPONSE, AND ERYTHROCYTE SOLUBLE CATECHOL-O-METHYLTRANSFERASE ACTIVITY IN PARKINSON'S DISEASE PATIENTS CONCOMITANTLY TREATED WITH LEVODOPA/DOPA-DECARBOXYLASE INHIBITOR | Parkinson MedDRA version: 9.1 Level: LLT Classification code 10013113 Term: Disease Parkinson's | Product Code: BIA 9-1067 Pharmaceutical Form: Capsule* CAS Number: 923287-50-7 Current Sponsor code: BIA 9-1067 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: -25 Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use Trade Name: SINEMET 25/100 Pharmaceutical Form: Tablet INN or Proposed INN: LEVODOPA CAS Number: 59927 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- INN or Proposed INN: CARBIDOPA CAS Number: 28860959 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- Product Code: BIA 9-1067 Pharmaceutical Form: Capsule* CAS Number: 923287-50-7 Current Sponsor code: BIA 9-1067 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: -100 | Bial - Portela & Cª, S.A. | Not Recruiting | Female: yes Male: yes | 12 | Portugal | ||||
898 | NCT00611481 | October 2008 | 19 February 2015 | Study of Tai Chi Exercise and Balance in Persons With Parkinson's Disease | Phase II Study of Tai Chi Exercise in Relation to Balance in Persons With Parkinson's Disease | Parkinson's Disease | Behavioral: Tai Chi;Behavioral: Strength training;Behavioral: Low-Impact Exercise Control | Oregon Research Institute | National Institute of Neurological Disorders and Stroke (NINDS) | Not recruiting | 40 Years | 85 Years | Both | 195 | Phase 2 | United States |
899 | NCT00906828 | October 2008 | 19 February 2015 | Pharmacokinetics of Levodopa/Carbidopa Infusion With and Without Oral Catechol-O-methyl Transferase (COMT) Inhibitors | Pharmacokinetics of Levodopa in Patients With Parkinson's Disease Treated With Levodopa/Carbidopa Infusion With and Without Oral COMT Inhibitors | Parkinson Disease | Drug: levodopa/carbidopa;Drug: entacapone;Drug: tolcapone | Uppsala University | Swedish Parkinson's Disease Foundation;Swedish Society for Medical Research | Not recruiting | 30 Years | 90 Years | Both | 10 | Phase 4 | Sweden |
900 | NCT01048229 | October 2008 | 19 February 2015 | Evaluation of the Tolerance and Acceptability of Rasagiline in the Treatment of Early-stage Parkinson's Disease | Evaluation of the Tolerance and Acceptability of Rasagiline in the Treatment of Early-stage Parkinson's Disease | Early-stage Parkinson's Disease | Drug: Rasagiline;Drug: Pramipexole | Qualissima | H. Lundbeck A/S | Not recruiting | 18 Years | 70 Years | Both | 112 | Phase 4 | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
901 | NCT02092168 | October 2008 | 19 October 2017 | Pharmacokinetics of BIA 9-1067 and Its Metabolites in Healthy Male Elderly Subjects and in Healthy Male Young Subjects | Single-dose and Steady-state Pharmacokinetics of BIA 9-1067 and Its Metabolites in Healthy Male Elderly Subjects Compared With Those in Healthy Male Young Subjects | Parkinson Disease | Drug: BIA 9-1067 | Bial - Portela C S.A. | Not recruiting | 18 Years | N/A | Male | 24 | Phase 1 | France | |
902 | NCT02169453 | October 2008 | 19 October 2017 | Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Carbidopa | Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Carbidopa: a Double-blind, Randomized, Four-way Crossover, Placebo-controlled Study in Healthy Male Subjects | Parkinson's Disease (PD) | Drug: BIA 9-1067;Drug: Placebo;Drug: Sinemet® CR 100/25 | Bial - Portela C S.A. | Not recruiting | 18 Years | 45 Years | Male | 12 | Phase 1 | Canada | |
903 | EUCTR2007-003051-36-AT | 10/09/2008 | 18 April 2012 | A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson’s Disease | A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson’s Disease | Psychosis in Parkinson's Disease MedDRA version: 9.1 Level: LLT Classification code 10037241 Term: Psychosis NOS | Product Name: Pimavanserin tartrate Product Code: ACP-103 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Pimavanserin tartrate CAS Number: 706782-28-7 Current Sponsor code: ACP-103 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: Pimavanserin tartrate Product Code: ACP-103 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Pimavanserin tartrate CAS Number: 706782-28-7 Current Sponsor code: ACP-103 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | Acadia Pharmaceuticals Inc | Not Recruiting | Female: yes Male: yes | 280 | Portugal;Spain;Austria;Sweden | ||||
904 | EUCTR2008-003225-16-FI | 10/09/2008 | 7 October 2014 | Aivostimulaattorin ja levodopainfuusion vaikutus elämänlaatuun ja autonomisen hermoston toimintaan Parkinsonin tautia sairastavilla potilailla | Aivostimulaattorin ja levodopainfuusion vaikutus elämänlaatuun ja autonomisen hermoston toimintaan Parkinsonin tautia sairastavilla potilailla | Vaikeahoitoinen Parkinsonin tauti potilailla, joille on aiemmin asetettu aivostimulaattori, tai on päädytty päivittäisten oireiden vuoksi aloittamaan Duodopa-infuusio. MedDRA version: 9.1 Level: LLT Classification code 10034007 Term: Parkinson's disease NOS | Trade Name: Duodopa | Organisation name was not entered | Not Recruiting | Female: yes Male: yes | Finland | |||||
905 | NCT00758849 | September 2008 | 19 February 2015 | Fipamezole in Neurogenic Orthostatic Hypotension | A Phase II, Randomised, Placebo-Controlled, Double-Blind, Replicated Crossover, Pilot Study on the Effect of Fipamezole on Neurogenic Orthostatic Hypotension in Patients With Multiple System Atrophy or Parkinson's Disease | Symptomatic Neurogenic Orthostatic Hypotension (NOH);Parkinson's Disease;Multiple System Atrophy | Drug: Placebo;Drug: Fipamezole | Juvantia Pharma Ltd | Santhera Pharmaceuticals | Not recruiting | 30 Years | 80 Years | Both | 24 | Phase 2 | France;Portugal |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
906 | NCT02169479 | September 2008 | 19 October 2017 | Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Diferente Single Doses of BIA 9-1067 and a Single-dose of Immediate-release 100/25 mg Levodopa/Carbidopa | Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Diferente Single Doses of BIA 9-1067 and a Single-dose of Immediate-release 100/25 mg Levodopa/Carbidopa: a Doubleblind, Randomized, Four-way Crossover, Placebo-controlled Study in Healthy Male Subjects | Parkinson's Disease (PD) | Drug: BIA 9-1067;Drug: Placebo;Drug: Sinemet® 100/25 | Bial - Portela C S.A. | Not recruiting | 18 Years | 45 Years | Male | 16 | Phase 1 | Canada | |
907 | NCT02169895 | September 2008 | 19 October 2017 | Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Immediate-release Levodopa/Benserazide | Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Different Single Doses of BIA 9-1067 and a Single-dose of Immediate-release 100/25 mg Levodopa/Benserazide: a Doubleblind, Randomized, Four-way Crossover, Placebo-controlled Study in Healthy Male Subjects | Parkinson's Disease (PD) | Drug: BIA 9-1067;Drug: Placebo;Drug: Prolopa® | Bial - Portela C S.A. | Not recruiting | 25 Years | 45 Years | Male | 16 | Phase 1 | Canada | |
908 | EUCTR2007-004235-37-GB | 19/08/2008 | 19 March 2012 | Long-term safety study of open-label pramipexole extended release (ER) in patients with advanced Parkinson’s disease (PD). - Open label extension in advanced PD | Long-term safety study of open-label pramipexole extended release (ER) in patients with advanced Parkinson’s disease (PD). - Open label extension in advanced PD | Male or female patients, with idiopathic PD diagnosed for at least 2 years, 30 years of age or older at time of diagnosis, with a modified Hoehn and Yahr scale of 2 to 4 at on-time. MedDRA version: 9.1 Level: LLT Classification code 10061536 Term: Parkinson's disease | Product Name: Pramipexole ER Product Code: SND 919 CL2 Y Pharmaceutical Form: Prolonged-release tablet INN or Proposed INN: Pramipexole Current Sponsor code: SND 919 CL2 Y Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.375- Pharmaceutical form of the placebo: Prolonged-release tablet Route of administration of the placebo: Oral use Product Name: Pramipexole ER Product Code: SND 919 CL2 Y Pharmaceutical Form: Prolonged-release tablet INN or Proposed INN: Pramipexole Current Sponsor code: SND 919 CL2 Y Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.75- Pharmaceutical form of the placebo: Prolonged-release tablet Route of administration of the placebo: Oral use Product Name: Pramipexole ER Product Code: SND 919 CL2 Y Pharmaceutical Form: Prolonged-release tablet INN or Proposed INN: Pramipexole Current Sponsor code: SND 919 CL2 Y Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1.5- Pharmaceutical form of the placebo: Prolonged-release tablet Route of administration of the placebo: Oral use Product Name: Pramipexole ER Product Code: SND 919 CL2 Y Pharmaceutical Form: Prolonged-release tablet INN or Proposed INN: Pramipexole Current Sponsor code: SND 919 CL2 Y Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 3.0- Pharmaceutical form of the placebo: Prolonged-release tablet Route of administration of the placebo: Oral use Product Name: Pramipexole ER Product Code: SND 919 CL2 Y Pharmaceutical Form: Prolonged-release tablet INN or Proposed INN: Pramipexole Current Sponsor code: SND 919 CL2 Y Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 4.5- Pharmaceutical form of the placebo: Prolonged-release tablet Route of administration of the placebo: Oral use | Boehringer Ingelheim | Not Recruiting | Female: yes Male: yes | 390 | Hungary;Czech Republic;United Kingdom;Spain;Italy;Poland;Austria;Sweden | ||||
909 | NCT00601978 | August 2008 | 19 February 2015 | Carbidopa/Levodopa Versus Carbidopa/Levodopa/Entacapone on Markers of Event Related Potentials (ERPs) in Patients With Idiopathic Parkinson's Disease (PD) and End-of-dose Wearing Off | A 12-Week, Multi-center, Randomized, Prospective, Open-Label, Blinded Rater, Crossover Study of the Effects of Immediate-Release Carbidopa/Levodopa Versus Carbidopa/Levodopa/Entacapone on Markers of Event-Related Potentials (ERPs) in Patients With Idiopathic Parkinson's Disease and End-of-Dose Wearing Off | Parkinson's Disease | Drug: carbidopa/levodopa;Drug: Carbidopa/Levodopa/Entacapone | Novartis Pharmaceuticals | Not recruiting | 45 Years | 75 Years | Both | 0 | Phase 4 | United States | |
910 | NCT00656253 | August 2008 | 19 February 2015 | Clinical Trial on the Effectiveness of Herbal Medicinal Mixture in Parkinson Disease | Parkinson's Disease | Drug: Herbal Medicinal Mixture (Roucongrong, Heshouwu etc.);Drug: Placebo | Fudan University | China's Ministry of Health; Administration of Traditional Chinese Medicine (SATCM) | Not recruiting | 50 Years | N/A | Both | 158 | Phase 2/Phase 3 | China | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
911 | NCT00745277 | August 2008 | 19 February 2015 | High and Low Dose Treatment of Carbidopa in Parkinson's Disease | A Randomized Controlled Trial of Four Week Outpatient Treatment of Parkinson's Disease Comparing High and Low Dose Carbidopa. | Parkinson's Disease | Drug: Carbidopa-Levodopa;Drug: Carbidopa- Levodopa | Oregon Health and Science University | Parkinson Disease Research, Education and Clinical Center at Portland VA Hospital;RJG Foundation;Oregon Clinical and Translational Research Institute | Not recruiting | 35 Years | 85 Years | Both | 12 | Phase 2 | United States |
912 | NCT01010802 | August 2008 | 14 October 2019 | Safety Study of Erythropoietin (EPO) in Parkinson's Disease | Phase 1 Study of Recombinant Human Erythropoietin (rhEPO) in Parkinson's Disease (PD) | Parkinson Disease | Drug: Erythropoietin human recombinant (EPOrh) | International Center for Neurological Restoration, Cuba | Centro de Immunologia Molecular, Cuba | Not recruiting | 45 Years | 75 Years | All | 10 | Phase 1 | Cuba |
913 | EUCTR2008-003581-26-SE | 18/07/2008 | 19 March 2012 | Pharmacokinetics of levodopa using duodenal levodopa/carbidopa infusion with and without oral COMT inhibitors - DuoCOMT | Pharmacokinetics of levodopa using duodenal levodopa/carbidopa infusion with and without oral COMT inhibitors - DuoCOMT | Parkinson's disease (G20.9), advanced, patients presently on Duodopa treatment. MedDRA version: 9.1 Level: LLT Classification code 10013113 Term: Disease Parkinson's | Trade Name: Duodopa Pharmaceutical Form: Gel INN or Proposed INN: levodopa CAS Number: 59-92-7 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- INN or Proposed INN: carbidopa CAS Number: 28860-95-9 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 5- Trade Name: Comtess Pharmaceutical Form: Tablet INN or Proposed INN: entacapone CAS Number: 130929-57-6 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- Trade Name: Tasmar Pharmaceutical Form: Tablet INN or Proposed INN: tolcapone CAS Number: 134308-13-7 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- | Dept of Neuroscience, Uppsala University | Authorised | Female: yes Male: yes | Sweden | |||||
914 | EUCTR2008-001336-13-FR | 16/07/2008 | 19 March 2012 | Effet de la Nicotine transdermique sur les symptomes moteurs de la maladie de Parkinson avancée (une administration quotidienne) .Etude contrôlée, randomisée, en deux groupes parallèles et en simple insu sur 40 patients. - NICOPARK2 | Effet de la Nicotine transdermique sur les symptomes moteurs de la maladie de Parkinson avancée (une administration quotidienne) .Etude contrôlée, randomisée, en deux groupes parallèles et en simple insu sur 40 patients. - NICOPARK2 | Maladie Parkinson MedDRA version: 8.1 Level: PT Classification code 10061536 Term: Parkinson's disease | Trade Name: Nicorette 5 mg/ 16 h Product Name: Nicorette 5 mg/ 16 h Pharmaceutical Form: Transdermal patch INN or Proposed INN: Nicotine Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 8.3- Product Name: Nicorette 10mg/ 16 h Pharmaceutical Form: Transdermal patch INN or Proposed INN: Nicotine Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 16.6- Product Name: Nicorette 15 mg/ 16 h Pharmaceutical Form: Transdermal patch INN or Proposed INN: Nicotine Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 24.9- | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | Authorised | Female: yes Male: yes | France | |||||
915 | EUCTR2007-003134-42-DE | 19/06/2008 | 26 June 2012 | A 12-Week, Multi-center, Randomized, Prospective, Open-Label, Blinded Rater, Crossover Study of the Effects of Immediate-Release Carbidopa/Levodopa Versus Stalevo® on Markers of Event-Related Potentials (ERPs) in Patients with Idiopathic Parkinson’s Disease and End-of-Dose Wearing Off. | A 12-Week, Multi-center, Randomized, Prospective, Open-Label, Blinded Rater, Crossover Study of the Effects of Immediate-Release Carbidopa/Levodopa Versus Stalevo® on Markers of Event-Related Potentials (ERPs) in Patients with Idiopathic Parkinson’s Disease and End-of-Dose Wearing Off. | Idiopathic Parkinson’s disease and end-of-dose wearing off. MedDRA version: 9.1 Level: LLT Classification code 10061536 Term: Parkinson's disease | Trade Name: Stalevo 100 mg/ 25 mg/ 200 mg Filmtabletten Product Name: Stalevo Pharmaceutical Form: Film-coated tablet INN or Proposed INN: LEVODOPA CAS Number: 59927 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- INN or Proposed INN: CARBIDOPA CAS Number: 28860959 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- INN or Proposed INN: ENTACAPONE CAS Number: 130929576 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- Trade Name: Nacom 100 Product Name: Nacom Pharmaceutical Form: Tablet INN or Proposed INN: LEVODOPA CAS Number: 59927 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- INN or Proposed INN: CARBIDOPA CAS Number: 38821-49-7 Other descriptive name: CARBIDOPA MONOHYDRATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 27- | Novartis Pharma Services AG | Not Recruiting | Female: yes Male: yes | 20 | Germany | ||||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
916 | NCT00822913 | June 2008 | 19 February 2015 | Botulinum A Toxin in Patients With Parkinson's Disease | The Use of Toxin Botulinum A Toxin in Patients With Parkinson's Disease and Multiple System Disease, Affected by Refractory Detrusor Overactivity. | Parkinson's Disease;Multiple System Atrophy;Detrusor Overactivity | Drug: Intravesical injection of Botulinum A toxin | University Of Perugia | University of Roma La Sapienza | Recruiting | 18 Years | 80 Years | Both | 20 | Phase 4 | |
917 | EUCTR2007-004009-93-IT | 20/05/2008 | 7 January 2013 | Prevalence of depression,anxiety and impulse control disorder (ICD) in patients with Parkinson's disease and effectiveness of escitalopram | Prevalence of depression,anxiety and impulse control disorder (ICD) in patients with Parkinson's disease and effectiveness of escitalopram | Depression, anxiety and ICD MedDRA version: 14.1 Level: SOC Classification code 10037175 Term: Psychiatric disorders System Organ Class: 10037175 - Psychiatric disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: CIPRALEX Pharmaceutical Form: Tablet INN or Proposed INN: Escitalopram Concentration unit: mg milligram(s) Concentration number: 10- Trade Name: CIPRALEX Pharmaceutical Form: Tablet INN or Proposed INN: Escitalopram Concentration unit: mg milligram(s) Concentration number: 20- | LUNDBECK ITALIA | Not Recruiting | Female: yes Male: yes | Italy | |||||
918 | EUCTR2007-004890-24-FR | 07/05/2008 | 19 March 2012 | A Phase II, Randomised, Placebo-Controlled, Double-Blind, Replicated Crossover, Pilot Study on the Effect of Fipamezole on Neurogenic Orthostatic Hypotension in Patients with Multiple System Atrophy or Parkinson’s Disease - FOEHN | A Phase II, Randomised, Placebo-Controlled, Double-Blind, Replicated Crossover, Pilot Study on the Effect of Fipamezole on Neurogenic Orthostatic Hypotension in Patients with Multiple System Atrophy or Parkinson’s Disease - FOEHN | Neurogenic orthostatic hypotension in patients with multiple system atrophy or Parkinson's disease MedDRA version: 9.1 Level: LLT Classification code 10013113 Term: Disease Parkinson's MedDRA version: 9.1 Level: LLT Classification code 10064060 Term: Multiple system atrophy | Product Name: Fipamezole hydrochloride 90 mg oral disintegrating tablets Product Code: JP-1730/F01 Pharmaceutical Form: Orodispersible tablet INN or Proposed INN: Fipamezole hydrochloride CAS Number: 150586-72-4 Current Sponsor code: JP-1730 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 90- Pharmaceutical form of the placebo: Orodispersible tablet Route of administration of the placebo: Sublingual use Product Name: Fipamezole hydrochloride 60 mg oral disintegrating tablets Product Code: JP-1730/F02 Pharmaceutical Form: Orodispersible tablet INN or Proposed INN: Fipamezole hydrochloride CAS Number: 150586-72-4 Current Sponsor code: JP-1730 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 60- Pharmaceutical form of the placebo: Orodispersible tablet Route of administration of the placebo: Sublingual use Product Name: Fipamezole hydrochloride 30 mg oral disintegrating tablets Product Code: JP-1730/F03 Pharmaceutical Form: Orodispersible tablet INN or Proposed INN: Fipamezole hydrochloride CAS Number: 150586-72-4 Current Sponsor code: JP-1730 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 30- Pharmaceutical form of the placebo: Orodispersible tablet Route of administration of the placebo: Sublingual use | Juvantia Pharma Ltd | Authorised | Female: yes Male: yes | 24 | Phase 2 | Portugal;France | |||
919 | NCT01238926 | May 2008 | 19 February 2015 | Vitamin B6, B12, Folic Acid and Exercise in Parkinson's Disease | Effects of Vitamin Supplementation and Strength Training in Parkinson's Disease | Parkinson's Disease | Dietary Supplement: PD vitamin supplementation;Other: PD exercise intervention;Other: PD vitamin + exercise | New York Institute of Technology | Stony Brook University | Not recruiting | 50 Years | 80 Years | Both | 40 | N/A | United States |
920 | NCT01416818 | May 2008 | 19 February 2015 | Treatment of Depression in Parkinson's Disease | A Randomized, Double-Blind, Placebo-Controlled Study of Xiaoyao Pill Treatment of Depression in Patients With Parkinson's Disease | Depression in Parkinson's Disease | Drug: Xiaoyao Pill;Drug: Bupleurum+Ginkgo;Drug: placebo | Xuanwu Hospital, Beijing | Recruiting | 30 Years | 80 Years | Both | 60 | Phase 2 | China | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
921 | NCT00605553 | April 2008 | 16 December 2017 | Study to Evaluate SYN115 in Parkinson's Disease | A Randomized, Double-blind, Placebo Controlled, Two-way Cross-over Study to Explore the Effects of 7 Days of Dosing With SYN115 20 mg p.o. BID or 60 mg p.o. BID on Clinical and fMRI Response to Intravenous Levodopa in Patients With Mild to Moderate Parkinson's Disease | Parkinson's Disease | Drug: Placebo;Drug: Tozadenant | Biotie Therapies Inc. | Not recruiting | 40 Years | 75 Years | All | 30 | Phase 2 | United States | |
922 | NCT00651183 | April 2008 | 19 October 2017 | Non-motor Symptoms (Depressive Symptoms) of Parkinson's Disease and Their Course Under Pramipexole Treatment | Non-motor Symptoms (Depressive Symptoms) of Parkinson's Disease and Their Course Under Pramipexole Treatment | Parkinson Disease | Drug: Pramipexole immediate release | Boehringer Ingelheim | Not recruiting | 18 Years | N/A | All | 286 | Phase 4 | Austria | |
923 | NCT00753636 | April 2008 | 19 October 2017 | Parkinson's Disease Isradipine Safety Study | Phase II Safety and Tolerability of Isradipine (A Potential Neuroprotective Agent) in Patients With Parkinson's Disease- Stage II | Parkinson's Disease | Drug: Dynacirc CR (Isradipine) | Northwestern University | Northwestern Memorial Hospital | Not recruiting | 30 Years | 75 Years | All | 31 | Phase 2 | United States |
924 | NCT02071810 | April 2008 | 19 October 2017 | Tolerability, Pharmacokinetics and Pharmacodynamics of BIA 9-1067 | A Double-blind, Randomised, Placebo-controlled Study to Evaluate the Tolerability, Pharmacokinetics and Pharmacodynamics of Four Multiple Rising Dose Regimens of BIA 9-1067 in Healthy Male Volunteers | Parkinson's Disease (PD) | Drug: BIA 9-1067;Drug: Placebo | Bial - Portela C S.A. | Not recruiting | 18 Years | 45 Years | Male | 34 | Phase 1 | France | |
925 | EUCTR2007-001095-36-HU | 27/03/2008 | 19 March 2012 | The Van Gogh Study: A Multicenter, Randomized, Double-blind, Parallel-group, Placebo and Pramipexole Controlled Study to Assess Efficacy and Safety of SLV308 as Adjunct Therapy to L-dopa in Patients with Parkinson’s Disease Experiencing Motor Fluctuations - The Van Gogh Study | The Van Gogh Study: A Multicenter, Randomized, Double-blind, Parallel-group, Placebo and Pramipexole Controlled Study to Assess Efficacy and Safety of SLV308 as Adjunct Therapy to L-dopa in Patients with Parkinson’s Disease Experiencing Motor Fluctuations - The Van Gogh Study | advanced stage of idiopathic PD with dose-dependent motor fluctuations. MedDRA version: 8.1 Level: LLT Classification code 10013113 Term: Disease Parkinson's | Product Name: Pardoprunox Product Code: SLV308 Pharmaceutical Form: Capsule, hard INN or Proposed INN: Pardoprunox hydrochloride CAS Number: 269718-83-4 Current Sponsor code: SLV308 hydrochloride Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.1- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Product Name: Pardoprunox Product Code: SLV308 Pharmaceutical Form: Capsule, hard INN or Proposed INN: Pardoprunox hydrochloride CAS Number: 269718-83-4 Current Sponsor code: SLV308 hydrochloride Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.2- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Product Name: Pardoprunox Product Code: SLV308 Pharmaceutical Form: Capsule, hard INN or Proposed INN: Pardoprunox hydrochloride CAS Number: 269718-83-4 Current Sponsor code: SLV308 hydrochloride Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Product Name: Pardoprunox Product Code: SLV308 Pharmaceutical Form: Capsule, hard INN or Proposed INN: Pardoprunox hydrochloride CAS Number: 269718-83-4 Current Sponsor code: SLV308 hydrochloride Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1.0- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Product Name: Pardoprunox Product Code: SLV308 Pharmaceutical Form: Capsule, hard INN or Proposed INN: Pardoprunox hydrochloride CAS Number: 269718-83-4 Current Sponsor code: SLV308 hydrochloride Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2.0- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Product Name: Pardoprunox Product Code: SLV308 | Solvay Pharmaceuticals | Not Recruiting | Female: yes Male: yes | 625 | Hungary | ||||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
926 | EUCTR2007-001096-10-HU | 27/03/2008 | 19 March 2012 | An Extension of the Van Gogh Study: An Open Label SLV308 Safety Extension to Study S308.3.004 in Patients with Parkinson’s Disease Experiencing Motor Fluctuations - An Extension of the Van Gogh Study | An Extension of the Van Gogh Study: An Open Label SLV308 Safety Extension to Study S308.3.004 in Patients with Parkinson’s Disease Experiencing Motor Fluctuations - An Extension of the Van Gogh Study | advanced stage of idiopathic PD with dose-dependent motor fluctuations. MedDRA version: 8.1 Level: LLT Classification code 10013113 Term: Disease Parkinson's | Product Name: Pardoprunox Product Code: SLV308 Pharmaceutical Form: Capsule, hard INN or Proposed INN: Pardoprunox hydrochloride CAS Number: 269718-83-4 Current Sponsor code: SLV308 hydrochloride Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.1- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Product Name: Pardoprunox Product Code: SLV308 Pharmaceutical Form: Capsule, hard INN or Proposed INN: Pardoprunox hydrochloride CAS Number: 269718-83-4 Current Sponsor code: SLV308 hydrochloride Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.2- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Product Name: Pardoprunox Product Code: SLV308 Pharmaceutical Form: Capsule, hard INN or Proposed INN: Pardoprunox hydrochloride CAS Number: 269718-83-4 Current Sponsor code: SLV308 hydrochloride Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Product Name: Pardoprunox Product Code: SLV308 Pharmaceutical Form: Capsule, hard INN or Proposed INN: Pardoprunox hydrochloride CAS Number: 269718-83-4 Current Sponsor code: SLV308 hydrochloride Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1.0- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Product Name: Pardoprunox Product Code: SLV308 Pharmaceutical Form: Capsule, hard INN or Proposed INN: Pardoprunox hydrochloride CAS Number: 269718-83-4 Current Sponsor code: SLV308 hydrochloride Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2.0- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Product Name: Pardoprunox Product Code: SLV308 | Solvay Pharmaceuticals | Not Recruiting | Female: yes Male: yes | 500 | Hungary | ||||
927 | EUCTR2007-005033-11-DE | 27/03/2008 | 19 March 2012 | A Comparison Of The Safety And Bioavailability Of Modified-Release Formulations Of Levodopa-Carbidopa In Subjects With Parkinson’s Disease | A Comparison Of The Safety And Bioavailability Of Modified-Release Formulations Of Levodopa-Carbidopa In Subjects With Parkinson’s Disease | Patients with Parkinson's Disease | Product Name: Levodopa-Carbidopa Multilayer Extended Release Tablet Product Code: Levodopa-Carbidopa XL tablet (M) Pharmaceutical Form: Modified-release tablet INN or Proposed INN: Levodopa CAS Number: 59-92-7 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- INN or Proposed INN: Carbidopa CAS Number: 38821-49-7 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Trade Name: Sinemet® CR Product Name: Sinemet CR Pharmaceutical Form: Modified-release tablet INN or Proposed INN: Levodopa CAS Number: 59-92-7 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- INN or Proposed INN: Carbidopa CAS Number: 38821-49-7 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- | CombinatoRx, Inc | Not Recruiting | Female: yes Male: yes | Germany | |||||
928 | NCT00607451 | March 2008 | 11 June 2018 | Safety, Tolerability, PK and PD Study of Neu-120 in the Treatment of Levodopa-induced Dyskinesia | A Double-blind, Placebo Controlled, Crossover, Ascending Single Dose Safety Tolerability, Pharmacokinetic and Pharmacodynamic Study of Neu-120 in Patients With Advanced Phase Idiopathic Parkinson's Disease With Levodopa Induced Dyskinesia | Levodopa-induced Dyskinesia | Drug: Neu-120 | Neurim Pharmaceuticals Ltd. | Not recruiting | 30 Years | 80 Years | All | 8 | Phase 1/Phase 2 | Israel | |
929 | NCT00642356 | March 2008 | 19 October 2017 | Carbidopa/Levodopa/Entacapone Versus Immediate Release (IR) Carbidopa/Levodopa on Non-motor Symptoms in Patients With Idiopathic Parkinson's Disease and Demonstrating Non-motor Symptoms of Wearing Off | An 8-week, Prospective, Randomized, Double-blind, Double-dummy, Active-controlled, Multi-center Comparison Study of the Effects of Carbidopa/Levodopa/Entacapone Versus Immediate Release Carbidopa/Levodopa on Non-motor Symptoms in Patients With Idiopathic Parkinson's Disease and Demonstrating Non-motor Symptoms of Wearing Off | Parkinson's Disease | Drug: Carbidopa/levodopa/entacapone;Drug: Immediate release carbidopa/levodopa | Novartis | Not recruiting | 30 Years | 85 Years | All | 14 | Phase 4 | United States | |
930 | NCT00658567 | March 2008 | 16 December 2017 | A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis | Parkinson's Disease Psychosis | Drug: Pimavanserin tartrate (ACP-103) | ACADIA Pharmaceuticals Inc. | Not recruiting | 40 Years | N/A | All | 123 | Phase 3 | United States;Austria;Belgium;Italy;Poland;Portugal;Serbia;Spain;Sweden | ||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
931 | NCT00727727 | March 2008 | 19 February 2015 | SEDPARK2: Post Marketing Surveillance to Observe Safety and Efficacy of Piribedil in Parkinson's Disease (PIR-002/K) | Stabilization on, or Change-Over to the Non-Ergot Dopamine Agonist Piribedil in Patients With Morbus Parkinson - a Post Marketing Surveillance Study in Private Practices. | Parkinson's Disease | Drug: Piribedil | Desitin Arzneimittel GmbH | Not recruiting | 18 Years | N/A | Both | 750 | N/A | Germany | |
932 | NCT00761137 | March 2008 | 19 October 2017 | Safety and Efficacy Study of NH004 Films for Relief of Sialorrhea Symptoms in Parkinson's Disease Patients | A Two-Phase, Double Blind, Placebo-Controlled, Randomized, Crossover Study of the Safety and Efficacy of Intra-Oral NH004 Films for the Short-Term Relief of Sialorrhea Symptoms in Parkinson's Disease Patients | Sialorrhea Secondary to Parkinson's Disease | Drug: 0.3 mg tropicamide;Drug: 1 mg tropicamide;Drug: 3 mg tropicamide;Drug: 0 mg tropicamide | NeuroHealing Pharmaceuticals Inc. | Michael J. Fox Foundation for Parkinson's Research | Not recruiting | 50 Years | 80 Years | All | 19 | Phase 2 | Argentina |
933 | EUCTR2007-002195-34-FR | 04/02/2008 | 19 March 2012 | Evaluation of the effect of 6 months treatment with DC158AM on fatigue in patients with Parkinson’s disease. Multicentre, randomised, double-blind, placebo-controlled study in parallel groups. | Evaluation of the effect of 6 months treatment with DC158AM on fatigue in patients with Parkinson’s disease. Multicentre, randomised, double-blind, placebo-controlled study in parallel groups. | Fatigue symptoms in Parkinson's disease. MedDRA version: 9.1 Level: LLT Classification code 10013113 Term: Disease Parkinson's | Trade Name: DEBRUMYL Product Code: DC158AM Pharmaceutical Form: Oral solution INN or Proposed INN: Heptaminol hydrochloride Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 180- INN or Proposed INN: Deanol pyroglutamate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 250- Pharmaceutical form of the placebo: Oral solution Route of administration of the placebo: Oral use | PIERRE FABRE MEDICAMENT | Authorised | Female: yes Male: yes | France | |||||
934 | NCT00624741 | February 2008 | 19 February 2015 | Compassionate Use Study of Pergolide in Patients With Parkinson's Disease | Compassionate Use of Pergolide as Adjunctive Therapy to Levodopa/Carbidopa for Treating Parkinson's Disease | Parkinson Disease | Drug: Pergolide | Valeant Pharmaceuticals International, Inc. | Not recruiting | N/A | N/A | Both | N/A | |||
935 | NCT00888186 | February 2008 | 19 February 2015 | Different Dyskinesias in Parkinson's Disease and Their Relation to Levodopa Pharmacokinetics | Different Dyskinesias in Parkinson's Disease and Their Relation to Levodopa Pharmacokinetics | Parkinson Disease;Dyskinesias | Drug: levodopa/carbidopa | Uppsala University | Swedish Parkinson's Disease Foundation;Swedish Society for Medical Research | Not recruiting | 30 Years | 90 Years | Both | 5 | Phase 4 | Sweden |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
936 | NCT02236728 | February 2008 | 19 February 2015 | Observational Study in Parkinson's Disease of the Primary Care Population of Patients Treated With Pramipexole | Observational Study in Parkinson's Disease of the Primary Care Population of Patients Treated With Pramipexole by Neurologists in France (ETAP) | Parkinson Disease | Drug: Pramipexole | Boehringer Ingelheim | Not recruiting | N/A | N/A | Both | 497 | N/A | ||
937 | EUCTR2007-002467-27-GB | 24/01/2008 | 19 March 2012 | Antidyskinetic Properties of Topiramate: A Double-Blind, Placebo-Controlled Trial in Patients with Parkinson's Disease and Levodopa-Induced Dyskinesias - Antidyskinetic properties of topiramate | Antidyskinetic Properties of Topiramate: A Double-Blind, Placebo-Controlled Trial in Patients with Parkinson's Disease and Levodopa-Induced Dyskinesias - Antidyskinetic properties of topiramate | Patients with idiopathic Parkinson's disease and levodopa-induced dyskinesias MedDRA version: 13.1 Level: PT Classification code 10013916 Term: Dyskinesia System Organ Class: 10029205 - Nervous system disorders MedDRA version: 13.1 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders MedDRA version: 13.1 Level: HLT Classification code 10034005 Term: Parkinson's disease and parkinsonism System Organ Class: 10029205 - Nervous system disorders | Product Name: Topiramate Pharmaceutical Form: Capsule* INN or Proposed INN: TOPIRAMATE CAS Number: 97240794 Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use | Salford Royal NHS Foundation Trust | Not Recruiting | Female: yes Male: yes | United Kingdom | |||||
938 | EUCTR2007-000350-31-FR | 22/01/2008 | 26 January 2015 | A 76-week prospective, open-label, multicenter study to evaluate the long-term effect of Exelon® capsule and transdermal patch on worsening of the underlying motor symptoms of PD in patients with mild to moderately severe dementia associated with Parkinson’s disease (PDD). | A 76-week prospective, open-label, multicenter study to evaluate the long-term effect of Exelon® capsule and transdermal patch on worsening of the underlying motor symptoms of PD in patients with mild to moderately severe dementia associated with Parkinson’s disease (PDD). | Mild to moderately severe dementia associated with Parkinson’s disease (PDD). MedDRA version: 9.1 Level: LLT Classification code 10012284 Term: Dementia due to Parkinson's disease | Trade Name: Exelon Pharmaceutical Form: Capsule, hard INN or Proposed INN: rivastigmine Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1.5- Trade Name: Exelon Pharmaceutical Form: Capsule, hard INN or Proposed INN: rivastigmine Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 3.0- Trade Name: Exelon Pharmaceutical Form: Capsule, hard INN or Proposed INN: rivastigmine Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 4.5- Trade Name: Exelon Pharmaceutical Form: Capsule, hard INN or Proposed INN: rivastigmine Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 6.0- Trade Name: Exelon 4.6 mg/24 h transdermal patch Pharmaceutical Form: Transdermal patch INN or Proposed INN: rivastigmine Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 9- Trade Name: Exelon 9.5 mg/24 h transdermal patch Pharmaceutical Form: Transdermal patch INN or Proposed INN: rivastigmine Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 18- | Novartis Pharma AG | Not Recruiting | Female: yes Male: yes | 550 | France;Spain;Italy | ||||
939 | NCT00335153 | January 2008 | 19 October 2017 | Levodopa-Carbidopa Intestinal Gel Open-Label Study in Advanced Parkinson's Disease | An Open-Label, 12-Month Safety and Efficacy Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Subjects With Advanced Parkinson's Disease and Severe Motor Fluctuations Despite Optimized Treatment With Available Parkinson's Disease Medications | Advanced Parkinson's Disease | Drug: Levodopa-carbidopa intestinal gel;Device: CADD-Legacy® 1400 ambulatory infusion pump;Device: PEG tube;Device: J-tube | AbbVie (prior sponsor, Abbott) | Quintiles, Inc. | Not recruiting | 30 Years | N/A | All | 354 | Phase 3 | United States;Australia;Canada;Czech Republic;Finland;Germany;Israel;Italy;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Thailand;United Kingdom;Greece |
940 | NCT00562198 | January 2008 | 19 February 2015 | PET-Study: Effects of Single Doses of Stalevo and Levodopa/Carbidopa on Striatal 11C-Raclopride Binding | Effects of Single Doses of Stalevo 200 and Levodopa/Carbidopa 200/50mg on Striatal 11C-Raclopride Binding Potential in Parkinson's Disease Patients With Wearing-Off Symptoms;an Open, Randomised, Active-Controlled,Two-Period Crossover Study. | Parkinson´s Disease | Drug: entacapone and carbidopa;Drug: Sinemet 200mg/50mg | Orion Corporation, Orion Pharma | Not recruiting | 45 Years | 80 Years | Both | 16 | Phase 2 | Finland | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
941 | NCT00600093 | January 2008 | 19 February 2015 | Perioperative Treatment of Parkinsonian Patients With Parenteral Amantadine | Perioperative Treatment of Parkinsonian Patients With Parenteral Amantadine | Parkinson Disease;Perioperative Care | Drug: Amantadine | Rabin Medical Center | Not recruiting | N/A | N/A | Both | 20 | Phase 2 | Israel | |
942 | NCT00608231 | January 2008 | 19 February 2015 | Dexmedetomidine Effects on Microelectrode Recording in Deep Brain Stimulation | Dexmedetomidine Effects on Microelectrode Recording in Deep Brain Stimulation | Parkinson's Disease;Essential Tremor;Dystonia | Drug: Dexmedetomidine Hydrochloride Infusion;Drug: Normal Saline | Vanderbilt University | Not recruiting | 18 Years | N/A | Both | 0 | Phase 2/Phase 3 | United States | |
943 | NCT00612872 | January 2008 | 15 April 2019 | Evaluation of [123I]CLINDE and SPECT as a Marker of Inflammation in Subjects With PD or AD and in Healthy Subjects | Evaluation of [123I]CLINDE and SPECT as a Marker of Inflammation in Subjects With Parkinson Disease or Alzheimer Disease and in Healthy Subjects | Parkinson Disease;Alzheimer Disease;Healthy Controls;Multiple Sclerosis | Drug: [123I]CLINDE | Institute for Neurodegenerative Disorders | Not recruiting | 30 Years | 50 Years | All | 46 | Phase 1 | United States | |
944 | NCT00623103 | January 2008 | 19 October 2017 | Long-term Safety of Rivastigmine Capsule and Patch in Patients With Mild to Moderately-severe Dementia Associated With Parkinson's Disease (PDD) | A 76-week Prospective, Open-label, Multicenter Study to Evaluate the Long-term Effect of Rivastigmine Capsule and Transdermal Patch on Worsening of the Underlying Motor Symptoms of PD in Patients With Mild to Moderately Severe Dementia Associated With Parkinson's Disease (PDD) | Parkinson's Disease Dementia | Drug: Rivastigmine capsule;Drug: Rivastigmine transdermal patch | Novartis | Not recruiting | 50 Years | 85 Years | All | 583 | Phase 3 | United States;Argentina;Australia;Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Spain;Turkey;United Kingdom | |
945 | NCT00623324 | January 2008 | 19 February 2015 | The Effects of Aplindore on the Treatment of Signs and Symptoms of Parkinson's Disease | A Phase II, Dose Ranging, Randomized, Double Blind, Placebo-controlled, Multi-center, Pilot Study to Assess the Safety, Tolerability, Efficacy and Pharmacokinetics of Aplindore in Patients With Early Stage Parkinson's Disease | Early Stage Parkinson's Disease | Drug: Aplindore;Drug: Placebo | Ligand Pharmaceuticals | Not recruiting | 30 Years | N/A | Both | 40 | Phase 2 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
946 | NCT00627588 | January 2008 | 19 February 2015 | Phase I/II Study of the Safety, Efficacy and Dose Evaluation of ProSavin for the Treatment of Bilateral Idiopathic Parkinson's Disease | A Phase I/II Study of the Safety, Efficacy and Dose Evaluation of ProSavin®, Administered Using Stereotactic Injection to the Striatum of Patients With Bilateral, Idiopathic Parkinson's Disease. | Parkinson's Disease | Biological: ProSavin | Oxford BioMedica | Not recruiting | 48 Years | 65 Years | Both | 15 | Phase 1/Phase 2 | France;United Kingdom | |
947 | NCT00664209 | January 2008 | 16 December 2017 | Treating H. Pylori in Parkinson's Patients With Motor Fluctuations | Helicobacter Pylori Eradication and Motor Fluctuations in Parkinson's Disease | Parkinson's Disease;Helicobacter Infections;Motor Fluctuations | Drug: clartihromycin, amoxicillin, and omeprazole;Drug: placebo | University of California, Los Angeles | Michael J. Fox Foundation for Parkinson's Research | Not recruiting | N/A | N/A | Male | 64 | Phase 3 | United States |
948 | NCT00725478 | January 2008 | 19 February 2015 | SEDPARK1: Safety and Efficacy Study With the Non-ergot Dopamine-agonist Piribedil in Parkinson's Disease | Stabilization on, or Change-over to the Non-ergot Dopamine Agonist Piribedil in Patients With Morbus Parkinson - a Post Marketing Surveillance Study in Parkinson Clinic Ambulances and Larger Private Practices. | Parkinson's Disease | Drug: Piribedil | Desitin Arzneimittel GmbH | Not recruiting | 18 Years | N/A | Both | 250 | N/A | ||
949 | NCT01628965 | January 2008 | 19 October 2017 | A Long-Term Extension Trial From Phase II/III of SPM 962 in Early Parkinson's Disease Patients | An Open-label Long-term Extension Trial From Phase II/III of SPM962 (243-07-001) in Early Parkinson's Disease Patients With Non-concomitant Treatment of L-dopa | Parkinson's Disease | Drug: SPM 962 | Otsuka Pharmaceutical Co., Ltd. | Not recruiting | N/A | N/A | All | 143 | Phase 2/Phase 3 | Japan | |
950 | EUCTR2008-004447-11-DE | 1 April 2013 | A Phase IIb Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study Investigating the Efficacy and Safety of Apomorphine Inhalation Powder in Patients With “On-Off” or “Wearing-Off” Effects Associated With Parkinson’s Disease | A Phase IIb Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study Investigating the Efficacy and Safety of Apomorphine Inhalation Powder in Patients With “On-Off” or “Wearing-Off” Effects Associated With Parkinson’s Disease | Unpredictable motor fluctuation or “On-Off” or “Wearing-Off” Effects Fluctuating associated with Idiopathic Parkinson’s Disease MedDRA version: 11 Level: LLT Classification code 10067209 Term: | Product Name: Apomorphine hydrochloride 1.8mg inhalation powder, pre-dispensed Product Code: VR040 Pharmaceutical Form: Inhalation powder, pre-dispensed INN or Proposed INN: Apomorphine hydrochloride CAS Number: 41372 20 7 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1.8- Pharmaceutical form of the placebo: Inhalation powder, pre-dispensed Route of administration of the placebo: Inhalation use Product Name: Apomorphine hydrochloride 2.8mg inhalation powder, pre-dispensed Product Code: VR040 Pharmaceutical Form: Inhalation powder, pre-dispensed INN or Proposed INN: Apomorphine hydrochloride CAS Number: 41372 20 7 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2.8- Pharmaceutical form of the placebo: Inhalation powder, pre-dispensed Route of administration of the placebo: Inhalation use Product Name: Apomorphine hydrochloride 4.0 mg inhalation powder, pre-dispensed Product Code: VR040 Pharmaceutical Form: Inhalation powder, pre-dispensed INN or Proposed INN: Apomorphine hydrochloride CAS Number: 41372 20 7 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 4.0- Pharmaceutical form of the placebo: Inhalation powder, pre-dispensed Route of administration of the placebo: Inhalation use Product Name: Apomorphine hydrochloride 5.8 mg inhalation powder, pre-dispensed Product Code: VR040 Pharmaceutical Form: Inhalation powder, pre-dispensed INN or Proposed INN: Apomorphine hydrochloride CAS Number: 41372 20 7 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5.8- Pharmaceutical form of the placebo: Inhalation powder, pre-dispensed Route of administration of the placebo: Inhalation use | Vectura Limited | Not Recruiting | Female: yes Male: yes | 66 | Phase 2b | Germany;Italy;United Kingdom | ||||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
951 | EUCTR2007-004400-12-ES | 27/12/2007 | 19 March 2012 | ENSAYO RANDOMIZADO A DOBLE CIEGO Y CONTROLADO CON PLACEBO DE RASAGILINA EN PACIENTES CON ENFERMEDAD DE PARKINSON Y SINTOMAS DE APATIA - Rasagiline and Apathy | ENSAYO RANDOMIZADO A DOBLE CIEGO Y CONTROLADO CON PLACEBO DE RASAGILINA EN PACIENTES CON ENFERMEDAD DE PARKINSON Y SINTOMAS DE APATIA - Rasagiline and Apathy | Apatía en la Enfermedad de Parkinson MedDRA version: 9.1 Level: LLT Classification code 10061536 Term: Parkinson's disease | Trade Name: Azilect Pharmaceutical Form: Tablet INN or Proposed INN: RASAGILINE CAS Number: 136236516 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use | Institut de Recerca de l'Hospital de la santa Creu i Sant Pau | Authorised | Female: yes Male: yes | Spain | |||||
952 | EUCTR2007-004654-81-GB | 20/12/2007 | 19 March 2012 | A phase IIa study to evaluate the relative efficacy and safety/tolerability of a single agent vs. a combination treatment for reducing saliva secretion in Parkinson’s disease patients | A phase IIa study to evaluate the relative efficacy and safety/tolerability of a single agent vs. a combination treatment for reducing saliva secretion in Parkinson’s disease patients | Sialorrhoea associated with Parkinson's Disease MedDRA version: 9.1 Level: LLT Classification code 10059812 Term: Sialorrhoea | Trade Name: Catapres ampoules Pharmaceutical Form: Solution for injection INN or Proposed INN: Clonidine hydrochloride Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: 150- Pharmaceutical form of the placebo: Oral solution Route of administration of the placebo: Oral use Trade Name: Ditropan elixir Pharmaceutical Form: Oral solution INN or Proposed INN: Oxybutynin hydrochloride Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 0.5- Pharmaceutical form of the placebo: Oral solution Route of administration of the placebo: Oral use | Summit (Cambridge) Ltd. | Not Recruiting | Female: yes Male: yes | Phase 2a | United Kingdom | ||||
953 | EUCTR2007-002963-28-FI | 12/12/2007 | 28 January 2013 | A trial to determine the efficacy and safety of a low (50mg/day) and high (100mg/day) dose of safinamide, as add-on therapy, in patients with early Parkinson's Disease treated with a single dopamine agonist. | A phase III, double-blind, placebo-controlled randomised trial to determine the efficacy and safety of a low (50 mg/day) and high (100 mg/day) dose of safinamide, as add-on therapy, in subjects with early idiopathic Parkinson’s Disease treated with a stable dose of a single dopamine agonist. - Safinamide in early IPD, as add-on to dopamine agonist | Idiopathic Parkinson's Disease MedDRA version: 14.1 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders | Product Name: Safinamide Product Code: NW-1015 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Safinamide CAS Number: 202825-46-5 Current Sponsor code: NW-1015 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Name: Safinamide Product Code: NW-1015 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Safinamide CAS Number: 202825-46-5 Current Sponsor code: NW-1015 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use | Newron Pharmaceuticals SpA | Not Recruiting | Female: yes Male: yes | 839 | Phase 3 | Portugal;United States;Finland;Spain;Chile;Colombia;Italy;India;Czech Republic;Mexico;Canada;Argentina;Poland;Brazil;Croatia;Bulgaria;South Africa;Germany | |||
954 | NCT00526630 | December 2007 | 19 October 2017 | Methylphenidate for the Treatment of Gait Impairment in Parkinson's Disease | Methylphenidate for the Treatment of Gain Impairment in Parkinson's Disease: a Randomized Double-Blind, Placebo-Controlled, Cross-over Study | Parkinson's Disease;Gait Impairment | Drug: Methylphenidate (MPD);Drug: Placebo | University of Cincinnati | Michael J. Fox Foundation for Parkinson's Research | Not recruiting | 35 Years | 85 Years | All | 23 | Phase 4 | United States |
955 | NCT00584025 | December 2007 | 11 June 2018 | Keppra IV for the Treatment of Motor Fluctuations in Parkinson's Disease | Parkinson's Disease | Drug: levetiracetam;Drug: Placebo | University of South Florida | Not recruiting | 30 Years | 80 Years | All | 0 | Phase 4 | United States | ||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
956 | EUCTR2007-004985-41-SE | 29/11/2007 | 19 March 2012 | Different dyskinesias in Parkinson's disease and their relation to levodopa pharmacokinetics - The dyskinesia study | Different dyskinesias in Parkinson's disease and their relation to levodopa pharmacokinetics - The dyskinesia study | Parkinson's disease, G20.9. Different dyskinesias related to advanced Parkinson's disease will be investigated. | Trade Name: Duodopa Pharmaceutical Form: Gel INN or Proposed INN: levodopa CAS Number: 59-92-7 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- INN or Proposed INN: carbidopa CAS Number: 28860-95-9 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 5- | Department of Neuroscience, neurology | Not Recruiting | Female: yes Male: yes | Sweden | |||||
957 | EUCTR2007-002906-23-GB | 14/11/2007 | 19 March 2012 | A Multi-Center, Placebo-Controlled, Double-Blind Trial To Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson's Disease | A Multi-Center, Placebo-Controlled, Double-Blind Trial To Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson's Disease | Psychosis in Parkinson's Disease MedDRA version: 9.1 Level: LLT Classification code 10037241 Term: Psychosis NOS | Product Name: Pimavanserin tartrate Product Code: ACP-103 Pharmaceutical Form: Tablet INN or Proposed INN: Pimavanserin tartrate CAS Number: 706782-28-7 Concentration unit: mg milligram(s) Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | Acadia Pharmaceuticals Inc | Not Recruiting | Female: yes Male: yes | 280 | United Kingdom;Bulgaria;France | ||||
958 | EUCTR2007-002496-14-FI | 05/11/2007 | 19 March 2012 | Effects of single doses of Stalevo 200 and levodopa/carbidopa 200/50 mg on striatal 11C-raclopride binding potential in Parkinson’s disease patients with wearing-off symptoms. An open, randomised, active-controlled, two-period crossover study. | Effects of single doses of Stalevo 200 and levodopa/carbidopa 200/50 mg on striatal 11C-raclopride binding potential in Parkinson’s disease patients with wearing-off symptoms. An open, randomised, active-controlled, two-period crossover study. | Parkinson’s disease MedDRA version: 9.1 Level: LLT Classification code 10061536 Term: Parkinson's disease | Product Name: Stalevo® Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Levodopa Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- INN or Proposed INN: Carbidopa Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- INN or Proposed INN: Entacapone Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- Trade Name: Sinemet® Pharmaceutical Form: Tablet INN or Proposed INN: Levodopa Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- INN or Proposed INN: Carbidopa Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- Product Name: 11C-Raclopride Pharmaceutical Form: Solution for injection Other descriptive name: 11C-Raclopride Concentration unit: Sv sievert Concentration type: equal Concentration number: 0.0017- | Orion Corporation Orion Pharma | Not Recruiting | Female: yes Male: yes | Finland | |||||
959 | ChiCTR-TRC-07000027 | 2007-11-01 | 18 April 2017 | A randomized controlled clinical study of Pramipexole for Parkinson's disease | A randomized controlled clinical study of Pramipexole for Parkinson's disease | Primary Parkinson's disease | Group 1:Artane oral 1-2mg, tid,+ Mirapexin, 0.25 mg/d at beginning, and add to 1.0 mg/d at the end of the second week; the dose will be added from the second weekend to the eighth week to 4. 5 mg/d(1.5 mg, tid); maintain the dose during 12 weeks and reduce the dose during 1-4weeks;Group 3:Artane oral 1-2mg, tid + Madopar, 62.5~500 mg, 2~4 times a day depends on the serious of disease + Mirapexin, the dose is same as group 1;Group 2:Artane oral 1-2mg, tid+ Benserazide-Levodopa (Madopar), oral 62.5~500 mg, 2~4 times a day depends on the serious of the disease; | First Affiliated Hospital of Xinjiang Medical University | Not Recruiting | 30 | 80 | Both | Group 1:45;Group 3:45;Group 2:45; | Post-market | China | |
960 | NCT00537017 | November 2007 | 19 October 2017 | Follow Up Safety Study of SCH 420814 in Subjects With Parkinson's Disease (P05175) | A Phase 2, 36-Week, Open-Label, Uncontrolled Safety Follow-up Study Assessing SCH 420814 (Preladenant) 5 mg BID (P05175) | Parkinson Disease;Neurodegenerative Diseases;Central Nervous System Diseases;Movement Disorders;Brain Diseases | Drug: Preladenant;Drug: L-dopa;Drug: Other Parkinson's Disease treatments | Merck Sharp & Dohme Corp. | Not recruiting | 30 Years | N/A | All | 140 | Phase 2 | Argentina;Australia;Canada;Chile;Colombia;France;Guatemala;Hong Kong;Singapore;Spain;United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
961 | NCT00558337 | November 2007 | 19 February 2015 | Efficacy, Safety, and Pharmacokinetics/Pharmacodynamic Study of L-Dopa/Carbidopa To Treat Parkinson's Disease | An Efficacy, Safety, and Pharmacokinetics/Pharmacodynamic Relationship Study of L-Dopa/Carbidopa in a Novel Release Formulation in Parkinson's Disease Patients | Parkinson's Disease | Drug: levodopa-carbidopa | Osmotica Pharmaceutical Corp. | Not recruiting | 30 Years | 80 Years | Both | 78 | Phase 2 | Argentina | |
962 | NCT00560508 | November 2007 | 19 October 2017 | A 12-week Study of Pramipexole Extended Release (ER) in Patients With Parkinson's Disease (PD), Followed by a 52-week Long-term Treatment Period | A Double-blind, Double-dummy, Randomised, Parallel-group Study to Investigate the Safety, Tolerability, Trough Plasma Concentration, and Efficacy of Pramipexole ER Versus Pramipexole Immediate Release (IR) Administered Orally for 12 Weeks in Patients With Parkinson's Disease (PD) on L-dopa Therapy, Followed by a 52-week Open-label Long-term Treatment Period to Evaluate the Long-term Safety and Efficacy of Pramipexole ER | Parkinson Disease | Drug: Pramipexole Immediate Release;Drug: Pramipexole Extended Release | Boehringer Ingelheim | Not recruiting | 1 Year | N/A | All | 112 | Phase 2/Phase 3 | Japan | |
963 | NCT00584090 | November 2007 | 19 February 2015 | Solifenacin Succinate (VESIcare) for the Treatment of Urinary Incontinence in Parkinson's Disease | Urinary Incontinence;Parkinson's Disease | Drug: Solifenacin Succinate (VESIcare);Drug: Placebo | University of South Florida | Not recruiting | 30 Years | 80 Years | Both | 0 | Phase 4 | United States | ||
964 | NCT00610103 | November 2007 | 16 December 2017 | Phase 2 Clinical Study of KW-6500 in Parkinson's Disease Patients With Motor Response Complication on Levodopa Therapy | A Phase 2 Clinical Study of KW-6500 (Apomorphine Hydrochloride) in Patients With Parkinson's Disease | Parkinson's Disease | Drug: apomorphine hydrochloride | Kyowa Hakko Kirin Co., Ltd | Not recruiting | 20 Years | N/A | All | 16 | Phase 2 | Japan | |
965 | NCT00632762 | November 2007 | 19 February 2015 | Long-Term Effects of Amantadine in Parkinsonian (AMANDYSK) | Evaluation of the Long-term Effects of Amantadine in Parkinsonian's Suffering From Dyskinesia Induced by Levodopa: Study Randomised Double-blind, Placebo - Cessation of a Chronic Prescription. STUDY AMANDYSK. | Parkinson's Disease | Drug: mantadix | University Hospital, Toulouse | Not recruiting | 30 Years | 80 Years | Both | 80 | Phase 4 | France | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
966 | NCT01301651 | November 2007 | 19 February 2015 | Effects of Virtual Reality Training in Patients With Parkinson's Disease | Effects of Virtual Reality Augmented Balance Training for Postural Control in Patients With Parkinson's Disease | Parkinson's Disease | Behavioral: balance training | National Taiwan University Hospital | National Science Council, Taiwan | Not recruiting | 50 Years | 80 Years | Both | 42 | Phase 1 | Taiwan |
967 | EUCTR2007-004234-16-NL | 29/10/2007 | 19 March 2012 | Long-term safety study of open-label pramipexole extended release (ER) in patients with early Parkinson’s disease (PD). | Long-term safety study of open-label pramipexole extended release (ER) in patients with early Parkinson’s disease (PD). | Male or female patients with early idiopathic Parkinson´s disease (PD) with Modified Hoehn and Yahr stage I-III. MedDRA version: 9.1 Level: LLT Classification code 10061536 Term: Parkinson's disease | Product Name: Pramipexole ER Product Code: SND 919 CL2 Y Pharmaceutical Form: Prolonged-release tablet INN or Proposed INN: Pramipexole Current Sponsor code: SND 919 CL2 Y Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.375- Pharmaceutical form of the placebo: Prolonged-release tablet Route of administration of the placebo: Oral use Product Name: Pramipexole ER Product Code: SND 919 CL2 Y Pharmaceutical Form: Prolonged-release tablet INN or Proposed INN: Pramipexole Current Sponsor code: SND 919 CL2 Y Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.75- Pharmaceutical form of the placebo: Prolonged-release tablet Route of administration of the placebo: Oral use Product Name: Pramipexole ER Product Code: SND 919 CL2 Y Pharmaceutical Form: Prolonged-release tablet INN or Proposed INN: Pramipexole Current Sponsor code: SND 919 CL2 Y Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1.5- Pharmaceutical form of the placebo: Prolonged-release tablet Route of administration of the placebo: Oral use Product Name: Pramipexole ER Product Code: SND 919 CL2 Y Pharmaceutical Form: Prolonged-release tablet INN or Proposed INN: Pramipexole Current Sponsor code: SND 919 CL2 Y Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 3.0- Pharmaceutical form of the placebo: Prolonged-release tablet Route of administration of the placebo: Oral use Product Name: Pramipexole ER Product Code: SND 919 CL2 Y Pharmaceutical Form: Prolonged-release tablet INN or Proposed INN: Pramipexole Current Sponsor code: SND 919 CL2 Y Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 4.5- Pharmaceutical form of the placebo: Prolonged-release tablet Route of administration of the placebo: Oral use | Boehringer Ingelheim bv | Not Recruiting | Female: yes Male: yes | 520 | Finland;Hungary;Czech Republic;Netherlands;France;Austria | ||||
968 | EUCTR2007-001717-42-FR | 25/10/2007 | 19 March 2012 | A Phase 2, 36 Week, Open-Label, Uncontrolled Safety Follow-Up Study Assessing SCH 420814 5 mg BID - N/A | A Phase 2, 36 Week, Open-Label, Uncontrolled Safety Follow-Up Study Assessing SCH 420814 5 mg BID - N/A | Patients with Moderate to Severe Parkinson's Disease Experiencing Motor Fluctuations and Dyskinesias | Product Name: SCH 420814 Product Code: N/A Pharmaceutical Form: Capsule, hard Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- | Schering Plough Research Institute | Authorised | Female: yes Male: yes | 200 | Phase 2 | France;Spain | |||
969 | EUCTR2007-003353-90-NL | 23/10/2007 | 19 March 2012 | A double-blind, double-dummy, randomized, parallel groups study to assess the Efficacy, Safety and Tolerability of switching patients with early Parkinson’s disease (PD) from Pramipexole IR to Pramipexole ER or Pramipexole IR. | A double-blind, double-dummy, randomized, parallel groups study to assess the Efficacy, Safety and Tolerability of switching patients with early Parkinson’s disease (PD) from Pramipexole IR to Pramipexole ER or Pramipexole IR. | Male or female patients with idiopathic Parkinson's disease diagnosed within 5 years, with a modified Hoehn and Yahr scale of 1 to 3. MedDRA version: 9.1 Level: LLT Classification code 10061536 Term: Parkinson's disease | Product Name: Pramipexole ER Product Code: SND 919 CL2 Y Pharmaceutical Form: Prolonged-release tablet INN or Proposed INN: Pramipexole Current Sponsor code: SND 919 CL2 Y Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.375- Pharmaceutical form of the placebo: Prolonged-release tablet Route of administration of the placebo: Oral use Product Name: Pramipexole ER Product Code: SND 919 CL2 Y Pharmaceutical Form: Prolonged-release tablet INN or Proposed INN: Pramipexole Current Sponsor code: SND 919 CL2 Y Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.75- Pharmaceutical form of the placebo: Prolonged-release tablet Route of administration of the placebo: Oral use Product Name: Pramipexole ER Product Code: SND 919 CL2 Y Pharmaceutical Form: Prolonged-release tablet INN or Proposed INN: Pramipexole Current Sponsor code: SND 919 CL2 Y Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1.5- Pharmaceutical form of the placebo: Prolonged-release tablet Route of administration of the placebo: Oral use Product Name: Pramipexole ER Product Code: SND 919 CL2 Y Pharmaceutical Form: Prolonged-release tablet INN or Proposed INN: Pramipexole Current Sponsor code: SND 919 CL2 Y Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 3.0- Pharmaceutical form of the placebo: Prolonged-release tablet Route of administration of the placebo: Oral use Product Name: Pramipexole ER Product Code: SND 919 CL2 Y Pharmaceutical Form: Prolonged-release tablet INN or Proposed INN: Pramipexole Current Sponsor code: SND 919 CL2 Y Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 4.5- Pharmaceutical form of the placebo: Prolonged-release tablet Route of administration of the placebo: Oral use Trade Name: Sifrol Product Name: Pramipexole Product Code: SND 919 CL2 Y Pharmaceutical Form: Tablet INN or Proposed INN: Pramipexole | Boehringer Ingelheim | Authorised | Female: yes Male: yes | 145 | Germany;Netherlands;France | ||||
970 | EUCTR2007-002900-16-DE | 01/10/2007 | 19 March 2012 | A multi-centre, randomized, double-blind, placebo-controlled, parallel-group, multiple oral dose titration study in patients with Parkinson’s disease to assess the efficacy of AFQ056 in reducing L-dopa induced dyskinesias, and the safety and tolerability of AFQ056 in combination with L-dopa | A multi-centre, randomized, double-blind, placebo-controlled, parallel-group, multiple oral dose titration study in patients with Parkinson’s disease to assess the efficacy of AFQ056 in reducing L-dopa induced dyskinesias, and the safety and tolerability of AFQ056 in combination with L-dopa | The main objective of this study is to assess the efficacy of AFQ056 in reducing L-dopa induced dyskinesias. | Product Code: AFQ056 Pharmaceutical Form: Capsule, hard CAS Number: 543906-09-8 Current Sponsor code: AFQ056 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use Product Code: AFQ056 Pharmaceutical Form: Capsule, hard CAS Number: 543906-09-8 Current Sponsor code: AFQ056 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use | Novartis Pharma Services AG | Not Recruiting | Female: yes Male: yes | 34 | Germany | ||||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
971 | NCT00547911 | October 2007 | 19 October 2017 | Augmenting Effects of L-DOPS With Carbidopa and Entacapone | L-Dihydroxyphenylserine (L-DOPS) for Norepinephrine Deficiency: Interactions With Carbidopa and Entacapone | Parkinson Disease;Multiple System Atrophy;Autonomic Nervous System Diseases | Drug: Droxidopa;Drug: Carbidopa;Drug: Entacapone | National Institute of Neurological Disorders and Stroke (NINDS) | Not recruiting | 18 Years | N/A | All | 14 | Phase 1/Phase 2 | United States | |
972 | NCT00559871 | October 2007 | 19 February 2015 | Safety and Efficacy Study of Fipamezole in Treatment of Motor Dysfunctions in Parkinson's Disease | A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose Response Study of the Efficacy, Safety and Tolerability of Fipamezole as an Oromucosal Fast Dissolving Tablet in the Treatment of Parkinson's Disease Patients. | Parkinson's Disease | Drug: fipamezole | Juvantia Pharma Ltd | Santhera Pharmaceuticals | Not recruiting | 30 Years | N/A | Both | 180 | Phase 2 | United States;India |
973 | NCT00566462 | October 2007 | 17 September 2018 | Assessment of Perampanel (E2007) on Synaptic Dopamine in Mild-moderate PD Patients: A Pilot Study With [^123I]-IBZM SPECT | Assessment of Perampanel (E2007) on Synaptic Dopamine in Mild-moderate PD Patients: A Pilot Study With [^123I]-IBZM SPECT | Parkinson's Disease | Drug: perampanel;Drug: placebo | Eisai Inc. | Not recruiting | 30 Years | N/A | All | 1 | Phase 2 | United States | |
974 | NCT00582673 | October 2007 | 19 February 2015 | Efficacy and Safety of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson's Disease Patients, and Safety in Combination With L-dopa | A Multi-centre, Randomized, Double-blind, Placebo Controlled, Parallel-group, Multiple Oral Dose Titration Study in Patients With Parkinson's Disease to Assess the Efficacy of AFQ056 in Reducing L-dopa Induced Dyskinesias, and the Safety and Tolerability of AFQ056 in Combination With L-dopa | Parkinson's Disease | Drug: AFQ056;Drug: Placebo | Novartis | Not recruiting | 30 Years | 85 Years | Both | 31 | Phase 2 | Germany | |
975 | NCT01520727 | October 2007 | 19 October 2017 | A Single Oral Ascending Dose Study of BIA 9-1067 in Healthy Male Subjects | A Single Oral Ascending Dose Study to Investigate the Safety, Pharmacokinetics and Catechol-O-methyltransferase (COMT) Inhibition Profiles of BIA 9-1067 in Healthy Male Subjects | Parkinson Disease | Drug: BIA 9-1067;Drug: Placebo | Bial - Portela C S.A. | Not recruiting | 18 Years | 45 Years | Male | 64 | Phase 1 | France | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
976 | EUCTR2007-002899-34-GB | 18/09/2007 | 19 March 2012 | Pilot Controlled Clinical Trial of Salvia Officinalis (Sage) for cognitive impairments in Parkinson's Disease | Pilot Controlled Clinical Trial of Salvia Officinalis (Sage) for cognitive impairments in Parkinson's Disease | Cognitive impairment in Parkinson's Disease | Product Name: Sage leaf Pharmaceutical Form: Capsule, hard | Newcastle Upon tyne Hospitals NHS Foundation Trust | Not Recruiting | Female: yes Male: yes | United Kingdom | |||||
977 | EUCTR2007-002874-75-IT | 10/09/2007 | 19 March 2012 | Safety and effectivness of Open- Label Melperone in the treatment of Patients with Psycosis Associated with Parkinson's Disease'' - OV-1005 | Safety and effectivness of Open- Label Melperone in the treatment of Patients with Psycosis Associated with Parkinson's Disease'' - OV-1005 | Psycosis associated to Parkinson's Disease MedDRA version: 9.1 Level: HLT Classification code 10027361 Term: Mental disorders due to a general medical condition NEC | Product Name: Melperon Pharmaceutical Form: Syrup Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- | OVATION PHARMACEUTICALS INC | Not Recruiting | Female: yes Male: yes | 90 | Italy | ||||
978 | NCT00524914 | September 2007 | 19 February 2015 | Apomorphine Effect on Nociceptive Perception in Parkinson's: a Clinical and Imaging Study | Apomorphine Effect on Nociceptive Perception in Parkinson's: a Clinical and Imaging Study. | Parkinson's Disease | Drug: apomorphine;Drug: placebo | University Hospital, Toulouse | Not recruiting | 30 Years | 70 Years | Both | 16 | N/A | France | |
979 | NCT00537485 | September 2007 | 19 October 2017 | A Placebo-controlled Study for SPM 962 in Early Parkinson's Disease Patients | A Placebo-controlled Study for SPM 962 in Early Parkinson's Disease Patients With Non-concomitant Treatment of L-dopa | Early Parkinson's Disease | Drug: SPM 962;Drug: placebo | Otsuka Pharmaceutical Co., Ltd. | Not recruiting | 30 Years | 79 Years | All | 180 | Phase 2/Phase 3 | Japan | |
980 | EUCTR2007-003512-57-FR | 24/08/2007 | 19 March 2012 | Randomized, dose-finding study of BF 2.649 5, 10, 20 and 40 mg/d in comparison to placebo in Excessive Daytime Sleepiness in Parkinson’s Disease patients (PD) | Randomized, dose-finding study of BF 2.649 5, 10, 20 and 40 mg/d in comparison to placebo in Excessive Daytime Sleepiness in Parkinson’s Disease patients (PD) | Excessive daytime sleepiness associated to Parkinson disease MedDRA version: 9.1 Level: LLT Classification code 10041014 Term: Sleepiness MedDRA version: 9.1 Level: LLT Classification code 10061536 Term: Parkinson's disease | Product Name: BF 2.649 Product Code: BF 2.649 Pharmaceutical Form: Capsule* Current Sponsor code: BF 2.649 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use Product Name: BF 2.649 Product Code: BF 2.649 Pharmaceutical Form: Capsule* Current Sponsor code: BF 2.649 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Product Name: BF 2.649 Product Code: BF 2.649 Pharmaceutical Form: Capsule* Current Sponsor code: BF 2.649 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- Product Name: BF 2.649 Product Code: BF 2.649 Pharmaceutical Form: Capsule* Current Sponsor code: BF 2.649 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- | Bioprojet | Authorised | Female: yes Male: yes | 130 | France | ||||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
981 | EUCTR2007-000801-30-CZ | 01/08/2007 | 19 March 2012 | A Multi-centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Subjects with Motor Fluctuations | A Multi-centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Subjects with Motor Fluctuations | Parkinson's Disease MedDRA version: 9.1 Level: LLT Classification code 10013113 Term: Disease Parkinson's | Product Name: E2007 Product Code: MARS Pharmaceutical Form: Film-coated tablet Current Sponsor code: E2007 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2- | Eisai Limited | Not Recruiting | Female: yes Male: yes | 726 | Hungary;Czech Republic;France;Estonia;Spain;Italy;Latvia;Poland;Lithuania | ||||
982 | NCT00335374 | August 2007 | 19 February 2015 | An Open Label SLV308 Safety Extension to Study S308.3.003 in Early PD Patients | An Open Label SLV308 Safety Extension to Study S308.3.003 in Early PD Patients | Early Stage Parkinson's Disease | Drug: Pardoprunox | Solvay Pharmaceuticals | Not recruiting | 30 Years | N/A | Both | 202 | Phase 3 | United States;Australia;Czech Republic;Estonia;Germany;India;Italy;Lithuania;Malaysia;Netherlands;Poland;Portugal;South Africa;Taiwan;Thailand;France;Spain;United Kingdom | |
983 | NCT00407095 | August 2007 | 19 February 2015 | An Open Label SLV308 Safety Extension to Study S308.3.002 in Patients With Parkinson's Disease Experiencing Motor Fluctuations. | An Open Label SLV308 Safety Extension to Study S308.3.002 in Patients With Parkinson's Disease Experiencing Motor Fluctuations. | Advanced Stage Parkinson's Disease | Drug: Pardoprunox | Solvay Pharmaceuticals | Not recruiting | 30 Years | N/A | Both | 140 | Phase 3 | United States;Albania;Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Latvia;Lithuania;Peru;Russian Federation;Ukraine | |
984 | NCT00442780 | August 2007 | 19 February 2015 | Dose-Finding Safety Study of BIIB014 in Early-Stage Parkinson's Disease | A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of Multiple Doses of BIIB014 Administered Orally in Subjects With Early Parkinson's Disease | Parkinson's Disease | Drug: BIIB014;Drug: Placebo | Biogen Idec | Not recruiting | 30 Years | N/A | Both | 36 | Phase 2 | Israel;Poland;Serbia;Former Serbia and Montenegro | |
985 | EUCTR2006-005318-11-FR | 06/07/2007 | 19 March 2012 | Effet de l'apomorphine sur la perception douloureuse chez le patient parkinsonien : étude clinique et en tomographie par émission de positons. | Effet de l'apomorphine sur la perception douloureuse chez le patient parkinsonien : étude clinique et en tomographie par émission de positons. | maladie de Parkinson MedDRA version: 8.1 Level: LLT Classification code 10013113 Term: Disease Parkinson's | Trade Name: APOKINON Pharmaceutical Form: Solution for injection Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use | CHU Toulouse | Authorised | Female: yes Male: yes | France | |||||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
986 | NCT00515437 | July 2007 | 13 May 2019 | A Multi-Center Study of MYOBLOC for the Treatment of Sialorrhea in Parkinson's Disease Patients | A Multi-Center, Randomized, Double-blind, Placebo-Controlled,Sequential Dose Escalation, Safety, Tolerability, and Preliminary Efficacy Study of MYOBLOC for the Treatment of Sialorrhea in Parkinson's Disease Patients | Drooling | Biological: Botulinum Toxin Type B (Myobloc);Biological: Matched placebo to Myobloc | Solstice Neurosciences | Not recruiting | 18 Years | 85 Years | All | 54 | Phase 2 | United States | |
987 | NCT00522379 | July 2007 | 19 October 2017 | Trial to Assess Parkinson's Disease (PD) Symptom Control to Four Doses of Rotigotine in a Transdermal Patch | A Multicenter, Randomized, Double-blind, Placebo-controlled, 5-arm, Parallel-group Trial to Assess Rotigotine Transdermal System Dose Response in Subjects With Advanced-stage Parkinson's Disease | Parkinson's Disease | Drug: Rotigotine;Other: Placebo | UCB Pharma | Not recruiting | 30 Years | N/A | All | 514 | Phase 3 | United States;Chile;India;Mexico;Peru | |
988 | NCT00550238 | July 2007 | 25 June 2018 | A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis | A Multi-Center, Open-Label Extension Study to Examine the Safety and Tolerability of ACP-103 in the Treatment of Psychosis in Parkinson's Disease | Parkinson's Disease Psychosis | Drug: Pimavanserin tartrate (ACP-103) | ACADIA Pharmaceuticals Inc. | Not recruiting | 40 Years | N/A | All | 459 | Phase 3 | United States;Austria;Belgium;France;India;Italy;Poland;Portugal;Russian Federation;Serbia;Sweden;Ukraine;United Kingdom | |
989 | NCT00556764 | July 2007 | 19 February 2015 | Development of Cognitive Assessment Tools in Parkinson Disease | Development of Cognitive Assessment Tools in Parkinson Disease | Parkinson Disease | Drug: [123I] IBVM and SPECT imaging;Drug: Subjects will undergo the 123-I IBVM imaging visit | Institute for Neurodegenerative Disorders | Department of Defense;University of Oklahoma | Not recruiting | 30 Years | N/A | Both | 75 | Phase 0 | United States |
990 | NCT00593606 | July 2007 | 19 October 2017 | Safety and Tolerability Trial of Switching From Ropinirole to Rotigotine | A Phase 3b, Open-Label, Multicenter Trial to Assess the Safety and Tolerability of Switching Korean Subjects From Ropinirole to the Rotigotine Transdermal System and Its Effect on Symptoms in Idiopathic Parkinson's Disease | Parkinson's Disease | Drug: Rotigotine | UCB Pharma | Not recruiting | 18 Years | N/A | All | 124 | Phase 3 | ||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
991 | EUCTR2006-000678-57-CZ | 18/06/2007 | 19 March 2012 | A multicenter, randomized, double blind, parallel-group placebo and pramipexole controlled study to assess efficacy and safety of SLV308 monotherapy in the treatment of patients with early stage Parkinson’s disease. - The Vermeer study | A multicenter, randomized, double blind, parallel-group placebo and pramipexole controlled study to assess efficacy and safety of SLV308 monotherapy in the treatment of patients with early stage Parkinson’s disease. - The Vermeer study | Parkinson 's Disease early stage MedDRA version: 8.1 Level: LLT Classification code 10013113 Term: Disease Parkinson's | Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 Pharmaceutical Form: Film-coated tablet CAS Number: 269718-83-4 Current Sponsor code: SLV308 Other descriptive name: SLV308 (mono) hydrochloride Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.1- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 Pharmaceutical Form: Film-coated tablet CAS Number: 269718-83-4 Current Sponsor code: SLV308 Other descriptive name: SLV308 (mono) hydrochloride Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.2- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 Pharmaceutical Form: Film-coated tablet CAS Number: 269718-83-4 Current Sponsor code: SLV308 Other descriptive name: SLV308 (mono) hydrochloride Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 Pharmaceutical Form: Film-coated tablet CAS Number: 269718-83-4 Current Sponsor code: SLV308 Other descriptive name: SLV308 (mono) hydrochloride Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1.0- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 Pharmaceutical Form: Film-coated tablet CAS Number: 269718-83-4 Current Sponsor code: SLV308 Other descriptive name: SLV308 (mono) hydrochloride Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2.0- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use | Solvay pharmaceuticals | Not Recruiting | Female: yes Male: yes | 330 | Portugal;United Kingdom;Germany;Czech Republic;Netherlands;France;Estonia;Italy;Lithuania | ||||
992 | EUCTR2007-000073-39-CZ | 18/06/2007 | 19 March 2012 | A double-blind, double-dummy, placebo-controlled, randomized, three parallel groups study comparing the Efficacy, Safety and Tolerability of Pramipexole ER versus placebo and versus Pramipexole IR administered orally over a 26-week maintenance phase in patients with early Parkinson's disease (PD) | A double-blind, double-dummy, placebo-controlled, randomized, three parallel groups study comparing the Efficacy, Safety and Tolerability of Pramipexole ER versus placebo and versus Pramipexole IR administered orally over a 26-week maintenance phase in patients with early Parkinson's disease (PD) | Male or female patients with idiopathic Parkinson’s disease (PD), diagnosed within 5 years, having Modified Hoehn and Yahr stage of 1 to 3. MedDRA version: 9.1 Level: LLT Classification code 10061536 Term: Parkinson's disease | Product Name: Pramipexole ER Product Code: SND 919 CL2 Y Pharmaceutical Form: Prolonged-release tablet INN or Proposed INN: Pramipexole Current Sponsor code: SND 919 CL2 Y Other descriptive name: Prolonged release tablet Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.375- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: Pramipexole ER Product Code: SND 919 CL2 Y Pharmaceutical Form: Prolonged-release tablet INN or Proposed INN: Pramipexole Current Sponsor code: SND 919 CL2 Y Other descriptive name: Prolonged release tablet Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.75- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: Pramipexole ER Product Code: SND 919 CL2 Y Pharmaceutical Form: Prolonged-release tablet INN or Proposed INN: Pramipexole Current Sponsor code: SND 919 CL2 Y Other descriptive name: Prolonged release tablet Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1.5- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: Pramipexole ER Product Code: SND 919 CL2 Y Pharmaceutical Form: Prolonged-release tablet INN or Proposed INN: Pramipexole Current Sponsor code: SND 919 CL2 Y Other descriptive name: Prolonged release tablet Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 3.0- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: Pramipexole ER Product Code: SND 919 CL2 Y Pharmaceutical Form: Prolonged-release tablet INN or Proposed INN: Pramipexole Current Sponsor code: SND 919 CL2 Y Other descriptive name: Prolonged release tablet Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 4.5- Pharmaceutical form of the placebo: Tablet | Boehringer Ingelheim RCV GmbH & Co KG | Not Recruiting | Female: yes Male: yes | 500 | Hungary;Finland;Czech Republic;Austria | ||||
993 | EUCTR2006-005438-19-DE | 12/06/2007 | 19 March 2012 | An explorative, multicenter, open-label pilot trial with Neupro® (Rotigotine transdermal patch) once daily treatment administered perioperatively in Patients with idiopathic Parkinson´s disease. - NEUPOS | An explorative, multicenter, open-label pilot trial with Neupro® (Rotigotine transdermal patch) once daily treatment administered perioperatively in Patients with idiopathic Parkinson´s disease. - NEUPOS | idiopathic Parkinson´s disease MedDRA version: 9.1 Level: LLT Classification code 10061536 Term: Parkinson's disease | Trade Name: Neupro 2 mg/24 h transdermal patch Pharmaceutical Form: Transdermal patch INN or Proposed INN: Rotigotine CAS Number: 99755-59-6 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 4,5 mg- Trade Name: Neupro 4 mg/24 h transdermal patch Pharmaceutical Form: Transdermal patch INN or Proposed INN: Rotigotine CAS Number: 99755-59-6 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 9,0 mg- Trade Name: Neupro 6 mg/24 h transdermal patch Pharmaceutical Form: Transdermal patch INN or Proposed INN: Rotigotine CAS Number: 99755-59-6 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 13,5 mg- Trade Name: Neupro 8 mg/24 h transdermal patch Pharmaceutical Form: Transdermal patch INN or Proposed INN: Rotigotine CAS Number: 99755-59-6 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 18,0 mg- | SCHWARZ PHARMA Deutschland GmbH | Not Recruiting | Female: yes Male: yes | 30 | Germany | ||||
994 | EUCTR2006-005861-21-IT | 11/06/2007 | 7 January 2013 | A PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED, 12-MONTH EXTENSION STUDY TO INVESTIGATE THE LONG-TERM EFFICACY AND SAFETY OF A LOW (50 MG/DAY) AND HIGH (100 MG/DAY) DOSE OF SAFINAMIDE, AS ADD-ON THERAPY, IN PATIENTS WITH IDIOPATHIC PARKINSON`S DISEASE WITH MOTOR FLUCTUATIONS, TREATED WITH A STABLE DOSE OF LEVODOPA AND WHO MAY BE RECEIVING CONCOMITANT TREATMENT WITH STABLE DOSES OF A DOPAMINE AGONIST, AND/OR AN ANTICHOLINERGIC. | A PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED, 12-MONTH EXTENSION STUDY TO INVESTIGATE THE LONG-TERM EFFICACY AND SAFETY OF A LOW (50 MG/DAY) AND HIGH (100 MG/DAY) DOSE OF SAFINAMIDE, AS ADD-ON THERAPY, IN PATIENTS WITH IDIOPATHIC PARKINSON`S DISEASE WITH MOTOR FLUCTUATIONS, TREATED WITH A STABLE DOSE OF LEVODOPA AND WHO MAY BE RECEIVING CONCOMITANT TREATMENT WITH STABLE DOSES OF A DOPAMINE AGONIST, AND/OR AN ANTICHOLINERGIC. | Patients with idiopathic Parkinson's disease with motor fluctuations MedDRA version: 14.1 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Safinamide Product Code: NW-1015 Pharmaceutical Form: Tablet INN or Proposed INN: Monoamine oxidase B inhibitors Concentration unit: mg milligram(s) Concentration number: 50- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oromucosal use Product Name: Safinamide Product Code: NW-1015 Pharmaceutical Form: Tablet INN or Proposed INN: Monoamine oxidase B inhibitors Concentration unit: mg milligram(s) Concentration number: 50- | NEWRON PHARMACEUTICALS | Not Recruiting | Female: yes Male: yes | 500 | Phase 3 | Italy | |||
995 | EUCTR2006-006684-22-FR | 08/06/2007 | 19 March 2012 | Evaluation des effets à long terme de l’amantadine chez le parkinsonien souffrant de dyskinésies induites par la lévodopa : Etude randomisée en double-insu versus placebo de l’arrêt d’une prescription chronique. - AMANDYSK | Evaluation des effets à long terme de l’amantadine chez le parkinsonien souffrant de dyskinésies induites par la lévodopa : Etude randomisée en double-insu versus placebo de l’arrêt d’une prescription chronique. - AMANDYSK | maladie de parkinson MedDRA version: 9.1 Level: LLT Classification code 10013113 Term: Disease Parkinson's MedDRA version: 9.1 Level: LLT Classification code 10013916 Term: Dyskinesia | Trade Name: MANTADIX Pharmaceutical Form: Capsule* Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use | CHU Toulouse | Authorised | Female: yes Male: yes | France | |||||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
996 | JPRN-UMIN000000780 | 2007/06/01 | 2 April 2019 | A randomized, double-blind, placebo-controlled, cross-over, multi-center study concerning the efficacy and safety of amantadine hydrochloride in treatment of dyskinesias in Parkinson's disease | Parkinson's disease | An observation period (2 to 3 weeks) An administration of amantadine hydrochloride (27 days) A wash out period (15 days) An administration of placebo (27 days) An observation period (2 to 3 weeks) An administration of placebo (27 days) A wash out period (15 days) An administration of amantadine hydrochloride (27 days) | Comprehensive clinical study group concerning diagnosis, treatment, and prevention of the neurological disorders | Musashi Hospital, National Center of Neurology and Psychiatry, Japan Ehime University Hospital | Not Recruiting | 20years-old | 75years-old | Male and Female | 60 | Not applicable | Japan | |
997 | NCT00460954 | June 2007 | 19 February 2015 | A Multiple-Dose Study of Sinemet® CR (Carbidopa/Levodopa) in Healthy Subjects | An Open Label, Multiple-Dose Study ot Determine the Plasma Levodopa Profiles of Sinemet® CR (Carbidopa/Levodopa) at 4 Daily Dose Levels in Healthy Subjects | Parkinson's Disease | Drug: Sinemet® controlled release (Carbidopa/levodopa) | Bristol-Myers Squibb | Not recruiting | 50 Years | 75 Years | Both | 20 | N/A | Canada | |
998 | NCT00462254 | June 2007 | 19 February 2015 | Ramelteon (ROZEREM) in the Treatment of Sleep Disturbances Associated With Parkinson's Disease | Ramelteon (ROZEREM) in the Treatment of Sleep Disturbances Associated With Parkinson's Disease | Parkinson's Disease | Drug: ROZEREM;Drug: Ramelteon | Southern California Institute for Research and Education | Not recruiting | 45 Years | 85 Years | Both | 4 | Phase 4 | United States | |
999 | NCT00477672 | June 2007 | 16 December 2017 | A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis | A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson's Disease | Parkinson's Disease Psychosis | Drug: Pimavanserin tartrate (ACP-103);Drug: Placebo | ACADIA Pharmaceuticals Inc. | Not recruiting | 40 Years | N/A | All | 298 | Phase 3 | United States;Bulgaria;France;India;Russian Federation;Ukraine;United Kingdom | |
1000 | NCT00485069 | June 2007 | 19 October 2017 | REQUIP (Ropinirole Hydrochloride) IR Long-Term Phase 4 Study | Post-Marketing Clinical Study of REQUIP (Ropinirole Hydrochloride) Tablets in Patients With Parkinson's Disease- Evaluation of Long-Term Efficacy and Safety - | Parkinson Disease;Parkinson's Disease | Drug: ROP;Drug: ROP+L-Dopa | GlaxoSmithKline | Not recruiting | 20 Years | N/A | All | 123 | Phase 4 | Japan | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1001 | NCT00571285 | June 2007 | 16 December 2017 | Clinical Effects of Vitamin D Repletion in Patients With Parkinson's Disease | Clinical Effects of Vitamin D Repletion in Patients With Parkinson's Disease | Parkinson's Disease | Dietary Supplement: Vitamin D3;Dietary Supplement: Vitamin D3 - high dose;Dietary Supplement: Placebo | Emory University | Not recruiting | 18 Years | 89 Years | All | 31 | Phase 4 | United States | |
1002 | NCT00696215 | June 2007 | 19 February 2015 | The Effects of Rasagiline on Cognitive Deficits Associated With Parkinson's Disease | The Effects of Rasagiline on Cognitive Deficits Associated With Parkinson's Disease: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Over 3 Months | Parkinson's Disease | Drug: placebo;Drug: rasagiline | Istanbul University | Recruiting | N/A | N/A | Both | 40 | Phase 4 | Turkey | |
1003 | EUCTR2007-000073-39-DE | 29/05/2007 | 3 June 2013 | A double-blind, double-dummy, placebo-controlled, randomized, three parallel groups study comparing the Efficacy, Safety and Tolerability of Pramipexole ER versus placebo and versus Pramipexole IR administered orally over a 26-week maintenance phase in patients with early Parkinson's disease (PD) | A double-blind, double-dummy, placebo-controlled, randomized, three parallel groups study comparing the Efficacy, Safety and Tolerability of Pramipexole ER versus placebo and versus Pramipexole IR administered orally over a 26-week maintenance phase in patients with early Parkinson's disease (PD) | Male or female patients with idiopathic Parkinson’s disease (PD), diagnosed within 5 years, having Modified Hoehn and Yahr stage of 1 to 3. MedDRA version: 9.1 Level: LLT Classification code 10061536 Term: Parkinson's disease | Product Name: Pramipexole ER Product Code: SND 919 CL2 Y Pharmaceutical Form: Prolonged-release tablet INN or Proposed INN: Pramipexole Current Sponsor code: SND 919 CL2 Y Other descriptive name: Prolonged release tablet Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.375- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: Pramipexole ER Product Code: SND 919 CL2 Y Pharmaceutical Form: Prolonged-release tablet INN or Proposed INN: Pramipexole Current Sponsor code: SND 919 CL2 Y Other descriptive name: Prolonged release tablet Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.75- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: Pramipexole ER Product Code: SND 919 CL2 Y Pharmaceutical Form: Prolonged-release tablet INN or Proposed INN: Pramipexole Current Sponsor code: SND 919 CL2 Y Other descriptive name: Prolonged release tablet Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1.5- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: Pramipexole ER Product Code: SND 919 CL2 Y Pharmaceutical Form: Prolonged-release tablet INN or Proposed INN: Pramipexole Current Sponsor code: SND 919 CL2 Y Other descriptive name: Prolonged release tablet Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 3.0- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: Pramipexole ER Product Code: SND 919 CL2 Y Pharmaceutical Form: Prolonged-release tablet INN or Proposed INN: Pramipexole Current Sponsor code: SND 919 CL2 Y Other descriptive name: Prolonged release tablet Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 4.5- Pharmaceutical form of the placebo: Tablet | Boehringer Ingelheim Pharma GmbH & Co. KG | Not Recruiting | Female: yes Male: yes | 500 | Hungary;Czech Republic;Finland;Austria;Germany | ||||
1004 | EUCTR2007-000074-23-GB | 11/05/2007 | 19 March 2012 | A double-blind, double-dummy, placebo-controlled, randomized, three parallel groups study comparing the Efficacy, Safety and Tolerability of Pramipexole ER versus placebo and versus Pramipexole IR administered orally over a 26-week maintenance phase in L-Dopa+ treated patients with advanced Parkinson’s disease (PD). | A double-blind, double-dummy, placebo-controlled, randomized, three parallel groups study comparing the Efficacy, Safety and Tolerability of Pramipexole ER versus placebo and versus Pramipexole IR administered orally over a 26-week maintenance phase in L-Dopa+ treated patients with advanced Parkinson’s disease (PD). | Male or female patients, with idiopathic PD diagnosed for at least 2 years, 30 years of age or older at time of diagnosis, with a modified Hoehn and Yahr scale of 2 to 4 at on-time. MedDRA version: 9.1 Level: LLT Classification code 10061536 Term: Parkinson's disease | Product Name: Pramipexole ER Product Code: SND 919 CL2Y Pharmaceutical Form: Prolonged-release tablet INN or Proposed INN: Pramipexole Current Sponsor code: SND 919 CL2 Y Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.375- Pharmaceutical form of the placebo: Prolonged-release tablet Route of administration of the placebo: Oral use Product Name: Pramipexole ER Product Code: SND 919 CL2Y Pharmaceutical Form: Prolonged-release tablet INN or Proposed INN: Pramipexole Current Sponsor code: SND 919 CL2 Y Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.75- Pharmaceutical form of the placebo: Prolonged-release tablet Route of administration of the placebo: Oral use Product Name: Pramipexole ER Product Code: SND 919 CL2Y Pharmaceutical Form: Prolonged-release tablet INN or Proposed INN: Pramipexole Current Sponsor code: SND 919 CL2 Y Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1.5- Pharmaceutical form of the placebo: Prolonged-release tablet Route of administration of the placebo: Oral use Product Name: Pramipexole ER Product Code: SND 919 CL2Y Pharmaceutical Form: Prolonged-release tablet INN or Proposed INN: Pramipexole Current Sponsor code: SND 919 CL2 Y Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 3.0- Pharmaceutical form of the placebo: Prolonged-release tablet Route of administration of the placebo: Oral use Product Name: Pramipexole ER Product Code: SND 919 CL2Y Pharmaceutical Form: Prolonged-release tablet INN or Proposed INN: Pramipexole Current Sponsor code: SND 919 CL2 Y Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 4.5- Pharmaceutical form of the placebo: Prolonged-release tablet Route of administration of the placebo: Oral use Trade Name: SIFROL Pharmaceutical Form: Tablet INN or Proposed INN: Pramipexole Current Sponsor code: SND 919 CL2 Y | Boehringer Ingelheim Limited | Not Recruiting | Female: yes Male: yes | 516 | Hungary;United Kingdom;Spain;Italy;Austria;Sweden | ||||
1005 | EUCTR2006-006752-35-FI | 09/05/2007 | 16 October 2012 | RECOVER: RANDOMIZED EVALUATION OF THE 24-HOUR COVERAGE: EFFICACY OF ROTIGOTINE PHASE 3B, MULTICENTER, MULTINATIONAL, DOUBLE-BLIND, PLACEBO CONTROLLED, 2-ARM TRIAL TO EVALUATE THE EFFECT OF THE 24-HOUR TRANSDERMAL DELIVERY OF ROTIGOTINE ON THE CONTROL OF EARLY MORNING MOTOR FUNCTION, SLEEP QUALITY, NOCTURNAL SYMPTOMS, AND NON-MOTOR SYMPTOMS IN SUBJECTS WITH IDIOPATHIC PARKINSON’S DISEASE - Recover | RECOVER: RANDOMIZED EVALUATION OF THE 24-HOUR COVERAGE: EFFICACY OF ROTIGOTINE PHASE 3B, MULTICENTER, MULTINATIONAL, DOUBLE-BLIND, PLACEBO CONTROLLED, 2-ARM TRIAL TO EVALUATE THE EFFECT OF THE 24-HOUR TRANSDERMAL DELIVERY OF ROTIGOTINE ON THE CONTROL OF EARLY MORNING MOTOR FUNCTION, SLEEP QUALITY, NOCTURNAL SYMPTOMS, AND NON-MOTOR SYMPTOMS IN SUBJECTS WITH IDIOPATHIC PARKINSON’S DISEASE - Recover | Parkinson's disease MedDRA version: 9.1 Level: LLT Classification code 10061536 Term: Parkinson's disease | Trade Name: Neupro 2mg/24 h transdermal patch Product Code: ND1587 Pharmaceutical Form: Transdermal patch INN or Proposed INN: Rotigotine CAS Number: 99755-59-6 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 4.5-mg Pharmaceutical form of the placebo: Transdermal patch Route of administration of the placebo: Transdermal use Trade Name: Neupro 4mg/24 h transdermal patch Product Code: ND1589 Pharmaceutical Form: Transdermal patch INN or Proposed INN: Rotigotine CAS Number: 99755-59-6 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 9.0-mg Pharmaceutical form of the placebo: Transdermal patch Route of administration of the placebo: Transdermal use Trade Name: Neupro 6mg/24 h transdermal patch Product Code: ND1590 Pharmaceutical Form: Transdermal patch INN or Proposed INN: Rotigotine CAS Number: 99755-59-6 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 13.5-mg Pharmaceutical form of the placebo: Transdermal patch Route of administration of the placebo: Transdermal use Trade Name: Neupro 8 mg/24 h transdermal patch Product Code: ND1702 Pharmaceutical Form: Transdermal patch INN or Proposed INN: Rotigotine CAS Number: 99755-59-6 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 18.0-mg Pharmaceutical form of the placebo: Transdermal patch Route of administration of the placebo: Transdermal use | Schwarz Biosciences GmbH | Not Recruiting | Female: yes Male: yes | 400 | Phase 3B | Hungary;Finland;Spain;Austria;Germany;United Kingdom;Italy | |||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1006 | NCT00477802 | May 2007 | 19 February 2015 | Botulinum Toxin Type A (Botox) in the Management of Levodopa-Induced Peak-Dose Dyskinesias in Parkinson's Disease | Botulinum Toxin Type A (Botox) in the Management of Levodopa-Induced Peak-Dose Dyskinesias in Parkinson's Disease: A Double-Blind, Randomized, Placebo Controlled, Cross-Over Design Study | Parkinson Disease | Biological: Botulinum Toxin Type A;Biological: Placebo | University of Cincinnati | Allergan | Not recruiting | 35 Years | 75 Years | Both | 8 | Phase 4 | United States |
1007 | NCT00489255 | May 2007 | 19 October 2017 | Safety/Efficacy of Tigan® to Control Nausea/Vomiting Experienced During Apokyn® Initiation and Treatment | A Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Trimethobenzamide (Tigan®) in the Control of Nausea and Vomiting During Initiation and Continued Treatment With Subcutaneous Apomorphine (Apokyn®) in Apomorphine-naïve Subjects With Parkinson's Disease Suffering From Acute Intermittent Off Episodes, With Phased Withdrawal of Subjects From Tigan® to Placebo | Parkinson's Disease | Drug: Tigan®;Drug: Placebo | Ipsen | INC Research Limited | Not recruiting | 18 Years | N/A | All | 117 | Phase 4 | United States |
1008 | NCT00505843 | May 2007 | 19 February 2015 | A Study of MK0657 in Parkinson's Disease Patients (0657-006) | A Randomized, Double-Blind, Placebo-Controlled, 2-Period Crossover Study to Evaluate Effectiveness of Single-Dose MK0657 in Combination With Levodopa on Motor Symptoms and Dyskinesias in Patients With Parkinson's Disease | Parkinson's Disease | Drug: MK0657;Drug: Comparator: Placebo (unspecified);Drug: Comparator: levodopa;Drug: Comparator: carbidopa | Merck Sharp & Dohme Corp. | Not recruiting | 40 Years | 80 Years | Both | 18 | Phase 1 | United States | |
1009 | EUCTR2007-000307-15-IT | 24/04/2007 | 19 March 2012 | Safety and Efficacy of Melperone in the Treatment of Patients with Psychosis Associated with Parkinson's Disease. | Safety and Efficacy of Melperone in the Treatment of Patients with Psychosis Associated with Parkinson's Disease. | Psicosi associata al morbo di Parkinson MedDRA version: 9.1 Level: LLT Classification code 10013113 Term: Disease Parkinson's | Product Name: Melperon Pharmaceutical Form: Syrup INN or Proposed INN: melperon Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Syrup Route of administration of the placebo: Oral use | OVATION PHARMACEUTICALS INC | Not Recruiting | Female: yes Male: yes | 90 | Italy | ||||
1010 | NCT00434304 | April 9, 2007 | 16 December 2017 | Clinical Evaluation of Ropinirole PR/XR Tablets in Monotherapy for Parkinson's Disease (PD) | Clinical Evaluation of Ropinirole PR/XR Tablets in Monotherapy for Parkinson's Disease - an Open-Label, Uncontrolled Study - | Parkinson Disease | Drug: Ropinirole prolonged release/extended release(PR/XR) | GlaxoSmithKline | Not recruiting | 20 Years | N/A | All | 62 | Phase 2 | Japan | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1011 | NCT00459420 | April 2007 | 28 April 2015 | Caffeine for Excessive Daytime Somnolence in Parkinson's Disease | Caffeine for Excessive Daytime Somnolence in Parkinson's Disease | Parkinson's Disease;Excessive Daytime Somnolence | Drug: Caffeine 100-200 mg BID;Drug: placebo | Ron Postuma | Canadian Institutes of Health Research (CIHR);University of Toronto | Not recruiting | 18 Years | N/A | Both | 58 | Phase 2/Phase 3 | Canada |
1012 | NCT00460148 | April 2007 | 7 November 2016 | Parkinson's Disease Patient Study On Absorption, Distribution, Metabolism And Excretion Of Ropinirole | An Open Label, Repeat Dose, Dose Escalation Study Conducted in Parkinson's Disease Patients to Characterize the Pharmacokinetics and Effect of Food on Ropinirole Prolonged Release (PR/CR) 12mg Tablets. | Parkinson Disease | Drug: Ropinirole | GlaxoSmithKline | Not recruiting | 30 Years | 85 Years | Both | 28 | Phase 2 | Germany;South Africa | |
1013 | NCT00466167 | April 2007 | 19 October 2017 | Pivotal Study in Advanced Parkinsons Disease Patients | A Double-blind, Double-dummy, Placebo-controlled, Randomized, Three Parallel Groups Study Comparing the Efficacy, Safety and Tolerability of Pramipexole Extended Release (ER) Versus Placebo and Versus Pramipexole Immediate Release (IR) Administered Orally Over a 26-week Maintenance Phase in L-Dopa+ Treated Patients With Advanced Parkinsons Disease (PD). | Parkinson Disease | Drug: Pramipexol Extended Release;Drug: Pramipexol Immediate Release;Drug: Placebo | Boehringer Ingelheim | Not recruiting | 32 Years | N/A | All | 517 | Phase 3 | Austria;Czech Republic;Hungary;India;Italy;Korea, Republic of;Philippines;Poland;Russian Federation;Slovakia;Spain;Sweden;Ukraine;United Kingdom | |
1014 | NCT00623363 | April 2007 | 19 February 2015 | Preliminary Study of Piclozotan in Patients With Motor Complications Associated With Parkinson's Disease | Parkinson's Disease | Drug: piclozotan;Drug: 0.9% sodium chloride (normal saline) | Asubio Pharmaceuticals, Inc. | Not recruiting | 40 Years | 85 Years | Both | 27 | Phase 2 | United States;Guatemala;Romania | ||
1015 | EUCTR2006-006209-94-DE | 15/03/2007 | 19 March 2012 | An open label, repeat dose, dose escalation study conducted in Parkinson’s Disease patients to characterize the pharmacokinetics and effect of food on ropinirole prolonged release (PR/CR) 12mg tablets. | An open label, repeat dose, dose escalation study conducted in Parkinson’s Disease patients to characterize the pharmacokinetics and effect of food on ropinirole prolonged release (PR/CR) 12mg tablets. | Parkinson's disease MedDRA version: 9.1 Level: LLT Classification code 10061536 Term: Parkinson's disease | Trade Name: Requip-Modutab Product Name: Requip-Modutab Product Code: SK&F101468 Pharmaceutical Form: Prolonged-release tablet INN or Proposed INN: Ropinirole CAS Number: 91374-20-8 Current Sponsor code: SK&F101468 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2- Trade Name: Requip-Modutab Product Name: Requip-Modutab Product Code: SK&F101468 Pharmaceutical Form: Prolonged-release tablet INN or Proposed INN: Ropinirole CAS Number: 91374-20-8 Current Sponsor code: SK&F101468 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 4- Trade Name: Requip-Modutab Product Name: Requip-Modutab Product Code: SK&F101468 Pharmaceutical Form: Prolonged-release tablet INN or Proposed INN: Ropinirole CAS Number: 91374-20-8 Current Sponsor code: SK&F101468 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 8- Product Name: Ropinirole Product Code: SK&F101468 Pharmaceutical Form: Prolonged-release tablet INN or Proposed INN: Ropinirole CAS Number: 91374-20-8 Current Sponsor code: SK&F101468 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 12- | GlaxoSmithKline Research & Development Limited | Not Recruiting | Female: yes Male: yes | 36 | Germany | ||||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1016 | NCT00406588 | March 2007 | 19 February 2015 | SLV308 for Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of SLV308 as Adjunct Therapy to Levodopa in Patients With Parkinson's Disease Experiencing Motor Fluctuations. | Advanced Stage Parkinson's Disease | Drug: Pardoprunox;Drug: Placebo Comparator | Solvay Pharmaceuticals | Not recruiting | 30 Years | N/A | Both | 295 | Phase 3 | United States;Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Latvia;Lithuania;Peru;Russian Federation;Ukraine | |
1017 | NCT00437125 | March 2007 | 19 October 2017 | Study on the Tolerability of Duloxetine in Depressed Patients With Parkinson's Disease | An Open Label Pilot Study on the Tolerability of Duloxetine in the Treatment of Depressed Patients With Parkinson's Disease | Major Depressive Disorder;Idiopathic Parkinson Disease | Drug: Duloxetine hydrochloride | Eli Lilly and Company | Not recruiting | 30 Years | 75 Years | All | 151 | Phase 4 | Italy | |
1018 | NCT00443872 | March 2007 | 19 October 2017 | Efficacy of Orally Disintegrating Selegiline in Parkinson's Patients Experiencing Adverse Effects With Dopamine Agonists | Adding Orally Disintegrating Selegiline (Zelapar) to Patients Taking Dopamine Agonists and Experiencing Complications | Parkinson's Disease | Drug: orally disintegrating selegiline (Zelapar) | Parkinson's Disease and Movement Disorder Center of Boca Raton | Valeant Pharmaceuticals International, Inc. | Not recruiting | 30 Years | 90 Years | All | 77 | Phase 4 | United States |
1019 | NCT00449865 | March 2007 | 19 October 2017 | NET-PD LS-1 Creatine in Parkinson's Disease | A Multicenter, Double-Blind, Parallel Group, Placebo Controlled Study of Creatine in Subjects With Treated Parkinson's Disease (PD) Long Term Study (LS-1) | Parkinson's Disease | Drug: creatine;Other: placebo | University of Rochester | National Institute of Neurological Disorders and Stroke (NINDS) | Not recruiting | N/A | N/A | All | 1741 | Phase 3 | United States;Canada |
1020 | NCT00451633 | March 2007 | 19 February 2015 | The Effect Of E2007 On Pharmacodynamic Responses To Levodopa Among Patients With Parkinson's Disease Who Experience Dyskinesia And Motor Fluctuations | A Randomized, Double Blind, Placebo-Controlled Study To Investigate The Effect Of E2007 On Pharmacodynamic Responses To Levodopa Among Patients With Parkinson's Disease Who Experience Dyskinesia And Motor Fluctuations | Parkinson's Disease | Drug: E2007 | Eisai Inc. | Not recruiting | 30 Years | 80 Years | Both | 0 | Phase 2 | Germany;Italy | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1021 | NCT00455507 | March 2007 | 19 February 2015 | A Phase 2b Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa | Placebo-controlled, Double-blind, Parallel Group, Fixed Dose Study of KW-6002 (Istradefylline) in the Treatment of Parkinson's Disease (Phase 2 Study) | Parkinson's Disease | Drug: Istradefylline;Drug: Placebo | Kyowa Hakko Kirin Company, Limited | Not recruiting | 20 Years | N/A | Both | 363 | Phase 2 | Japan | |
1022 | NCT01693081 | March 2007 | 19 February 2015 | Phase IIa Multicentre Study Investigating of VR040 in Parkinson's Disease | A Clinic-Based, Phase IIa, Double-Blind, Placebo- Controlled, Ascending-Dose, Multicentre Study of Safety, Tolerability, Efficacy and Pharmacokinetics of VR040 in Parkinson's Disease | Parkinson's Disease | Drug: VR040/Aspirair® inhaler;Drug: placebo | South Glasgow University Hospitals NHS Trust | Vectura Limited | Not recruiting | 30 Years | 90 Years | Both | 47 | Phase 2 | Serbia;United Kingdom |
1023 | EUCTR2006-002408-32-ES | 27/02/2007 | 19 March 2012 | Modulación dopaminérgica de las funciones cognitivas y afectivas por el tratamiento con diferentes métodos de estimulación dopaminérgica en la enfermedad de Parkinson . Implicaciones para el tratamiento con levodopa. | Modulación dopaminérgica de las funciones cognitivas y afectivas por el tratamiento con diferentes métodos de estimulación dopaminérgica en la enfermedad de Parkinson . Implicaciones para el tratamiento con levodopa. | Fluctuaciones motoras, cognitivas y del humor en la enfermedad de Parkinson. MedDRA version: 8.1 Level: PT Classification code 10061536 Term: Parkinson's disease | Trade Name: Stalevo 150 Product Name: Levodopa-carbidopa-entacapone Pharmaceutical Form: Capsule, hard Trade Name: Sinemet Product Name: Levodopa/Carbidopa Pharmaceutical Form: Capsule, hard | Institut de Recerca del Hospital de la Santa Creu i Sant Pau | Authorised | Female: yes Male: yes | 20 | Spain | ||||
1024 | EUCTR2006-005714-12-IT | 27/02/2007 | 19 March 2012 | A randomized, double blind, placebo-controlled study to investigate the effect of E2007 on pharmacodynamic responses to levodopa among patients with Parkinson's disease who experience dyskinesia and motor fluctuations. - E2007-E044-213 | A randomized, double blind, placebo-controlled study to investigate the effect of E2007 on pharmacodynamic responses to levodopa among patients with Parkinson's disease who experience dyskinesia and motor fluctuations. - E2007-E044-213 | Patients with idiopathic Parkinson's disease who respond to levodopa treatment but who experience peak-effect levodopa-induced dyskinesia and end-of-dose 'wearing-off' motor fluctuations MedDRA version: 6.1 Level: HLT Classification code 10034005 | Product Name: E2007 Product Code: E2007 Pharmaceutical Form: Tablet INN or Proposed INN: OTHER NERVOUS SYSTEM DRUGS Current Sponsor code: E2007 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Trade Name: SINEMET Pharmaceutical Form: Tablet INN or Proposed INN: levodopa-carbidopa Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 275- | EISAI LTD UK | Not Recruiting | Female: yes Male: yes | 24 | Italy | ||||
1025 | NCT00332917 | February 2007 | 19 February 2015 | An Open Label SLV308 Safety Extension to Study S308.3.001 in Early PD Patients | An Open Label SLV308 Safety Extension to Study S308.3.001 in Early PD Patients | Early Stage Parkinson's Disease | Drug: Pardoprunox | Solvay Pharmaceuticals | Not recruiting | 30 Years | N/A | Both | 224 | Phase 3 | United States;Argentina;Belgium;Bulgaria;Canada;Chile;Colombia;Croatia;Finland;India;Israel;Mexico;New Zealand;Peru;Romania;Russian Federation;Serbia;Slovakia;South Africa;Sweden;Ukraine;Former Serbia and Montenegro | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1026 | NCT00427011 | February 2007 | 19 October 2017 | A Study of E2007 In Patients With Parkinson's Disease | A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of E2007 In Patients With Parkinson's Disease Who Experience End-of-Dose Wearing-Off Motor Fluctuations | Parkinson's Disease | Drug: E2007 | Eisai Inc. | Not recruiting | 18 Years | N/A | All | 25 | Phase 2 | United States | |
1027 | NCT00480701 | February 2007 | 19 February 2015 | Evaluation of 123-I Iodobenzovesamicol (IBVM) and SPECT Imaging of Healthy Subjects and Patients With Alzheimer Disease | Evaluation of 123-I Iodobenzovesamicol (IBVM) and SPECT as a Marker of Acetylcholine Transporter Density in the Brain of Healthy Subjects and Patients With Alzheimer Disease | Alzheimer Disease;Parkinson Disease | Drug: [123I]-IBVM | Institute for Neurodegenerative Disorders | Not recruiting | 50 Years | N/A | Both | 26 | Phase 2 | United States | |
1028 | EUCTR2006-003732-30-DE | 31/01/2007 | 19 March 2012 | Transdermal Use of Lisuride in Early Parkinson´s Disease: A double blind, randomized, Placebo and Pramipexole controlled study to evaluate the efficacy and safety of Lisuride TTS - TULEP 1 | Transdermal Use of Lisuride in Early Parkinson´s Disease: A double blind, randomized, Placebo and Pramipexole controlled study to evaluate the efficacy and safety of Lisuride TTS - TULEP 1 | Early Parkinson's Disease MedDRA version: 8.1 Level: PT Classification code 10061536 Term: Parkinson's disease | Product Name: Lisuride TTS 10cm² Pharmaceutical Form: Transdermal patch INN or Proposed INN: LISURIDE CAS Number: 18016803 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2,5- Pharmaceutical form of the placebo: Transdermal patch Route of administration of the placebo: Transdermal use Trade Name: Sifrol 0,088 Pharmaceutical Form: Capsule* INN or Proposed INN: PRAMIPEXOLE CAS Number: 104632260 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0,088- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use Product Name: Lisuride TTS 20cm² Pharmaceutical Form: Transdermal patch INN or Proposed INN: LISURIDE CAS Number: 18016803 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5,0- Pharmaceutical form of the placebo: Transdermal patch Route of administration of the placebo: Transdermal use Trade Name: Sifrol 0,18 Pharmaceutical Form: Capsule* INN or Proposed INN: PRAMIPEXOLE CAS Number: 104632260 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0,18- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use Trade Name: Sifrol 0,35 Pharmaceutical Form: Capsule* INN or Proposed INN: PRAMIPEXOLE CAS Number: 104632260 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0,35- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use Trade Name: Sifrol 0,7 Pharmaceutical Form: Capsule* INN or Proposed INN: PRAMIPEXOLE CAS Number: 104632260 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0,7- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use | Axxonis Pharma AG | Authorised | Female: yes Male: yes | 350 | Germany;Italy;Poland | ||||
1029 | NCT00427674 | January 2007 | 19 February 2015 | Assessment of the Biodistribution and Safety of 123-I MZINT in Healthy Subjects and Parkinson Disease Patients | Phase I Evaluation of (123-I)MZINT as a Brain SPECT Tracer of Serotonin Transporters in Healthy Human Subjects | Parkinson Disease | Drug: [123I] mZINT injection and serial dynamic SPECT imaging | Institute for Neurodegenerative Disorders | Molecular NeuroImaging | Not recruiting | 18 Years | 70 Years | Both | 28 | Phase 1 | United States |
1030 | NCT00465452 | January 2007 | 19 February 2015 | Impact of Switching to Continuous Release Dopamine Agonists | The Impact of Switching to Continuous Release Dopamine Agonists on Non-Motor Side Effects | Parkinson Disease | Drug: Continuous Release Dopamine Agonists | University of Toledo Health Science Campus | Not recruiting | 55 Years | N/A | Both | 15 | Phase 3 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1031 | NCT00640159 | January 2007 | 19 February 2015 | Tolerability and Efficacy of Switch From Oral Selegiline to Orally Disintegrating Selegiline (Zelapar) in Patients With Parkinson's Disease | Tolerability and Efficacy of Switch From Oral Selegiline to Orally Disintegrating Selegiline (Zelapar) in Patients With Parkinson's Disease. | Parkinson's Disease | Drug: Zelapar | Baylor College of Medicine | Not recruiting | 30 Years | 90 Years | Both | 55 | Phase 4 | United States | |
1032 | NCT01187966 | January 2007 | 19 February 2015 | Efficacy and Safety of Safinamide (50 and 100mg/Day) Versus Placebo, in Patients With Mid-late Stage Parkinson's Disease | A Phase III, Double-blind, Placebo-controlled Study to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Patients With Idiopathic Parkinson's Disease With Motor Fluctuations, Treated With a Stable Dose of Levodopa and Who May be Receiving Concomitant Treatment With Stable Doses of a Dopamine Agonist, and/or an Anticholinergic | Parkinson's Disease | Drug: Safinamide;Drug: Placebo | Newron | Not recruiting | 30 Years | 80 Years | Both | 669 | Phase 3 | ||
1033 | EUCTR2006-005509-79-GB | 21/12/2006 | 8 August 2016 | A Clinic-Based, Phase IIa, Randomised, Double-Blind, Placebo-Controlled, Ascending-Dose, Multicentre Study Investigating the Safety, Tolerability, Efficacy, and Pharmacokinetics of VR040 in Patients with Established Idiopathic Parkinson’s Disease | A Clinic-Based, Phase IIa, Randomised, Double-Blind, Placebo-Controlled, Ascending-Dose, Multicentre Study Investigating the Safety, Tolerability, Efficacy, and Pharmacokinetics of VR040 in Patients with Established Idiopathic Parkinson’s Disease | Idiopathic Parkinson's Disease patients who have motor fluctuations with recognisable motor “off” periods | Product Name: apomorphine hydrochloride Product Code: VR040 Pharmaceutical Form: Inhalation powder INN or Proposed INN: apomorphine hydrochloride CAS Number: 41372-20-7 Current Sponsor code: VR040 Concentration unit: µg microgram(s) Concentration type: range Concentration number: 3200-9000 Pharmaceutical form of the placebo: Inhalation powder Route of administration of the placebo: Inhalation use | Vectura Group plc | Not Recruiting | Female: yes Male: yes | 42 | Phase 2 | United Kingdom | |||
1034 | EUCTR2006-003490-27-GB | 19/12/2006 | 19 March 2012 | A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of Single and Multiple Oral Dose Administration of BIIB014 in Subjects with Moderate to Late Stage Parkinson’s Disease Who Are Also Receiving Treatment with Levodopa | A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of Single and Multiple Oral Dose Administration of BIIB014 in Subjects with Moderate to Late Stage Parkinson’s Disease Who Are Also Receiving Treatment with Levodopa | Parkinson's disease MedDRA version: 8.1 Level: PT Classification code 10061536 Term: Parkinson's disease | Product Code: BIIB014 Pharmaceutical Form: Capsule, hard CAS Number: 442908-10-3 Current Sponsor code: BIIB014 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2.5- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Product Code: BIIB014 Pharmaceutical Form: Capsule, hard CAS Number: 442908-10-3 Current Sponsor code: BIIB014 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Product Code: BIIB014 Pharmaceutical Form: Capsule, hard CAS Number: 442908-10-3 Current Sponsor code: BIIB014 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use | BIOGEN IDEC LTD | Not Recruiting | Female: yes Male: yes | 137 | United Kingdom | ||||
1035 | EUCTR2006-005860-14-IT | 19/12/2006 | 19 March 2012 | A phase III, double-blind, placebo-controlled study to determine the efficacy and safety of a low (50 mg/day) and high (100 mg/day) dose of safinamide, as add-on therapy, in patients with idiopathic parkinson?s disease with motor fluctuations, treated with a stable dose of levodopa and who may be receiving concomitant treatment with stable doses of a dopamine agonist and/or an anticholinergic - ND | A phase III, double-blind, placebo-controlled study to determine the efficacy and safety of a low (50 mg/day) and high (100 mg/day) dose of safinamide, as add-on therapy, in patients with idiopathic parkinson?s disease with motor fluctuations, treated with a stable dose of levodopa and who may be receiving concomitant treatment with stable doses of a dopamine agonist and/or an anticholinergic - ND | PATIENTS WITH IDIOPATHIC PARKINSON?S DISEASE WITH MOTOR FLUCTUATIONS MedDRA version: 9.1 Level: LLT Classification code 10061536 Term: Parkinson's disease | Product Name: Safinamide Product Code: NW-1015 Pharmaceutical Form: Tablet Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Buccal use Product Name: Safinamide Product Code: NW-1015 Pharmaceutical Form: Tablet Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- | NEWRON PHARMACEUTICALS | Not Recruiting | Female: yes Male: yes | 600 | Phase 3 | Italy | |||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1036 | EUCTR2006-005140-89-NL | 11/12/2006 | 19 March 2012 | A PHASE I, DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMIZED (WITHIN EACH GROUP) STUDY TO EVALUATE THE INTERACTION BETWEEN ORALLY ADMINISTERED TYRAMINE HYDROCHLORIDE AND RASAGILINE MESILATE IN HEALTHY SUBJECTS - Tyramine challenge study | A PHASE I, DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMIZED (WITHIN EACH GROUP) STUDY TO EVALUATE THE INTERACTION BETWEEN ORALLY ADMINISTERED TYRAMINE HYDROCHLORIDE AND RASAGILINE MESILATE IN HEALTHY SUBJECTS - Tyramine challenge study | This postmarketing Phase I study is performed in healthy volunteers. The IMP rasagiline 1mg is indicated for the treatment of Parkinson's Disease (PD). MedDRA version: 9.1 Level: PT Classification code 10061536 | Trade Name: Selegiline HCl 5 PCH Pharmaceutical Form: Tablet Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Trade Name: Nardil Pharmaceutical Form: Tablet Product Name: Rasagiline 1mg tablet Product Code: TVP-1012 Pharmaceutical Form: Tablet INN or Proposed INN: Rasagiline CAS Number: 161735-79-1 Current Sponsor code: TVP-1012 Other descriptive name: Rasagiline mesilate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Product Name: Rasagiline 2 mg tablet Product Code: TVP-1012 Pharmaceutical Form: Tablet INN or Proposed INN: Rasagiline CAS Number: 161735-79-1 Current Sponsor code: TVP-1012 Other descriptive name: Rasagiline mesilate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use | TEVA Pharmaceuticals Industries Ltd | Authorised | Female: yes Male: yes | 160 | Phase 1 | Netherlands | |||
1037 | NCT00036296 | December 2006 | 19 February 2015 | Effects of Talampanel on Patients With Advanced Parkinson's Disease | Effects of Talampanel on Patients With Advanced Parkinson's Disease Who Have Been on Sinemet for More Than 5 Years and Have Dyskinesia (Abnormal Involuntary Movements) | Dyskinesias;Parkinson Disease;Movement Disorders | Drug: talampanel | Teva Pharmaceutical Industries | Not recruiting | 40 Years | 85 Years | Both | 22 | Phase 1/Phase 2 | United States;Canada | |
1038 | NCT00853879 | December 2006 | 25 May 2015 | An Exploratory, Randomized, Blinded, Placebo-Controlled Trial of Folic Acid and L-methylfolate in Parkinson's Disease | An Exploratory, Randomized, Blinded, Placebo-Controlled Trial of Folic Acid and L-methylfolate in Parkinson's Disease | Parkinson's Disease | Dietary Supplement: Folic Acid, Vitamin B6, Vitamin B12;Dietary Supplement: B6, B12, L-methylfolate;Dietary Supplement: B6, B12, Placebo | North Shore Long Island Jewish Health System | Not recruiting | 30 Years | N/A | Both | 150 | N/A | United States | |
1039 | NCT01631812 | December 2006 | 19 October 2017 | A Long-Term Extension Trial From Late Phase II of SPM 962 in Advanced Parkinson's Disease Patients | An Open-label Long-term Extension Trial From Late Phase II of SPM962 (243-05-001) in Advanced Parkinson's Disease Patients With Concomitant Treatment of L-dopa | Parkinson's Disease | Drug: SPM 962 | Otsuka Pharmaceutical Co., Ltd. | Not recruiting | N/A | N/A | All | 130 | Phase 2 | Japan | |
1040 | NCT01964573 | December 2006 | 19 February 2015 | Trial to Evaluate the Pharmacokinetics, Safety, and Tolerability of Rotigotine in Healthy Korean Subjects | A Single-site, Randomized, Double-blind, Placebo-controlled, Repeated-dose Trial to Evaluate the Pharmacokinetics, Safety, and Tolerability of Rotigotine in 2 Different Dosages (2 mg / 24 Hours [10 cm2], 4 mg / 24 Hours [20 cm2]) in Healthy Korean Subjects | Parkinson's Disease | Drug: Rotigotine;Other: Placebo | UCB Pharma | Not recruiting | 19 Years | 45 Years | Both | 48 | Phase 1 | Korea, Republic of | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1041 | EUCTR2006-004112-51-IT | 14/11/2006 | 19 March 2012 | A randomised, double-blind, double-dummy, two-period, cross-over study to determine the pharmacokinetics, pharmacodynamics and safety of multiple doses of V1512 effervescent tablets in Parkinson s Disease PD patients compared to standard levodopa/carbidopa Sinemet oral tablets - ND | A randomised, double-blind, double-dummy, two-period, cross-over study to determine the pharmacokinetics, pharmacodynamics and safety of multiple doses of V1512 effervescent tablets in Parkinson s Disease PD patients compared to standard levodopa/carbidopa Sinemet oral tablets - ND | Parkinson s disease MedDRA version: 8.1 Level: LLT Classification code 10061536 Term: Parkinson's disease | Trade Name: SIRIO*30CPR EFF 25MG+100MG Pharmaceutical Form: Effervescent tablet INN or Proposed INN: Melevodopa and decarboxylase inhibitor Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Effervescent tablet Route of administration of the placebo: Oral use Trade Name: SINEMET*50CPR 100MG+25MG Pharmaceutical Form: Tablet INN or Proposed INN: LEVODOPA DC.IT FU CAS Number: 59-92-7 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- INN or Proposed INN: CARBIDOPA FU CAS Number: 28860-95-9 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | VERNALIS DEVELOPMENT LIMITED | Not Recruiting | Female: yes Male: yes | Italy | |||||
1042 | EUCTR2006-004582-33-GB | 03/11/2006 | 8 August 2016 | A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Escalating Study Investigating the Efficacy and Safety of VR040 in the Treatment of Unpredictable “Off” or End-of-Dose “Wearing Off” Episodes in Patients With Advanced Idiopathic Parkinson’s Disease | A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Escalating Study Investigating the Efficacy and Safety of VR040 in the Treatment of Unpredictable “Off” or End-of-Dose “Wearing Off” Episodes in Patients With Advanced Idiopathic Parkinson’s Disease | Hypomobility (off or freezing) episodes associated with advanced Parkinson's disease | Product Name: Apomorphine hydrochloride Product Code: VR040 Pharmaceutical Form: Inhalation powder Pharmaceutical form of the placebo: Inhalation powder Route of administration of the placebo: Inhalation use | Vectura Group plc | Not Recruiting | Female: yes Male: yes | 48 | Phase 2 | United Kingdom | |||
1043 | NCT00335166 | November 2006 | 19 February 2015 | SLV 308 and Pramipexole for Treatment of Patients With Early Parkinson Disease | A Multicenter, Randomized, Double Blind, Parallel-Group Placebo and Pramipexole Controlled Study to Assess Efficacy and Safety of SLV308 Monotherapy in the Treatment of Patients With Early Stage Parkinson's Disease. | Early Stage Parkinson Disease | Drug: Placebo Comparator;Drug: pramipexole;Drug: Pardaprunox | Solvay Pharmaceuticals | Not recruiting | 30 Years | N/A | Both | 330 | Phase 3 | United States;Australia;Czech Republic;Estonia;France;Germany;India;Italy;Lithuania;Malaysia;Netherlands;Poland;Portugal;South Africa;Spain;Taiwan;Thailand;United Kingdom | |
1044 | NCT00360308 | November 2006 | 19 October 2017 | Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations | A Multi-centre, Randomised, Double-blind, Placebo and Entacapone Controlled, Parallel Group Study of the Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations | Parkinson's Disease | Drug: Placebo;Drug: E2007 | Eisai Limited | Not recruiting | 30 Years | N/A | All | 723 | Phase 3 | France | |
1045 | NCT00387075 | November 2006 | 15 April 2019 | A Study Evaluating Potential Screening Tools for Detecting Parkinson Disease | Parkinson Associated Risk Factor Study (PARS): Evaluating Potential Screening Tools for Parkinson Disease | Parkinson Disease | Procedure: [123I]ß-CIT and SPECT imaging;Drug: [123I]ß-CIT | Institute for Neurodegenerative Disorders | United States Department of Defense;Molecular NeuroImaging | Not recruiting | 50 Years | N/A | All | 3000 | Phase 2 | United States |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1046 | NCT00397228 | November 2006 | 9 January 2017 | ALTROPANE® SPECT Imaging in Patients With Parkinson Disease | Optimizing the Performance of ALTROPANE® SPECT Imaging in Patients With Parkinson Disease | Parkinson Disease | Drug: ALTROPANE® | Molecular NeuroImaging | Institute for Neurodegenerative Disorders | Not recruiting | 30 Years | N/A | Both | 27 | Phase 2 | United States |
1047 | NCT00397696 | November 2006 | 19 February 2015 | Evaluation of 5-[123I]-A-85380 and SPECT Imaging in Individuals With Parkinsons Disease | Evaluation of 5-[123I]-A-85380 and SPECT Imaging as a Marker of Nicotinic Receptor Density in the Brain of Parkinson Disease Subjects | Parkinson Disease | Drug: [123I] 5-IA | Institute for Neurodegenerative Disorders | Department of Defense | Not recruiting | 21 Years | N/A | Both | 9 | Phase 2 | United States |
1048 | NCT00402233 | November 2006 | 19 October 2017 | A Randomized, Double-blind, Active (Pramipexole 0.5 mg Tid) and Placebo Controlled, Study of Pramipexole Given 0.5 mg and 0.75 mg Bid Over 12-week Treatment in Early Parkinson's Disease (PD) Patients | A Randomized, Double-blind, Active (Pramipexole 0.5 mg Tid) and Placebo Controlled, Efficacy Study of Pramipexole Given 0.5 mg and 0.75 mg Bid Over a 12-week Treatment Phase in Early Parkinson's Disease Patients (PramiBID) | Parkinson Disease | Drug: Pramipexole;Drug: Placebo | Boehringer Ingelheim | Not recruiting | 31 Years | N/A | All | 312 | Phase 4 | United States | |
1049 | NCT00404170 | November 2006 | 15 April 2019 | Assessing Imaging as a Tool in Monitoring and Predicting the Progression of Parkinson Disease | Assessing the Determinants of PD Progression - Long-term Dopamine Transporter Imaging in the PRECEPT Cohort | Parkinson Disease | Drug: B-CIT and SPECT imaging | Institute for Neurodegenerative Disorders | United States Department of Defense | Not recruiting | 30 Years | N/A | All | 396 | Phase 2 | United States |
1050 | NCT00406029 | November 2006 | 19 October 2017 | Dyskinesia in Parkinson's Disease (Study P04501) | A Phase 2, 12-Week, Double-Blind, Dose-Finding, Placebo-Controlled Study to Assess the Efficacy and Safety of a Range of SCH 420814 Doses in Subjects With Moderate to Severe Parkinson's Disease Experiencing Motor Fluctuations and Dyskinesias | Parkinson Disease;Movement Disorders;Central Nervous System Diseases;Neurodegenerative Diseases;Brain Diseases | Drug: Preladenant;Drug: Placebo;Drug: L-dopa;Drug: Other Parkinson's Disease treatments | Merck Sharp & Dohme Corp. | Not recruiting | 30 Years | N/A | All | 253 | Phase 2 | Argentina;Australia;Canada;Chile;Colombia;France;Guatemala;Hong Kong;Italy;New Zealand;Peru;Singapore;South Africa;Spain;United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1051 | NCT00468078 | November 2006 | 25 January 2016 | Efficacy and Safety of F-18 FPCIT PET in Parkinson's Disease and Essential Tremor Patients | The Single Center, Phase III Clinical Trial to Evaluate the Efficacy and the Safety of [18F]FPCIT Positron Emission Tomography in Parkinson's Disease and Essential Tremor Patients | Parkinson's Disease | Procedure: PET/CT;Drug: F-18 FPCIT | Asan Medical Center | Not recruiting | 40 Years | N/A | Both | 78 | Phase 3 | Korea, Republic of | |
1052 | NCT00491998 | November 2006 | 19 February 2015 | PK, PD and Safety of Multiple Doses of V1512 Tablets in PD Patients Compared to Standard Levodopa/Carbidopa Oral Tablets | Randomised, Double-blind, Double-dummy, Two-period, Cross-over Study to Determine the PK, PD and Safety of Multiple Doses of V1512 Effervescent Tablets in Parkinson's Disease Patients Compared to Sinemet® Oral Tablets | Parkinson's Disease | Drug: V1512;Drug: V1512 and Entacapone | Vernalis (R&D) Ltd | Cita NeuroPharmaceuticals;INC Research | Not recruiting | 30 Years | N/A | Both | 27 | Phase 1/Phase 2 | Italy |
1053 | EUCTR2005-002038-36-GB | 31/10/2006 | 11 September 2012 | A randomised, double-blind, placebo-controlled, 6-month study of the efficacy and safety of memantine in patients with Parkinson’s disease dementia or dementia with Lewy Bodies | A randomised, double-blind, placebo-controlled, 6-month study of the efficacy and safety of memantine in patients with Parkinson’s disease dementia or dementia with Lewy Bodies | Patients with Parkinson’s disease dementia or dementia with Lewy Bodies MedDRA version: 8.1 Level: LLT Classification code 10012284 Term: Dementia due to Parkinson's disease ;Patients with Parkinson’s disease dementia or dementia with Lewy Bodies MedDRA version: 8.1 Level: LLT Classification code 10012284 Term: Dementia due to Parkinson's disease | Trade Name: Ebixa Product Name: Ebixa Pharmaceutical Form: Film-coated tablet INN or Proposed INN: MEMANTINE HYDROCHLORIDE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Code: Lu 00-800 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: memantine hydrochloride Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Name: Ebixa Pharmaceutical Form: Film-coated tablet INN or Proposed INN: MEMANTINE HYDROCHLORIDE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Code: Lu 00-800 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: memantine hydrochloride Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use | H. Lundbeck A/S | Authorised | Female: yes Male: yes | 200 | Germany;United Kingdom;France;Spain;Italy;Greece;Austria | ||||
1054 | NCT00360412 | October 2006 | 19 October 2017 | A Study of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations | A Multi-centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations | Parkinson's Disease | Drug: E2007 | Eisai Inc. | Not recruiting | 30 Years | N/A | Male | 997 | Phase 3 | Germany | |
1055 | NCT00373087 | October 2006 | 19 February 2015 | COMT Polymorphism and Entacapone Efficacy | Influence of Catechol-O-methyltransferase Polymorphism on Entacapone Efficacy in Parkinson's Disease | Parkinson's Disease | Drug: entacapone;Drug: l dopa versus placebo | Assistance Publique - Hôpitaux de Paris | Not recruiting | 30 Years | N/A | Both | 60 | Phase 4 | France | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1056 | NCT00391898 | October 2006 | 19 October 2017 | Efficacy of Levodopa/Carbidopa/Entacapone vs Levodopa/Carbidopa in Parkinson's Disease Patients With Early Wearing-off | A 3-month, Multi-center, Double-blind, Randomized Study to Evaluate the Efficacy of Levodopa/Carbidopa/Entacapone vs Levodopa/Carbidopa in Parkinson's Disease Patients With Impairment of Activities of Daily Living and Early Wearing-off With Levodopa | Parkinson's Disease | Drug: Levodopa/carbidopa/entacapone;Drug: Levodopa/carbidopa | Novartis | Not recruiting | 30 Years | 80 Years | All | 95 | Phase 4 | Spain | |
1057 | NCT00399477 | October 2006 | 19 February 2015 | A Non-Blinded Study Demonstrating the Effectiveness and Safety of Azilect Alone or in Combination Therapy in Parkinson's Disease | Open-label, Multicenter, Effectiveness and Safety Study of Once Daily AZILECT® as Mono- or Adjunct Therapy in Patients With Idiopathic Parkinson's Disease (PD) | Parkinson's Disease | Drug: rasagiline mesylate;Drug: Rasagiline mesylate plus Mirapex;Drug: Rasagiline mesylate with Levodopa;Drug: Rasagiline mesylate with Requip | Teva Neuroscience, Inc. | Not recruiting | 30 Years | N/A | Both | 200 | Phase 4 | United States | |
1058 | NCT00590122 | October 2006 | 19 February 2015 | Parcopa Versus Carbidopa-Levodopa in a Single Dose Cross-Over Comparison Study | COMPARISON OF ORALLY DISSOLVING LEVODOPA (PARCOPA®) TO CONVENTIONAL ORAL LEVODOPA: A SINGLE DOSE, DOUBLE-BLIND, PLACEBO CONTROLLED, CROSS-OVER TRIAL | Parkinson's Disease | Drug: Parcopa;Drug: carbidopa-levodopa | Baylor College of Medicine | UCB Pharma | Not recruiting | 31 Years | 80 Years | Both | 20 | Phase 4 | United States |
1059 | NCT03103399 | September 26, 2006 | 16 December 2017 | Efficacy and Tolerability of Nebicapone in Parkinson's Disease Patients With Wearingoff Phenomenon | A Multicentre, Double-blind, Randomised, Active- and Placebo-controlled Trial to Investigate the Efficacy and Tolerability of Nebicapone in Parkinson's Disease Patients With Wearingoff Phenomenon Treated With Levodopa/Carbidopa or Levodopa/Benserazide | Parkinson Disease | Drug: Comtan®;Drug: Nebicapone;Drug: Levodopa/DDCI;Drug: Placebo | Bial - Portela C S.A. | Not recruiting | 30 Years | 80 Years | All | 254 | Phase 2 | ||
1060 | EUCTR2005-002038-36-AT | 22/09/2006 | 11 September 2012 | A randomised, double-blind, placebo-controlled, 6-month study of the efficacy and safety of memantine in patients with Parkinson’s disease dementia or dementia with Lewy Bodies | A randomised, double-blind, placebo-controlled, 6-month study of the efficacy and safety of memantine in patients with Parkinson’s disease dementia or dementia with Lewy Bodies | Patients with Parkinson’s disease dementia or dementia with Lewy Bodies | Trade Name: Ebixa Product Name: Ebixa Pharmaceutical Form: Film-coated tablet INN or Proposed INN: MEMANTINE HYDROCHLORIDE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Trade Name: Ebixa Product Name: Ebixa Pharmaceutical Form: Film-coated tablet INN or Proposed INN: MEMANTINE HYDROCHLORIDE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Name: Ebixa Pharmaceutical Form: Film-coated tablet INN or Proposed INN: MEMANTINE HYDROCHLORIDE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Trade Name: Ebixa Product Name: Ebixa Pharmaceutical Form: Film-coated tablet INN or Proposed INN: MEMANTINE HYDROCHLORIDE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use | H. Lundbeck A/S | Not Recruiting | Female: yes Male: yes | 200 | Germany;United Kingdom;France;Spain;Italy;Greece;Austria | ||||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1061 | EUCTR2005-005146-39-IT | 14/09/2006 | 19 March 2012 | A Phase-2, 12-week, Double-Blind, Dose-Finding, Placebo-Controlled Study to Assess the Efficacy and Safety of a range of SCH 420814 Doses 1 mg BID, 2 mg BID, 5 mg BID and Possibly 10 mg BID in Subjects With Moderate to Severe Parkinson s Disease Experiencing Motor Fluctuations and Dyskinesias. - ND | A Phase-2, 12-week, Double-Blind, Dose-Finding, Placebo-Controlled Study to Assess the Efficacy and Safety of a range of SCH 420814 Doses 1 mg BID, 2 mg BID, 5 mg BID and Possibly 10 mg BID in Subjects With Moderate to Severe Parkinson s Disease Experiencing Motor Fluctuations and Dyskinesias. - ND | Moderate to severe Parkinson s disease with motor fluctuation and dyskinesias. MedDRA version: 8.1 Level: LLT Classification code 10061536 Term: Parkinson's disease | Product Code: SCH 420814 Pharmaceutical Form: Capsule, hard CAS Number: 377727-87-2 Current Sponsor code: SCH 420814 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Product Code: SCH 420814 Pharmaceutical Form: Capsule, hard CAS Number: 377727-87-2 Current Sponsor code: SCH 420814 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use | Schering Plough Research Institute | Not Recruiting | Female: yes Male: yes | 160 | Italy | ||||
1062 | NCT00208611 | September 2006 | 19 February 2015 | Vitamin B12 Status and Response to Vitamin B12 Supplementation in Patients With Parkinson's Disease | Assessment of Cobalamin Status and Responses to Supplementation in Patients With Parkinson's Disease : a Pilot Study | Parkinson's Disease | Dietary Supplement: Vitamin B12 Supplementation | Emory University | National Institutes of Health (NIH) | Not recruiting | 21 Years | N/A | Both | 57 | Phase 2/Phase 3 | United States |
1063 | NCT00355927 | September 2006 | 19 February 2015 | Sedation During Microelectrode Recordings Before Deep Brain Stimulation for Movement Disorders. | Changes of the Neuronal Activity in the Subthalamic Nucleus Under Propofol Sedation During Stereotactic Electrode Implantation. | Movement Disorders;Parkinson Disease;Parkinsonian Disorders;Dystonia;Tourette Syndrome | Procedure: Sedation with IV propofol | Hadassah Medical Organization | Recruiting | N/A | N/A | Both | 20 | N/A | Israel | |
1064 | NCT00462007 | September 2006 | 4 May 2015 | Study to Evaluate Initiation of Stalevo in Early Wearing-off | Efficacy and Safety of Stalevo® in Subjects With Early Wearing-off Identified Using a Screening Tool WOQ-9; an Open, Non-randomised, Multinational, Multicentre 6-week Direct Switch Study in Levodopa-treated Parkinson's Disease Patients | Parkinson's Disease | Drug: Stalevo | Orion Corporation, Orion Pharma | Not recruiting | 35 Years | N/A | Both | 115 | Phase 4 | Germany;Sweden;United Kingdom | |
1065 | NCT00507715 | September 2006 | 19 February 2015 | Study of the Modification of the Pharmacokinetic Profile of Levodopa by the Fiber Plantago Ovata Husk | Clinical Trial to Study the Modification of the Pharmacokinetic Profile of Levodopa by the Fiber Plantago Ovata Husk | Parkinson's Disease, Idiopathic | Drug: Plantago ovata husk;Other: hemicellulose crystalline | Rottapharm Spain | Not recruiting | 60 Years | 80 Years | Both | 18 | Phase 1 | Spain | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1066 | EUCTR2006-001755-36-SE | 09/08/2006 | 1 May 2012 | Efficacy and safety of Stalevo in subjects with early wearing-off identified using a screening tool WOQ-9; An open, non-randomised, multinational, multi-centre 6-week direct switch study in levodopa-treated Parkinson's disease patients - SENSE | Efficacy and safety of Stalevo in subjects with early wearing-off identified using a screening tool WOQ-9; An open, non-randomised, multinational, multi-centre 6-week direct switch study in levodopa-treated Parkinson's disease patients - SENSE | Parkinson’s disease MedDRA version: 8.1 Level: LLT Classification code 10061536 Term: Parkinson's disease | Trade Name: Stalevo Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Levodopa Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- INN or Proposed INN: Carbidopa Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 12.5- INN or Proposed INN: Entacapone Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- Trade Name: Stalevo Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Levodopa Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- INN or Proposed INN: Carbidopa Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- INN or Proposed INN: Entacapone Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- Trade Name: Stalevo Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Levodopa Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- INN or Proposed INN: Carbidopa Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 37.5- INN or Proposed INN: Entacapone Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- | Orion Corporation Orion Pharma, FI-02200 Espoo, Finland | Not Recruiting | Female: yes Male: yes | 100 | United Kingdom;Germany;Sweden | ||||
1067 | NCT00368108 | August 2006 | 19 October 2017 | Efficacy, Safety, and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations | A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy, Safety, and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations | Parkinson's Disease | Drug: 2 mg perampanel;Drug: 4 mg perampanel;Drug: placebo comparator | Eisai Inc. | Not recruiting | 30 Years | N/A | All | 752 | Phase 3 | United States;Canada | |
1068 | NCT00640952 | August 2006 | 23 November 2015 | Acamprosate for Treatment of Compulsive Behaviors and Craving in Parkinson's Disease | Acamprosate for Treatment of Compulsive Behaviors and Craving in Parkinson's Disease | Parkinson's Disease | Drug: acamprosate | Baylor College of Medicine | National Parkinson Foundation | Not recruiting | 18 Years | N/A | Both | 0 | N/A | United States |
1069 | EUCTR2006-001793-24-AT | 31/07/2006 | 19 March 2012 | A MULTICENTRE, DOUBLE-BLIND, RANDOMIZED, ACTIVE- AND PLACEBO-CONTROLLED TRIAL TO INVESTIGATE THE EFFICACY AND TOLERABILITY OF NEBICAPONE IN PARKINSON’S DISEASE PATIENTS WITH “WEARING-OFF” PHENOMENON TREATED WITH LEVODOPA/CARBIDOPA OR LEVODOPA/BENSERAZIDE - not available | A MULTICENTRE, DOUBLE-BLIND, RANDOMIZED, ACTIVE- AND PLACEBO-CONTROLLED TRIAL TO INVESTIGATE THE EFFICACY AND TOLERABILITY OF NEBICAPONE IN PARKINSON’S DISEASE PATIENTS WITH “WEARING-OFF” PHENOMENON TREATED WITH LEVODOPA/CARBIDOPA OR LEVODOPA/BENSERAZIDE - not available | Patients with idiopathic Parkinson’s disease (PD) and with end-of-dose deterioration (wearing-off) phenomenon although currently treated with levodopa/DDCI. MedDRA version: 7 Level: LLT Classification code 10061536 | Product Name: Nebicapone Product Code: BIA 3-202 Pharmaceutical Form: Tablet CAS Number: 274925-86-9 Current Sponsor code: BIA 3-202 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: Entacapone Pharmaceutical Form: Tablet INN or Proposed INN: Entacapone CAS Number: 130929-57-6 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- Product Name: Nebicapone Product Code: BIA 3-202 Pharmaceutical Form: Tablet CAS Number: 274925-86-9 Current Sponsor code: BIA 3-202 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: Nebicapone Product Code: BIA 3-202 Pharmaceutical Form: Tablet CAS Number: 274925-86-9 Current Sponsor code: BIA 3-202 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | BIAL - Portela & Cª, SA | Not Recruiting | Female: yes Male: yes | 250 | Portugal;Austria | ||||
1070 | NCT03097211 | July 17, 2006 | 16 December 2017 | Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose of Levodopa/Benserazide 200/50 mg Plus a Single-dose of Nebicapone 150 mg | A Double-blind, Randomised, Placebo-controlled, Rising Multiple Dose Study in Healthy Volunteers to Investigate the Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics When Administered in Combination With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose of Levodopa/Benserazide 200/50 mg Plus a Single-dose of Nebicapone 150 mg | Parkinson Disease | Drug: Placebo;Drug: BIA 6-512;Drug: Madopar® 250;Drug: Nebicapone | Bial - Portela C S.A. | Not recruiting | 18 Years | 45 Years | All | 38 | Phase 1 | Portugal | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1071 | EUCTR2006-000680-28-ES | 07/07/2006 | 2 February 2015 | Estudio multicéntrico, doble ciego, aleatorizado y de tres meses de seguimiento para evaluar la eficacia de levodopa/carbidopa/entacapona frente a levodopa/carbidopa en pacientes con enfermedad de Parkinson y “wearing-off” A 3-months, multicenter, double-blind, randomized study to evaluate the efficacy of levodopa/carbidopa/entacapone vs. levodopa/carbidopa in Parkinson's disease patients with 'wearing-off' - DERBI | Estudio multicéntrico, doble ciego, aleatorizado y de tres meses de seguimiento para evaluar la eficacia de levodopa/carbidopa/entacapona frente a levodopa/carbidopa en pacientes con enfermedad de Parkinson y “wearing-off” A 3-months, multicenter, double-blind, randomized study to evaluate the efficacy of levodopa/carbidopa/entacapone vs. levodopa/carbidopa in Parkinson's disease patients with 'wearing-off' - DERBI | Enfermedad de Parkinson (Parkinson Disease) | Trade Name: Stalevo 100 Product Name: Stalevo (levodopa/carbidopa/entacapona) Pharmaceutical Form: Coated tablet INN or Proposed INN: LEVODOPA Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- INN or Proposed INN: CARBIDOPA Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- INN or Proposed INN: ENTACAPONA Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- Trade Name: Sinemet plus Product Name: Sinemet plus (levodopa/carbidopa) Pharmaceutical Form: Tablet INN or Proposed INN: LEVODOPA Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- INN or Proposed INN: CARBIDOPA Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- Trade Name: Stalevo 150 Product Name: Stalevo (levodopa/carbidopa/entacapona) Pharmaceutical Form: Coated tablet INN or Proposed INN: LEVODOPA Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- INN or Proposed INN: CARBIDOPA Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 37.5- INN or Proposed INN: ENTACAPONA Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- | NOVARTIS FARMACEUTICA, S.A | Not Recruiting | Female: yes Male: yes | 200 | Spain | ||||
1072 | NCT00346827 | July 2006 | 22 July 2019 | Apomorphine Nasal Powder in the Treatment of Parkinson's Disease Off Periods. | Parkinson's Disease | Drug: Apomorphine Nasal Powder | Britannia Pharmaceuticals Ltd. | Not recruiting | 18 Years | 85 Years | All | 36 | Phase 2/Phase 3 | |||
1073 | NCT00354133 | July 2006 | 2 July 2018 | Controlled Trial With Deep Brain Stimulation in Patients With Early Parkinson's Disease | The Effect of Deep Brain Stimulation of the Subthalamic Nucleus (STN-DBS) on Quality of Life in Comparison to Best Medical Treatment in Patients With Complicated Parkinson's Disease and Preserved Psychosocial Competence (EARLYSTIM-study) | Parkinson Disease | Device: Kinetra and Soletra (neurostimulator, Medtronic);Drug: Best Medical Treatment | German Parkinson Study Group (GPS) | University of Schleswig-Holstein;Assistance Publique - Hôpitaux de Paris;KKS Netzwerk | Not recruiting | 18 Years | 60 Years | All | 251 | Phase 4 | France;Germany |
1074 | EUCTR2006-000361-11-GB | 23/06/2006 | 19 March 2012 | A Proof of Concept Study to Determine the Minimum Effective Dose and to Assess the Efficacy and Safety of Subcutaneous Injections of FPFS-1169 in Parkinson's Disease Patients - Parkinson's Disease FPFS-1169 Proof of Concept Study (RD639/24201) | A Proof of Concept Study to Determine the Minimum Effective Dose and to Assess the Efficacy and Safety of Subcutaneous Injections of FPFS-1169 in Parkinson's Disease Patients - Parkinson's Disease FPFS-1169 Proof of Concept Study (RD639/24201) | Treatment of Parkinson's Disease MedDRA version: 8.0 Classification code 10029205 | Product Name: FPFS-1169 Pharmaceutical Form: Solution for injection INN or Proposed INN: R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane hydrochloride CAS Number: 265130-22-1 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 6- | Fujimoto Pharmaceutical Corporation | Authorised | Female: yes Male: yes | 10 | United Kingdom | ||||
1075 | NCT00331149 | June 20, 2006 | 16 December 2017 | A Comparison of Ropinirole Immediate Release With Ropinirole Prolonged Release in Patients With Advanced Parkinson's | A Randomised, Double-Blind, Double-Dummy, Parallel Group Comparison of 24 Weeks of Treatment With Ropinirole Immediate Release Tablets (REQUIP IR) or Ropinirole Prolonged Release Tablets (SK&F-101468) in Advanced Stage Parkinson's Disease Subjects Who Are Not Adequately Controlled on L-dopa. | Parkinson Disease | Drug: Ropinirole prolonged release;Drug: ropinirole immediate release | GlaxoSmithKline | Not recruiting | 30 Years | N/A | All | 343 | Phase 3 | Bulgaria;Canada;Czechia;France;Germany;Hungary;Italy;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;Czech Republic | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1076 | EUCTR2005-005423-34-DE | 19/06/2006 | 19 March 2012 | A Randomised, Double-Blind, Double-Dummy, Parallel Group Comparison of 24 Weeks of Treatment with Ropinirole Immediate Release (IR) Tablets or Ropinirole Prolonged Release / Extended Release (PR/XR) Tablets in Advanced Stage Parkinson’s Disease Subjects who are not Adequately Controlled on L-dopa. | A Randomised, Double-Blind, Double-Dummy, Parallel Group Comparison of 24 Weeks of Treatment with Ropinirole Immediate Release (IR) Tablets or Ropinirole Prolonged Release / Extended Release (PR/XR) Tablets in Advanced Stage Parkinson’s Disease Subjects who are not Adequately Controlled on L-dopa. | Parkinson's disease | Product Name: Ropinirole PR/XR Tablets Pharmaceutical Form: Tablet INN or Proposed INN: Ropinirole CAS Number: 91374-20-8 Current Sponsor code: SKF101468-A Other descriptive name: Ropinirole hydrochloride Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2.0- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: Ropinirole PR/XR Tablets Pharmaceutical Form: Tablet INN or Proposed INN: Ropinirole CAS Number: 91374-20-8 Current Sponsor code: SKF101468-A Other descriptive name: Ropinirole hydrochloride Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 4.0- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: Ropinirole PR/XR Tablets Pharmaceutical Form: Tablet INN or Proposed INN: Ropinirole CAS Number: 91374-20-8 Current Sponsor code: SKF101468-A Other descriptive name: Ropinirole hydrochloride Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 8.0- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: Ropinirole IR Tablets Pharmaceutical Form: Tablet INN or Proposed INN: Ropinirole CAS Number: 91374-20-8 Current Sponsor code: SKF101468-A Other descriptive name: Ropinirole hydrochloride Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.25- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: Ropinirole IR Tablets Pharmaceutical Form: Tablet INN or Proposed INN: Ropinirole CAS Number: 91374-20-8 Current Sponsor code: SKF101468-A Other descriptive name: Ropinirole hydrochloride Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: Ropinirole IR Tablets Pharmaceutical Form: Tablet | GlaxoSmithKline Research & Development Ltd | Not Recruiting | Female: yes Male: yes | 516 | Hungary;United Kingdom;Czech Republic;Germany;Spain;Italy | ||||
1077 | EUCTR2006-000391-32-GB | 06/06/2006 | 19 March 2012 | A 2 Treatment Period Study with Period 1 Comprising a 3-Week Randomised, Double-Blind, Crossover Comparison of Apomorphine Nasal Powder (2 and 4 mg) and Placebo in Combination with a 12-Week Open, Active, Efficacy, safety and Tolerability Assessment of APO Nasal Powder (2 and 4 mg) in the Alleviation of Acute Episodes of Motor Symptoms Associated with PD, Followed by Period 2 Comprising a 36-Week Open, Active Treatment, Safety Assessment of APO Nasal Powder (2 and 4 mg), in Subjects with PD. - Apomorphine Nasal Powder (2 and 4 mg) and Placebo in Subjects with Parkinson's Disease | A 2 Treatment Period Study with Period 1 Comprising a 3-Week Randomised, Double-Blind, Crossover Comparison of Apomorphine Nasal Powder (2 and 4 mg) and Placebo in Combination with a 12-Week Open, Active, Efficacy, safety and Tolerability Assessment of APO Nasal Powder (2 and 4 mg) in the Alleviation of Acute Episodes of Motor Symptoms Associated with PD, Followed by Period 2 Comprising a 36-Week Open, Active Treatment, Safety Assessment of APO Nasal Powder (2 and 4 mg), in Subjects with PD. - Apomorphine Nasal Powder (2 and 4 mg) and Placebo in Subjects with Parkinson's Disease | Alleviation of acute episodes of motor symptoms associated with Parkinson's Disease MedDRA version: 8.1 Level: LLT Classification code 10061536 Term: Parkinson's disease | Product Name: Apomorphine Nasal Powder Pharmaceutical Form: Nasal powder Other descriptive name: 6aß - apomorphine-10,11-diol hydrochloride hemihydrate Concentration unit: % (W/W) percent weight/weight Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Nasal powder Route of administration of the placebo: Nasal use | Britannia Pharmaceuticals Limited | Not Recruiting | Female: yes Male: yes | 130 | Germany;United Kingdom;Netherlands | ||||
1078 | NCT00269516 | June 2006 | 19 February 2015 | SLV308 for Treatment of Patients With Early Parkinson's Disease | A Randomized, Double Blind, Placebo Controlled Parallel-Group Fixed and Flexible SLV308 Dose Arm Study to Assess Efficacy and Safety of SLV308 Monotherapy in the Treatment of Patients With Early Stage Parkinson's Disease | Early Stage Parkinson's Disease | Drug: pardoprunox;Drug: Pardoprunox;Drug: Placebo | Solvay Pharmaceuticals | Not recruiting | 30 Years | N/A | Both | 468 | Phase 3 | United States;Argentina;Belgium;Bulgaria;Canada;Chile;Colombia;Croatia;Finland;India;Israel;Mexico;New Zealand;Peru;Romania;Russian Federation;Serbia;Slovakia;South Africa;Sweden;Ukraine;Former Serbia and Montenegro | |
1079 | NCT00291733 | May 2006 | 19 February 2015 | Levetiracetam Administration for the Management of Levodopa-Induced Dyskinesias in Parkinson's Disease | Levetiracetam Administration for the Management of Levodopa-Induced Dyskinesias in Parkinson's Disease: A Double-Blind,Placebo-Controlled, Crossover Trial | Levodopa Induced Dyskinesia | Drug: Levetiracetam;Drug: Placebo | 1st Hospital of Social Security Services | UCB Pharma | Not recruiting | 30 Years | 80 Years | Both | 50 | Phase 2 | Greece |
1080 | NCT00321854 | May 2006 | 19 October 2017 | Study of (Mirapex) Pramipexole for the Early Treatment of Parkinsons Disease (PD) | A Randomized, Double-blind, Placebo-controlled, Parallel-group Clinical Trial to Examine the Efficacy and Safety of Early Pramipexole (PPX) Treatment Versus Delayed Pramipexole Treatment in Patients With New Onset Parkinson's Disease. | Parkinson Disease | Drug: pramipexole | Boehringer Ingelheim | Not recruiting | 30 Years | 79 Years | All | 535 | Phase 4 | United States;Austria;Finland;France;Germany;Italy;Japan;Spain;Sweden;United Kingdom | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1081 | NCT00324896 | May 2006 | 19 October 2017 | Treatment of Insomnia in Patients With Parkinson's Disease: A Multi-site, Placebo-controlled Study of Eszopiclone | Treatment of Insomnia in Patients With Parkinson's Disease: A Multi-site, Placebo-controlled Study of Eszopiclone | Parkinson's Disease;Insomnia | Drug: eszopiclone;Other: placebo | University of Medicine and Dentistry of New Jersey | Sunovion | Not recruiting | 35 Years | 85 Years | All | 30 | Phase 3 | United States |
1082 | NCT00329056 | May 2006 | 19 February 2015 | A Trial of MitoQ for the Treatment of People With Parkinson's Disease | A Double-Blind, Prospective, Randomized Comparison of 2 Doses of MitoQ and Placebo for the Treatment of Patients With Parkinson's Disease | Parkinson's Disease | Drug: MitoQ | Antipodean Pharmaceuticals, Inc. | Not recruiting | 30 Years | N/A | Both | 128 | Phase 2 | Australia;New Zealand | |
1083 | NCT03094156 | April 26, 2006 | 16 December 2017 | Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics | A Double-blind, Randomised, Placebo-controlled, Rising Multiple Dose Study in Healthy Volunteers to Investigate the Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics When Administered in Combination With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose of Levodopa/Benserazide 200/50 mg Plus a Single-dose of Entacapone 200 mg | Parkinson Disease | Drug: Placebo;Drug: BIA 6-512;Drug: Madopar® 250;Drug: Comtan® | Bial - Portela C S.A. | Not recruiting | 18 Years | 45 Years | All | 39 | Phase 1 | Portugal | |
1084 | EUCTR2005-005791-32-GB | 24/04/2006 | 3 April 2012 | Chemical Safety/Tolerability of HF0220 and its Effect on Biochemical Markers Relevant to Patients with a Diagnosis of Mild to Moderate Alzheimer's Disease. | Chemical Safety/Tolerability of HF0220 and its Effect on Biochemical Markers Relevant to Patients with a Diagnosis of Mild to Moderate Alzheimer's Disease. | HF0220 experimentally appears to exert its potential beneficial effects within the CNS and possibly other tissues by attenuating the adverse effects of oxidative stress. It is believed that this mechanism has the potential to reduce disease progression in a wide range of disorders of the nervous system, e.g. Alzheimer's and Parkinson's disease, and brain damage due to acute stroke and head injury. It may also apply to the protection of peripheral tissues, such as the heart and/or kidney. MedDRA version: 9.1 Level: HLT Classification code 10001897 Term: Alzheimer's disease (incl subtypes) | Product Name: HF0220 Product Code: HF0220 Pharmaceutical Form: Powder for oral suspension Current Sponsor code: HF0220 Other descriptive name: 7-beta-hydroxyepiandrosterone Concentration unit: g gram(s) Concentration type: range Concentration number: 0.001-0.22- Pharmaceutical form of the placebo: Oral suspension Route of administration of the placebo: Oral use | Hunter-Fleming Ltd | Authorised | Female: yes Male: yes | 40 | United Kingdom;Sweden | ||||
1085 | EUCTR2005-006033-32-FI | 20/04/2006 | 19 March 2012 | A Randomized, Double-blind, Placebo Controlled Parallel-group Fixed and Flexible SLV308 Dose Arm Study to Assess Efficacy and Safety of SLV308 Monotherapy in the Treatment of Patients with Early Stage Parkinson’s Disease - The Rembrandt study | A Randomized, Double-blind, Placebo Controlled Parallel-group Fixed and Flexible SLV308 Dose Arm Study to Assess Efficacy and Safety of SLV308 Monotherapy in the Treatment of Patients with Early Stage Parkinson’s Disease - The Rembrandt study | Parkinson's Disease Early Stage | Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 (mono) hydrochloride Pharmaceutical Form: Film-coated tablet Other descriptive name: SLV308 (mono) hydrochloride Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.1- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 (mono) hydrochloride Pharmaceutical Form: Film-coated tablet Other descriptive name: SLV308 (mono) hydrochloride Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.2- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 (mono) hydrochloride Pharmaceutical Form: Film-coated tablet Other descriptive name: SLV308 (mono) hydrochloride Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 (mono) hydrochloride Pharmaceutical Form: Film-coated tablet Other descriptive name: SLV308 (mono) hydrochloride Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1.0- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 (mono) hydrochloride Pharmaceutical Form: Film-coated tablet Other descriptive name: SLV308 (mono) hydrochloride Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2.0- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 (mono) hydrochloride Pharmaceutical Form: Film-coated tablet Other descriptive name: SLV308 (mono) hydrochloride | Solvay Pharmaceuticals | Not Recruiting | Female: yes Male: yes | 440 | Finland;Slovakia;Sweden | ||||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1086 | EUCTR2005-004949-34-AT | 18/04/2006 | 1 May 2012 | A randomized, double-blind, placebo-controlled, parallel-group clinical trial to examine the efficacy and safety of early pramipexole treatment versus delayed pramipexole treatment in patients with new onset Parkinson’s disease The main protocol includes DAT SPECT brain imaging of a sub-set of patients - Pramipexole Early Start Study | A randomized, double-blind, placebo-controlled, parallel-group clinical trial to examine the efficacy and safety of early pramipexole treatment versus delayed pramipexole treatment in patients with new onset Parkinson’s disease The main protocol includes DAT SPECT brain imaging of a sub-set of patients - Pramipexole Early Start Study | Parkinson's disease MedDRA version: 6.1 Level: pref Classification code 10061536 | Product Name: Sifrol Product Code: SND 919 CL2 Y Pharmaceutical Form: Tablet INN or Proposed INN: Pramipexole Current Sponsor code: SND 919 CL2 Y Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0,088- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: Sifrol Product Code: SND 919 CL2 Y Pharmaceutical Form: Tablet INN or Proposed INN: Pramipexole Current Sponsor code: SND 919 CL2 Y Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0,18- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: Sifrol Product Code: SND 919 CL2 Y Pharmaceutical Form: Tablet INN or Proposed INN: Pramipexole Current Sponsor code: SND 919 CL2 Y Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0,35- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | Boehringer Ingelheim Austria GmbH | Not Recruiting | Female: yes Male: yes | 500 | Finland;Germany;United Kingdom;Spain;Italy;Austria;Sweden | ||||
1087 | EUCTR2005-001006-12-AT | 02/04/2006 | 7 August 2012 | Double-blind, placebo-controlled, randomized, multicentre Phase II / III study to evaluate the efficacy and safety of Lisparin®, applied subcutaneously by means of a minipump in patients with advanced Parkinson’s Disease refractory to conventional oral therapy. - CALIPSO | Double-blind, placebo-controlled, randomized, multicentre Phase II / III study to evaluate the efficacy and safety of Lisparin®, applied subcutaneously by means of a minipump in patients with advanced Parkinson’s Disease refractory to conventional oral therapy. - CALIPSO | Patients with advanced Parkinson’s disease with motor fluctuations and “OFF” periods refractory to conventional treatment. | Product Name: Lisparin Pharmaceutical Form: Solution for infusion INN or Proposed INN: Lisuride Hydrogenmaleate CAS Number: 018016803 Other descriptive name: 3- (9,10- Didehydro- 6- methyl- 8?- ergolinyl)-1,1- diethylurea hydrogenmaleate Concentration unit: mg milligram(s) Concentration type: up to Concentration number: 2.0- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Subcutaneous use Trade Name: Sifrol, 0,35 mg Tablette Product Name: Pramipexol Pharmaceutical Form: Capsule, hard INN or Proposed INN: Pramipexol CAS Number: 104632260 Other descriptive name: (S)- 2- Amino- 4,5,6,7- tetrahydro- 6- (propylamino)benzothiazol Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.35- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Trade Name: Sifrol, 0,70 mg Tablette Product Name: Pramipexol Pharmaceutical Form: Capsule, hard INN or Proposed INN: Pramipexol CAS Number: 104632260 Other descriptive name: (S)- 2- Amino- 4,5,6,7- tetrahydro- 6- (propylamino)benzothiazol Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.7- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Trade Name: Cabaseril, 1,0 mg Tablette Product Name: Cabergoline Pharmaceutical Form: Capsule, hard INN or Proposed INN: Cabergoline CAS Number: 081409907 Other descriptive name: 1[(6- Allyl- 8ß- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- 3- ethylurea Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1.0- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Trade Name: Cabaseril, 2,0 mg Tablette Product Name: Cabergoline Pharmaceutical Form: Capsule, hard INN or Proposed INN: Cabergoline CAS Number: 081409907 | Axxonis Pharma GmbH | Not Recruiting | Female: yes Male: yes | 60 | Phase 2 | Germany;Czech Republic;Italy;Austria | |||
1088 | NCT00294554 | April 2006 | 16 December 2017 | Memantine for Treatment of Cognitive Impairment in Patients With Parkinson's Disease and Dementia | Double-Blind Placebo-Controlled Trial of Memantine for Treatment of Cognitive Impairment in Patients With Parkinson's Disease and Dementia | Parkinson's Disease;Cognitive Impairment;Dementia | Drug: Memantine;Drug: Placebo Oral Tablet | Johns Hopkins University | Forest Laboratories | Not recruiting | 50 Years | N/A | All | 20 | N/A | United States |
1089 | NCT00349310 | April 2006 | 19 February 2015 | Profile of Depressive Symptoms in Parkinsons Disease | Profile of Depressive Symptoms in Parkinson's Disease (PRODEST-PD) | Parkinson Disease;Depression | Drug: Pramipexole | Boehringer Ingelheim | Not recruiting | 18 Years | N/A | Both | 1018 | Phase 4 | Austria;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom | |
1090 | NCT00461942 | April 2006 | 19 February 2015 | Efficacy and Safety of Green Tea Polyphenol in De Novo Parkinson's Disease Patients | A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Assess the Neuroprotection Effect of Green Tea Polyphenol in De Novo Parkinson's Disease Patients | Parkinson's Disease | Drug: Green Tea Polyphenols (EGCG/ECG) | Xuanwu Hospital, Beijing | Ministry of Health, China;Michael J. Fox Foundation for Parkinson's Research | Not recruiting | 30 Years | N/A | Both | 480 | Phase 2 | China |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1091 | NCT00467597 | April 2006 | 19 October 2017 | Developing Objective Measures of Levodopa Induced Dyskinesia: (Study 1) | Quantification of Levodopa Induced Dyskinesia in Parkinson Disease: Developing Objective Measures of Levodopa Induced Dyskinesia (Study One) | Dyskinesias;Movement Disorders;Parkinson Disease | Drug: Levodopa (delivered intravenously) | VA Office of Research and Development | Oregon Health and Science University | Not recruiting | 21 Years | N/A | All | 36 | N/A | United States |
1092 | NCT00646204 | April 2006 | 19 February 2015 | Namenda (Memantine) for Non-Motor Symptoms in Parkinson's Disease | A 16 WEEK, INVESTIGATOR-INITIATED, SINGLE-CENTER, DOUBLE BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF NAMENDA® (MEMANTINE HCL) FOR NON-MOTOR SYMPTOMS IN PARKINSON'S DISEASE | Parkinson's Disease | Drug: placebo;Drug: Memantine | Baylor College of Medicine | Forest Laboratories | Not recruiting | 18 Years | 80 Years | Both | 40 | Phase 4 | United States |
1093 | EUCTR2005-004109-27-SE | 24/03/2006 | 19 March 2012 | A double-blind, placebo-controlled multi-centre trial of memantine in patients with Parkinsons’ disease dementia or dementia with Lewy bodies - MEMDLBPDD | A double-blind, placebo-controlled multi-centre trial of memantine in patients with Parkinsons’ disease dementia or dementia with Lewy bodies - MEMDLBPDD | Parkinsons disease (PD)and dementia with Lewy bodies (DLB) are both common disease of the elderly. The majority of patients who survive for more than 10 years with PD eventually develope dementia (PDD). The brain changes and clinical presentations of PDD and DLB are similar. The clinical characteristics are cognitive impairment with pronounced visuospatial and executive impairment, visual hallucinations, parkinsonism, fluctuations in cognition and REM sleep disorder. | Trade Name: Ebixa Product Name: Ebixa Pharmaceutical Form: Tablet Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | Neuropsychiatric clinic | Authorised | Female: yes Male: yes | 60 | Sweden | ||||
1094 | EUCTR2005-001032-72-PT | 23/03/2006 | 19 March 2012 | A 39-week randomized, double-blind, parallel group, multicenter study to evaluate the effect of fixed dose Stalevo 100 (t.i.d.) vs. immediate release carbidopa/levodopa (t.i.d.) in Parkinson's disease patients requiring levodopa. - First Step | A 39-week randomized, double-blind, parallel group, multicenter study to evaluate the effect of fixed dose Stalevo 100 (t.i.d.) vs. immediate release carbidopa/levodopa (t.i.d.) in Parkinson's disease patients requiring levodopa. - First Step | Parkinson disease | Trade Name: Stalevo Product Code: ELC200 Pharmaceutical Form: Capsule* INN or Proposed INN: levodopa/carbidopa/entacapone Current Sponsor code: ELC200 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100/25/200- Trade Name: SINEMET Product Name: sinemet Pharmaceutical Form: Tablet INN or Proposed INN: levodopa/carbidopa Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25/100- | Novartis Pharma AG | Not Recruiting | Female: yes Male: yes | 424 | Portugal;Czech Republic;Italy | ||||
1095 | NCT00282152 | March 2006 | 16 December 2017 | Deep Brain Stimulation (DBS) for Early Stage Parkinson's Disease (PD) | Safety and Tolerability of Neurostimulation in Early Stage Parkinson's Disease | Parkinson's Disease | Device: B-STN DBS;Drug: Optimal drug therapy | Vanderbilt University Medical Center | Not recruiting | 50 Years | 75 Years | All | 37 | N/A | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1096 | NCT00305331 | March 2006 | 19 February 2015 | Domperidone as a Treatment for Dopamine Agonist-induced Peripheral Edema in Patients With Parkinson's Disease | Phase II Clinical Trial of Domperidone as a Treatment for Dopamine Agonist-induced Peripheral Edema in Patients With Parkinson's Disease | Parkinson's Disease;Peripheral Edema | Drug: Domperidone (drug) | University Health Network, Toronto | Not recruiting | 30 Years | 90 Years | Both | 25 | Phase 2 | Canada | |
1097 | NCT00307450 | March 2006 | 19 February 2015 | Efficacy and Safety of Levetiracetam Versus Placebo on Levodopa-induced Dyskinesias in Advanced Parkinson's Disease | Efficacy and Safety of Levetiracetam Versus Placebo on Levodopa-induced Dyskinesias in Advanced Parkinson's Disease (LeLeDys Study) - A Multicenter, Randomized, Stratified, Double-blinded, Placebo-controlled Phase IV Study | Parkinson's Disease | Drug: Levetiracetam | Technische Universität Dresden | UCB GmbH, Huettenstrasse 205, 50170 Kerpen, Germany | Not recruiting | 30 Years | 80 Years | Both | 34 | Phase 4 | Germany |
1098 | NCT00393562 | March 2006 | 3 August 2015 | Comparison of Modafinil and Methylphenidate in Treatment of Excessive Daytime Sleepiness in Patients With Parkinson's Disease | Comparison of Modafinil and Methylphenidate in Treatment of Excessive Daytime Sleepiness in Patients With Parkinson's Disease | Parkinson's Disease | Drug: modafinil;Drug: methylphenidate | Department of Veterans Affairs | Not recruiting | 50 Years | 80 Years | Both | 0 | N/A | United States | |
1099 | NCT00630500 | February 2006 | 10 August 2015 | Efficacy and Safety of Memantine for Parkinson's Disease Dementia (PDD) and Dementia With Lewy Bodies (DLB) | A Double-blind, Placebo-controlled Multicentre Trial of Memantine in Patients With Parkinson's Disease Dementia or Dementia With Lewy Bodies | Dementia Associated With Parkinson's Disease;Dementia With Lewy Bodies | Drug: Memantine;Drug: Placebo | Helse Stavanger HF | King's College London;Lund University | Not recruiting | N/A | N/A | Both | 75 | Phase 2 | Norway;Sweden;United Kingdom |
1100 | EUCTR2005-004290-19-DE | 25/01/2006 | 3 April 2012 | A double-blind, placebo-controlled, parallel group, proof of concept trial to assess the tolerabiltiy, safety and efficacy of rotigotine nasal spray for the acute treatment of 'off' symptoms in subjects with advanced-stage, idiopathic Parkinson's disease | A double-blind, placebo-controlled, parallel group, proof of concept trial to assess the tolerabiltiy, safety and efficacy of rotigotine nasal spray for the acute treatment of 'off' symptoms in subjects with advanced-stage, idiopathic Parkinson's disease | advanced-stage, idiopathic Parkinson's disease MedDRA version: 8.1 Level: LLT Classification code 10061536 | Product Name: Rotigotine Nasal Spray Product Code: ND1421 Pharmaceutical Form: Nasal spray, solution INN or Proposed INN: Rotigotine hydrochloride CAS Number: 125572-93-2 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 2.5- Pharmaceutical form of the placebo: Nasal spray, solution Route of administration of the placebo: Nasal use | Schwarz Biosciences GmbH | Not Recruiting | Female: yes Male: yes | 100 | United Kingdom;Germany;Spain | ||||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1101 | NCT03095105 | January 24, 2006 | 16 December 2017 | Pharmacokinetic Profile of BIA 6-512 in Healthy Elderly Subjects Versus Healthy Young Subjects | An Open-label, Parallel-group Study to Compare the Pharmacokinetic Profile in Healthy Elderly Subjects Versus Healthy Young Subjects After Single and Repeated Oral Administration of BIA 6-512 (Trans-resveratrol) | Parkinson Disease | Drug: 200 mg BIA 6-512 | Bial - Portela C S.A. | Not recruiting | 18 Years | N/A | All | 25 | Phase 1 | Germany | |
1102 | EUCTR2005-004314-33-EE | 17/01/2006 | 18 April 2012 | A Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of the Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations | A Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of the Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations | Levodopa treated Parkinson's disease patients with motor fluctuations MedDRA version: 8.1 Classification code 10061536 | Product Name: MARS Product Code: E2007 Pharmaceutical Form: Film-coated tablet Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Name: MARS Product Code: E2007 Pharmaceutical Form: Film-coated tablet Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use | Eisai Limited | Not Recruiting | Female: yes Male: yes | 1260 | Portugal;Hungary;Germany;United Kingdom;Estonia;Spain;Italy;Lithuania;Sweden | ||||
1103 | EUCTR2005-003788-22-GB | 06/01/2006 | 18 April 2012 | A randomized, double-blind, placebo-controlled, parallel group, efficacy study of pramipexole and placebo administered orally over a 12-week treatment phase in Parkinson’s disease patients with stable motor function and depressive symptoms. | A randomized, double-blind, placebo-controlled, parallel group, efficacy study of pramipexole and placebo administered orally over a 12-week treatment phase in Parkinson’s disease patients with stable motor function and depressive symptoms. | A randomized, double-blind, placebo-controlled, parallel group, efficacy study of pramipexole and placebo administered orally over a 12-week treatment phase in Parkinson’s disease patients with stable motor function and depressive symptoms | Trade Name: Sifrol Product Name: Sifrol Product Code: SND 919 CL2 Y Pharmaceutical Form: Tablet INN or Proposed INN: Pramipexole Current Sponsor code: SND 919 CL2 Y Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0,088- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Trade Name: Sifrol Product Name: Sifol Product Code: SND 919 CL2 Y Pharmaceutical Form: Tablet INN or Proposed INN: Pramipexole Current Sponsor code: SND 919 CL2 Y Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0,18- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Trade Name: Sifrol Product Name: Sifol Product Code: SND 919 CL2 Y Pharmaceutical Form: Tablet INN or Proposed INN: Pramipexole Current Sponsor code: SND 919 CL2 Y Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0,35- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Trade Name: Sifrol Product Name: Sifol Product Code: SND 919 CL2 Y Pharmaceutical Form: Tablet INN or Proposed INN: Pramipexole Current Sponsor code: SND 919 CL2 Y Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0,7- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | Boehringer Ingelheim Limited | Authorised | Female: yes Male: yes | 318 | Finland;Germany;United Kingdom;Spain;Italy;Sweden | ||||
1104 | NCT00272688 | January 2006 | 18 January 2016 | Continuous Delivery of Levodopa in Patients With Advanced Idiopathic Parkinsons Disease - Cost-benefit | Continuous Delivery of Levodopa/Carbidopa (Duodopa) in Patients With Advanced Idiopathic Parkinsons Disease - a Health Economic Evaluation | Parkinson Disease | Drug: Levodopa (drug), intraduodenal administration | University Hospital, Akershus | Solvay Pharmaceuticals | Not recruiting | N/A | N/A | Both | 10 | Phase 4 | Norway |
1105 | NCT00273351 | January 2006 | 19 February 2015 | Imaging and Genetic Biomarkers of Parkinson Disease (PD) Onset and Progression in High-risk Families | Assessment of Pre-symptomatic and Symptomatic Patients With Parkinson Disease to Identify and Characterize Genetic and Phenotypic Biomarkers for Disease Onset and Progression. | Parkinson Disease;Parkinsonian Syndrome | Drug: [123I]B-CIT | Institute for Neurodegenerative Disorders | Department of Defense;Molecular NeuroImaging | Not recruiting | 21 Years | N/A | Both | 62 | Phase 2 | United States |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1106 | NCT00275275 | January 2006 | 19 October 2017 | Pramipexole Conversion to Ropinirole Controlled Release (CR) | An Open Label Conversion Study of Pramipexole to Ropinirole Controlled Release (CR) in Patients With Parkinson's Disease. | Parkinson Disease | Drug: Requip PR;Drug: Mirapex | Rajesh Pahwa, MD | GlaxoSmithKline | Not recruiting | 18 Years | N/A | All | 61 | Phase 3 | United States |
1107 | NCT00279825 | January 2006 | 4 November 2019 | Comparison of IPX054, IR Carbidopa-Levodopa, and CR Carbidopa-Levodopa in Subjects With Parkinson's Disease | A Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Compare IPX054 200 mg and 250 mg to CD-LD IR 200 (2x100) mg Tablets and CD-LD CR 200 mg Tablet in Subjects With Parkinson's Disease | Idiopathic Parkinson's Disease | Drug: IPX054 200 mg;Drug: IPX054 250 mg;Drug: CD-LD IR;Drug: CD-LD CR;Drug: IPX054 200 mg Placebo;Drug: IPX054 250 mg Placebo;Drug: CD-LD IR Placebo;Drug: CD-LD CR Placebo | Impax Laboratories, LLC | Not recruiting | 30 Years | N/A | All | 16 | Phase 2 | United States | |
1108 | NCT00292227 | January 2006 | 19 October 2017 | Cardiac Effects of Rotigotine Transdermal System in Subjects With Advanced-stage Idiopathic Parkinson's Disease | Double-blind, Randomized, Placebo- and Positive-controlled, Parallel-group Trial to Assess the Potential Electrocardiographic Effects of Rotigotine Transdermal System up to 120 cm2/54.0 mg/Day in Subjects With Advanced-stage Idiopathic Parkinson's Disease: A Thorough QT/QTc Trial. | Parkinson's Disease | Drug: Rotigotine;Other: Placebo;Drug: Moxifloxacin infusion;Other: Placebo infusion | UCB Pharma | Not recruiting | 18 Years | N/A | All | 130 | Phase 1 | South Africa | |
1109 | NCT00315250 | January 2006 | 19 February 2015 | Development of Imaging, Clinical and Biochemical Bio-Markers for Parkinson's Disease | Development of Imaging, Clinical and Biochemical Bio-Markers for Parkinson's Disease | Parkinson's Disease;Parkinsonian Syndrome | Drug: [123I]ß-CIT | Institute for Neurodegenerative Disorders | Department of Defense;Molecular NeuroImaging | Not recruiting | 22 Years | N/A | Both | 225 | Phase 2 | United States |
1110 | NCT01683292 | January 2006 | 19 February 2015 | Single-Centre Study of VR040(Inhaled Apomorphine) in Idiopathic Parkinson's Disease | An Ascending-Dose, Single-Centre Study Investigating the Safety, Tolerability, Efficacy, and Pharmacokinetics of VR040(Inhaled Apomorphine)in Parkinson's Disease | Parkinson's Disease | Drug: Inhaled VR040;Drug: Placebo for VR040 | South Glasgow University Hospitals NHS Trust | Vectura Limited | Not recruiting | 30 Years | N/A | Both | 29 | Phase 2 | United Kingdom |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1111 | NCT02772614 | January 2006 | 23 May 2016 | Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 3-202 and Metabolites | An Open-label Study in Healthy Male Subjects to Assess the Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 3-202 and Metabolites Following a Single-dose Oral Administration | Parkinson's Disease | Drug: BIA 3-202 (200 mg) | Bial - Portela C S.A. | Not recruiting | 40 Years | 55 Years | Male | 4 | Phase 1 | Switzerland | |
1112 | EUCTR2006-006907-35-DE | 1 May 2012 | Long-term extension of RECOVER A MULTICENTER, MULTINATIONAL, PHASE 3B, OPEN-LABEL EXTENSION TRIAL TO EVALUATE THE LONG-TERM EFFECT OF THE 24-HOUR TRANSDERMAL DELIVERY OF ROTIGOTINE ON MOTOR FUNCTION, SLEEP QUALITY, AND NOCTURNAL AND NON-MOTOR SYMPTOMS IN SUBJECTS WITH IDIOPATHIC PARKINSON’S DISEASE - Long-term extension of RECOVER | Long-term extension of RECOVER A MULTICENTER, MULTINATIONAL, PHASE 3B, OPEN-LABEL EXTENSION TRIAL TO EVALUATE THE LONG-TERM EFFECT OF THE 24-HOUR TRANSDERMAL DELIVERY OF ROTIGOTINE ON MOTOR FUNCTION, SLEEP QUALITY, AND NOCTURNAL AND NON-MOTOR SYMPTOMS IN SUBJECTS WITH IDIOPATHIC PARKINSON’S DISEASE - Long-term extension of RECOVER | Parkinson's disease MedDRA version: 9.1 Level: LLT Classification code 10061536 Term: Parkinson's disease | Trade Name: Neupro 2mg/24h transdermal patch Product Code: ND1587 Pharmaceutical Form: Transdermal patch INN or Proposed INN: Rotigotine CAS Number: 99755-59-6 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 4.5-mg Trade Name: Neupro 4mg/24h transdermal patch Product Code: ND1589 Pharmaceutical Form: Transdermal patch INN or Proposed INN: Rotigotine CAS Number: 99755-59-6 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 9.0-mg Trade Name: Neupro 6mg/24h transdermal patch Product Code: ND1590 Pharmaceutical Form: Transdermal patch INN or Proposed INN: Rotigotine CAS Number: 99755-59-6 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 13.5-mg Trade Name: Neupro 8mg/24h transdermal patch Product Code: ND1702 Pharmaceutical Form: Transdermal patch INN or Proposed INN: Rotigotine CAS Number: 99755-59-6 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 18.0-mg | Schwarz Biosciences GmbH | Not Recruiting | Female: yes Male: yes | 270 | Phase 3B | Hungary;Finland;United Kingdom;Germany;Spain;Italy;Austria | ||||
1113 | EUCTR2005-005120-13-GB | 21/12/2005 | 8 August 2016 | A clinic based, Phase IIa, randomised, double-blind, placebo-controlled, ascending dose, single centre study investigating the safety, tolerability, efficacy, and pharmacokinetics of VR040 in patients with established idiopathic Parkinson’s Disease | A clinic based, Phase IIa, randomised, double-blind, placebo-controlled, ascending dose, single centre study investigating the safety, tolerability, efficacy, and pharmacokinetics of VR040 in patients with established idiopathic Parkinson’s Disease | Hypomobility (“off” or “freezing”) episodes associated with advanced Parkinson’s disease | Product Name: Apomorphine hydrochloride Product Code: VR040 Pharmaceutical Form: Inhalation powder INN or Proposed INN: apomorphine hydrochloride CAS Number: 41372-20-7 Current Sponsor code: VR040 Concentration unit: µg microgram(s) Concentration type: range Concentration number: 400 to-1600 Pharmaceutical form of the placebo: Inhalation powder Route of administration of the placebo: Inhalation use | Vectura Group plc | Not Recruiting | Female: yes Male: yes | 24 | Phase 2 | United Kingdom | |||
1114 | EUCTR2005-002010-38-DE | 21/11/2005 | 19 March 2012 | Assessment of the acceptability of a sublingual formulation of piribedil (S90049), 10 to 30 mg on request (maximum 5 times a day) on the top of L-dopa and a dopamine agonist in advanced Parkinson Disease patients with motor fluctuations: a 4-week open label pilot study | Assessment of the acceptability of a sublingual formulation of piribedil (S90049), 10 to 30 mg on request (maximum 5 times a day) on the top of L-dopa and a dopamine agonist in advanced Parkinson Disease patients with motor fluctuations: a 4-week open label pilot study | Advanced Parkinson´s Disease | Product Name: Trivastal Product Code: S 90049 Pharmaceutical Form: Orodispersible tablet INN or Proposed INN: Piribedil Current Sponsor code: S 90049 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- | Institut de Recherches Internationales Servier (I.R.I.S.) | Not Recruiting | Female: yes Male: yes | 80 | Germany | ||||
1115 | NCT00250393 | November 2005 | 19 February 2015 | A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease | Placebo-Controlled , Crossover , Double-Blind Study of KW-6002(Istradefylline) in the Treatment of Parkinson's Disease. [Monotherapy] | Parkinson's Disease | Drug: Istradefylline (KW-6002) | Kyowa Hakko Kirin Company, Limited | Not recruiting | 30 Years | N/A | Both | 64 | Phase 2 | Japan | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1116 | NCT00253084 | November 2005 | 4 November 2019 | Comparison of IPX054 and Immediate-Release Carbidopa-Levodopa in Patients With Parkinson's Disease | A Randomized, Double-Blind, Cross-Over Study to Compare IPX054 to Carbidopa-Levodopa Immediate-Release Tablets in Subjects With Parkinson's Disease | Parkinson's Disease | Drug: IPX054 200 mg;Drug: CD-LD IR;Drug: IPX054 Placebo;Drug: CD-LD IR Placebo | Impax Laboratories, LLC | Not recruiting | 30 Years | N/A | All | 12 | Phase 2 | United States | |
1117 | NCT00256204 | November 2005 | 19 October 2017 | A Randomized Placebo Controlled Study to Show That Rasagiline May Slow Disease Progression for Parkinson's Disease | A Multi Center, Double Blind, Randomized Start, Placebo-Controlled, Parallel-Group Study to Assess Rasagiline as a Disease Modifying Therapy in Early Parkinson's Disease Subjects | Parkinson's Disease | Drug: Rasagiline Mesylate;Other: Placebo | Teva Pharmaceutical Industries | Not recruiting | 30 Years | 80 Years | All | 1174 | Phase 3 | Argentina;Austria;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;Portugal;Romania;Spain;United Kingdom;United States | |
1118 | NCT00260793 | November 2005 | 19 February 2015 | Open Label High Dose Ropinirole (Requip) Study for Patients With Parkinson's Disease | Open Label Prospective Study of High Dose Ropinirole for Motor Fluctuations and Dyskinesias in Advanced Parkinson's Disease | Parkinson's Disease | Drug: Ropinirole Hydrochloride | Agarwal, Pinky, M.D. | Colorado Neurology;GlaxoSmithKline | Recruiting | 25 Years | N/A | Both | 20 | Phase 3 | United States |
1119 | EUCTR2005-000314-12-ES | 14/10/2005 | 19 March 2012 | Effect of 3 doses (20, 40 and 60 mg) of a sublingual formulation of piribedil (S 90049) in combination with levodopa on end-of-dose fluctuations in advanced Parkinson’s disease patients after a 14-day treatment-period (one administration t.i.d.). A randomised, double-blind study consisting of 3 cross-over: 40 mg versus placebo, 20 mg versus 60 mg and 40 mg versus 20 mg. - PARKOPI | Effect of 3 doses (20, 40 and 60 mg) of a sublingual formulation of piribedil (S 90049) in combination with levodopa on end-of-dose fluctuations in advanced Parkinson’s disease patients after a 14-day treatment-period (one administration t.i.d.). A randomised, double-blind study consisting of 3 cross-over: 40 mg versus placebo, 20 mg versus 60 mg and 40 mg versus 20 mg. - PARKOPI | Parkinson's Disease aggravated MedDRA version: 7.0 Level: LLT Classification code 10034006 | Product Name: piribedil Product Code: S 90049 - F36 Pharmaceutical Form: Orodispersible tablet INN or Proposed INN: piribedil Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Orodispersible tablet Route of administration of the placebo: Sublingual use Product Name: piribedil Product Code: S 90049 - F38 Pharmaceutical Form: Orodispersible tablet INN or Proposed INN: piribedil Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40- Pharmaceutical form of the placebo: Orodispersible tablet Route of administration of the placebo: Sublingual use | Institut de Recherches Internationales Servier | Authorised | Female: yes Male: yes | 80 | Germany;Spain | ||||
1120 | NCT00134251 | October 2005 | 19 February 2015 | Ascending Dose Tolerability/Safety of SLV308 for the Treatment of Parkinson's Disease | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending Dose, Parallel Group Study Exploring Effects of SLV308 up to 42 mg/Day Administered as an Adjunctive Therapy to L-Dopa in Patients With Advanced Stage Parkinson's Disease | Parkinson's Disease | Drug: SLV308 | Solvay Pharmaceuticals | Not recruiting | 30 Years | N/A | Both | Phase 3 | Bulgaria;Malta;Serbia;Former Serbia and Montenegro | ||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1121 | NCT00199381 | October 2005 | 19 October 2017 | An Extension of Istradefylline in North American Parkinson's Disease Patients Who Have Completed Study 6002-INT-001 | An Open-Label Multicenter Study of the Continued Safety of Istradefylline (KW-6002) In Subjects With Parkinson's Disease Who Have Recently Completed One Year of Treatment With Istradefylline. | Parkinson's Disease | Drug: Istradefylline | Kyowa Kirin Pharmaceutical Development, Inc. | Not recruiting | 30 Years | N/A | All | 504 | Phase 3 | United States | |
1122 | NCT00239564 | October 2005 | 4 November 2019 | Pharmacokinetics and Pharmacodynamics of IPX054 in Subjects With Parkinson's Disease | An Open-Label Study to Assess the Pharmacokinetics and Pharmacodynamics of IPX054 in Subjects With Parkinson's Disease | Idiopathic Parkinson's Disease | Drug: IPX054 100 mg;Drug: IPX054 150 mg;Drug: IPX054 200 mg;Drug: IPX054 250 mg;Drug: IPX054 300 mg | Impax Laboratories, LLC | Not recruiting | 30 Years | N/A | All | 12 | Phase 1/Phase 2 | United States | |
1123 | NCT00472355 | October 2005 | 10 December 2018 | Low Dose Apomorphine and Parkinsonism | Does Presynaptic Dopamine Receptor Stimulation Transiently Worsen Parkinsonism? | Parkinson's Disease | Drug: apomorphine | Oregon Health and Science University | National Institute of Neurological Disorders and Stroke (NINDS) | Not recruiting | 35 Years | 85 Years | All | 0 | Phase 2 | United States |
1124 | NCT00517842 | October 2005 | 19 February 2015 | A Triple-blinded, Randomised, Placebo-controlled Trial to Examine the Efficacy and Safety of ViNeuro in Patients With Parkinson's Disease | A Triple-blinded, Randomised, Placebo-controlled Trial to Examine the Efficacy and Safety of ViNeuro in Patients With Parkinson's Disease | Parkinson Disease | Drug: ViNeuro | Hospital Authority, Hong Kong | Vigconic (International) Ltd. | Not recruiting | 30 Years | N/A | Both | 160 | N/A | China |
1125 | NCT00912808 | October 2005 | 11 June 2018 | Cholinergic Augmentation in Frequently Falling Subjects With Parkinson's Disease | A Study of Cholinergic Augmentation in Frequently Falling Subjects With Parkinson's | Parkinson's Disease | Drug: Donepezil;Drug: Sugar Pill (placebo) | Oregon Health and Science University | Not recruiting | 21 Years | N/A | All | 23 | N/A | ||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1126 | EUCTR2005-001416-42-GB | 15/09/2005 | 24 April 2012 | A Multicenter, Double-Blind, Randomized Start, Placebo-Controlled, Parallel-Group Study to Assess Rasagiline as a Disease Modifying Therapy in Early Parkinson’s Disease Subjects - ADAGIO | A Multicenter, Double-Blind, Randomized Start, Placebo-Controlled, Parallel-Group Study to Assess Rasagiline as a Disease Modifying Therapy in Early Parkinson’s Disease Subjects - ADAGIO | Parkinson's Disease MedDRA version: 7.1 Level: PT Classification code 10061536 | Trade Name: Azilect Product Name: rasagiline tablets Product Code: TVP-1012 Pharmaceutical Form: Tablet INN or Proposed INN: rasagiline CAS Number: 161735-79-1 Current Sponsor code: TVP-1012 Other descriptive name: rasagiline mesilate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5, 1, 2- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: Rasagiline Product Code: TVP-1012 Pharmaceutical Form: Tablet | Teva Pharmaceuticals Industries LtD | Authorised | Female: yes Male: yes | 1100 | Portugal;Hungary;Germany;United Kingdom;Spain;Italy | ||||
1127 | NCT00165789 | September 2005 | 19 October 2017 | A Study to Explore the Safety And Tolerability of Doses of E2007 Up to a Maximum of 8 mg In Patients With Parkinson's Disease Who Experience End-of-Dose Wearing Off Motor Fluctuations | A Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Explore the Safety And Tolerability of Doses of E2007 Up to a Maximum of 8 mg In Patients With Parkinson's Disease Who Experience End-of-Dose Wearing Off Motor Fluctuations | Parkinson's Disease | Drug: E2007 | Eisai Inc. | Not recruiting | 18 Years | N/A | All | 75 | Phase 2 | United States | |
1128 | NCT00224263 | September 2005 | 19 February 2015 | Efficacy and Safety of Lingzhi in Patients With Early Parkinson's Disease | A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Assess the Efficacy and Safety of Lingzhi in Patients With Early Parkinson's Disease Receiving Stable L-dopa/DCI | Parkinson's Disease | Drug: Lingzhi (Ganoderma) | Xuanwu Hospital, Beijing | Not recruiting | 30 Years | 80 Years | Both | 360 | Phase 2 | China | |
1129 | NCT02774564 | September 2005 | 30 May 2016 | Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Carbidopa | Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 3-202 and a Single Dose of Controlled-release 200/50 mg Levodopa/Carbidopa (Sinemet® cr 200/50): a Double-blind, Randomised, Four-way Crossover, Placebo-controlled Study in Healthy Volunteers | Parkinson's Disease | Drug: BIA 3-202;Drug: Placebo;Drug: Sinemet® | Bial - Portela C S.A. | Not recruiting | 18 Years | 45 Years | Both | 16 | Phase 1 | Portugal | |
1130 | NCT02778594 | September 2005 | 27 June 2016 | Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Benserazide | Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 3-202 and a Single-dose of Controlled-release 100/25 mg Levodopa/Benserazide (Madopar® HBS 125): a Double-blind, Randomised, Four-way Crossover, Placebo-controlled Study in Healthy Volunteers | Parkinson's Disease (PD) | Drug: BIA 3-202;Drug: Placebo;Drug: levodopa 100 mg / benserazide 25 mg | Bial - Portela C S.A. | Not recruiting | 18 Years | 45 Years | Both | 17 | Phase 1 | Portugal | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1131 | EUCTR2005-002654-21-SE | 08/08/2005 | 19 March 2012 | A long-term health economics study of intraduodenal levodopa (Duodopa®) in routine care for patients with advanced idiopathic Parkinson’s disease with severe motor fluctuations and hyper-/dyskinesia. - DAPHNE | A long-term health economics study of intraduodenal levodopa (Duodopa®) in routine care for patients with advanced idiopathic Parkinson’s disease with severe motor fluctuations and hyper-/dyskinesia. - DAPHNE | Treatment of advanced levodopa-responsive Parkinson’s disease with severe motor fluctuations and hyper-/dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results. | Trade Name: Duodopa intestinal gel Pharmaceutical Form: Gastroenteral suspension INN or Proposed INN: Levodopa CAS Number: 59-92-7 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20 - INN or Proposed INN: Carbidopa CAS Number: 28860-95-9 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 5- | Solvay Pharmaceuticals GmbH | Not Recruiting | Female: yes Male: yes | Sweden | |||||
1132 | NCT00134966 | August 2005 | 16 December 2017 | A Study to Evaluate Fixed Dose Carbidopa/Levodopa/Entacapone Versus Immediate Release Carbidopa/Levodopa | A 39 Week Randomized, Double-Blind, Parallel Group, Multicenter Study to Evaluate the Effect of Fixed Dose Carbidopa/Levodopa/Entacapone 100 mg t.i.d. vs. Immediate Release Carbidopa/Levodopa 25/100 mg (t.i.d.) in Parkinson's Disease Patients Requiring Levodopa | Parkinson's Disease | Drug: capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg) | Novartis | Not recruiting | 30 Years | 80 Years | All | 493 | Phase 3 | United States;Canada;Czechia;Israel;Italy;Poland;Portugal;Turkey;Czech Republic | |
1133 | NCT00692328 | August 2005 | 25 May 2015 | Expectation and Response to Levodopa and Acupuncture in Parkinson's Disease | Expectation and Response to Levodopa & Acupuncture in Parkinson's Disease | Parkinson's Disease | Behavioral: Levodopa or acupuncture | Oregon Health and Science University | National Center for Complementary and Integrative Health (NCCIH) | Not recruiting | 18 Years | 80 Years | Both | 63 | N/A | United States |
1134 | NCT00125138 | July 2005 | 19 October 2017 | Melperone (an Anti-Psychotic) in Patients With Psychosis Associated With Parkinson's Disease | Safety and Efficacy of Melperone in the Treatment of Patients With Psychosis Associated With Parkinson's Disease | Parkinson's Disease;Psychotic Disorders | Drug: Melperone HCl;Drug: Placebo | Lundbeck LLC | Not recruiting | N/A | N/A | All | 90 | Phase 2 | United States;India;Italy | |
1135 | NCT00143026 | July 2005 | 16 December 2017 | Study to Compare the Effect of Treatment With Carbidopa/Levodopa/Entacapone on the Quality of Life of Patients With Parkinson's Disease. This Study is Not Recruiting in the United States | Study to Compare the Effect of Treatment With Carbidopa/Levodopa/Entacapone on the Quality of Life of Patients With Parkinson's Disease. | Parkinson's Disease | Drug: carbidopa, levodopa, entacapone | Novartis | Not recruiting | 30 Years | N/A | All | 184 | Phase 4 | Australia;Philippines;Taiwan;Thailand | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1136 | EUCTR2005-000444-84-AT | 22/06/2005 | 29 April 2013 | An open-label, multicenter, multinational Phase III follow-up study to investigate the long-term safety and efficacy of Sarizotan HCl 1 mg b.i.d. in patients with Parkinson's disease suffering from treatment-associated dyskinesia - PADDY-O | An open-label, multicenter, multinational Phase III follow-up study to investigate the long-term safety and efficacy of Sarizotan HCl 1 mg b.i.d. in patients with Parkinson's disease suffering from treatment-associated dyskinesia - PADDY-O | Treatment-Associated Dyskinesia in Parkinson's Disease | Product Code: EMD128130 Pharmaceutical Form: Tablet INN or Proposed INN: Sarizotan hydrochloride CAS Number: 195068-07-6 Current Sponsor code: EMD128130 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1- | Merck KGaA | Not Recruiting | Female: yes Male: yes | 800 | Phase 3 | Finland;Spain;Austria;Italy;United Kingdom | |||
1137 | NCT00086190 | June 2005 | 19 October 2017 | Study of Antidepressants in Parkinson's Disease | Study of Antidepressants in Parkinson's Disease | Parkinson Disease;Depression | Drug: paroxetine;Drug: venlafaxine;Other: placebo | University of Rochester | National Institute of Neurological Disorders and Stroke (NINDS) | Not recruiting | 30 Years | N/A | All | 115 | Phase 3 | United States;Canada;Puerto Rico |
1138 | NCT00139880 | June 2005 | 19 February 2015 | A Single Center, Randomized, Double-blind, Crossover Pilot Trial Comparing the Onset of Action of Parcopa™ With Sinemet® in Subjects With Stable Parkinson's Disease | A Single Center, Randomized, Double-blind, Crossover Pilot Trial Comparing the Onset of Action of Parcopa™ With Sinemet® in Subjects With Stable Parkinson's Disease | Parkinson's Disease | Drug: Parcopa | UCB Pharma | Not recruiting | 40 Years | N/A | Both | Phase 3 | United States | ||
1139 | NCT00148369 | June 2005 | 19 February 2015 | A Multi-Center, Observational Safety Registry of Subjects With Idiopathic Parkinson's Disease Previously Treated With Intraputaminal Infusion of Liatermin | A Multi-Center, Observational Safety Registry of Subjects With Idiopathic Parkinson's Disease Previously Treated With Intraputaminal Infusion of Liatermin | Idiopathic Parkinson's Disease | Drug: Safety observation | Amgen | Medtronic | Not recruiting | 35 Years | 70 Years | Both | 31 | N/A | Canada;United Kingdom;United States |
1140 | NCT00642889 | June 2005 | 19 February 2015 | Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist (12 Month Extension) | A PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED, 12-MONTH EXTENSION STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF A DOSE RANGE OF SAFINAMIDE OF 50-200 MG/DAY, AS ADD-ON THERAPY IN PATIENTS WITH EARLY IDIOPATHIC PARKINSON'S DISEASE TREATED WITH A STABLE DOSE OF A SINGLE DOPAMINE AGONIST. | Parkinson's Disease | Drug: Safinamide;Drug: Placebo | Newron | Not recruiting | 30 Years | 80 Years | Both | 227 | Phase 3 | ||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1141 | EUCTR2004-005234-39-GB | 27/05/2005 | 1 May 2012 | Multicentre, randomised, double-blind study to compare Stalevo® to levodopa/carbidopa in patients with Parkinson's disease experiencing symptoms of early wearing-off - SEWOP | Multicentre, randomised, double-blind study to compare Stalevo® to levodopa/carbidopa in patients with Parkinson's disease experiencing symptoms of early wearing-off - SEWOP | Parkinson's disease MedDRA version: 7.0 Level: LLT Classification code 10061536 | Trade Name: Stalevo Product Name: Stalevo Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Levodopa Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- INN or Proposed INN: Carbidopa Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 12.5- INN or Proposed INN: Entacapone Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- Trade Name: Stalevo Product Name: Stalevo Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Levodopa Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- INN or Proposed INN: Carbidopa Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- INN or Proposed INN: Entacapone Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- Trade Name: Sinemet Product Name: Sinemet Pharmaceutical Form: Tablet INN or Proposed INN: Levodopa Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- INN or Proposed INN: Carbidopa Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 12.5- Trade Name: Sinemet Product Name: Sinemet Pharmaceutical Form: Tablet INN or Proposed INN: Levodopa Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- INN or Proposed INN: Carbidopa Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- | Orion Corporation, ORION PHARMA, Finland | Authorised | Female: yes Male: yes | 240 | Finland;Germany;United Kingdom;Denmark;Ireland;Latvia;Lithuania;Sweden | ||||
1142 | NCT03095092 | May 23, 2005 | 16 December 2017 | Effect of Food on BIA 6-512 (Trans-resveratrol) | The Effect of Food on the Pharmacokinetics of a Single 400 mg Oral Dose of BIA 6-512 (Trans-resveratrol) in Healthy Subjects | Parkinson Disease | Drug: BIA 6-512 400 mg | Bial - Portela C S.A. | Not recruiting | 18 Years | 45 Years | All | 24 | Phase 1 | Portugal | |
1143 | EUCTR2004-005034-39-GB | 17/05/2005 | 19 March 2012 | Nicotinamide,vitamin B3, metabolic pathways in patients with early idiopathic parkinson's disease | Nicotinamide,vitamin B3, metabolic pathways in patients with early idiopathic parkinson's disease | Idiopathic Parkinson's disease | Trade Name: Nicotinamide Product Name: NICOTINAMIDE Pharmaceutical Form: Tablet INN or Proposed INN: Nicotinamide Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- | Queen Elizabeth Hospital | Authorised | Female: yes Male: yes | United Kingdom | |||||
1144 | EUCTR2004-002608-13-GB | 16/05/2005 | 28 February 2019 | Pragmatic Randomised Control Trial of Quetiapine for psychosis in Parkinson’s Disease - Quetiapine for psychosis in Parkinson’s disease | Pragmatic Randomised Control Trial of Quetiapine for psychosis in Parkinson’s Disease - Quetiapine for psychosis in Parkinson’s disease | Parkinson's Disease with psychosis | Trade Name: Seroquel Product Name: Seroquel Pharmaceutical Form: Film-coated tablet Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Trade Name: Seroquel Product Name: Seroquel Pharmaceutical Form: Film-coated tablet Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use | King’s College London & King’s College Hospital | Not Recruiting | Female: yes Male: yes | 60 | Phase 4 | United Kingdom | |||
1145 | NCT03093389 | May 11, 2005 | 16 December 2017 | Tolerability and Steady-state Pharmacokinetics of BIA 6-512 | A Double-blind, Randomised, Placebo-controlled, Rising Multiple-dose Study to Investigate the Tolerability and Steady-state Pharmacokinetics of BIA 6-512 (Trans-resveratrol) in Healthy Volunteers | Parkinson Disease | Drug: BIA 6-512;Drug: Placebo | Bial - Portela C S.A. | Not recruiting | 18 Years | 45 Years | All | 40 | Phase 1 | Portugal | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1146 | NCT00163085 | May 2005 | 19 February 2015 | The Effects of an NR2B NMDA Antagonist, CP-101,606, in Patients With Parkinson's Disease | A Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Explore The Efficacy And Safety Of The NR2B NMDA Antagonist CP-101,606 In Patients With Idiopathic Parkinson's Disease | Parkinson's Disease | Drug: NR2B NMDA Antagonist CP-101,606 (traxoprodil) | Pfizer | Not recruiting | 30 Years | 80 Years | Both | 12 | Phase 2 | United States | |
1147 | NCT00199433 | May 2005 | 8 August 2016 | A Study of Istradefylline (KW-6002) as Monotherapy in Parkinson's Disease (PD) Patients | A Phase 2, Double-blind, Placebo-controlled, Randomized, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of 40mg/Day KW-6002 (Istradefylline) as Monotherapy in Subjects With Parkinson's Disease | Parkinson's Disease;Movement Disorder Syndrome | Drug: Istradefylline (KW-6002) | Kyowa Kirin Pharmaceutical Development, Inc. | Not recruiting | 30 Years | N/A | Both | 160 | Phase 2 | United States | |
1148 | EUCTR2004-001485-41-AT | 20/04/2005 | 22 April 2013 | A single-blinded assessment of the short-term effects of cabergoline vs. carbidopa/levodopa on SPECT dopamine transporter density in out-patient subjects with Parkinson’s Disease - N/A | A single-blinded assessment of the short-term effects of cabergoline vs. carbidopa/levodopa on SPECT dopamine transporter density in out-patient subjects with Parkinson’s Disease - N/A | Approximately 120 recently diagnosed/early Parkinson’s disease subjects, who are untreated (see exclusionary criteria). | Trade Name: Sinemet Product Name: Sinemet Pharmaceutical Form: Tablet INN or Proposed INN: carbidopa/levodopa Trade Name: Cabaseril Product Name: Cabaseril Pharmaceutical Form: Tablet INN or Proposed INN: Cabergoline Trade Name: DaTSCAN Product Name: DatSCAN Pharmaceutical Form: Solution for injection INN or Proposed INN: Ioflupane [123 I] Concentration unit: Bq/ml becquerel(s)/millilitre | Institute for Neurodegenerative Disorders | Authorised | Female: yes Male: yes | 120 | Spain;Austria;United Kingdom | ||||
1149 | EUCTR2004-004139-74-DK | 20/04/2005 | 3 October 2016 | Parkinson’s Disease: PET scan and evaluation of memantines pharmacological effect. (Parkinsons sygdom bedømt med PET skanning, herunder memantins farmakologiske effekt.) - N/A | Parkinson’s Disease: PET scan and evaluation of memantines pharmacological effect. (Parkinsons sygdom bedømt med PET skanning, herunder memantins farmakologiske effekt.) - N/A | Parkinson's Disease | Trade Name: Ebixa Product Name: Ebixa Pharmaceutical Form: Tablet INN or Proposed INN: memantine Concentration unit: mg/g milligram(s)/gram Concentration type: equal Concentration number: 10 mg- | Neurologisk afdeling F | Authorised | Female: yes Male: yes | 12 | Phase 2 | Denmark | |||
1150 | NCT00108667 | April 2005 | 19 February 2015 | Talampanel to Treat Parkinson's Disease | AMPA Receptor Antagonist Treatment of Parkinson's Disease | Parkinson Disease | Drug: IV Levodopa;Drug: Talampanel | National Institute of Neurological Disorders and Stroke (NINDS) | Not recruiting | N/A | N/A | Both | 40 | Phase 2 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1151 | NCT00199355 | April 2005 | 19 February 2015 | A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa | Placebo-Controlled , Double-Blind , Exploratory Study of KW-6002(Istradefylline) in the Treatment of Parkinson's Disease. [Adjunctive Therapy to Levodopa] | Parkinson's Disease | Drug: Istradefylline (KW-6002) | Kyowa Hakko Kirin Company, Limited | Not recruiting | 30 Years | N/A | Both | 75 | Phase 2 | Japan | |
1152 | NCT00203957 | March 2005 | 19 February 2015 | Study of KW-6002 (Istradefylline) in Parkinson's Disease in Patients With Motor Response Complications on Levodopa | A Long-Term, Multicenter, Open-Label Safety Study With Oral 20 or 40 mg/d Doses of KW-6002 (Istradefylline) as Treatment for Parkinson's Disease in Patients With Motor Response Complications on Levodopa Therapy | Parkinson's Disease | Drug: Istradefylline | University of Chicago | Not recruiting | 18 Years | N/A | Both | 10 | Phase 3 | United States | |
1153 | NCT02834507 | March 2005 | 8 August 2016 | Effect of Two Multiple-dose Regimens of BIA 3-202 on the Pharmacokinetics and Motor Response of Levodopa, and on the Erythrocyte Comt Activity in Parkinson's Disease Patients | A Double-blind, Randomised, Placebo- and Active-controlled, Cross-over Study to Investigate the Effect of Two Multiple-dose Regimens of BIA 3-202 on the Pharmacokinetics and Motor Response of Levodopa, and on the Erythrocyte Comt Activity in Parkinson's Disease Patients | Parkinson's Disease (PD) | Drug: Placebo;Drug: BIA 3-202;Drug: Comtan®;Drug: Sinemet® | Bial - Portela C S.A. | Not recruiting | 30 Years | 75 Years | Both | 19 | Phase 2 | ||
1154 | EUCTR2004-002844-93-LT | 08/02/2005 | 9 October 2012 | A Long-Term, Multicenter, Open-Label Safety Study with Oral 20 or 40 mg/d Doses of KW-6002 (Istradefylline) as Treatment for Parkinson’s Disease in Patients with Motor Response Complications on Levodopa Therapy - | Parkinson's Disease | Product Name: Istradefylline Product Code: KW-6002 Pharmaceutical Form: Tablet INN or Proposed INN: Istradefylline Current Sponsor code: KW-6002 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- | Kyowa Hakko U.K. Limited | Not Recruiting | Female: yes Male: yes | 1175 | United Kingdom;Estonia;Spain;Italy;Latvia;Lithuania | |||||
1155 | EUCTR2004-002650-59-GB | 03/02/2005 | 21 August 2012 | A phase 3b, open-label, multicentre, multinational trial to assess the tolerability of switching subjects from ropinerole, pramipexole or cabergoline to the rotigotine transdermal system and its effect on symptoms with idiopathic Parkinson's disease - n/a | A phase 3b, open-label, multicentre, multinational trial to assess the tolerability of switching subjects from ropinerole, pramipexole or cabergoline to the rotigotine transdermal system and its effect on symptoms with idiopathic Parkinson's disease - n/a | Idiopathic Parkinson's disease | Product Name: rotigotine Product Code: SPM 962 Pharmaceutical Form: Transdermal patch INN or Proposed INN: rotigotine CAS Number: 99755-59-6 Current Sponsor code: SPM 962 Concentration unit: mg/m2 milligram(s)/square meter Concentration type: range Concentration number: 4.5, 9.0, -13.5, 18 | SCHWARZ BIOSCIENCES | Authorised | Female: yes Male: yes | 130 | Phase 3b | United Kingdom | |||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1156 | NCT00153972 | February 2005 | 19 February 2015 | Dopamine Turnover Rate as Surrogate Parameter for Diagnosis of Early Parkinson's Disease | Dopamine Turnover Rate Measured With F-Dopa-PET as Surrogate Parameter for Diagnosis and Progression Analysis of Early Parkinson's Disease | Parkinson's Disease | Drug: Cabergoline;Drug: Levodopa | Technische Universität Dresden | Pfizer | Not recruiting | 40 Years | 85 Years | Both | 39 | Phase 4 | Germany |
1157 | EUCTR2004-002641-12-AT | 21/01/2005 | 22 April 2013 | A multicenter, multinational, phase 3b, open-label extension trial to assess the safety and tolerability of long-term treatment of rotigotine patch in subjects with idiopathic Parkinson's disease | A multicenter, multinational, phase 3b, open-label extension trial to assess the safety and tolerability of long-term treatment of rotigotine patch in subjects with idiopathic Parkinson's disease | Parkinson's disease | Product Name: Rotigotine Product Code: SPM 962 Pharmaceutical Form: Transdermal patch INN or Proposed INN: Rotigotine CAS Number: [99755-59-6] Current Sponsor code: SPM 962 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 4.5- Product Name: Rotigotine Product Code: SPM 962 Pharmaceutical Form: Transdermal patch INN or Proposed INN: Rotigotine CAS Number: [99755-59-6] Current Sponsor code: SPM 962 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 9.0- Product Name: Rotigotine Product Code: SPM 962 Pharmaceutical Form: Transdermal patch INN or Proposed INN: Rotigotine CAS Number: [99755-59-6] Current Sponsor code: SPM 962 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 13.5- Product Name: Rotigotine Product Code: SPM 962 Pharmaceutical Form: Transdermal patch INN or Proposed INN: Rotigotine CAS Number: [99755-59-6] Current Sponsor code: SPM 962 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 18.0- | Schwarz Biosciences GmbH | Not Recruiting | Female: yes Male: yes | 220 | Phase 3b | Spain;Austria;Italy;United Kingdom | |||
1158 | NCT00286949 | January 6, 2005 | 16 December 2017 | Treatment of Executive Dysfunction in Parkinson's Disease | Atomoxetine for the Treatment of Executive Dysfunction in Patients With Parkinson's Disease: A Pilot Open-label Study | Parkinson's Disease | Drug: Atomoxetine | Johns Hopkins University | Eli Lilly and Company | Not recruiting | 21 Years | 65 Years | All | 12 | N/A | United States |
1159 | NCT00103597 | January 2005 | 19 February 2015 | Efficacy of Therapeutic Interventions for Orthostatic Hypotension in Parkinson's Disease and Multiple System Atrophy | Efficacy of Therapeutic Interventions for Orthostatic Hypotension in Parkinson's Disease and Multiple System Atrophy | Parkinson's Disease;Multiple System Atrophy;Orthostatic Hypotension | Drug: Fludrocortisone;Drug: Domperidone;Behavioral: Conservative Measures for Orthostatic Hypotension | Royal Brisbane and Women's Hospital | Not recruiting | 40 Years | 95 Years | Both | 50 | Phase 1 | Australia | |
1160 | NCT00129181 | January 2005 | 19 February 2015 | Study of the Effects of Dopaminergic Medications on Dopamine Transporter Density in Subjects With Parkinson's Disease | A Single-blinded Assessment of the Short-term Effects of Cabergoline vs. Carbidopa/Levodopa on SPECT Dopamine Transporter Density in Out-patient Subjects With Parkinson's Disease | Parkinson Disease;Parkinsonian Syndrome | Drug: cabergoline;Drug: carbidopa/levodopa;Procedure: DATscan and SPECT imaging | Institute for Neurodegenerative Disorders | Pfizer;GE Healthcare | Not recruiting | 40 Years | N/A | Both | 30 | N/A | Austria;Germany;Italy;Spain;United Kingdom |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1161 | NCT00144300 | January 2005 | 19 October 2017 | Ophthalmologic Safety Study of Pramipexole Immediate Release (IR) Versus Ropinirole in Early Parkinson's Disease (PD) Patients | A Two Year Open Label, Randomized, Parallel Group, Blinded Assessment Ophthalmologic Safety Study of Pramipexole IR Versus Ropinirole in Early Parkinson's Disease Patients | Parkinson Disease | Drug: Mirapex;Drug: Requip | Boehringer Ingelheim | Not recruiting | 30 Years | N/A | All | 246 | Phase 4 | United States | |
1162 | NCT00219284 | January 2005 | 16 December 2017 | Effects of Carbidopa/Levodopa/Entacapone on Motor Function and Quality of Life in Patients With Parkinson's Disease | A Prospective, Multi-center, Randomized, Open-label Study With Blinded Raters to Evaluate the Effects of Immediate Versus Delayed Switch to Carbidopa/Levodopa/Entacapone on Motor Function and Quality of Life in Patients With Parkinson's Disease With End-of-dose Wearing Off | Parkinson's Disease With End of Dose Wearing Off | Drug: Carbidopa/levodopa/entacapone | Novartis Pharmaceuticals | Not recruiting | 30 Years | 85 Years | All | 359 | Phase 4 | United States;Puerto Rico | |
1163 | NCT01634243 | January 2005 | 19 October 2017 | A Dose-ranging Study for SPM 962 in Parkinson's Disease Patients | A Open-label Dose-ranging Study for SPM 962 in Parkinson's Disease Patients | Parkinson's Disease | Drug: SPM 962 | Otsuka Pharmaceutical Co., Ltd. | Not recruiting | 30 Years | 79 Years | All | 64 | Phase 2 | Japan | |
1164 | EUCTR2004-001594-25-FI | 30/12/2004 | 19 March 2012 | A double-blind, placebo-controlled, multicenter, multinational Phase III study to evaluate the safety and efficacy of Sarizotan HCl 1 mg b.i.d. in patients with Parkinson's disease suffering from treatment-associated dyskinesia - PADDY 2 | A double-blind, placebo-controlled, multicenter, multinational Phase III study to evaluate the safety and efficacy of Sarizotan HCl 1 mg b.i.d. in patients with Parkinson's disease suffering from treatment-associated dyskinesia - PADDY 2 | Treatment-Associated Dyskinesia in Parkinson's Disease | Product Code: EMD128130 Pharmaceutical Form: Tablet INN or Proposed INN: Sarizotan hydrochloride CAS Number: 195068-07-6 Current Sponsor code: EMD128130 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | Merck KGaA | Not Recruiting | Female: yes Male: yes | 600 | Phase 3 | Finland;Spain | |||
1165 | EUCTR2004-002598-21-AT | 22/12/2004 | 22 April 2013 | A phase 3b, open-label, multicenter, multinational trial to evaluate the effects of rotigotine transdermal patch on early morning motor impairment and sleep disorders in patients with idiopathic Parkinson's disease | A phase 3b, open-label, multicenter, multinational trial to evaluate the effects of rotigotine transdermal patch on early morning motor impairment and sleep disorders in patients with idiopathic Parkinson's disease | Parkinson's Disease | Product Name: Rotigotine Product Code: SPM 962 Pharmaceutical Form: Transdermal patch INN or Proposed INN: Rotigotine CAS Number: [99755-59-6] Current Sponsor code: SPM 962 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 4.5- Product Name: Rotigotine Product Code: SPM 962 Pharmaceutical Form: Transdermal patch INN or Proposed INN: Rotigotine CAS Number: [99755-59-6] Current Sponsor code: SPM 962 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 9.0- Product Name: Rotigotine Product Code: SPM 962 Pharmaceutical Form: Transdermal patch INN or Proposed INN: Rotigotine CAS Number: [99755-59-6] Current Sponsor code: SPM 962 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 13.5- Product Name: Rotigotine Product Code: SPM 962 Pharmaceutical Form: Transdermal patch INN or Proposed INN: Rotigotine CAS Number: [99755-59-6] Current Sponsor code: SPM 962 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 18.0- | Schwarz Biosciences GmbH | Not Recruiting | Female: yes Male: yes | 50 | Phase 3b | Austria;United Kingdom | |||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1166 | EUCTR2004-002609-66-DE | 06/12/2004 | 19 March 2012 | A phase 3, randomized, open-label, two-arm, parallel-group, multicenter, multinational trial to compare the efficacy of rotigotine transdermal patch to that of ropinirole on early morning motor impairment and sleep disorders in subjects with early-stage, idiopathic Parkinson's disease | A phase 3, randomized, open-label, two-arm, parallel-group, multicenter, multinational trial to compare the efficacy of rotigotine transdermal patch to that of ropinirole on early morning motor impairment and sleep disorders in subjects with early-stage, idiopathic Parkinson's disease | Parkinson's Disease | Product Name: Rotigotine Product Code: SPM962 Pharmaceutical Form: Transdermal patch INN or Proposed INN: Rotigotine CAS Number: 99755-59-6 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 4.5- Product Name: Rotigotine Product Code: SPM962 Pharmaceutical Form: Transdermal patch INN or Proposed INN: Rotigotine CAS Number: 99755-59-6 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 9.0- Product Name: Rotigotine Product Code: SPM962 Pharmaceutical Form: Transdermal patch INN or Proposed INN: Rotigotine CAS Number: 99755-59-6 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 13.5- Product Name: Rotigotine Product Code: SPM962 Pharmaceutical Form: Transdermal patch INN or Proposed INN: Rotigotine CAS Number: 99755-59-6 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 18.0- Trade Name: Requip Product Name: Requip Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Ropinirole Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.25- Trade Name: Requip Product Name: Requip Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Ropinirole Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5- Trade Name: Requip Product Name: Requip Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Ropinirole Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1- Trade Name: Requip Product Name: Requip Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Ropinirole Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2- | Schwarz Biosciences GmbH | Not Recruiting | Female: yes Male: yes | 60 | Phase 3 | Germany;Italy | |||
1167 | EUCTR2004-000835-27-IT | 03/12/2004 | 19 March 2012 | A phase III, double-blind, placebo-controlled, 12-month extension study to investigate the efficacy and safety of a dose range of safinamide of 50-200 mg/day, as add-on therapy in patients with early idiopathic Parkinson's Disease treated with a stable dose of a single dopamine agonist | A phase III, double-blind, placebo-controlled, 12-month extension study to investigate the efficacy and safety of a dose range of safinamide of 50-200 mg/day, as add-on therapy in patients with early idiopathic Parkinson's Disease treated with a stable dose of a single dopamine agonist | Parkinson's Disease MedDRA version: 6.1 Level: PT Classification code 10061536 | Product Name: Safinamide Product Code: NW-1015 Pharmaceutical Form: Capsule, hard Current Sponsor code: NW-1015 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- | NEWRON PHARMACEUTICALS | Not Recruiting | Female: yes Male: yes | Phase 3 | Spain;Italy | ||||
1168 | EUCTR2004-000833-12-ES | 02/12/2004 | 19 March 2012 | A phase III, double-blind, placebo-controlled study to determine the efficacy and safety of a low (50-100 mg/day) and high (150-200 mg/day) dose range of safinamide, as add-on therapy, in patients with early idiopathic parkinson’s disease treated with a stable dose of a single dopamine agonist. | A phase III, double-blind, placebo-controlled study to determine the efficacy and safety of a low (50-100 mg/day) and high (150-200 mg/day) dose range of safinamide, as add-on therapy, in patients with early idiopathic parkinson’s disease treated with a stable dose of a single dopamine agonist. | Early idiopathic Parkinson’s disease MedDRA version: 7.0 Level: LLT Classification code 10013113 | Product Name: Safinamide Product Code: NW-1015 Pharmaceutical Form: Capsule, hard INN or Proposed INN: Safinamide CAS Number: 202825-46-5 Current Sponsor code: NW-1015 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Product Name: Safinamide Product Code: NW-1015 Pharmaceutical Form: Capsule, hard INN or Proposed INN: Safinamide CAS Number: 202825-46-5 Current Sponsor code: NW-1015 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Product Name: Safinamide Product Code: NW-1015 Pharmaceutical Form: Capsule, hard INN or Proposed INN: Safinamide CAS Number: 202825-46-5 Current Sponsor code: NW-1015 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Product Name: Safinamide Product Code: NW-1015 Pharmaceutical Form: Capsule, hard INN or Proposed INN: Safinamide CAS Number: 202825-46-5 Current Sponsor code: NW-1015 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use | Newron Pharmaceuticals S.p.A. | Authorised | Female: yes Male: yes | 250 | Phase 3 | Spain;Italy | |||
1169 | EUCTR2004-001593-10-IT | 02/12/2004 | 29 May 2012 | A double-blind, placebo-controlled, multicenter, multinational Phase III study to evaluate the safety and efficacy of Sarizotan HCl 1 mg b.i.d. in patients with Parkinson's disease suffering from treatment-associated dyskinesia (PADDY 1) | A double-blind, placebo-controlled, multicenter, multinational Phase III study to evaluate the safety and efficacy of Sarizotan HCl 1 mg b.i.d. in patients with Parkinson's disease suffering from treatment-associated dyskinesia (PADDY 1) | Treatment-Associated Dyskinesia in Parkinson's Disease | Product Name: Sarizotan hydrochloride Product Code: EMD 128130 Pharmaceutical Form: Tablet INN or Proposed INN: Sarizotan hydrochloride CAS Number: 195068-07-6 Current Sponsor code: EMD 128130 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1- | MERCK S.P.A. | Not Recruiting | Female: yes Male: yes | Phase 3 | United Kingdom;Italy | ||||
1170 | NCT00643045 | December 2004 | 19 February 2015 | Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist | A Phase III, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of a Low (50 100 mg/Day) and High (150 200 mg/Day) Dose Range of Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist | Idiopathic Parkinson's Disease | Drug: Safinamide;Drug: Placebo | Newron | Not recruiting | 30 Years | 80 Years | Both | 269 | Phase 3 | ||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1171 | NCT03091868 | November 3, 2004 | 16 December 2017 | Pharmacokinetics of Rising Single-doses of BIA 6-512 and Their Effect on the Levodopa Pharmacokinetics | A Double-blind, Randomised, Placebo-controlled Study in Healthy Volunteers to Investigate the Tolerability and Pharmacokinetics of Rising Single-doses of BIA 6-512 and Their Effect on the Levodopa Pharmacokinetics When Administered in Combination With a Single-dose of Levodopa/Carbidopa 100/25 mg or With a Single-dose of Levodopa/Carbidopa 100/25 mg Plus a Single-dose of Entacapone 200 mg | Parkinson Disease | Drug: Placebo oral capsule;Drug: Sinemet® 100/25;Drug: Comtan®;Drug: BIA 6-512 25 mg;Drug: BIA 6-512 100 mg | Bial - Portela C S.A. | Not recruiting | 18 Years | 45 Years | All | 80 | Phase 1 | Portugal | |
1172 | NCT00199394 | November 2004 | 8 August 2016 | A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease | A 16-week, Double-Blind, Placebo-Controlled, Randomised, Parallel-Group, Multicentre, International Study to Evaluate the Efficacy and Safety of 40 mg/Day KW-6002 (Istradefylline) and That of Entacapone Versus Placebo as Treatment for Parkinson's Disease in Patients With Motor Response Complications on Levodopa Therapy. | Parkinson's Disease | Drug: Istradefylline (KW-6002) | Kyowa Hakko Kirin UK, Ltd. | Not recruiting | 30 Years | N/A | Both | 405 | Phase 3 | United Kingdom | |
1173 | NCT00296946 | November 2004 | 26 February 2018 | Ipratropium Spray for Drooling Saliva in Parkinson's Disease | Phase II Clinical Trial of Ipratropium Bromide Spray as a Treatment for Sialorrhea in Patients With Parkinson's Disease | Parkinson's Disease | Drug: ipratropium bromide (drug) | University Health Network, Toronto | Parkinson's Disease Foundation | Not recruiting | 30 Years | N/A | All | 20 | Phase 2 | Canada |
1174 | NCT01518309 | November 2004 | 16 December 2017 | An Open-label Safety Study of Pimavanserin in Parkinson's Disease Patients | Parkinson's Disease Psychosis | Drug: pimavanserin tartrate (ACP-103) | ACADIA Pharmaceuticals Inc. | Not recruiting | N/A | N/A | All | 39 | Phase 2 | United States | ||
1175 | EUCTR2004-000817-20-LV | 22/10/2004 | 3 September 2012 | A 16-week, Double-Blind, Placebo-Controlled, Randomised, Parallel-Group, Multicentre, International Study to Evaluate the Efficacy and Safety of 40 mg/day KW-6002 (istradefylline) and that of Entacapone versus Placebo as Treatment for Parkinson's Disease in Patients with Motor Response Complications on Levodopa Therapy. | A 16-week, Double-Blind, Placebo-Controlled, Randomised, Parallel-Group, Multicentre, International Study to Evaluate the Efficacy and Safety of 40 mg/day KW-6002 (istradefylline) and that of Entacapone versus Placebo as Treatment for Parkinson's Disease in Patients with Motor Response Complications on Levodopa Therapy. | Parkinson's Disease | Product Name: Istradefylline Product Code: KW-6002 Pharmaceutical Form: Capsule* INN or Proposed INN: Istradefylline Current Sponsor code: KW-6002 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use Trade Name: Comtess Product Name: Comtess Pharmaceutical Form: Capsule* INN or Proposed INN: Entacapone CAS Number: 130929-57-6 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use | Kyowa Hakko U.K. Limited | Not Recruiting | Female: yes Male: yes | 405 | Spain;Italy;Latvia;Lithuania | ||||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1176 | EUCTR2004-000361-35-CZ | 18/10/2004 | 19 March 2012 | A 48-MONTH OPEN LABEL MULTI-CENTERED EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY, TOLERABILITY AND EFFICACY OF E2007 IN PATIENTS WITH PARKINSON’S DISEASE WITH “WEARING OFF” MOTOR FLUCTUATIONS AND “ON” PERIOD DYSKINESIAS. | A 48-MONTH OPEN LABEL MULTI-CENTERED EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY, TOLERABILITY AND EFFICACY OF E2007 IN PATIENTS WITH PARKINSON’S DISEASE WITH “WEARING OFF” MOTOR FLUCTUATIONS AND “ON” PERIOD DYSKINESIAS. | Parkinson's Disease | Product Name: MARS Product Code: E2007 Pharmaceutical Form: Coated tablet Current Sponsor code: E2007 Other descriptive name: MARS Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5- Current Sponsor code: E2007 Other descriptive name: MARS Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1- Current Sponsor code: E2007 Other descriptive name: MARS Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2- | Eisai Limited | Not Recruiting | Female: yes Male: yes | 225 | Czech Republic;Italy | ||||
1177 | NCT00199368 | October 2004 | 8 August 2016 | An Extension of Istradefylline in Parkinson's Disease Patients Who Have Completed Studies 6002-EU-007, 6002-US-013 or 6002-US-018 | A Long-Term, Multicenter, Open-Label Safety Study With Oral 20 or 40 mg/d Doses of KW-6002 (Istradefylline) as Treatment for Parkinson's Disease in Patients With Motor Response Complications on Levodopa Therapy. | Parkinson's Disease | Drug: Istradefylline ( KW-6002) | Kyowa Kirin Pharmaceutical Development, Inc. | Kyowa Hakko Kirin UK, Ltd. | Not recruiting | 30 Years | N/A | Both | 1100 | Phase 3 | United States |
1178 | NCT00105508 | September 30, 2004 | 20 August 2018 | Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia | A Double-blind, Placebo-controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan HCl 1 mg b.i.d. in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia | Parkinson's Disease;Dyskinesia | Drug: Sarizotan;Drug: Placebo | EMD Serono | Not recruiting | 30 Years | N/A | All | 506 | Phase 3 | United States | |
1179 | EUCTR2004-000185-12-FI | 21/09/2004 | 19 March 2012 | A long term, double-blind, randomized, parallel-group, carbidopa/levodopa controlled, multi-center study to evaluate the effect of Stalevo® in patients with Parkinson’s disease requiring initiation of levodopa therapy. - STRIDE-PD | A long term, double-blind, randomized, parallel-group, carbidopa/levodopa controlled, multi-center study to evaluate the effect of Stalevo® in patients with Parkinson’s disease requiring initiation of levodopa therapy. - STRIDE-PD | Parkinson's disease MedDRA version: 7.0 Level: LLT Classification code 10061536 | Trade Name: Stalevo Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Levodopa Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- INN or Proposed INN: Carbidopa Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 12.5- INN or Proposed INN: Entacapone Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- Trade Name: Stalevo Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Levodopa Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- INN or Proposed INN: Carbidopa Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- INN or Proposed INN: Entacapone Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- Trade Name: Sinemet Pharmaceutical Form: Tablet INN or Proposed INN: Levodopa Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- INN or Proposed INN: Carbidopa Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 12.5- Trade Name: Sinemet Pharmaceutical Form: Tablet INN or Proposed INN: Levodopa Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- INN or Proposed INN: Carbidopa Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- Trade Name: Sinemet Pharmaceutical Form: Tablet INN or Proposed INN: Levodopa Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- INN or Proposed INN: Carbidopa Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 12.5- Trade Name: Sinemet Pharmaceutical Form: Tablet INN or Proposed INN: Levodopa Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- INN or Proposed INN: Carbidopa Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- | Orion Corporation, ORION PHARMA | Not Recruiting | Female: yes Male: yes | 740 | Finland;United Kingdom;Italy;Sweden | ||||
1180 | EUCTR2004-003355-39-AT | 14/09/2004 | 22 April 2013 | A 52-week, multicentre, open label extension study of the safety, tolerability and efficacy of donepezil (Aricept) in Parkinson's disease patients with dementia. | A 52-week, multicentre, open label extension study of the safety, tolerability and efficacy of donepezil (Aricept) in Parkinson's disease patients with dementia. | Dementia associated with Parkinson's disease | Trade Name: Aricept 5 mg-Filmtabletten Product Name: Aricept 5mg-Filmtabletten Pharmaceutical Form: Tablet | Eisai Limited | Not Recruiting | Female: yes Male: yes | 468 | Austria | ||||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1181 | NCT00099268 | September 2004 | 19 October 2017 | Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy | A Long Term, Double-blind, Randomized, Parallel-group, Carbidopa/Levodopa Controlled, Multi-center Study to Evaluate the Effect of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy | Parkinson's Disease | Drug: Carbidopa/levodopa/entacapone;Drug: Immediate release carbidopa/levodopa | Novartis Pharmaceuticals | Orion Corporation, Orion Pharma | Not recruiting | 30 Years | 70 Years | All | 747 | Phase 3 | United States;Austria;Belgium;Canada;Finland;France;Germany;Greece;Italy;Spain;Sweden;Switzerland;Turkey;United Kingdom |
1182 | NCT00105521 | September 2004 | 16 December 2017 | Sarizotan HCl in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia | A Double-blind, Placebo-controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan HCl 1 mg b.i.d. in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia | Parkinson's Disease;Dyskinesia | Drug: Sarizotan HC1 | EMD Serono | Not recruiting | 30 Years | N/A | All | 594 | Phase 3 | United States | |
1183 | NCT00296959 | September 2004 | 19 February 2015 | Topiramate as a Treatment for Levodopa-Induced Dyskinesia in Parkinson's Disease | Anti-Dyskinetic Properties of Topiramate: A Double-Blind, Placebo-Controlled Trial in Patients With Parkinson's Disease and Levodopa-Induced Dyskinesias | Parkinson's Disease | Drug: topiramate (drug) | University Health Network, Toronto | Not recruiting | 30 Years | 75 Years | Both | 20 | Phase 2 | Canada | |
1184 | NCT00641186 | September 2004 | 19 February 2015 | Trial of Xyrem for Excessive Daytime Sleepiness and Sleep Disturbance in Parkinson's Disease (PD) | A Phase II, Eight Week, Multi-Center, Open Label Trial of Xyrem(R) (Sodium Oxybate) for Excessive Daytime Sleepiness and Nocturnal Sleep Disturbance in Patients With Mild to Moderate Parkinson's Disease | Parkinson Disease | Drug: sodium oxybate | Baylor College of Medicine | Jazz Pharmaceuticals | Not recruiting | 30 Years | 75 Years | Both | 30 | N/A | |
1185 | NCT00089622 | August 4, 2004 | 16 December 2017 | Lisuride Patch to Treat Parkinson's Disease | Transcutaneous Lisuride Therapy of Parkinson's Disease | Parkinson Disease | Drug: Intravenous Levodopa;Drug: Lisuride Transdermal System | National Institute of Neurological Disorders and Stroke (NINDS) | Not recruiting | 40 Years | 80 Years | All | 40 | Phase 2 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1186 | EUCTR2004-000148-26-FI | 30/07/2004 | 17 December 2012 | A multi-centre, multinational, phase 3, open-label extension trial to assess the safety of long-term treatment of rotigotine patch in subjects with advanced stage, idiopathic Parkinson's disease who are not well controlled on levodopa - N/A | A multi-centre, multinational, phase 3, open-label extension trial to assess the safety of long-term treatment of rotigotine patch in subjects with advanced stage, idiopathic Parkinson's disease who are not well controlled on levodopa - N/A | Parkinson's Disease | Product Name: Rotigotine Product Code: SPM 962 Pharmaceutical Form: Transdermal patch INN or Proposed INN: Rotigotine CAS Number: [99755-59-6] Current Sponsor code: SPM 962 Other descriptive name: (6S)-6-{propyl-[2-[2-thienyl]ethyl]amino}-5,6,7,8-tetrahydro-1-naphtalenol Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 9.0, 13.5, 18.0-amount per patch | Schwarz BioSciences Inc. | Not Recruiting | Female: yes Male: yes | 360 | Phase 3 | Czech Republic;Hungary;Finland;Spain;Italy;Sweden | |||
1187 | NCT00174239 | July 2004 | 19 February 2015 | Study Of Cabaser and Sinemet CR For The Treatment Of Nighttime Symptoms Associated With Parkinson's Disease. | A Double-Blind, Randomized, Comparative Study of Cabaser and Sinemet CR For The Treatment Of Nocturnal Disability In Levodopa -Treated Parkinson's Disease Patients. | Parkinson Disease | Drug: cabergoline;Drug: controlled-release levodopa / carbidopa | Pfizer | Not recruiting | 18 Years | 80 Years | Both | 220 | Phase 4 | Australia;Italy;Spain;United Kingdom | |
1188 | NCT00199420 | July 2004 | 8 August 2016 | A Study of Istradefylline (KW-6002) in Treating Patients With Parkinson's Disease on Levodopa | A 12-week, Double Blind, Placebo-controlled, Randomized, Parallel Group, Multicenter, Fixed Dose Study to Evaluate the Efficacy and Safety of 10, 20 and 40 mg/d Oral Dose of KW-6002 (Istradefylline) as Treatment for Parkinson's Disease in Patients With Motor Response Complications on Levodopa/Carbidopa Therapy. | Parkinson's Disease | Drug: Istradefylline (KW-6002) | Kyowa Kirin Pharmaceutical Development, Inc. | Not recruiting | 30 Years | N/A | Both | 580 | Phase 3 | United States | |
1189 | NCT00304161 | July 2004 | 19 October 2017 | Effectiveness of Antidepressant Treatment for Depression in People With Parkinson's Disease | Depression Diagnosis and Treatment in Parkinson Disease | Depressive Disorder;Parkinson Disease | Drug: Atomoxetine;Drug: Placebo | University of Pennsylvania | National Institute of Mental Health (NIMH) | Not recruiting | 30 Years | 79 Years | All | 55 | Phase 4 | United States |
1190 | NCT00359723 | July 2004 | 10 December 2018 | Methylphenidate and Parkinson's Disease | Subacute Trial of Methylphenidate in Parkinson's Disease | Parkinson's Disease | Drug: methylphenidate | Oregon Health and Science University | National Institute of Neurological Disorders and Stroke (NINDS) | Not recruiting | 21 Years | N/A | All | 13 | Phase 2 | United States |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1191 | NCT00086294 | June 25, 2004 | 16 December 2017 | ACP-103 to Treat Parkinson's Disease | 5HT2A/C Serotonin Blockade in Parkinson's Disease | Parkinson's Disease;Dyskinesias | Drug: Intravenous Levodopa;Drug: ACP-103 | National Institute of Neurological Disorders and Stroke (NINDS) | Not recruiting | 30 Years | 80 Years | All | 40 | Phase 2 | United States | |
1192 | NCT00199407 | June 2004 | 8 August 2016 | A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa | A 12-week, Double Blind, Placebo-controlled, Randomized, Parallel Group, Multicenter, Fixed Dose Study to Evaluate the Efficacy and Safety of a 20 mg/d Oral Dose of KW-6002 (Istradefylline) as Treatment for Parkinson's Disease in Patients With Motor Response Complications on Levodopa/Carbidopa Therapy. | Parkinson's Disease | Drug: Istradefylline (KW-6002) | Kyowa Kirin Pharmaceutical Development, Inc. | Not recruiting | 30 Years | N/A | Both | 230 | Phase 3 | United States | |
1193 | NCT00203138 | June 2004 | 19 February 2015 | Safety, Tolerability, and Effectiveness of Rasagiline Mesylate in Patients With Parkinson's Disease | A Multicenter, Open-Label, Phase III Study for the Safety, Tolerability and Clinical Effect of Rasagiline Mesylate in Patients With Parkinson's Disease | Parkinson's Disease | Drug: rasagiline mesylate | Teva Pharmaceutical Industries | Not recruiting | 35 Years | N/A | Both | 306 | Phase 3 | United States | |
1194 | NCT00211588 | June 2004 | 19 February 2015 | Galantamine Executive Function in Parkinson's Disease | Investigator Initiated Study: Galantamine CR Potential Enhancement of Attentional and Executive Function in Non-Demented Patients With Parkinson's Disease | Parkinson's Disease | Drug: galantamine | Memorial Hospital of Rhode Island | Ortho-McNeil Neurologics, Inc. | Not recruiting | 60 Years | 85 Years | Both | 90 | N/A | United States |
1195 | NCT03091543 | May 4, 2004 | 16 December 2017 | Tolerability, Safety and Pharmacokinetics of Four Single-doses of BIA 6-512 (Trans-resveratrol) and Their Effect on the Levodopa Pharmacokinetics | A Double-blind, Randomised, Crossover, Placebo-controlled Study in Healthy Volunteers to Investigate the Tolerability, Safety and Pharmacokinetics of Four Single-doses of BIA 6-512 (Trans-resveratrol) and Their Effect on the Levodopa Pharmacokinetics When Administered in Combination With a Single-dose of Levodopa/Benserazide 100/25 mg | Parkinson Disease | Drug: Madopar® HBS 125;Drug: Placebo;Drug: BIA 6-512 25 mg dose;Drug: BIA 6-512 50 mg dose;Drug: BIA 6-512 100 mg dose;Drug: BIA 6-512 200 mg dose | Bial - Portela C S.A. | Not recruiting | 18 Years | 45 Years | All | 20 | Phase 1 | Portugal | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1196 | NCT01172379 | May 2004 | 19 February 2015 | A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Safety, Tolerability and Efficacy of E2007 in Parkinson's Disease Patients With Wearing Off Motor Fluctuations and On Period Dyskinesias | A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Safety, Tolerability and Efficacy of E2007 in Parkinson's Disease Patients With Wearing Off Motor Fluctuations and On Period Dyskinesias | Parkinson's Disease | Drug: E2007;Other: Placebo Comparator | Eisai Limited | Not recruiting | 30 Years | 75 Years | Both | 2 | Phase 2 | Czech Republic;France;Germany;Italy;Serbia;Spain | |
1197 | NCT00087542 | March 2004 | 19 February 2015 | Treatment of Hallucinosis/Psychosis in Parkinson's Disease by an Investigational Drug | Hallucinations;Psychoses;Parkinson's Disease | Drug: ACP-103 | ACADIA Pharmaceuticals Inc. | Not recruiting | N/A | N/A | Both | 60 | Phase 2 | United States | ||
1198 | NCT00200447 | March 2004 | 19 February 2015 | An Open-Label Feasibility/Pilot Study With [123I]-IBZM SPECT (DOPA-SYN) | Assessment of Carbidopa/l-Dopa and Carbidopa/l Dopa/Entacapone on Synaptic Dopamine in Parkinson's Patients: An Open-Label Feasibility/Pilot Study With [123I]-IBZM SPECT (DOPA-SYN) | Parkinson's Disease | Drug: carbidopa/l-dopa;Drug: carbidopa/l-dopa/entacapone;Drug: Stalevo;Procedure: [123I]-IBZM imaging | Molecular NeuroImaging | Not recruiting | 30 Years | N/A | Both | 3 | Phase 2 | ||
1199 | NCT00244387 | March 2004 | 19 February 2015 | Rotigotine Patch in Subjects With Advanced Stage, Idiopathic Parkinson's Disease Who Are Not Well Controlled on Levodopa | A Multi-centre, Multi-national, Phase 3, Randomized, Double-blind, Double-dummy, 3- Arm Parallel Group, Placebo- and Pramipexole- Controlled Trial of the Efficacy and Safety of Rotigotine Patch in Subjects With Advanced Stage, Idiopathic Parkinson's Disease Who Are Not Well Controlled on Levodopa | Parkinson Disease, Idiopathic | Drug: SPM 962 | UCB Pharma | Not recruiting | 30 Years | N/A | Both | 506 | Phase 3 | Germany | |
1200 | NCT00096720 | February 2004 | 19 February 2015 | Study of the Effects of Dopaminergic Medications on Dopamine Transporter Imaging in Parkinson's Disease | Investigating Effects of Short-term Treatment With Pramipexole or Levodopa on [123I]B-CIT and SPECT Imaging in Early Parkinson's | Parkinson Disease;Parkinsonian Syndrome | Drug: levodopa;Drug: Mirapex (pramipexole);Procedure: [123I]ß-CIT and SPECT imaging | Institute for Neurodegenerative Disorders | Boehringer Ingelheim;Department of Defense | Not recruiting | 30 Years | N/A | Both | 112 | Phase 2 | United States |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1201 | NCT00632736 | February 2004 | 16 December 2017 | An Open-label Continuation Study Evaluating the Long-term Safety of Extended Release Ropinirole XL (Formerly CR) in Parkinson''s Disease | An Open-Label Extension Study With REQUIP (Ropinirole) CR for Subjects From Studies 101468/165, 101468/168 and 101468/169 | Parkinson Disease;Parkinson's Disease | Drug: Ropinirole XL (formerly CR) | GlaxoSmithKline | Not recruiting | 30 Years | N/A | All | 419 | Phase 3 | United States;Belgium;Czech Republic;France;Hungary;Italy;Poland;Spain;United Kingdom;Germany;Philippines | |
1202 | NCT00673088 | February 2004 | 29 January 2018 | A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ropinirole 0.25 mg Tablets Und Fasted Conditions | A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ropinirole 0.25 mg Tablets Und Fasted Conditions | Parkinson's Disease;Restless Leg Syndrome | Drug: Ropinirole Hydrochloride | Roxane Laboratories | Not recruiting | 18 Years | 45 Years | All | 30 | N/A | ||
1203 | NCT00674310 | February 2004 | 29 January 2018 | A Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ropinirole 0.25 mg Tablets Under Fed Conditions | A Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ropinirole 0.25 mg Tablets Under Fed Conditions | Parkinson's Disease;Restless Leg Syndrome | Drug: Ropinirole Hydrochloride | Roxane Laboratories | Not recruiting | 18 Years | 45 Years | All | 29 | N/A | ||
1204 | NCT02248181 | February 2004 | 19 February 2015 | Post Marketing Surveillance Study of Sifrol® in Patients With Idiopathic Parkinson's Disease | Post Marketing Surveillance Study of Sifrol® - Monotherapy in Patients With Idiopathic Parkinson's Disease | Parkinson Disease | Drug: Pramipexole | Boehringer Ingelheim | Not recruiting | N/A | N/A | Both | 442 | N/A | ||
1205 | NCT00076492 | January 2004 | 19 February 2015 | NINDS Parkinson's Disease Neuroprotection Trial of CoQ10 and GPI 1485 | A Multi-center, Double-blind, Pilot Study of CoQ10 and GPI 1485 in Subjects With Early Untreated Parkinson's Disease | Parkinson Disease | Drug: CoQ10;Drug: GPI 1485 | University of Rochester | National Institute of Neurological Disorders and Stroke (NINDS) | Not recruiting | 30 Years | N/A | Both | 195 | Phase 2 | United States |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1206 | NCT00076674 | January 2004 | 3 October 2016 | Levetiracetam Treatment of L-dopa Induced Dyskinesias | Levetiracetam Treatment of L-dopa Induced Dyskinesias | Dyskinesias;Parkinson Disease | Drug: Intravenous Levodopa | National Institute of Neurological Disorders and Stroke (NINDS) | Not recruiting | N/A | N/A | Both | 40 | Phase 2 | United States | |
1207 | NCT00139867 | January 2004 | 19 February 2015 | A Multicenter, Open-label Trial to Assess Subject Preference of PARCOPA, Carbidopa/Levodopa Orally Disintegrating Tablets, Compared to Conventional Carbidopa/Levodopa Tablets in Subjects With Stable Parkinson's Disease | A Multicenter, Open-label Trial to Assess Subject Preference of PARCOPA, Carbidopa/Levodopa Orally Disintegrating Tablets, Compared to Conventional Carbidopa/Levodopa Tablets in Subjects With Stable Parkinson's Disease | Parkinson's Disease | Drug: PARCOPA | UCB Pharma | Not recruiting | 18 Years | N/A | Both | Phase 3 | United States | ||
1208 | NCT00212693 | January 2004 | 19 February 2015 | Controlled Study of ONO-2506PO in Patients With Parkinson's Disease in Japan | Controlled Study of ONO-2506PO in Patients With Parkinson's Disease in Japan | Parkinson's Disease | Drug: ONO-2506PO | Ono Pharmaceutical Co. Ltd | Not recruiting | 20 Years | 79 Years | Both | 165 | Phase 2 | ||
1209 | NCT00220272 | January 2004 | 19 February 2015 | Study of the Effect of SR57667B on 18F-Dopa PET Imaging in Patients With Parkinson's Disease | A Phase II, Randomized, Multicenter, Multinational, Double-Blind, Placebo-Controlled, Study of the Effect of SR57667B on Dopaminergic Nigro-Striatal Function Assessed by 18F-Dopa PET Imaging in Outpatients With Early Parkinson's Disease | Parkinson Disease | Drug: SR57667B | Sanofi | Not recruiting | 35 Years | N/A | Both | 183 | Phase 2 | Canada;Finland;France;Netherlands;Spain;Switzerland;United Kingdom | |
1210 | NCT02231905 | January 2004 | 19 February 2015 | Safety, Tolerability and Efficacy of Switching From Talipexole to Pramipexole in Patients With Parkinson's Disease | Open Label, Exploratory Clinical Trial to Assess the Safety, Tolerability and Effectiveness of a Switching From Talipexole to Pramipexole | Parkinson Disease | Drug: BI-Sifrol® | Boehringer Ingelheim | Not recruiting | 20 Years | N/A | Both | 29 | Phase 4 | ||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1211 | NCT00111982 | December 2003 | 19 February 2015 | Trial of Extended Treatment With Liatermin (r-metHuGDNF) Administered by Continuous Intraputaminal (IPu)Infusion to Subjects With Idiopathic Parkinson's Disease Who Have Completed a Previous Trial of Liatermin | Multi-Center, Open-Label Trial of Extended Treatment With Liatermin (r-metHuGDNF) Administered by Continuous Intraputaminal (IPu) Infusion to Subjects With Idiopathic Parkinson's Disease Who Have Completed a Previous Trial of Liatermin (Protocol 20020168) | Parkinson's Disease | Biological: Liatermin | Amgen | Medtronic | Not recruiting | 35 Years | 70 Years | Both | 34 | Phase 1/Phase 2 | United States |
1212 | NCT00363727 | December 2003 | 16 December 2017 | Onset Motor Complications Using REQUIP CR (Ropinirole Controlled-release) As Add-on Therapy To L-dopa In Parkinson's | A Two Year Phase IIIb Randomised, Multicenter, Double-blind, SINEMET Controlled, Parallel Group, Flexible Dose Study, to Assess the Effectiveness of Controlled Release Ropinirole add-on Therapy to L-dopa at Increasing the Time to Onset of Dyskinesia in Parkinson's Disease Subjects. | Parkinson's Disease;Parkinson Disease;Dyskinesias | Drug: ropinirole controlled-release (REQUIP CR) for RLS | GlaxoSmithKline | Not recruiting | 30 Years | 70 Years | All | 209 | Phase 3 | United States | |
1213 | NCT01941732 | November 2003 | 19 February 2015 | Motor Response to Sildenafil in PD | Motor Response to Acute Challenge to Sildenafil in Parkinsons Disease | Parkinsons Disease;Erectile Dysfunction | Drug: Sildenafil | Bispebjerg Hospital | Not recruiting | 18 Years | 80 Years | Male | 8 | Phase 4 | Denmark | |
1214 | NCT00234676 | October 2003 | 19 February 2015 | POETRY: Study of Estrogen Replacement Therapy in Postmenopausal Women With Parkinson's Disease | A Multi-Center, Double Blind, Randomized, Placebo-Controlled, Parallel Group Study for the Safety, Tolerability and Efficacy of Estrogen Replacement Therapy (Conjugated Equine Estrogens 0.625 mg Daily) in Post Menopausal Women With Parkinson's Disease | Parkinson's Disease | Drug: Premarin ® | The Parkinson Study Group | Wyeth is now a wholly owned subsidiary of Pfizer;Joseph and Rosalyn Newman Foundation | Not recruiting | N/A | 75 Years | Female | 23 | Phase 2 | United States |
1215 | NCT00615472 | October 2003 | 19 October 2017 | Intravenous Versus Inhalational Anesthesia in Parkinson's Disease | Intravenous General Anesthesia Versus Inhalational General Anesthesia in Parkinson's Disease | Parkinson's Disease | Drug: Isoflurane;Drug: Remifentanil;Drug: Propofol | Columbia University | Not recruiting | 18 Years | N/A | All | 58 | N/A | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1216 | NCT00180037 | September 2003 | 19 February 2015 | Coenzyme Q10 as a Symptomatic Treatment in Parkinson's Disease | Multicenter, Placebo Controlled, Randomized, Double-Blinded Study: Coenzyme Q10 Nanodispersion Versus Placebo as Symptomatic Treatment in Parkinson's Disease | Parkinson's Disease | Drug: Coenzyme Q10 Nanodispersion (Nanoquinone);Drug: Placebo | Technische Universität Dresden | Deutsche Parkinson-Vereinigung e.V.;MSE Pharmazeutika GmbH, Bad Homburg | Not recruiting | 40 Years | 75 Years | Both | 132 | Phase 3 | Germany |
1217 | NCT01177319 | September 2003 | 19 February 2015 | Glutathione (GSH) In The Treatment of Parkinson's Disease | Glutathione (GSH) In The Treatment of Parkinson's Disease | Parkinson's Disease | Drug: Glutathione | University of South Florida | Wellness Health & Pharmaceuticals, Inc. | Not recruiting | 18 Years | N/A | Both | 20 | Phase 2 | United States |
1218 | NCT00215904 | August 2003 | 19 February 2015 | D-serine Adjuvant Treatment for Parkinson's Disease | D-serine Adjuvant Treatment for Parkinson's Disease | Parkinson's Disease | Drug: D-serine (~2g/day) | Herzog Hospital | Not recruiting | 30 Years | 75 Years | Both | 13 | Phase 4 | Israel | |
1219 | NCT00070941 | July 2003 | 19 October 2017 | SAM-e for the Treatment of Depression in Patients With Parkinson's Disease | SAM-e Treatment of Depression in Parkinson's Disease. | Parkinson's Disease;Depression | Drug: SAM-e;Drug: oral escitalopram;Drug: placebo | New York University School of Medicine | National Center for Complementary and Integrative Health (NCCIH);Office of Dietary Supplements (ODS) | Not recruiting | 30 Years | 80 Years | All | 29 | Phase 2/Phase 3 | United States |
1220 | NCT00095810 | July 2003 | 19 February 2015 | Aripiprazole in Patients With Psychosis Associated With Parkinson's Disease | An Open-Label Study of Aripiprazole to Evaluate the Safety and Tolerability in Patients With Psychosis Associated With Parkinson's Disease | Parkinson's Disease;Psychoses | Drug: aripiprazole | Otsuka Pharmaceutical Development & Commercialization, Inc. | Otsuka America Pharmaceutical | Not recruiting | 50 Years | N/A | Both | 50 | Phase 4 | United States |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1221 | NCT00160576 | July 2003 | 19 February 2015 | Levetiracetam Treatment in Adult Subjects With Parkinson's Disease Experiencing Troublesome Dyskinesias | A Therapeutic Exploratory, Single Arm, Multicenter Trial to Evaluate the Efficacy and Safety of Levetiracetam up to 4000 mg/Day (500mg Oral Tablets) on Levodopa Induced Dyskinesias in Adults With Idiopathic Parkinson's Disease | Idiopathic Parkinson Disease | Drug: Levetiracetam | UCB Pharma | Not recruiting | 30 Years | N/A | Both | 30 | Phase 2 | ||
1222 | NCT00228150 | July 2003 | 19 February 2015 | Study of the Effect of SR57667B on the Progression of Symptoms in Patients With Parkinson's Disease | A Phase II, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety and Tolerability Study of SR57667B in Outpatients With Early Parkinson's Disease | Parkinson Disease | Drug: SR57667B | Sanofi | Not recruiting | 35 Years | N/A | Both | 564 | Phase 2 | Austria;Canada;Denmark;France;Germany;Morocco;Netherlands;Portugal;South Africa;Spain;Sweden;Tunisia;United Kingdom | |
1223 | NCT00240409 | July 2003 | 19 February 2015 | Randomized Single-blind Placebo Controlled Comparative Trial of Pramipexole and Bromocriptine in Parkinson's Disease | A Randomized Single-blind Placebo Controlled Comparative Trial of Pramipexole Tablets and Bromocriptine Tablets in Patients With Parkinson's Disease. | Parkinson Disease | Drug: Pramipexole;Drug: Bromocriptine | Boehringer Ingelheim | Not recruiting | 30 Years | 80 Years | Both | 208 | Phase 3 | China | |
1224 | NCT00666653 | July 2003 | 19 February 2015 | Effects of a Dopamine Agonist on Pharmacodynamics of Levodopa in Parkinson's Disease | Effects of a Dopamine Agonist on Pharmacodynamics of Levodopa in Parkinson's Disease: a Double-Blind Placebo Controlled Crossover Study | Parkinson's Disease | Drug: pramipexole | Oregon Health and Science University | Boehringer Ingelheim | Not recruiting | 30 Years | 80 Years | Both | 13 | Phase 1 | United States |
1225 | NCT00062738 | June 2003 | 19 October 2017 | Treatment of Depression in Parkinson's Disease Trial | Treatment of Depression in Patients With Parkinson's Disease | Parkinson Disease;Depression | Drug: paroxetine;Drug: Nortriptyline;Other: placebo | Rutgers, The State University of New Jersey | GlaxoSmithKline | Not recruiting | 35 Years | 80 Years | All | 52 | Phase 2 | United States |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1226 | NCT00148486 | June 2003 | 19 February 2015 | A Fourteen-Week Placebo-Controlled Dose-Response Efficacy and Safety Study of NS 2330 in Early Parkinson's Disease Patients (Study for Proof of Concept in Early Parkinson's Disease of a Triple Reuptake Inhibitor, NS 2330 / SCEPTRE) | A Fourteen-week Placebo-controlled Dose-response Efficacy and Safety Study of NS 2330 in Early Parkinson's Disease Patients (Study for Proof of Concept in Early Parkinson's Disease of a Triple Reuptake Inhibitor, NS 2330 / SCEPTRE) | Parkinson Disease | Drug: NS 2330 | Boehringer Ingelheim | Not recruiting | 40 Years | 80 Years | Both | 261 | Phase 2 | United States;Canada | |
1227 | NCT00381472 | June 2003 | 16 December 2017 | Investigational Parkinson's Disease In Patients Not Well Controlled On L-dopa | A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of Six Months Treatment With Ropinirole CR as Adjunctive Therapy in Patients With Parkinson's Disease Who Are Not Optimally Controlled on L-dopa | Parkinson Disease | Drug: Ropinirole | GlaxoSmithKline | Not recruiting | 30 Years | N/A | All | 393 | Phase 3 | United States;Belgium;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain | |
1228 | NCT00063193 | May 2003 | 1 February 2016 | National Institute of Neurological Disorders and Stroke (NINDS) Parkinson's Disease Neuroprotection Trial | A Multi-center, Double-blind, Pilot Study of Minocycline and Creatine in Subjects With Early Untreated Parkinson's Disease | Parkinson's Disease | Drug: minocycline;Drug: creatine | University of Rochester | National Institute of Neurological Disorders and Stroke (NINDS) | Not recruiting | 30 Years | N/A | Both | 195 | Phase 2 | United States |
1229 | NCT00058721 | April 2003 | 19 February 2015 | Single Photon Emission Computed Tomography to Study Receptors in Parkinson's Disease | SPECT Evaluation of Nicotinic Cholinergic Receptors in Parkinson's Disease | Parkinson Disease | Drug: I-123-5-IA85380 | National Institute of Neurological Disorders and Stroke (NINDS) | Not recruiting | N/A | N/A | Both | 60 | N/A | United States | |
1230 | NCT00058838 | April 2003 | 19 February 2015 | Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's Disease | A Phase III, Double-Blind, Placebo-Controlled, Fixed-Dose Response Study Comparing the Efficacy and Safety of Sumanirole Versus Placebo in Patients With Early Parkinson's Disease. | Parkinson Disease | Drug: sumanirole | Pfizer | Not recruiting | 30 Years | N/A | Both | 854 | Phase 3 | United States;Argentina;Australia;Austria;Belgium;Colombia;France;Germany;Greece;Italy;Mexico;Peru;Puerto Rico;Spain | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1231 | NCT00115427 | March 2003 | 19 February 2015 | Study of Liatermin (r-metHuGDNF) Administered by Bilateral Intraputaminal (IPu) Infusion to Subjects With Idiopathic Parkinson's Disease | Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial of Liatermin (r-metHuGDNF) Administered by Bilateral Intraputaminal (IPu) Infusion to Subjects With Idiopathic Parkinson's Disease | Idiopathic Parkinson's Disease | Drug: Liatermin (r-metHuGDNF) | Amgen | Not recruiting | 35 Years | 70 Years | Both | Phase 1 | United States | ||
1232 | NCT00148512 | March 2003 | 19 February 2015 | A Randomized, Double-blind, Placebo-controlled, Five Parallel Groups Efficacy and Safety Study of NS 2330 (Tesofensine) (0.125 mg, 0.25 mg, 0.5 mg and 1.0 mg) Administered Orally Once Daily Over 14 Weeks in Levodopa Treated Parkinson Patients With Motor Fluctuations | A Randomized, Double-blind, Placebo-controlled, Five Parallel Groups Efficacy and Safety Exploratory Study of NS 2330 (0.125 mg, 0.25 mg, 0.5 mg and 1.0 mg) Administered Orally Once Daily Over 14 Weeks in Levodopa Treated Parkinson Patients With Motor Fluctuations (Study for Proof of Concept in ADVAnced Parkinson Disease of NS 2330 / ADVANS) | Parkinson Disease | Drug: 1. Tesofensine (NS 2330) | Boehringer Ingelheim | Not recruiting | 42 Years | 80 Years | Both | 254 | Phase 2 | Austria;France;Germany;Netherlands;Spain;United Kingdom;El Salvador | |
1233 | NCT00056524 | February 2003 | 8 August 2016 | Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter) | An Open-Label Multicenter Study to Assess the Safety of AVP-923 in the Treatment of Patients With Pseudobulbar Affect. | Alzheimer's Disease;Stroke;Parkinson's Disease;Traumatic Brain Injury | Drug: AVP-923 | Avanir Pharmaceuticals | Not recruiting | 18 Years | 80 Years | Both | 600 | Phase 3 | United States | |
1234 | NCT00129675 | February 2003 | 19 February 2015 | Study of Individuals With Parkinson's Symptoms But in Whom There is Diagnostic Uncertainty | Development of a Imaging Marker for Parkinson's Disease Through Use of Dynamic SPECT Imaging With [123I] Beta-CIT in Individuals With Parkinson's Symptoms | Parkinsonian Syndrome | Drug: [123I]ß CIT | Institute for Neurodegenerative Disorders | Molecular NeuroImaging | Not recruiting | 21 Years | N/A | Both | 169 | Phase 2 | United States |
1235 | NCT00237263 | February 2003 | 16 December 2017 | An Extension Study of Entacapone in Patients With Parkinson's Disease With End-of-dose Wearing-off. This Study is Not Recruiting in the United States | An Extension Study to Phase IIb Dose-finding Study of Entacapone in Patients With Parkinson's Disease With End-of-dose Wearing-off | Parkinson's Disease | Drug: Entacapone | Novartis | Not recruiting | 20 Years | N/A | All | 285 | Phase 2 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1236 | NCT00206687 | January 2003 | 19 February 2015 | STEPS Trial - Spheramine Safety and Efficacy Study | Study of the Safety, Tolerability and Efficacy of Spheramine Implanted Bilaterally Into the Postcommissural Putamen of Patients With Advanced Parkinson's Disease | Parkinson Disease | Biological: Spheramine (BAY86-5280);Procedure: Placebo | Bayer | Titan Pharmaceuticals | Not recruiting | 30 Years | 70 Years | Both | 71 | Phase 2 | United States;Germany;Spain;Austria;France |
1237 | NCT00451815 | January 2003 | 19 February 2015 | BIIB014 Phase 2a Monotherapy | A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of Multiple Oral Dose Administration of BIIB014 in Subjects With Early Parkinson’s Disease | Parkinson's Disease | Drug: active drug (BIIB014) at 10, 30, 100, or 300 mg once daily.;Drug: placebo | Biogen Idec | Not recruiting | 30 Years | 78 Years | Both | Phase 2 | |||
1238 | NCT02248207 | January 2003 | 19 February 2015 | Tolerability of Sifrol® in Ambulatory Patients Suffering From Parkinson's Disease | Management of Parkinson's Disease Patients at Their First Visits in a Neurological Practice | Parkinson Disease | Drug: Pramipexole | Boehringer Ingelheim | Not recruiting | N/A | N/A | Both | 1293 | N/A | ||
1239 | NCT00247247 | December 2002 | 19 February 2015 | Comtess® Versus Cabaseril® as Add-on to Levodopa in the Treatment of Parkinsonian Patients Suffering From Wearing- Off. | Efficacy and Tolerability of Comtess® Versus Cabaseril® as Add-on to Levodopa in the Treatment of Parkinsonian Patients Suffering From Wearing-Off Phenomenon | Parkinson's Disease | Drug: Comtess® | Orion Corporation, Orion Pharma | Not recruiting | 60 Years | N/A | Both | 300 | Phase 4 | Germany | |
1240 | NCT00209508 | November 2002 | 19 February 2015 | 2 Year Study to Evaluate the Effects of GPI 1485 on [123I]b-CIT/SPECTScanning and Clinical Efficacy in Patients With PD | Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 2-Year Study To Evaluate The Effects Of GPI 1485 On [123I]b-CIT/SPECT Scanning And Clinical Efficacy In Symptomatic PD Patients Receiving Dopamine Agonist Therapy. | Parkinson's Disease | Drug: GPI 1485 | Eisai Inc. | Symphony Neuro Development Company | Not recruiting | 40 Years | 80 Years | Both | 200 | Phase 2 | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1241 | NCT00165815 | August 2002 | 19 February 2015 | The Efficacy, Tolerability and Safety of Donepezil (Aricept) in Parkinson's Disease Patients With Dementia | Dementia With Parkinson's Disease | Drug: ARICEPT | Eisai Limited | Not recruiting | 40 Years | N/A | Both | Phase 3 | Germany;Ireland | |||
1242 | NCT00594386 | August 2002 | 19 October 2017 | An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Advance-Stage Parkinson's Disease | An Open-Label Extension to the Double-Blind SP650 Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Subjects With Advanced-Stage Idiopathic Parkinson's Disease. | Parkinson's Disease | Drug: Rotigotine | UCB Pharma | Not recruiting | 31 Years | N/A | All | 258 | Phase 3 | United States;Canada | |
1243 | NCT00599196 | August 2002 | 19 October 2017 | An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's Disease | An Open-Label Extension to the Double-Blind SP513 Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Subjects With Early-Stage Idiopathic Parkinson's Disease | Early Stage Parkinson's Disease | Drug: Rotigotine | UCB Pharma | Not recruiting | 30 Years | N/A | All | 381 | Phase 3 | Australia;Austria;Belgium;Croatia;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;South Africa;Spain;Sweden;Switzerland;United Kingdom | |
1244 | NCT00955045 | August 2002 | 8 August 2016 | A Long-Term, Safety Study With a Flexible Dose Range of KW-6002 in Patients With Motor Response Complications on Levodopa/Carbidopa Therapy | A Long-Term, Multicenter, Open-Label, Safety Study With a Flexible Dose Range of KW-6002 as Treatment for Parkinson's Disease in Patients With Motor Response Complications on Levodopa/Carbidopa Therapy | Parkinson's Disease | Drug: istradefylline | Kyowa Kirin Pharmaceutical Development, Inc. | Not recruiting | 30 Years | N/A | Both | Phase 2/Phase 3 | United States | ||
1245 | NCT00043849 | July 2002 | 19 February 2015 | Treatment of Agitation/Psychosis in Dementia/Parkinsonism (TAP/DAP) | Treatment of Agitation/Psychosis in Dementia/Parkinsonism (TAP/DAP) | Dementia;Parkinson Disease | Drug: Quetiapine | National Institute on Aging (NIA) | Not recruiting | 50 Years | N/A | Both | 60 | Phase 4 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1246 | NCT00314288 | July 2002 | 16 December 2017 | Sarizotan in Parkinson Patients With L-dopa-induced Dyskinesia | A Multicenter, Multinational, Randomised, Double-blind, Placebo-controlled, Parallel-group, Dose-finding Study to Investigate the Anti-dyskinetic Efficacy and Safety of Sarizotan in Parkinson Patients With L-dopa-induced Dyskinesia | Parkinson's Disease;Dyskinesia | Drug: Sarizotan HCl | EMD Serono | Not recruiting | 30 Years | N/A | All | 360 | Phase 2 | United States;Belgium;Bulgaria;Canada;France;Germany;Hungary;Portugal;Romania;South Africa;United Kingdom | |
1247 | NCT00040209 | June 2002 | 19 February 2015 | JP-1730 to Treat Parkinson's Disease | Alpha-2 Adrenergic Antagonist Treatment of Parkinson's Disease | Parkinson Disease | Drug: JP 1730;Drug: IV Levodopa;Drug: IV Apomorphine | National Institute of Neurological Disorders and Stroke (NINDS) | Not recruiting | N/A | N/A | Both | 30 | Phase 2 | United States | |
1248 | NCT00594165 | June 2002 | 19 October 2017 | An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's Disease. | An Open-Label Extension to the Double-Blind SP512 Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Subjects With Early-Stage Idiopathic Parkinson's Disease. | Early-Stage Parkinson's Disease | Drug: Rotigotine | UCB Pharma | Not recruiting | 31 Years | N/A | All | 217 | Phase 3 | United States;Canada | |
1249 | NCT00203164 | May 2002 | 19 February 2015 | Study to Evaluate the Safety and Tolerability of Rasagiline in Advanced Parkinson's Disease Patients | A Bi-national, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Tolerability of Rasagiline Mesylate in Advanced Parkinson's Disease (PD) Patients With Motor Fluctuations Treated With Chronic Levodopa/Carbidopa Therapy | Parkinson's Disease | Drug: rasagiline mesylate | Teva Pharmaceutical Industries | Not recruiting | 30 Years | N/A | Both | 254 | Phase 3 | United States | |
1250 | NCT00650104 | May 2002 | 19 October 2017 | Long-term Extension Study Evaluating Extended Release Ropinirole XL (Formerly Referred to as Ropinirole CR) in Patients Who Already Completed Either Study 167 or 164 | 101648/196: A Long-Term, Open-Label Continuation Study of Once Daily Administration of Ropinirole CR Tablets to Patients With Parkinson's Disease Who Completed the Previous Ropinirole CR Studies 167 or 164 | Parkinson Disease | Drug: Ropinirole XL (formerly CR) | GlaxoSmithKline | Not recruiting | 30 Years | N/A | All | 76 | Phase 3 | United States;Belgium;France;Netherlands;Norway | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1251 | NCT01044992 | May 2002 | 19 February 2015 | Motor Activation in Multiple System Atrophy and Parkinson Disease: a Positron Emission Tomography (PET) Study | Motor Activation in Patients With Multi Systemic Atrophy and Comparison With Parkinson Disease and Dopaminergic Challenge | Multisystemic Atrophy | Radiation: H215O PET;Drug: Levodopa | University Hospital, Toulouse | Not recruiting | 40 Years | 75 Years | Both | 38 | N/A | France | |
1252 | NCT00456586 | April 2002 | 8 August 2016 | 12-Week, Double-Blind, Placebo-Controlled, Randomized Study of the Efficacy of 40 mg/Day KW-6002 in Parkinson's Disease Patients on Levodopa/Carbidopa | A 12-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study of the Efficacy of 40 mg/Day KW-6002 as Treatment for Parkinson's Disease in Patients With Motor Response Complications on Levodopa/Carbidopa Therapy | Parkinson's Disease | Drug: KW-6002 (istradefylline) | Kyowa Kirin Pharmaceutical Development, Inc. | Not recruiting | 30 Years | N/A | Both | 180 | Phase 2 | United States | |
1253 | NCT00032812 | March 2002 | 19 February 2015 | The Role of Dopamine in Motor Learning in Healthy Subjects and Patients With Parkinson's Disease | Motor Memory: Study of the Role of Dopamine in Healthy Subjects and Patients With Parkinson's Disease Using PET and EEG | Parkinson Disease;Healthy | Drug: Raclopride | National Institute of Neurological Disorders and Stroke (NINDS) | Not recruiting | N/A | N/A | Both | 64 | N/A | United States | |
1254 | NCT00040404 | March 2002 | 19 February 2015 | Safety and Efficacy Study of CEP-1347 in the Treatment of Parkinson's Disease | A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Assess the Efficacy and Safety of CEP-1347 in Patients With Parkinson's Disease | Parkinson Disease | Drug: CEP-1347 10mg;Drug: CEP1347 25mg;Drug: CEP-1347 50mg;Other: Placebo Comparator | Cephalon | H. Lundbeck A/S;The Parkinson Study Group | Not recruiting | 30 Years | N/A | Both | 806 | Phase 2/Phase 3 | United States;Canada;Puerto Rico |
1255 | NCT00456794 | March 2002 | 8 August 2016 | 12-Week, Double-Blind, Placebo-Controlled Study of 20 and 60 mg/Day Istradefylline in Parkinson's Disease Patients on Levodopa/Carbodopa | A 12-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study of the Efficacy of Doses of 20 and 60 mg/Day Istradefylline as Treatment for Parkinson's Disease in Patients With Motor Response Complications on Levodopa/Carbidopa | Parkinson's Disease | Drug: Istradefylline (KW-6002) | Kyowa Kirin Pharmaceutical Development, Inc. | Not recruiting | 30 Years | N/A | Both | 325 | Phase 2 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1256 | NCT02248168 | March 2002 | 19 February 2015 | Post Marketing Surveillance And Special Surveillance for Mirapex® Tablet in Patients With Idiopathic Parkinson's Disease | Mirapex PMS Study Final Report | Parkinson Disease | Drug: Pramipexole | Boehringer Ingelheim | Not recruiting | N/A | N/A | Both | 1449 | N/A | ||
1257 | NCT00030979 | February 2002 | 19 February 2015 | Donepezil to Treat Dementia in Parkinson's Disease | Donepezil for Dementia in Parkinson's Disease: A Randomized, Double Blinded Placebo Controlled Crossover Trial | Parkinson Disease | Drug: Donepezil | National Institute of Neurological Disorders and Stroke (NINDS) | Not recruiting | N/A | N/A | Both | 28 | Phase 4 | United States | |
1258 | NCT02162979 | February 2002 | 11 June 2018 | Sildenafil (Viagra) for the Treatment of Dyskinesias in Parkinson's Disease | A Double-Blind, Placebo-Controlled, Cross-Over Study of Sildenafil (Viagra) for the Treatment of Dyskinesias in Parkinson's Disease | Parkinson's Disease | Drug: sildenafil;Drug: Placebo | Loma Linda University | Not recruiting | 18 Years | 80 Years | All | 2 | Phase 2 | United States | |
1259 | NCT02231255 | February 2002 | 19 February 2015 | Post Marketing Surveillance Study in Patients With Idiopathic Parkinson's Disease | Switch Post Marketing Surveillance Study in Patients With Idiopathic Parkinson's Disease | Parkinson Disease | Drug: Sifrol® | Boehringer Ingelheim | Not recruiting | N/A | N/A | Both | 1216 | N/A | ||
1260 | NCT00407212 | January 2002 | 19 February 2015 | A Study of Three Doses of TCH346 in Patients With Early Parkinson's Disease to Evaluate Safety and Efficacy | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Dose-ranging, Efficacy and Safety Study of Three Doses of TCH346 (1mg, 5mg and 20mg Daily) in Patients With Early Parkinson's Disease | Parkinson's Disease | Drug: TCH346 (dibenz[b,f]oxepin-10-ylmethyl-prop-2-ynyl-amine, hydrogen maleate salt) | Novartis | Not recruiting | 30 Years | 80 Years | Both | 301 | Phase 1/Phase 2 | United States;Brazil;Canada;France;Germany;Italy;Netherlands;Portugal;United Kingdom | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1261 | NCT00036218 | December 2001 | 19 February 2015 | Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's Disease. | A Phase III, Double-Blind, Placebo-Controlled, Randomized Study Comparing the Efficacy, Safety, and Tolerability of Sumanirole Versus Placebo or Ropinirole in Patients With Early Parkinson's Disease. | Parkinson Disease | Drug: sumanirole;Drug: ropinirole | Pfizer | Not recruiting | 30 Years | N/A | Both | 600 | Phase 3 | United States;Argentina;Mexico;Puerto Rico | |
1262 | NCT00203177 | October 2001 | 19 February 2015 | Rasagiline in Advanced Parkinson's Disease Patients With Motor Fluctuations Treated With Levodopa/Carbidopa Therapy. | A Bi-national, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Tolerability of Rasagiline Mesylate in Advanced Parkinson's Disease (PD) Patients With Motor Fluctuations Treated With Chronic Levodopa/Carbidopa Therapy. | Parkinson's Disease | Drug: rasagiline mesylate;Drug: rasagiline mesylate 1.0 mg | Teva Pharmaceutical Industries | Not recruiting | 30 Years | N/A | Both | 254 | Phase 3 | United States;Canada | |
1263 | NCT02772627 | September 2001 | 23 May 2016 | Study to Investigate the Tolerability, Steady-state Pharmacokinetics and Erythrocyte COMT Inhibition of BIA 3-202 | A Double-blind, Randomised, Placebo-controlled, Rising Multiple Dose Study to Investigate the Tolerability, Steady-state Pharmacokinetics and Erythrocyte COMT Inhibition of BIA 3-202 in Healthy Volunteers. | Parkinson's Disease | Drug: Nebicapone;Drug: Placebo | Bial - Portela C S.A. | Not recruiting | 18 Years | 45 Years | Both | 22 | Phase 1 | Portugal | |
1264 | NCT00200525 | July 2001 | 19 February 2015 | Continued Efficacy and Safety of Apomorphine in Patients With Late-Stage Parkinsons Disease | A Randomized, Placebo-Controlled Study of the Continued Efficacy and Safety of SC Apomorphine in the Treatment of Off Episodes in Patients With On/Off or Wearing-Off Effects Associated With Late-Stage PD After Apomorphine Use | Parkinson Disease | Drug: apomorphine HCl injection | Mylan Bertek Pharmaceuticals | Not recruiting | 18 Years | N/A | Both | 60 | Phase 3 | ||
1265 | NCT02763839 | April 2001 | 17 May 2016 | Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose of Levodopa/Carbidopa (100/25 mg) | Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose of Levodopa/Carbidopa (100/25 mg): a Double-blind, Randomised, Crossover, Placebo Controlled Study in Healthy Volunteers | Parkinson's Disease | Drug: BIA 3-202;Drug: Placebo;Drug: Sinemet 25/100 | Bial - Portela C S.A. | Not recruiting | 18 Years | 45 Years | Both | 19 | Phase 1 | Portugal | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1266 | NCT02763852 | April 2001 | 17 May 2016 | Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose of Levodopa/Benserazide (100/25 mg) | Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose of Levodopa/Benserazide (100/25 mg): a Double-blind, Randomised, Crossover, Placebo Controlled Study in Healthy Volunteers | Parkinson's Disease | Drug: BIA 3-202;Drug: Placebo;Drug: Madopar® 125 | Bial - Portela C S.A. | Not recruiting | 18 Years | 45 Years | Both | 18 | Phase 1 | Portugal | |
1267 | NCT00013624 | March 2001 | 19 February 2015 | Riluzole to Treat Parkinson's Disease | Effect of Antiglutamatergic Treatment in Parkinson's Disease | Parkinson's Disease | Drug: IV Levodopa | National Institute of Neurological Disorders and Stroke (NINDS) | Not recruiting | N/A | N/A | Both | 20 | Phase 2 | United States | |
1268 | NCT00117819 | March 2001 | 19 February 2015 | A Study of Brain Imaging With Nuclear Medicine Technology in Individuals With and at Risk for Parkinson's Disease | Dynamic SPECT Imaging With [123I] B-CIT in Individuals With Parkinsonian Syndrome (PS) and in Individuals at Risk for Parkinsonian Syndrome | Parkinsonian Syndrome | Drug: [123I]ß CIT and SPECT imaging | Institute for Neurodegenerative Disorders | Indiana University;Albany Medical College | Not recruiting | 22 Years | N/A | Both | 232 | Phase 2 | United States |
1269 | NCT00145171 | February 2001 | 19 February 2015 | A Sub-Study With Patients in APO401 to Evaluate Adverse Events During Dose Introduction in Apomorphine-naïve Patients. | Study of Orthostatic Changes Upon Apomorphine Dose Initiation in Late Stage Parkinson’s Disease Patients. A Dose Escalation Study With a Double-Blind Placebo-Controlled Efficacy Determination at 4 Mg. | Parkinson Disease | Drug: apomorphine HCl injection | Mylan Bertek Pharmaceuticals | Not recruiting | 18 Years | N/A | Both | 56 | Phase 3 | ||
1270 | NCT00009048 | January 2001 | 19 February 2015 | EMD 128130 for the Treatment of Parkinson's Disease | Effect of Serotoninergic Treatment in Parkinson's Disease | Parkinson's Disease | Drug: EMD 128130;Drug: IV Levodopa | National Institute of Neurological Disorders and Stroke (NINDS) | Not recruiting | N/A | N/A | Both | 30 | Phase 2 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1271 | NCT00006337 | October 2000 | 19 February 2015 | KW-6002 to Treat Parkinson's Disease | Adenosine A2A Blockade With KW-6002 in Parkinson's Disease | Parkinson's Disease | Drug: KW-6002;Drug: IV Levodopa | National Institute of Neurological Disorders and Stroke (NINDS) | Not recruiting | N/A | N/A | Both | 16 | Phase 2 | United States | |
1272 | NCT00006488 | October 2000 | 19 February 2015 | Continuously Infused Intracerebral (IC) Recombinant-Methionyl Human Glial Cell Line-Derived Neurotrophic Factor (r-metHuGDNF) for the Treatment of Idiopathic Parkinson's Disease | Parkinson Disease | Drug: recombinant-methionyl human glial cell line-derived neurotrophic factor | National Center for Research Resources (NCRR) | Not recruiting | 18 Years | 75 Years | Both | Phase 1 | United States | |||
1273 | NCT00203125 | October 2000 | 19 February 2015 | A Study to Evaluate the Effects of Tyramine in Patients Who Completed the PRESTO Study. | Sub-study to Evaluate the Effect of An Oral Dose of Tyramine in Subjects Completing 26 Weeks of Participation in PRESTO (TVP-1012/133) | Parkinson's Disease | Drug: rasagiline mesylate;Other: tyramine | Teva Pharmaceutical Industries | Not recruiting | N/A | N/A | Both | 55 | Phase 3 | United States | |
1274 | NCT00070928 | September 2000 | 19 February 2015 | Valerian to Improve Sleep in Patients With Parkinson's Disease | Polysomnographic Assessment of Alternative Treatments for Sleep Disturbance in Parkinson's Disease | Insomnia;Parkinson's Disease | Drug: valerian | National Center for Complementary and Integrative Health (NCCIH) | Not recruiting | 30 Years | 80 Years | Both | 80 | Phase 2 | United States | |
1275 | NCT02763800 | September 2000 | 17 May 2016 | Study to Investigate the Safety, Tolerability, Steady State Pharmacokinetic and Pharmacodynamic Profile of BIA 3-202 | Double-Blind, Randomised, Placebo-Controlled, Rising Multiple Dose Study to Investigate the Safety, Tolerability, Steady State Pharmacokinetic and Pharmacodynamic Profile of BIA 3-202, in Young Healthy Volunteers | Parkinson's Disease | Drug: BIA 3-202;Drug: Placebo | Bial - Portela C S.A. | Not recruiting | 18 Years | 35 Years | Male | 33 | Phase 1 | United Kingdom | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1276 | NCT00006077 | August 2000 | 19 February 2015 | Effects of Monoamine Reuptake Inhibitor NS2330 in Parkinson's Disease | Effects of Monoamine Reuptake Inhibitor NS2330 in Parkinson's Disease | Parkinson's Disease | Drug: NS2330;Drug: Levodopa and Domperidone | National Institute of Neurological Disorders and Stroke (NINDS) | Not recruiting | N/A | N/A | Both | 50 | Phase 2 | United States | |
1277 | NCT00036205 | August 2000 | 19 February 2015 | Open Label Sumanirole Study of Safety, Tolerability, and Therapeutic Response In Patients With Parkinson's Disease | Open-Label, Long Term, Flexible Dose Study Of Safety, Tolerability, And Therapeutic Response In Patients With Parkinson's Disease. | Parkinson Disease | Drug: sumanirole | Pfizer | Not recruiting | 30 Years | N/A | Both | 984 | Phase 3 | United States;Argentina;Colombia;Puerto Rico | |
1278 | NCT02231294 | July 2000 | 19 February 2015 | The Effect of Sifrol® on Tremor and Depression in Patients With Idiopathic Parkinson's Disease | The Effect of SIFROL® on Tremor and Depression in Patients With Idiopathic Parkinson's Disease Patients. | Parkinson Disease | Drug: Sifrol® | Boehringer Ingelheim | Not recruiting | N/A | N/A | Both | 1464 | N/A | ||
1279 | NCT00203034 | May 2000 | 19 February 2015 | Multicenter Study of Rasagiline in Parkinson's Disease Patients Using Levodopa and Experiencing Motor Fluctuations | A Multicenter, US and Canada, Double Blind, Randomized, Placebo-Controlled, Parallel Group Study, for the Efficacy, Tolerability and Safety of Rasagiline Mesylate in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations | Parkinson's Disease | Drug: rasagiline mesylate;Drug: 1.0 mg rasagiline mesylate;Other: Placebo | Teva Pharmaceutical Industries | Not recruiting | 30 Years | N/A | Both | 472 | Phase 3 | United States | |
1280 | NCT00134784 | April 2000 | 19 October 2017 | Long-Term Dopamine Transporter Imaging and Clinical Assessment of Parkinson's Disease Progression | [123I]ß-CIT and SPECT in Vivo Three Year Imaging Assessment of Dopamine Transporter Density in Subjects With Early Parkinson's Disease Participating in Earlier vs. Later Levodopa in Parkinson's Disease | Parkinson Disease | Drug: [123I]B-CIT SPECT imaging | Institute for Neurodegenerative Disorders | United States Department of Defense | Not recruiting | 22 Years | N/A | All | 142 | Phase 2 | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1281 | NCT02763787 | April 2000 | 23 May 2016 | Safety, Tolerability, Pharmacokinetics (Including Food Interaction), and Pharmacodynamics of BIA 3-202 | A Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics (Including Food Interaction), and Pharmacodynamics of Single Doses of BIA 3-202 in Healthy Volunteers. | Parkinson's Disease | Drug: BIA 3-202;Drug: Placebo | Bial - Portela C S.A. | Not recruiting | 18 Years | 35 Years | Male | 71 | Phase 1 | United Kingdom | |
1282 | NCT00004576 | February 2000 | 19 February 2015 | Study of LY300164 for the Treatment of Parkinson's Disease | AMPA Receptor Blockade With LY300164 in the Treatment of Parkinson's Disease | Dyskinesias;Parkinson Disease | Drug: LY300164 | National Institute of Neurological Disorders and Stroke (NINDS) | Not recruiting | N/A | N/A | Both | 20 | Phase 2 | United States | |
1283 | NCT00761436 | February 2000 | 19 February 2015 | Pilot Study of Safety and Efficacy of Spheramine | Stereotactic Intrastriatal Implantation of Spheramine in Advanced Parkinson's Disease Patients: A Pilot Study of Tolerability and Efficacy. | Parkinson's Disease | Biological: Spheramine (BAY86-5280) | Bayer | Titan Pharmaceuticals | Not recruiting | 40 Years | 70 Years | Both | 6 | Phase 2 | United States |
1284 | NCT00037830 | November 1999 | 19 October 2017 | GM1 Ganglioside Effects on Parkinson's Disease | The Study of GM1 Ganglioside, A Potential New Parkinson's Disease Medication | Parkinson Disease | Drug: GM1 ganglioside;Drug: Placebo | Thomas Jefferson University | National Institute of Neurological Disorders and Stroke (NINDS) | Not recruiting | 39 Years | 85 Years | All | 94 | Phase 2 | United States |
1285 | NCT00200512 | September 1999 | 19 February 2015 | Continued Efficacy of Apomorphine After Previous Exposure of at Least Three Months | A Prospective, Randomized, Placebo-Controlled, Crossover Study of the Safety and Effectiveness of Subcutaneous Injections of Apomorphine in the Treatment of Off Episodes in Patients With On/Off or Wearing Off Effects Associated With Late Stage Parkinson's Disease | Parkinson Disease | Drug: apomorphine HCl injection | Mylan Bertek Pharmaceuticals | Not recruiting | 18 Years | N/A | Both | 16 | Phase 2/Phase 3 | United Kingdom | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1286 | NCT00142545 | July 1999 | 19 February 2015 | Long Term Safety and Efficacy of SC Apomorphine in Treatment of Off Episodes in Late-Stage Parkinson's Disease | Long-Term Safety and Effectiveness of Subcutaneous Injections of Apomorphine in the Treatment of “Off” Episodes in Patients With “On-Off” or “Wearing-Off” Effects Associated With Late-Stage Parkinson’s Disease | Parkinson Disease | Drug: apomorphine HCl injection | Mylan Bertek Pharmaceuticals | Not recruiting | 18 Years | N/A | Both | 800 | Phase 3 | United States | |
1287 | NCT00001931 | May 1999 | 19 February 2015 | Treatment of Parkinson's Disease With a Transdermal Skin Patch | Transdermal Application of Dopamine Agonist N-0923 in Parkinson's Disease | Parkinson Disease | Drug: N-0923 | National Institute of Neurological Disorders and Stroke (NINDS) | Not recruiting | N/A | N/A | Both | 20 | Phase 2 | United States | |
1288 | NCT02172573 | April 1999 | 19 February 2015 | Safety and Efficacy of Pramipexole and Bromocriptine Combined With L-dopa in Parkinson's Disease | A Double-blind, Placebo-controlled, Randomised, Multicenter Trial to Compare the Safety and Efficacy of Oral Administration of Pramipexole up to 4.5mg and Bromocriptine up to 22.5mg Combined With L-dopa in Advanced Parkinson's Disease | Parkinson Disease | Drug: Pramipexole;Drug: Bromocriptine;Drug: Placebo pramipexole;Drug: Placebo bromocriptine | Boehringer Ingelheim | Not recruiting | 20 Years | N/A | Both | 315 | Phase 3 | ||
1289 | NCT00001929 | March 1999 | 19 February 2015 | Treatment of Parkinson's Disease With Eliprodil | NMDA-Receptor Blockade With Eliprodil in Parkinson's Disease | Movement Disorders;Parkinson Disease | Drug: Eliprodil | National Institute of Neurological Disorders and Stroke (NINDS) | Not recruiting | N/A | N/A | Both | 20 | Phase 2 | United States | |
1290 | NCT00274131 | December 1998 | 19 February 2015 | Long-term Administration Study of SND 919 Tablets in Parkinson's Disease | Long-term Administration Study of SND 919 Tablets in Parkinson's Disease | Parkinson Disease | Drug: Pramipexole 0.125 mg tablets;Drug: Pramipexole 0.5 mg tablets | Boehringer Ingelheim | Not recruiting | 20 Years | N/A | Both | 170 | Phase 3 | ||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1291 | NCT02177357 | November 1998 | 19 February 2015 | Pramipexole in Untreated and Levodopa-treated Parkinson's Disease Patients | Pramipexole: Efficacy, Safety and Tolerability Study in Untreated and Levodopa-Treated Parkinson's Disease Patients, a Multinational Study | Parkinson Disease | Drug: Pramipexole;Drug: Placebo | Boehringer Ingelheim | Not recruiting | 30 Years | N/A | Both | 150 | Phase 3 | ||
1292 | NCT02248220 | October 1998 | 19 February 2015 | Efficacy and Tolerability of Sifrol® (Pramipexole) in Patients With Advanced Idiopathic Parkinson's Disease | Observation of the Efficacy and Tolerability of Sifrol® (Pramipexole) in Patients With Advanced Idiopathic Parkinson's Disease | Parkinson Disease | Drug: Pramipexole | Boehringer Ingelheim | Not recruiting | N/A | N/A | Both | 657 | N/A | ||
1293 | NCT00004731 | September 1998 | 19 February 2015 | Parkinson's Disease Treatment With Coenzyme Q10 | Effects of Coenzyme Q10 in Early Parkinson's Disease | Parkinson's Disease | Drug: Coenzyme Q10 | National Institute of Neurological Disorders and Stroke (NINDS) | Not recruiting | 30 Years | N/A | Both | Phase 2 | United States | ||
1294 | NCT02233023 | June 1998 | 19 February 2015 | Ophthalmologic Safety of Long Term Treatment With Pramipexole Compared to Bromocriptine or Other Dopamine Agonists in Patients With Parkinson's Disease | Matched Pair, Assessor Blinded, Open Label Clinical Trial to Assess the Ophthalmologic Safety of Long Term Oral Treatment With Pramipexole Compared to Bromocriptine or Other Dopamine Agonists in Patients With Parkinson's Disease | Parkinson Disease | Drug: Pramipexole;Drug: Bromocriptine and other dopamine agonists | Boehringer Ingelheim | Not recruiting | N/A | N/A | Both | 705 | Phase 4 | ||
1295 | NCT00004451 | March 1998 | 19 February 2015 | Randomized Study of the Effects of Glucose on Cognition in Healthy Young and Elderly People and Parkinson's Disease Patients | Parkinson Disease | Drug: Glucose | National Institute of Mental Health (NIMH) | University of Virginia | Not recruiting | 18 Years | N/A | Both | 120 | N/A | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1296 | NCT00004733 | January 1998 | 19 February 2015 | Timing of Levodopa Treatment in Parkinson's Disease | Earlier Versus Later L-Dopa in Parkinson's Disease | Parkinson's Disease | Drug: levodopa | National Institute of Neurological Disorders and Stroke (NINDS) | Not recruiting | 30 Years | N/A | Both | Phase 3 | United States | ||
1297 | NCT00226460 | August 1997 | 30 March 2015 | Phase 2, Double-blind, Randomized, Controlled Multi-center Clinical Trial of the Safety and Efficacy of Transplanted Fetal Porcine Cells in Patients With Parkinson's Disease. | Parkinson's Disease | Drug: Fetal porcine cells, Neurocell-PD | Genzyme, a Sanofi Company | Diacrin/Genzyme Corporation LLC | Not recruiting | 40 Years | 70 Years | Both | Phase 2 | United States | ||
1298 | NCT00203060 | July 1997 | 19 February 2015 | Effectiveness, Tolerability and Safety of Rasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa | A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group, Phase III Clinical Trial For The Efficacy, Tolerability And Safety Of Two Doses Of Rasagiline Mesylate In Early Parkinson's Disease (PD) Patients Not Treated With Levodopa | Parkinson's Disease | Drug: Rasagiline Mesylate;Drug: placebo | Teva Neuroscience, Inc. | Not recruiting | 35 Years | N/A | Both | 404 | Phase 3 | United States | |
1299 | NCT00038116 | May 1995 | 19 February 2015 | Embryonic Dopamine Cell Implants for Parkinson's Disease | Embryonic Dopamine Cell Implants for Parkinson's Disease: A Double-Blind Study | Parkinson Disease | Procedure: embryonic dopamine cell implant surgery;Procedure: placebo | University of Colorado, Denver | Not recruiting | 20 Years | 75 Years | Both | 40 | Phase 3 | United States | |
1300 | NCT00004826 | October 1993 | 7 April 2015 | Study of Clozapine for the Treatment of Psychosis in Patients With Idiopathic Parkinson's Disease | Parkinson Disease | Drug: clozapine | Memorial Hospital of Rhode Island | Not recruiting | N/A | N/A | Both | 60 | N/A | |||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1301 | NCT00001365 | July 1993 | 19 February 2015 | Dextromethorphan for the Treatment of Parkinson's Disease and Similar Conditions of the Nervous System | NMDA Receptor Antagonist Treatment of Neurodegenerative Disease | Neurodegenerative Disease;Parkinson's Disease | Drug: dextromethorphan | National Institute of Neurological Disorders and Stroke (NINDS) | Not recruiting | N/A | N/A | Both | 42 | Phase 2 | United States | |
1302 | NCT00132626 | September 1992 | 15 April 2019 | Study of Brain Imaging With Nuclear Technology in Individuals With Parkinsonian Syndrome | Dynamic SPECT Imaging With [123I]ß-CIT in Patients With Parkinsonism | Parkinson's Disease;Parkinsonian Syndrome | Drug: [123I]ß-CIT and SPECT imaging | Institute for Neurodegenerative Disorders | Molecular NeuroImaging;National Institutes of Health (NIH) | Not recruiting | 35 Years | N/A | All | 500 | Phase 2 | |
1303 | JPRN-JapicCTI-050099 | 23 April 2019 | Double blind, parallel-group clinical study of AD-810N (zonisamide) for Parkinson's disease | Double blind, parallel-group clinical study of AD-810N (zonisamide) for Parkinson's disease | Parkinson's disease | Intervention name : AD-810N (zonisamide) Dosage And administration of the intervention : oral | Dainippon Sumitomo Pharma Co., Ltd. | 20 | 79 | BOTH | NA | |||||
1304 | JPRN-JapicCTI-070377 | 23 April 2019 | Double-blind, parallel-group confirmatory study of AD-810N (zonisamide) in patients with Parkinson's disease | Double-blind, parallel-group confirmatory study of AD-810N (zonisamide) in patients with Parkinson's disease | Parkinson's disease | Intervention name : AD-810N (zonisamide) Dosage And administration of the intervention : oral | Dainippon Sumitomo Pharma Co., Ltd. | 20 | 74 | BOTH | Phase 3 | |||||
1305 | JPRN-JapicCTI-101020 | 2 April 2019 | Phase II study on FPF1100NW monotherapy | Study on FPF1100NW monotherapy with early Parkinson's disease patients (Phase II study) | Parkinson's disease | Intervention name : FPF1100NW INN of the intervention : Selegiline Dosage And administration of the intervention : oral Control intervention name : null | FP Pharmaceutical Corp. | 20 | 74 | BOTH | 90 | Phase 2 | ||||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1306 | JPRN-JapicCTI-111699 | 2 April 2019 | Study of Safety, Tolerability, Pharmacokinetics, and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease | An Open-Label, Single-Arm, Baseline-Controlled, Multicenter Study to Explore the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABT-SLV187 in Subjects with Advanced Parkinson's Disease | Advanced Parkinson's disease | Intervention name : ABT-SLV187 Dosage And administration of the intervention : Usually 2-6 ml/hour (40-120 mg levodopa/hour), dose will be individually optimized for each subject based on the subject's symptoms Control intervention name : null | Abbott Japan Co., Ltd. | 30 | BOTH | 8 | Phase 2 | |||||
1307 | JPRN-JapicCTI-121954 | 2 April 2019 | Phase III study on FPF1100NW monotherapy | Randomized, double-blind, placebo-controlled study on FPF1100NW monotherapy with early Parkinson's disease patients (Phase III study) | Early Parkinson's disease | Intervention name : FPF1100NW INN of the intervention : Selegiline Dosage And administration of the intervention : oral Control intervention name : null | FP Pharmaceutical Corp. | 20 | 74 | BOTH | 280 | Phase 3 |